http://nih.technologypublisher.comBe the first to know about the latest inventions and technologies available from NIH Technology Transferen-USFri, 17 Apr 2026 13:18:57 GMTThu, 16 Apr 2026 07:15:08 GMThttp://blogs.law.harvard.edu/tech/rssnihott@nih.govCopyright 2026, NIH Technology TransferTAB-4999https://nih.technologypublisher.com/tech/Methods_To_Regulate_Metabolism_For_Treatment_Of_Neural_Injuries_and_NeurodegenerationThu, 16 Apr 2026 07:15:08 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Methods_To_Regulate_Metabolism_For_Treatment_Of_Neural_Injuries_and_NeurodegenerationTAB-5088https://nih.technologypublisher.com/tech/DNA_Methylation-Based_Cancer_Diagnostics_for_Accurate_Tumor_ClassificationFri, 10 Apr 2026 11:34:38 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/DNA_Methylation-Based_Cancer_Diagnostics_for_Accurate_Tumor_ClassificationTAB-5097https://nih.technologypublisher.com/tech/Nucleophosmin_1_(NPM1)_Mutation-Specific_T_Cell_Receptors_for_Targeted_Treatment_of_Acute_Myeloid_LeukemiaFri, 10 Apr 2026 06:41:17 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Nucleophosmin_1_(NPM1)_Mutation-Specific_T_Cell_Receptors_for_Targeted_Treatment_of_Acute_Myeloid_LeukemiaTAB-5096https://nih.technologypublisher.com/tech?title=48-Position_Custom_Deep_Well_Plate_For_In_Vitro_Equilibrium_Dialysis_at_a_1%3a1_Sample_to_Buffer_Volume_RatioCDC scientists have developed a new design for a multi-well dialysis microplate for equilibrium dialysis. The unique design accommodates a 1:1 buffer to sample ratio and provides additional room at the base of the well to enable optimal cartridge immersion and analyte diffusion. The microplate is readily adaptable into existing automated analytical systems and meets the criteria of American National Standards Institute (ANSI). The microplate is designed for measuring blood or other biological fluid samples over a wide range of sample volumes and may be used in a high throughput manner. Use of ...Wed, 08 Apr 2026 14:47:43 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech?title=48-Position_Custom_Deep_Well_Plate_For_In_Vitro_Equilibrium_Dialysis_at_a_1%3a1_Sample_to_Buffer_Volume_RatioTAB-5094https://nih.technologypublisher.com/tech/Novel_malaria_vaccine_candidates_comprising_engineered_nanoparticlesMon, 23 Mar 2026 11:17:08 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Novel_malaria_vaccine_candidates_comprising_engineered_nanoparticlesTAB-5095https://nih.technologypublisher.com/tech/Gene_Editing_for_ALPK1_p.Thr237MetMon, 23 Mar 2026 10:51:01 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Gene_Editing_for_ALPK1_p.Thr237MetTAB-5091https://nih.technologypublisher.com/tech/Pigment_Epithelium-Derived_Factor_Peptides_and_Their_Use_for_Treating_Retinal_DegenerationFri, 13 Mar 2026 09:56:22 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Pigment_Epithelium-Derived_Factor_Peptides_and_Their_Use_for_Treating_Retinal_DegenerationTAB-4466https://nih.technologypublisher.com/tech/Systems_and_Methods_to_Automatically_Detect_Ellipsoid_Zone_Loss_in_SD-OCT_ImagingSummary: The National Eye Institute (NEI) seeks research co-development partners and/or licensees for an automatic deep learning-based algorithm to detect and quantitate ellipsoid zone (EZ) loss in Spectral Domain Optical Coherence Tomography (SD-OCT) images. Description of Technology: The present disclosure generally relates a method of automatically detecting ellipsoid zone (EZ) loss in spectral domain optical coherence tomography (SD-OCT) imaging. EZ band represents outer segments of photoreceptors in the retina, and its loss reflects a deterioration of the photoreceptors. EZ loss has ...Wed, 11 Mar 2026 08:19:33 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Systems_and_Methods_to_Automatically_Detect_Ellipsoid_Zone_Loss_in_SD-OCT_ImagingTAB-5092https://nih.technologypublisher.com/tech/MODIFIED_PIGMENT_EPITHELIUM-DERIVED_FACTOR_PEPTIDES_AND_METHODS_OF_USESummary: The National Eye Institute (NEI) seeks research co-development partners and/or licensees for the development of an eyedrop formulation to deliver a series of peptides as a gene-agnostic approach to treating inherited retinal diseases. Description of Technology: Retinitis pigmentosa (RP) is one of the most common inherited retinal diseases (IRDs) that is estimated to affect 1 in 4,000 people in the United States and worldwide. Over 100,000 people in the US, and 1.5 million people worldwide suffer from RP. RP leads to progressive photoreceptor cell degeneration and ultimately vision ...Wed, 11 Mar 2026 07:57:59 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/MODIFIED_PIGMENT_EPITHELIUM-DERIVED_FACTOR_PEPTIDES_AND_METHODS_OF_USETAB-5089https://nih.technologypublisher.com/tech/Real-time_AI_System_for_Echocardiography_Analysis_and_QuantificationSummary: We are seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize this technology. Description of Technology: Scientists have developed an artificial intelligence (AI) system to automatically extract predictive biomarkers from echocardiography. This AI system takes an echocardiography study as input and produces predictive biomarkers as output in real-time. It performs several automated image analysis tasks including echocardiography quality (quality for the acquired echo clips) assessment, echocardio...Wed, 18 Feb 2026 10:38:44 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Real-time_AI_System_for_Echocardiography_Analysis_and_QuantificationTAB-5090https://nih.technologypublisher.com/tech/Humanized_40H3_AntibodyThu, 05 Feb 2026 13:30:32 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Humanized_40H3_AntibodyTAB-5085https://nih.technologypublisher.com/tech?title=Humanized_Monoclonal_Antibodies_Specific_Against_Human_Soluble_Tissue_Factor_(hsTF)_as_Diagnosis%2c_Prevention_and_Therapeutic_Agents_for_ThrombosisMon, 29 Sep 2025 14:10:01 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech?title=Humanized_Monoclonal_Antibodies_Specific_Against_Human_Soluble_Tissue_Factor_(hsTF)_as_Diagnosis%2c_Prevention_and_Therapeutic_Agents_for_ThrombosisTAB-5084https://nih.technologypublisher.com/tech/Combination_PDL1_and_TGF_Beta_Blockade_in_Patients_with_HPV-Associated_MalignanciesMon, 29 Sep 2025 13:47:56 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Combination_PDL1_and_TGF_Beta_Blockade_in_Patients_with_HPV-Associated_MalignanciesTAB-5083https://nih.technologypublisher.com/tech/Identification_and_Characterization_of_HLA-A24_Agonist_Epitopes_of_MUC1_OncoproteinSummary: The National Cancer Institute (NCI) seeks co-development partners and licensees for a human cytotoxic T lymphocyte agonist epitope from the C-terminal subunit of mucin 1 (MUC1-C), which can be used as a peptide, polypeptide (protein), in a cancer vaccine or T-cell targeted therapy to target many tumor types. Description of Technology: Many human carcinomas and hematologic malignancies overexpress mucin 1 (MUC1), a transmembrane glycoprotein composed of heterodimers formed by a large, N-terminal subunit (MUC1-N) and a smaller, C-terminal subunit (MUC1-C). In tumors, the MUC-1 hetero...Mon, 29 Sep 2025 13:26:30 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Identification_and_Characterization_of_HLA-A24_Agonist_Epitopes_of_MUC1_OncoproteinTAB-5082https://nih.technologypublisher.com/tech/Novel_Human_Immunogenic_Epitopes_of_the_Human_Endogenous_Retrovirus_ERVMER34-1Summary: The National Cancer Institute (NCI) seeks research co-development partners and/or licensees for the clinical translation of novel peptide-based therapeutic cancer vaccines derived from ERVMER34-1, a human endogenous retrovirus (HERV) antigen, offering a unique opportunity to address a significant unmet need in the treatment of various carcinomas. Description of Technology: Human Endogenous Retroviruses (HERVs), remnants of ancient retroviral germline infections that comprise ~8% of the human genome, represent a promising yet underexplored frontier in targeted cancer therapy. Althou...Mon, 29 Sep 2025 13:15:21 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Novel_Human_Immunogenic_Epitopes_of_the_Human_Endogenous_Retrovirus_ERVMER34-1TAB-5081https://nih.technologypublisher.com/tech/Generating_Conditional_and_Reverse_Conditional_Loss-of-Function_Alleles_in_Mouse_Casq2Mon, 29 Sep 2025 12:58:10 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Generating_Conditional_and_Reverse_Conditional_Loss-of-Function_Alleles_in_Mouse_Casq2TAB-5080https://nih.technologypublisher.com/tech/Innovative_Antibody_Conjugation_Technology_for_Therapeutic_and_Diagnostic_ApplicationsThis pioneering technology introduces a novel method for conjugating antibodies, designed to dramatically enhance their therapeutic and diagnostic performance. By improving both binding efficiency and target specificity, this approach overcomes critical limitations of existing antibody-based therapies and imaging tools. The result is a versatile platform that enables more effective treatments and more precise diagnostics, unlocking new possibilities in disease management. With particular impact in oncology, where accurate targeting is vital, and in infectious diseases, where rapid and reliabl...Mon, 22 Sep 2025 09:01:47 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Innovative_Antibody_Conjugation_Technology_for_Therapeutic_and_Diagnostic_ApplicationsTAB-5079https://nih.technologypublisher.com/tech/Advanced_Biodegradable_Polymers_for_Medical_DevicesMon, 22 Sep 2025 08:49:26 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Advanced_Biodegradable_Polymers_for_Medical_DevicesTAB-5078https://nih.technologypublisher.com/tech/Rapid_Spectral_Unmixing_Using_Spectrally_Interpolated_Background_Reduction_(SIBR)_for_Fluorescence_ImagingThis breakthrough technology introduces Spectrally Interpolated Background Reduction (SIBR), a novel process that enables the rapid and efficient calculation of fluorescence signals from individual probes in complex, multi-labeled samples. Unlike traditional methods that require extensive computational power, SIBR provides real-time unmixing of signals from more than eight distinct fluorophores, dramatically simplifying fluorescence imaging workflows. By combining speed, precision, and scalability, SIBR transforms fluorescence imaging into a more accessible and streamlined process. Researcher...Mon, 22 Sep 2025 08:44:04 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Rapid_Spectral_Unmixing_Using_Spectrally_Interpolated_Background_Reduction_(SIBR)_for_Fluorescence_ImagingTAB-5077https://nih.technologypublisher.com/tech/Innovative_Antibody_Conjugates_for_Targeted_TherapyThis advanced technology introduces innovative antibody conjugates that redefine the possibilities of targeted therapy. By coupling therapeutic agents to engineered antibodies with highly specific binding sites, these conjugates deliver treatments directly to diseased cells while sparing healthy tissues. The result is a powerful increase in treatment efficacy, accompanied by a meaningful reduction in side effects. Designed with cutting-edge engineering techniques, the platform offers exceptional versatility, enabling adaptation across a wide range of therapeutic areas. Its greatest potential ...Mon, 22 Sep 2025 08:38:27 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Innovative_Antibody_Conjugates_for_Targeted_TherapyTAB-5076https://nih.technologypublisher.com/tech/Innovative_Antibody_Conjugates_for_Targeted_TherapeuticsThis cutting-edge technology leverages innovative conjugated antibodies to transform the way diseases are treated. By engineering antibodies to deliver therapeutic agents directly to specific cells, this approach offers a powerful combination of precision, potency, and safety. Unlike traditional therapies that often impact healthy tissues and cause significant side effects, these conjugated antibodies provide highly targeted delivery, ensuring that treatment is concentrated where it is needed most. This next-generation strategy addresses the critical limitations of conventional treatments by ...Mon, 22 Sep 2025 08:26:44 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Innovative_Antibody_Conjugates_for_Targeted_TherapeuticsTAB-5074https://nih.technologypublisher.com/tech/Selective_Expansion_of_Engineered_TCR-T_Cells_for_Use_in_Adoptive_Cell_ImmunotherapySummary: The National Cancer Institute (NCI) seeks capable licensees interested in commercializing T cell receptor (TCR)-engineered T cells expressing murine/human hybrid receptors. Description of Technology: TCR-T therapies, particularly those targeting patient-specific neoantigens, remain a promising approach to the treatment metastatic cancers. Contemporary gene engineering techniques permit both the targeted integration of the exogenous receptor(s) and further genetic manipulation of the host cells to enhance persistence and performance following adoptive transfer (e.g., through disrupt...Mon, 25 Aug 2025 11:28:40 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Selective_Expansion_of_Engineered_TCR-T_Cells_for_Use_in_Adoptive_Cell_ImmunotherapyTAB-5073https://nih.technologypublisher.com/tech?title=Chimeric_Antigen_Receptors_Targeting_the_Gamma_Delta_(%ce%b3%ce%b4)_T-Cell_ReceptorMon, 25 Aug 2025 11:15:42 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech?title=Chimeric_Antigen_Receptors_Targeting_the_Gamma_Delta_(%ce%b3%ce%b4)_T-Cell_ReceptorTAB-5072https://nih.technologypublisher.com/tech/Method_of_Manufacturing_Papilloma_Infiltrating_Lymphocyte_(PIL)_Cell_Therapy_Products_as_a_Treatment_for_Patients_with_Chronic_Viral_Infection(s)Thu, 21 Aug 2025 13:53:32 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Method_of_Manufacturing_Papilloma_Infiltrating_Lymphocyte_(PIL)_Cell_Therapy_Products_as_a_Treatment_for_Patients_with_Chronic_Viral_Infection(s)TAB-5071https://nih.technologypublisher.com/tech/Method_of_Detecting_Circulating_Cell-Free_HPV_6_and_11_DNA_in_Patients_Afflicted_With_Diseases_Caused_by_Chronic_HPV_6_or_11_Infection_and_Use_ThereofSummary: The National Cancer Institute (NCI) and Frederick National Laboratory for Cancer Research (FNLCR) seek research co-development partners and/or licensees for commercial development of a novel liquid biopsy diagnostic for non-invasive detection of cell-free HPV 6 and 11 DNA for recurrent respiratory papillomatosis (RRP). Description of Technology: Recurrent respiratory papillomatosis (RRP), caused by chronic infection with human papillomavirus (HPV) types 6 and 11, is a rare but potentially fatal disease characterized by the growth of papillomas throughout the respiratory tract. Whil...Thu, 21 Aug 2025 08:39:27 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Method_of_Detecting_Circulating_Cell-Free_HPV_6_and_11_DNA_in_Patients_Afflicted_With_Diseases_Caused_by_Chronic_HPV_6_or_11_Infection_and_Use_ThereofTAB-5070https://nih.technologypublisher.com/tech/C8166-45_CellsTue, 19 Aug 2025 07:28:37 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/C8166-45_CellsTAB-5069https://nih.technologypublisher.com/tech/Chimeric_VLP_vaccines_to_Prevent_HTLV-1_InfectionSummary: The National Cancer Institute (NCI) seeks research co-development partners and/or licensees for Chimeric VLP Vaccines to Prevent HTLV-1 Infection. Description of Technology: There is currently no approved vaccine to prevent human T-cell leukemia virus type I (HTLV-1) infection, a highly oncogenic virus linked to serious diseases like adult T-cell leukemia/lymphoma (ATLL) and Tropical Spastic paraparesis /HTLV-1-Associated Myelopathy (HAM/TSP). Existing interventions are limited to behavioral prevention, leaving millions at risk, especially in underserved global regions. A safe and ...Tue, 12 Aug 2025 08:27:49 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Chimeric_VLP_vaccines_to_Prevent_HTLV-1_InfectionTAB-5068https://nih.technologypublisher.com/tech/T_Cell_Receptor_Targeting_HPV6_E2_and_a_Panel_of_Cos7_Cells_Expressing_Different_HLA_Class_I_Proteins_for_Use_in_Validation_and_Potency_StudiesMon, 28 Jul 2025 13:04:21 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/T_Cell_Receptor_Targeting_HPV6_E2_and_a_Panel_of_Cos7_Cells_Expressing_Different_HLA_Class_I_Proteins_for_Use_in_Validation_and_Potency_StudiesTAB-5067https://nih.technologypublisher.com/tech/A_conserved_viral_peptide_for_use_in_cancer_immunotherapySummary: The National Cancer Institute (NCI) seeks research co-development partners and/or licensees for viral peptide (CE1)-based therapeutics for HCC prevention and treatment. Description of Technology: Hepatocellular carcinoma (HCC) is a common and aggressive primary liver cancer. It develops mainly from at-risk individuals with underlying chronic liver diseases, such as hepatitis and cirrhosis. HCC is a leading cause of cancer-related death worldwide and its global incidence and mortality rate continues to rise. The current methods for early detection, surveillance and treatment are sub...Mon, 28 Jul 2025 07:10:44 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/A_conserved_viral_peptide_for_use_in_cancer_immunotherapyTAB-5066https://nih.technologypublisher.com/tech/Compositions_and_Methods_for_Producing_Dendritic_Cell-based_Vaccines_with_Enhanced_EfficacyTue, 15 Jul 2025 07:19:48 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Compositions_and_Methods_for_Producing_Dendritic_Cell-based_Vaccines_with_Enhanced_EfficacyTAB-5065https://nih.technologypublisher.com/tech?title=Enhanced_Tumor_Reactivity_of_T_Cells_Lacking_SIT1%2c_LAX1_or_TRAT1Summary: The Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) is actively seeking potential licensees interested in further developing these inhibitory transmembrane adapter proteins as targets for T-cell immunotherapy for the treatment of cancer, infectious diseases, and autoimmune diseases. Description of Technology: Cellular immunotherapy holds much promise for the treatment of cancer. However, certain cellular therapies have limited success because of immunosuppression in the tumor microenvironment. Thus, there is an unmet need for improved methods...Mon, 14 Jul 2025 10:35:22 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech?title=Enhanced_Tumor_Reactivity_of_T_Cells_Lacking_SIT1%2c_LAX1_or_TRAT1TAB-5064https://nih.technologypublisher.com/tech/Anti-Nucleoprotein_Crimean-Congo_Hemorrhagic_Fever_Virus_Monoclonal_Antibodies_for_Assay_CreationCrimean-Congo hemorrhagic fever (CCHF) is the most widespread form of viral hemorrhagic fever, found in Eastern and Southern Europe, the Mediterranean, northwestern China, central Asia, Africa, the Middle East, and the Indian subcontinent. Typically beginning with non-specific fever, myalgia, nausea, diarrhea, and general malaise, symptoms of infection with the tick-borne CCHF virus (CCHFV) can rapidly progress to hemorrhagic manifestations, with case fatality rates as high as 30-40% in some regions. Critically, there are no approved vaccines for CCHF, and prevention is limited to control of e...Thu, 03 Jul 2025 10:11:55 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Anti-Nucleoprotein_Crimean-Congo_Hemorrhagic_Fever_Virus_Monoclonal_Antibodies_for_Assay_CreationTAB-5063https://nih.technologypublisher.com/tech/Vascularized_Thyroid-on-a-Chip_for_Personalized_Drug_Screening_and_Disease_ModelingThu, 03 Jul 2025 06:20:36 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Vascularized_Thyroid-on-a-Chip_for_Personalized_Drug_Screening_and_Disease_ModelingTAB-5062https://nih.technologypublisher.com/tech/EV-D68_Monoclonal_Antibodies_Isolated_from_Immunized_Rhesus_MacaquesEnterovirus D68 (EV-D68) has been linked to the widespread outbreaks of respiratory illness and acute flaccid myelitis (AFM) in the United States and Europe in 2014, 2016, and 2018. Although EV-D68 is now the most frequently encountered enterovirus (41.1% of cases), with an estimated global prevalence of 4%, there are no specific, FDA-approved therapeutic interventions targeting this virus. Researchers at the Vaccine Research Center (VRC) of the National Institute of Allergy and Infectious Disease (NIAID) have identified four monoclonal antibodies that potently bind and neutralize multiple su...Wed, 02 Jul 2025 11:38:48 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/EV-D68_Monoclonal_Antibodies_Isolated_from_Immunized_Rhesus_MacaquesTAB-5057https://nih.technologypublisher.com/tech/Synergistic_Interactions_for_Improved_Cancer_TreatmentFri, 27 Jun 2025 07:28:28 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Synergistic_Interactions_for_Improved_Cancer_TreatmentTAB-5060https://nih.technologypublisher.com/tech/Establishment_and_characterization_of_the_A_1847_human_ovarian_carcinoma_lineSummary: The National Cancer Institute (NCI) seeks licensees for a tumorigenic cell line, A1847, from a patient with metastatic ovarian cancer. As a BRCA1 deficient cell line, it serves as a model to researchers studying cell cycle regulation, tumor suppression and effective drugs aiding in repair of DNA damage. Description of Technology: Mutations, such as loss of function, in the BRCA1 gene increase the risk of developing ovarian cancer. In its early stages, ovarian cancer may not cause any definitive symptoms but can rapidly progress within a year to advanced stage. This metastatic growt...Fri, 27 Jun 2025 07:01:35 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Establishment_and_characterization_of_the_A_1847_human_ovarian_carcinoma_lineTAB-5061https://nih.technologypublisher.com/tech/Discovery_of_potent_and_selective_D3_antagonist_with_alleviated_hERG_liability_and_optimized_pharmacokinetic_propertiesFri, 13 Jun 2025 05:33:28 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Discovery_of_potent_and_selective_D3_antagonist_with_alleviated_hERG_liability_and_optimized_pharmacokinetic_propertiesTAB-3845https://nih.technologypublisher.com/tech?title=P2Y14_Receptor_Antagonists_for_the_Treatment_of_Inflammatory_Diseases%2c_Including_Pulmonary_and_Renal_Conditions_and_Chronic_PainThis technology includes the development of selective P2Y14R antagonists for the treatment of asthma, sterile inflammation of the kidney, diabetes, and neurodegeneration. The P2Y14 receptor (P2Y14R) is a target for the treatment of inflammatory diseases, including pulmonary and renal conditions. Selective P2Y14R antagonists have demonstrated efficacy in animal models of asthma, pain, diabetes, and acute kidney injury. However, the prototypical antagonist is not optimal for in vivo administration, as it displays a low oral bioavailability. This invention includes P2Y14R antagonists that contain...Wed, 11 Jun 2025 14:42:16 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech?title=P2Y14_Receptor_Antagonists_for_the_Treatment_of_Inflammatory_Diseases%2c_Including_Pulmonary_and_Renal_Conditions_and_Chronic_PainTAB-5058https://nih.technologypublisher.com/tech?title=First_in_class_Small_Molecule_Agonists_of_the_mammalian_Relaxin_family_receptor_1_(RXFP1)_and_use_in_treatment_of_cancer%2c_fibrotic%2c_and_vascular_disorders_(HHS_Ref_No._E-145-2024-0-US-02)It is well documented in literature that activation of RXFP1 by relaxin induces: 1) up-regulation of the endothelin system which leads to vasodilation; 2) extracellular matrix remodeling through regulation of collagen deposition, cell invasiveness, proliferation, and overall tissue homeostasis; 3) a moderation of inflammation by reducing levels of inflammatory cytokines, such as TNF-a and TGF-b; and 4) angiogenesis by activating transcription of VEGF. The present invention is directed to novel relaxin receptor (RFXP1 receptor) small molecule agonists useful for treating relaxin-related disord...Thu, 29 May 2025 12:54:47 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech?title=First_in_class_Small_Molecule_Agonists_of_the_mammalian_Relaxin_family_receptor_1_(RXFP1)_and_use_in_treatment_of_cancer%2c_fibrotic%2c_and_vascular_disorders_(HHS_Ref_No._E-145-2024-0-US-02)TAB-4595https://nih.technologypublisher.com/tech/Antibodies_to_TMC1_Protein_for_Hearing_LossThis technology includes antibodies for TMC1 protein as a treatment for hearing loss. TMC1 is one of the common genes causing hereditary hearing loss. Our laboratory used synthetic peptides corresponding to the TMC1 protein to immunize rabbits. The resulting antisera were shown to bind to TMC1 protein expressed in heterologous expression systems. TMC1 protein is required for the transduction of sound into electrical impulses in inner ear sensory cells.Mon, 19 May 2025 05:33:33 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Antibodies_to_TMC1_Protein_for_Hearing_LossTAB-5004https://nih.technologypublisher.com/tech/PET_Imaging_Agents_for_Fungal_InfectionsFri, 09 May 2025 13:01:01 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/PET_Imaging_Agents_for_Fungal_InfectionsTAB-5045https://nih.technologypublisher.com/tech/Fluorophthalimides_as_Anti-inflammatory_Agents_for_Systemic_and_Neurodegenerative_DisorderSummary: The National Institute on Aging (NIA) seeks research co-development partners and/or licensees for the pre-clinical and clinical development of the compounds as anti-inflammatory therapeutics for systemic and neurodegenerative disorders. Description of Technology: Numerous systemic, as well as neurological disorders, have a hallmark inflammatory element that can drive disease progression. However, the use of currently available anti-inflammatory agents have failed to demonstrate efficacy as potential treatment for systemic and neurological disorders in clinical trials. The immunomo...Fri, 02 May 2025 10:11:16 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Fluorophthalimides_as_Anti-inflammatory_Agents_for_Systemic_and_Neurodegenerative_DisorderTAB-5046https://nih.technologypublisher.com/tech?title=4-Amino-2-(piperidin-3-yl)isoindoline-1%2c3-diones_as_Anti-inflammatory_Agents_for_Systemic_Degenerative_and_Neurodegenerative_DisordersMon, 28 Apr 2025 09:11:13 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech?title=4-Amino-2-(piperidin-3-yl)isoindoline-1%2c3-diones_as_Anti-inflammatory_Agents_for_Systemic_Degenerative_and_Neurodegenerative_DisordersTAB-5026https://nih.technologypublisher.com/tech/Bioplatform_to_Identify_and_Characterize_Pathogens_and_Therapies_against_Tuberculosis_and_Other_Granulomatous_Diseases.Treatment for human tuberculosis (TB) and other granulomatous diseases would benefit from high- throughput screening (HTS)-compatible platform replicating physiological conditions in hallmark granuloma lesions. However, currently available screening platforms and 2-D and 3-D cell culture systems lack throughput and key features, and relevant microenvironments present in human TB granulomas, such as the formation of well-organized tuberculoma structure, granuloma lesions, biochemical and physiological gradients, diverse forms, and development of features like enhanced central hypoxia, necrosis,...Thu, 24 Apr 2025 13:39:14 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Bioplatform_to_Identify_and_Characterize_Pathogens_and_Therapies_against_Tuberculosis_and_Other_Granulomatous_Diseases.TAB-3944https://nih.technologypublisher.com/tech/Margaric_Acid_Decreases_PIEZO2_Mediated_PainAbstract: Some existing therapies for treatment of pain are administered systematically and have significant side effects, such as addiction and drowsiness. Alternative therapy that does not impair normal touch function could be used to treat pain caused by mechanical injury or chronic inflammation. Administration of margaric acid was shown to ameliorate pain in mouse models of pain. In vitro data shows that margaric acid counteracts PIEZO2 (Piezo-type mechanosensitive ion channel component 2) potentiation evoked by bradykinin (i.e. a peptide that promotes inflammation) by reducing the mechan...Mon, 10 Mar 2025 07:20:32 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Margaric_Acid_Decreases_PIEZO2_Mediated_PainTAB-3794https://nih.technologypublisher.com/tech?title=In-vivo_System_to_Interrogate_the_Functions_of_Mucous_Membranes_and_Identify_Mucin%2fGlycan_Mimetics_and_JAK%2fSTAT_Inhibitors_for_the_Treatment_of_Diseases_of_the_Oral_Cavity_and_Digestive_TractThis technology includes a Drosophila mutant strain that can be used as an in vivo model for diseases of the oral cavity and digestive tract (Sjogren's syndrome, colitis, colon cancer, inflammatory bowel disease), where the mucous membrane is disrupted or non-functional. This mutant lacks a mucous membrane and displays epithelial cell damage, uncontrolled cell proliferation and the up-regulation of conserved signaling pathways (JAK/STAT). Specifically, this mutant could be used to screen for compounds that either: 1) act to minimize damage to the epithelial cells in vivo; 2) stop uncontrolled ...Thu, 26 Dec 2024 11:14:14 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech?title=In-vivo_System_to_Interrogate_the_Functions_of_Mucous_Membranes_and_Identify_Mucin%2fGlycan_Mimetics_and_JAK%2fSTAT_Inhibitors_for_the_Treatment_of_Diseases_of_the_Oral_Cavity_and_Digestive_TractTAB-4982https://nih.technologypublisher.com/tech/Fluorinated_MU-Opioid_Receptor_AgonistsFri, 20 Dec 2024 16:59:45 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Fluorinated_MU-Opioid_Receptor_AgonistsTAB-4535https://nih.technologypublisher.com/tech/Advanced_Human_Cell_Line_Technology_for_RSV_Replication_Complex_Production_and_Antiviral_Drug_DiscoveryTue, 10 Dec 2024 20:03:28 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Advanced_Human_Cell_Line_Technology_for_RSV_Replication_Complex_Production_and_Antiviral_Drug_DiscoveryTAB-4534https://nih.technologypublisher.com/tech/Enhanced_S10-3_Cell_Line_for_Advanced_Hepatitis_E_Virus_Research_and_Therapeutic_DevelopmentThe Huh-7 cell line underwent a detailed sub-cloning process to enhance its effectiveness for Hepatitis E Virus (HEV) infection studies. This involved diluting and culturing cells in 96-well plates until confluent monolayers formed, followed by selection and expansion of the most suitable cells. The sub-clone S10-3, derived from this process, was identified as the most efficient for transfection and infection by HEV. Prepared using standard cell culture methods, these S10-3 cells from the Huh-7 line demonstrated superior abilities in both transfectability and infectivity, making them highly va...Tue, 10 Dec 2024 20:01:41 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Enhanced_S10-3_Cell_Line_for_Advanced_Hepatitis_E_Virus_Research_and_Therapeutic_DevelopmentTAB-4963https://nih.technologypublisher.com/tech/A_Fundamental_Tool_for_Efficient_Recovery_of_RNA_Viruses_through_Reverse_GeneticsBSR T7/5 cells represent a foundational advancement in virology, offering a robust platform for the recovery of RNA viruses via reverse genetics. Established over 20 years ago, these cells have proven instrumental in the recovery of a wide array of RNA viruses, particularly those belonging to the mononegavirales order. By enabling the insertion of antigenome sequences into cDNA plasmids under a T7 RNA polymerase promoter, BSR T7/5 cells facilitate the transcription of RNA antigenomes and mRNA encoding RNP elements, leading to the assembly of infectious viruses. Notably, this system does not re...Tue, 10 Dec 2024 19:53:26 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/A_Fundamental_Tool_for_Efficient_Recovery_of_RNA_Viruses_through_Reverse_GeneticsTAB-4928https://nih.technologypublisher.com/tech/A_Key_Advancement_for_Human_Norovirus_Research_and_Reverse_GeneticsThe HEK293T/T7 cell line is a novel development in virology research, particularly for studying human noroviruses. This cell line expresses the T7 RNA polymerase, a key enzyme used in reverse genetics systems. Unlike existing technologies, the HEK293T/T7 cell line offers the unique advantage of being able to produce functional T7 RNA polymerase, which is essential for driving transcription from T7 promoters. This capability opens up new possibilities for studying human noroviruses, which cannot be propagated in cell culture, and may facilitate the development of a reverse genetics system for t...Tue, 10 Dec 2024 19:52:34 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/A_Key_Advancement_for_Human_Norovirus_Research_and_Reverse_GeneticsTAB-4913https://nih.technologypublisher.com/tech/Bispecific_Antibody_Targeting_Anthrax_Toxins_and_Capsule_for_Enhanced_BiodefenseThe technology focuses on the development of a tetravalent bispecific antibody effective against Bacillus anthracis, the bacterium responsible for anthrax. This antibody combines the specificities of two monoclonal antibodies (mAbs): one targeting anthrax protective antigen (PA) and the other targeting the bacterial capsule. The anti-PA mAb shows potent toxin-neutralizing activity, while the anti-capsule mAb efficiently kills anthrax bacteria. By merging these specificities into a single lgG framework, the resulting bispecific antibody can simultaneously neutralize toxins and kill bacteria, po...Tue, 10 Dec 2024 19:51:46 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Bispecific_Antibody_Targeting_Anthrax_Toxins_and_Capsule_for_Enhanced_BiodefenseTAB-4883https://nih.technologypublisher.com/tech?title=Advancements_in_Postexposure_Prophylaxis%3a_Evaluating_High-Potency_Rabies-Neutralizing_Monoclonal_AntibodiesThis technology represents a significant advancement in the field of rabies prevention, focusing on the development of highly potent rabies-neutralizing monoclonal antibodies (mAbs) for use in postexposure prophylaxis (PEP). With two mAbs, F2 and G5a, displaying exceptional neutralizing titers of 1154 and 3462 International Units (IUs) per milligram, respectively, these antibodies have the potential to offer enhanced protection against rabies when administered alongside rabies vaccines. The production of these mAbs involves genetic engineering of mammalian cell lines, enabling their consistent...Tue, 10 Dec 2024 19:50:37 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech?title=Advancements_in_Postexposure_Prophylaxis%3a_Evaluating_High-Potency_Rabies-Neutralizing_Monoclonal_AntibodiesTAB-4855https://nih.technologypublisher.com/tech?title=Advancing_VZV_Antibody_Detection%3a_A_High-Throughput_LIPS_Assay_for_Varicella_Vaccine_RecipientsThe technology described is a sophisticated and high-throughput luciferase immunoprecipitation system (LIPS) assay designed to detect antibodies specific to Varicella-zoster virus (VZV) glycoprotein E (gE). By transfecting cells with VZV protein-Renilla luciferase fusion protein constructs and subsequently performing immunoprecipitations with protein A/G beads, this innovative assay enables the quantitative measurement of VZV gE antibody levels in blood serum samples. Notably, it demonstrates a sensitivity comparable to the established fluorescent antibody to membrane antigen test (FAMA), maki...Tue, 10 Dec 2024 19:49:27 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech?title=Advancing_VZV_Antibody_Detection%3a_A_High-Throughput_LIPS_Assay_for_Varicella_Vaccine_RecipientsTAB-4852https://nih.technologypublisher.com/tech/Optimizing_RSV_Infection_Monitoring_and_High-Throughput_Screening_Through_GFP_Expression_in_the_First-Gene_Position_of_Respiratory_Syncytial_Virus_(RSV)_Strain_A2In this technology, researchers have engineered a modified version of Respiratory Syncytial Virus (RSV) strain A2 using reverse genetics to incorporate green fluorescent protein (GFP) into the first-gene position. This genetic modification allows for the efficient monitoring of RSV infection and the screening of potential chemical inhibitors. The GFP expression can be easily detected through fluorescence microscopy in live or fixed cells, providing a sensitive tool for both research and drug discovery. Importantly, placing GFP in the first-gene position minimizes interference with the expressi...Tue, 10 Dec 2024 19:48:39 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Optimizing_RSV_Infection_Monitoring_and_High-Throughput_Screening_Through_GFP_Expression_in_the_First-Gene_Position_of_Respiratory_Syncytial_Virus_(RSV)_Strain_A2TAB-4851https://nih.technologypublisher.com/tech?title=Enhanced_GFP-Expressing_Human_Metapneumovirus_(HMPV)%3a_A_Versatile_Tool_for_Virology_Research_and_Antiviral_Drug_ScreeningThe technology involves genetically engineering Human Metapneumovirus (HMPV) to express enhanced green fluorescent protein (GFP), enabling the monitoring of virus infection and gene expression through GFP fluorescence. This system serves as a sensitive and versatile tool for virology research, antiviral drug screening, and diagnostic applications. Researchers can use it to study HMPV behavior in real-time, identify potential antiviral compounds, and quantify viral particles in samples, making it invaluable for advancing our understanding of HMPV infections and the development of antiviral inte...Tue, 10 Dec 2024 19:47:46 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech?title=Enhanced_GFP-Expressing_Human_Metapneumovirus_(HMPV)%3a_A_Versatile_Tool_for_Virology_Research_and_Antiviral_Drug_ScreeningTAB-4847https://nih.technologypublisher.com/tech/Development_of_a_High-Throughput_Screening_Tool_for_RSV_Inhibition_Using_Engineered_RSV_Expressing_GFP_and_Luciferase_GenesThe technology involves the genetic engineering of Respiratory Syncytial Virus (RSV) to express two additional genes, green fluorescent protein (GFP) and Renilla luciferase, from different positions within the viral genome. GFP serves as a visual marker for RSV infection, allowing researchers to monitor and track infected cells using fluorescence microscopy, while luciferase functions as a highly sensitive reporter gene that enables quantitative assessment of viral replication through enzymatic assays. The engineered RSV strain also contains a mutation in the RSV G protein, making it a valuabl...Tue, 10 Dec 2024 19:46:40 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Development_of_a_High-Throughput_Screening_Tool_for_RSV_Inhibition_Using_Engineered_RSV_Expressing_GFP_and_Luciferase_GenesTAB-4832https://nih.technologypublisher.com/tech?title=Replicative-Defective_Mutant_Human_Cytomegalovirus%3a_Potential_Applications_in_Vaccinology_and_Cancer_ImmunotherapyThe potential applications of a replicative-defective mutant form of human cytomegalovirus (HCMV) are significant in the fields of vaccinology and cancer immunotherapy. This innovative approach involves engineering a mutant HCMV that can selectively target specific cells. Firstly, it holds promise as a vaccine candidate for protecting against HCMV infection, given the success of a similar strategy against herpes simplex virus in animal models. Secondly, as an immunotherapeutic agent for cancer treatment, the mutant HCMV could stimulate the immune system to recognize and combat cancer cells, an...Tue, 10 Dec 2024 19:45:27 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech?title=Replicative-Defective_Mutant_Human_Cytomegalovirus%3a_Potential_Applications_in_Vaccinology_and_Cancer_ImmunotherapyTAB-4878https://nih.technologypublisher.com/tech?title=Transgenic_Mouse_Models_for_Studying_HLA-B57%3a01_and_HLA-B15%3a02_Linked_Immune_Responses_and_Hypersensitivity_ReactionsTransgenic mouse models expressing human HLA-B57:01 and HLA-B15:02 molecules have emerged as invaluable tools for unraveling the intricacies of immune responses and hypersensitivity reactions. The major histocompatibility complex (MHC) encoded proteins play a pivotal role in the immune system by presenting peptide fragments to T lymphocytes, and HLA-B57:01 has been associated with severe hypersensitivity reactions triggered by abacavir, a widely used anti-retroviral drug. These transgenic mice, with HLA-B57:01 broadly expressed on their nucleated cells, provide a unique platform for investigat...Tue, 10 Dec 2024 09:39:42 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech?title=Transgenic_Mouse_Models_for_Studying_HLA-B57%3a01_and_HLA-B15%3a02_Linked_Immune_Responses_and_Hypersensitivity_ReactionsTAB-4861https://nih.technologypublisher.com/tech?title=TACSTD2_in_HCV_Infection_and_Hepatocellular_Carcinoma%3a_Transcriptomics_InsightsTue, 10 Dec 2024 09:30:12 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech?title=TACSTD2_in_HCV_Infection_and_Hepatocellular_Carcinoma%3a_Transcriptomics_InsightsTAB-4834https://nih.technologypublisher.com/tech/Soluble_Antigen-Based_ELISA_for_the_Detection_of_B._malayi_InfectionsTue, 10 Dec 2024 09:27:34 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Soluble_Antigen-Based_ELISA_for_the_Detection_of_B._malayi_InfectionsTAB-4898https://nih.technologypublisher.com/tech?title=Characterization_and_Comparison_of_LAD2_and_LADR_Mast_Cell_Lines%3a_Insights_into_Mastocytosis_and_HIV_InfectionLAD2 and LADR cell lines are invaluable tools in mast cell research, offering insights into mastocytosis and immune responses. Derived from CD34+ cells, LAD2 cells have been extensively used for over 18 years, while LADR cells, a newer variant, exhibit enhanced characteristics such as larger size, increased granulation, and faster doubling time. Both cell lines release granular contents upon FceRI aggregation and can be infected with various strains of HIV. LADR cells, in particular, show greater expression of certain surface receptors and mRNA compared to LAD2 cells. Additionally, gene expres...Tue, 10 Dec 2024 09:24:23 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech?title=Characterization_and_Comparison_of_LAD2_and_LADR_Mast_Cell_Lines%3a_Insights_into_Mastocytosis_and_HIV_InfectionTAB-5023https://nih.technologypublisher.com/tech/Machine_Learning_Model_for_the_Prioritization_of_Cancer_NeoepitopesFri, 29 Nov 2024 17:09:18 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Machine_Learning_Model_for_the_Prioritization_of_Cancer_NeoepitopesTAB-5022https://nih.technologypublisher.com/tech/Fully_Human_Chimeric_Antigen_Receptors_Against_CD276_for_the_Treatment_of_Solid_TumorsFri, 29 Nov 2024 17:06:16 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Fully_Human_Chimeric_Antigen_Receptors_Against_CD276_for_the_Treatment_of_Solid_TumorsTAB-5007https://nih.technologypublisher.com/tech/Methods_of_Detecting_Loss_of_Heterozygosity_and_Damaging_Mutations_in_Immune-Related_Genes_Using_Liquid_BiopsiesFri, 29 Nov 2024 17:01:52 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Methods_of_Detecting_Loss_of_Heterozygosity_and_Damaging_Mutations_in_Immune-Related_Genes_Using_Liquid_BiopsiesTAB-5032https://nih.technologypublisher.com/tech?title=Degrader_Molecules_for_hRpn13Pru%2c_PCLAF%2c_RRM2_and_Other_KEN_Box-containing_ProteinsSummary: The National Cancer Institute (NCI) seeks research co-development partners and/or licensees for three small molecules that target hRpn13, an overexpressed protein in certain cancers. Description of Technology: Over 35,000 new cases of multiple myeloma are diagnosed each year in the US. Standard of care and experimental therapies include monoclonal antibodies, immunomodulatory drugs, proteasome inhibitors and corticosteroids. While these therapies can be effective, a majority of patients experience relapse within four years. New proteasome-targeting drugs are needed to improve curr...Wed, 27 Nov 2024 04:38:47 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech?title=Degrader_Molecules_for_hRpn13Pru%2c_PCLAF%2c_RRM2_and_Other_KEN_Box-containing_ProteinsTAB-4990https://nih.technologypublisher.com/tech/Suppression_Of_Uveitis_By_A_STAT3_Single_Domain_AntibodyThu, 21 Nov 2024 20:43:27 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Suppression_Of_Uveitis_By_A_STAT3_Single_Domain_AntibodyTAB-5024https://nih.technologypublisher.com/tech/Immunotherapy_Delivery_System_to_Improve_Organ_Transplantation_OutcomesWed, 13 Nov 2024 01:13:44 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Immunotherapy_Delivery_System_to_Improve_Organ_Transplantation_OutcomesTAB-5029https://nih.technologypublisher.com/tech?title=NeoExpansion_%e2%80%93_A_Method_to_Identify_and_Selectively_Expand_Neoantigen-specific_T_Cells%2c_Including_T_Cell_Receptor-engineered_T_Cells_and_Tumor_Infiltrating_LymphocytesTue, 12 Nov 2024 20:56:10 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech?title=NeoExpansion_%e2%80%93_A_Method_to_Identify_and_Selectively_Expand_Neoantigen-specific_T_Cells%2c_Including_T_Cell_Receptor-engineered_T_Cells_and_Tumor_Infiltrating_LymphocytesTAB-5025https://nih.technologypublisher.com/tech/Peptide_Hydrogels_for_Delivery_of_Immunosuppressive_Drugs_and_Uses_ThereofWed, 06 Nov 2024 19:23:01 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Peptide_Hydrogels_for_Delivery_of_Immunosuppressive_Drugs_and_Uses_ThereofTAB-5028https://nih.technologypublisher.com/tech?title=HLA-class_II-restricted_T_Cell_Receptors_for_PIK3CA_%e2%80%9cHotspot%e2%80%9d_Mutations%2c_E545K_and_N345KWed, 06 Nov 2024 18:48:13 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech?title=HLA-class_II-restricted_T_Cell_Receptors_for_PIK3CA_%e2%80%9cHotspot%e2%80%9d_Mutations%2c_E545K_and_N345KTAB-5021https://nih.technologypublisher.com/tech/Novel_Kinase_Inhibitory_ThiazinesMon, 04 Nov 2024 10:30:05 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Novel_Kinase_Inhibitory_ThiazinesTAB-5005https://nih.technologypublisher.com/tech/Monoclonal_Antibodies_That_Bind_to_the_Underside_of_Influenza_Viral_NeuraminidaseThu, 31 Oct 2024 08:38:51 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Monoclonal_Antibodies_That_Bind_to_the_Underside_of_Influenza_Viral_NeuraminidaseTAB-5020https://nih.technologypublisher.com/tech/Reverse_Thiazine_Kinase_InhibitorsWed, 30 Oct 2024 11:18:02 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Reverse_Thiazine_Kinase_InhibitorsTAB-5019https://nih.technologypublisher.com/tech/Novel_Kinase_Inhibitory_AplithianinesTue, 29 Oct 2024 21:44:12 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Novel_Kinase_Inhibitory_AplithianinesTAB-5010https://nih.technologypublisher.com/tech/Single_Source-Detector_Separation_Approach_to_Calculate_Tissue_Oxygen_SaturationMon, 30 Sep 2024 20:51:15 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Single_Source-Detector_Separation_Approach_to_Calculate_Tissue_Oxygen_SaturationTAB-4079https://nih.technologypublisher.com/tech/Oxynitidine_Derivatives_Useful_as_Inhibitors_of_Topoisomerase_IB_(TOP1)_and_Tyrosyl-DNA_Phosphodiesterase_1_(TDP1)_for_Treating_CancerFri, 13 Sep 2024 11:31:27 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Oxynitidine_Derivatives_Useful_as_Inhibitors_of_Topoisomerase_IB_(TOP1)_and_Tyrosyl-DNA_Phosphodiesterase_1_(TDP1)_for_Treating_CancerTAB-4993https://nih.technologypublisher.com/tech?title=Improved_Methods_For_Cryopreservation_Of_Cells%2c_Tissues%2c_And_OrgansThu, 15 Aug 2024 02:16:59 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech?title=Improved_Methods_For_Cryopreservation_Of_Cells%2c_Tissues%2c_And_OrgansTAB-4992https://nih.technologypublisher.com/tech/Using_Artificial_Intelligence_To_Diagnose_UveitisWed, 14 Aug 2024 20:46:56 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Using_Artificial_Intelligence_To_Diagnose_UveitisTAB-4995https://nih.technologypublisher.com/tech/Using_Artificial_Intelligence_To_Predict_The_Risk_Of_Age-Related_Macular_DegenerationWed, 14 Aug 2024 20:45:00 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Using_Artificial_Intelligence_To_Predict_The_Risk_Of_Age-Related_Macular_DegenerationTAB-4991https://nih.technologypublisher.com/tech/TYROSINASE_Gene_Therapy_for_Oculocutaneous_Albinism_type_1AWed, 14 Aug 2024 20:42:18 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/TYROSINASE_Gene_Therapy_for_Oculocutaneous_Albinism_type_1ATAB-4996https://nih.technologypublisher.com/tech/Interleukin-27_Producing_B-Cell_Population_and_Uses_ThereofWed, 14 Aug 2024 20:39:22 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Interleukin-27_Producing_B-Cell_Population_and_Uses_ThereofTAB-4998https://nih.technologypublisher.com/tech/Using_FDA-approved_Small_Molecule_Drug_Reserpine_and_related_compounds_(especially_Halofantrine)_To_Protect_Photoreceptors_In_Inherited_Retinal_Degenerations_And_Age-Related_Macular_DegenerationMon, 05 Aug 2024 20:55:56 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Using_FDA-approved_Small_Molecule_Drug_Reserpine_and_related_compounds_(especially_Halofantrine)_To_Protect_Photoreceptors_In_Inherited_Retinal_Degenerations_And_Age-Related_Macular_DegenerationTAB-4596https://nih.technologypublisher.com/tech/Affinity_Purified_Polyclonal_Antibody_Against_Vangl2_(Van_Gogh-like)_as_a_Research_Tool_ProductThis technology includes an antibody that enables the identification and isolation of the protein and protein partners of Vangl2 for application by western blotting, immunoprecipitation and immunocytochemistry. Because planar cell polarity signaling disruption leads to direct or indirect pathologies including malformation of the neural tube, mental retardation, disruption of sensory functions (hearing, balance, vision), cancers (polykystic kidneys disease), or cardiac malformations and disruption of chirality (situs inversus), we can envision that the antibody could be used as a diagnostic to...Tue, 26 Mar 2024 23:12:23 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Affinity_Purified_Polyclonal_Antibody_Against_Vangl2_(Van_Gogh-like)_as_a_Research_Tool_ProductTAB-4547https://nih.technologypublisher.com/tech/Mass_Spectrometry_Derived_Protein_Biomarkers_of_Atherosclerotic_Cardiovascular_Disease_RiskThis technology includes a combination of protein biomarkers and clinical risk factors to be used as an In Vitro Diagnostic Multivariate Index Assay (IVDMIA) that can improve the identification of individuals at high risk for atherosclerotic cardiovascular disease (ASCVD) and myocardial infarction (MI). Incorporation of novel protein biomarkers of ASCVD risk into risk assessment algorithms may improve their ability to identify individuals at high risk for ASCVD. We conducted mass spectrometry (iTRAQ) profiling of 861 circulating plasma proteins in 135 MI cases from the Framingham Heart Study (...Tue, 26 Mar 2024 23:11:31 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Mass_Spectrometry_Derived_Protein_Biomarkers_of_Atherosclerotic_Cardiovascular_Disease_RiskTAB-4546https://nih.technologypublisher.com/tech/Immunoassay-derived_Protein_Biomarkers_of_Atherosclerotic_Cardiovascular_Disease_RiskThis technology includes a combination of 6 protein biomarkers and clinical risk factors to be used as an In Vitro Diagnostic Multivariate Index Assay (IVDMIA) that can improve the identification of individuals at high risk for atherosclerotic cardiovascular disease (ASCVD). Incorporation of novel protein biomarkers of ASCVD risk into risk assessment algorithms may improve their ability to identify individuals at high risk for ASCVD. We conducted an immunoassay profiling of 47 circulating plasma proteins in over 5,000 participants from the Framingham Heart Study (FHS) free of overt cardiovascu...Tue, 26 Mar 2024 23:10:49 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Immunoassay-derived_Protein_Biomarkers_of_Atherosclerotic_Cardiovascular_Disease_RiskTAB-4542https://nih.technologypublisher.com/tech/Bivalent_Tn5_Complex_and_its_Application_to_Map_Enhancer-Promoter_Interactions_for_Use_in_DiagnosticsThis technology includes a new reagent, termed bivalent Tn5 complex, and applied it to mapping genome-wide enhancer-promoter interactions to be utilized for disease diagnostics. Chromatin structure is critical for regulating transcription in normal development and disease states. In particular, the interaction between enhancers and promotes are essential for the temporospatial control of gene expression.Tue, 26 Mar 2024 23:09:04 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Bivalent_Tn5_Complex_and_its_Application_to_Map_Enhancer-Promoter_Interactions_for_Use_in_DiagnosticsTAB-4588https://nih.technologypublisher.com/tech/PET_Imaging_of_lntegrin_Expression_with_Suitably_Labeled_RGD_Peptides_for_Multiple_Diagnostic_PurposesThis technology includes a number of dimeric RGD peptides which been developed and labeled with various PET isotopes (1BF, 68Ga, and 64Cu) for imaging integrin expression in cancer, inflammation, rheumatoid arthritis, myocardial infarct, stroke and traumatic injury. A number of these peptides have been translated into clinic for diagnosis and therapy response monitoring.Tue, 26 Mar 2024 23:08:14 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/PET_Imaging_of_lntegrin_Expression_with_Suitably_Labeled_RGD_Peptides_for_Multiple_Diagnostic_PurposesTAB-4539https://nih.technologypublisher.com/tech/Transgene_Free_Non-human_Primate_Induced_Pluripotent_Stem_Cells_(iPSCs)_for_Use_in_Pre-clinical_Regenerative_Medicine_ResearchThis technology includes rhesus macaque induced pluripotent stem cells (iPSCs) lines from multiple animals and various types of cells to establish this pre-clinical model. iPSCs are a type of pluripotent stem cell that can be generated from adult somatic cells. The iPSC technology holds great potential for regenerative medicine. Before clinical application, it is critical to evaluate safety and efficacy in a clinically-relevant animal model. We propose that non-human primate models are particularly relevant to test iPSC-based cell therapies.Tue, 26 Mar 2024 23:07:37 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Transgene_Free_Non-human_Primate_Induced_Pluripotent_Stem_Cells_(iPSCs)_for_Use_in_Pre-clinical_Regenerative_Medicine_ResearchTAB-4537https://nih.technologypublisher.com/tech/An_Automated_System_for_Myocardial_Perfusion_Mapping_and_Machine_Diagnosis_to_Detect_Ischemic_Heart_Disease_with_First-pass_Perfusion_Cardiac_Magnetic_Resonance_ImagingThis technology includes a fully automated computer aided diagnosis system to quantify myocardial blood flow (MBF) and myocardial perfusion reserve (MPR) pixel maps from the first-pass contrast-enhanced cardiac magnetic resonance (CMR) perfusion images. This system performs automated image registration, motion compensation, segmentation, and modeling to extract quantitative features from different myocardial regions of interest. It then performs automated classification to detect potential lesions in the myocardium and generates analysis reports to summarize global and regional myocardial perf...Tue, 26 Mar 2024 23:06:43 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/An_Automated_System_for_Myocardial_Perfusion_Mapping_and_Machine_Diagnosis_to_Detect_Ischemic_Heart_Disease_with_First-pass_Perfusion_Cardiac_Magnetic_Resonance_ImagingTAB-4532https://nih.technologypublisher.com/tech?title=Immunogens%2c_Compositions%2c_and_Methods_for_the_Treatment_of_DyslipidemiaThis technology includes a novel vaccine for forming autoantibodies against apoC-III, a plasma enzyme that inhibits lipolysis. The vaccine can possibly be used to treat patients with high triglycerides and are at risk for pancreatitis and cardiovascular disease. This disclosure describes an ApoC3 immunogen that includes an antigenicApoC3 peptide linked to a bacteriophage virus-like-particle (VLP) immunogenic carrier.Tue, 26 Mar 2024 23:06:09 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech?title=Immunogens%2c_Compositions%2c_and_Methods_for_the_Treatment_of_DyslipidemiaTAB-4531https://nih.technologypublisher.com/tech/Electronic_Fringe_Scanning_for_the_Improvement_of_Medical_Imaging_TechnologyTue, 26 Mar 2024 23:05:21 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Electronic_Fringe_Scanning_for_the_Improvement_of_Medical_Imaging_TechnologyTAB-4529https://nih.technologypublisher.com/tech/Prazoles_as_Potential_Broad_Spectrum_Anti-viral_AgentsTue, 26 Mar 2024 23:04:09 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Prazoles_as_Potential_Broad_Spectrum_Anti-viral_AgentsTAB-4523https://nih.technologypublisher.com/tech/Encapsulation_of_Fluorescent_Nanodiamonds_into_Poly-dopamine_(PDA)_Shell_and_Further_Covalent_Functionalization_of_the_PDA_Shell_for_Diagnostic_Imaging_ApplicationsThis technology includes a new class of nanoparticles in the carbon family, fluorescent nanodiamonds (FNDs), exhibiting superb physical and chemical properties for diagnostic imaging applications. We have developed a simple, fast, and robust method to encapsulate FNDs in polydopamine that can be further functionalized. By integrating anatomical and molecular based imaging capabilities, multimodal nanoparticle probes are becoming important in the paradigm shift from conventional to future imaging technologies. FNDs provide a highly stable, biocompatible, and nontoxic multimodal nanoprobe for ef...Tue, 26 Mar 2024 23:03:11 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Encapsulation_of_Fluorescent_Nanodiamonds_into_Poly-dopamine_(PDA)_Shell_and_Further_Covalent_Functionalization_of_the_PDA_Shell_for_Diagnostic_Imaging_ApplicationsTAB-4522https://nih.technologypublisher.com/tech/Background-free_Imaging_by_Selective_Modulation_of_Nanodiamond_Fluorescence_Using_a_Magnetic_FieldThis technology includes the use of nanodiamonds to achieve background-free imaging. We present several techniques to reduce or eliminate background florescence by exploiting properties of the fluorescent nanodiamonds. In particular, magnetic field modulation of the fluorescence intensity offers a simple, robust, and easily adaptable method to obtain background free imaging in a variety of imaging modalities, i.e., fluorescence microscopy and wide field fluorescence animal imaging. The product would consist of a means of modulating a magnetic field in an imaging system combined with the fluore...Tue, 26 Mar 2024 23:02:34 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Background-free_Imaging_by_Selective_Modulation_of_Nanodiamond_Fluorescence_Using_a_Magnetic_FieldTAB-4519https://nih.technologypublisher.com/tech/3D_Bioprinting_of_Cardiac_Patch_with_Anisotropic_and_Perfusable_Architecture_for_the_Repair_of_Damaged_Cardiac_MuscleThis technology includes a novel cardiac patch which was 3D printed to repair damaged cardiac tissue. Based on biological and anatomical understanding of myocardial tissue, a novel 3D bioprinting technique was developed to directly fabricate the cellularized and vascularized cardiac patch with anisotropic fiber and perfusable vessel architecture. The design will integrate biomimetic aligned myocardial fibers and perfusable blood vessels to create a thick, functional cardiac patch, suitable for the human heart implantation. Due to the anisotropic contraction properties, it not only provides a p...Tue, 26 Mar 2024 23:02:00 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/3D_Bioprinting_of_Cardiac_Patch_with_Anisotropic_and_Perfusable_Architecture_for_the_Repair_of_Damaged_Cardiac_MuscleTAB-4518https://nih.technologypublisher.com/tech/A_Highly_Efficient_Differentiation_Protocol_for_Placental_Cells_Derived_from_Human_Pluripotent_Stem_Cells_for_Diagnostic_and_Therapeutic_ApplicationsThis technology includes in vitro-generated trophectoderm (TE) cells, which are ideal for modeling diseases of the placenta, drug screening, and cell-based therapies. The TE lineage which gives rise to placental cells during early human development. Derivation of definitive placental cells from human pluripotent stem cells in culture remains controversial and so far, placental cells can only be derived directly from primary placental tissue, which largely limits their access and study in the laboratory. This invention describes highly efficient TE differentiation, including cytotrophoblast and...Tue, 26 Mar 2024 23:01:23 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/A_Highly_Efficient_Differentiation_Protocol_for_Placental_Cells_Derived_from_Human_Pluripotent_Stem_Cells_for_Diagnostic_and_Therapeutic_ApplicationsTAB-4515https://nih.technologypublisher.com/tech/Systems_and_Methods_for_Retrieving_Implanted_MagnetsTue, 26 Mar 2024 23:00:08 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Systems_and_Methods_for_Retrieving_Implanted_MagnetsTAB-4512https://nih.technologypublisher.com/tech/Fluorogen-binding_RNA_Aptamers_for_Imaging_and_Analysis_of_RNATue, 26 Mar 2024 22:59:39 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Fluorogen-binding_RNA_Aptamers_for_Imaging_and_Analysis_of_RNATAB-4509https://nih.technologypublisher.com/tech/High_Relaxivity_Mulitivalent_Gadolinium_on_a_Peptide_Scaffold_for_Targeted_MRI_Applications_in_Disease_DiagnosisTue, 26 Mar 2024 22:59:03 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/High_Relaxivity_Mulitivalent_Gadolinium_on_a_Peptide_Scaffold_for_Targeted_MRI_Applications_in_Disease_DiagnosisTAB-4507https://nih.technologypublisher.com/tech/Novel_ApoC-11_Mimetic_Peptides_That_Activate_LPL_for_the_Treatment_of_ApoC-11_Deficiency_and_HypertriglyceridemiaThis technology includes a new class of synthetic peptides that activate Lipoprotein Lipase (LPL), a key plasma enzyme that lowers triglycerides. Mutations in apoC-II is a genetic cause of severe hypertriglyceridemia, which can lead to cardiovascular disease and pancreatitis. The last helical domain (3rd helix) of apoC-ll activates LPL, and we discovered by making a series of amino acids substitutions in the second helix to increase its ability to bind to lipoproteins that we were able to produce novel apoC-II mimetic peptides that potently activate LPL and are less likely to be immunogenic.Tue, 26 Mar 2024 22:58:18 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Novel_ApoC-11_Mimetic_Peptides_That_Activate_LPL_for_the_Treatment_of_ApoC-11_Deficiency_and_HypertriglyceridemiaTAB-4594https://nih.technologypublisher.com/tech?title=Development_of_High-Throughput_ELISA_Based_Binding_Assays_to_Detect_p53%2fp63%2fp73_Family_Protein-DNA_Interaction_in_the_96-well_Microplate_Format_for_Drug_Screening_and_Other_Clinical_and_Diagnostic_UsesThis technology includes ELISA based binding assays of p53, p63 or p73 provide possibilities to validate genome sequencing results, and allow the performance of more in-depth investigation to address scientific mechanisms, as well as to develop applications for high-throughput clinical and diagnosis usages. While quantitative p53 binding assays have been commercially developed, there is a lack of high-throughput method to detect binding activity of all three p53/p63/p73 family members, which are an important step for these transcription factors to perform their function. Targeting these transc...Tue, 26 Mar 2024 22:57:42 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech?title=Development_of_High-Throughput_ELISA_Based_Binding_Assays_to_Detect_p53%2fp63%2fp73_Family_Protein-DNA_Interaction_in_the_96-well_Microplate_Format_for_Drug_Screening_and_Other_Clinical_and_Diagnostic_UsesTAB-4593https://nih.technologypublisher.com/tech/Transgenic_Mouse_Expressing_Cre_for_the_Development_for_Delivery_of_Gene_TherapyThis technology includes a mouse model containing a hypothetical, previously undescribed, gene that we have proven is expressed in hair cells of the inner ear and few other tissues in the body. The hair-cell limited expression of Cre is a genetic tool for creating conditional mutations affecting hair cells almost exclusively. Hair cells are the sensory receptors of both the auditory system and the vestibular system in the ears of all vertebrates.Tue, 26 Mar 2024 22:57:12 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Transgenic_Mouse_Expressing_Cre_for_the_Development_for_Delivery_of_Gene_TherapyTAB-4504https://nih.technologypublisher.com/tech/Blocking_CD38_using_Daratumumab_F(ab)2_to_Protect_Natural_Killer_Cells_from_Daratumumab-induced_Apoptosis_and_Cell_Death_for_the_Treatment_of_Multiple_MyelomaThis technology includes the method of blocking CD38 in expanded natural killer (NK) cell therapy in combination with daratumumab in patients with multiple myeloma. Our in vitro studies have already confirmed the addition of NK cells to myeloma cells that have been exposed to daratumumab enhances myeloma killing compared to single agent treatment. Studies exploring adoptive NK cell transfer after daratumumab treatment to bolster daratumumab-mediated killing of myeloma via ADCC could be limited by the fact that these transferred NK cells might be killed by the antibody before they could reach t...Tue, 26 Mar 2024 22:56:35 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Blocking_CD38_using_Daratumumab_F(ab)2_to_Protect_Natural_Killer_Cells_from_Daratumumab-induced_Apoptosis_and_Cell_Death_for_the_Treatment_of_Multiple_MyelomaTAB-4503https://nih.technologypublisher.com/tech/Methods_to_Produce_Very_Long_Chain_Fatty_Acids_(VLCFA)_for_Use_as_Nutritional_Formulas_and_as_Therapeutics_for_DiseaseThis technology includes a new method to prepare very long chain fatty acids (VLCFA), which does not use the previously reported toxic mercury amalgam, for use as nutritional supplements, and as therapeutics for various diseases. The key coupling step involves an organocopper mediated coupling of the Grignard regent derived from the bromo alkyl tetraene with a bromoalkyl containing a protected alcohol. After the coupling the alcohol Is deprotected and oxidized to prepare the very long fatty acid. The synthetic approach is flexible and can be used to prepare the other VLCFA compounds. Similar m...Tue, 26 Mar 2024 22:55:49 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Methods_to_Produce_Very_Long_Chain_Fatty_Acids_(VLCFA)_for_Use_as_Nutritional_Formulas_and_as_Therapeutics_for_DiseaseTAB-4501https://nih.technologypublisher.com/tech/Monoclonal_Antibody_Against_Human_Zinc_Finger_RNA-binding_Protein_(ZFR)This technology includes monoclonal antibody was raised in mice against amino acids 703-1074 of ZFR. Antibody specificity was confirmed by immunoblotting lysates from cells depleted of ZFR using shRNAs.Tue, 26 Mar 2024 22:55:09 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Monoclonal_Antibody_Against_Human_Zinc_Finger_RNA-binding_Protein_(ZFR)TAB-4500https://nih.technologypublisher.com/tech/Highly_Efficient_Gene_Transfer_into_Primary_and_Expanded_Human_Natural_Killer_Cells_by_Lentiviral_Transduction_for_Cancer_TherapyThis technology includes an efficient lentiviral vector-based method for gene transfer into NK cells and demonstrates a stable and long-term robust expression of transgenes for the treatment of cancer. High gene transfer rates into primary cells being transduced and the ability to produce high titers of virus particles for large-scale transduction of patient cells are prerequisites for clinical trials. Lentiviral vectors can be produced in high titer and concentrated without compromising their transduction efficiency. Additionally, the described method is cheaper and simpler to apply clinicall...Tue, 26 Mar 2024 22:54:33 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Highly_Efficient_Gene_Transfer_into_Primary_and_Expanded_Human_Natural_Killer_Cells_by_Lentiviral_Transduction_for_Cancer_TherapyTAB-4499https://nih.technologypublisher.com/tech/A_Pre-emphasis_Technique_Based_on_the_Temperature-dependent_Gradient_System_Behavior_for_Trajectory_Correction_in_MR_ImagingThis technology includes the determination of temperature dependent temporal deviations of the real from the intended gradient waveforms and k-space trajectories during MRI image acquisition, and the use of appropriate temperature dependent pre-compensations to avoid or reduce the image distortion caused by these temporal deviations on the gradient waveforms and k-space trajectories, which will improve imaging quality. The determination of the temperature dependence includes a) direct measurements of the trajectory at the temperature the system operates during the scan, and b) measurements of ...Tue, 26 Mar 2024 22:52:43 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/A_Pre-emphasis_Technique_Based_on_the_Temperature-dependent_Gradient_System_Behavior_for_Trajectory_Correction_in_MR_ImagingTAB-4498https://nih.technologypublisher.com/tech/A_Method_to_Remove_Fluid-motion_Related_Artifacts_in_Magnetic_Resonance_Thermometry_Images_Using_Magnetic_Field_GradientsThis technology includes the incorporation of a magnetic field gradient waveform (consisting of two or more pulses) between excitation and encoding to eliminate signal from moving fluid for imaging applications. Proton Resonance Frequency (PRF) thermometry is a widely used Magnetic Resonance Imaging (MRI) based technique to monitor changes in tissue temperature in response to thermal therapy. The use of PRF thermometry with thermal therapy procedures is indispensable to ensure delivery of desired thermal dose to the target tissue, and to minimize unintended damage to the normal tissue. Motion ...Tue, 26 Mar 2024 22:51:47 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/A_Method_to_Remove_Fluid-motion_Related_Artifacts_in_Magnetic_Resonance_Thermometry_Images_Using_Magnetic_Field_GradientsTAB-4497https://nih.technologypublisher.com/tech/Antibody_to_Mitochondrial_Uniporter_(MCUTue, 26 Mar 2024 22:51:11 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Antibody_to_Mitochondrial_Uniporter_(MCUTAB-4496https://nih.technologypublisher.com/tech/A_Principal_Component_Analysis_Based_Multi-baseline_Phase_Correction_Method_for_PRF_ThermometryThis technology includes a novel Principal Component Analysis (PCA) based approach to correct motion related B0 changes in PRF thermometry. Proton Resonance Frequency (PRF) thermometry is a widely used Magnetic Resonance Imaging (MRI) based technique to monitor changes in tissue temperature in response to thermal therapy. The use of PRF thermometry with thermal therapy procedures is indispensable to ensure delivery of desired thermal dose to the target tissue, and to minimize unintended damage to the normal tissue. PRF thermometry relies on phase difference between the acquired images, and the...Tue, 26 Mar 2024 22:48:28 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/A_Principal_Component_Analysis_Based_Multi-baseline_Phase_Correction_Method_for_PRF_ThermometryTAB-4493https://nih.technologypublisher.com/tech/Genetic_Manipulation_of_Natural_Killer_Cells_to_Express_c-MPL_Growth_Factor_Receptor_as_a_Therapy_for_CancerThis technology includes genetic manipulation of natural killer (NK) cells to express thrombopoietin receptor (c-MPL) growth factor receptor as strategy to augment NK cell proliferation and anti-tumor immunity. Many investigational adoptive immunotherapy regimens utilizing NK cells require the administration of IL-2 or IL-15 cytokines to support the survival and function of the cells in patients, however administration of these cytokines causes a number of serious dose-dependent toxicities. In the presence of thrombopoietin (TPO) ligand, lentiviral transduction of primary human NK cells to ex...Tue, 26 Mar 2024 22:47:29 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Genetic_Manipulation_of_Natural_Killer_Cells_to_Express_c-MPL_Growth_Factor_Receptor_as_a_Therapy_for_CancerTAB-4492https://nih.technologypublisher.com/tech/Human_Monoclonal_Antibodies_to_Generate_Chimeric_Antigen_Receptor_(CAR)_T-cells_to_Treat_Patients_with_Advanced_Clear_Cell_Renal_Cell_Carcinoma_(ccRCC).Tue, 26 Mar 2024 22:46:45 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Human_Monoclonal_Antibodies_to_Generate_Chimeric_Antigen_Receptor_(CAR)_T-cells_to_Treat_Patients_with_Advanced_Clear_Cell_Renal_Cell_Carcinoma_(ccRCC).TAB-4490https://nih.technologypublisher.com/tech/Epstein-Barr_Virus_(EBV)-feeder_Cell_LineThis technology includes irradiated Epstein-Barr virus-transformed lymphoblastoid cell lines (EBV-LCL) as feeder cells for the ex vivo expansion of natural killer (NK) cells. EBV-LCL feeder cells, altered by radiation to prevent uncontrolled growth, provide a supportive environment for NK cells to multiply effectively. This method addresses the challenge of obtaining sufficient quantities of functionally active NK cells, which are crucial components of the immune system known for their ability to target and destroy tumor cells and virally infected cells. The use of EBV-LCL feeder cells permits...Tue, 26 Mar 2024 22:45:48 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Epstein-Barr_Virus_(EBV)-feeder_Cell_LineTAB-4487https://nih.technologypublisher.com/tech/Isotopes_of_Alpha_Ketoglutarate_and_Related_Compounds_for_Hyperpolarized_MRI_ImagingThis technology includes 1-13C-ketoglutarate which can be used for imaging the conversion to hydroxyglutarate (HG) or Gln in cancer cells with an IDH1 mutations by hyperpolarized MRI. The ability to detect the status of IDH1 mutations is clinically prognostic for multiple cancers. These exciting observations are limited by two factors, the major one being that the natural abundance of 13C at position C5 overlaps with 1-13C-2-hydroxyglutarate peak, which limits the sensitivity of analysis and prevents simultaneous observations of HG and Gln formation. The other issue is that the ketoglutarate ...Tue, 26 Mar 2024 22:44:38 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Isotopes_of_Alpha_Ketoglutarate_and_Related_Compounds_for_Hyperpolarized_MRI_ImagingTAB-4486https://nih.technologypublisher.com/tech?title=Real-time_Monitoring_of_In_Vivo_Free_Radical_Scavengers_Through_Hyperpolarized_%5b1-13C%5d_N-acetyl_Cysteine_as_a_Diagnostic_and_Disease_Monitoring_ToolThis technology includes synthesized demonstrated [1-13C] NAC as a promising novel probe for hyperpolarized 13C MRI methodologies which could provide diagnostic, and evaluation of response to treatment in various cancers and neurological diseases. N-acetyl cysteine (NAC) is a widely used therapeutic and involved to stimulate glutathione synthesis. Glutathione elevates detoxification and works directly as a free radical scavenger. In vivo hyperpolarized NAC was broadly distributed throughout the body. The chemical conversions into products were observed in pancreatic tumor xenografts, Hs766t, ...Tue, 26 Mar 2024 22:43:13 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech?title=Real-time_Monitoring_of_In_Vivo_Free_Radical_Scavengers_Through_Hyperpolarized_%5b1-13C%5d_N-acetyl_Cysteine_as_a_Diagnostic_and_Disease_Monitoring_ToolTAB-4485https://nih.technologypublisher.com/tech/Device_for_Closure_of_Transvascular_or_Transcameral_Access_PortsThis technology includes part of transcatheter aortic valve replacement and to enable non-surgical thoracic aortic aneurysm endograft repair. The invention enables a completely new way to access the arterial circulation to allow introduction of large devices, such as transcatheter aortic valve replacement, percutaneous left ventricular assist devices, and thoracic aortic endografts. It also can be used in most labeled and off-label applications of Amplatzer (AGA Medical, St Jude) nitinol occluder devices to occlude intracardiac holes and to allow non-surgical direct access to the heart. This i...Tue, 26 Mar 2024 22:41:41 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Device_for_Closure_of_Transvascular_or_Transcameral_Access_PortsTAB-4592https://nih.technologypublisher.com/tech/Mouse_model_of_TRIOBP_Human_Deafness_for_Research_and_Drug_DiscoveryThis technology includes a mouse model of TRIOBP human deafness which can be used for research and treatment development for deafness. This model contains mutations altering the TRIOP-5 isoform.Tue, 26 Mar 2024 22:40:05 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Mouse_model_of_TRIOBP_Human_Deafness_for_Research_and_Drug_DiscoveryTAB-4484https://nih.technologypublisher.com/tech/Prior_Enhanced_Compressed_Sensing_(PRINCE-CS)_Reconstruction_for_Dynamic_2D-radial_Cardiac_MRIThis technology includes a method to reduce scanning time while retaining high image quality during MRI scans. A reconstructed image is rendered from a set of MRI data by first estimating an image with an area which does not contain artifacts or has an artifact with a relatively small magnitude. Corresponding data elements in the estimated image and a trial image are processed, for instance by multiplication, to generate an intermediate data set. The intermediate data set is transformed and minimized iteratively to generate a reconstructed image that is free or substantially free of artifacts....Tue, 26 Mar 2024 22:39:22 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Prior_Enhanced_Compressed_Sensing_(PRINCE-CS)_Reconstruction_for_Dynamic_2D-radial_Cardiac_MRITAB-4483https://nih.technologypublisher.com/tech/A_New_Molecular_Scaffold_for_Targeting_hRpn13_as_a_Treatment_for_CancerThis technology includes a new chemical scaffold (with lead compound XL5) against hRpn13 that induces apoptosis, which may have clinical efficacy against cancer. The structure of XL5-conjugated hRpn13 guided the design of XL5-PROTAC degrader compounds that exhibit greater efficacy than previous hRpn13-targeting compounds, as evaluated by selectivity for hRpn13, induction of apoptosis, and loss of cell viability. In cells, XL5-PROTACs revealed the presence of a truncated hRpn13 product that binds to proteasomes and is selectively degraded by XL5-PROTACs. The presence of this truncated hRpn13 pr...Tue, 26 Mar 2024 22:38:06 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/A_New_Molecular_Scaffold_for_Targeting_hRpn13_as_a_Treatment_for_CancerTAB-4482https://nih.technologypublisher.com/tech/ApoE-ApoCII_Chimeric_Peptides_for_Treating_HypertriglyceridemiaThis technology includes apoE-apoCII chimeric peptides that possess the ability to lower the triglyceride level both in vitro and in vivo. These peptides can be used for treating hypertriglyceridemia and alleviating other diseases and conditions associated with increased triglycerides.Tue, 26 Mar 2024 22:37:23 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/ApoE-ApoCII_Chimeric_Peptides_for_Treating_HypertriglyceridemiaTAB-4479https://nih.technologypublisher.com/tech/Methods_and_Systems_for_Automatically_Determining_Magnetic_Field_Inversion_Time_of_a_Tissue_SpeciesThis technology includes a computer-implemented method for determining magnetic field inversion time of a tissue species using a T1-mapping image, information about the region of interest, and a tissue classification algorithm. This method includes T1-mapping image comprising a plurality of T1 values within an expected range of T1 values for the tissue of interest. An image mask is created based on predetermined identification information about the tissue of interest. Next, an updated image mask is created based on a largest connected region in the image mask. The updated image mask is applied...Tue, 26 Mar 2024 22:36:38 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Methods_and_Systems_for_Automatically_Determining_Magnetic_Field_Inversion_Time_of_a_Tissue_SpeciesTAB-4476https://nih.technologypublisher.com/tech/Free_Breathing_Motion_Corrected_Pixel-wise_MRI_Myocardial_T1_Parameter_Mapping_for_Clinical_Cardiac_ImagingThis technology includes a method for performing cardiac imaging without the need for the patient to hold their breath. Free breathing pixel-wise myocardial T1 parameter mapping includes performing a free-breathing scan of a cardiac region at a plurality of varying saturation recovery times to acquire a k-space dataset; generating an image dataset based on the k-space dataset; and performing a respiratory motion correction process on the image dataset. The respiratory motion correction process comprises selecting a target image, co-registering each image in the dataset to the target image to d...Tue, 26 Mar 2024 22:35:25 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Free_Breathing_Motion_Corrected_Pixel-wise_MRI_Myocardial_T1_Parameter_Mapping_for_Clinical_Cardiac_ImagingTAB-4591https://nih.technologypublisher.com/tech/Functions_and_Targets_of_Therapeutic_MicroRNAs_to_Treat_and_Diagnose_CancerThis technology includes a method to identify potentially therapeutic microRNAs in cancer, particularly squamous cell carcinoma of the head and neck (HNSCC). This approach first utilizes a large and publicly available expression dataset, which is then validated by a smaller independent dataset to determine deregulated microRNAs expression. These results are then intersected with in vitro functional anti-proliferative screening data to select for microRNAs that play a functional tumor suppressive role and likely serve as therapeutic targets. Utilizing the recently published data from 279 tumor ...Tue, 26 Mar 2024 22:34:49 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Functions_and_Targets_of_Therapeutic_MicroRNAs_to_Treat_and_Diagnose_CancerTAB-4590https://nih.technologypublisher.com/tech/Concurrent_Use_of_Atorvastatin_During_Chemotherapy_Reduces_Cisplatin-induced_OtotoxicityThis technology includes the use of atorvastatin, a medication to manage hypercholesterolemia, as a method to protect patients receiving cisplatin from hearing loss. Cisplatin chemotherapy is indicated in various cancer types in adults and children and is known to cause hearing loss. A patient on atorvastatin during chemotherapy is 46% less likely to acquire a significant cisplatin-induced hearing loss relative to a non-statin user. Atorvastatin is an FDA-approved medication routinely prescribed and well-tolerated clinically. The quality of life in cisplatin-treated cancer patients may be dram...Tue, 26 Mar 2024 22:33:30 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Concurrent_Use_of_Atorvastatin_During_Chemotherapy_Reduces_Cisplatin-induced_OtotoxicityTAB-4478https://nih.technologypublisher.com/tech/System_for_Automated_Anatomical_Structures_Segmentation_of_Contrast-Enhanced_Cardiac_Computed_Tomography_ImagesThis technology includes a fully automatic 3D image processing system to segment the heart as well as other organs from contrast-enhanced cardiac computed tomography (CCT) images. Our method detects four cardiac chambers including left ventricle, right ventricle, left atrium, right atrium, as well as the ascending aorta and left ventricular myocardium. It also classifies noncardiac tissue structures in the CCT images such as lung, chest wall, spine, descending aorta, and liver. This automated system is based on computer vision algorithms to improve commonly used multi-atlas approach for automa...Tue, 26 Mar 2024 22:29:08 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/System_for_Automated_Anatomical_Structures_Segmentation_of_Contrast-Enhanced_Cardiac_Computed_Tomography_ImagesTAB-4494https://nih.technologypublisher.com/tech/General-purpose_Deep_Learning_Image_Denoising_Based_on_Magnetic_Resonance_Imaging_PhysicsThis technology includes a novel method to train deep learning convolution neural network model to improve the signal-noise-ratio for the magnetic resonance (MR) imaging. The novelty lies on the fact that actual MR imaging physics information is used in the deep learning training. The resulting model achieves significant signal-to-noise ratio (SNR) improved for different acceleration factors in MR imaging. The resulting model can be used for many body anatomies (e.g., brain, heart, liver, spine, etc.) to significantly improve the SNR. This solution is fast enough to be used clinically and has ...Tue, 26 Mar 2024 22:25:58 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/General-purpose_Deep_Learning_Image_Denoising_Based_on_Magnetic_Resonance_Imaging_PhysicsTAB-4603https://nih.technologypublisher.com/tech/Paper_Strip_Tool_with_Gold_Nanoparticle_Conjugated_Probes_for_Rapid_Detection_of_Pathogens_in_StoolThis technology includes a paper strip tool that may be used at the point-of care to detect the presence of a multiplex of pathogen nucleic acid sequences in stool without the need for molecular amplification, laboratory or instrumentation. This invention can be used to rapidly and inexpensively detect gastrointestinal and diarrheal disease in order to guide treatment.Tue, 26 Mar 2024 22:18:59 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Paper_Strip_Tool_with_Gold_Nanoparticle_Conjugated_Probes_for_Rapid_Detection_of_Pathogens_in_StoolTAB-4508https://nih.technologypublisher.com/tech/Phase_Sensitive_Motion_Correction_and_T1_Mapping_for_Cardiovascular_Magnetic_Resonance_ImagingThis technology includes a method of correcting the motion during T1 mapping using cardiovascular magnetic resonance imaging (MRI). Ischemic heart disease is the leading cause of death in the United States. The lack of blood supply among myocardial tissue, especially for scar regions, changes the T1 relaxation value of heart muscles. The non-invasive quantification of T1 value of myocardium (T1 mapping) is therefore of great importance for the diagnosis and treatment of cardiovascular disease. However, the accurate T1 measurement of myocardium is hard to achieve, mainly due to the inevitable r...Tue, 26 Mar 2024 22:16:53 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Phase_Sensitive_Motion_Correction_and_T1_Mapping_for_Cardiovascular_Magnetic_Resonance_ImagingTAB-4571https://nih.technologypublisher.com/tech?title=Generation_of_AAVS1_and_C13_%e2%80%9cSafe_Harbor%e2%80%9d_Transcription_Activator-life_Effector_Nucleases_(TALENs)_for_Drug_Screening_or_Gene_Therapy_DevelopmentTue, 26 Mar 2024 22:15:15 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech?title=Generation_of_AAVS1_and_C13_%e2%80%9cSafe_Harbor%e2%80%9d_Transcription_Activator-life_Effector_Nucleases_(TALENs)_for_Drug_Screening_or_Gene_Therapy_DevelopmentTAB-4570https://nih.technologypublisher.com/tech/Generation_of_Safe-harbor_Gene_Targeting_Donor_PlasmidsThis technology includes two safe harbor gene targeting donors, specifically designed for applications in the study of induced pluripotent stem cells (iPSC). These include the pAAVS1D-CMV.RFP-EF1a.copGFPpuro and pAAVS1-iCLHN donors. A key feature of these donors is their ability to integrate various transgenes into specific loci through homologous recombination, facilitated by sequences homologous to safe harbor loci. When paired with TALENs targeting these loci, these plasmids enable precise and efficient genome engineering in human cells. Unlike existing AAVS1 gene targeting vectors, these d...Tue, 26 Mar 2024 22:14:51 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Generation_of_Safe-harbor_Gene_Targeting_Donor_PlasmidsTAB-4569https://nih.technologypublisher.com/tech/Generation_of_Gene_Specific_Targeting_Donor_Plasmid_(p5KI-GP-CHN_and_p3KI-GP-CHN)This technology includes the use of engineered human induced pluripotent stem cells (iPSCs) for various applications such as studying cell differentiation, drug screening, and gene transfer therapy. It employs gene targeting donors flanked by DNA sequences compatible with endogenous loci to integrate transgenes through homologous recombination. A key aspect is the flexible gene targeting donor design, used in conjunction with safe harbor transcription activator-like effector nucleases (TALENs). These TALENs target specific endogenous loci, enabling high-efficiency and versatile genome engineer...Tue, 26 Mar 2024 22:14:28 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Generation_of_Gene_Specific_Targeting_Donor_Plasmid_(p5KI-GP-CHN_and_p3KI-GP-CHN)TAB-4568https://nih.technologypublisher.com/tech/Astrocyte_Differentiation_of_Neural_Stem_Cells_with_StemPro_Embryonic_Stem_Cell_Serum_Free_Medium_for_Research_and_Potential_Therapeutic_UseThis technology includes an innovative method for differentiating astrocytes from neural stem cells (NSCs). The process involves using Life Technologies StemPro embryonic stem cell serum-free medium to initially guide NSCs towards a neuronal lineage. Over a period of 28-35 days, as the cells are continually passaged, neurons gradually die off, leading to the proliferation of astrocytes. By the end of this differentiation protocol, approximately 70% of the cells exhibit markers characteristic of mature astrocytes, specifically GFAP. Additionally, this method allows for the astrocytes to be froz...Tue, 26 Mar 2024 22:14:06 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Astrocyte_Differentiation_of_Neural_Stem_Cells_with_StemPro_Embryonic_Stem_Cell_Serum_Free_Medium_for_Research_and_Potential_Therapeutic_UseTAB-4567https://nih.technologypublisher.com/tech/Conditional_Cell_Immortalization_Plasmid_for_Basic_Science_ResearchThis technology includes a novel plasmid design for cell immortalization. It uniquely combines the conditional activation of human telomerase and c-myc genes through cumate addition, a method distinct from traditional immortalization techniques which commonly use SV40 T-antigen, telomerase, or c-myc. This plasmid also includes a GFP reporter and a puromycin resistance gene, enhancing the efficiency of the immortalization process. A significant breakthrough of this technology is its ability to immortalize neural cells like astrocytes, neurons, and Schwann cells, which have previously shown resi...Tue, 26 Mar 2024 22:13:36 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Conditional_Cell_Immortalization_Plasmid_for_Basic_Science_ResearchTAB-4566https://nih.technologypublisher.com/tech/Neural_Stem_Cells_from_an_iPSC_Line_Ubiquitously_Expressing_Green_Fluorescent_Protein_for_Basic_Science_Research_and_Cell_Line_TrackingThis technology involves neural stem cells (NSCs) derived from pluripotent stem cells (PSCs) that can differentiate into neurons and glia. The key feature of this technology is the CY2 EEF1A1 GFP iPSC line, which includes a green fluorescent protein (GFP) expressed under the EEF1A1 promoter, leading to its ubiquitous expression in cells. This characteristic makes the NSCs and the neural cells differentiated from this line exhibit green fluorescence. Such cells, when transplanted into animal models like mice and rats, can be easily tracked due to their fluorescence. This tracking is critical fo...Tue, 26 Mar 2024 22:13:02 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Neural_Stem_Cells_from_an_iPSC_Line_Ubiquitously_Expressing_Green_Fluorescent_Protein_for_Basic_Science_Research_and_Cell_Line_TrackingTAB-4565https://nih.technologypublisher.com/tech/A_Neural_Stem_Line_from_a_Niemann_Pick_C_(NPC)_Type_1_Patient_for_Therapy_DevelopmentThis technology includes a neural stem cell (NSC) line derived from a Niemann Pick C (NPC) patient, aimed at advancing research and drug development for NPC, an inherited neurodegenerative disorder characterized by the accumulation of cholesterol in neurons. The NSCs, which serve as a crucial intermediate cell type, can be differentiated into any neuronal or glial cell of the brain or spinal cord under appropriate culture conditions. These cells originate from fibroblasts reprogrammed into induced pluripotent stem cells. Their ability to differentiate into various central nervous system cell t...Tue, 26 Mar 2024 22:12:32 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/A_Neural_Stem_Line_from_a_Niemann_Pick_C_(NPC)_Type_1_Patient_for_Therapy_DevelopmentTAB-4564https://nih.technologypublisher.com/tech/Neuronal_Differentiation_of_Neural_Stem_Cells_with_StemPro_Embryonic_Stem_Cell_Serum_Free_Medium_for_Research_and_Therapeutic_DevelopmentThis technology involves an innovative method for differentiating neural stem cells (NSCs) into neurons, primarily for use in basic science research and in developing therapies for brain and spinal cord disorders. Existing methods for generating neurons from NSCs typically result in high efficiency but low survival rates, especially when neurons are dissociated and regrown. This new method utilizes Life Technologies StemPro embryonic stem cell serum-free medium, which significantly enhances differentiation efficiency into neurons with minimal cell death. A notable aspect of this technology is ...Tue, 26 Mar 2024 22:12:10 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Neuronal_Differentiation_of_Neural_Stem_Cells_with_StemPro_Embryonic_Stem_Cell_Serum_Free_Medium_for_Research_and_Therapeutic_DevelopmentTAB-4561https://nih.technologypublisher.com/tech/SARS-CoV-2_Neutralizing_Nanobodies_for_Therapeutic_and_Diagnostic_UsesTue, 26 Mar 2024 22:10:46 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/SARS-CoV-2_Neutralizing_Nanobodies_for_Therapeutic_and_Diagnostic_UsesTAB-4558https://nih.technologypublisher.com/tech/Mouse_Models_of_Cryopyrin-Associated_Periodic_Syndrome_(CAPS)_for_Drug_DiscoveryTue, 26 Mar 2024 22:09:43 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Mouse_Models_of_Cryopyrin-Associated_Periodic_Syndrome_(CAPS)_for_Drug_DiscoveryTAB-4557https://nih.technologypublisher.com/tech/Three_Cell_Lines_of_Motor_Neuron_Progenitors_for_Various_Diagnostic_and_Therapeutic_UsesThis technology includes three distinct cell lines of motor neuron progenitors, derived from different sources: human induced pluripotent stem cell (iPSC) line BC1, human iPSC line X1, and human embryonic stem cell (hESC) line H14. These cell lines hold significant potential for multiple diagnostic and therapeutic applications. A key advantage of these cell lines is the commercial availability of their starting materials (iPSC-BC1, iPSC-X1, and hESC-H14), which are not restricted in terms of usage of their derivatives. This aspect is particularly beneficial as it can considerably reduce the fi...Tue, 26 Mar 2024 22:09:22 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Three_Cell_Lines_of_Motor_Neuron_Progenitors_for_Various_Diagnostic_and_Therapeutic_UsesTAB-4556https://nih.technologypublisher.com/tech/Cell_Lines_of_Dopaminergic_Neurons_Derived_from_Human_Induced_Pluripotent_Stem_Cell_(iPSC)_lines_for_Multiple_Neurological_Therapeutic_and_Diagnostic_UsesThis technology includes three cell lines of dopaminergic neurons derived from human induced pluripotent stem cell (iPSC) line BC1, human iPSG line X1 and human embryonic stem cell (hESC) line H14 to be utilized in neurology research. These cell lines will be used for to study the biology of brain development and may also be used to test different characterization and differentiation assays. The dopaminergic neurons and/or their derivatives may also be used as controls in studies to screen for small molecules to change cell fate and/or to alleviate the phenotypes of various diseases.Tue, 26 Mar 2024 22:09:01 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Cell_Lines_of_Dopaminergic_Neurons_Derived_from_Human_Induced_Pluripotent_Stem_Cell_(iPSC)_lines_for_Multiple_Neurological_Therapeutic_and_Diagnostic_UsesTAB-4555https://nih.technologypublisher.com/tech/Engineered_Human_Induced_Pluripotent_Stell_Cell_(iPSC)_Lines_for_Multiple_Therapeutic_and_Diagnostic_UsesThis technology includes ten engineered human induced pluripotent stem cell (iPSC) lines with reported genes inserted into safe harbor sites for use in therapy and diagnostic screening assay development as well as basic stem cell biology research. These cell lines have the potential to differentiate into all cells in the body, and theoretically can proliferate/self-renew indefinitely.Tue, 26 Mar 2024 22:08:30 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Engineered_Human_Induced_Pluripotent_Stell_Cell_(iPSC)_Lines_for_Multiple_Therapeutic_and_Diagnostic_UsesTAB-4550https://nih.technologypublisher.com/tech?title=DLX3_Knockout_Mice_for_the_Study_Mouse_Models_of_Tooth%2c_Hair%2c_and_Epidermal_DefectsThis technology includes K14creDLX3 conditional knockout (cKO) mice which will be used to study ectodermal dysplasia disorders such as Amelogenesis Imperfecta, and to study molecular mechanisms of DLX3 regulation in skin and ectodermal appendages. DLX3 is expressed in the epidermis, hair matrix cells in the hair follicle and in the mesenchymal and epithelial compartment of the tooth during embryonic development. To determine the transcriptional network dependent on DLX3-function, we will generate and analyze an epithelial-specific conditional knockout of DLX3.Tue, 26 Mar 2024 22:06:28 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech?title=DLX3_Knockout_Mice_for_the_Study_Mouse_Models_of_Tooth%2c_Hair%2c_and_Epidermal_DefectsTAB-4549https://nih.technologypublisher.com/tech?title=DLX3-floxed_mice_(DLX3f%2ff)_for_Use_in_Drug_Development_and_In_Vivo_Research_Studies_for_Ectodermal_Dysplasia_DisordersThis technology includes the creation of DLX3-floxed mice, specifically designed for conditional deletion of the DLX3 gene via Cre-mediated recombination. This innovative approach aims to develop mouse models for studying ectodermal dysplasia disorders. Ectodermal dysplasias are a diverse group of genetic conditions affecting the development of ectodermal structures, including hair, teeth, and bones. The DLX3f/f mice are particularly valuable for modeling specific disorders such as Tricho-dento-osseous syndrome (TDO), Amelogenesis Imperfecta (AI), and Dentinogenesis Imperfecta (DI). By selecti...Tue, 26 Mar 2024 22:05:48 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech?title=DLX3-floxed_mice_(DLX3f%2ff)_for_Use_in_Drug_Development_and_In_Vivo_Research_Studies_for_Ectodermal_Dysplasia_DisordersTAB-4587https://nih.technologypublisher.com/tech/Producing_Isotropic_Super-Resolution_Images_from_Line_Scanning_Confocal_MicroscopyThis technology includes a microscopy technique that produces super-resolution images from diffraction-limited images obtained from a line scanning confocal microscope. First, the operation of the confocal microscope is modified so that images with sparse line excitation are recorded. Second, these images are processed to increase resolution in one dimension. Third, by taking a series of such super-resolved images from a given sample type, a neural network may be trained to produce images with 1D super-resolution from new diffraction-limited images. Finally, by rotating a given diffraction-lim...Tue, 26 Mar 2024 21:30:28 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Producing_Isotropic_Super-Resolution_Images_from_Line_Scanning_Confocal_MicroscopyTAB-4586https://nih.technologypublisher.com/tech/Accelerating_Multiview_Registration_and_Iterative_Deconvolution_to_Improve_Spatial_Resolution_and_Contrast_in_Fluorescence_MicroscopyThis technology includes algorithms and software that improve the speed of iterative deconvolution, a common method for improving spatial resolution and contrast in fluorescence microscopy images. These algorithms also improve the registration of multiview datasets, and apply deep learning to accelerate spatially varying deconvolution.Tue, 26 Mar 2024 21:30:08 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Accelerating_Multiview_Registration_and_Iterative_Deconvolution_to_Improve_Spatial_Resolution_and_Contrast_in_Fluorescence_MicroscopyTAB-4585https://nih.technologypublisher.com/tech/Radiotherapy_and_Imaging_Agent-based_on_Peptide_Conjugated_to_Novel_Evans_Blue_Derivatives_with_Long_Half-life_and_High_Accumulation_in_Target_TissueThis technology includes a newly designed, truncated Evans Blue (EB) form which allows labeling with metal isotopes for nuclear imaging and radiotherapy. Unlike previous designs, this new form of truncated EB confers site specific mono-labeling of desired molecules. The newly designed truncated EB form can be conjugated to various molecules including small molecules, peptides, proteins and aptamers to improve blood half-life and tumor uptake, and confer better imaging, therapy and radiotherapy. As a proof of concept, we chose to conjugate the new truncated EB to Arg-Gly-Asp (RGD) tripeptide, w...Tue, 26 Mar 2024 21:29:46 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Radiotherapy_and_Imaging_Agent-based_on_Peptide_Conjugated_to_Novel_Evans_Blue_Derivatives_with_Long_Half-life_and_High_Accumulation_in_Target_TissueTAB-4583https://nih.technologypublisher.com/tech/Improvement_of_Axial_Resolution_via_Photoswitching_and_Standing_Wave_IlluminationThis technology includes an illuminator and reflector that enables flexible standing wave illumination on an inverted microscope stand, and procedures for using such illumination to improve axial resolution in confocal or instant SIM imaging systems. The axial resolution in conventional fluorescence microscopy is typically limited by diffraction to ~700 nm. This method that improves axial resolution ~7-fold over the diffraction limit, and that can be applied to any fluorescence microscope. By exciting the sample with standing wave illumination of different spatial frequencies, acquiring a corr...Tue, 26 Mar 2024 21:28:49 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Improvement_of_Axial_Resolution_via_Photoswitching_and_Standing_Wave_IlluminationTAB-4581https://nih.technologypublisher.com/tech/Fluorescence_Scanning_System_for_Improvement_of_Analytical_UltracentrifugationThis technology includes improvements in the fluorescence scanner to increase efficiency. This method works by eliminating the need to radially slide the optical assembly during scanning, instead using a galvanometric mirror deflecting a laser beam to different positions in the sample. This allows the scanner to be incorporated into existing commercial analytical ultracentrifugation (AUC) systems with minimal modifications. A further improvement designed to increase detection efficiency is the use of plano-convex windows replacing planar windows in the sample cell assembly, which can help focu...Tue, 26 Mar 2024 21:27:48 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Fluorescence_Scanning_System_for_Improvement_of_Analytical_UltracentrifugationTAB-4580https://nih.technologypublisher.com/tech/Three-dimensional_Fluorescence_Polarization_Excitation_via_Multiview_ImagingThis technology includes a method that extends fluorescence polarization imaging so that the dipole moment of a fluorescent dye may be excited regardless of its 3D orientation. By exciting the dipole from multiple directions, we ensure that excitation may occur even if the dipole is unfavorably oriented along the axial (propagation) axis. If the dye can be rigidly attached to the structure of interest, our method also enables the 3D orientation of the structure to be estimated accurately. This method can be advantageously applied in light-sheet microscopy, where two perpendicular objectives ar...Tue, 26 Mar 2024 21:27:18 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Three-dimensional_Fluorescence_Polarization_Excitation_via_Multiview_ImagingTAB-4579https://nih.technologypublisher.com/tech/Evans_Blue_Modified_Small_Molecule-based_Prostate-specific_Membrane_Antigen_(PSMA)_Radiotherapy_and_Nuclear_ImagingTue, 26 Mar 2024 21:26:57 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Evans_Blue_Modified_Small_Molecule-based_Prostate-specific_Membrane_Antigen_(PSMA)_Radiotherapy_and_Nuclear_ImagingTAB-4578https://nih.technologypublisher.com/tech/Computational_Alleviation_of_Depth-dependent_Degradation_in_Fluorescence_ImagesTue, 26 Mar 2024 21:25:30 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Computational_Alleviation_of_Depth-dependent_Degradation_in_Fluorescence_ImagesTAB-4575https://nih.technologypublisher.com/tech/Intranasal_or_Inhaled_Delivery_of_a_Custom_IgA_Antibody_for_Protection_Against_COVID-19Tue, 26 Mar 2024 21:23:27 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Intranasal_or_Inhaled_Delivery_of_a_Custom_IgA_Antibody_for_Protection_Against_COVID-19TAB-4574https://nih.technologypublisher.com/tech/Multiview_Super-resolution_Microscopy_System_and_Methods_for_Research_and_Diagnostic_ApplicationsThis technology includes a microscopy technique that combines the strengths of multiview imaging (better resolution isotropy, better depth penetration) with resolution-improving structured illumination microscopy (SIM). The proposed microscope uses a sharp line-focused illumination structure to excite and confocally detect sample fluorescence from 3 complementary views. Since resolution along any particular axis is defined by the super-resolved lateral resolution improvement obtained via that axis, axial resolution is improved ~2-fold over the current state of the art (traditional 3D SIM), whi...Tue, 26 Mar 2024 21:22:01 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Multiview_Super-resolution_Microscopy_System_and_Methods_for_Research_and_Diagnostic_ApplicationsTAB-4573https://nih.technologypublisher.com/tech?title=Instant_Total_Internal_Reflection_Fluorescence%2fStructured_Illumination_Microscopy_(instant_TIRF%2fSIM)This technology includes a method which enables high-speed, super-resolution microscopy at a very high signal-to-noise ratio (SNR), for biological applications within ~200 nm (the evanescent wave decay length) of a coverslip surface. Instant TIRF/SIM may be implemented simply by modifying and adding to the excitation optics that are already present within a conventional instant SIM design. We enforce TIRF excitation by removing all wave vectors that propagate into the objective lens at sub-critical angles.Tue, 26 Mar 2024 21:13:34 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech?title=Instant_Total_Internal_Reflection_Fluorescence%2fStructured_Illumination_Microscopy_(instant_TIRF%2fSIM)TAB-4572https://nih.technologypublisher.com/tech/Resolution_Doubling_with_Digital_Confocal_MicroscopyThis technology includes a microscopy method that reduces the speed penalty at least 1000-fold, while retaining resolution improvement. A Digital mirror device (DMD) or sweptfield confocal unit is used to create hundreds to thousands of excitation foci that are imaged to a sample mounted in a conventional microscope and record the resulting emissions on an array detector. Detection of each confocal spot is done in our proprietary software, as is the processing and deconvolution that is used for a 2x resolution enhancement. Our method provides some optical sectioning, as we can implement a vari...Tue, 26 Mar 2024 21:12:58 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Resolution_Doubling_with_Digital_Confocal_MicroscopyTAB-3834https://nih.technologypublisher.com/tech/TSLP_Induces_Neutrophil-mediated_Killing_of_Methicillin-resistant_Staphylococcus_Aureus_(MRSA)This technology includes the use of thymic stromal lymphopoetin (TSLP) for the treatment of MRSA. Our studies show that mouse neutrophils express the TSLP receptor, TSLPR, and that TSLP protein is increased during cutaneous MRSA infection. Using in vitro MRSA whole blood killing assays, we show that TSLP acts on mouse neutrophils to enhance MRSA killing. In an in vivo MRSA intradermal ear infection, TSLPR-deficient mice exhibit increased MRSA burden compared to wild-type mice. Moreover, TSLP treatment increases cutaneous MRSA killing in wild-type mice, as intradermal TSLP treatment of wild-typ...Wed, 20 Mar 2024 12:14:41 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/TSLP_Induces_Neutrophil-mediated_Killing_of_Methicillin-resistant_Staphylococcus_Aureus_(MRSA)TAB-4608https://nih.technologypublisher.com/tech/Intralipid_as_a_Contrast_Agent_to_Enhance_Subsurface_Blood_Flow_ImagingThis technology includes a blood flow imaging method that allows for a higher density of smaller particles to be detected. Current imaging methods that are based on Doppler measurements are limited by the discontinuity in the capillary flow in the space between red blood cells. The core technology is to use a scattering agent to enhance capillary flow or microcirculation. This technology has been tested for optical coherence Doppler tomography, but can be expended to any Doppler based flow imaging techniques such as laser speckle imaging. The fundamental discovery or idea is that in capillarie...Wed, 20 Mar 2024 12:04:41 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Intralipid_as_a_Contrast_Agent_to_Enhance_Subsurface_Blood_Flow_ImagingTAB-4606https://nih.technologypublisher.com/tech/Synthesis_and_Characterization_of_d8-JD5037_for_Drug_Discovery_StudiesWed, 20 Mar 2024 11:58:23 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Synthesis_and_Characterization_of_d8-JD5037_for_Drug_Discovery_StudiesTAB-4545https://nih.technologypublisher.com/tech/Transcatheter_MRI-guided_Implantable_Cavopulmonary_Bypass_Endograft_for_the_Treatment_of_Congenital_Heart_DiseaseThis technology includes a catheter-delivered endograft designed to treat congenital heart disease without surgery. The specific surgical procedure averted is cavopulmonary bypass graft. The key innovations are features to effect distal end-to-side anastomosis and proximal end-to-end anastomosis without surgery. The system operates under X-ray and MRI guidance.Wed, 20 Mar 2024 11:52:02 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Transcatheter_MRI-guided_Implantable_Cavopulmonary_Bypass_Endograft_for_the_Treatment_of_Congenital_Heart_DiseaseTAB-4544https://nih.technologypublisher.com/tech?title=Segmented%2c_Braided_MRI_Catheter_for_Cardiovascular_ProceduresThis technology includes a catheter design to be used for cardiovascular procedures. This catheter has intrinsic freedom from MRI heating by segmenting and insulating the braiding material, yet that retains most of the mechanical properties of a braided catheter aligning the segment interruptions out-of-phase with each other.Wed, 20 Mar 2024 11:51:20 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech?title=Segmented%2c_Braided_MRI_Catheter_for_Cardiovascular_ProceduresTAB-4543https://nih.technologypublisher.com/tech/Endo-cameral_Closure_Device_for_Structural_Heart_Defects_and_Blood_Vessel_RepairThis technology includes a device to close a hole in the wall of a large blood vessel or cardiac chamber from the inside out, delivered over a guidewire and through a catheter or sheath. First, the proximal portion deploys within the vessel or chamber and is advanced over a guidewire to oppose the wall and seal the hole. Second, the distal portion self-assembles outside the vessel or chamber upon withdrawal of the guidewire. Deployment of the distal portion anchors the device securely in place.Wed, 20 Mar 2024 11:50:08 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Endo-cameral_Closure_Device_for_Structural_Heart_Defects_and_Blood_Vessel_RepairTAB-4541https://nih.technologypublisher.com/tech/Segmented_Metallic_MRI_Guidewires_Using_Stiffness-matched_Nonconductive_Connectors_for_Catheterization_ProceduresThis technology includes a metallic guidewire that is suitable for MRI catheterization, because it is mechanically long but electrically consists of short conductive segments that cannot resonate during MRI. The invention consists of stiffness-matched non-conductive connectors or connections that are used along with short metallic segments. The embodiment reduced to practice has torquability and flexibility comparable to marketed metallic guidewires, yet is free from MRI heating.Wed, 20 Mar 2024 11:47:24 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Segmented_Metallic_MRI_Guidewires_Using_Stiffness-matched_Nonconductive_Connectors_for_Catheterization_ProceduresTAB-4540https://nih.technologypublisher.com/tech/Expanded_Claims_for_Transcatheter_Coronary_Sinus_Mitral_Valve_Annuloplasty_Procedure_and_Coronary_Artery_and_Myocardial_ProtectionWed, 20 Mar 2024 11:46:10 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Expanded_Claims_for_Transcatheter_Coronary_Sinus_Mitral_Valve_Annuloplasty_Procedure_and_Coronary_Artery_and_Myocardial_ProtectionTAB-4528https://nih.technologypublisher.com/tech/Devices_and_Methods_for_Cerclage_of_Luminal_SystemsThis technology includes a family of transcatheter endovenous intramyocardial tether (MIRTH) procedures to impose myocardial constraint on the LV (MIRTH), LV and RV (SCIMITAR), and cardiac resynchronization procedures. Included is a set of advanced cardiac treatment technologies that focus on minimally invasive procedures for heart patients. The main technology is the transcatheter endovenous intramyocardial tether (MIRTH) procedure, which is designed to apply physical constraint to the left ventricle (LV) of the heart. This method aims to aid in the treatment of certain heart conditions by al...Wed, 20 Mar 2024 11:45:25 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Devices_and_Methods_for_Cerclage_of_Luminal_SystemsTAB-4527https://nih.technologypublisher.com/tech?title=Annuloplasty_Procedures%2c_Related_Devices_and_MethodsThis technology includes design enhancements to transcatheter mitral cerclage annuloplasty. They include a device to convert from crossing guidewire to tension element, refinements to the tension element which incorporates a coronary artery protection device, a target/capture/snare device, a wishbone locking device, and a cutting device.Wed, 20 Mar 2024 11:40:51 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech?title=Annuloplasty_Procedures%2c_Related_Devices_and_MethodsTAB-4521https://nih.technologypublisher.com/tech/Novel_Bicuspid_Transcatheter_Heart_Valve_Frame_and_Leaflets_for_Mitro_Valve_ImplantationThis technology includes a pair of subsystems for a novel transcatheter bicuspid valve (frame and leaflets) intended for implantation in the mitral position. It is simple, it overcomes key limitations to transcatheter bicuspid mitral valve implants, and it overcomes key limitations to transcatheter tricuspid mitral valve implants.Wed, 20 Mar 2024 11:39:07 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Novel_Bicuspid_Transcatheter_Heart_Valve_Frame_and_Leaflets_for_Mitro_Valve_ImplantationTAB-4510https://nih.technologypublisher.com/tech?title=Use_of_VDAC_inhibitor%2c_VBIT4%2c_as_a_Treatment_for_LupusThis technology includes a small molecule drug (VDAC inhibitor, also known as VBIT4) that may be useful for inhibiting lupus disease. To test lupus animal model, VBIT4 was continuously administered for 5 weeks to mice and there was no mortality or clinical symptoms in these animals. Additionally, VBIT4 treatment blocked the development of skin lesions and alopecia of the ears and face, and suppressed the thickening of the epidermis that accompanies leukocyte infiltration. Supporting these results, VBIT4 treatment reduced both spleen and lymph node weight, as well as significantly diminished th...Wed, 20 Mar 2024 11:37:25 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech?title=Use_of_VDAC_inhibitor%2c_VBIT4%2c_as_a_Treatment_for_LupusTAB-4502https://nih.technologypublisher.com/tech/Device_for_Closure_of_Transvascular_or_Transcameral_Access_PortsThis technology includes a novel method to access the arterial circulation to allow introduction of large devices, such as transcatheter aortic valve replacement, percutaneous left ventricular assist devices, and thoracic aortic endografts. It also can be used in most labeled and off-label applications of Amplatzer nitinol occluder devices to occlude intracardiac holes and to allow non-surgical direct access to the heart. This new disclosure adds additional design features that have been tested in vivo. These include a new compression member design that enhances wall apposition and hemostasis,...Wed, 20 Mar 2024 11:36:15 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Device_for_Closure_of_Transvascular_or_Transcameral_Access_PortsTAB-4495https://nih.technologypublisher.com/tech/A_Method_to_Guide_Protocol_Development_for_Magnetic_Resonance_ThermometryThis technology includes tools to guide optimization of thermometry imaging/post-processing protocols. Proton Resonance Frequency (PRF) thermometry is a widely used Magnetic Resonance Imaging (MRI) based technique to monitor changes in tissue temperature in response to thermal therapy. The use of PRF thermometry with thermal therapy procedures is indispensable to ensure delivery of desired thermal dose to the target tissue, and to minimize unintended damage to the normal tissue.Wed, 20 Mar 2024 11:35:25 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/A_Method_to_Guide_Protocol_Development_for_Magnetic_Resonance_ThermometryTAB-4489https://nih.technologypublisher.com/tech/Helical_Guidewires_and_Related_Systems_for_Transcatheter_Heart_Valve_ProceduresThis technology includes a guidewire purpose-built for delivery of bulky transcatheter heart valves (THV). Conventional THV guidewires are rigid and have a distal tip shaped like a pigtail to prevent apical ventricular perforation. This invention is a 3-dimensional helical or antihelical curve that can protect against apical perforation, possibly better, and that allows subtle 3-mensional deflection to aid the operator in achieving coaxiality or overcoming delivery obstacles such as calcific spicules.Wed, 20 Mar 2024 11:33:59 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Helical_Guidewires_and_Related_Systems_for_Transcatheter_Heart_Valve_ProceduresTAB-4488https://nih.technologypublisher.com/tech/Systems_and_Methods_for_Applying_Pressure_to_the_Heart_for_the_Treatment_of_Tricuspid_Valve_RegurgitationThis technology includes structures and methods for cinching a band around the heart for treating conditions including tricuspid valve regurgitation (TR). When positioned appropriately along the atrioventricular groove, the band is tightened around the heart which narrows the tricuspid annulus and relieves TR.Wed, 20 Mar 2024 11:32:48 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Systems_and_Methods_for_Applying_Pressure_to_the_Heart_for_the_Treatment_of_Tricuspid_Valve_RegurgitationTAB-3836https://nih.technologypublisher.com/tech/Vascular_Anchoring_Introducer_Sheath_for_Interventional_Cardiac_ProceduresThis technology includes a device and method for maintaining access to a location in the body while reducing or eliminating the potential for pulling an access device (i.e., catheter) back through an opening, such as a cardiac procedure. An introducer sheath includes a distal indented portion and a balloon, so that once placed in a desired location through tissue, the balloon can be inflated to anchor the sheath against retraction. Wed, 20 Mar 2024 10:30:29 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Vascular_Anchoring_Introducer_Sheath_for_Interventional_Cardiac_ProceduresTAB-4551https://nih.technologypublisher.com/tech/Treatment_of_Periodontal_Disease_via_ENPPI_InhibitionThis technology focuses on enhancing cementum production, a key component in treating periodontal regression. The method involves inhibiting ectonucleotide pyrophosphatase phosphodiesterases (ENPP1), enzymes that play a significant role in mineralization processes. Pyrophosphate (PPi) is known to impede the growth of hydroxyapatite crystals, essential for mineralization. ENPP1 catalyzes the hydrolysis of ATP, generating PPi, which then hinders mineralization. Research indicates that the balance between inorganic phosphate (Pi) and PPi (Pi/PPi ratio) significantly influences cementum formation,...Wed, 20 Mar 2024 07:28:42 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Treatment_of_Periodontal_Disease_via_ENPPI_InhibitionTAB-4480https://nih.technologypublisher.com/tech/Method_to_Detect_and_Quantify_In_Vivo_MitophagyThis technology includes a transgenic reporter mouse that expresses a fluorescent protein called mt-Keima, to be used to detect and quantify in vivo mitophagy. This fluorescent protein was originally described by a group in Japan and shown to be able to measure both the general process of autophagy and mitophagy. We extended these results by creating a living animal so that we could get a measurement for in vivo mitophagy. Our results demonstrate that our mt-Keima mouse allows for a straightforward and practical way to quantify mitophagy in vivo. There is considerable interest in this process ...Wed, 20 Mar 2024 07:24:50 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Method_to_Detect_and_Quantify_In_Vivo_MitophagyTAB-4526https://nih.technologypublisher.com/tech/Clonal_Spodoptera_Frugiperda_Cell_lines_for_Enhanced_ExpressionThis technology includes Spodoptera frugiperda (Sf9) cells which were developed to produce recombinant adeno-associated virus. The cells maintain a copy of the vector genome and for production, require infection with a single baculovirus that expresses either structural and nonstructural proteins to produce rAAV, or the non-structural (Rep) proteins to produce ceDNA.Wed, 20 Mar 2024 07:23:26 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Clonal_Spodoptera_Frugiperda_Cell_lines_for_Enhanced_ExpressionTAB-4516https://nih.technologypublisher.com/tech/Cas9_Protein_Delivery_with_Lentiviral_Vector_Particles_as_a_Therapy_for_Sickle_Cell_DiseaseThis technology includes efficient lentiviral gene delivery system for both guide RNA and Cas9 endonuclease as a method to cure sickle cell disease. Gene correction is an ideal gene therapy strategy for hereditary disease, including sickle cell disease. To deliver both guide RNA and Cas9 endonuclease into target cells, we used HIV-l based lentiviral vector system, which allows for efficient gene delivery in various cells, including hematopoietic stem cells and ES/1PS cells in this system, transgene expression cassettes can be integrated into genomic DNA in target cells, which results in long‐ ...Wed, 20 Mar 2024 07:21:30 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Cas9_Protein_Delivery_with_Lentiviral_Vector_Particles_as_a_Therapy_for_Sickle_Cell_DiseaseTAB-4514https://nih.technologypublisher.com/tech?title=Derivation_of_a_%3e25_million-year-old_Adeno-associated_Virus_Coat_Protein_Sequence_for_Gene_Transfer_Studies25-million-year-old adeno-associated virus which circulated among host species sometime during the...]]>Wed, 20 Mar 2024 07:20:36 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech?title=Derivation_of_a_%3e25_million-year-old_Adeno-associated_Virus_Coat_Protein_Sequence_for_Gene_Transfer_StudiesTAB-4481https://nih.technologypublisher.com/tech/Compositions_and_Methods_for_Reducing_Serum_TriglyceridesThis technology includes a vaccine for lowering plasma triglycerides by inducing the formation of autoantibodies against either ANGPTL3 or ANGPTL4, which are inhibitors of Lipoprotein Lipase. This was done by conjugating synthetic peptides based on ANGPTL3 or ANGPTL4 to virus- like particles (VLPS). Injection of the vaccine in animal models was shown to induce the autoantibody against the target and to lower plasma triglycerides.Wed, 20 Mar 2024 07:17:46 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Compositions_and_Methods_for_Reducing_Serum_TriglyceridesTAB-4513https://nih.technologypublisher.com/tech/High_Density_Lipoprotein_Targeting_Protease_Inhibitor_Peptide_for_the_Treatment_of_Alpha-1-antitrypsin_(A1AT)_DeficiencyThis technology includes a novel concept and design for a lipoprotein targeting protease inhibitor for the treatment of Alpha-1-antitrypsin (A1AT) deficiency. A1AT deficiency occurs in about 1 in 2500 individuals in the United States and Europe, and people with this condition develop severe liver disease and emphysema/chronic obstructive pulmonary disease (COPD). Current treatment involves intravenous infusion of purified human A1AT protein, which is very expensive and only modestly effective. A recent study has demonstrated improvement in A1AT treatment effectiveness in a mouse model of emphy...Wed, 20 Mar 2024 07:17:03 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/High_Density_Lipoprotein_Targeting_Protease_Inhibitor_Peptide_for_the_Treatment_of_Alpha-1-antitrypsin_(A1AT)_DeficiencyTAB-4506https://nih.technologypublisher.com/tech/Anti-sense_Therapy_Against_ApoC-III_as_a_Treatment_for_High_CholesterolThis technology includes a new class of synthetic peptides that activate Lipoprotein Lipase (LPL), a key plasma enzyme that lowers triglycerides, by displacing apoC-111, a potent inhibitor of LPL. ApoC-11 is a known activator of LPL, whereas ApoC-111 inhibits LPL and raises triglycerides either directly by blocking lipolysis and or by preventing hepatic uptake of lipoproteins. Both apoC-II and apoC-III have to bind to the surface of a lipoprotein particle to mediate their effects. We discovered that we can displace apoC-III from lipoproteins and improve lipolysis by adding short synthetic pept...Wed, 20 Mar 2024 07:15:46 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Anti-sense_Therapy_Against_ApoC-III_as_a_Treatment_for_High_CholesterolTAB-4505https://nih.technologypublisher.com/tech/Blocking_CD38_using_Protein_G_Complexed_Daratumumab_Antibodies_(PGDARA)_to_Protect_Natural_Killer_Cells_from_Daratumumab-induced_Apoptosis_and_Cell_Death_for_the_Treatment_of_Multiple_MyelomaThis technology includes the method of blocking CD38 in expanded natural killer (NK) cell therapy in combination with daratumumab in patients with multiple myeloma. Our in vitro studies have already confirmed the addition of NK cells to myeloma cells that have been exposed to daratumumab enhances myeloma killing compared to single agent treatment. Studies exploring adoptive NK cell transfer after daratumumab treatment to bolster daratumumab-mediated killing of myeloma via ADCC could be limited by the fact that these transferred NK cells might be killed by the antibody before they could reach t...Wed, 20 Mar 2024 07:14:23 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Blocking_CD38_using_Protein_G_Complexed_Daratumumab_Antibodies_(PGDARA)_to_Protect_Natural_Killer_Cells_from_Daratumumab-induced_Apoptosis_and_Cell_Death_for_the_Treatment_of_Multiple_MyelomaTAB-4511https://nih.technologypublisher.com/tech/Programmable_and_Modular_Nucleic_Acid_Nanoassemblies-based_(NAN)_Platforms_to_Regulate_Mechanosensitive_Activation_of_T-cellsThis technology includes mechanobiological nucleic acid nanoassemblies-based platforms with dynamically controlled efficiency of T-cell activation. T-cells are the central players in adaptive immune response led by a T-cell receptor (TCR) centric machinery. Current T-cell activation strategy (e.g., micron-scale beads) focuses on 2D TCR-agonist biomimetic surfaces and biomimetic 2D immune synapses with planar traction, which requires non-physiological hyper-stimulatory cytokines levels (e.g., IL-2), and thus, is incompatible with clinical applications. This described technology is based on the ...Wed, 20 Mar 2024 07:04:39 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Programmable_and_Modular_Nucleic_Acid_Nanoassemblies-based_(NAN)_Platforms_to_Regulate_Mechanosensitive_Activation_of_T-cellsTAB-4477https://nih.technologypublisher.com/tech/Cycioxygenase-2_Inhibition_for_the_Treatment-SAA-high_Asthma 108.843 ug/ml. RNA-seq identified that high-density lipoprotein (HDL) enriched with SAA 1 increased the expression of COX-2 in CD14+ monocytes from asthmatics, which was confirmed by Western blotting. The selective COX-2 inhibitors, celecoxib and d...]]>Wed, 20 Mar 2024 07:02:56 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Cycioxygenase-2_Inhibition_for_the_Treatment-SAA-high_AsthmaTAB-4548https://nih.technologypublisher.com/tech/Antibody_Targeting_of_Cell_Surface_Deposited_Complement_Protein_C3d_as_a_Treatment_for_CancerThis technology includes monoclonal antibodies (mAb) that specifically and with high affinity bind the final complement components C3dg and C3d (subsequently referred to as C3d), which can be used to kill tumor cells that carry C3d on their cell surface. We show that tumor cells of patients treated with the therapeutic anti-CD20 mAb ofatumumab carry C3d on the cell surface and can bind and be killed by addition of anti-C3 mAbs. In contrast, further addition of more ofatumumab has only minimal effects. This invention is a novel therapeutic concept to enhance the efficacy of therapeutic antibodi...Wed, 20 Mar 2024 06:41:10 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Antibody_Targeting_of_Cell_Surface_Deposited_Complement_Protein_C3d_as_a_Treatment_for_CancerTAB-4538https://nih.technologypublisher.com/tech/Identification_of_a_Novel_Parvovirus_for_Vaccine_Development_and_Use_as_a_Diagnostic_ToolThis technology includes a procedure for novel virus identification in a variety of human specimens by solexa high-throughput sequencing, which allows for the screening a large number of clinical specimens for novel virus discovery in a highly efficient and relatively economical method. By using this technique, we have successfully identified a novel parvovirus from samples of seronegative hepatitis patients. In a total of 70 samples tested, nineteen of them (27%) were positive by solexa sequencing and 23 (33%) were positive by PCR, which was developed based on the viral sequences obtained fro...Wed, 20 Mar 2024 06:40:20 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Identification_of_a_Novel_Parvovirus_for_Vaccine_Development_and_Use_as_a_Diagnostic_ToolTAB-4530https://nih.technologypublisher.com/tech/Enhancing_Activity_of_Bispecific_Antibodies_in_Combination_with_Ibrutinib_for_the_Treatment_of_CancerThis technology includes the combination of a kinase inhibitor (specifically ibrutinib) with a bispecific antibody (specifically a CD19/CD3 bispecific antibody) to be used to treat cancer. CD19/CD3 bispecific antibodies (bsAbs) can be used to recruit endogenous T cells against CD19+ tumor cells via the formation of cytolytic synapses. lbrutinib, a BTK inhibitor, has been shown to normalize T cell dysfunction characteristic of CLL. We show that achieved significantly more killing of ibrutinib-treated CLL cells compared to treatment-naive CLL cells after 3 days of exposure (56.85% versus -3.29% ...Wed, 20 Mar 2024 06:37:11 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Enhancing_Activity_of_Bispecific_Antibodies_in_Combination_with_Ibrutinib_for_the_Treatment_of_CancerTAB-4602https://nih.technologypublisher.com/tech/New_Fluorescent_Indicator_Alleles_in_Mice_that_Expand_the_Power_of_Recombinase-based_Labeling_to_Uncover_Cellular_DiversityThis technology includes a series of recombinase responsive indicator alleles in genetically modified laboratory mice which uniquely permit non-invasive labeling of cells defined by the overlap of up to three distinct gene expression domains. In response to any combination of Cre, Flp and Dre recombinases, these alleles express high levels of eGFP and/or tdTomato that allow the visualization of cells in live and fixed tissue, including samples processed using modern tissue clearing techniques. Together, these features provide experimental access to cell populations at unprecedented resolution ...Wed, 20 Mar 2024 06:35:50 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/New_Fluorescent_Indicator_Alleles_in_Mice_that_Expand_the_Power_of_Recombinase-based_Labeling_to_Uncover_Cellular_DiversityTAB-4601https://nih.technologypublisher.com/tech/Cytochrome_P450_CYP2J_Polyclonal_Antibodies_and_Recombinant_Proteins_for_Immunoblotting_and_Metabolism_StudiesThis technology includes identified members of the mouse cytochromes P450 CYP2J subfamily and antibodies to them for P450 expression studies and metabolism research. Recombinant proteins of the CYP2J subfamily members have also been expressed. The CYP2J subfamily members have a wide tissue distribution and may be useful as model systems for studies of cardiovascular disease, drug metabolism, and toxicity.Wed, 20 Mar 2024 06:34:24 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Cytochrome_P450_CYP2J_Polyclonal_Antibodies_and_Recombinant_Proteins_for_Immunoblotting_and_Metabolism_StudiesTAB-4600https://nih.technologypublisher.com/tech/Inhibition_of_Epoxide_Hydrolase_1_in_the_Treatment_of_Cardiovascular_DiseasesThis technology includes EPHX1/EPHX2 null mice and showed that disruption of both EPHX1 and EPHX2 almost completely abolished hydrolysis of several EETs which can be used in the treatment of cardiovascular diseases. EPHX 1 is significantly involved in EET hydrolysis, and we believe the combined use of EPHX1 and EPHX2 inhibitors would provide a better alternative to currently available therapeutic options or the EPHX2-based therapies currently in trials for the treatment of cardiovascular diseases.Wed, 20 Mar 2024 06:03:46 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Inhibition_of_Epoxide_Hydrolase_1_in_the_Treatment_of_Cardiovascular_DiseasesTAB-4599https://nih.technologypublisher.com/tech/p300_KO_HEK293T_Cell_Line_for_Multiple_Research_ApplicationsWed, 20 Mar 2024 05:45:16 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/p300_KO_HEK293T_Cell_Line_for_Multiple_Research_ApplicationsTAB-4598https://nih.technologypublisher.com/tech/Developing_a_Stable_Cell_as_a_Screening_Tool_for_Environmental_ChemicalsThis technology includes a stable cell line (293T2-PGC) which has an intact PGC-1 alpha/ERR-alpha pathway to screen for environmental chemicals. The estrogen-related receptor alpha (ERR-alpha) and proliferator-activated receptor gamma coactivator - 1alpha (PGC-1 alpha) play critical roles in the control of several physiological functions, including the regulation of genes involved in energy homeostasis. However, little is known about the environmental chemicals that could disrupt or modulate this pathway leading to adverse health effects. Currently, hundreds of in vitro cell-based assays have ...Wed, 20 Mar 2024 05:41:58 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Developing_a_Stable_Cell_as_a_Screening_Tool_for_Environmental_ChemicalsTAB-4597https://nih.technologypublisher.com/tech/A_BL21_(ED3)_Codon_Plus_Competent_Cell-derived_Bacterial_Strain_for_Research_UseThis technology includes a bacterial strain derived from BL21 (ED3) CodonPlus Competent Cells containing an expression vector for human POLR2C gene for research purposes. The bacterial strain can be used to produce the full-length human RNA polymerase II subunit, RPB3 protein, which can be in turn isolated and purified.Wed, 20 Mar 2024 05:40:22 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/A_BL21_(ED3)_Codon_Plus_Competent_Cell-derived_Bacterial_Strain_for_Research_UseTAB-4524https://nih.technologypublisher.com/tech?title=LZK_and_DLK_Inhibitors_to_Target_LZK_and_Suppress_MYC_Expression%2c_Inhibit_AKT_Activation%2c_and_Promote_Cancer_Cell_Death_and_Tumor_RegressionThis technology includes the use of LZK and DLK inhibitors to be used for the treatment of head and neck squamous cell carcinoma (HNSCC) or lung squamous cell carcinoma (LSCC). Specifically, we demonstrate that inhibitors that can be repurposed to target LZK suppresses LZK kinase-dependent stabilization of MYC and activation of the PI3K/AKT pathway. In vivo preclinical cell line xenograft mouse model demonstrates that targeting LZK will suppress tumor growth. We also demonstrate that several additional compounds potently inhibit LZK and could serve as new therapeutic modalities.Wed, 20 Mar 2024 05:37:17 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech?title=LZK_and_DLK_Inhibitors_to_Target_LZK_and_Suppress_MYC_Expression%2c_Inhibit_AKT_Activation%2c_and_Promote_Cancer_Cell_Death_and_Tumor_RegressionTAB-4897https://nih.technologypublisher.com/tech?title=T_Cell_Receptors_Targeting_EGFR_L858R_mutation_on_HLA-A*11%3a01%7e_Tumors_for_Use_as_Research_ToolsDescription of Technology: Tumor-specific mutated proteins can create neoepitopes, mutation-derived antigens that distinguish tumor cells from healthy cells, which are attractive targets for adoptive cell therapies. However, the process of precisely identifying the neoepitopes to target is complex and challenging. One method to identify such neoepitopes is Mass Spectrometry (MS) when used in conjunction with elution of peptides bound to a specific Human Leukocyte Antigen (HLA) allele. Using MS in this context can demonstrate which oncogene derived neoepitopes are presented by common HLA allel...Fri, 16 Feb 2024 08:12:35 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech?title=T_Cell_Receptors_Targeting_EGFR_L858R_mutation_on_HLA-A*11%3a01%7e_Tumors_for_Use_as_Research_ToolsTAB-3846https://nih.technologypublisher.com/tech/Selective_A3_Adenosine_Receptor_Agonists_for_the_Treatment_of_Chronic_Neuropathic_Pain_and_Other_ConditionsThis technology includes the creation and use of A3 adenosine receptor (A3AR)-selective agonists for treating chemotherapy-induced peripheral neuropathy, chronic neuropathic pain, rheumatoid arthritis, psoriasis, and other conditions. A3 receptors for adenosine are found in most cells and endogenous activation of the A3 receptors can result in apoptosis, thereby relieving the inflammation or targeting a tumor. A3AR agonists have been a promising strategy for the treatment of various diseases. A3AR agonists can reverse neuropathic pain by modulating the production of anti-inflammatory cytokines...Tue, 23 Jan 2024 16:48:29 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Selective_A3_Adenosine_Receptor_Agonists_for_the_Treatment_of_Chronic_Neuropathic_Pain_and_Other_ConditionsTAB-3844https://nih.technologypublisher.com/tech?title=Vitamin_C_renal_leak_as_a_clinical_diagnostic_tool_in_the_detection%2c_monitoring%2c_and_management_of_acute_and_chronic_diseasesTue, 23 Jan 2024 16:43:20 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech?title=Vitamin_C_renal_leak_as_a_clinical_diagnostic_tool_in_the_detection%2c_monitoring%2c_and_management_of_acute_and_chronic_diseasesTAB-3841https://nih.technologypublisher.com/tech/Method_To_Generate_Chondrocytes_from_Human_Induced_Pluripotent_Stem_Cells_(hIPSCs)_and_their_use_in_Repairing_Human_Injury_and_Degenerative_DiseasesThis technology includes a method for differentiating human induced pluripotent stem cells (hiPSCs) into stable chondrocytes, capable of producing cartilage, and their use in cartilage repair in human injury and degenerative diseases. In suspension culture, hiPSC aggregates demonstrate gene and protein expression patterns similar to articular cartilage. Transplantation of cells from the aggregates into a mouse/rat femoral articular cartilage defect leads to the formation of stable, hyaline-like cartilage that persists for up to 5 months in immunocompromised mice and rats, demonstrating that hi...Wed, 17 Jan 2024 06:36:14 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Method_To_Generate_Chondrocytes_from_Human_Induced_Pluripotent_Stem_Cells_(hIPSCs)_and_their_use_in_Repairing_Human_Injury_and_Degenerative_DiseasesTAB-4828https://nih.technologypublisher.com/tech?title=T_Cell_Receptors_Targeting_the_KRAS_G13D_Mutation_in_the_Context_of_HLA-A11%3a01_for_Research_UseTue, 16 Jan 2024 13:37:06 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech?title=T_Cell_Receptors_Targeting_the_KRAS_G13D_Mutation_in_the_Context_of_HLA-A11%3a01_for_Research_UseTAB-4736https://nih.technologypublisher.com/tech/Treatment_of_the_beta-globinopathies_through_inhibition_of_RIOK3_activityDisorders of adult beta-globin synthesis, which include sickle cell disease (SCD) and beta-thalassemia, are the most common monogenic disorders in the world. While the curative potential of bone marrow transplantation has been demonstrated, this approach is limited to a small fraction of affected patients due to the requirement for an HLA-matched donor, the highly specialized approach that requires critical infrastructure, and the high cost. Scientists at the National Heart, Lung, and Blood Institute (NHLBI), have developed lentiviral vectors encoding shRNA to Rio-Kinase 3 (RIOK3) that decrea...Fri, 22 Dec 2023 07:46:38 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Treatment_of_the_beta-globinopathies_through_inhibition_of_RIOK3_activityTAB-4525https://nih.technologypublisher.com/tech/Single_cell_profiling_of_chromatin_Occupancy_and_RNAs_Sequencing_(scPCOR-seq)Cell-to-cell heterogeneity in gene expression is a widespread phenomenon, and may play important roles in cellular differentiation, function and disease development. Human Cell Atlas aims to profile gene expression in every single human cells. Recent studies have implicated a potential role of chromatin in the heterogeneity in gene expression. Understanding the mechanisms of cellular heterogeneity requires simultaneous measurement of RNA and occupancy of histone modifications and transcription factors on chromatin due to their critical roles in transcriptional regulation. However, methods for ...Wed, 20 Dec 2023 06:53:44 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Single_cell_profiling_of_chromatin_Occupancy_and_RNAs_Sequencing_(scPCOR-seq)TAB-4471https://nih.technologypublisher.com/tech/A_Wearable_Device_for_Monitoring_Pregnancy_HealthMon, 27 Nov 2023 10:06:03 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/A_Wearable_Device_for_Monitoring_Pregnancy_HealthTAB-4472https://nih.technologypublisher.com/tech/A_Protocol_to_Enhance_Therapeutic_Effects_of_Transcranial_Magnetic_Stimulation_and_the_Methods_to_Realize_ItWed, 25 Oct 2023 22:02:43 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/A_Protocol_to_Enhance_Therapeutic_Effects_of_Transcranial_Magnetic_Stimulation_and_the_Methods_to_Realize_ItTAB-4467https://nih.technologypublisher.com/tech/A3_Adenosine_Receptor_Positive_Allosteric_ModulatorsFri, 22 Sep 2023 10:02:33 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/A3_Adenosine_Receptor_Positive_Allosteric_ModulatorsTAB-3848https://nih.technologypublisher.com/tech/Treating_Kidney_Disorders_and_Diabetic_Nephropathy_with_N-acetyl_mannosamine_(ManNAc)N-acetylmannosamine (ManNAc) is a small uncharged physiological molecule that crosses membranes readily and is the natural precursor of intracellular sialic acid synthesis. NHGRI investigators discovered that ManNAc can be used for therapeutic purposes, including treating certain kidney diseases (e.g., those involving proteinuria and hematuria), resulting primarily or secondarily from hyposialylation (lack of sialic acid). Notably, ManNAc can also be used to treat diabetic nephropathy or diabetes. ManNAc therapy is given orally and shows long-term safety and biochemical efficacy, consistent...Fri, 15 Sep 2023 14:55:05 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Treating_Kidney_Disorders_and_Diabetic_Nephropathy_with_N-acetyl_mannosamine_(ManNAc)TAB-4464https://nih.technologypublisher.com/tech/Alpha-galactosidase-A_Knockout_Mouse_Model_for_Studying_Fabry_DiseaseThis technology includes an alpha-galactosidase-A knockout mouse model that can be used to study Fabry disease, an X-linked lysosomal storage disorder. Alpha-galactosidase-A is a crucial enzyme responsible for the breakdown of glycolipids, particularly globotriaosylceramide (Gb3), within lysosomes. In Fabry disease, a rare and inherited lysosomal storage disorder, mutations in the GLA gene lead to deficient or non-functional alpha-galactosidase-A enzyme activity. This enzymatic deficiency results in the progressive accumulation of Gb3 and related glycolipids in various cells and tissues, causi...Wed, 30 Aug 2023 10:49:46 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Alpha-galactosidase-A_Knockout_Mouse_Model_for_Studying_Fabry_DiseaseTAB-4463https://nih.technologypublisher.com/tech/Apparatus_for_Cryogenic-Electron_Microscopy_Sample_PreparationCryo-Electron Microscopy (cryo-EM) is used to obtain high-resolution structural images of macromolecular structures. Samples must be purified and loaded onto cryo-EM grids before imaging. The ideal cryo-EM grid consists of particles that are evenly and richly distributed in a broad distribution of orientations throughout the holes of the support film. Current techniques to prepare cryo-EM grids are performed manually and require trial and error, resulting in a bottleneck in cryo-EM workflows. Researchers from NIEHS developed a device and method for time-resolved preparation of liquid samples ...Wed, 16 Aug 2023 11:19:54 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Apparatus_for_Cryogenic-Electron_Microscopy_Sample_PreparationTAB-4459https://nih.technologypublisher.com/tech/Transperineal_Ultrasound-Guided_Prostate_BiopsyAbstract: Prostate cancer is the most common male cancer in the United States, and the third most common worldwide. Prostate biopsies are often performed to confirm a cancer diagnosis and examine suspect tissue. Prostate biopsies are most often performed under transrectal ultrasound imaging (TRUS) guidance. TRUS images in real-time, at relatively low cost, and shows both prostate and boundaries. However, major problems with TRUS imaging are poor spatial resolution and low sensitivity for cancer detection. Fusion of TRUS images with preoperative images such as Magnetic Resonance (MR) or CAT may...Wed, 02 Aug 2023 07:04:28 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Transperineal_Ultrasound-Guided_Prostate_BiopsyTAB-4458https://nih.technologypublisher.com/tech/Photoactivatable_Lipid-based_Nanoparticles_as_a_Vehicle_for_Dual_Agent_DeliveryAbstract: The invention relates to novel lipid-based nanoparticles (liposomes) for use in targeted, on demand and on site drug delivery. The particles include a wall surrounding a cavity, wherein the wall is comprised of: A lipid bilayer comprising 1,2-bis(tricosa-10,12-diynoyl)-sn-glycero-3-phosphocholine (DC8,9PC), dipalmitoylphosphatidylcholine (DPPC), and 1,2-distearoyl-sn-glycero-3- phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000] (DSPE-PEG2000), and A tetrapyrollic photosensitizer, 2-[1-hexyloxyethyl]-2-devinyl pyropheophorbide-a (HPPH) within the lipid bilayer. The p...Wed, 02 Aug 2023 07:04:26 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Photoactivatable_Lipid-based_Nanoparticles_as_a_Vehicle_for_Dual_Agent_DeliveryTAB-4452https://nih.technologypublisher.com/tech/CNS_Therapeutics_That_Target_Neuronal_Ceroid-Lipofuscinoses_and_Thioesterase_Deficiency_DisordersAbstract: Clinically known as Neuronal Ceroid-Lipofuscinoses (NCL), Batten disease, is a rare neuron killing disease and one of the lysosomal storage disorders (LSDs).  It is associated with a mutation or lack of palmitoyl-protein thioesterase-1 (PPT1) gene. It manifests very early in a child's life causing absence of brain activity as early as 4 years of age. Dr. Mukherje of NICHD has discovered and developed N-t-BuHA, a chemical derivative of hydroxylamine that mimics the action of PPT1 enzyme.  Compared to hydroxylamine, N-t-BuHA has been shown to be non-toxic in mice expressing batten dise...Wed, 02 Aug 2023 07:04:22 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/CNS_Therapeutics_That_Target_Neuronal_Ceroid-Lipofuscinoses_and_Thioesterase_Deficiency_DisordersTAB-4450https://nih.technologypublisher.com/tech?title=A_Sensitive%2c_High_Throughput_Pseudovirus-Based_Papillomavirus_Neutralization_Assay_for_HPV_16_and_HPV_18Abstract: Human Papilloma Viruses (HPV) is a very common virus; nearly 80 million people—about one in four—are currently infected in the United States. HPV is a group of more than 150 related viruses. Each HPV virus in this large group is given a number which is called its HPV type. HPV is named for the warts (papillomas) some that HPV types can cause. Some other HPV types can lead to cancer, especially cervical cancer. There are more than 40 HPV types that can infect the genital areas of males and females. Each year, about 38,793 new cases of cancer are found in parts of the body where HPV is...Wed, 02 Aug 2023 07:04:19 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech?title=A_Sensitive%2c_High_Throughput_Pseudovirus-Based_Papillomavirus_Neutralization_Assay_for_HPV_16_and_HPV_18TAB-4449https://nih.technologypublisher.com/tech?title=Lentiviral_Vectors_with_Dual_Fluorescence%2fLuminescence_ReportersAbstract: The National Cancer Institute’s Protein Expression Laboratory seeks parties to co-develop dual luminescent/fluorescent cancer biomarkers. In research settings, visualization of  tumors or tumor cells is often done using either bioluminescence or fluorescence.  However, both of these methods have shortcomings: bioluminescence is not sensitive enough to sort individual tumor cells, and fluorescence cannot be used effectively to view internal tumors and is best used with surface tumors. Researchers at NCI developed twelve lentiviral vectors that express both fluorescent and luminescent ...Wed, 02 Aug 2023 07:04:17 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech?title=Lentiviral_Vectors_with_Dual_Fluorescence%2fLuminescence_ReportersTAB-4448https://nih.technologypublisher.com/tech/National_Cancer_Institute_Dosimetry_System_for_Nuclear_Medicine_(NCINM)_Computer_ProgramAbstract: Nuclear medicine is the second largest source of medical radiation exposure to the general population after computed tomography imaging. Imaging modalities utilizing nuclear medicine produce a more detailed view of internal structure and function and are most commonly used to diagnose diseases such as heart disease, Alzheimer’s and brain disorders. They are used to visualize tumors, abscesses due to infection or abnormalities in abdominal organs. When using radionuclides for diagnosis or therapy in nuclear medicine, it is critical to accurately estimate unintended dose to organs at r...Wed, 02 Aug 2023 07:04:16 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/National_Cancer_Institute_Dosimetry_System_for_Nuclear_Medicine_(NCINM)_Computer_ProgramTAB-4447https://nih.technologypublisher.com/tech/Cancer_Therapeutic_Based_on_Hypoxia_Inducible_Factor_1_(HIF-1)_InhibitorsAbstract: Hypoxia is a characteristic of many solid tumors resulting from accelerated cellular proliferation and inadequate vascularization. HIF-1 is a transcription factor critical for maintaining cellular homeostasis in, and adaptively responding to, low oxygen environments. HIF-1 becomes activated through binding to the transcriptional co-activator protein p300. Disruption of the HIF-1/p300 interaction could potentially modulate HIF-1 activity. Researchers at the National Cancer Institute (NCI) have developed small molecule compounds that inhibit the activity of HIF-1. The HIF-1 inhibitor c...Wed, 02 Aug 2023 07:04:15 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Cancer_Therapeutic_Based_on_Hypoxia_Inducible_Factor_1_(HIF-1)_InhibitorsTAB-4445https://nih.technologypublisher.com/tech?title=Tissue_Clamp_for_Repeated_Opening_and_Closure_of_Incisions%2fWoundsAbstract: Medical clamps currently available are not efficient nor are they sufficiently precise in closure and alignment of the edges of an incision or wound. Many available designs are difficult to use and handle, especially in situations where repeated opening and closure of an incision or wound is required. The functional short-comings of existing clamp designs may result in surgical complications, such as excess loss of fluids and pressure and hemostasis during some procedures. These functional deficiencies may increase the difficulty and expense of a surgery or altogether limit the abili...Wed, 02 Aug 2023 07:04:13 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech?title=Tissue_Clamp_for_Repeated_Opening_and_Closure_of_Incisions%2fWoundsTAB-4444https://nih.technologypublisher.com/tech/Nitric_Oxide-Releasing_Polysaccharide_MaterialsAbstract: Diazeniumdiolates comprise a diverse class of NO-releasing compounds and materials that are known to exhibit sufficient stability to be useful as therapeutics. Diazeniumdiolated compounds have been attached to polymers, substrates, and medical devices for the treatment and management of a variety of diseases including cancer, inflammation, heart disease, and hypertension.  Despite the extensive literature available on NO and nitric oxide-releasing compounds, there remains a need for stable nitric oxide-releasing polymers, such as polysaccharides, or small molecules, such as monosacch...Wed, 02 Aug 2023 07:04:12 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Nitric_Oxide-Releasing_Polysaccharide_MaterialsTAB-4443https://nih.technologypublisher.com/tech/Polypeptides_for_Stimulation_of_Immune_Response_(Adjuvants)Abstract: HMGN polypeptides belong to the high mobility group (HMG) family of chromosomal binding peptides. HMGN polypeptides typically function inside the cell nucleus to bind to DNA and nucleosomes and regulate the transcription of various genes. HMGN polypeptides also can be released by peripheral blood mononuclear cells. However, the extracellular release of a HMGN polypeptide initiates activation of the immune system. Therefore, it has potential use as a biological therapeutic for stimulating an immune response. Therefore, HMGN has potential use as a clinically effective immunoadjuvant f...Wed, 02 Aug 2023 07:04:11 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Polypeptides_for_Stimulation_of_Immune_Response_(Adjuvants)TAB-4438https://nih.technologypublisher.com/tech/T-Cell_Immunotherapy_that_Targets_Aggressive_Epithelial_TumorsAbstract: Metastatic cancers cause up to 90% of cancer deaths, yet few treatment options exist for patients with metastatic disease. Adoptive transfer of T cells that express tumor-reactive T-cell receptors (TCRs) has been shown to mediate regression of metastatic cancers in some patients. Unfortunately, identification of antigens expressed solely by cancer cells and not normal tissues has been a major challenge for the development of T-cell based immunotherapies. Thus, it is essential to find novel target antigens differentially expressed in cancer versus normal tissues. Inventors at the Na...Wed, 02 Aug 2023 07:04:09 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/T-Cell_Immunotherapy_that_Targets_Aggressive_Epithelial_TumorsTAB-4436https://nih.technologypublisher.com/tech/High-Affinity_Mouse_Monoclonal_Antibodies_to_GPC-3_for_Liver_Cancer_ResearchAbstract: The National Cancer Institute Laboratory of Molecular Biology seeks parties for collaborative research to co-develop and commercialize antibody drug/toxin conjugates as liver cancer therapy and diagnostics.  There is great interest and value in developing more sensitive and efficient agents for earlier detection of hepatocellular cancer (HCC).  Glypican-3 (GPC3) is a cell surface heparin sulfate glycoprotein that is expressed on the vast majority of HCC cells. The correlation between GPC3 expression and HCC makes GPC3 an attractive candidate for studying the disease progression and t...Wed, 02 Aug 2023 07:04:06 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/High-Affinity_Mouse_Monoclonal_Antibodies_to_GPC-3_for_Liver_Cancer_ResearchTAB-4435https://nih.technologypublisher.com/tech/Levonorgestrel_Butanoate_Formulation_and_Methods_Relating_TheretoAbstract: This invention is a potential subcutaneous or intramuscular progestin-only, injectable contraceptive for women. Forty-five percent (45%) of pregnancies in the United States are unintended. In this group, one-third of reproductive age women are obese – increasing the risk of diabetes, hypertension and venous thromboembolism (VTE). All these are conditions for which most hormonal methods are contraindicated. Thus, additional safe and effective injectable contraceptive options are needed. A subcutaneous formulation may be self-injected without the need of a skilled care provider or medi...Wed, 02 Aug 2023 07:04:04 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Levonorgestrel_Butanoate_Formulation_and_Methods_Relating_TheretoTAB-4433https://nih.technologypublisher.com/tech?title=Improved_Antibodies_Against_ERBB4%2fHER4Abstract: The Eunice Kennedy Shriver National Institute of Child Health and Human Development, Section on Molecular Neurobiology is seeking statements of capability or interest from parties interested in collaborative research to further evaluate or commercialize specific rabbit monoclonal antibodies generated against the ErbB4 receptor (also known as HER4) that have been validated for specificity using tissue sections and extracts from ErbB4 knockout mice. ErbB4/Her4 is a receptor tyrosine kinase that regulates cell proliferation, cell differentiation and cell survival.  ErbB4 has been implic...Wed, 02 Aug 2023 07:04:03 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech?title=Improved_Antibodies_Against_ERBB4%2fHER4TAB-4431https://nih.technologypublisher.com/tech/Nanoparticle_delivery_of_lung_cancer_therapeuticAbstract: Non-small cell lung cancer (NSCLC) is the leading cause of cancer-related deaths in developed countries.  Despite the availability of several synergistic, targeted therapy regiments, the 5-year survival rate for NSCLC is only 15%.  The poor prognosis of NSCLS is due in part to limitations of current treatments, which do not trigger an immune response against NSCLC, nor can they be directly delivered into the lungs.   Researchers at NCI developed a novel method for synthesizing polyketal nanoparticles with adsorbed CpG oligonucleotides (NP-CpG) that possess immunomodulatory and potent...Wed, 02 Aug 2023 07:04:00 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Nanoparticle_delivery_of_lung_cancer_therapeuticTAB-4430https://nih.technologypublisher.com/tech/Radioprotectants_and_Tumor_Radiosensitizers_Targeting_Thrombospondin-1_and_CD47Abstract: The National Cancer Institute''s Laboratory of Pathology is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize CD47-targeting agents as radioprotectants and tumor sensitizers. Radiation therapy not only damages cancer cells, but it also damages healthy cells and can cause serious side effects for patients.  One effort to enhance the therapeutic potential of radiotherapy, while reducing its detrimental effects on normal tissue and maintaining tumor sensitivity, is centered upon the development o...Wed, 02 Aug 2023 07:03:58 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Radioprotectants_and_Tumor_Radiosensitizers_Targeting_Thrombospondin-1_and_CD47TAB-4427https://nih.technologypublisher.com/tech/Anti-Py1235-Met_Immunological_Binding_Reagent_as_Cancer_DiagnosticAbstract: This technology consists of highly specific rabbit monoclonal antibodies reactive with phosphorylated tyrosine located at amino acid 1235 in the human MET sequence. Binding to this pYl235 residue is independent of the phosphorylation of other tyrosines in the vicinity (1230 and 1234), does not cross-react with these nearby phosphotyrosine residues, and does not occur when Y1235 is unphosphorylated. The receptor tyrosine kinase MET is an important drug target for treatment of various diseases including diseases mediated by dysregulated cell proliferation (e.g., cancer). A key event in...Wed, 02 Aug 2023 07:03:56 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Anti-Py1235-Met_Immunological_Binding_Reagent_as_Cancer_DiagnosticTAB-4425https://nih.technologypublisher.com/tech/Combination_of_Near_Infrared_Photoimmunotherapy_Targeting_Cancer_Cells_and_Host-Immune_ActivationAbstract: Common methods of cancer therapy largely rely on either direct killing of cancer cells or activation of the host immune response to do so, but not both. A recently developed treatment of tumors uses an antibody/photo-absorber, Ab-IR700, with near infrared photoimmunotherapy (NIR-PIT), to selectively kill IR700-bound and NIR-light-exposed cancer cells by activating an immunogenic cell death pathway. NIR-PIT has been shown in human clinical trials to effectively target tumor cells via a host immune response with relatively few side effects. However, the depth of NIR-light penetration i...Wed, 02 Aug 2023 07:03:54 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Combination_of_Near_Infrared_Photoimmunotherapy_Targeting_Cancer_Cells_and_Host-Immune_ActivationTAB-4424https://nih.technologypublisher.com/tech/Coumarin_Luciferins_and_Mutant_Luciferases_for_Bioluminescence_ImagingAbstract: Bioluminescence imaging with luciferin-luciferase pairs is a well-established technique for tracking cells and other biological features in animal models. Bioluminescent is a chemical process which does not require an external input for excitation. Bioluminescent imaging is often limited to monitoring single processes in vivo due to the lack of distinguishable probes. Additionally, existing probes typically operate with light in the visible range, which is highly scattered and exhibits poor tissue penetration.  To address these issues, researchers at UCI and NCI synthesized a new fam...Wed, 02 Aug 2023 07:03:53 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Coumarin_Luciferins_and_Mutant_Luciferases_for_Bioluminescence_ImagingTAB-4423https://nih.technologypublisher.com/tech/Polymeric_Delivery_Platform_for_TherapeuticsAbstract: Drug delivery technologies have long claimed the ability to selectively deliver therapeutic cargo to target cells. Despite advances in nanomedicine and drug delivery systems, there are no targeted nanoscale drug delivery technologies on the market. Thus, there is still tremendous potential in improved therapeutic efficacy when targeted drug delivery is achieved.  Investigators at the Nanotechnology Characterization Laboratory at the National Cancer Institute (NCI) developed a drug delivery platform that targets scavenger receptor A1 (SR-A1), a receptor highly expressed in macrophages...Wed, 02 Aug 2023 07:03:51 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Polymeric_Delivery_Platform_for_TherapeuticsTAB-4422https://nih.technologypublisher.com/tech/Antibody_and_Immunotoxin_Treatments_for_Mesothelin-expressing_CancersAbstract: Mesothelin is a cell surface protein that is highly expressed in aggressive cancers such as malignant mesothelioma, ovarian cancer, pancreatic cancer, lung cancer, breast cancer, cholangiocarcinoma, bile duct carcinoma and gastric cancer. As a result, mesothelin is an excellent candidate for tumor targeted immunotherapeutics. However, the antibodies against mesothelin that are available for clinical trials are of murine origin. These antibodies have the potential to elicit immune responses in patients, which may adversely affect the ability to provide patients with repeated doses. Th...Wed, 02 Aug 2023 07:03:50 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Antibody_and_Immunotoxin_Treatments_for_Mesothelin-expressing_CancersTAB-4420https://nih.technologypublisher.com/tech/Chimeric_Antigen_Receptors_that_Recognize_Mesothelin_for_Cancer_ImmunotherapyAbstract: Chimeric antigen receptors (CARs) with high affinity for mesothelin that can be used as an immunotherapy to treat cancers that express mesothelin, such as pancreatic cancer, ovarian cancer, and mesothelioma. The technology includes CAR constructs with one of three different mesothelin-specific antibody portions, including either the mouse-derived SS or SS1 antibody fragments or the human HN1 antibody fragment. Mesothelin is a protein cancer antigen with limited expression on normal cells that is overexpressed by cancer cells. CARs are hybrid proteins consisting of an antibody portion...Wed, 02 Aug 2023 07:03:48 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Chimeric_Antigen_Receptors_that_Recognize_Mesothelin_for_Cancer_ImmunotherapyTAB-4419https://nih.technologypublisher.com/tech/Device_for_Simulating_Explosive_Blast_and_Imaging_Biological_SpecimensAbstract: Traumatic brain injury (TBI) is a major health problem.  Between 3.2 and 5.3 million people live with long-term disabilities resulting from TBI, and thus, contribute to the need to develop therapies that treat TBI-induced cellular damage. Researchers at the National Institute of Child Health and Human Development (NICHD) have developed a device that simulates the pressure waves resulting from explosions. This invention can be used to study the in vitro effects of shock waves on cells in culture and could be used to determine the effects of potential treatments for TBI in an in vitro ...Wed, 02 Aug 2023 07:03:46 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Device_for_Simulating_Explosive_Blast_and_Imaging_Biological_SpecimensTAB-4418https://nih.technologypublisher.com/tech?title=Novel_Human_Insulin_C%ce%b1-Peptide_as_an_Antagonist_for_Islet_and_Brain_AmyloidosisWed, 02 Aug 2023 07:03:45 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech?title=Novel_Human_Insulin_C%ce%b1-Peptide_as_an_Antagonist_for_Islet_and_Brain_AmyloidosisTAB-4416https://nih.technologypublisher.com/tech/Therapeutics_for_Neurodegenerative_Disorders_and_Cancer_Using_Lenalidomide_AnalogsAbstract: Inflammatory processes associated with the over-production of tumor necrosis-alpha (TNF-alpha), a potent activator of the immune system accompany numerous neurodegenerative diseases. TNF-alpha has been validated as a drug target with the development of the inhibitors Enbrel and Remicade (fusion antibodies) as prescription medications. Both, however, are large macromolecules that require direct injection and have limited brain access. The classical drug, thalidomide is being increasingly used in the clinical management of a wide spectrum of immunologically-mediated and infectious dise...Wed, 02 Aug 2023 07:03:43 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Therapeutics_for_Neurodegenerative_Disorders_and_Cancer_Using_Lenalidomide_AnalogsTAB-4415https://nih.technologypublisher.com/tech?title=Treatment_of_GPR101-Related%2c_Growth_Hormone-Related_Disorders_Such_as_Gigantism%2c_Dwarfism_or_AcromegalyAbstract: Microduplications of the GPR101 gene (located on chromosome Xq26.3 and encodes a G-protein coupled receptor) can result in an excess of growth hormone causing gigantism, that has an onset in early childhood. It is also associated with the growth of sporadic growth hormone producing adenomas in some patients with acromegaly. Current therapies (such as surgical resection of tumors or treatment with somatostatin analogs) for acromegaly, gigantism and other disorders of pituitary hormone hypersecretion can be ineffective, thereby creating a need for alternative therapies in this space. T...Wed, 02 Aug 2023 07:03:42 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech?title=Treatment_of_GPR101-Related%2c_Growth_Hormone-Related_Disorders_Such_as_Gigantism%2c_Dwarfism_or_AcromegalyTAB-4413https://nih.technologypublisher.com/tech/Small_Molecule_Inhibitors_of_Histone_Demethylases_for_Treating_Rhabdomyosarcoma_(RMS)_and_Other_CancersAbstract: Rhabdomyosarcoma (RMS) is the most common type of soft tissue sarcoma in children and makes up 3% of all childhood cancers. Aveloar Rhabdomyosarcoma is the most aggressive subtype and is primarily established through a chromosomal translocation resulting in the fusion protein PAX3-FOXO1. Despite aggressive therapy, the 5-year survival rate for patients with high risk or recurrent Fusion Positive RMS (FP-RMS) is low (~30% and ~17%, respectively). Therefore, new therapies targeting the PAX3-FOXO1 oncogenic driver are urgently needed.   To identify inhibitors of PAX3-FOXO1, scientists a...Wed, 02 Aug 2023 07:03:40 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Small_Molecule_Inhibitors_of_Histone_Demethylases_for_Treating_Rhabdomyosarcoma_(RMS)_and_Other_CancersTAB-4412https://nih.technologypublisher.com/tech/Methods_For_Treating_or_Preventing_Inflammation_and_PeriodontitisAbstract: Bone-loss-related diseases, such as periodontitis, are characterized by an imbalance between the formation and activity of osteoblasts and osteoclasts, leading to bone loss. There are several signaling pathways that participate in the osteoclastogenesis process. Finding inhibitors of these pathways and other osteoclastogenesis-related pathways may have an effect on bone-loss diseases. Researchers at the National Cancer Institute (NCI), in collaboration with researchers at the University of Campinas, Brazil, have identified cinnamolyoxy-mammeisin (CNM), a 4-phenylcoumarin, which can b...Wed, 02 Aug 2023 07:03:38 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Methods_For_Treating_or_Preventing_Inflammation_and_PeriodontitisTAB-4411https://nih.technologypublisher.com/tech/Gene_Therapy_for_Treatment_of_CRX-Autosomal_Dominant_RetinopathiesAbstract: Mutations in the cone rod homeobox (CRX) transcription factor lead to distinct retinopathy phenotypes, including early-onset vision impairment in dominant Leber congenital amaurosis (LCA). Adeno-Associated virus (AAV) vector-mediated delivery of a CRX cDNA under the control of a CRX promoter region partially restored photoreceptor phenotype and expression of phototransduction genes in an in vitro model of CRX-LCA. Gene therapy using the CRX-AAV vector to retinal organoids derived from induced pluripotent stem cells (iPSCs) of a patient with the dominant CRX-I138fs mutation partially ...Wed, 02 Aug 2023 07:03:37 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Gene_Therapy_for_Treatment_of_CRX-Autosomal_Dominant_RetinopathiesTAB-4410https://nih.technologypublisher.com/tech/Human_Antibodies_Against_Middle_East_Respiratory_Syndrome_CoronavirusAbstract: No effective therapeutics or vaccines against Middle East Respiratory Syndrome Coronavirus (MERS-CoV) are available. The human-to-human aspect of transmission and the high mortality rate associated with MERS-CoV infection have raised concerns over the potential for a future MERS-CoV pandemic and emphasized the need for development of effective therapeutics and vaccines. The MERS-CoV-S protein is believed to be required for binding and virus entry during MERS-CoV infection. The antibodies of this technology represent candidate antibody-based therapeutics for treatment of MERS-CoV infe...Wed, 02 Aug 2023 07:03:35 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Human_Antibodies_Against_Middle_East_Respiratory_Syndrome_CoronavirusTAB-4408https://nih.technologypublisher.com/tech/Improved_HIV_Vaccines_Through_Ras_ActivationAbstract: Researchers at the National Cancer Institute (NCI) have developed a new method of improving the efficacy of vaccines in patients with human immunodeficiency virus (HIV) by activating Ras. This method can be used to develop more efficacious vaccine compositions by activating Ras before, during, or after vaccination. Additionally, the researchers discovered that modulation of the Ras pathways could be a predictive biomarker of protection against HIV. This novel method has been shown to effectively stimulate the Ras pathway and to improve vaccine protection from Simian Immunodeficiency ...Wed, 02 Aug 2023 07:03:32 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Improved_HIV_Vaccines_Through_Ras_ActivationTAB-4407https://nih.technologypublisher.com/tech/Convolutional_Neural_Networks_for_Organ_SegmentationAbstract: Accurate automated organ and disease feature segmentation is a challenge for medical imaging analysis. The pancreas, for example, is a small, soft, organ with low uniformity of shape and volume between patients. Because of the lack of uniform image patterns, there are few features that can be used to aid in automated identification of anatomy and boundaries. Segmentation of high variability features is uniquely difficult for a computer to perform. Due to these difficulties, high variability anatomical features are currently analyzed and determined only by trained physicians who can r...Wed, 02 Aug 2023 07:03:31 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Convolutional_Neural_Networks_for_Organ_SegmentationTAB-4406https://nih.technologypublisher.com/tech/High_Efficacy_Vaccine_and_Microbicide_Combination_For_Use_Against_HIVAbstract: Human immunodeficiency virus (HIV) remains a major global health challenge despite the advancement made in development of effective antiretrovirals (ARVs). ARVs are effective at limiting replication and spread of the virus, and progression to acquired immuno-deficiency syndrome (AIDS). However, ARVs often lead to emergence of drug-resistant virus strains insensitive to treatment and with toxic effects following long-term usage. In addition, access to ARVs is limited in certain regions, particularly in sub-Saharan Africa – where the HIV epidemic continues unabated and disproportionate...Wed, 02 Aug 2023 07:03:29 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/High_Efficacy_Vaccine_and_Microbicide_Combination_For_Use_Against_HIVTAB-4404https://nih.technologypublisher.com/tech/Modified_griffithsin_tandemers_for_enhanced_activity_and_reduced_viral_aggregationAbstract: Griffithsin (GRFT) is a lectin with potent antiviral properties that is capable of preventing and treating infections caused by a number of enveloped viruses (including HIV, SARS, HCV, HSV, and Japanese encephalitis) and is currently in clinical development as an anti-HIV microbicide. In addition to its broad antiviral activity, GRFT is stable at high temperature and at a broad pH range, displays low toxicity and immunogenicity, and is amenable to large-scale manufacturing. Native GRFT is a domain-swapped homodimer that binds to viral envelope glycoproteins and has displayed mid-pico...Wed, 02 Aug 2023 07:03:28 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Modified_griffithsin_tandemers_for_enhanced_activity_and_reduced_viral_aggregationTAB-4403https://nih.technologypublisher.com/tech/Novel_Chemoattractant-Based_Toxins_To_Improve_Vaccine_Immune_Responses_for_Cancer_and_Infectious_DiseasesWed, 02 Aug 2023 07:03:26 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Novel_Chemoattractant-Based_Toxins_To_Improve_Vaccine_Immune_Responses_for_Cancer_and_Infectious_DiseasesTAB-4402https://nih.technologypublisher.com/tech/Novel_Anti-HIV_Compounds_Using_Peptides_or_Peptide_MimeticsAbstract: The subject invention describes a new class of compounds (such as peptides or mimetics) that target viral RNAs and inhibit the viral life cycle by blocking the viral recognition process. More specifically, these compounds are the first against an RNA Target - currently there are no clinical drugs against RNA targets in the treatment of any type of human disease. Anti-HIV drugs currently on the market are complicated by the development of resistance and substantial side-effects; however, these compounds would unlikely develop any side effects because of their very high specificity aga...Wed, 02 Aug 2023 07:03:25 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Novel_Anti-HIV_Compounds_Using_Peptides_or_Peptide_MimeticsTAB-4401https://nih.technologypublisher.com/tech/Methods_for_Selection_of_Cancer_Patients_and_Predicting_Efficacy_of_Combination_TherapyAbstract: Available for licensing from the Laboratory of Cancer Biology and Genetics of the National Cancer Institute (NCI) is a novel gene signature of thirty-seven drug-responsive genes that links changes in gene expression to the clinically desirable outcome of improved overall survival. Expression of these genes has been linked to prognosis in several cancers, including, but not limited to: multiple myeloma, melanoma, and lung and breast cancers. Patients identified by this signature would be predicted to benefit from combined HDAC inhibitor/mTOR inhibitor therapy. Competitive Advantages: ...Wed, 02 Aug 2023 07:03:23 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Methods_for_Selection_of_Cancer_Patients_and_Predicting_Efficacy_of_Combination_TherapyTAB-4394https://nih.technologypublisher.com/tech/Increased_Therapeutic_Effectiveness_of_PE-Based_ImmunotoxinsAbstract: Patients receiving immunotoxin cancer therapy are less likely to experience the deleterious side-effects associated with non-discriminate therapies such as chemotherapy or radiation therapy. Unfortunately, the continued administration of immunotoxins often leads to a reduced patient response due to the formation of neutralizing antibodies against immunogenic epitopes contained within Pseudomonas exotoxin A (PE).  To improve the therapeutic effectiveness of PE-based immunotoxins through multiple rounds of drug administration, NIH inventors have sought to identify and remove the human...Wed, 02 Aug 2023 07:03:21 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Increased_Therapeutic_Effectiveness_of_PE-Based_ImmunotoxinsTAB-4393https://nih.technologypublisher.com/tech/Fully_Human_Antibodies_and_Antibody_Drug_Conjugates_Targeting_CD276_(B7-H3)_for_the_Treatment_of_CancerAbstract: Angiogenesis is the formation of new blood vessels from pre-existing blood vessels. Angiogenesis occurs during normal growth and development, where it is known as physiological angiogenesis, and during the growth of solid tumors, where it is known as pathological angiogenesis. CD276, also known as B7-H3, is a cell surface tumor endothelial marker that is highly expressed in the tumor vessels of human lung, breast, colon, endometrial, renal, and ovarian cancer, but not in the angiogenic vessels of healthy tissue. This differential expression makes CD276 an attractive target for cancer...Wed, 02 Aug 2023 07:03:19 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Fully_Human_Antibodies_and_Antibody_Drug_Conjugates_Targeting_CD276_(B7-H3)_for_the_Treatment_of_CancerTAB-4392https://nih.technologypublisher.com/tech/Methods_of_analyzing_virus-derived_therapeuticsAbstract: Researchers at the National Cancer Institute’s Biopharmaceutical Development Program recently developed massively parallel sequencing methods for virus-derived therapeutics such as viral vaccines and oncolytic immunotherapies. The methods allow for the determination of micro-heterogeneity and quantitation of low frequency sequence variants, which have the possibility of supplanting monkey neurovirulence safety testing (MNVT), mutant analysis by PCR, and restriction enzyme cleavage (MAPREC) methods that are currently used to screen RNA virus-derived therapeutics. The technology is cur...Wed, 02 Aug 2023 07:03:18 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Methods_of_analyzing_virus-derived_therapeuticsTAB-4390https://nih.technologypublisher.com/tech/Diagnostic_Marker_for_Improving_Treatment_Outcomes_of_Hepatitis_CAbstract: The National Cancer Institute (NCI) Division of Cancer Epidemiology and Genetics (DCEG)  Immunoepidemiology Branch is seeking statements of capability or interest from parties interested in collaborative research to further co-develop a gene-based diagnostic for Hepatitis C virus (HepC, HCV). NCI Researchers have discovered Interferon-lambda 4 (IFNL4), a protein found through analysis of genomic data. Preliminary studies indicate that this protein may play a role in the clearance of HCV and may be a new target for diagnosing and treating HCV infection. One of the unfortunate aspects ...Wed, 02 Aug 2023 07:03:16 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Diagnostic_Marker_for_Improving_Treatment_Outcomes_of_Hepatitis_CTAB-4389https://nih.technologypublisher.com/tech/T_Cell_Receptors_Targeting_CDKN2A_Mutations_for_Cancer_ImmunotherapyAbstract: Cyclin-dependent kinase inhibitor 2A gene, also known as CDKN2A, is a tumor suppressor gene and is commonly inactivated through somatic mutations in many human cancers. For example, inactivation of CDKN2A is highly prevalent in melanoma, gastrointestinal and pancreatic cancers. Through germline mutations, CDKN2A is associated with predisposition for a variety of cancers, including melanoma and pancreatic cancers. Despite the high frequency of CDKN2A mutations in cancer, there have been no successful therapies targeting these mutations to date. Adoptive cell therapy, a promising form ...Wed, 02 Aug 2023 07:03:15 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/T_Cell_Receptors_Targeting_CDKN2A_Mutations_for_Cancer_ImmunotherapyTAB-4385https://nih.technologypublisher.com/tech/Methods_for_Producing_Stem_Cell-Like_Memory_T_Cells_for_Use_in_T_Cell-Based_ImmunotherapiesAbstract: T cells currently employed for T cell-based immunotherapies are often senescent, terminally differentiated cells with poor proliferative and survival capacity. Recently, however, scientists at the National Cancer Institute (NCI) identified and characterized a new human memory T cell population with stem cell-like properties. Since these T cells have limited quantities in vivo, the scientists have developed methods by which high numbers of these cells can be generated ex vivo for use in T cell-based immunotherapies. Specifically, this invention describes a method for generating the st...Wed, 02 Aug 2023 07:03:13 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Methods_for_Producing_Stem_Cell-Like_Memory_T_Cells_for_Use_in_T_Cell-Based_ImmunotherapiesTAB-4384https://nih.technologypublisher.com/tech/Agonist_Epitopes_for_the_Development_of_a_Human_Papillomavirus_(HPV)_Therapeutic_VaccineAbstract: Human papillomavirus (HPV) has been associated with the cause of several cancer types, including cervical, anal, and head and neck cancers. There has been great success in preventing HPV infections with the development of prophylactic HPV vaccines, Gardasil and Cervarix. However, these vaccines have only been shown to prevent HPV infection and not treat those already infected with HPV. These vaccines elicit antibody responses to late HPV genes, and thus would not be effective in treating established tumors. To date, no therapeutic HPV vaccine has been approved by the FDA, and there i...Wed, 02 Aug 2023 07:03:11 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Agonist_Epitopes_for_the_Development_of_a_Human_Papillomavirus_(HPV)_Therapeutic_VaccineTAB-4381https://nih.technologypublisher.com/tech/Methods_of_Producing_Thymic_Emigrants_from_Induced_Pluripotent_Stem_CellsWed, 02 Aug 2023 07:03:09 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Methods_of_Producing_Thymic_Emigrants_from_Induced_Pluripotent_Stem_CellsTAB-4380https://nih.technologypublisher.com/tech/AT-3_Mouse_Breast_Tumor_Cell_LineAbstract: Tumor cell lines are important tools for the study of cancer. However, most tumor cell lines available today do not mimic physiological tumor development, progression, and host immune responses. Autochthonous tumors include spontaneously occurring tumors and chemical, viral, or physical carcinogen-induced tumors. They are considered to model human tumors more closely than transplanted tumors. Autochthonous tumors can be generated de novo in a model organism of interest and are thought to resemble physiological human tumor conditions. There is therefore a need for development of cell ...Wed, 02 Aug 2023 07:03:08 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/AT-3_Mouse_Breast_Tumor_Cell_LineTAB-4377https://nih.technologypublisher.com/tech?title=Use_of_Repurposed_Compounds_for_the_Treatment_of_Alzheimer%e2%80%99s_DiseaseAbstract: There are no effective treatments for Alzheimer’s disease (AD), a progressive brain disease that slowly destroys a person’s memory, cognitive skills and ability to carry out the simplest tasks. AD affects more than 5 million individuals in the United States and ranks as the sixth leading cause of death. The ε4 allele of the apolipoprotein-E (APOE) gene is the strongest genetic risk factor for sporadic or late-onset AD. Heterozygous carriers of the ε4 allele are at three-to-four times greater risk; homozygous carriers are at ten times greater risk. In fact, APOE ε4 carriers accumulate...Wed, 02 Aug 2023 07:03:06 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech?title=Use_of_Repurposed_Compounds_for_the_Treatment_of_Alzheimer%e2%80%99s_DiseaseTAB-4375https://nih.technologypublisher.com/tech/Peptide_Hydrogels_for_Rate-Controlled_Delivery_of_TherapeuticsAbstract: Hydrogels represent an attractive controlled drug-delivery system that have been used in various clinical applications, such as: tissue engineering for wound healing, surgical procedures, pain management, cardiology, and oncology. High-water content of hydrogels confers tissue-like physical properties and the crosslinked fibrillar network enables encapsulation of labile small molecule drugs, peptides, proteins, nucleic acids, proteins, nanoparticles, or cells. The porosity of the mesh-like network contributes to enhanced protection and controlled release of therapeutics compared with...Wed, 02 Aug 2023 07:03:04 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Peptide_Hydrogels_for_Rate-Controlled_Delivery_of_TherapeuticsTAB-4374https://nih.technologypublisher.com/tech/Convolutional_Neural_Networks_for_Organ_SegmentationAbstract: Accurate automated organ and disease feature segmentation is a challenge for medical imaging analysis. The pancreas, for example, is a small, soft, organ with low uniformity of shape and volume between patients. Because of the lack of uniform image patterns, there are few features that can be used to aid in automated identification of anatomy and boundaries. Segmentation of high variability features is uniquely difficult for a computer to perform. Due to these difficulties, high variability anatomical features are currently analyzed and determined only by trained physicians who can r...Wed, 02 Aug 2023 07:03:03 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Convolutional_Neural_Networks_for_Organ_SegmentationTAB-4373https://nih.technologypublisher.com/tech/A_Viral_Exposure_Signature_to_Define_and_Detect_Early_Onset_Hepatocellular_CarcinomaAbstract: Early detection of liver cancer, such as hepatocellular carcinoma (HCC), is key to improve cancer-related mortality. More than 800,000 people are diagnosed with this cancer each year throughout the world. Liver cancer is also a leading cause of cancer deaths worldwide, accounting for more than 700,000 deaths each year. Currently, millions of Americans and possibly billions in the world are considered at risk for developing liver cancer. Individuals are considered at risk for developing liver cancer if they have underlying chronic liver diseases such as fibrosis and cirrhosis which in...Wed, 02 Aug 2023 07:03:01 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/A_Viral_Exposure_Signature_to_Define_and_Detect_Early_Onset_Hepatocellular_CarcinomaTAB-4371https://nih.technologypublisher.com/tech?title=Monoclonal_Antibodies_and_Immunoconjugates_Directed_to_the_Non-ShedPortion_(%e2%80%9cStalk%e2%80%9d)__of_Mesothelin_are_Excellent_Candidates_for_Developing_Therapeutic_AgentsAbstract: Human mesothelin is overexpressed by various cancers such as synovial sarcoma, mesothelioma, and ovarian, lung, esophageal, and gastric cancers. This selective expression on certain cancers suggests that mesothelin is an excellent target for anticancer therapeutics. However, a large fragment (“the shed portion”) of mesothelin is constantly shed from cells, and all current anti-mesothelin antibodies bind to the shed portion. As a result, the therapeutic efficacy of these antibodies has been low because they are unable to exert their therapeutic effect on the cell before their binding ...Wed, 02 Aug 2023 07:03:00 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech?title=Monoclonal_Antibodies_and_Immunoconjugates_Directed_to_the_Non-ShedPortion_(%e2%80%9cStalk%e2%80%9d)__of_Mesothelin_are_Excellent_Candidates_for_Developing_Therapeutic_AgentsTAB-4370https://nih.technologypublisher.com/tech/T_cell_Receptors_Which_Recognize_Mutated_EGFRAbstract: Epidermal growth factor receptor (EGFR) is a transmembrane protein involved in cell growth and proliferation. Mutations in this protein can lead to overexpression, causing several types of cancer; notably, non-small cell lung cancer (NSCLC). For example, mutations in EGFR are found in up to 50% of NSCLC patients and the E746-A750 deletion accounts for 30-40% of such EGFR mutations. Currently, there are no available therapeutics that specifically target the E746-A750 deletion.  Researchers at the National Cancer Institute (NCI) have isolated T cells that recognize the EGFR E746-A750 d...Wed, 02 Aug 2023 07:02:58 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/T_cell_Receptors_Which_Recognize_Mutated_EGFRTAB-4366https://nih.technologypublisher.com/tech?title=Methods_for_Single_Cell_Analysis_of_the_Epigenome%2c_Transcriptome%2c_and_GenomeAbstract: There are currently no methodologies that allow for epigenome, genome and transcriptome analysis all in a single cell. In addition, there are currently no methodologies that permit repeating the results of these analyses on the same single cells. Scientists at the National Cancer Institute (NCI) Laboratory of Cellular Oncology have developed a method for generating a “reusable” single cell by crosslinking cellular proteins and DNA to a polyacrylamide scaffold, thus preserving the proteins and genomic DNA in their location even after repeated experiments on the same cell. Given the re...Wed, 02 Aug 2023 07:02:56 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech?title=Methods_for_Single_Cell_Analysis_of_the_Epigenome%2c_Transcriptome%2c_and_GenomeTAB-4365https://nih.technologypublisher.com/tech/Adjuvanted_Mucosal_Subunit_Vaccines_for_Preventing_SARS-CoV-2_Transmission_and_InfectionAbstract: The Corona virus disease, 2019 (COVID-19) pandemic is a worldwide public health crisis with over 153 million confirmed cases and 3.2 million deaths as of April 2021. COVID-19 is caused by a novel coronavirus called SARS-CoV-2. SARS-COV-2 infects hosts via its spike (S) protein, which has two portions, S1 that binds the cell and S2 that is involved in viral entry via fusion with the cell membrane. There are several vaccines available for COVID-19 patients that directly target SARS-CoV-2 by systemic immunization.   Investigators at NCI have designed a unique adjuvanted mucosal subunit ...Wed, 02 Aug 2023 07:02:55 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Adjuvanted_Mucosal_Subunit_Vaccines_for_Preventing_SARS-CoV-2_Transmission_and_InfectionTAB-4363https://nih.technologypublisher.com/tech/Human_T_Cell_Receptors_for_Treating_CancerAbstract: T cell receptors (TCRs) are proteins that recognize antigens in the context of infected or transformed cells and activate T cells to mediate an immune response and destroy abnormal cells. TCRs consist of two domains, one variable domain that recognizes the antigen and one constant region that helps the TCR anchor to the membrane and transmit recognition signals by interacting with other proteins. When a TCR is stimulated by an antigen, such as a tumor antigen, some signaling pathways activated in the cell lead to the production of cytokines, which mediate the immune response. There ...Wed, 02 Aug 2023 07:02:52 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Human_T_Cell_Receptors_for_Treating_CancerTAB-4359https://nih.technologypublisher.com/tech?title=Mice%2c_Organs%2c_and_Mouse_Alleles_Carrying_Germline_and_Conditional_Deletions_of_the_Zbtb7b_GeneAbstract: The Zbtb7b gene encodes the zinc finger transcription factor ThPOK (also known as cKrox) that promotes CD4 lineage differentiation in immature T cells. CD4+ T cells, also known as “helper” T cells, are critical for long-term immunity against pathogens as well as for promoting CD8+ “effector” T cell and effective B cell responses. ThPOK is needed for the development and functional fitness of CD4+ T cells as well as multiple aspects of the immune response to infection. As such, ThPOK offers a potential target for immune regulation. For example, increasing the activity of ThPOK may enha...Wed, 02 Aug 2023 07:02:49 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech?title=Mice%2c_Organs%2c_and_Mouse_Alleles_Carrying_Germline_and_Conditional_Deletions_of_the_Zbtb7b_GeneTAB-4358https://nih.technologypublisher.com/tech?title=Osmogels%3a_A_New_Method_for_Stabilizing_Weak_Molecular_Complex_InteractionsAbstract: The Eunice Kennedy Schriver National Institute of Child Health and Human Development is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize a new method for stabilizing molecular complexes in polyacrylamide gels. This invention describes a new method for stabilizing molecular complexes in polyacrylamide gels for analysis by the electrophoretic mobility shift assay. By adding specific osmolytes directly to the gel, investigators have found that weakly interacting molecular complexes can be suffi...Wed, 02 Aug 2023 07:02:48 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech?title=Osmogels%3a_A_New_Method_for_Stabilizing_Weak_Molecular_Complex_InteractionsTAB-4357https://nih.technologypublisher.com/tech/Single_Domain_Antibodies_Targeting_the_S2_Subunit_of_SARS-CoV-2_Spike_ProteinAbstract: The COVID-19 pandemic is a worldwide public health crisis with over 100 million confirmed cases and 2.4 million deaths as of February 2021. COVID-19 is caused by a novel coronavirus called SARS-CoV-2. Almost all the neutralizing antibodies targeting SARS-CoV-2 that are in development recognize the receptor binding domain (RBD) on the spike (S) protein. Blocking the interaction of RBD and the ACE2 receptor on human cells is the first of the two critical steps for neutralization of the virus. However, the S2 subunit of the spike is also critical for viral infection and entry into human...Wed, 02 Aug 2023 07:02:47 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Single_Domain_Antibodies_Targeting_the_S2_Subunit_of_SARS-CoV-2_Spike_ProteinTAB-4354https://nih.technologypublisher.com/tech?title=Highly_Soluble_Pyrimido-Dione-Quinoline_Compounds%3a_Small_Molecules_that_Stabilize_and_Activate_p53_in_Transformed_CellsAbstract: The tumor-suppressor p53 protein plays a major role in tumor development. Most human cancers fail to normally activate wild-type p53, which is at least partly responsible for the unregulated growth of cancer cells and their failure to undergo apoptosis. While many chemotherapeutics enhance p53 levels, their non-specific DNA damage (genotoxicity) causes unfavorable side effects.   Defects in the pathways that control the stabilization and activation of p53 in response to stress can contribute to cancer development, without the requirement for mutation within the p53 gene itself. Man...Wed, 02 Aug 2023 07:02:45 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech?title=Highly_Soluble_Pyrimido-Dione-Quinoline_Compounds%3a_Small_Molecules_that_Stabilize_and_Activate_p53_in_Transformed_CellsTAB-4353https://nih.technologypublisher.com/tech/Efficient_Methods_to_Prepare_Hematopoietic_Progenitor_Cells_in_vitro_for_Therapeutic_UseAbstract: Hematopoietic progenitor cells (HPC) are multi-potent hematopoietic lineage cells that can differentiate into any type of blood cell, including but not limited to erythrocytes, T cells, B cells, and natural killer cells. As such, they have high therapeutic potential in the fields of regenerative medicine and cancer immunotherapy, especially when generated from patient-derived induced pluripotent stem cells (iPSC). Currently, the most efficient protocol to produce HPCs is co-culturing human iPSCs (hiPSC) with mouse stromal cells as a two-dimensional (2D) monolayer. However, animal cel...Wed, 02 Aug 2023 07:02:43 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Efficient_Methods_to_Prepare_Hematopoietic_Progenitor_Cells_in_vitro_for_Therapeutic_UseTAB-4352https://nih.technologypublisher.com/tech/Inhibition_of_T_Cell_Lactate_Dehydrogenase_(LDH)_ex_vivo_Enhances_the_Anti-tumor_Efficacy_of_Adoptive_T_Cell_TherapyAbstract: Adoptive T cell therapy (ACT) with tumor infiltrating lymphocytes (TIL), T cell receptor (TCR) and Chimeric Antigen Receptor (CAR) engineered T cells, or hematopoietic stem cell transplantation, is a promising new approach to cancer treatment. ACT harnesses an individual's adaptive immune system to fight against cancer, with fewer side-effects and more specific anti-tumor activity. Despite their promise of ACT as curative, these therapies are often limited by the persistence and robustness of the responses of the T cells to the cancer cells. Altering metabolic pathways is one way to ...Wed, 02 Aug 2023 07:02:42 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Inhibition_of_T_Cell_Lactate_Dehydrogenase_(LDH)_ex_vivo_Enhances_the_Anti-tumor_Efficacy_of_Adoptive_T_Cell_TherapyTAB-4350https://nih.technologypublisher.com/tech?title=A_Novel_Genetically_Encoded_Inhibitor_of_Hippo_Signaling_Pathway_to_Study_YAP1%2fTAZ-TEAD_Dependent_Events_in_CancerAbstract: The Hippo signaling pathway regulates a multitude of biological processes including cell proliferation, apoptosis, differentiation, tissue homeostasis, and stem cell functions. This axis has been recently listed as one of the top 10 signaling pathways altered in human cancer. Its role in modulating cell growth and proliferation is mediated by the activation of Yes-associated protein 1 (YAP1) and transcriptional co-activator with PDZ-binding domain (TAZ). Under low cell density conditions, YAP1/TAZ translocate to the nucleus, bind to various transcription factors including TEA domain ...Wed, 02 Aug 2023 07:02:40 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech?title=A_Novel_Genetically_Encoded_Inhibitor_of_Hippo_Signaling_Pathway_to_Study_YAP1%2fTAZ-TEAD_Dependent_Events_in_CancerTAB-4349https://nih.technologypublisher.com/tech/Induced_Pluripotent_Stem_Cells_Derived_from_Patients_with_CEP290-associated_Ciliopathies_and_Unaffected_Family_MembersAbstract: Approximately one-third of non-syndromic retinal dystrophies involve a defect in a ciliary protein. Non-syndromic retinal ciliopathies include retinitis pigmentosa, cone dystrophy, cone-rod dystrophy, macular dystrophy, and Leber-congenital amaurosis (LCA). Many CEP290-LCA patients also exhibit auditory and olfactory defects. Induced pluripotent stem cells (iPS) cells were derived from patients with LCA and unaffected relatives.  The National Eye Institute (NEI) seeks research collaborations and/or licensees for the use of these iPS cells. Competitive Advantages: Extensive character...Wed, 02 Aug 2023 07:02:39 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Induced_Pluripotent_Stem_Cells_Derived_from_Patients_with_CEP290-associated_Ciliopathies_and_Unaffected_Family_MembersTAB-4347https://nih.technologypublisher.com/tech/Vaccines_for_HIVAbstract: The development of an effective HIV vaccine has been an ongoing area of research. The high variability in HIV-1 virus strains has represented a major challenge in successful development.  Ideally, an effective candidate vaccine would provide protection against the majority of clades of HIV.  Two major hurdles to overcome are immunodominance and sequence diversity.  This vaccine utilizes a strategy for overcoming these two issues by identifying the conserved regions of the virus and exploiting them for use in a targeted therapy.  Researchers at the National Cancer Institute's Vaccine ...Wed, 02 Aug 2023 07:02:38 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Vaccines_for_HIVTAB-4346https://nih.technologypublisher.com/tech/Human_and_Improved_Murine_Monoclonal_Antibodies_Against_CD22Abstract: CD22 is a common cell surface glycoprotein expressed in B-cells and present in B-cell lymphomas; e.g., hairy cell leukemia (HCL), non-Hodgkins lymphoma (NHL), chronic lymphoblastic leukemia (CLL), and other cancers. It is therefore a target for cancer immunotherapy. Conjugation of anti-CD22 monoclonal antibodies with toxins or drugs has shown promise in clinical trials. However, all monoclonal anti-CD22 antibodies used in clinical trials are of murine origin. This is problematic because they have the potential of causing immunogenic reactions when used repeatedly in patients to achie...Wed, 02 Aug 2023 07:02:36 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Human_and_Improved_Murine_Monoclonal_Antibodies_Against_CD22TAB-4345https://nih.technologypublisher.com/tech/Single-domain_monoclonal_antibodies_for_the_treatment_of_hepatocellular_carcinomaAbstract: The National Cancer Institute seeks parties to license human monoclonal antibodies and immunoconjugates and co-develop, evaluate, and/or commercialize large-scale antibody production and hepatocellular carcinoma (HCC) xenograft mouse models. An advantage of these monoclonal antibodies as a potential therapeutic is their specificity, which would reduce deleterious side-effects. HCC is the most common form of liver cancer, and is among the more deadly cancers in the world. There is a need for new treatments that can be successfully applied to a large population of patients. Glypican-3 ...Wed, 02 Aug 2023 07:02:35 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Single-domain_monoclonal_antibodies_for_the_treatment_of_hepatocellular_carcinomaTAB-4344https://nih.technologypublisher.com/tech/Non-invasive_diagnostic_and_prognostic_assay_for_early_stage_lung_cancerAbstract: In the United States alone, one of four cancer deaths occur from lung cancer and there are over 8 million individuals considered to be at high-risk due to cigarette smoking and other behaviors. It's well known that early detection of cancer significantly improves survival of this disease, however a lack of lung cancer screenings and analysis precludes fast results at a low cost. Low-dose computer tomography (LD-CT) is the current standard and provides indication of potentially cancerous nodules above a certain size, however it suffers from low sensitivity and specificity (55 and 81%,...Wed, 02 Aug 2023 07:02:33 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Non-invasive_diagnostic_and_prognostic_assay_for_early_stage_lung_cancerTAB-4342https://nih.technologypublisher.com/tech?title=CD206_Small_Molecule_Modulators%2c_Their_Use_and_Methods_for_PreparationAbstract: Pancreatic ductal adenocarcinoma (PDA) accounts for more than 90% of pancreatic cancer cases, and it is one of the most aggressive malignancies with a 5-year survival rate of 6%. The high mortality rate caused by PDA is primarily from the lack of early diagnosis – it is often asymptomatic in early stages – and a poor response to conventional chemotherapy and radiotherapy. One of the major immune cell types present in the PDA microenvironment is a subset of macrophages commonly termed tumor-associated macrophages (TAM). TAMs originate, in part, from circulating monocytes upon activati...Wed, 02 Aug 2023 07:02:31 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech?title=CD206_Small_Molecule_Modulators%2c_Their_Use_and_Methods_for_PreparationTAB-4340https://nih.technologypublisher.com/tech?title=Natural_product-based_anti-cancer_agents%3a_aza-Englerin_analoguesAbstract: Chemotherapy resistance in a wide array of cancers is often associated with enhanced glucose uptake and dysregulation of the insulin signaling pathway.  Therapeutics capable of inhibiting insulin signaling would be valuable as a stand-alone treatment and for sensitizing resistant tumors to standard chemotherapy regiments.  Researchers at NCI’s Genitourinary Malignancies Branch have synthesized and developed a series of Englerin-A analogues with potent anti-tumor activity that is linked to inhibition of the insulin pathway. The researchers have previously shown that Englerin A has pot...Wed, 02 Aug 2023 07:02:29 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech?title=Natural_product-based_anti-cancer_agents%3a_aza-Englerin_analoguesTAB-4338https://nih.technologypublisher.com/tech?title=Dopamine_D3_Receptor_Agonist_Compounds%2c_Methods_of_Preparation%2c_Intermediates_Thereof%2c_and_their_Methods_of_UseAbstract: Due to the large degree of homology among dopamine D2-like receptors, discovering ligands capable of discriminating between the D2, D3, and D4 receptor subtypes remains a significant challenge. The development of subtype-selective pharmaceutical small molecules to activate (agonists) signals regulated by D2-like receptors has been especially difficult.  The inventors at the National Institute on Aging (NIDA) have recently synthesized a new generation of D3R selective agonists by applying a well-established bitopic molecular approach. Inventors were able to combine a primary pharmacop...Wed, 02 Aug 2023 07:02:26 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech?title=Dopamine_D3_Receptor_Agonist_Compounds%2c_Methods_of_Preparation%2c_Intermediates_Thereof%2c_and_their_Methods_of_UseTAB-4337https://nih.technologypublisher.com/tech/Human_Monoclonal_Antibodies_Cross-reacting_to_Insulin-like_Growth_Factors_IGF-I_and_IGF-II_as_Potential_Anti-tumor_AgentsAbstract: The National Cancer Institute's  Cancer and Inflammation Program is seeking statements of capability or interest from parties interested in licensing this technology.  The type 1 insulin-like growth factor (IGF) receptor (IGF1R) is over-expressed by many tumors and mediates proliferation, motility, and protection from apoptosis. Agents that inhibit IGF1R expression or function can potentially block tumor growth and metastasis. Its major ligands, IGF-I, and IGF-II are over-expressed by multiple tumor types. Previous studies indicate that inhibition of IGF-I, and/or IGF-II binding to i...Wed, 02 Aug 2023 07:02:25 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Human_Monoclonal_Antibodies_Cross-reacting_to_Insulin-like_Growth_Factors_IGF-I_and_IGF-II_as_Potential_Anti-tumor_AgentsTAB-4334https://nih.technologypublisher.com/tech/Small_Molecule_Anti-cancer_Agents_that_Stabilize_the_MYC-G-QuadruplexAbstract: The proto-oncogene c-Myc is deregulated and overexpressed in ~70% of all cancers. Thus, c-Myc is an attractive therapeutic target since disrupting c-Myc activity could be used as pan-chemotherapy. Beyond cancer, Myc is also a positive effector of tissue inflammation, and its function has been implicated in the pathophysiology of heart failure. Because c-Myc is a transcription factor, a rationally designed small molecule targeting c-Myc would be required to exhibit significant specificity. Unfortunately, several physical characteristics of Myc make it a very difficult protein to targ...Wed, 02 Aug 2023 07:02:23 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Small_Molecule_Anti-cancer_Agents_that_Stabilize_the_MYC-G-QuadruplexTAB-4333https://nih.technologypublisher.com/tech?title=Learning_to_Read_Chest_X-Rays%3a_Recurrent_Neural_Cascade_Model_for_Automated_Image_AnnotationAbstract: Medical image datasets are an important clinical resource. Effectively referencing patient images against similar related images and case histories can inform and produce better treatment outcomes. Labeling and identifying disease features and relations between images within a large image database has not been a task capable of automation. Rather, it is a task that must be performed by highly trained clinicians who can identify and label the medically meaningful image features. The time constraints on clinicians versus the size of these data sets greatly limits the ability to analyze...Wed, 02 Aug 2023 07:02:22 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech?title=Learning_to_Read_Chest_X-Rays%3a_Recurrent_Neural_Cascade_Model_for_Automated_Image_AnnotationTAB-4332https://nih.technologypublisher.com/tech/High_Affinity_Cross_Species_Single_Domain_Antibodies_Targeting_MesothelinAbstract: Mesothelin is a cell surface protein that is an excellent target for immunotherapy because of its limited expression on normal tissues and its high expression on many cancers, including mesothelioma, cholangiocarcinoma, pancreatic, ovarian, lung, stomach, bile duct, and triple-negative breast cancer. Researchers at the National Cancer Institute’s (NCI) Laboratory of Molecular Biology have isolated two anti-mesothelin single domain antibodies (also known as nanobodies), A101 and G8. These antibodies have been isolated from newly developed camel single domain (VHH) libraries by phage d...Wed, 02 Aug 2023 07:02:20 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/High_Affinity_Cross_Species_Single_Domain_Antibodies_Targeting_MesothelinTAB-4330https://nih.technologypublisher.com/tech?title=Anti-Viral_Polypeptide_Griffithsin%3a_Compounds%2c_Compositions%2c_and_Methods_of_UseAbstract: This technology describes additional methods of using the griffithsin anti-viral polypeptides described in related NCI invention (reference number E-106-2003).  Specifically, this invention describes the use of GRFT to inhibit viral infection of hepatitis C viral infection, a severe acute respiratory syndrome (SARS) viral infection, an H5N1 viral infection, or an Ebola viral infection.  Issued patents: US 8,088,729 (Jan. 3, 2012) and foreign rights in France, Germany, Ireland, United Kingdom, Switzerland (all granted) Competitive Advantages: Highly Potent Broad-Spectrum Antiviral Lec...Wed, 02 Aug 2023 07:02:17 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech?title=Anti-Viral_Polypeptide_Griffithsin%3a_Compounds%2c_Compositions%2c_and_Methods_of_UseTAB-4326https://nih.technologypublisher.com/tech/Extremely_Rapid_Method_to_Isolate_Neoantigen_Reactive_T_Cell_Receptors_(TCRs)Abstract: Adoptive cell transfer (ACT) uses tumor infiltrating lymphocytes (TILs) that recognize unique antigens expressed by cancer cells (“neoantigens”). Neoantigen specific TIL administration in patients has resulted in long term regression of certain metastatic cancers. However, one of the challenges of ACT and engineered T cell receptor (TCR) therapies more broadly, is the identification and isolation of these mutation specific TILs and TCRs. Only a fraction of TILs in a given patient is known to be tumor reactive, while the majority are not useful for cell therapy. The current procedures...Wed, 02 Aug 2023 07:02:13 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Extremely_Rapid_Method_to_Isolate_Neoantigen_Reactive_T_Cell_Receptors_(TCRs)TAB-4323https://nih.technologypublisher.com/tech/Mouse_Embryo_Culture_Chamber_and_Imaging_System_and_Methods_of_UseAbstract: The culture of mouse embryos ex utero and continuous monitoring and imaging of embryos as they develop have applications in drug testing, genetic studies, and basic research on embryonic development. However, the embryo culture systems currently available for post-implantation embryos include rolling bottle culture systems, which do not permit imaging of the developing embryos and do not support the long-term survival and development of embryos ex utero. Current culture systems for pre-implantation stage embryos, including microfluidic culture systems, are suitable for short-term cu...Wed, 02 Aug 2023 07:02:12 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Mouse_Embryo_Culture_Chamber_and_Imaging_System_and_Methods_of_UseTAB-4322https://nih.technologypublisher.com/tech/Chimeric_Antigen_Receptors_(CAR)-T_Cells_that_Target_the_Non-Shed_Portion_of_Mesothelin_as_a_Therapeutic_AgentAbstract: Mesothelin (MSLN) is an excellent target for antibody-based therapies of cancer because of its high expression in many malignancies but lack of expression on essential normal tissues. Unfortunately, a large fragment of MSLN is shed from cancer cells, causing the currently available anti-MSLN antibodies (and immunoconjugates thereof) which bind to the shed portion of MSLN to quickly lose their therapeutic effectiveness over time. Indeed, the shed portion of MSLN can act as a decoy for these antibodies, further limiting them from reaching and destroying tumor cells. Scientists at NCI p...Wed, 02 Aug 2023 07:02:10 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Chimeric_Antigen_Receptors_(CAR)-T_Cells_that_Target_the_Non-Shed_Portion_of_Mesothelin_as_a_Therapeutic_AgentTAB-4321https://nih.technologypublisher.com/tech/Anti-Glypican_2_Chimeric_Antigen_Receptor_(CAR)_Containing_CD28_Hinge_And_Transmembrane_Domains_For_Treating_NeuroblastomaAbstract: Neuroblastomas are the most common extracranial solid tumors in pediatric patients, with 700-800 new cases annually in the United States. Metastatic neuroblastomas have a five-year survival rate of 50% and account for 15% of all pediatric cancer deaths. As such, more effective treatments against high-risk neuroblastomas are urgently needed. Glypican-2 (GPC2) is a cell surface protein that is highly expressed in neuroblastomas and other cancers, including medulloblastoma, retinoblastoma, small-cell lung cancers, uterine carcinosarcomas and high-grade gliomas, which makes GPC2 an attra...Wed, 02 Aug 2023 07:02:09 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Anti-Glypican_2_Chimeric_Antigen_Receptor_(CAR)_Containing_CD28_Hinge_And_Transmembrane_Domains_For_Treating_NeuroblastomaTAB-4319https://nih.technologypublisher.com/tech/Enhanced_Antigen_Reactivity_of_Immune_Cells_Expressing_a_Mutant_Non-Signaling_CD3_Zeta_ChainAbstract: Immunotherapy is a cutting-edge new category of treatment that aims to harness and, in some cases, modify the patient’s own immune cells to improve their ability to cure diseases. It can be an effective approach for a variety of conditions, ranging from cancer to inflammatory diseases.  However, a number of obstacles to the overall success of immunotherapy still exist.  For example, reactivity against a target antigen can be attenuated or the lifespan of the “modified” immune cells can be too short. In cancer, some tumor cells could express antigen with very low reactivity, thus rema...Wed, 02 Aug 2023 07:02:08 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Enhanced_Antigen_Reactivity_of_Immune_Cells_Expressing_a_Mutant_Non-Signaling_CD3_Zeta_ChainTAB-4318https://nih.technologypublisher.com/tech?title=Automatic_System_and_Method_for_Tissue_Sectioning%2c_Staining%2c_and_ScanningAbstract: Computer and imaging technologies led to the development of digital pathology and the capture and storage of pathological specimens as digitally formatted images. The use of artificial intelligence (AI) in digital pathology, such as in three-dimensional (3D) reconstruction, requires analyses of high volumes of data. This results in increased demands for processing and acquisition of digital images of pathology samples. Increased usage cannot be met by the time-consuming, manual, and laborious methods currently used. Therefore, there is a need for automation of techniques used in proc...Wed, 02 Aug 2023 07:02:06 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech?title=Automatic_System_and_Method_for_Tissue_Sectioning%2c_Staining%2c_and_ScanningTAB-4317https://nih.technologypublisher.com/tech/Method_for_HLA_LOH_Detection_in_Liquid_BiopsiesAbstract: Human leukocyte antigen (HLA) LOH (LOH) is a known resistance mechanism by which cancers evade T cell receptor-(TCR-)based immunotherapies. This class of therapies includes immune checkpoint inhibition (ICI, e.g., Pembrolizumab), engineered TCR (T cell receptor)-T cell adoptive transfer, tumor infiltrating lymphocytes (TIL), T-cell engagers, and other modalities. Dozens of therapies in this category were developed with many in clinical trials. The resistance mechanism noted here, HLA LOH, causes these therapies to fail. Therefore, it is beneficial to know before treating a patient wh...Wed, 02 Aug 2023 07:02:05 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Method_for_HLA_LOH_Detection_in_Liquid_BiopsiesTAB-4316https://nih.technologypublisher.com/tech/Fully_Human_Antibodies_and_Antibody_Drug_Conjugates_Targeting_Tumor_Endothelial_Marker_8_(TEM8)_for_the_Treatment_of_CancerAbstract: The tumor microenvironment consists of a heterogenous population of cells which includes tumor cells and tumor-associated stroma cells (TASCs). The TASCs promote tumor angiogenesis, proliferation, invasion and metastasis. Because stroma cells are found in both healthy and cancerous tissue, targeting the tumor stroma has been difficult due to the lack of targets with high tumor specificity. TEM8 (also known as ANTXR1) is a cell surface tumor endothelial marker that is most highly expressed in human tumor-associated stroma of pancreatic, breast, colon, lung, esophageal, bladder, and ov...Wed, 02 Aug 2023 07:02:03 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Fully_Human_Antibodies_and_Antibody_Drug_Conjugates_Targeting_Tumor_Endothelial_Marker_8_(TEM8)_for_the_Treatment_of_CancerTAB-4315https://nih.technologypublisher.com/tech/Modulating_Chemotherapeutic_CytotoxicityAbstract: Many chemotherapeutic agents cause significant cytotoxicity to non-cancer ("normal") cells, resulting in undesirable side-effects and often limiting the dose and/or duration of chemotherapy that can be administered to a patient. Investigators at the National Cancer Institute’s Laboratory of Pathology have demonstrated that deficiency or blockade of the ubiquitously expressed receptor CD47 results in remarkable cell and tissue protection against ischemic and radiation stress. Antagonists of CD47 or its ligand THBS1/thrombospondin 1 enhance cell survival and preserve their proliferativ...Wed, 02 Aug 2023 07:02:02 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Modulating_Chemotherapeutic_CytotoxicityTAB-4312https://nih.technologypublisher.com/tech/Use_of_Anti-CD47_Antibodies_for_the_Treatment_of_CancerAbstract: High expression of CD47, a cell surface receptor on several types of cancer cells, has been identified as a ‘don’t eat me signal’ that inhibits their killing by macrophages or NK cells. Conversely, the CD47 antibody B6H12 that blocks SIRPα binding enhances macrophage-dependent clearance of tumors in several mouse models, although others have shown that such clearance can be independent of SIRPα signaling. Cancer stems cells (CSCs) are tumorigenic cells that are difficult to target with conventional chemotherapies due to their undifferentiated state. Stem cells also play an important ...Wed, 02 Aug 2023 07:02:00 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Use_of_Anti-CD47_Antibodies_for_the_Treatment_of_CancerTAB-4310https://nih.technologypublisher.com/tech/Synthetic_lipopeptide_inhibitors_of_RAS_oncoproteinsAbstract: It is well known that overactive Ras signaling is linked to many forms of cancer, and despite intensive efforts worldwide to develop effective inhibitors of Ras, to date there is no anti-Ras inhibitor in clinical use. Researchers at the NCI’s Cancer and Inflammation Program, in collaboration with scientists at Vanderbilt University and the University of Illinois in Chicago, have identified a number of small peptidomimetic compounds that bind to Ras proteins with nanomolar affinity.  The development of compounds was based on two previously unknown mechanisms of Ras regulation uncovere...Wed, 02 Aug 2023 07:01:59 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Synthetic_lipopeptide_inhibitors_of_RAS_oncoproteinsTAB-4308https://nih.technologypublisher.com/tech/Eye_Tracking_Application_in_Computer_Aided_Diagnosis_and_Image_Processing_in_RadiologyAbstract: Medical imaging is an important resource for early diagnostic, detection, and effective treatment of cancers. However, the screening and review processes for radiologists have been shown to overlook a certain percentage of potentially cancerous image features. Such review errors may result in misdiagnosis and failure to identify tumors. These errors result from human fallibility, fatigue, and from the complexity of visual search required. Screening for early detection of cancers in visual images requires physicians to scan vast amounts of complex visual information thoroughly and int...Wed, 02 Aug 2023 07:01:57 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Eye_Tracking_Application_in_Computer_Aided_Diagnosis_and_Image_Processing_in_RadiologyTAB-4307https://nih.technologypublisher.com/tech/High-Throughput_Generation_of_Induced_Pluripotent_Stem_Cells_Carrying_Antigen-Specific_T_Cell_Receptors_from_Tumor_Infiltrated_LymphocytesAbstract: One form of adoptive T cell therapy (ACT) consists of harvesting tumor infiltrating lymphocytes (TIL), screening and isolating TIL which display tumor antigen-specific T-cell receptors (TCR), expanding the isolated T cells in vitro, and reinfusing them into the patient for treatment. While highly active in the treatment of certain cancers (e.g., melanoma), current methods used to produce cancer-reactive T cells require significant time and may not adequately identify the desired TCRs which bind cancer targets. Researchers at the National Cancer Institute (NCI) Surgery Branch have dev...Wed, 02 Aug 2023 07:01:56 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/High-Throughput_Generation_of_Induced_Pluripotent_Stem_Cells_Carrying_Antigen-Specific_T_Cell_Receptors_from_Tumor_Infiltrated_LymphocytesTAB-4306https://nih.technologypublisher.com/tech?title=Single_domain_CD4%2c_HIV-1_Antibodies%2c_and_Fusion_Proteins_for_treatment_of_HIVAbstract: Soluble forms of human CD4 (sCD4) inhibit HIV-1 entry into immune cells.  Different forms of sCD4 and their fusion proteins have been extensively studied in animal models and clinical trials as promising HIV-1 inhibitors. However, they have not been successful in clinical trials due to their transient efficacy.  sCD4 is also known to interact with class II major histocompatibility complex (MHCII) and, at low concentrations, could enhance HIV-1 infectivity.  NCI researchers developed highly soluble, stable single-domain sCD4 with increased neutralizing activity and decreased non-speci...Wed, 02 Aug 2023 07:01:54 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech?title=Single_domain_CD4%2c_HIV-1_Antibodies%2c_and_Fusion_Proteins_for_treatment_of_HIVTAB-4305https://nih.technologypublisher.com/tech/PIM-Targeted_PROTACsAbstract: Proviral Integration for the Moloney murine leukemia virus (PIM) kinases are overexpressed in many solid cancers – including prostate, breast, colon, endometrial, gastric and pancreatic. High of PIM1 expression is predictive of poor survival in multiple cancer types. While several selective pan-PIM inhibitors were developed and tested in clinical trials, all ultimately increased PIM1-3 protein levels and developed intrinsic resistance.  Researchers at the National Institutes of Health (NIH) developed multiple PIM kinase-targeting proteolysis-targeting chimeras (PROTACs) that lead to ...Wed, 02 Aug 2023 07:01:53 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/PIM-Targeted_PROTACsTAB-4304https://nih.technologypublisher.com/tech/Immunogenic_Antigen_Selective_Cancer_ImmunotherapyAbstract: Melanoma is a particularly aggressive form of cancer primarily caused by over-exposure to sunlight.  Although melanoma can strike at any age, the malignancy disproportionately impacts persons of advanced age, as these individuals often have decades of repeated exposure to harmful levels of ultraviolet radiation.  Scientists at NIH among others have clarified the link between advanced melanoma and other malignancies and expression of SPANX-B. Researchers at the National Institutes of Health (NIH) characterized this novel tumor-associated antigen, SPANX-B, as naturally immunogenic and ...Wed, 02 Aug 2023 07:01:52 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Immunogenic_Antigen_Selective_Cancer_ImmunotherapyTAB-4303https://nih.technologypublisher.com/tech/Anti-Viral_Compounds_that_Inhibit_HIV_ActivityAbstract: Several novel tropolone derivatives have been identified that inhibit HIV-1 RNase H function and have potential for anti-viral activity due to reduced cellular toxicity.  Inhibiting RNase H function is a potential treatment for many viral infections, since RNase H function is essential for viral replication for many pathogenic retroviruses such as HIV-1 and HIV-2.  Although many hydroxytropolone compounds are potent RNase H inhibitors biding at the enzymatic active site, they are limited as therapeutic candidates by their toxicity in mammalian cells.  The toxicity thought to be a res...Wed, 02 Aug 2023 07:01:50 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Anti-Viral_Compounds_that_Inhibit_HIV_ActivityTAB-4299https://nih.technologypublisher.com/tech/Chimeric_Antigen_Receptor_(CAR)_that_Targets_Chemokine_Receptor_CCR4_and_its_Use_in_Treating_CancerAbstract: The chemokine receptor, CCR4 is a seven transmembrane G protein-coupled cell surface receptor molecule with selective expression on cells of the hematopoietic system. In adult T cell leukemia (ATL), the cell-surface expression of CCR4 on leukemic cells has been found to be nearly universal. Therefore, a CCR4-directed chimeric antigen receptor (CAR) -cell may provide an effective therapeutic against ATL. Researchers at the National Cancer Institute (NCI), Lymphoid Malignancies Branch, developed a lentivirus-derived CAR against the CCR4 molecule. The CAR can be directed to either genet...Wed, 02 Aug 2023 07:01:46 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Chimeric_Antigen_Receptor_(CAR)_that_Targets_Chemokine_Receptor_CCR4_and_its_Use_in_Treating_CancerTAB-4298https://nih.technologypublisher.com/tech?title=IL7R%ce%b1-Specific_Antibody_for_Treating_Acute_Lymphoblastic_Leukemia_(ALL)Abstract: Acute lymphoblastic leukemia (ALL) is the most common cancer in children with approximately 3,250 new cases occurring per year in the United States. About 20% of cases are refractory to current treatment protocols and there is a desperate need for targeted therapies that do not result in adverse side effects such as cognitive impairment.  The Interleukin-7 receptor-α (IL-7Rα) was identified as a major pathway driving T-cell derived ALL (T-ALL). Researchers at the National Cancer Institute (NCI) developed antibodies selectively targeting IL-7Rα. Two lead antibody candidates, designate...Wed, 02 Aug 2023 07:01:45 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech?title=IL7R%ce%b1-Specific_Antibody_for_Treating_Acute_Lymphoblastic_Leukemia_(ALL)TAB-4297https://nih.technologypublisher.com/tech/T_Cell_Receptors_Targeting_p53_Mutations_for_Cancer_Immunotherapy_and_Adoptive_Cell_TherapyWed, 02 Aug 2023 07:01:43 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/T_Cell_Receptors_Targeting_p53_Mutations_for_Cancer_Immunotherapy_and_Adoptive_Cell_TherapyTAB-4296https://nih.technologypublisher.com/tech/Methods_of_preventing_tissue_ischemiaAbstract: The National Cancer Institute's Laboratory of Pathology is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize therapeutics targeting vasodialation. Nitric oxide (NO) plays an important role as a major intrinsic vasodilator, and increases blood flow to tissues and organs. Disruption of this process leads to peripheral vascular disease, ischemic heart disease, stroke, vascular insufficiency associated with diabetes, and many more diseases that are significant. Researchers at the NIH have discov...Wed, 02 Aug 2023 07:01:42 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Methods_of_preventing_tissue_ischemiaTAB-4289https://nih.technologypublisher.com/tech/A_Dendritic_Cell_Vaccine_to_Immunize_Cancer_Patients_Against_Mutated_Neoantigens_Expressed_by_the_Autologous_CancerAbstract: Vaccines against non-viral cancers target mainly differentiation antigens, cancer testis antigens, and overexpressed antigens.  One common feature to these antigens is their presence in central immunological tolerance. Using these vaccines, T cells underwent depletion of high avidity clones directed against such antigens. This depletion can cause the loss of T cells bearing high affinity T cell receptors (TCRs) for their cognate antigens which have superior cytotoxic capacity, longer persistence in the tumor microenvironment, and decreased susceptibility to immune suppression. The Su...Wed, 02 Aug 2023 07:01:37 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/A_Dendritic_Cell_Vaccine_to_Immunize_Cancer_Patients_Against_Mutated_Neoantigens_Expressed_by_the_Autologous_CancerTAB-4285https://nih.technologypublisher.com/tech/Molecular_Nanotags_for_Detection_of_Single_MoleculesAbstract: Biological nanoparticles, like extracellular vesicles (EVs), possess unique biological characteristics making them attractive therapeutic agents, targets, or disease biomarkers. However, their use is hindered by the lack of tools available to accurately detect, sort, and analyze. Flow cytometers are used to sort and study individual cells. But, they are unable to detect and sort nanomaterials smaller than 200 nanometers with single epitope sensitivity. Researchers at the National Cancer Institute (NCI) developed a new class of nanoscale molecular tags (nanotags) allowing the detectio...Wed, 02 Aug 2023 07:01:34 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Molecular_Nanotags_for_Detection_of_Single_MoleculesTAB-4284https://nih.technologypublisher.com/tech/Exo-Clean_Technology_for_Purifying_Extracellular_Vesicle_Preparations_from_ContaminantsAbstract: Extracellular Vesicles (EVs), including exosomes and microvesicles, are nanometer-sized membranous vesicles that can carry different types of cargos, such as proteins, nucleic acids and metabolites. EVs are produced and released by most cell types. They act as biological mediators for intercellular communication via delivery of their cargos. This unique ability spurred translational research interest for targeted delivery of therapeutic molecules to treat a wide range of diseases. EVs also contain interesting information of their specific cellular origin. Thus, EVs can reveal nature,...Wed, 02 Aug 2023 07:01:32 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Exo-Clean_Technology_for_Purifying_Extracellular_Vesicle_Preparations_from_ContaminantsTAB-4283https://nih.technologypublisher.com/tech/Enhanced_Cancer_Chemotherapy_Using_the_Bioactive_Peptide_Recifin_And_Its_AnaloguesAbstract: Topoisomerase enzymes play an important role in cancer progression by controlling changes in DNA structure through catalyzing the breaking and rejoining of the phosphodiester backbone of DNA strands during the normal cell cycle. Therefore, topoisomerases are important targets for cancer chemotherapy. Many topoisomerase 1 (TOP1) inhibitors such as camptothecin, rinotecan, and topotecan are widely used anti-cancer agents that work by stabilizing the TOP1-DNA cleavage complex. Stabilization causes irreversible double-strand DNA breaks, eventually leading to the death of replicating canc...Wed, 02 Aug 2023 07:01:31 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Enhanced_Cancer_Chemotherapy_Using_the_Bioactive_Peptide_Recifin_And_Its_AnaloguesTAB-4281https://nih.technologypublisher.com/tech/High_Affinity_Nanobodies_Targeting_B7-H3_(CD276)_for_Treating_Solid_TumorsAbstract: CD276 (also called B7-H3) is a pan-cancer antigen expressed in multiple solid tumors and an emerging cancer target. CD276 protein is overexpressed in pancreatic cancer, prostate cancer, breast cancer, colon cancer, lung cancer, and brain tumors (such as neuroblastoma) – making it an ideal target for cancer therapy.  Investigators at the National Cancer Institute (NCI) have isolated a panel of anti-CD276 single domain antibodies (also known as nanobodies) from novel camel and rabbit single domain (VHH) libraries by phage display.  Nanobodies are the smallest known antigen-binding frag...Wed, 02 Aug 2023 07:01:29 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/High_Affinity_Nanobodies_Targeting_B7-H3_(CD276)_for_Treating_Solid_TumorsTAB-4280https://nih.technologypublisher.com/tech/Scytovirin_Domain_1_Related_PolypeptidesAbstract: Despite therapeutic advances, human immunodeficiency virus (HIV) is still a pervasive disease, with approximately 37 million people infected worldwide. Peptides have become popular therapeutic agents, as these proteins offer structural diversity for many different diseases. Several peptides were commercially developed as HIV therapeutics, demonstrating the high potential for peptides in treating HIV.  Researchers at the National Cancer Institute developed a novel small polypeptide, known as SD1, for use as an HIV therapeutic. SD1 is derived from scytovirin, a potent anti-HIV protein ...Wed, 02 Aug 2023 07:01:25 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Scytovirin_Domain_1_Related_PolypeptidesTAB-4276https://nih.technologypublisher.com/tech/Design_and_Biological_Activity_of_Novel_Stealth_Polymeric_Lipid_Nanoparticles_for_Enhanced_Delivery_of_Hydrophobic_Photodynamic_Therapy_DrugsWed, 02 Aug 2023 07:01:18 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Design_and_Biological_Activity_of_Novel_Stealth_Polymeric_Lipid_Nanoparticles_for_Enhanced_Delivery_of_Hydrophobic_Photodynamic_Therapy_DrugsTAB-4275https://nih.technologypublisher.com/tech/Development_of_Next_Generation_Antibody_Drug_Conjugates_(ADCs)_Against_CD276Abstract: Angiogenesis is the formation of new blood vessels from pre-existing blood vessels. Angiogenesis occurs during normal growth and development (physiological angiogenesis) and during the growth of solid tumors (pathological angiogenesis). CD276, also known as B7-H3, is a cell surface tumor endothelial marker that is highly expressed in the tumor vessels of human lung, breast, colon, endometrial, renal, and ovarian cancer, but not in the angiogenic vessels of normal, healthy tissue. This differential expression makes CD276 an attractive target for cancer treatment due to the ability to ...Wed, 02 Aug 2023 07:01:13 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Development_of_Next_Generation_Antibody_Drug_Conjugates_(ADCs)_Against_CD276TAB-4274https://nih.technologypublisher.com/tech/Synthesis_and_Characterization_of_Bismuth_Beads_for_Trans_Arterial_Chemo_Embolization_Under_Computed_Tomography_(CT)_GuidanceAbstract: Existing microsphere technologies are used as therapy for certain cancers. The therapy is by way of occlusion, when the microspheres are delivered into blood vessels that feed a tumor. The physical dimensions of the microspheres occlude the blood supply and thus, killing the tumor. Some microspheres have also been modified to bind protein, elute drugs, and reduce inflammatory reactions as part of the therapy. However, one technical short-coming of existing microsphere technology is a limited capability to be visualized in real-time. The inability to visualize embolic microspheres dur...Wed, 02 Aug 2023 07:01:09 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Synthesis_and_Characterization_of_Bismuth_Beads_for_Trans_Arterial_Chemo_Embolization_Under_Computed_Tomography_(CT)_GuidanceTAB-4271https://nih.technologypublisher.com/tech/Bacteriophage_Based-Vaccine_SystemAbstract: Vaccines have become one of the most important tools in the fight against cancers and infectious diseases. However, some vaccines have shown limitations due to their high cost and low immune responses. To overcome these limitations, bacteriophages were proposed for the development of more cost-effective, immunogenic vaccines. Phages have shown a strong ability to activate induced and adaptive immune systems. The genome of these viral particles can be engineered, and their surface proteins can be exploited for antigen display. Researchers at National Cancer Institute (NCI) developed a...Wed, 02 Aug 2023 07:01:04 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Bacteriophage_Based-Vaccine_SystemTAB-4270https://nih.technologypublisher.com/tech/A_Novel_Transgenic_Zebrafish_Line_Reporting_Dynamic_Epigenetic_ChangesAbstract: Currently, there is no other whole-animal reporter for epigenetic regulation established in any vertebrate.  The inventors generated this novel zebrafish line using a transgene construct containing dazl gene silencing sequences (CpG island) fused to a destabilized GFPd2 gene driven by the ubiquitously expressing ef1alpha promoter. The resulting transgenic line permits detailed tissue- or cellular- level visualization of dynamic changes in GFPd2 expression in response to changes in DNA methylation or downstream epigenetic regulation in developing or adult animals. GFPd2 is “off” in th...Wed, 02 Aug 2023 07:01:02 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/A_Novel_Transgenic_Zebrafish_Line_Reporting_Dynamic_Epigenetic_ChangesTAB-4269https://nih.technologypublisher.com/tech/HIV-1_IN_Mutant_in_a_Single_Round_VectorAbstract: Antiretroviral therapy (ART) has changed the prognosis of HIV-1 infection to a chronic illness that, in most cases, can be managed or controlled. Integrase strand transfer inhibitors (INSTIs) and reverse transcription inhibitors are essential components of ART drug cocktails. In compliant individuals, ART has been found to block viral replication completely. Additionally, blocking viral replication can prevent the emergence of drug resistance. Researchers at the Retroviral Replication Laboratory of the National Cancer Institute have introduced mutations into the nucleotides encoding ...Wed, 02 Aug 2023 07:01:00 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/HIV-1_IN_Mutant_in_a_Single_Round_VectorTAB-4268https://nih.technologypublisher.com/tech?title=Bivalent%2c_Dual_Specific_Anti-CD22_Anti-CD19_Chimeric_Antigen_Receptors_(CARs)Abstract: Chimeric antigen receptors (CARs) combine an antibody-based binding domain (and single chain fragment variable region, scFv) with T cell receptor signaling domains (CD3 zeta with a costimulatory domain, typically CD28 or 41BB). When T cells express CARs, they are activated in a major histocompatibility complex- (MHC) independent manner to kill tumor cells expressing the target to which the scFv binds.  CAR T cells targeting the B cell antigen CD19 have resulted in remissions in 60-80% of patients with pre-B cell precursor acute lymphoblastic leukemia (BCP-ALL). However, not all patie...Wed, 02 Aug 2023 07:00:59 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech?title=Bivalent%2c_Dual_Specific_Anti-CD22_Anti-CD19_Chimeric_Antigen_Receptors_(CARs)TAB-4267https://nih.technologypublisher.com/tech/Synthetic_Bacterial_Nanoparticles_as_Drug_and_Vaccine_Delivery_VehiclesAbstract: Bacterial spores can be modified to display molecules of interest, including drugs, immunogenic peptides, antibodies and other functional proteins of interest (such as enzymes).  The resulting engineered bacterial spores can provide many useful functions such as the treatment of infections, use as an adjuvant for the delivery of vaccines, and the enzymatic degradation of environmental pollutants. Researchers at the National Cancer Institute’s (NCI) Laboratory of Molecular Biology have developed a novel, synthetic spore husk-encased lipid bilayer (SSHEL) particle that is uniquely suit...Wed, 02 Aug 2023 07:00:57 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Synthetic_Bacterial_Nanoparticles_as_Drug_and_Vaccine_Delivery_VehiclesTAB-4265https://nih.technologypublisher.com/tech/Method_for_Generating_Pluripotent_and_Multipotent_CellsAbstract: Research and clinical applications of induced pluripotent stem (iPS) cells are currently limited by reprogramming methods that may modify the host genome, and therefore be potentially unsafe and problematic for use in basic research, cell-based therapies, and drug-discovery applications.  Researchers at the National Cancer Institute’s Laboratory of Pathology have overcome this challenge by using CD47 inhibiting peptides, antibodies, and morpholinos to generate and expand iPS cells.  This technology represents a safe yet highly efficient strategy for somatic cell reprogramming, and ha...Wed, 02 Aug 2023 07:00:56 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Method_for_Generating_Pluripotent_and_Multipotent_CellsTAB-4263https://nih.technologypublisher.com/tech/Therapeutic_Antitumor_Combination_Containing_TLR4_Agonist_HMGN1Abstract: Immune checkpoint inhibitors (e.g. CTLA-4, PD-L1) have recently shown significant promise in the treatment of cancer.  However, when used alone, these checkpoint inhibitors are limited by the absence or repression of immune cells within the targeted cancer.  For those cancers associated with these limited immune systems, there remains a need for effective therapies.  Agents capable of recruiting and activating immune cells to these types of cancers could extend the overall and complete response rates of combination therapies within the immunooncology domain.  Researchers at the Natio...Wed, 02 Aug 2023 07:00:54 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Therapeutic_Antitumor_Combination_Containing_TLR4_Agonist_HMGN1TAB-4262https://nih.technologypublisher.com/tech/Cancer_Inhibitors_Isolated_from_an_African_PlantWed, 02 Aug 2023 07:00:52 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Cancer_Inhibitors_Isolated_from_an_African_PlantTAB-4260https://nih.technologypublisher.com/tech/Inducible_Activation_Nucleic_Acid_Hybrid_Switch_for_Conditional_Generation_of_OligonucleotidesAbstract: Gene therapy research has yielded FDA-approved treatments for an array of diseases. However, challenges facing nucleic-acid based therapeutics include non-specific delivery and degradation of the nanoparticles. NCI investigators have developed a solution to address these challenges in their novel nucleic-based therapy based on the conditional activation strategy.  The inducible activation nucleic acid hybrid switch overcomes the drawbacks of current technologies through its unique design. The implementation of nucleic acid logic elements in these constructs circumvents off-target eff...Wed, 02 Aug 2023 07:00:50 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Inducible_Activation_Nucleic_Acid_Hybrid_Switch_for_Conditional_Generation_of_OligonucleotidesTAB-4257https://nih.technologypublisher.com/tech/Neoantigen_T_Cell_Therapy_with_Neoantigen_Vaccination_as_a_Combination_Immunotherapy_Against_CancerAbstract: Adoptive cell therapy (ACT) is a breakthrough form of cancer immunotherapy that utilizes autologous, antitumor T cells to attack tumors through recognition of tumor-specific mutations, or neoantigens. A major hurdle in the development of ACT is the exhausted phenotype exhibited by many neoantigen-specific T cells, which limits their efficacy and prevents a sustained immune response.  Researchers at the National Cancer Institute (NCI) have developed a combination immunotherapy to rescue the function of exhausted, neoantigen-specific T cells and, thus, enhance ACT. The method involves...Wed, 02 Aug 2023 07:00:46 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Neoantigen_T_Cell_Therapy_with_Neoantigen_Vaccination_as_a_Combination_Immunotherapy_Against_CancerTAB-4256https://nih.technologypublisher.com/tech/Antisense_Oligonucleotides_against_Cancer_Cell_Migration_and_InvasionAbstract: Advanced stage cancers are typically marked by metastases of the primary cancer to secondary sites such as lungs, liver, and bones. Such metastatic cancers result in strikingly low 5-year survival rates, underscoring the need for novel therapeutics. For example, bone metastasis of primary breast cancer has a 5-year survival rate of 13%, lung cancer only 1%. There is a need for targeted therapy options specific to metastases. One approach to targeting metastases is to reduce cancer cell migration and invasion. Several mRNAs become localized to subcellular destinations during the metas...Wed, 02 Aug 2023 07:00:44 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Antisense_Oligonucleotides_against_Cancer_Cell_Migration_and_InvasionTAB-4255https://nih.technologypublisher.com/tech/HIV-1_Therapeutic_Inhibits_Viral_EntryAbstract: Soluble forms (sCD4) of human CD4, the HIV-1 primary receptor, are potent HIV-1 entry inhibitors. Both four-domain (D1-4) and two-domain (D1D2) sCD4 and their fusion proteins have been tested as candidate therapeutics in animal models and in human clinical trials and were well tolerated by patients with no significant clinical or immunologic toxicities and exhibited significant inhibitory activities. However, their activities were transient and the virus rapidly rebound. Additionally, sCD4 is known to interact with the class II major histocompatibility complex (MHCII) and, at low con...Wed, 02 Aug 2023 07:00:43 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/HIV-1_Therapeutic_Inhibits_Viral_EntryTAB-4254https://nih.technologypublisher.com/tech/Anti-CD133_Monoclonal_Antibodies_as_Cancer_TherapeuticsAbstract: Most early work on CD133 was carried out using one of two monoclonal antibodies (mAbs), AC133 and AC141, which recognize an undefined glycosylated epitope of CD 133. Researchers from NCI's Pharmacodynamic Assay Development and Implementation Section generated novel anti-human CD133 monoclonal antibodies from large extracellular domain loops of CD133 using peptide residues selected from the native extracellular domains of CD133 protein as an immunogen. They selected sequences for immunization that do not overlap with known glycosylation sites. Peptide antigens comprising the amino aci...Wed, 02 Aug 2023 07:00:42 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Anti-CD133_Monoclonal_Antibodies_as_Cancer_TherapeuticsTAB-4253https://nih.technologypublisher.com/tech/Novel_Biased_Potent_Opioid-Like_Agonists_as_Improved_Medications_to_Treat_Chronic_and_Acute_PainAbstract: There are no analgesics to ameliorate chronic pain without adverse side-effects (e.g., respiratory depression, gastrointestinal effects, tolerance, dependence), thus forcing patients into a difficult choice of negative impacts on quality of life. Most of the analgesics used for chronic and acute pain are drugs such as oxycodone, morphine, oxymorphone, and codeine. All of these opioids have been subject to misuse; prescription drug abuse is a severe problem worldwide, causing high mortality and greatly increased emergency room visits. Recently, research indicated that the analgesic an...Wed, 02 Aug 2023 07:00:41 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Novel_Biased_Potent_Opioid-Like_Agonists_as_Improved_Medications_to_Treat_Chronic_and_Acute_PainTAB-4252https://nih.technologypublisher.com/tech/Method_for_Targeted_Therapeutic_Delivery_of_Proteins_into_CellsAbstract: Current methods to deliver proteins into cells (e.g., using retrovirus, DNA transfection, protein transduction, microinjection, complexing the protein with lipids, etc.) have many shortcomings, such as lack of target specificity toxicity, or unwanted random integration into the host chromosome.  Protein transduction is an emerging technology for delivering proteins into cells by exploiting the ability of certain proteins to penetrate the cell membrane.  However, the majority of the proteins delivered by this means are usually trapped and subsequently degraded in the endosomes-lysosom...Wed, 02 Aug 2023 07:00:39 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Method_for_Targeted_Therapeutic_Delivery_of_Proteins_into_CellsTAB-4251https://nih.technologypublisher.com/tech/Autophagy_Modulators_For_Use_in_Treating_CancerAbstract: Cancer cells can upregulate autophagy – cell destruction – as a response to chemotherapy. Investigators in Dr. Melvin DePamphilis’ laboratory at the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) have shown that compounds identified by screening a library of compounds blocks autophagy in some cancer cells (e.g., melanoma) but are not toxic to normal cells. Cancer cells with mutations in the BRAF oncogene are especially dependent on autophagy. Treatment of cancer cells with the BRAF mutation can increase the efficacy of chemotherapy. Proof of c...Wed, 02 Aug 2023 07:00:36 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Autophagy_Modulators_For_Use_in_Treating_CancerTAB-4250https://nih.technologypublisher.com/tech/Argon_to_Improve_Bioanalyte_Stability_in_Fixed_Tissue_SpecimensWed, 02 Aug 2023 07:00:34 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Argon_to_Improve_Bioanalyte_Stability_in_Fixed_Tissue_SpecimensTAB-4247https://nih.technologypublisher.com/tech/High-throughput_Assay_to_Identify_New_Cancer_DrugsAbstract:  The National Cancer Institute seeks parties interested in collaborative research to evaluate or commercialize a diagnostic tool that can identify new drugs that increase chromosome instability.  Although chromosomal instability is generally thought of as a driver of tumor growth, a threshold level exists where CIN becomes a barrier to tumor growth and therefore can be exploited therapeutically. Most human malignant solid tumors have been shown to contain chromosomal abnormalities.  Chromosomal instability (CIN) is the continuous formation of novel chromosome mutations at a higher ra...Wed, 02 Aug 2023 07:00:32 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/High-throughput_Assay_to_Identify_New_Cancer_DrugsTAB-4246https://nih.technologypublisher.com/tech/Gene_Signature_for_Predicting_Solid_Tumors_Patient_PrognosisAbstract: HCC is the most frequent malignant tumor in the liver and the third leading cause of cancer death worldwide.  A progressive sequence of somatic mutations and epigenetic changes of oncogenes or tumor suppressor genes are believed to cause tumor development. However, high genomic instability in tumors causes the accumulation of genomic aberrations that do not contribute to tumor progression. Therefore, it is important to distinguish between ''driver'' mutations that are functionally important and ''passenger'' mutations that do not provide a selective advantage to the tumor cells. The...Wed, 02 Aug 2023 07:00:31 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Gene_Signature_for_Predicting_Solid_Tumors_Patient_PrognosisTAB-4244https://nih.technologypublisher.com/tech/New_Insect_Sf9-ET_Cell_Line_for_Determining_Baculovirus_TitersAbstract: The baculovirus-based protein expression system has gained increased prominence as a method for expressing recombinant proteins that are used in a wide range of biomedical applications. An important step in the use of this system is the ability to determine the virus infectious titer, i.e., the number of active baculovirus particles produced during an infection of the insect host cell. The current “gold standard” methods used for determining baculovirus titers, such as the plaque and end point dilution assays, can be costly, take a long time to complete (up to 7-8 days), and are some...Wed, 02 Aug 2023 07:00:29 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/New_Insect_Sf9-ET_Cell_Line_for_Determining_Baculovirus_TitersTAB-4243https://nih.technologypublisher.com/tech/Methods_of_Producing_T-cell_Populations_Using_P38_MAPK_InhibitorsAbstract: Adoptive cell therapy (ACT) uses cancer reactive T-cells to effectively treat patients. However, several obstacles inhibit the successful use of ACT for cancer treatment.  Current approaches for the expansion of T-cells may produce T-cells with a terminally differentiated phenotype that is associated with diminished anti-tumor activity and poor capacity for long-term persistence. Studies have shown that improving metabolic properties and persistence of T-cells during ex vivo expansion could improve anti-tumor efficacy of T-cells. Thus, there is a need for improved methods of obtainin...Wed, 02 Aug 2023 07:00:28 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Methods_of_Producing_T-cell_Populations_Using_P38_MAPK_InhibitorsTAB-4242https://nih.technologypublisher.com/tech/Improved_Gene_Therapy_Vectors_for_the_Treatment_of_Glycogen_Storage_Disease_Type_Ia_(GSD-1a)Abstract: GSD-Ia is an inherited disorder of metabolism associated with life-threatening hypoglycemia, hepatic malignancy, and renal failure caused by the deficiency of glucose-6-phosphatase-alpha (G6Pase-alpha or G6PC). Current therapy, which primarily consists of dietary modification, fails to prevent long-term complications in many patients, including growth failure, gout, pulmonary hypertension, renal dysfunction, osteoporosis, and hepatocellular adenomas (HCA). Gene therapy-based techniques, which directly address the underlying genetic deficiency driving the disorder, offer the prospect ...Wed, 02 Aug 2023 07:00:26 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Improved_Gene_Therapy_Vectors_for_the_Treatment_of_Glycogen_Storage_Disease_Type_Ia_(GSD-1a)TAB-4239https://nih.technologypublisher.com/tech/ELISA-Based_Biodosimeter_for_Measuring_and_Quantifying_DNA_DamageWed, 02 Aug 2023 07:00:25 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/ELISA-Based_Biodosimeter_for_Measuring_and_Quantifying_DNA_DamageTAB-4233https://nih.technologypublisher.com/tech/Human_Monoclonal_Antibodies_Targeting_Glypican-2_in_NeuroblastomaAbstract: Neuroblastoma is a rare pediatric cancer that affects one in every hundred thousand children under the age of fifteen in the United States. Current standards of care  are chemotherapy and surgery, followed by stem-cell treatments, radiation and anti-ganglioside antibody therapy, which yield an average three-year survival rate of 10-45%. This demonstrates a need for more effective therapies. Glypican-2 (GPC2) is a cell surface protein that has been shown to be preferentially expressed on numerous pediatric cancers, including neuroblastoma. Due to this preferential expression, GPC2 rep...Wed, 02 Aug 2023 07:00:21 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Human_Monoclonal_Antibodies_Targeting_Glypican-2_in_NeuroblastomaTAB-4230https://nih.technologypublisher.com/tech/Fully-human_Heavy-chain-only_Anti-B-cell_Maturation_Antigen_(BCMA)_Chimeric_Antigen_Receptors_(CARs)Abstract: Immortalization of plasma cells leads to plasma cell malignancy diseases such as multiple myeloma (MM). B-cell maturation antigen (BCMA) is a protein that is preferentially expressed by malignant and normal B cells and plasma cells, butnot on other cells in the body. This limited expression profile suggests that BCMA is a promising target for anticancer therapeutics for cancers in which there is excess production of plasma cells and B cells.  Researchers in the National Cancer Institute (NCI) Experimental Transplantation and Immunology Branch (ETIB) previously reported anti-BCMA CAR...Wed, 02 Aug 2023 07:00:19 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Fully-human_Heavy-chain-only_Anti-B-cell_Maturation_Antigen_(BCMA)_Chimeric_Antigen_Receptors_(CARs)TAB-4228https://nih.technologypublisher.com/tech/Time_Efficient_Multi-Pulsed_Field_Gradient_(mPFG)_MRI_Without_Concomitant_Gradient_Field_ArtifactsAbstract: Measuring and mapping nervous tissue microstructure noninvasively is a long sought-after goal in neuroscience. Clinically, several neuropathologies such as cancer and stroke, are associated with changes in tissue microstructure. Diffusion tensor imaging (DTI), which models diffusion anisotropy, is an ideal imaging modality to elucidate these changes. However, DTI provides a mean diffusion tensor averaged over the entire MRI voxel. This has limitations when applied to heterogeneous neural tissue. Although some of these could be overcome by increased spatial resolution, this comes at t...Wed, 02 Aug 2023 07:00:18 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Time_Efficient_Multi-Pulsed_Field_Gradient_(mPFG)_MRI_Without_Concomitant_Gradient_Field_ArtifactsTAB-4227https://nih.technologypublisher.com/tech/Strategies_to_Protect_Mammalian_Neural_Tissue_Against_Cold_and_Potentially_Other_Metabolic_Stresses_and_Physical_DamagesWed, 02 Aug 2023 07:00:16 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Strategies_to_Protect_Mammalian_Neural_Tissue_Against_Cold_and_Potentially_Other_Metabolic_Stresses_and_Physical_DamagesTAB-4226https://nih.technologypublisher.com/tech/Use_of_a_Modified_Adaptor_Molecule_LAT_to_Improve_Immunotherapy_for_Cancer_and_Other_DiseasesAbstract: One problem with the development of immunotherapy for cancer or other diseases is the inability to stimulate a sufficient immune response in patients to tumor associated antigens. The Linker Adapted for T Cell Signaling molecule (LAT) has been shown to be an important molecule in T cell signaling. The inventions described and claimed in this patent application illustrate a new supportive role for LAT which may be harnessed to improve a patient's immune response to tumor-associated antigens. A number of approaches to improving the immune response in cancer immunotherapy have been inve...Wed, 02 Aug 2023 07:00:15 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Use_of_a_Modified_Adaptor_Molecule_LAT_to_Improve_Immunotherapy_for_Cancer_and_Other_DiseasesTAB-4225https://nih.technologypublisher.com/tech/Nitroxide_Radical_as_a_Treatment_for_NeurodegenerationAbstract: The Human Iron Metabolism Section of the National Institute of Child Health and Human Development (NICHD) is seeking statements of capability or interest from parties interested in collaborative research to obtain pre-clinical data to be used to further develop, evaluate, or commercialize nitroxide radicals as a treatment for neurodegeneration and other neurological disorders related to iron-deficiencies. Over 22 million people suffer from neurodegenerative diseases worldwide, and in 2050, this number could triple due to increased life expectancy and an increased aging population. ...Wed, 02 Aug 2023 07:00:14 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Nitroxide_Radical_as_a_Treatment_for_NeurodegenerationTAB-4224https://nih.technologypublisher.com/tech/Monomeric_and_Oligomeric_Compounds_as_Contraceptives_and_Endocrine_TherapeuticsWed, 02 Aug 2023 07:00:12 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Monomeric_and_Oligomeric_Compounds_as_Contraceptives_and_Endocrine_TherapeuticsTAB-4223https://nih.technologypublisher.com/tech/Chimeric_Antigen_Receptors_to_CD22_for_Treating_Hematological_CancersAbstract: Chimeric antigen receptors (CARs) are hybrid proteins consisting of an antibody binding fragment fused to protein signaling domains that cause T-cells which express the CAR to become cytotoxic.  Once activated, these cytotoxic T-cells can selectively eliminate the cells which they recognize via the antibody binding fragment of the CAR.  Thus, by engineering a T-cell to express a CAR that is specific for a certain cell surface protein, it is possible to selectively target those cells for destruction.  This promising new therapeutic approach is known as adoptive cell therapy.   CD22 ...Wed, 02 Aug 2023 07:00:11 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Chimeric_Antigen_Receptors_to_CD22_for_Treating_Hematological_CancersTAB-4222https://nih.technologypublisher.com/tech/Novel_HPPK_(Bacterial_Protein)_Inhibitors_for_Use_as_Antibacterial_AgentsAbstract: Research and development leading to the discovery of novel antibiotics has waned in recent years. At the same time, the emergence and spread of antimicrobial resistance has compounded the global danger to human health from bacterial infections.  The bacterial protein 6-hydroxymethyl-7,8-dihydropterin pyrophosphokinase (HPPK) is a key enzyme in the folate biosynthetic pathway. This pathway is essential for bacteria and microorganisms but is absent in mammals – making it an attractive target for antibiotics. HPPK is a novel target for antibiotics as none of the antimicrobial agents cur...Wed, 02 Aug 2023 07:00:10 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Novel_HPPK_(Bacterial_Protein)_Inhibitors_for_Use_as_Antibacterial_AgentsTAB-4220https://nih.technologypublisher.com/tech/3D_Image_Rendering_Software_for_Biological_TissuesAbstract: Available for commercial development is software that provides automatic visualization of features inside biological image volumes in 3D. The software provides a simple and interactive visualization for the exploration of biological datasets through dataset-specific transfer functions and direct volume rendering. The method employs a K-Means++ clustering algorithm to classify a two-dimensional histogram created from the input volume. The classification process utilizes spatial and data properties from the volume. Then using properties derived from the classified clusters, the softwar...Wed, 02 Aug 2023 07:00:08 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/3D_Image_Rendering_Software_for_Biological_TissuesTAB-4218https://nih.technologypublisher.com/tech/Inhibition_of_T_Cell_Differentiation_and_Senescence_by_Overexpression_of_Transcription_Factor_c-MybAbstract: Adoptive Cell Therapy (ACT) is a promising technique that uses a patient's own T cells to treat cancer. The process requires removing and engineering a patient's T cells to express a chimeric antigen receptor (CAR) or T cell receptor (TCR) that targets a specific cancer antigen. When the modified T cells are reintroduced into the patient, the T cells attack and kill cancer cells that express the antigen, thereby treating the patient. Although ACT holds a great deal of promise, there are still technical drawbacks to be overcome, such as loss of anti-tumor activity due to T cell senesc...Wed, 02 Aug 2023 07:00:05 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Inhibition_of_T_Cell_Differentiation_and_Senescence_by_Overexpression_of_Transcription_Factor_c-MybTAB-4216https://nih.technologypublisher.com/tech/New_Heterocyclic_Scaffold-Based_Inhibitors_of_the_Polo-Box_Domain_of_Polo-like_Kinase_1_for_the_Treatment_of_CancerAbstract: Polo-like kinase 1 (Plk1), a member of the Polo-like kinase family, plays a critical role in regulating mitosis and cell cycle progression. Aberrant expression of Plk1 has been observed in a variety of human cancers, and it is known to be associated with tumorigenesis as well as poor prognosis in cancer patients. Unlike normal cells, some cancer cells are dependent on augmented Plk1 levels to remain viable and are killed when Plk1 function is attenuated. Although Plk1 has proven to be an attractive target in cancer treatment, currently available Plk1 inhibitors have shown limited eff...Wed, 02 Aug 2023 07:00:03 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/New_Heterocyclic_Scaffold-Based_Inhibitors_of_the_Polo-Box_Domain_of_Polo-like_Kinase_1_for_the_Treatment_of_CancerTAB-4215https://nih.technologypublisher.com/tech/High_Affinity_Monoclonal_Antibodies_Targeting_Glypican-2_for_Treating_Childhood_CancersAbstract: Neuroblastoma is a rare pediatric cancer with approximately 1,000 new cases arising annually. Current therapies have a less than forty-five percent (45%), three-year survival rate which demonstrate a need for a more effective treatment against this disease. Glypican-2 (GPC2) is a cell surface protein that is preferentially expressed in pediatric cancers including neuroblastoma, which makes GPC2 an attractive candidate for targeted therapy.    Researchers at the National Cancer Institute’s (NCI) Laboratory of Molecular Biology have developed and isolated two new antibodies that targ...Wed, 02 Aug 2023 07:00:02 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/High_Affinity_Monoclonal_Antibodies_Targeting_Glypican-2_for_Treating_Childhood_CancersTAB-4214https://nih.technologypublisher.com/tech/Surgical_Tool_for_Sub-retinal_Tissue_ImplantationWed, 02 Aug 2023 07:00:01 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Surgical_Tool_for_Sub-retinal_Tissue_ImplantationTAB-4213https://nih.technologypublisher.com/tech/Cell_Lines_that_Constitutively_Express_High-Frequency_KRAS_and_P53_Mutations_and_Human_Leukocyte_Antigens_(HLAs)Abstract: Adoptive cell therapy (ACT) is a breakthrough form of cancer immunotherapy that utilizes tumor infiltrating lymphocytes (TILs) or genetically engineered T cells to attack tumor cells through recognition of tumor-specific antigens. A major hurdle in the development of ACT is the identification and isolation of T cells that recognize antigens that are expressed by tumor cells but not by healthy tissues. Current methods to identify such T cells involve extracting autologous antigen presenting cells (APCs) from patients in an expensive, laborious, and time-consuming process. In addition,...Wed, 02 Aug 2023 06:59:59 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Cell_Lines_that_Constitutively_Express_High-Frequency_KRAS_and_P53_Mutations_and_Human_Leukocyte_Antigens_(HLAs)TAB-4212https://nih.technologypublisher.com/tech?title=T_Cell_Receptors_Targeting_KRAS_Mutants_for_Cancer_Immunotherapy%2fAdoptive_Cell_TherapyAbstract: Mutations in the Kirsten rat sarcoma viral oncogene homolog (KRAS) gene are among the most common oncogenic drivers in human cancers, affecting nearly a third of all solid tumors. Point mutations in the KRAS gene most frequently affect amino acid position 12, resulting in the substitution of the native glycine (G) residue for other amino acids (e.g., aspartic acid (D), valine (V), cysteine (C) or arginine (R)). The mutations in KRAS occur early in the process of carcinogenesis, and only tumor cells express driver mutations, making them an attractive cancer-specific therapeutic targe...Wed, 02 Aug 2023 06:59:58 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech?title=T_Cell_Receptors_Targeting_KRAS_Mutants_for_Cancer_Immunotherapy%2fAdoptive_Cell_TherapyTAB-4211https://nih.technologypublisher.com/tech?title=Single_Domain_Antibodies_targeting_HPV_E6%2fE7_Oncogenic_Peptide%2fMHC_complexesDescription of Technology: Human papillomavirus (HPV) has been linked to many cancers including cervix, uterine, anus, vulva, vagina, and penis. Although HPV vaccines exist to prevent HPV-associated cancers, there are still more than 5,000 deaths caused by HPV-associated cancers each year in the US and cervical cancer continues to be the second leading cause of cancer death in women ages 20 to 39. Engineered T cell receptor (TCR) therapy has been effective in some patients with HPV16 E6 expressing cancers, however, there continues to be a need for more therapies targeting HPV16 E6, when curre...Wed, 02 Aug 2023 06:59:57 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech?title=Single_Domain_Antibodies_targeting_HPV_E6%2fE7_Oncogenic_Peptide%2fMHC_complexesTAB-4209https://nih.technologypublisher.com/tech?title=AngleNav%3a_Micro-Electro-Mechanical_Systems_(MEMs)_Trackers_to_Facilitate_Computed_Topography_(CT)-Guided_Needle_PunctureAbstract: Conventional free-hand needle puncture procedures for biopsy and other procedures, often rely on unguided manual movements to guide a needle to its destination. Freehand procedures risk missing the tumor, or accidental injury, such as puncturing a vital organ. Needle guidance systems may improve accuracy and reduce risks but available guidance technologies are cumbersome and expensive and may carry other risks. For example, Computed Topography (CT)-guided fluoroscopy for needle guidance may be used, but fluoroscopy requires expensive bulky equipment and exposes patients to increased ...Wed, 02 Aug 2023 06:59:55 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech?title=AngleNav%3a_Micro-Electro-Mechanical_Systems_(MEMs)_Trackers_to_Facilitate_Computed_Topography_(CT)-Guided_Needle_PunctureTAB-4207https://nih.technologypublisher.com/tech/Novel_Fixative_for_Improved_Biomolecule_Quality_from_Paraffin-Embedded_TissueAbstract: Tissues samples collected during medical procedures, such as biopsies, are used to diagnose a wide variety of diseases. Before diagnosis, patient samples are typically processed by fixation and paraffin embedding. This fixation/embedding process is used to preserve tissue morphology and histology for subsequent evaluation. Unfortunately, most fixative agents can damage or destroy nucleic acids (RNA and DNA) and damage proteins during the fixation process, thereby potentially impairing diagnostic assessment of tissue. Researchers in the National Cancer Institute’s Laboratory of Pathol...Wed, 02 Aug 2023 06:59:54 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Novel_Fixative_for_Improved_Biomolecule_Quality_from_Paraffin-Embedded_TissueTAB-4206https://nih.technologypublisher.com/tech/In_vitro_Generation_of_an_Autologous_Thymic_Organoid_from_Human_Pluripotent_Stem_CellsAbstract: The thymus is an integral part of the adaptive immune system as it generates T cells. Its function diminishes rapidly as the body ages, leading to a compromise of the immune system in the elderly. Reconstitution of adaptive immunity through mass production of different T cell types is therefore a therapeutic need in immunocompromised populations. Furthermore, production of T cells with specific receptors targeting cancer cells is an important cancer immunotherapy approach. However, current in vitro methods are not efficient in producing conventional CD4 or CD8 positive T cells, as th...Wed, 02 Aug 2023 06:59:52 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/In_vitro_Generation_of_an_Autologous_Thymic_Organoid_from_Human_Pluripotent_Stem_CellsTAB-4204https://nih.technologypublisher.com/tech/A_peptide_hydrogel_for_use_in_vascular_anastomosisAbstract: In collaboration with surgery specialists from Johns Hopkins University, researchers at the National Cancer Institute (NCI) developed novel hydrogel compositions and methods of using them in the microsurgical suturing of blood vessels, which is particularly beneficial for surgeons in whole tissue transplant procedures. The lead candidate electropositive hydrogels, called APC1, was demonstrated in anastomosis mice models to be well tolerated, biocompatible, and non-toxic. Synthetic preparation of APC1 is simple, and has been easy to use by surgeons to accomplish anastomosis in animal ...Wed, 02 Aug 2023 06:59:50 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/A_peptide_hydrogel_for_use_in_vascular_anastomosisTAB-4203https://nih.technologypublisher.com/tech/Anti-bacterial_Treatments_Using_Peptide-Based_Inhibitors_of_the_STAT3-IL10_PathwayAbstract: Tuberculosis (TB) is an infectious disease that typically affects the lungs. Current therapies include a panel of antibiotics given over a range of 6-9 months. As a result of the expense of treatment, the extended timeframe needed for effective treatment, and the scarcity of medicines in some developing countries, patient compliance with TB treatment is very low and results in multi-drug resistant TB (MDR-TB). There remains a need for a faster, more effective treatment for TB. Short, metabolically stable, cell-penetrating lipopeptide mimics of conserved regions of IL-10 and STAT3 inh...Wed, 02 Aug 2023 06:59:48 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Anti-bacterial_Treatments_Using_Peptide-Based_Inhibitors_of_the_STAT3-IL10_PathwayTAB-4202https://nih.technologypublisher.com/tech?title=Improved_PE-based_Targeted_Toxins%3a_A_Therapeutic_with_Increased_EffectivenessAbstract: Targeted toxins (e.g., immunotoxins) are therapeutics that have at least two important components: (1) a toxin domain that is capable of killing cells and (2) a targeting domain that is capable of selectively localizing the toxic domain to only those cells which should be killed. By selecting a targeting domain that binds only to certain diseased cells (e.g., a cell which only expresses a cell surface receptor when in a diseased state), targeted toxins can kill the diseased cells while allowing healthy, essential cells to survive. As a result, patients receiving a targeted toxin are ...Wed, 02 Aug 2023 06:59:47 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech?title=Improved_PE-based_Targeted_Toxins%3a_A_Therapeutic_with_Increased_EffectivenessTAB-4201https://nih.technologypublisher.com/tech/Novel_Small_Molecule_Inhibitors_of_Tyrosyl-DNA_Phosphodiesterase_1_(TDP1)_for_Treatment_of_Solid_TumorsAbstract: Topoisomerase 1 (TOP1) is an essential enzyme that plays a critical role in DNA transcription and replication. TOP1 inhibitors are a known class of anti-cancer agents that work to interrupt DNA replication in cancer cells, causing cell death. Since the discovery of the TOP1 inhibitor camptothecin (CPT) from plant extracts more than 60 years ago, two CPT analogs (irinotecan and topotecan) were approved by the FDA for cancer treatment. Tyrosyl-DNA phosphodiesterase 1 (TDP1) is an enzyme involved in DNA repair created when TOP1 is inhibited. As a result, targeting TDP1 is considered a p...Wed, 02 Aug 2023 06:59:46 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Novel_Small_Molecule_Inhibitors_of_Tyrosyl-DNA_Phosphodiesterase_1_(TDP1)_for_Treatment_of_Solid_TumorsTAB-4200https://nih.technologypublisher.com/tech/A_Preclinical_Orthotopic_Model_for_Glioblastoma_Multiforme_that_Represents_Key_Pathways_Aberrant_in_Human_Brain_CancerAbstract: Current therapies for glioblastoma multiforme (GBM), the highest grade malignant brain tumor, are mostly ineffective, and better preclinical model systems are needed to increase the successful translation of drug discovery efforts into the clinic. Scientists at the National Cancer Institute (NCI) have developed and characterized an orthotopic genetically engineered mouse (GEM)-derived model of GBM that closely recapitulates various human GBM subtypes and is useful for preclinical evaluation of candidate therapeutics. The GEM-derived GBM model harbors perturbations in the receptor ty...Wed, 02 Aug 2023 06:59:44 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/A_Preclinical_Orthotopic_Model_for_Glioblastoma_Multiforme_that_Represents_Key_Pathways_Aberrant_in_Human_Brain_CancerTAB-4199https://nih.technologypublisher.com/tech/Anti-Mesothelin_Monoclonal_Antibodies_for_the_Treatment_of_CancerAbstract: The National Cancer Institute seeks parties interested in collaborative research to further co-develop monoclonal antibodies for the treatment of mesothelin-expressing cancers. The antibody was able to inhibit tumor growth in mouse xenograft models, and corresponding immunotoxins were able to inhibit tumor cell growth in vitro Mesothelin is a cell surface protein that is highly expressed in aggressive cancers such as malignant mesothelioma, ovarian cancer, pancreatic cancer, lung cancer, breast cancer, cholangiocarcinoma, bile duct carcinoma and gastric cancer. This selective express...Wed, 02 Aug 2023 06:59:43 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Anti-Mesothelin_Monoclonal_Antibodies_for_the_Treatment_of_CancerTAB-4198https://nih.technologypublisher.com/tech/Novel_Murine_T-Cell_Receptors_for_Treating_Metastatic_Thyroid_CancerAbstract: The occurrence of thyroid cancer has been increasing in the United States. For some patients, with particularly advanced and metastatic cancer, current treatments such as thyroidectomy and adjuvant radioactive iodine therapy can lead to poor outcomes. Hence, there is a need for new thyroid cancer treatments. Researchers at the NCI have developed novel T-cell receptors (TCRs) to target thyroid cancer. They immunized HLA-A2+ transgenic mice to generate TCRs that recognize human thyroglobulin (TG). TG, a tissue-differentiation antigen, is only expressed in thyroid cancer and normal thyr...Wed, 02 Aug 2023 06:59:42 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Novel_Murine_T-Cell_Receptors_for_Treating_Metastatic_Thyroid_CancerTAB-4197https://nih.technologypublisher.com/tech/T_Cell_Receptors_Targeting_BRAF_V600E_Mutation_for_Cancer_ImmunotherapyAbstract: BRAF is an oncogene that encodinges a serine-threonine kinase (B-Raf kinase) important in regulating cell growth and differentiation. Spontaneous mutations in the BRAF gene allow cells to continuously divide, leading to the development of cancer. A substitution of glutamic acid for valine at amino acid number 600 (designated V600E) accounts for 90% of BRAF mutations and is a driver of many cancers. The V600E mutation is present in ~3% of all cancer cases, representing a patient population of 540,000 patients per year. Though While the V600E mutation is found in a wide variety of canc...Wed, 02 Aug 2023 06:59:40 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/T_Cell_Receptors_Targeting_BRAF_V600E_Mutation_for_Cancer_ImmunotherapyTAB-4195https://nih.technologypublisher.com/tech/Novel_Regulatory_B_cells_for_Treatment_of_Cancer_and_Autoimmune_DiseaseAbstract: The manner by which cancers evade the immune response is not well-understood. What is known is that the manner is an active process that regulates immune responses employing at least two types of suppressive cells, myeloid-derived suppressive cells and regulatory T cells (Tregs), a key subset of CD4+ T cells that controls peripheral tolerance to self- and allo-antigens. Tregs are considered to play a key role in the escape of cancer cells from anti-tumor effector T cells. Cancer cells have been found to directly activate resting B cells to form suppressive regulatory B cells (tBregs...Wed, 02 Aug 2023 06:59:38 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Novel_Regulatory_B_cells_for_Treatment_of_Cancer_and_Autoimmune_DiseaseTAB-4194https://nih.technologypublisher.com/tech/Peptide_Mimetic_Ligands_of_Polo-like_Kinase_1_Polo_Box_DomainAbstract: Polo-like kinase 1 (Plk1) is a critical protein involved in regulation of mitosis, and aberrant expression of this kinase is found in various cancer types.  Inhibition of Plk1 is currently being pursued in pre-clinical drug development for novel anti-cancer therapeutics.  Plk1 contains an allosteric domain, known as the polo-box domain (PBD), that is responsible for localizing the kinase domain to mitotic structures through protein-protein interactions.   This technology is an improvement and continuation of Dr. Terry Burke’s research program centered around PBD modulation. The “Plk1...Wed, 02 Aug 2023 06:59:36 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Peptide_Mimetic_Ligands_of_Polo-like_Kinase_1_Polo_Box_DomainTAB-4193https://nih.technologypublisher.com/tech/Assay_to_Screen_Anti-metastatic_DrugsWed, 02 Aug 2023 06:59:35 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Assay_to_Screen_Anti-metastatic_DrugsTAB-4192https://nih.technologypublisher.com/tech/89Zr-Oxine_Complex_for_In_Vivo_PET_Imaging_of_Labelled_Cells_and_Associated_MethodsAbstract: This technology from the NCI Molecular Imaging Program relates to a Zirconium-89 (89Zr)-oxine complex for cell labeling, tracking of labeled cells by whole-body positron emission tomography/computed tomography (PET/CT) imaging, and associated methods. A long half-life of 89Zr (78.4 hours), high sensitivity of PET, and absence of background signal in the recipient enable tracking cells over a week using low levels of labeling radioactivity without causing cellular toxicity. The 89Zr-oxine complex is synthesized quickly by mixing components at room temperature and produces high yields....Wed, 02 Aug 2023 06:59:34 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/89Zr-Oxine_Complex_for_In_Vivo_PET_Imaging_of_Labelled_Cells_and_Associated_MethodsTAB-4191https://nih.technologypublisher.com/tech/Renal_Selective_Unsaturated_Englerin_AnaloguesAbstract: Englerin A, a natural product, has shown growth-inhibiting activity against renal cancer cell lines. The compound is an agonist of protein kinase C (PCK) theta, which results in cell cytotoxicity, insulin inhibition, and selective activation of viral replication in T cells.  Englerin A derivatives are promising treatment strategies for any diseases associated with PKC theta and/or ion channel proteins. Researchers at the National Cancer Institute have developed a series of Englerin A analogs for the treatment of renal cancer. The new derivatives are less toxic than the parent compoun...Wed, 02 Aug 2023 06:59:33 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Renal_Selective_Unsaturated_Englerin_AnaloguesTAB-4190https://nih.technologypublisher.com/tech/Fully_Human_Antibody_Targeting_Tumor_Necrosis_Factor_Receptor_Type_2_(TNFR2)_for_Cancer_ImmunotherapyAbstract: Tumor necrosis factor receptor type 2 (TNFR2)-expressing regulatory T cells (Tregs), present in the tumor microenvironment, play an important role in tumor immune evasion. TNFR2 plays a crucial role in stimulating the activation and proliferation of Tregs, a major checkpoint of antitumor immune responses. In addition to its expression on Tregs, TNFR2 is also known to be overexpressed on some types of tumors and the survival and growth of these tumor cells is promoted by ligands of TNFR2. Therefore, antagonists of TNFR2 may act as checkpoint inhibitors that suppress Tregs but may also...Wed, 02 Aug 2023 06:59:31 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Fully_Human_Antibody_Targeting_Tumor_Necrosis_Factor_Receptor_Type_2_(TNFR2)_for_Cancer_ImmunotherapyTAB-4186https://nih.technologypublisher.com/tech/Mitotic_Figures_Electronic_Counting_Application_for_Surgical_PathologyAbstract: Cancer diagnosis depends on the assessment of patient biopsies to determine tumor type, grading, and stage of malignancy. Pathologists visually review specimens and count mitotic figures (MF) in a variety of cancer types to help gauge aggressiveness, guide treatment, and inform patient prognosis. Current technology for recording MF counts in surgical pathology is lacking in objectivity, and enumeration of MF by microscopy can be error prone. In particular, a lack of systematic means for recording contributes to recognized variability. Cell counting instruments have been employed in t...Wed, 02 Aug 2023 06:59:27 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Mitotic_Figures_Electronic_Counting_Application_for_Surgical_PathologyTAB-4183https://nih.technologypublisher.com/tech/Size-dependent_brain_distribution_of_macromolecular_drug_delivery_platformAbstract: The blood brain barrier (BBB) is a specialized endothelium that prevents the uptake of substances from the systemic circulation into the central nervous system. This barrier, while protecting the sensitive physiological environment of the brain, is also a major impediment in administering therapeutics that need to pass through the BBB. A drug delivery platform that could deliver therapeutic agents directly to the brain is needed, and could have wide ranging significance in a variety of psychiatric, oncology, infectious, and neurodegenerative diseases. Currently, there are no approved...Wed, 02 Aug 2023 06:59:24 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Size-dependent_brain_distribution_of_macromolecular_drug_delivery_platformTAB-4182https://nih.technologypublisher.com/tech/Metastatic_ovarian_cancer_mouse_models_and_cell_lines_for_preclinical_studiesAbstract: The high mortality rate from ovarian cancers can be attributed to late-stage diagnosis and lack of effective treatment. Despite enormous effort to develop better targeted therapies, platinum-based chemotherapy still remains the standard of care for ovarian cancer patients, and resistance occurs at a high rate. One of the rate limiting factors for translation of new drug discoveries into clinical treatments has been the lack of suitable preclinical cancer models with high predictive value. Researchers at NCI's Center for Advanced Preclinical Research (CAPR) developed Tri-allelic K18-T...Wed, 02 Aug 2023 06:59:22 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Metastatic_ovarian_cancer_mouse_models_and_cell_lines_for_preclinical_studiesTAB-4181https://nih.technologypublisher.com/tech/Denoising_of_Dynamic_Magnetic_Resonance_Spectroscopic_Imaging_Using_Low_Rank_Approximations_in_the_Kinetic_DomainAbstract: Accurate measurement of low metabolite concentrations produced by medically important enzymes is commonly obscured by noise during magnetic resonance imaging (MRI). Measuring the turnover rate of low-level metabolites can directly quantify the activity of enzymes of interest, including possible drug targets in cancer and other diseases. Noise can cause the in vivo signal to fall below the limit of detection. A variety of denoising methods have been proposed to enhance spectroscopic peaks, but still fall short for the detection of low-intensity signals. Dynamic nuclear polarization (D...Wed, 02 Aug 2023 06:59:21 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Denoising_of_Dynamic_Magnetic_Resonance_Spectroscopic_Imaging_Using_Low_Rank_Approximations_in_the_Kinetic_DomainTAB-4180https://nih.technologypublisher.com/tech/Brachyury-directed_Vaccine_for_the_Prevention_or_Treatment_of_CancersAbstract: Tumor invasion and metastasis are the primary drivers of cancer-related mortality. Therapies that have an ability to specifically target invasive and/or metastatic cells are anticipated to have a significant impact in the clinical management of advanced cancers. Researchers at the NCI have developed a vaccine technology that stimulates the immune system to selectively destroy metastasizing cells. Brachyury, a master transcription factor that governs the epithelial-mesenchymal transition, was shown to be significantly overexpressed in primary and metastasizing tumors relative to norma...Wed, 02 Aug 2023 06:59:20 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Brachyury-directed_Vaccine_for_the_Prevention_or_Treatment_of_CancersTAB-4179https://nih.technologypublisher.com/tech/Multi-epitope_Vaccines_against_TARP_(ME-TARP)_for_Treating_Prostate_and_Breast_CancerAbstract: The development of more targeted means of treating cancer is vital. One option for a targeted treatment is the creation of a vaccine that induces an immune response only against cancer cells. In this sense, vaccination involves the introduction of a peptide into a patient that causes the formation of antibodies or T cells that recognize the peptide. If the peptide is from a protein found selectively on/in cancer cells, those antibodies or T cells can trigger the death of those cancer cells without harming non-cancer cells. This can result in fewer side effects for the patient. TARP (...Wed, 02 Aug 2023 06:59:18 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Multi-epitope_Vaccines_against_TARP_(ME-TARP)_for_Treating_Prostate_and_Breast_CancerTAB-4175https://nih.technologypublisher.com/tech/Parental_A2780_Ovarian_Cancer_Cell_Line_and_Derivative_Cisplatin-resistant_and_Adriamycin-resistant_A2780_Cell_LinesAbstract: Ovarian cancer is one of the most common and lethal types of gynecological malignancies worldwide, accounting for approximately 295,000 new cases and 185,000 deaths annually. The high lethality rate is due to multiple reasons, including recurrence and the resistance of recurrent tumors to chemotherapy. Cell line models are crucial for preclinical cancer studies, to identify mechanisms of disease, to study drug resistance, and to screen for candidate therapeutics.  Researchers at the National Cancer Institute (NCI), Laboratory of Cellular and Molecular Biology have derived a cell line...Wed, 02 Aug 2023 06:59:16 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Parental_A2780_Ovarian_Cancer_Cell_Line_and_Derivative_Cisplatin-resistant_and_Adriamycin-resistant_A2780_Cell_LinesTAB-4173https://nih.technologypublisher.com/tech/Personalized_Tumor_Vaccine_and_Use_Thereof_for_Cancer_ImmunotherapyAbstract: Immune checkpoint inhibitors (ICIs) vastly improved the outcome of various advanced cancers; however, many are less likely to respond to single-agent ICI. Tumors with low T-cell infiltration are "immunologically cold" and less likely to respond to single-agent ICI therapy. This diminished response is presumably due to the lack of neoantigens necessary to activate an adaptive immune response. On the other hand, an "immunologically hot" tumor with high T-cell infiltration has an active anti-tumor immune response following ICI treatment. Therefore, converting immunologically “cold: tumo...Wed, 02 Aug 2023 06:59:14 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Personalized_Tumor_Vaccine_and_Use_Thereof_for_Cancer_ImmunotherapyTAB-4170https://nih.technologypublisher.com/tech/Bone_Marrow_Mesenchymal_Stem_Cell_(BMSC)-Derived_Exosomes_for_the_Treatment_of_GlaucomaAbstract: Glaucoma is one of the world’s leading causes of irreversible blindness. There is no cure and vision lost from glaucoma cannot be restored. Glaucoma is associated with fluid build-up in the eye resulting in an increased intraocular pressure (IOP). The pressure may cause damage to the optic nerve and lead to progressive degeneration of retinal ganglion cells (RGC) and vision loss. Currently, available treatments for glaucoma delay progression by reducing IOP, but no therapies exist to directly protect RGC from degradation and loss.  Scientists at the National Eye Institute (NEI) have ...Wed, 02 Aug 2023 06:59:12 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Bone_Marrow_Mesenchymal_Stem_Cell_(BMSC)-Derived_Exosomes_for_the_Treatment_of_GlaucomaTAB-4169https://nih.technologypublisher.com/tech/Nanoparticles_for_the_targeted_treatment_of_infected_cellsAbstract: Current treatments for cancer and viral infection are limited remedies that often suppress cell or viral replication rather than eliminate diseased cells entirely from the body. A further limitation is that these therapies often compromise healthy cells as well, leaving problems of recurrence and side effects. Researchers at developed a novel therapeutic nanoparticle (NP) system harboring therapeutic small siRNA that can significantly enhance effectiveness and specificity of treatments by killing diseased cells. Nanoparticles attached to RNA/DNA hybrids encode recognition sites for t...Wed, 02 Aug 2023 06:59:11 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Nanoparticles_for_the_targeted_treatment_of_infected_cellsTAB-4168https://nih.technologypublisher.com/tech/Tamperless_Tensor_Elastography_ImagingAbstract: Measuring and mapping nervous tissue microstructure noninvasively is a long sought-after goal in neuroscience. Several neuropathologies – such as cancer and stroke – are associated with changes in tissue microstructure. Changes in material properties, such as stiffness, represent a sensitive measure of underlying changes in tissue architecture, organization, and microstructure. Elastography techniques used to map material stiffness typically involves measuring displacement resulting from shear waves of known frequency imposed on the material by an external actuator or tamper. Materi...Wed, 02 Aug 2023 06:59:09 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Tamperless_Tensor_Elastography_ImagingTAB-4167https://nih.technologypublisher.com/tech/Gene-based_Diagnostic_Predicts_Patient_Response_to_Cancer_ImmunotherapyAbstract: Immunotherapy is a promising method of treating cancer that leverages the immune system to promote tumor rejection. However, certain somatic mutations in cancer cells confer resistance to T cell-mediated cytolysis. To improve the effectiveness of immunotherapies for cancer, there exists a need to prospectively identify patients who are most likely to respond to such therapies. Researchers at the National Cancer Institute (NCI) have developed a method of selecting a therapy for a cancer patient by screening for known mutations which confer immune resistance. By performing a whole geno...Wed, 02 Aug 2023 06:59:06 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Gene-based_Diagnostic_Predicts_Patient_Response_to_Cancer_ImmunotherapyTAB-4166https://nih.technologypublisher.com/tech?title=Composite_Gels_and_Methods_of_their_Use_in_Tissue_Repair%2c_Drug_Delivery%2c_and_as_ImplantsAbstract: Gel materials, particularly hydrogels, typically lose their mechanical strength and stiffness as they swell. This property  limits their use in both biological (e.g., cartilage and ECM repair) and non-biological (e.g., sealant) applications. Innovative materials in both medical and non-medical application areas are sorely needed. Recent innovations in this space, from the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), include self-reinforcing composite hydrogels. These composite materials comprise novel combinations of solvents, swellable cro...Wed, 02 Aug 2023 06:59:03 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech?title=Composite_Gels_and_Methods_of_their_Use_in_Tissue_Repair%2c_Drug_Delivery%2c_and_as_ImplantsTAB-4165https://nih.technologypublisher.com/tech/MRI-Based_Method_for_Characterizing_Axonal_Microstructure_in_Traumatic_Brain_InjuryAbstract: Neurites of the central nervous system can be conceptualized as cylindrical pores with finite lengths and radii. In response to physical trauma, axons may assume a “beaded” morphology which alters their ability to conduct electrical impulses, impairing brain function. These microstructural changes are thought to underlie some of the cognitive defects observed in patients with traumatic brain injury (TBI). Current methods for characterizing traumatic brain injury (TBI) cannot provide microstructural detail on the 3-dimensional shape of axonal segments. Such detail is useful for the cl...Wed, 02 Aug 2023 06:59:02 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/MRI-Based_Method_for_Characterizing_Axonal_Microstructure_in_Traumatic_Brain_InjuryTAB-4164https://nih.technologypublisher.com/tech/Chimeric_Antigen_Receptors_(CARs)_for_Treating_Lymphoma_and_Other_CancersAbstract: Chimeric antigen receptors (CARs) are hybrid proteins that consist of two major components: a targeting domain and a signaling domain.  The targeting domain allows T cells which express the CAR to selectively recognize and bind to diseased cells that express a particular protein.  Once the diseased cell is bound by the targeting domain of the CAR, the signaling domain of the CAR activates the T cell, thereby allowing it to kill the diseased cell.  This is a promising new therapeutic approach known as adoptive cell therapy (ACT). Researchers at the NCI Experimental Transplantation and...Wed, 02 Aug 2023 06:59:00 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Chimeric_Antigen_Receptors_(CARs)_for_Treating_Lymphoma_and_Other_CancersTAB-4163https://nih.technologypublisher.com/tech/Mouse_Model_for_the_Preclinical_Study_of_Metastatic_DiseaseAbstract: The successful development of new cancer therapeutics requires reliable preclinical data that are obtained from mouse models for cancer. Human tumor xenografts, which require transplantation of human tumor cells into an immune compromised mouse, represent the current standard mouse model for cancer. Since the immune system plays an important role in tumor growth, progression and metastasis, the current standard mouse model is not ideal for accurate prediction of therapeutic effectiveness in patients. This may contribute to increased failure in later phases of clinical trials, as appr...Wed, 02 Aug 2023 06:58:59 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Mouse_Model_for_the_Preclinical_Study_of_Metastatic_DiseaseTAB-4162https://nih.technologypublisher.com/tech/Methods_and_Compositions_for_Treating_Genetically_Linked_Diseases_of_the_EyeAbstract: X-linked retinoschisis (XLRS) is an inherited, monogenetic ocular disease caused by mutations in the retinoschisin (RS1) gene, resulting in the development of cystic cavities throughout the retina and leading to juvenile macular degeneration. Approximately 1:15,000 males in the US are affected, classifying the condition as an orphan indication.  The National Eye Institute (NEI) has developed a tissue-specific gene therapy approach based upon adeno-associated virus (AAV) mediated delivery of the full coding sequence for human retinoschisin to retinal cells under the control of a retin...Wed, 02 Aug 2023 06:58:58 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Methods_and_Compositions_for_Treating_Genetically_Linked_Diseases_of_the_EyeTAB-4160https://nih.technologypublisher.com/tech/Virus-Like_Particles_That_Can_Deliver_Proteins_and_RNAAbstract: The National Cancer Institute's Protein Expression Laboratory seeks parties interested in licensing the novel delivery of RNA to mammalian cells using virus-like particles. Current methods of delivering proteins or RNA to mammalian cells are limited by a lack of target specificity and toxicity, among other shortcomings.  NCI researchers have created novel virus-like particles (VLPs) that are capable of binding to and replicating within a target mammalian cell, including human cells.  The claimed VLPs are safer than viral delivery because they are incapable of re-infecting target cell...Wed, 02 Aug 2023 06:58:56 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Virus-Like_Particles_That_Can_Deliver_Proteins_and_RNATAB-4159https://nih.technologypublisher.com/tech/Murine_metastatic_pancreatic_adenocarcinoma_cell_linesAbstract: Researchers at the National Cancer Institute (NCI) have developed orthotopic allograft models for pancreatic cancer that utilize low passage primary pancreatic adenocarcinoma cells or tumor fragments implanted into the cancer-free pancreata of recipient syngeneic immunocompetent mice. Tumor development in these models is more synchronized, latency is substantially shortened, and tumors develop only in one location, as pre-determined by the choice of a site for cells/tumor fragment implantation. This technology is the first in vivo model of metastatic pancreatic cancer utilizing an or...Wed, 02 Aug 2023 06:58:55 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Murine_metastatic_pancreatic_adenocarcinoma_cell_linesTAB-4158https://nih.technologypublisher.com/tech/Micro-Dose_Calibrator_for_Pre-clinical_Radiotracer_AssaysWed, 02 Aug 2023 06:58:54 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Micro-Dose_Calibrator_for_Pre-clinical_Radiotracer_AssaysTAB-4157https://nih.technologypublisher.com/tech/T-Cell_Therapy_Against_Patient-Specific_Cancer_MutationsAbstract: Human cancers contain genetic mutations that are unique to each patient. Some of the mutated peptides are immunogenic, can be recognized by T cells, and therefore, may serve as therapeutic targets. Scientists at the National Cancer Institute's Surgery Branch developed a method to identify T cells that specifically recognize immunogenic mutations expressed only by cancer cells. The scientists identified cancer-specific mutations from a patient with widely metastatic cholangiocarcinoma by sequencing tumor samples and comparing with normal cells. Using tandem minigene constructs encodin...Wed, 02 Aug 2023 06:58:52 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/T-Cell_Therapy_Against_Patient-Specific_Cancer_MutationsTAB-4156https://nih.technologypublisher.com/tech/PARP_Inhibitor_and_NO-Donor_Dual_Prodrugs_as_Anticancer_AgentsAbstract: Poly-ADP ribose polymerase-1 (PARP-1) is a critical enzyme involved in DNA repair.  The inhibition of PARP has emerged as a promising strategy in cancer therapy.  Numerous PARP inhibitors have been developed and advanced into clinical trials, both for use as single agents in specific patient populations and as combination therapies with various chemotherapeutics.  The induction of strand break damage to DNA, as has been demonstrated in cancer cells treated with O2-arylated diazeniumdiolates, coupled with inhibition of DNA repair by PARP inhibitors, represents a novel rationale for ef...Wed, 02 Aug 2023 06:58:51 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/PARP_Inhibitor_and_NO-Donor_Dual_Prodrugs_as_Anticancer_AgentsTAB-4155https://nih.technologypublisher.com/tech/Aryl_Hydantoin_Heterocycle_Compounds_that_Target_the_Androgen_Receptor_for_Prostate_Cancer_TreatmentAbstract: Prostate cancer is the most prevalent form of cancer among all men in the United States (US). It is also the second leading cause of cancer-related deaths in the US among men, largely due to the progressively treatment resistant nature of the disease. Treatment options for early stage prostate cancer include watchful waiting, radical prostatectomy, radiation therapy, and importantly androgen-deprivation therapy (ADT). Prostate cancer is dependent on androgen hormones, such as testosterone, for sustaining and promoting growth. Androgen hormones bind to the Androgen receptor (AR), caus...Wed, 02 Aug 2023 06:58:50 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Aryl_Hydantoin_Heterocycle_Compounds_that_Target_the_Androgen_Receptor_for_Prostate_Cancer_TreatmentTAB-4153https://nih.technologypublisher.com/tech/Agonistic_Human_Monoclonal_Antibodies_against_Death_Receptor_4_(DR4)Abstract: The National Cancer Institute is seeking parties interested in licensing human monoclonal antibodies (mAbs) that bind to death receptor 4 ("DR4"). The tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) and its functional receptors, DR4 and DR5, have been recognized as promising targets for cancer treatment.  Therapeutics targeting TRAIL and its receptors are not only effective in killing many types of tumors but they also synergize with traditional therapies, and show efficacy against tumors that are otherwise resistant to conventional treatments.   Researchers a...Wed, 02 Aug 2023 06:58:48 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Agonistic_Human_Monoclonal_Antibodies_against_Death_Receptor_4_(DR4)TAB-4152https://nih.technologypublisher.com/tech?title=Fatty_Acid_Derivatives_and_Their_Use_for_the_Treatment_and_Prevention_of_Autoimmune%2c_Inflammatory%2c_and_Pain_DisordersAbstract: The discovery and selection of suitable compounds for the treatment and prevention of autoimmune, inflammatory, and pain disorders is a significant challenge. Researchers at National Institute of Aging (NIA) mitigated this issue. They discovered and synthesized numerous novel fatty acid derivatives (novel small molecules) that may ameliorate these conditions and provide treatment options for these disorders. In a relevant rat model, the fatty acid derivatives developed by NIA demonstrated: increased activity lower toxicity greater stability longer half-life These beneficial results f...Wed, 02 Aug 2023 06:58:47 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech?title=Fatty_Acid_Derivatives_and_Their_Use_for_the_Treatment_and_Prevention_of_Autoimmune%2c_Inflammatory%2c_and_Pain_DisordersTAB-4150https://nih.technologypublisher.com/tech?title=Tempol%3a_A_Commercially-Available_Nitroxide_as_a_Cancer_TherapeuticAbstract: The National Cancer Institute's Urologic Oncology Branch is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize the use of Tempol to target HIF-2a in cancer. Elevated HIF-2a is associated with clear cell kidney cancer characterized by mutation of the VHL tumor suppressor gene and with many other cancers. A commercially-available stable nitroxide, TEMPOL, can effectively reduce the level of hypoxia-inducible transcription factor (HIF)-2a.  Therefore, TEMPOL can potentially be developed into a ca...Wed, 02 Aug 2023 06:58:44 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech?title=Tempol%3a_A_Commercially-Available_Nitroxide_as_a_Cancer_TherapeuticTAB-4148https://nih.technologypublisher.com/tech/Iodonium_Analogs_as_Inhibitors_of_NADPH_Oxidases_and_Other_Flavin_Dehydrogenases_for_the_Treatment_of_Cancer_and_Inflammatory_ConditionsWed, 02 Aug 2023 06:58:42 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Iodonium_Analogs_as_Inhibitors_of_NADPH_Oxidases_and_Other_Flavin_Dehydrogenases_for_the_Treatment_of_Cancer_and_Inflammatory_ConditionsTAB-4146https://nih.technologypublisher.com/tech/Progressive_and_Multipath_Neural_Network_for_Medical_Image_SegmentationAbstract: The technology relates to software, systems, and methods for automated medical image segmentation via deep learning. Standard holistically-nested networks (HNNs) used in computer vision and medical imaging for segmentation and edge detection have a problem with coarsening resolution. The described technology addresses this.   Simple, progressive multipath connections enhance the standard HNN model.  Processing in this new model achieves improved segmentations detail levels without need for additional model parameters.  Variations in appearance are handled without being affected by ...Wed, 02 Aug 2023 06:58:40 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Progressive_and_Multipath_Neural_Network_for_Medical_Image_SegmentationTAB-4145https://nih.technologypublisher.com/tech/Method_of_Neoantigen-Reactive_T_Cell_Receptor_(TCR)_Isolation_from_Peripheral_Blood_of_Cancer_PatientsAbstract: Adoptive cell transfer (ACT) uses tumor infiltrating lymphocytes (TILs) that recognize antigens expressed by cancer cells (neoantigens). Neoantigen specific TIL administration in patients has resulted in long-term regression of certain metastatic cancers. However, current procedures for TIL therapy are highly invasive, labor-intensive, and time consuming. The success of these procedures is limited and differs between patients and histologies. Isolation of neoantigen reactive TCRs have historically been challenging due to very low precursor frequencies of these T-cells as well as lack...Wed, 02 Aug 2023 06:58:39 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Method_of_Neoantigen-Reactive_T_Cell_Receptor_(TCR)_Isolation_from_Peripheral_Blood_of_Cancer_PatientsTAB-4144https://nih.technologypublisher.com/tech/Potassium_Hydroxy_Citrate_Promotes_Longevity_and_Efficacy_of_Anti-Tumor_T_cells_for_Adoptive_Cell_Therapy_(ACT)Abstract: Adoptive cell therapy (ACT) using tumor-specific T cells can produce positive clinical responses in some cancer patients. Nevertheless, several obstacles to the successful use of ACT for the treatment of cancer and other conditions remain. For example, one or more of the in vivo persistence, survival, and antitumor activity of tumor-specific T cells can, in some cases, decrease following adoptive transfer. Accordingly, there is a need for methods of obtaining a robust population of tumor-specific T cells for ACT. Researchers at the National Cancer Institute (NCI) have discovered a no...Wed, 02 Aug 2023 06:58:38 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Potassium_Hydroxy_Citrate_Promotes_Longevity_and_Efficacy_of_Anti-Tumor_T_cells_for_Adoptive_Cell_Therapy_(ACT)TAB-4141https://nih.technologypublisher.com/tech/Analogues_of_Modafinil_for_treating_sleep_and_attention_disordersAbstract: Modafinil has attracted attention for the treatment of cognitive dysfunction in disorders such as attention-deficit/hyperactivity disorder (ADHD) as well as cocaine and methamphetamine dependence.  However, modafinil has relatively low affinity for binding to the dopamine transporter (DAT) to block dopamine reuptake, and is water-insoluble, thus requiring large doses to achieve pharmacological effects. Investigators at the National Institute of Drug Abuse have synthesized a series of modafinil analogues that have higher affinity for the dopamine (DAT), serotonin (SERT) and/or norepin...Wed, 02 Aug 2023 06:58:35 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Analogues_of_Modafinil_for_treating_sleep_and_attention_disordersTAB-4140https://nih.technologypublisher.com/tech/Optimized_Monospecific_or_Bicistronic_Chimeric_Antigen_Receptor_(CAR)_Constructs_Targeting_CD19_and_CD20Abstract: Patients with chemotherapy-refractory, diffuse large B-cell lymphoma (DLBCL) have poor prognoses. CD19 and CD20 are promising targets for the treatment of B-Cell malignancies. However, despite the initial promising results from anti-CD19 CAR therapy, only 30-35% of patients with DLBCL achieve remissions lasting longer than 2-3 years after anti-CD19 CAR T-cell therapy. Relapse and non-response are likely due to diminished CD19 expression after anti-CD19 therapy and low expression of CD19 in some lymphomas.  To overcome the limitations of the CD19 CAR T therapy, inventors developed an ...Wed, 02 Aug 2023 06:58:34 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Optimized_Monospecific_or_Bicistronic_Chimeric_Antigen_Receptor_(CAR)_Constructs_Targeting_CD19_and_CD20TAB-4136https://nih.technologypublisher.com/tech/IgG4_Hinge_Containing_Chimeric_Antigen_Receptors_Targeting_Glypican-1_For_Treating_Solid_TumorsAbstract: Pancreatic cancer is the fourth most common cause of cancer deaths in the U.S. The overall 5-year survival rate is 8.5%. Glypican-1 (GPC1) is a cell surface heparan sulfate proteoglycan protein overexpressed in pancreatic cancer. Due to preferential expression, GPC1 represents a potential candidate for targeted therapy for pancreatic cancer and other GPC1-expressing cancers, such as prostate. Researchers at National Cancer Institute (NCI) developed novel Chimeric Antigen Receptors (CARs) specific for GPC1 that include short Immunoglobulin subclass 4 (IgG4) hinge sequences between the...Wed, 02 Aug 2023 06:58:31 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/IgG4_Hinge_Containing_Chimeric_Antigen_Receptors_Targeting_Glypican-1_For_Treating_Solid_TumorsTAB-4135https://nih.technologypublisher.com/tech/3-o-sulfo-galactosylceramide_Analogs_for_Targeting_Lung_MetastasesWed, 02 Aug 2023 06:58:30 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/3-o-sulfo-galactosylceramide_Analogs_for_Targeting_Lung_MetastasesTAB-4134https://nih.technologypublisher.com/tech/Isotropic_Generalized_Diffusion_Tensor_MRIWed, 02 Aug 2023 06:58:26 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Isotropic_Generalized_Diffusion_Tensor_MRITAB-4133https://nih.technologypublisher.com/tech?title=CytoSig%3a_A_Software_Platform_for_Predicting_Cytokine_Signaling_Activities%2c_Target_Discovery%2c_and_Clinical_Decision_Support_System_(CDSS)_from_Transcriptomic_ProfilesAbstract: Cytokines are a broad category of intercellular signaling proteins that are critical for intercellular communication in human health and disease. However, systematic profiling of cytokine signaling activities has remained challenging due to the short half-lives of cytokines, and the pleiotropic functions and redundancy of cytokine activities within specific cellular contexts. The redundancy and pleiotropy in cytokine activities are not fully captured by most immunological assays such as the enzyme-linked immunosorbent assay (ELISA) and Luminex xMAP, which only measures the cytokine r...Wed, 02 Aug 2023 06:58:24 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech?title=CytoSig%3a_A_Software_Platform_for_Predicting_Cytokine_Signaling_Activities%2c_Target_Discovery%2c_and_Clinical_Decision_Support_System_(CDSS)_from_Transcriptomic_ProfilesTAB-4131https://nih.technologypublisher.com/tech/Target_for_Anti-Tumor_Immune_ResponsesAbstract: The Surgery Branch of the National Cancer Institute is seeking statements of capability or interest from parties interested in collaborative research to carry out genotypic as well as phenotypic analysis of the 888 mel cell line in order to better understand the nature of tumor cells that respond to therapy. In addition, this cell line can be used as a target of humoral or cell mediated immune responses as a part of studies characterizing the nature of immune responses directed against tumor cells.  A human melanoma cell line designated 888-mel has been developed from the resected tu...Wed, 02 Aug 2023 06:58:23 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Target_for_Anti-Tumor_Immune_ResponsesTAB-4130https://nih.technologypublisher.com/tech/Griffithsin-Based_Anti-viral_Therapeutics_with_Improved_Stability_and_SolubilityWed, 02 Aug 2023 06:58:22 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Griffithsin-Based_Anti-viral_Therapeutics_with_Improved_Stability_and_SolubilityTAB-4129https://nih.technologypublisher.com/tech/High-Affinity_Rabbit_Monoclonal_Antibodies_for_Cancer_TreatmentAbstract: Mesothelin is a cell surface protein that is highly expressed in aggressive cancers, such as malignant mesothelioma, ovarian cancer and pancreatic cancer, lung cancer, breast cancer, cholangiocarcinoma, bile duct carcinoma and gastric cancer.  Because of this selective expression, mesothelin is an excellent candidate for targeted therapeutics, such as monoclonal antibodies (mAbs) and chimeric molecules.  Current anti-mesothelin therapeutic mAb candidates bind to an epitope in Region I of mesothelin.  Unfortunately, Region I contains the interaction site MUC16/CA125, a mesothelin-inte...Wed, 02 Aug 2023 06:58:20 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/High-Affinity_Rabbit_Monoclonal_Antibodies_for_Cancer_TreatmentTAB-4127https://nih.technologypublisher.com/tech/Computer-Aided_Diagnostic_for_Use_in_Multiparametric_MRI_for_Prostate_CancerAbstract: Multiparametric MRI improves image detail and prostate cancer detection rates compared to standard MRI. Computer aided diagnostics (CAD) used in combination with multiparametric MRI images may further improve prostate cancer detection and visualization. The technology, developed by researchers at the National Institutes of Health Clinical Center (NIHCC), is an automated CAD system for use in processing and visualizing prostate lesions on multiparametric MRI images. The system uses specialized algorithms (an ensemble of multiple random decision tress, Random Forest) that is trained ag...Wed, 02 Aug 2023 06:58:19 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Computer-Aided_Diagnostic_for_Use_in_Multiparametric_MRI_for_Prostate_CancerTAB-4126https://nih.technologypublisher.com/tech/T-cell_Receptor_Targeting_Human_Papillomavirus-16_E7_OncoproteinAbstract: Human papillomavirus (HPV) is a group of human viruses known to cause various malignancies. Of the group, HPV-16 is the most prevalent strain – an estimated 90% of adults have been exposed. HPV-16 is also the strain most commonly associated with malignancy, causing the vast majority of cervical, anal, vaginal, vulvar, and penile cancers. Currently, HPV-positive malignancies non-responsive to surgery or radiation are incurable and poorly palliated by existing systemic therapies. Thus, an alternative therapeutic approach for HPV-positive malignancies is needed.  Researchers at the Nati...Wed, 02 Aug 2023 06:58:17 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/T-cell_Receptor_Targeting_Human_Papillomavirus-16_E7_OncoproteinTAB-4123https://nih.technologypublisher.com/tech/Combined_RNA_and_DNA_Vaccination_Strategy_for_Improving_the_Vaccine_Immune_ResponseWed, 02 Aug 2023 06:58:15 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Combined_RNA_and_DNA_Vaccination_Strategy_for_Improving_the_Vaccine_Immune_ResponseTAB-4122https://nih.technologypublisher.com/tech/Development_and_Characterization_of_the_SLC46A3_Knockout_Mouse_LineAbstract: Nonalcoholic fatty liver disease is caused by several factors including 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), an environmental contaminant. TCDD causes lipid accumulation in humans by inducing the Solute Carrier Family 46 Member 3 (SLC46A3) gene expression. To effectively study TCDD-mediated lipid accumulation, research tools such as SLC46A3 knockout cells and animal models are required. Researchers at the National Cancer Institute (NCI) have developed an SLC46A3 knockout mouse line and demonstrated that TCDD-induced hepatic triglyceride accumulation was significantly reduced i...Wed, 02 Aug 2023 06:58:14 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Development_and_Characterization_of_the_SLC46A3_Knockout_Mouse_LineTAB-4119https://nih.technologypublisher.com/tech/Establishment_of_Induced_Pluripotent_Stem_Cells_(iPSC)_from_the_Thirteen-lined_Ground_SquirrelWed, 02 Aug 2023 06:58:11 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Establishment_of_Induced_Pluripotent_Stem_Cells_(iPSC)_from_the_Thirteen-lined_Ground_SquirrelTAB-4118https://nih.technologypublisher.com/tech?title=Methods_of_making_and_using_dopamine_receptor_selective_antagonists%2fpartial_agonistsAbstract: Dopamine is a major neurotransmitter in the central nervous system and among other functions is directly related to the rewarding effects of drugs of abuse.  Dopamine signaling is mediated by D1, D2, D3, D4 and D5 receptors.  The dopamine D3 receptor is a known target to treat a variety of neuropsychiatric disorders, including substance use disorders (e.g. cocaine and opioid), schizophrenia and depression.  Despite extensive efforts, it has proven difficult to identify a lead molecule that selectively binds to D3 receptors (versus D2 receptors, for example), with the desired pharmaco...Wed, 02 Aug 2023 06:58:10 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech?title=Methods_of_making_and_using_dopamine_receptor_selective_antagonists%2fpartial_agonistsTAB-4117https://nih.technologypublisher.com/tech/Method_for_HLA_LOH_Detection_in_Liquid_BiopsiesDescription of Technology: Human leukocyte antigen (HLA) LOH (LOH) is a known resistance mechanism by which cancers evade T cell receptor-(TCR-)based immunotherapies. This class of therapies includes immune checkpoint inhibition (ICI, e.g., Pembrolizumab), engineered TCR (T cell receptor)-T cell adoptive transfer, tumor infiltrating lymphocytes (TIL), T-cell engagers, and other modalities. Dozens of therapies in this category were developed with many in clinical trials. The resistance mechanism noted here, HLA LOH, causes these therapies to fail. Therefore, it is beneficial to know before tre...Wed, 02 Aug 2023 06:58:08 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Method_for_HLA_LOH_Detection_in_Liquid_BiopsiesTAB-4116https://nih.technologypublisher.com/tech/A_Preclinical_Model_for_Mutant_Human_EGFR-driven_Lung_AdenocarcinomaAbstract: Previously described epidermal growth factor receptor- (EGFR) driven tumor mouse models develop diffuse tumors, which are dissimilar to human lung tumor morphology and difficult to measure by CT and MRI scans. Scientists at the National Cancer Institute (NCI) have developed and characterized a genetically engineered mouse (GEM) model of human EGFR-driven tumor model (hEGFR-TL) that recapitulates the discrete lung tumor nodules similar to those found in human lung tumor morphology. Individual tumor nodules can be easily measured by live animal imaging and the nodules can be harvested...Wed, 02 Aug 2023 06:58:07 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/A_Preclinical_Model_for_Mutant_Human_EGFR-driven_Lung_AdenocarcinomaTAB-4115https://nih.technologypublisher.com/tech/Mouse_Lines_with_Fluorescently_Labelled_Membrane_Proteins_Regulating_Cellular_Motility_and_Membrane_TraffickingAbstract: Cell motility and membrane trafficking play important roles in regulating cell division, cell migration, cell death and autophagy. Impairment of these processes can result in enhanced cell proliferation and survival and increased migration and invasion leading to cancer. Several proteins involved in cell motility and membrane trafficking have been shown to be dysregulated in various cancers. There is therefore a need for development of animal models for studying the roles of these proteins in cancer and their responses to drug treatment in vivo. Researchers at the National Cancer In...Wed, 02 Aug 2023 06:58:06 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Mouse_Lines_with_Fluorescently_Labelled_Membrane_Proteins_Regulating_Cellular_Motility_and_Membrane_TraffickingTAB-4114https://nih.technologypublisher.com/tech/Ratio_Based_Biomarkers_for_the_Prediction_of_Cancer_SurvivalAbstract: The AKT pathway plays a key role in the regulation of cellular survival, apoptosis, and protein translation and has been shown to have prognostic significance in a number of cancers.  Recently, the inventors have identified several functions of the AKT pathway in certain cancers, such as extrahepatic cholangiocarcinoma (EHCC). The NCI seeks partners to license or co-develop this technology, which describes compositions, methods and kits for identifying, characterizing biomolecules expressed in a sample that are associated with the presence, the development, or progression of cancer. ...Wed, 02 Aug 2023 06:58:04 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Ratio_Based_Biomarkers_for_the_Prediction_of_Cancer_SurvivalTAB-4113https://nih.technologypublisher.com/tech/New_Chimeric_Antigen_Receptor_(CAR)_Format_for_Developing_Improved_Adoptive_Cell_TherapiesAbstract: Adoptive cell therapy (ACT) is an attractive new therapeutic approach for treating various cancers. ACT has recently demonstrated a high degree of efficacy when treating patients with hematological malignancies. However, to date, no effective Chimeric Antigen Receptors (CAR) T cell therapy exists for solid tumors. Researchers in the National Cancer Institute (NCI) Laboratory of Molecular Biology (LMB) have created a new CAR format that is available for licensing and further co-development. This new format uses a specific promoter and signal peptide in a specific order allowing for i...Wed, 02 Aug 2023 06:58:03 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/New_Chimeric_Antigen_Receptor_(CAR)_Format_for_Developing_Improved_Adoptive_Cell_TherapiesTAB-4112https://nih.technologypublisher.com/tech/Improved_Production_of_Prenylated_Protein_in_Insect_CellsAbstract: KRAS and other Ras-family enzymes are an important component of over 30% of human cancers, however, no effective therapeutics targeting Ras or Ras-driven cancers are currently available.  The production of Ras proteins in vitro is required for the identification and characterization of Ras targeting drugs.  An important step in producing the Ras protein involves prenylation of the C-terminus of the protein via farnesyltransferase, a modification that does not occur in prokaryotic organisms.  Previous attempts to generate properly processed Ras in eukaryotic cells has produced only lo...Wed, 02 Aug 2023 06:58:02 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Improved_Production_of_Prenylated_Protein_in_Insect_CellsTAB-4111https://nih.technologypublisher.com/tech/Cancer_Vaccines_against_POTE_for_Treating_Solid_TumorsAbstract: POTE is a novel tumor antigen expressed in a variety of cancers including breast, prostate, colon, lung, ovary, and pancreas cancers.  POTE has limited expression in normal tissues and therefore a specific target for cancer treatments, including immunotherapy.  The researchers seek statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize immunogenic peptides.  Antigen-specific cancer immunotherapy often relies on identification of epitopes expressed by cancer cells that can targeted by cytotoxic T cells (CTL...Wed, 02 Aug 2023 06:58:01 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Cancer_Vaccines_against_POTE_for_Treating_Solid_TumorsTAB-4110https://nih.technologypublisher.com/tech/RP2_and_RPGR_Vectors_For_Treating_X-linked_Retinitis_PigmentosaAbstract: X-linked forms of retinitis pigmentosa (XLRP) are relatively severe blinding disorders, resulting from progressive photoreceptor dysfunction primarily caused by mutations in RPGR or RP2 gene. This technology is poised to advance RPGR or RP2 gene therapy to clinical stage using AAV8 or AAV9 vector carrying human full-length RPGR or RP2-coding sequence.  The investigators have performed a wide dose range study over 18-months and found it to preserve rod and/or cone function as evidenced by ERG and/or OCT, optomotor tests. Morphologically, the treatment preserved rod and cone viability,...Wed, 02 Aug 2023 06:57:59 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/RP2_and_RPGR_Vectors_For_Treating_X-linked_Retinitis_PigmentosaTAB-4109https://nih.technologypublisher.com/tech/Glial_Cell_Line-Derived_Neurotrophic_Factor_for_the_Treatment_of_Neurodegenerative_Diseases_and_DiabetesAbstract: The National Institute on Drug Abuse (NIDA) is seeking interested parties to license or co-develop GDNFOS peptides and non-coding RNAs as therapeutic agents for neurodegenerative diseases. Glial cell line-derived neurotrophic factor (GDNF) is a small human protein encoded by the GDNF gene. GDNF has been effective therapy in laboratory animal models of Parkinson's disease and protects several types of neurons in the brain and peripheral nervous system. Researchers at the NIDA have discovered primate-specific GDNFOS, encoded by the opposite strand of glial cell derived neurotrophic fac...Wed, 02 Aug 2023 06:57:58 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Glial_Cell_Line-Derived_Neurotrophic_Factor_for_the_Treatment_of_Neurodegenerative_Diseases_and_DiabetesTAB-4108https://nih.technologypublisher.com/tech?title=Automated_Cancer_Diagnostic_Tool_of_Detecting%2c_Quantifying_and_Mapping_Mitotically-Active_Proliferative_Cells_in_Tumor_Tissue_Histopathology_Whole-Slide_ImagesAbstract: Cancer diagnosis is based on the assessment of patient biopsies to determine the tumor type, grade, and stage of malignancy. The proliferative potential of tumors correlates to their growth and metastasis. Visually identifying and quantifying mitotic figures (MF) in cancer biopsy tissue can be used as a surrogate for proliferative activity in tumors. The manual examination and quantification of stained tissue sections to determine tumor areas with the greatest number of MF, known as mitotic hotspots (HS), is subjective because the current method of assessment is based on the skill of...Wed, 02 Aug 2023 06:57:57 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech?title=Automated_Cancer_Diagnostic_Tool_of_Detecting%2c_Quantifying_and_Mapping_Mitotically-Active_Proliferative_Cells_in_Tumor_Tissue_Histopathology_Whole-Slide_ImagesTAB-4107https://nih.technologypublisher.com/tech/High_Affinity_Monoclonal_Antibodies_Targeting_Glypican-1Abstract: Pancreatic cancer is the fourth most common cause of death from cancer in the U.S. The overall 5-year survival rate for this disease is 8.5%. Glypican-1 (GPC1), a cell surface heparan sulfate proteoglycan protein that is overexpressed in pancreatic cancer. Due to this preferential expression, GPC1 represents a potential candidate for targeted therapy for patients with pancreatic cancer and other GPC1 expressing cancers such as prostate cancer. Researchers at the National Cancer Institute’s (NCI) Laboratory of Molecular Biology have developed and isolated two new antibodies that targe...Wed, 02 Aug 2023 06:57:55 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/High_Affinity_Monoclonal_Antibodies_Targeting_Glypican-1TAB-4106https://nih.technologypublisher.com/tech?title=Novel_Immunotherapy_for_Cancer_Treatment%3a_Chimeric_Antigen_Receptors_Targeting_CD70_AntigenAbstract: Scientists at the NCI's Surgery Branch have developed anti-CD70 chimeric antigen receptors (CARs) to treat cancers. CD70 is an antigen that is expressed on a variety of human cancers such as renal cell carcinoma, glioblastoma, non-Hodgkin's lymphoma, and chronic lymphocytic leukemia. The anti-CD70 CARs are hybrid proteins consisting of a receptor portion that recognizes CD70 antigen, and intracellular T cell signaling domains selected to optimally activate the CAR expressing T cells.  Genetically engineered T cells that express this CARs will bind to CD70 on the cancer cells and will...Wed, 02 Aug 2023 06:57:54 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech?title=Novel_Immunotherapy_for_Cancer_Treatment%3a_Chimeric_Antigen_Receptors_Targeting_CD70_AntigenTAB-4105https://nih.technologypublisher.com/tech/Antibodies_and_CARs_Targeting_FLT3_for_the_Treatment_of_Acute_Myeloid_Leukemia_and_Acute_Lymphoid_LeukemiaAbstract: Fms-like tyrosine kinase 3 (FLT3) is a cytokine receptor which belongs in the receptor tyrosine kinase class III.  FLT3 is expressed on the surface of many hematopoietic progenitor cells and plays an important role in hematopoietic stem/progenitor cell survival and proliferation.  It is often overexpressed in acute lymphoblastic leukemia (ALL) and is frequently mutated in acute myeloid leukemia (AML).  The standard therapies for ALL and AML are still suboptimal for many patients, especially pediatric.  In certain types of ALL or AML, the survival rate is less than 40 and 60%, respect...Wed, 02 Aug 2023 06:57:53 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Antibodies_and_CARs_Targeting_FLT3_for_the_Treatment_of_Acute_Myeloid_Leukemia_and_Acute_Lymphoid_LeukemiaTAB-4103https://nih.technologypublisher.com/tech/A_Rabbit_Anti-pT1989_ATR_Monoclonal_Antibody_for_Use_in_ImmunoassaysAbstract: Ataxia telangiectasia mutated and Rad3 Related (ATR) protein kinase is essential for regulating DNA damage checkpoints during the cell cycle. ATR, is phosphorylated at threonine 1989 site (T1989) in response to DNA damage and ATR activation leads to activation of downstream substrates, signaling cascades and cell cycle arrest. ATR is a potential target for anticancer therapeutics to induce cancer cell death by inhibiting cell cycle arrest pathways in response to chemotherapeutics. Researchers at the National Cancer Institute (NCI) have developed a monoclonal antibody against ATR. The...Wed, 02 Aug 2023 06:57:50 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/A_Rabbit_Anti-pT1989_ATR_Monoclonal_Antibody_for_Use_in_ImmunoassaysTAB-4099https://nih.technologypublisher.com/tech/Prognostic_Biomarkers_for_Patients_with_Early_Stage_Lung_CancerAbstract: Surgery is the standard care for patients with stage I lung cancer. Despite successful surgery, 20-30% of patients will relapse. Chemotherapy can improve patient survival; however, it is controversial if early stage cancer patients should be treated with chemotherapy since, for many cases, it will harm quality of life with little therapeutic benefit. Utilizing patient samples, the investigators conducted a retrospective study in eight patient cohorts that validated the gene classifier set. These prognostic methods can guide physicians to select appropriate treatment and follow-up whi...Wed, 02 Aug 2023 06:57:47 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Prognostic_Biomarkers_for_Patients_with_Early_Stage_Lung_CancerTAB-4097https://nih.technologypublisher.com/tech/Cancer_Therapeutic_based_on_Stimulation_of_Natural_Killer_T-cell_Anti-tumor_ActivityAbstract: Natural killer T cells (NKT) are a unique lymphocyte population that has T-cell and NK cell functional properties in order to rapidly elicit an immune response.  alpha-galactosylceramide (alpha-GalCer) is a potent NKT stimulator and induces of IFN-gamma release to promote immunity against tumors and infectious agents.  Humans have natural antibodies against alpha-galactose, which may be one of the reasons why the human clinical trials of alpha-GalCer or KRN7000 were not very successful. Beta-ManCer is a new class of NKT agonist that induces immune responses alone, through nitric oxid...Wed, 02 Aug 2023 06:57:46 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Cancer_Therapeutic_based_on_Stimulation_of_Natural_Killer_T-cell_Anti-tumor_ActivityTAB-4095https://nih.technologypublisher.com/tech/Cancer_Therapies_Using_Engineered_Monomeric_Fc_MoleculesAbstract: The National Cancer Institute, Nanobiology Program seeks parties interested in collaborative research to co-develop engineered molecules therapies. Efforts to engineer antibody-based therapeutics, to date, have encountered technical limitations due to the relatively large fragment size and short fragment half-life. Antibody fragments are emerging as promising biopharmaceuticals because of their relatively small size and other unique properties. However, compared with full-size antibodies, these antibody fragments lack the ability to bind to some Fc receptor and have reduced half-live...Wed, 02 Aug 2023 06:57:44 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Cancer_Therapies_Using_Engineered_Monomeric_Fc_MoleculesTAB-4093https://nih.technologypublisher.com/tech/3D_Vascularized_Human_Ocular_Tissue_for_Cell_Therapy_and_Drug_DiscoveryAbstract: Degeneration of retinal tissues occurs in many ocular disorders resulting in the loss of vision. Dysfunction and/or loss of Retinal Pigment Epithelium Cells (RPE) and disruption of the associated blood retinal barrier (BRB) tissue structures are linked with many ocular diseases and conditions including: age-related macular degeneration (AMD), Best disease, and retinitis pigmentosa. Engineered tissue structures that are able to replicate the function of lost BRB structures may restore lost vision and provide insight into new treatments and mechanisms of the underlying conditions.  Sci...Wed, 02 Aug 2023 06:57:43 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/3D_Vascularized_Human_Ocular_Tissue_for_Cell_Therapy_and_Drug_DiscoveryTAB-4090https://nih.technologypublisher.com/tech/Topical_Antibiotic_for_Faster_Wound_HealingAbstract: Currently available topical antibiotic formulations effectively eliminate bacteria at a wound site. Eliminating bacteria in the wound also eliminates the molecular signals present in bacterial DNA that stimulate the immune system's wound healing processes. Without these signals, the rate of wound healing is diminished.   The present technology provides a means of improving the activity of topical antibiotics by supplementing the antibiotic formulation with immunostimulatory oligodeoxynucleotides (ODN).  These ODN express the CpG motifs present in bacterial DNA and safely mimic the im...Wed, 02 Aug 2023 06:57:40 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Topical_Antibiotic_for_Faster_Wound_HealingTAB-4088https://nih.technologypublisher.com/tech/High-Throughput_Assay_for_Detection_and_Monitoring_of_Endocrine_Disrupting_Chemicals_in_Water_SourcesDescription of Technology: There is growing awareness that a wide variety of synthetic and natural compounds that may be present in water sources, such as streams, wells, and ground water, may lead to adverse health effects, including increased cancer risk. Even low concentrations of these compounds are of concern, as they may have biological effects at concentrations of parts per billion or less. In particular, the presence of endocrine disrupting chemicals (EDCs) in the environment is under examination for potential adverse effects on human health, such as immune suppression, impaired ferti...Wed, 02 Aug 2023 06:57:38 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/High-Throughput_Assay_for_Detection_and_Monitoring_of_Endocrine_Disrupting_Chemicals_in_Water_SourcesTAB-4085https://nih.technologypublisher.com/tech/Bioluminescent_Bladder_Cancer_Cell_Line_for_Tracking_Cancer_ProgressionAbstract: Bladder cancer is the fifth most common cancer in the United States and one of the costliest cancers to treat. Compared to other cancer types, bladder cancer has been understudied, and there is a need for informative mouse bladder cancer models that resemble the clinical situation and allow for evaluation of chemotherapeutic or immunotherapeutic agents. The orthotopic murine bladder cancer model MB49 resembles non-muscle invasive, nonmetastatic urothelial carcinomas and provides an opportunity to study the anti-tumor effects of immune cell checkpoint inhibitors. Moreover, successful ...Wed, 02 Aug 2023 06:57:37 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Bioluminescent_Bladder_Cancer_Cell_Line_for_Tracking_Cancer_ProgressionTAB-4082https://nih.technologypublisher.com/tech/Bicistronic_Chimeric_Antigen_Receptor_(CAR)_Constructs_Targeting_CD19_and_CD20Abstract: CD19 and CD20 are promising targets for the treatment of B-Cell malignancies.  Unfortunately, some clinical studies have shown that there is a loss of CD19 or CD20 expression in various cases of lymphomas and leukemias, particularly after treatment with an agent that targets CD19 (e.g., anti-CD19 CAR-T). However, studies have shown that expression of one protein is retained when the other is lost. This suggests that a therapeutic with the ability to simultaneously target both CD19 and CD20 could represent a solution to the drawbacks of current therapies.  Researchers at the National ...Wed, 02 Aug 2023 06:57:35 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Bicistronic_Chimeric_Antigen_Receptor_(CAR)_Constructs_Targeting_CD19_and_CD20TAB-4081https://nih.technologypublisher.com/tech/Diagnostic_Assay_for_Determining_Patient_Response_to_Apoptosis-related_Cancer_TherapyAbstract: Many known chemotherapeutic drugs kill abnormal cells through a process called apoptosis. Bcl-2 proteins are negative regulators of apoptosis that control cell survival and death. Increased expression of anti-apoptotic Bcl-2 proteins commonly occurs in up to 30% of all cancers, providing cancer cells a pro-survival advantage to evade cell death, grow, and proliferate. Drugs targeting these specific anti-apoptotic proteins are potential anti-cancer therapeutics. A need exists for improved methods to select patients that may benefit from drugs targeting apoptotic pathway, such as Bcl-2...Wed, 02 Aug 2023 06:57:34 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Diagnostic_Assay_for_Determining_Patient_Response_to_Apoptosis-related_Cancer_TherapyTAB-4078https://nih.technologypublisher.com/tech/Module_to_Freeze_and_Store_Frozen_TissueAbstract: Tissue obtained for both clinical and research purposes is routinely frozen, commonly in Optimal Cutting Temperature (OCT), an embedding media, for eventual downstream analysis, commonly including sectioning on a cryostat. Though OCT is the standard compound used for freezing, there is no standard freezing protocol. Thus, current methods of handling, labeling, and storing OCT-embedded tissue vary widely, and specimens are often damaged or degraded due to undesirable temperature fluctuations during handling and freezing. To address these issues, researchers from the NCI Laboratory of ...Wed, 02 Aug 2023 06:57:31 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Module_to_Freeze_and_Store_Frozen_TissueTAB-4077https://nih.technologypublisher.com/tech/Multifunctional_RNA_Nanoparticles_as_Cancer_and_HIV_TherapeuticsAbstract: The promise of RNA interference based therapeutics is made evident by the recent surge of biotechnological drug companies that pursue such therapies and their progression into human clinical trials. The present invention discloses novel RNA  and RNA/DNA nanoparticles including  multiple siRNAs, RNA aptamers, fluorescent dyes, and proteins. These RNA nanoparticles are useful for various nanotechnological applications. This technology has a higher detection sensitivity and higher silencing efficiencies of targeted genes than conventional siRNAs.  This technology has significant therape...Wed, 02 Aug 2023 06:57:29 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Multifunctional_RNA_Nanoparticles_as_Cancer_and_HIV_TherapeuticsTAB-4075https://nih.technologypublisher.com/tech/RNASEH-Assisted_Detection_Assay_for_RNAAbstract: Several viral epidemics – such as the epidemics caused by H1N1 influenza virus, human immunodeficiency virus (HIV), Ebola virus, Zika virus, severe acute respiratory syndrome (SARS) virus, Middle East respiratory syndrome (MERS) virus and SARS-CoV-2 – have profoundly impacted global human health. Early identification of infected and/or infectious persons and isolating them from the population are some of the most effective and evident measures to prevent human-to-human spreading. In addition, areas with low resources and infrastructure may benefit from this technique for the detectio...Wed, 02 Aug 2023 06:57:27 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/RNASEH-Assisted_Detection_Assay_for_RNATAB-4072https://nih.technologypublisher.com/tech/Synergistic_Use_of_Exo_VII_Inhibitors_And_Quinolone_Antibiotics_For_Treating_Bacterial_InfectionAbstract: Topoisomerase poisons, such as quinolone antibiotics, are widely used as anticancer drugs and antibiotics. Quinolone antibiotics act by trapping prokaryotic type IIA topoisomerases (DNA gyrase and TOPO IV), resulting in irreversible topoisomerase cleavage complexes. However, current U.S. Food and Drug Administration (FDA) guidance reserves the use of quinolones for the most serious bacterial infections due to their associated side effects and to limit the occurrence of drug-resistant bacterial strains. Resistance to available antibiotics in pathogenic bacteria is a global challenge a...Wed, 02 Aug 2023 06:57:24 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Synergistic_Use_of_Exo_VII_Inhibitors_And_Quinolone_Antibiotics_For_Treating_Bacterial_InfectionTAB-4071https://nih.technologypublisher.com/tech/Peptide_Inhibitors_for_Viral_Infections_and_as_Anti-inflammatory_AgentsAbstract: IFN-gamma and IL-10 are cytokine signaling molecules that play fundamental roles in inflammation, cancer growth and autoimmune diseases.  Unfortunately, there are no specific inhibitors of IFN-gamma or IL-10 on the market to date. NCI investigators at the Cancer and Inflammation Program have synthesized short peptides that selectively interfere with dimerization of the cytokines and their binding to the corresponding receptor. The peptides include metabolically stable lipopeptides mimicking conserved regions of IL-10 and IFN-gamma receptors that interfere with STAT3 and STAT1 phospho...Wed, 02 Aug 2023 06:57:23 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Peptide_Inhibitors_for_Viral_Infections_and_as_Anti-inflammatory_AgentsTAB-4070https://nih.technologypublisher.com/tech/Human_Synovial_Sarcoma_Cell_Line_A2243Abstract: Synovial sarcoma is a cancer affecting mesenchymal cells in connective tissues. This rare cancer is typically linked to genetic abnormalities or exposure to radiation. Metastatic growth throughout the body can occur primarily through blood circulation. More than 90% of synovial sarcomas show a characteristic t(X;18)(p11;q11) translocation involving the SYT and SSX genes. The resulting SYT-SSX abnormal fusion protein causes misregulation of downstream gene expression, leading to tumor formation. Researchers at the National Cancer Institute (NCI), Laboratory of Cellular and Molecular B...Wed, 02 Aug 2023 06:57:21 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Human_Synovial_Sarcoma_Cell_Line_A2243TAB-4068https://nih.technologypublisher.com/tech/Conformational_Restriction_of_Cyanine_Fluorophores_in_Far-Red_and_Near-IR_RangeAbstract: Small molecule fluorescent probes are important tools in diagnostic medicine. Existing far-red and near-IR cyanine fluorophores (e.g. Cy5, Alexa 647, Cy7, ICG) are active in the far-red and near-range, but these agents suffer from modest quantum yields (brightness) which limit wide utility. It has been reported that the limited brightness of these fluorophores is due to an excited-state C-C rotation pathway. The invention is directed to a new class of conformationally restricted cyanines that exhibit significantly improved quantum yield (3-4-fold increase in fluorescence quantum yiel...Wed, 02 Aug 2023 06:57:20 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Conformational_Restriction_of_Cyanine_Fluorophores_in_Far-Red_and_Near-IR_RangeTAB-4065https://nih.technologypublisher.com/tech/Novel_Anti-HIV_Proteins_from_Coral_ReefsAbstract: Scientists at the National Cancer Institute's Molecular Targets Laboratory have discovered that Cnidarins as a novel class of highly potent proteins capable of blocking the HIV virus from penetrating T-cells. Cnidarins were found in a soft coral collected in waters off Australia's northern coast. Cnidarins can block virus fusion/entry but do not block viral attachment. In addition, Cnidarins do not have lectin-like activity and therefore possibly a unique mechanism of action. Thus, Cnidarins may represent important new leads for HIV microbicides or for systemic therapeutics for HIV. ...Wed, 02 Aug 2023 06:57:18 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Novel_Anti-HIV_Proteins_from_Coral_ReefsTAB-4063https://nih.technologypublisher.com/tech/A_New_Class_of_Stable_Heptamethine_Cyanine_Fluorophores_and_Biomedical_Applications_ThereofAbstract: Heptamethine cyanines are among the most widely used near-IR fluorophores. The near-IR range (between about 650 nm and 900 nm) is very useful for imaging applications due to the absence of background autofluorescence. Despite extensive use, many of these fluorophores suffer from chemical instability. Specifically, most of the current and commonly used fluorophores undergo a phenoxy to thiol exchange reaction in the presence of primary thiols. This exchange reaction is problematic during conjugation reactions of cysteine containing macromolecules. These exchange reactions are further ...Wed, 02 Aug 2023 06:57:17 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/A_New_Class_of_Stable_Heptamethine_Cyanine_Fluorophores_and_Biomedical_Applications_ThereofTAB-4062https://nih.technologypublisher.com/tech/Thalidomide_Analogs_that_Inhibit_Inflammation_and_AngiogenesisAbstract: Thalidomide and its close analogs (lenalidomide and pomalidomide) are widely used to treat a variety of diseases, such as multiple myeloma and other cancers as well as the symptoms of several inflammatory disorders. However, thalidomide is known for its teratogenic adverse effects when first clinically introduced in the 1950s, and is associated with drowsiness and peripheral neuropathy. Hence, there is intense interest to synthesize, identify and develop safer analogs.  Researchers at the National Cancer Instituten synthesized novel thalidomide analogs that demonstrate clinical poten...Wed, 02 Aug 2023 06:57:15 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Thalidomide_Analogs_that_Inhibit_Inflammation_and_AngiogenesisTAB-4061https://nih.technologypublisher.com/tech?title=Novel_Human_Islet_Amyloid_Polypeptides_as_Alzheimer%e2%80%99s_Disease_Biomarkers_and_Inhibitors_of_Amyloid_FormationWed, 02 Aug 2023 06:57:14 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech?title=Novel_Human_Islet_Amyloid_Polypeptides_as_Alzheimer%e2%80%99s_Disease_Biomarkers_and_Inhibitors_of_Amyloid_FormationTAB-4060https://nih.technologypublisher.com/tech/Biomarker_for_Predicting_Taxane_Chemotherapy_OutcomeAbstract: Over the past decades, taxanes such as paclitaxel and docetaxel have emerged as effective chemotherapy agents for breast cancer and other malignancies. Taxanes are effective in many patients, however, not all patients benefit from this type of chemotherapy. A significant need remains for a means of predicting clinical outcome from taxane-based chemotherapy. Akt, a serine/threonine kinase that can block apoptosis, has been implicated in the regulation of microtubule dynamics and organization. Akt phosphorylation and its transducing downstream events play a central role in cell surviv...Wed, 02 Aug 2023 06:57:13 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Biomarker_for_Predicting_Taxane_Chemotherapy_OutcomeTAB-4059https://nih.technologypublisher.com/tech/Small_Molecule_Ephrin_(Eph)_Tyrosine_Kinase_Inhibitors_for_the_Treatment_of_Colorectal_Cancer_and_Other_Eph_Growth-dependent_Solid_TumorsAbstract: Advanced colorectal carcinoma is currently incurable, and new therapies are urgently needed. Ephrin (Eph) receptors are a clinically relevant class of receptor tyrosine kinases. Related signaling pathways are associated with oncogenesis of a number of cancers. NCI investigators found that phosphotyrosine-dependent Eph receptor signaling sustains colorectal carcinoma cell survival, thereby uncovering a survival pathway active in colorectal carcinoma cells. Furthermore, colorectal cancers express the EphrinB2 ligand and its Eph receptors at significantly higher levels than numerous oth...Wed, 02 Aug 2023 06:57:11 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Small_Molecule_Ephrin_(Eph)_Tyrosine_Kinase_Inhibitors_for_the_Treatment_of_Colorectal_Cancer_and_Other_Eph_Growth-dependent_Solid_TumorsTAB-4058https://nih.technologypublisher.com/tech/Silica-Coated_Nanodiamonds_for_Imaging_and_Delivery_of__Therapeutic_AgentsAbstract: The NCI Radiation Oncology Branch and the  NHLBI Laboratory of Single Molecule Biophysics seek parties to co-develop fluorescent  nanodiamonds for use as in vivo and in vitro optical tracking probes toward commercialization.   NCI and NHLBI investigators invented a robust and easily implemented method of synthesizing silica-coated nanodiamonds for imaging and therapeutic applications. A patent estate covering these methods is offered for licensing to commercial entities. The method generally includes coating nanodiamonds with a silica precursor, e.g, tetraethylorthosilicate (TEOS), i...Wed, 02 Aug 2023 06:57:10 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Silica-Coated_Nanodiamonds_for_Imaging_and_Delivery_of__Therapeutic_AgentsTAB-4056https://nih.technologypublisher.com/tech/Cancer_Therapeutic_Agents_that_Bind_to_STAT_ProteinsAbstract: The National Cancer Institute, Cancer and Inflammation Program seeks parties interested in collaborative research to further co-develop inhibitors of STAT proteins for the treatment of cancer. Signal transducer and activator transcription (STAT) proteins, specifically STAT1, 2, 3, 4, 5a, 5b, and 6, are involved in the cellular and biological processes of cell proliferation, differentiation, apoptosis, host defense, and transformation. Constitutively active STAT proteins occur in many human tumor cells and cells transformed by oncoproteins. Inhibiting these STAT proteins has great the...Wed, 02 Aug 2023 06:57:09 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Cancer_Therapeutic_Agents_that_Bind_to_STAT_ProteinsTAB-4054https://nih.technologypublisher.com/tech/Methods_of_Determining_Homeostatic_PerturbationsWed, 02 Aug 2023 06:57:07 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Methods_of_Determining_Homeostatic_PerturbationsTAB-4051https://nih.technologypublisher.com/tech/Rapid_Methods_for_Human_Artificial_Chromosome_(HAC)_FormationAbstract: Gene therapy is a promising strategy to treat a wide range of human diseases, and several gene therapy vectors have been developed to deliver these novel treatments. However,  risks and challenges of using these vectors remain, such as: gene integration, potential infection, immune response and maintaining long term, stable gene expression. Human artificial chromosomes (HACs) provide a unique opportunity to develop a new generation of nonviral vectors for therapeutic use as gene expression and delivery systems. HACs are partial or “micro” chromosomes, functioning and behaving as new,...Wed, 02 Aug 2023 06:57:05 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Rapid_Methods_for_Human_Artificial_Chromosome_(HAC)_FormationTAB-4048https://nih.technologypublisher.com/tech/A_Gene-Based_Prognostic_for_Hepatocellular_Carcinoma_Patient_Response_to_Adjuvant_Transcatheter_Arterial_ChemoembolizationAbstract: Hepatocellular Carcinoma (HCC) is one of the most common cancers worldwide with largely unfavorable outcomes due to a lack of effective treatment options for patients in the later state of disease. The gold standard of care for HCC patients with intermediate to locally advanced tumors is transcatheter arterial chemoembolization (TACE), a procedure whereby the tumor is targeted both with local chemotherapy and restriction of local blood supply. TACE procedures are often not effective however, and a need exists to identify patients that will respond to TACE. NCI scientists have identif...Wed, 02 Aug 2023 06:57:01 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/A_Gene-Based_Prognostic_for_Hepatocellular_Carcinoma_Patient_Response_to_Adjuvant_Transcatheter_Arterial_ChemoembolizationTAB-4047https://nih.technologypublisher.com/tech/Devices_for_Improved_Tissue_Cryopreservation_and_RecoveryAbstract: Problem: Cryopreservation is a process where living biological materials like cells, tissues, and cell therapies (which are susceptible to damage caused by unregulated chemical kinetics) are preserved by cooling to very low temperatures in the presence of specific cryopreservation media that protects the biological material from damage. In order to be used, the biological material ideally should be thawed in a controlled manner that minimizes damage and desirably brings the material back to a viable state. While this is not a problem for single cell suspensions, cryopreservation and ...Wed, 02 Aug 2023 06:57:00 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Devices_for_Improved_Tissue_Cryopreservation_and_RecoveryTAB-4045https://nih.technologypublisher.com/tech/Nanoparticle-hydrogel_Composite_for_Nucleic_Acid_Molecule_DeliveryAbstract: Mesothelioma is an aggressive cancer covering anatomic surfaces (e.g. lining of the lungs, heart, abdomen, etc.) that resists multi-modality therapies. Regional recurrence of mesothelioma from residual tumor cells prevents long-term benefits after surgical resection. Furthermore, there is no clinical consensus on intracavitary adjuvants that are effective in extending the tumor reduction effect of surgery. Researchers at the National Cancer Institute (NCI) have developed a new technology which fulfills this unmet clinical need by providing a local regional therapeutic platform to shu...Wed, 02 Aug 2023 06:56:58 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Nanoparticle-hydrogel_Composite_for_Nucleic_Acid_Molecule_DeliveryTAB-4044https://nih.technologypublisher.com/tech/Efficacious_Fluorinated_Cytidine_Analog_Cancer_Therapeutic_With_Low_Toxicity_In_Animal_StudiesWed, 02 Aug 2023 06:56:57 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Efficacious_Fluorinated_Cytidine_Analog_Cancer_Therapeutic_With_Low_Toxicity_In_Animal_StudiesTAB-4043https://nih.technologypublisher.com/tech/IgG4_Hinge_Containing_Nanobody-based_CARs_Targeting_GPC3_for_Treating_Liver_CancerAbstract: Hepatocellular carcinoma (HCC) is the most common type of liver cancer. Globally, HCC is the sixth most prevalent cancer and third leading cause of cancer-related morbidity. Standard treatment for HCC is not suitable for a large proportion of liver cancer patients. Part of this is because less than a quarter of HCC patients are surgical candidates for curative-intent treatment. As a result, alternative treatments are needed. Chimeric antigen receptor (CAR) T cell therapy is a promising alternative approach selectively targets targeting tumors via tumor-specific antigens. However, to ...Wed, 02 Aug 2023 06:56:56 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/IgG4_Hinge_Containing_Nanobody-based_CARs_Targeting_GPC3_for_Treating_Liver_CancerTAB-4042https://nih.technologypublisher.com/tech/Sensitive_and_Economic_RNA_Virus_Detection_Using_a_Novel_RNA_Preparation_MethodAbstract: DNA or RNA-based diagnostic tests for infectious diseases are critical in modern medicine. The current gold standard for COVID-19 detection is testing SARS-CoV-2 viral RNA by quantitative reverse transcription Polymerase Chain Reaction (RT-qPCR). This method involves patient sample collection with a nasopharyngeal swab, storage of the swab in a universal transport medium during transport to testing site, RNA extraction, and analysis of the extracted RNA sample. Collected patient samples – in addition to the possible presence of SARS-CoV-2 – also contain inhibitors for downstream enzy...Wed, 02 Aug 2023 06:56:54 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Sensitive_and_Economic_RNA_Virus_Detection_Using_a_Novel_RNA_Preparation_MethodTAB-4039https://nih.technologypublisher.com/tech/MADCO-Accelerated_Multidimensional_Diffusion_MRIAbstract: Although multidimensional diffusion/relaxation NMR experiments are widely used in materials sciences and engineering applications, preclinical and clinical MRI applications of these techniques were not feasible. Moreover, higher-field MRI scanners posed another obstacle to translation of this NMR method. Their specific absorption rate (SAR) limits the use of multi-echo or CPMG pulse trains, so that the large amounts of data required by these methods cannot be collected in vivo due to exceedingly long scan times. Therefore, the primary challenges this invention overcomes are the migr...Wed, 02 Aug 2023 06:56:52 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/MADCO-Accelerated_Multidimensional_Diffusion_MRITAB-4038https://nih.technologypublisher.com/tech?title=Calcium_(Ca2%7e)_Flux-Dependent_Method_to_Detect_and_Isolate_Tumor_Reactive_T_Cell_Receptors_(TCRs)Abstract: T cells with T cell receptors (TCRs) for cancer-specific antigens are used for adoptive cell therapy (ACT), wherein a patient’s T cells are redirected against their own cancer. However, these isolated T cells may require further ex vivo manipulation to enhance their anti-tumor activity. The ex vivo manipulation of these T cells, or the selection of less functionally inert T cells, and genetic insertion of tumor specific TCRs may circumvent these limitations. To address this issue, it is crucial to recognize, select, and isolate tumor reactive T cells from a plethora of other non-reac...Wed, 02 Aug 2023 06:56:50 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech?title=Calcium_(Ca2%7e)_Flux-Dependent_Method_to_Detect_and_Isolate_Tumor_Reactive_T_Cell_Receptors_(TCRs)TAB-4036https://nih.technologypublisher.com/tech/Nitric_Oxide-Releasing_Polymers_for_Wound_HealingAbstract:  A number of factors can play a detrimental role in the process of wound healing such as poor nutritional status, smoking, various drugs, cancer, and diabetes.  Wound healing impairment is a challenging clinical problem with no efficacious treatments currently available.  Nitric oxide (NO) has been shown to play a role in the process of wound healing by promoting both the proliferative and remodeling phases of healing.  The present invention from NCI's Chemical Biology Laboratory is a polyvinylpyrrolidone (PVP)-based polymer that is capable of releasing NO at therapeutic levels over ...Wed, 02 Aug 2023 06:56:48 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Nitric_Oxide-Releasing_Polymers_for_Wound_HealingTAB-4033https://nih.technologypublisher.com/tech/Conserved_Elements_Vaccine_for_HIVAbstract: The development of an effective HIV vaccine has been an ongoing area of research. High variability in HIV-1 virus strains, however,  represents a major challenge.  Ideally, an effective candidate vaccine would provide protection against the majority of clades of HIV.  Two major hurdles to overcome are immunodominance and sequence diversity. Researchers at the National Cancer Institute (NCI) have developed a vaccine that overcomes these major hurdles by utilizing a strategy that identifies conserved regions of the virus and exploits them for use in a targeted therapy. NCI researchers ...Wed, 02 Aug 2023 06:56:45 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Conserved_Elements_Vaccine_for_HIVTAB-4032https://nih.technologypublisher.com/tech/Reporter_Assay_for_Detection_and_Quantitation_of_Replication-Competent_GammaretrovirusWed, 02 Aug 2023 06:56:44 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Reporter_Assay_for_Detection_and_Quantitation_of_Replication-Competent_GammaretrovirusTAB-4031https://nih.technologypublisher.com/tech?title=Adriamycin-Resistant_Ovarian_Tumor_Cell_Line%2c_NCI%2fADR-RESAbstract: Cancer cells may acquire drug resistance after prolonged chemotherapy. In many cases, cancer cells develop resistance to several drugs with distinct structures and modes of action. This multi-drug resistance phenomenon increases the complexity of cancer treatment. Researchers at the National Cancer Institute (NCI) have derived an Adriamycin-resistant cell line, NCI/ADR-RES, from human ovarian cancer cells. The parental cell line is OVCAR-8, obtained from a high-grade ovarian serous adenocarcinoma. NCI/ADR-RES is resistant to Adriamycin and found to express high levels of the Multi-Dr...Wed, 02 Aug 2023 06:56:42 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech?title=Adriamycin-Resistant_Ovarian_Tumor_Cell_Line%2c_NCI%2fADR-RESTAB-4030https://nih.technologypublisher.com/tech?title=Overexpression_of_Phf19_on_T_Cells_Enhances_Therapeutic_Effects_of_T_Cell-Based_Therapies_(such_as_Chimeric_Antigen_Receptor_%5bCAR%5d_Therapies)Abstract: T cell-based immunotherapy (such as CAR therapies) is a promising approach for the treatment of several cancers. However, T cells currently employed for various T cell-based immunotherapies are usually senescent and terminally differentiated leading to poor proliferative and survival capacity, limiting their therapeutic effectiveness once transferred into a patient’s blood.  Researchers in the National Cancer Institute (NCI) Experimental Transplantation and Immunology Branch (ETIB) have epigenetically reprogrammed CD8+ T cell fate by overexpressing Phf19. The inventors found that ove...Wed, 02 Aug 2023 06:56:41 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech?title=Overexpression_of_Phf19_on_T_Cells_Enhances_Therapeutic_Effects_of_T_Cell-Based_Therapies_(such_as_Chimeric_Antigen_Receptor_%5bCAR%5d_Therapies)TAB-4029https://nih.technologypublisher.com/tech/Nanobodies_Neutralizing_Lassa_VirusAbstract: Lassa Hemorrhagic Fever (LHF) is a serious disease caused by infection with Lassa virus (LASV) – highly prevalent in West Africa and spreading globally. LASV is associated with high morbidity and mortality rates, annually infecting 100,000 to 300,000 individuals and causing 5,000 deaths. Developing prophylactics and treatment for LASV is difficult due to challenges in inducing neutralizing antibodies and producing their target, the LASV glycoprotein trimer (GPC). LASV poses a severe public health threat with infections expanding outside the traditional endemic areas and no LHF- speci...Wed, 02 Aug 2023 06:56:40 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Nanobodies_Neutralizing_Lassa_VirusTAB-4028https://nih.technologypublisher.com/tech/Small_Molecule_Inhibitors_of_Drug_Resistant_Forms_of_HIV-1_IntegraseAbstract: Integrase strand transfer inhibitors (“INSTIs”) are currently in use as a component of prophylactic antiretroviral therapy for preventing HIV-1 infection from progressing to AIDS. Three INSTIs are approved by the FDA for inclusion in antiretroviral regiments: raltegravir (RAL), elvitegravir (EVG) and dolutegravir (DTG). Clinicians have already identified several HIV-1 integrase mutations that confer resistance to RAL and EVG, and additional mutations that confer resistance to all three INSTIs has been identified in the laboratory. Researchers at the National Cancer Institute discover...Wed, 02 Aug 2023 06:56:38 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Small_Molecule_Inhibitors_of_Drug_Resistant_Forms_of_HIV-1_IntegraseTAB-4027https://nih.technologypublisher.com/tech/Fusion_Proteins_as_HIV-1_Entry_InhibitorsAbstract: Soluble forms of human CD4 (sCD4) inhibit HIV-1 entry into immune cells.  Different forms of sCD4 and their fusion proteins have been extensively studied as promising HIV-1 inhibitors – including in animal models and clinical trials.  However, they have not been successful in human studies due to their transient efficacy.  sCD4 is also known to interact with class II major histocompatibility complex (MHCII) and, at low concentrations, could enhance HIV-1 infectivity.  NCI researchers previously described a novel bispecific multivalent fusion protein called 4Dm2m which contains a sing...Wed, 02 Aug 2023 06:56:37 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Fusion_Proteins_as_HIV-1_Entry_InhibitorsTAB-4026https://nih.technologypublisher.com/tech/Brain_endothelial_reporter_cellsAbstract: Aberrant function of the WNT-b-catenin pathway is a common underlying cause of tumorigenesis.  Despite the attractiveness of the WNT-b-catenin pathway as a therapeutic target, WNT dependent cell signaling is also crucial for normal tissue development, and is ubiquitous in all organs.  As a result, WNT-b-catenin pathway inhibitors cause many side effects and fail to meet FDA safety standards.  A more targeted approach is needed to develop safe and effective WNT signaling inhibitors. Researchers at the NCI Mouse Cancer Genetics Program have developed a reporter cell based assay to iden...Wed, 02 Aug 2023 06:56:36 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Brain_endothelial_reporter_cellsTAB-4025https://nih.technologypublisher.com/tech/Nucleic_Acid_Nanoparticles_(NANP)_and_Methods_of_Using_Same_for_Controlled_ImmunomodulationAbstract: The technology is directed to compositions and methods of designing nucleic acid nanoparticles (NANPs) composed entirely of DNA, RNA, or DNA and RNA to achieve desirable immunostimulation and decrease undesirable effects on the immune system by changing the composition of the NANP. Benefits of the invention include the desirable activation of the immune system by these particles to increase the efficacy of vaccines and immunotherapies. In contrast, the NANPs with minimal to no recognition by the host's immune cells serve as an effective tool for the delivery of therapeutic payloads (...Wed, 02 Aug 2023 06:56:35 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Nucleic_Acid_Nanoparticles_(NANP)_and_Methods_of_Using_Same_for_Controlled_ImmunomodulationTAB-4023https://nih.technologypublisher.com/tech/Improved_Personalized_Cancer_ImmunotherapyAbstract: Scientists at NIH have identified a process to select highly tumor-reactive T cells from a patient tumor sample based on the expression of four specific T cell surface markers: programmed cell death protein 1 (PD-1; CD279), 4-1BB (CD137), T cell lg-and mucin-domain-containing molecule-3 (TIM-3), and/or lymphocyte activation gene 3 (LAG-3). After this enriched population of tumor fighting T cells, primarily tumor infiltrating lymphocytes (TIL), is selected and expanded to large quantities, it gets re-infused into the patient via an adoptive cell transfer (ACT) regimen. The key finding...Wed, 02 Aug 2023 06:56:33 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Improved_Personalized_Cancer_ImmunotherapyTAB-4022https://nih.technologypublisher.com/tech?title=Genetically_Modified_Hematopoietic_Stem_And_Progenitor_Cells_(HSPCs)_And_Mesenchymal_Cells_As_A_Platform_To_Reduce_Or_Prevent_Metastasis%2c_Treat_Autoimmune_And_Inflammatory_Disorders%2c_And_Rebalance_The_Immune_Milieu_And_Dysregulated_NichesAbstract: Cancer cells can spread to various regions in the body in a process called metastasis which is associated with non-responsive to treatment and thus reduced survival. Identifying the markers of metastasis has been a major concern in the field of cancer diagnosis and therapy. Interestingly, research has shown that there is an increase in myeloid progenitors and myeloid cells at various stages of metastasis in an attempt by the immune system to  suppress cancer cells. This presents a promising technology for cancer immunotherapy. Researchers at National Cancer Institute (NCI) developed ...Wed, 02 Aug 2023 06:56:32 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech?title=Genetically_Modified_Hematopoietic_Stem_And_Progenitor_Cells_(HSPCs)_And_Mesenchymal_Cells_As_A_Platform_To_Reduce_Or_Prevent_Metastasis%2c_Treat_Autoimmune_And_Inflammatory_Disorders%2c_And_Rebalance_The_Immune_Milieu_And_Dysregulated_NichesTAB-4020https://nih.technologypublisher.com/tech/Use_of_Acetalax_for_Treatment_of_Triple_Negative_Breast_CancerAbstract: Triple negative (progesterone receptor (PR)-, estrogen receptor (ER)-, human epidermal growth receptor 2 (HER2)-) breast cancer (TNBC) is an aggressive subtype that affects 15-20% of the 1.7 million cases of breast cancer occurring annually.  Currently, standard treatments of TNBC include cytotoxic chemotherapies, surgery, and radiation. However, TNBC readily becomes resistant to chemotherapy, and those with TNBC are more likely to have a recurrence or die within five years compared to those with other breast cancer types. Therefore, there is a need for safer and more effective TNBC ...Wed, 02 Aug 2023 06:56:30 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Use_of_Acetalax_for_Treatment_of_Triple_Negative_Breast_CancerTAB-4018https://nih.technologypublisher.com/tech/Nitric_Oxide_Based_Therapeutics_for_the_Treatment_of_Lung_CancerAbstract: Nitric oxide (NO) has a broad spectrum of actions in physiological and pathological processes.  NO-donor drugs have shown therapeutic effect in several cancer types by inducing apoptosis but the concentrations required have suggested limited clinical applicability.  For cancers such as non-small cell lung cancer where most therapies are not curative, there remains a need for effective treatments.  Scientists at the National Cancer Institute have identified a diazeniumdiolate-based NO releasing prodrug, JS-36-25, with selective cytotoxicity towards cancer cells.  This prodrug has pote...Wed, 02 Aug 2023 06:56:29 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Nitric_Oxide_Based_Therapeutics_for_the_Treatment_of_Lung_CancerTAB-4017https://nih.technologypublisher.com/tech/Dual_Specific_Anti-CD22_Anti-CD19_Bicistronic_Chimeric_Antigen_Receptors_(CARs)Abstract: Treatment of B-cell acute lymphoblastic leukemia (ALL) and lymphoma using chimeric antigen receptors (CARs) targeting B-cell surface protein CD19 has demonstrated impressive clinical results in children and young adults. Despite the promising results from CD19 CAR therapy, up to 40% of patients, who initially achieve remission, eventually relapse. Relapse or non-response to CD19-directed CAR therapy may be due to low or diminished CD19 expression. Such patients would be predicted to benefit from CAR therapies targeting other B-cell surface proteins, such as CD22. Scientists at the Na...Wed, 02 Aug 2023 06:56:27 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Dual_Specific_Anti-CD22_Anti-CD19_Bicistronic_Chimeric_Antigen_Receptors_(CARs)TAB-4016https://nih.technologypublisher.com/tech/Therapeutics_Against_Pathogenic_CoronavirusesAbstract: The COVID-19 pandemic is a worldwide public health crisis with over 440 million confirmed cases and 6.0 million deaths as of March 2022. COVID-19 is caused by a novel coronavirus called Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). While there are several vaccines available for COVID-19, there are few therapeutics available that specifically target SARS-CoV-2. Middle East respiratory syndrome coronavirus (MERS-CoV) is less understood than SARS-CoV-2. MERS-CoV patients have a 65% long-term survival rate, according the World Health Organization (WHO). Researchers at the...Wed, 02 Aug 2023 06:56:26 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Therapeutics_Against_Pathogenic_CoronavirusesTAB-4015https://nih.technologypublisher.com/tech/Monoclonal_Antibody_Fragments_for_Targeting_Therapeutics_to_Growth_Plate_CartilageAbstract: A child's growth is dependent on the proper functioning of the growth plate, a specialized cartilage structure located at the ends of long bones and within the vertebrae. The primary function of the growth plate is to generate new cartilage, which is then converted into bone tissue and results in the lengthening of bones. Failure of the growth plate to function properly can result in short stature or sometimes a skeletal dysplasia, such as achondroplasia, in which the bones are not just short but also malformed. Current treatments for severe short stature and skeletal growth disorder...Wed, 02 Aug 2023 06:56:25 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Monoclonal_Antibody_Fragments_for_Targeting_Therapeutics_to_Growth_Plate_CartilageTAB-4014https://nih.technologypublisher.com/tech?title=Machine_Learning_and%2for_Neural_Networks_to_Validate_Stem_Cells_and_Their_Derivatives_for_Use_in_Cell_Therapy%2c_Drug_Delivery%2c_and_DiagnosticsAbstract: Many biological and clinical procedures require functional validation of a desired cell type. Current techniques to validate rely on various assays and methods, such as staining with dyes, antibodies, and nucleic acid probes, to assess stem cell health, death, proliferation, and functionality. These techniques potentially destroy stem cells and risk contaminating cells and cultures by exposing them to the environment; they are low-throughput and difficult to scale-up. Therefore, there is a significant need for potentially less invasive, scalable, higher throughput methods of validati...Wed, 02 Aug 2023 06:56:23 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech?title=Machine_Learning_and%2for_Neural_Networks_to_Validate_Stem_Cells_and_Their_Derivatives_for_Use_in_Cell_Therapy%2c_Drug_Delivery%2c_and_DiagnosticsTAB-4013https://nih.technologypublisher.com/tech/Cancer_Immunotherapy_Using_Virus-like_ParticlesAbstract: One major challenge in the development of effective cancer therapies is a lack of universal, cancer specific markers in target cells. The current standard therapies rely on surgery, chemotherapy, and radiation therapy. Such procedures lead to a population of resistant cancer cells that makes further applications of chemotherapy/radiation therapy ineffective. Additionally, the systemic application of chemotherapy lacks specificity and has  off-target systemic effects that lead to adverse side effects. A considerable effort has been devoted to identifying and targeting specific extrace...Wed, 02 Aug 2023 06:56:22 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Cancer_Immunotherapy_Using_Virus-like_ParticlesTAB-4010https://nih.technologypublisher.com/tech?title=Novel_Cancer_Immunotherapy%3a_A_T_Cell_Receptor_That_Specifically_Recognizes_Common_KRAS_MutationsAbstract: Several malignancies associated with a poor prognosis such as lung, pancreatic and colorectal cancers frequently harbor constitutively active KRAS mutants, which play a pivotal role in oncogenesis.  Currently, there are no potentially curative treatments against most mutant KRAS harboring cancers once they become metastatic and unresectable.  Despite intensive efforts to develop potent mutant KRAS inhibitors, none have shown a significant improvement to patients. Researchers at NCI’s Surgery Branch have used their expertise in T-cell based therapies to develop a T cell receptor (TCR)...Wed, 02 Aug 2023 06:56:20 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech?title=Novel_Cancer_Immunotherapy%3a_A_T_Cell_Receptor_That_Specifically_Recognizes_Common_KRAS_MutationsTAB-4006https://nih.technologypublisher.com/tech/MUC-1_Tumor_Antigen_Agonist_Epitopes_for_Enhancing_T-cell_Responses_to_Human_TumorsAbstract: The MUC-1 tumor associated antigen has been shown to be overexpressed and/or underglycosylated in a wide range of human cancers.  The C-terminus region of MUC-1 (MUC-1C) has been shown to be an oncogene and has been associated with a more aggressive phenotype in several different cancers. Scientists at NIH have identified 7 new agonist epitopes of the MUC-1 tumor associated antigen.  Compared to their native epitope counterparts, peptides reflecting these agonist epitopes have been shown to enhance the generation of human tumor cells, which in turn have a greater ability to kill hum...Wed, 02 Aug 2023 06:56:19 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/MUC-1_Tumor_Antigen_Agonist_Epitopes_for_Enhancing_T-cell_Responses_to_Human_TumorsTAB-4004https://nih.technologypublisher.com/tech/Genetically_Engineered_Mouse-Derived_Allograft_for_Preclinical_Studies_of_Metastatic_MelanomaAbstract: The invention listed below is owned by an agency of the U.S. Government and is available for licensing and/or co-development in the U.S. in accordance with 35 U.S.C. 209 and 37 CFR part 404 to achieve expeditious commercialization of results of federally-funded research and development. Before testing drugs in humans, drug developers are required to demonstrate a reasonable expectation of safety and efficacy by performing so-called pre-clinical studies.  A key element of such trials is the use of animal models, typically mice or rats that are selected for demonstrating hallmarks of a...Wed, 02 Aug 2023 06:56:17 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Genetically_Engineered_Mouse-Derived_Allograft_for_Preclinical_Studies_of_Metastatic_MelanomaTAB-4003https://nih.technologypublisher.com/tech/Functionally-Interdependent_Shape-Switching_Nucleic_Acid_NanoparticlesAbstract: RNA interference (RNAi) is a naturally occurring post-transcriptional gene regulation process that represses the expression of specific genes. Exploiting endogenous RNAi by externally-delivered small-interfering RNA (siRNA) is a promising therapeutic for the treatment of various diseases representing several major unmet medical needs.  Researchers at the National Cancer Institute (NCI) have developed DNA- and RNA-based nanoparticles that can induce RNA interference (RNAi), molecular imaging, or a combination thereof. Two DNA- or RNA-based nanoparticles are required to induce RNAi: on...Wed, 02 Aug 2023 06:56:16 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Functionally-Interdependent_Shape-Switching_Nucleic_Acid_NanoparticlesTAB-4002https://nih.technologypublisher.com/tech/Oligonucleotide_Production_ProcessAbstract: This technology provides improved processes for production and purification of nucleic acid-containing compositions, such as non-naturally occurring viruses, for example, recombinant polioviruses that can be employed as oncolytic agents. Some of the improved processes relate to improved processes for producing viral DNA template. Also provided are improved processes for chromatography purification of nucleic acid-containing compositions, in which the nucleic acid is quantified in chromatography fractions using a rapid detection method of the one or more nucleic acid sequences of the ...Wed, 02 Aug 2023 06:56:14 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Oligonucleotide_Production_ProcessTAB-4000https://nih.technologypublisher.com/tech/Near-IR_Light-Cleavable_Antibody_Conjugates_and_Conjugate_PrecursorsAbstract: This invention describes a general way to trigger the release of a bioactive small molecule from a targeting antibody. The key “trigger” is a fluorescent linker that is chemically disassembled upon irradiation with light in the near-IR range (~800 nm). This linker technology is a dramatic step forward for the field. The molecules can be tracked using conventional fluorescence imaging technology, and with the application of a higher light dose, drug-release can be initiated in a targeted manner. In current clinical practice, a bulk tumor is often removed through a guided surgical appr...Wed, 02 Aug 2023 06:56:12 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Near-IR_Light-Cleavable_Antibody_Conjugates_and_Conjugate_PrecursorsTAB-3998https://nih.technologypublisher.com/tech/Quantitative_In_Vivo_Methods_for_Measuring_Brain_NetworksAbstract: The pattern or latency connectome was hypothesized to change in physiological development and disease.  For example, in amyotrophic lateral sclerosis (ALS), large diameter axons are damaged selectively – while in autism, small-diameter axons may be over-expressed. These anatomical changes are expected to alter the latency connectome or pattern of delays of information transmission between different gray matter areas involved in salient brain networks.  Researchers at the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) developed Magnetic Resonan...Wed, 02 Aug 2023 06:56:10 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Quantitative_In_Vivo_Methods_for_Measuring_Brain_NetworksTAB-3997https://nih.technologypublisher.com/tech/Method_for_Reproducible_Differentiation_of_Clinical_Grade_Retinal_Pigment_Epithelium_CellsAbstract: The retinal pigment epithelium (RPE) is a cell monolayer with specialized functions crucial to maintaining the metabolic environment and chemistry of the sub-retinal and choroidal layers in the eye. Damage or disease causing RPE cell loss leads to progressive photoreceptor damage and impaired vision. Loss of RPE is observed in many of the most prevalent cases of vision loss, including age related macular degeneration (AMD) and Best disease. Retinal degenerative diseases linked to loss of RPE result in a substantial economic, social, and healthcare burden for individuals and governmen...Wed, 02 Aug 2023 06:56:08 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Method_for_Reproducible_Differentiation_of_Clinical_Grade_Retinal_Pigment_Epithelium_CellsTAB-3996https://nih.technologypublisher.com/tech?title=Use_of_Neurotrophic_Factor-alpha1%2fCarboxypeptidase_E_(CPE)_to_Treat_Alzheimer_DiseaseAbstract: There is no known cure for Alzheimer’s disease, a brain disorder that severely affects memory, thinking, learning, and organizing skills. It eventually decreases a person’s ability to carry out simple, daily activities. It is predicted that over 14 million Americans will develop Alzheimer’s without effective treatment options. Mild cognitive impairment (MCI) is a stage prior to Alzheimer’s when memory problems become noticeable. A patient’s ability to function and live independently remain intact as the brain compensates for disease-related changes. Disease symptoms worsen over a per...Wed, 02 Aug 2023 06:56:07 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech?title=Use_of_Neurotrophic_Factor-alpha1%2fCarboxypeptidase_E_(CPE)_to_Treat_Alzheimer_DiseaseTAB-3995https://nih.technologypublisher.com/tech?title=Her2_Monoclonal_Antibodies%2c_Antibody_Drug_Conjugates_as_Cancer_TherapeuticsAbstract: Antibody drug conjugates (ADC) can demonstrate high efficacy as cancer therapeutics, however, much more can be done to improve their efficacy and safety profile. Site-specific antibody drug conjugation is a promising way to do this. Scientists at the NCI’s Laboratory of Experimental Immunology have identified a fully human monoclonal antibody, m860, that binds to cell surface-associated Her2 with affinity comparable to that of Trastuzumab (Herceptin) but to a different epitope. In addition, the scientist developed a site-specific glycan engineering method to conjugate the antibody to...Wed, 02 Aug 2023 06:56:06 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech?title=Her2_Monoclonal_Antibodies%2c_Antibody_Drug_Conjugates_as_Cancer_TherapeuticsTAB-3993https://nih.technologypublisher.com/tech/Cancer_Therapeutic_Based_on_T_Cell_Receptors_Designed_to_Regiospecifically_Release_Interleukin-12Abstract: Adoptive immunotherapy is a promising new approach to cancer treatment that engineers an individual''s innate and adaptive immune system to fight against specific diseases, including cancer with fewer side-effects and more specific anti-tumor activity in individual patients. T cell receptors (TCRs) and Chimeric Antigen Receptors (CARs) are proteins that recognize antigens in the context of infected or transformed cells and activate T cells to mediate an immune response to destroy abnormal cells. When a TCR/CAR is stimulated by an antigen,  signaling pathways activated in the T cell l...Wed, 02 Aug 2023 06:56:04 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Cancer_Therapeutic_Based_on_T_Cell_Receptors_Designed_to_Regiospecifically_Release_Interleukin-12TAB-3991https://nih.technologypublisher.com/tech/Anti-SLAMF7_Chimeric_Antigen_ReceptorsAbstract: Immortalization of plasma cells leads to Multiple Myeloma (MM). Signaling Lymphocyte Activation Molecule F7 (SLAMF7) is highly expressed on the malignant plasma cells that constitute Multiple Myeloma. The expression of SLAMF7 by MM cells and lack of expression on nonhematologic cells makes SLAMF7 a promising target for chimeric antigen receptor (CAR) T cell therapies for the treatment of MM.  In addition to expression on normal and malignant plasma cells, SLAMF7 is also known to be expressed on a variety of other leukocytes including most natural killer (NK) cells, some CD8+ T cells,...Wed, 02 Aug 2023 06:56:02 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Anti-SLAMF7_Chimeric_Antigen_ReceptorsTAB-3990https://nih.technologypublisher.com/tech/T-cell_Receptors_Targeting_CD20-Positive_Lymphomas_and_LeukemiasAbstract: CD20 is a protein expressed by wide ranges of lymphoid malignancies originating from B cells but not by indispensable normal tissues, making it an attractive target for therapies such as T-cell receptor (TCR) therapy. Current anti-CD20 therapeutics face a number of limitations. The most important limitation to current anti-CD20 therapies include cancer cells becoming resistant to the therapy. Resistance mechanisms to the existing CD20 therapies include loss of target antigen expression from the cell surface, loss of antibody epitope, or modulation of antibody epitope – all of which m...Wed, 02 Aug 2023 06:56:01 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/T-cell_Receptors_Targeting_CD20-Positive_Lymphomas_and_LeukemiasTAB-3988https://nih.technologypublisher.com/tech/Engineered_Biological_PacemakersAbstract: The National Institute on Aging's (NIA) Cellular Biophysics Section is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize biological pacemakers. A common symptom of many heart diseases is an abnormal heart rhythm or arrhythmia. While effectively improving the lives of many patients, implantable pacemakers have significant limitations such as limited power sources, risk of infections, potential for interference from other devices, and absence of autonomic rate modulation. The technology develop...Wed, 02 Aug 2023 06:55:59 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Engineered_Biological_PacemakersTAB-3987https://nih.technologypublisher.com/tech/GATA-3_Reporter_Plasmids_for_Revealing_Underlying_Mechanisms_in_Breast_CancerAbstract: GATA-3 is a transcription factor that is highly expressed in normal cells of the mammary luminal epithelium. GATA-3 plays a regulatory role in determining the fate of cells in the mammary gland. Disruption of GATA-3 expression leads to defects in the development of mammary cells, including an inability to differentiate properly into the correct cell type. GATA-3 function is also disrupted in various breast cancer models indicating that GATA-3 has tumor suppressive properties in normal cells. Mammary cell differentiation during a cell's development and lifespan helps determine the pro...Wed, 02 Aug 2023 06:55:58 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/GATA-3_Reporter_Plasmids_for_Revealing_Underlying_Mechanisms_in_Breast_CancerTAB-3984https://nih.technologypublisher.com/tech/A_Method_to_Isolate_Tumor_Specific_T-Cells_or_T-Cell_Receptors_from_Peripheral_Blood_using_In-vitro_Stimulation_of_Memory_T-CellsAbstract: Adoptive cell transfer (ACT) and T-cell receptor (TCR) therapies use lymphocytes that target somatic mutations expressed by tumors cells to treat cancer patients. One of the challenges of these therapies is the identification and isolation of mutation-specific cells and TCRs. While neoantigen specific cells are relatively abundant in the tumor, they are far less common in peripheral blood, a more accessible source of T cells.  Researchers at the National Cancer Institute (NCI) have developed a method to isolate neoantigen specific cells or TCRs from selected populations of peripheral...Wed, 02 Aug 2023 06:55:56 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/A_Method_to_Isolate_Tumor_Specific_T-Cells_or_T-Cell_Receptors_from_Peripheral_Blood_using_In-vitro_Stimulation_of_Memory_T-CellsTAB-3983https://nih.technologypublisher.com/tech/Metformin_for_the_Treatment_of_Age-related_Retinal_DegenerationAbstract: Retinal Degenerations (RD) are the leading cause of blindness in the United States. The degeneration of the Retinal Pigment Epithelium (RPE) is associated with various types of RD such as Stargardt’s disease, retinitis pigmentosa, choroideremia, Late-Onset Retinal Degeneration (L-ORD), and Age-related Macular Degeneration (AMD). The RPE as a layer of cells in the back of the eye. Therefore, it is essential to maintain the health and integrity of retinal photoreceptors. RPE dysfunction and degeneration leads to photoreceptor cell death and vision loss, a common factor among several fo...Wed, 02 Aug 2023 06:55:55 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Metformin_for_the_Treatment_of_Age-related_Retinal_DegenerationTAB-3982https://nih.technologypublisher.com/tech/Cell_Line_for_Production_of_Recombinant_Human_Tissue_Inhibitor_of_Metalloproteinase-2Abstract: Studies have shown that Tissue Inhibitor of Metalloproteinases 2 (TIMP-2) suppresses tumor growth and tumor-associated angiogenesis. Currently, the main obstacle in using TIMP-2 as a biologic therapeutic has been the inability to produce sufficient quantities of the protein for testing and development.  NCI Radiation Oncology Branch (ROB) researchers have developed a unique HEK-293F cell line that stably expresses rhTIMP-2, increasing the production of TIMP-2 to quantities sufficient to be used for testing and development as a therapeutic for various cancers, ischemic diseases (myoc...Wed, 02 Aug 2023 06:55:54 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Cell_Line_for_Production_of_Recombinant_Human_Tissue_Inhibitor_of_Metalloproteinase-2TAB-3980https://nih.technologypublisher.com/tech/Polymer-Cast_Inserts_for_Cell_Histology_and_MicroscopyAbstract: Three-dimensional (3D) cell cultures systems are important for studying cell biology because they provide in vivo-like microenvironments more physiologically relevant than two-dimensional (2D) culture systems. In 3D culture systems, cells are grown in culture matrixes and turn into spheroids and organoids later processed for downstream analysis by microscopy and histology techniques. The processing of 3D cultures for analysis by microscopy or histology is laborious and time-consuming due to incompatibility of the 3D culture vessels and the microscopy and pathology blocks. Therefore, ...Wed, 02 Aug 2023 06:55:51 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Polymer-Cast_Inserts_for_Cell_Histology_and_MicroscopyTAB-3975https://nih.technologypublisher.com/tech/B-cell_Surface_Reactive_Antibodies_for_the_Treatment_of_B-Cell_Chronic_Lymphocytic_LeukemiaAbstract: B-cell chronic lymphocytic leukemia (B-CLL) is a cancer characterized by a progressive accumulation of functionally incompetent lymphocytes.  Despite high morbidity and mortality, the only available potential cure is allogeneic hematopoietic stem cell transplantation (alloHSCST).  However, there is less than a 50% chance of finding a matching bone marrow or blood donor for B-CLL patients.  Other clinically tested targeted therapies such as rituximab and alemtuzumab target both malignant and normal B cells, resulting in immunosuppression. Available for licensing are fully human monocl...Wed, 02 Aug 2023 06:55:49 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/B-cell_Surface_Reactive_Antibodies_for_the_Treatment_of_B-Cell_Chronic_Lymphocytic_LeukemiaTAB-3973https://nih.technologypublisher.com/tech/Synthetic_Lethality-mediated_Precision_Oncology_via_the_Tumor_TranscriptomeAbstract: The use of tumor transcriptomics for precision oncology has made significant advances, mainly by identifying cancer driver genes or actionable mutations for treatment with targeted therapies.  However, this strategy misses out on broader genetic interactions that could reveal additional biologically testable biomarkers for therapy response prediction and inform the selection of more effective drugs for targeted treatment. Scientists at the National Cancer Institute (NCI) have developed SELECT, a computational, precision-oncology framework that uses the tumor’s whole transcriptome to ...Wed, 02 Aug 2023 06:55:47 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Synthetic_Lethality-mediated_Precision_Oncology_via_the_Tumor_TranscriptomeTAB-3970https://nih.technologypublisher.com/tech/Multidimensional_MRI_Signature_for_Specific_Detection_of_Traumatic_Brain_Injury_In_VivoAbstract: Traumatic brain injury (TBI) represents a major medical, social and economic concern worldwide due to significant mortality – especially among younger populations – and long-term disabilities. Various pathological brain lesions (e.g., intracerebral bleedings, necrotic-ischemic lesions, tissue avulsion) are produced by impacting mechanical forces. Among these, diffuse axonal injury (DAI) is one of the most significant brain lesions typically associated with trauma. However, DAI is not necessarily linked with TBI exposure. Therefore, the term “traumatic axonal injury (TAI)” is commonly...Wed, 02 Aug 2023 06:55:44 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Multidimensional_MRI_Signature_for_Specific_Detection_of_Traumatic_Brain_Injury_In_VivoTAB-3969https://nih.technologypublisher.com/tech/Nandrolone_17_Beta-CarbonatesAbstract: The available options for male contraceptives are limited. Androgens are administered as part of hormone-based male contraception and have also been used in the treatment of hypogonadism and hormone replacement therapy HRT. Many synthetic androgens require an oil-based delivery vehicle and have limited durations of action. This technology describes androgenic compounds and pharmaceutical compositions thereof for use in a number of diseases or conditions, most notably as a potential male contraceptive, and as an androgenic agent suppressing the release of hormones such as the lute...Wed, 02 Aug 2023 06:55:42 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Nandrolone_17_Beta-CarbonatesTAB-3968https://nih.technologypublisher.com/tech?title=Molecular_Classification_of_Primary_Mediastinal_Large_B_Cell_Lymphoma_Using_Formalin-Fixed%2c_Paraffin-Embedded_Tissue_SpecimensAbstract: Primary mediastinal B-cell lymphoma (PMBCL) is an aggressive type of non-Hodgkin lymphoma that mostly occurs in people between the ages of 30-40. It accounts for 5-7% of all aggressive lymphomas. The diagnosis of PMBCL is challenging as the histological features of PMBCL overlap with diffuse large B-cell lymphoma (DLBCL), another most common type of non-Hodgkin lymphoma. Available evidence suggests that PMBCL responds much more favorably to the DA-EPOCH-R chemotherapy regimen than to the standard R-CHOP regimen used to treat DLBCL. The diagnostic uncertainty of PMBCL can result in de...Wed, 02 Aug 2023 06:55:41 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech?title=Molecular_Classification_of_Primary_Mediastinal_Large_B_Cell_Lymphoma_Using_Formalin-Fixed%2c_Paraffin-Embedded_Tissue_SpecimensTAB-3967https://nih.technologypublisher.com/tech/Cancer_Immunotherapies_That_Harness_Pre-Existing_Antiviral_ImmunityAbstract: The treatment of cancer using immunotherapies has garnered substantial attention and excitement considering the clinical benefits observed in patient populations previously refractory to treatment. Tumor infiltrating T cells can significantly impact cancer progression and immunotherapy response; however, immunosuppressive tumor microenvironments can impede antitumor T cell induction, trafficking, and local activity. Thus, personalized immunotherapy approaches have shown limited efficacy against most solid tumors. In addition, manufacturing complexities remain, with high costs of deve...Wed, 02 Aug 2023 06:55:39 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Cancer_Immunotherapies_That_Harness_Pre-Existing_Antiviral_ImmunityTAB-3966https://nih.technologypublisher.com/tech/Immunogens_for_Use_in_a_High_Efficacy_HIV_VaccineAbstract: Human immunodeficiency virus (HIV) infections remain a pandemic, most prevalent in Africa and the Americas. Anti-retroviral treatments have been effective in preventing spread of the virus and active outbreaks of acquired immune deficiency syndrome (AIDS). However, the development and deployment of an effective vaccine would provide long-lasting protection and alleviate the need to depend heavily on prevention methods that require continued access and adherence. Immunization with the genetically engineered versions of HIV surface glycoprotein gp120, along with env, gag, pol, has been...Wed, 02 Aug 2023 06:55:38 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Immunogens_for_Use_in_a_High_Efficacy_HIV_VaccineTAB-3965https://nih.technologypublisher.com/tech/Nucleic_Acid_Nanoparticles_for_Triggering_RNA_InterferenceAbstract: RNA interference (RNAi) is a naturally occurring cellular post-transcriptional gene regulation process that utilizes small double-stranded RNAs to trigger and guide gene silencing. By introducing synthetic RNA duplexes called small-interfering RNAs (siRNAs), we can harness the RNAi machinery for therapeutic gene control and the treatment of various diseases.   NCI researchers created RNA, RNA-DNA, or DNA-RNA hybrid nanocubes consisting of a DNA or RNA core (composed of six strands) with attached RNA or DNA hybrid duplexes. The nanocubes can induce the reassociation of the RNA duple...Wed, 02 Aug 2023 06:55:37 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Nucleic_Acid_Nanoparticles_for_Triggering_RNA_InterferenceTAB-3964https://nih.technologypublisher.com/tech?title=Tni-FNL%3a_An_Improved_Trichoplusia_Ni_Cell_Line_for_Protein_ExpressionAbstract: Researchers at the National Cancer Institute (NCI) have developed an improved insect cell line, Tni-FNL, derived from the cabbage looper, Trichoplusia ni.  The Tni-FNL cell line is capable of high level expression of heterologous proteins using baculovirus-based expression systems.  When compared to commercially available cell lines used for the same purpose, the Tni-FNL cell line often outperforms those for protein expression.  These cells have a high growth rate and are capable of growth at a lower temperature. The complete genome sequence of the Tni-FNL cell line has been determin...Wed, 02 Aug 2023 06:55:36 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech?title=Tni-FNL%3a_An_Improved_Trichoplusia_Ni_Cell_Line_for_Protein_ExpressionTAB-3963https://nih.technologypublisher.com/tech?title=SMAD3_Reporter_Mouse_for_Assessing_TGF-%c3%9f%2fActivin_Pathway_ActivationAbstract: The Transforming Growth Factor Beta (TGF-ß) ligands (i.e., TGF-ß1, -ß2, -ß3) are key regulatory proteins in animal physiology. Disruption of normal TGF-ß signaling is associated with many diseases from cancer to fibrosis. In mice and humans, TGF-ß activates TGF-ß receptors (e.g., TGFBR1), which activates SMAD proteins that alter gene expression and contribute to tumorigenesis.  Reliable animal models are essential for the study of TGF-ß signaling. A previously developed animal model for TGF-ß signaling utilizes a luciferase expression system under the control of SMAD protein responsi...Wed, 02 Aug 2023 06:55:34 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech?title=SMAD3_Reporter_Mouse_for_Assessing_TGF-%c3%9f%2fActivin_Pathway_ActivationTAB-3962https://nih.technologypublisher.com/tech/NSAIDs_that_Assist_the_Treatment_of_Human_DiseasesAbstract: Non-steroidal anti-inflammatory drugs (NSAIDs) have long been used to treat a variety of inflammatory conditions.  Many of these conditions, such as cancer or arthritis, require long term use of the NSAIDs due to the chronic nature of the disease.  However, the NSAIDs in current use have toxicities associated with their long-term use that hinder their use for these chronic conditions.     Researchers at the NCI, in collaboration with Wake Forest University, have developed novel hybrid compounds which combine a NSAID with a nitroxyl (HNO) releasing agent. These modified NSAIDs have si...Wed, 02 Aug 2023 06:55:33 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/NSAIDs_that_Assist_the_Treatment_of_Human_DiseasesTAB-3960https://nih.technologypublisher.com/tech/Camel_VHH_Nanobodies_Bind_the_S2_Subunit_of_SARS-CoV-2_and_Broadly_Neutralize_Variants_including_OmicronAbstract: Since its emergence in 2019, COVID-19 infected over 600 million people and over 6 million people have died from the disease. COVID-19 is an infectious disease caused by the SARS-CoV-2 virus. Neutralizing antibodies have been developed to bind to the receptor binding domain (RBD) on the spike (S) protein. Blocking the interaction of the RBD and the ACE2 receptor, is critical in neutralizing the virus. However, the S2 subunit, is also critical for viral infection and entry into human cells. The S2 subunit is highly conserved across many coronaviruses, however, there are currently no ef...Wed, 02 Aug 2023 06:55:31 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Camel_VHH_Nanobodies_Bind_the_S2_Subunit_of_SARS-CoV-2_and_Broadly_Neutralize_Variants_including_OmicronTAB-3959https://nih.technologypublisher.com/tech/Interleukin_24_(IL-24)_to_treat_inflammatory_diseasesWed, 02 Aug 2023 06:55:30 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Interleukin_24_(IL-24)_to_treat_inflammatory_diseasesTAB-3958https://nih.technologypublisher.com/tech?title=Treatment_of_Oculocutaneous%2fOcular_Albinism_and_for_Increasing_PigmentationAbstract: Albinism (also called achromia, achromasia, or achromatosis) is a congenital disorder characterized by the complete or partial absence of pigment in the skin, hair and eyes due to absence or defect in any one of a number of proteins involved in the production of melanin.  Certain forms of albinism are known to be due to mutations in tyrosine metabolism.  In oculocutaneous albinism (OCA), pigment is lacking in the eyes, skin and hair.  In ocular albinism, only the eyes lack pigment.  Patients with albinism experience varying degrees of vision loss associated with foveal hypoplasia, ny...Wed, 02 Aug 2023 06:55:29 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech?title=Treatment_of_Oculocutaneous%2fOcular_Albinism_and_for_Increasing_PigmentationTAB-3957https://nih.technologypublisher.com/tech/Biomarker_Analysis_Software_for_High-Throughput_Diagnostic_Multiplex_DataAbstract: Extracellular vesicles (EVs) are lipid bilayer-enclosed particles that are released from cells. EVs may contain proteins derived from their cells of origin with the potential as diagnostic biomarkers indicating the state of the cells when released. However, due to their small size (50-1000nm), the methods currently used to phenotype EVs have limited sensitivity and scale. A need exists for development of novel technologies improving EV detection and phenotyping. National Cancer Institute (NCI) scientists have developed a software package to perform high-throughput multi-dimensional a...Wed, 02 Aug 2023 06:55:28 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Biomarker_Analysis_Software_for_High-Throughput_Diagnostic_Multiplex_DataTAB-3955https://nih.technologypublisher.com/tech/Video_Monitoring_and_Analysis_System_for_Vivarium_Cage_RacksAbstract: This invention pertains to a system for continuous observation of rodents in home-cage environments with the specific aim to facilitate the quantification of activity levels and behavioral patterns for mice housed in a commercial ventilated cage rack.  The home-cage in-rack provides daytime and nighttime monitoring with the stability and consistency of a home cage environment. The system is made up of a dual-video camera hardware design mounted on a video rack and an executable software means for automatic detection and processing for tracking multiple animals. The National Cancer In...Wed, 02 Aug 2023 06:55:26 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Video_Monitoring_and_Analysis_System_for_Vivarium_Cage_RacksTAB-3953https://nih.technologypublisher.com/tech/Method_and_System_of_Building_Hospital-Scale_Medical_Image_DatabaseAbstract: Developing computer systems that can recognize and locate image features associated with disease is a challenge for developing fully-automated and high precision computer assisted diagnostics. Joint learning of language tasks in association with vision tasks (association of image features with text annotation) adds an additional level of challenge.  Furthermore, scaling-up approaches from small to large datasets presents additional issues, particularly related to medical images. In this case, identifying such features requires specialized skill for even a human and the text descripti...Wed, 02 Aug 2023 06:55:25 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Method_and_System_of_Building_Hospital-Scale_Medical_Image_DatabaseTAB-3952https://nih.technologypublisher.com/tech/Reporter_Plasmid_to_Identify_Cancer_Stem_CellsAbstract: Cancer stem cells are a minority population of cells in tumors that initiate and sustain the cancer and which are resistant to therapy; they may cause tumors to recur after curative treatment.  Current therapies generally do not target cancer stem cells. Scientists at the National Cancer Institute Laboratory of Cancer Biology and Genetics have developed an efficient lentiviral plasmid to visualize and purify cancer stem cells, which is useful for screening compounds that specifically kill or inhibit cancer stem cells.  The NCI lentiviral plasmid can identify the putative cancer stem ...Wed, 02 Aug 2023 06:55:23 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Reporter_Plasmid_to_Identify_Cancer_Stem_CellsTAB-3951https://nih.technologypublisher.com/tech/Selective_estrogen-receptor_modulators_(SERMs)_confer_protection_against_photoreceptor_degenerationAbstract: Retinal degeneration is a deteriorative condition of the human retina caused by the progressive and eventual death of photoreceptor cells. To date, no effective treatment for genetically inherited or age-associated retinal degeneration, which includes a large patient population worldwide, is available. Researchers at the National Eye Institute (NEI) have discovered a novel therapeutic strategy of using one or more SERMs compounds, which may include the FDA-approved drug, Tamoxifen, for treating retinal degenerative diseases, like retinitis pigmentosa (RP) and age-related degeneration...Wed, 02 Aug 2023 06:55:22 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Selective_estrogen-receptor_modulators_(SERMs)_confer_protection_against_photoreceptor_degenerationTAB-3950https://nih.technologypublisher.com/tech/A_Specialized_Tissue_Collection_Device_for_the_Preservation_and_Transportation_of_Needle_BiopsiesWed, 02 Aug 2023 06:55:21 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/A_Specialized_Tissue_Collection_Device_for_the_Preservation_and_Transportation_of_Needle_BiopsiesTAB-3949https://nih.technologypublisher.com/tech/Cross_Species_Single_Domain_Antibodies_Targeting_PD-L1_for_Treating_Solid_TumorsAbstract: Programed Death-Ligand 1 (PD-L1, also known as B7-H1 or CD274) is a cell surface protein that binds to Programmed Cell Death Protein 1 (PD-1, also known as CD279). An imbalance in PD-1/PD-L1 activity contributes to cancer immune escape.  PD-1 is expressed on the surface of antigen-stimulated T cells. The interaction between PD-L1 and PD-1 negatively regulates T cell-mediated immune responses. It has been suggested that disrupting the PD-L1/PD-1 signaling pathway can be used to treat cancers. The aberrant expression of PD-L1 on multiple tumor types supports this suggestion. As a resul...Wed, 02 Aug 2023 06:55:19 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Cross_Species_Single_Domain_Antibodies_Targeting_PD-L1_for_Treating_Solid_TumorsTAB-3948https://nih.technologypublisher.com/tech/Zirconium-89_PET_Imaging_Agent_for_CancerAbstract: Researchers at the NCI Radiation Oncology Branch  and NIH CIT Center for Molecular Modeling developed a tetrahydroxamate chelation technology that provides a more-stable Zr-89 complex as an immuno-PET cancer imaging agent. In either the linear or the macrocyclic form, the tetrahydroxamate complexes exhibit greater stability as chelating agents compared to Zr-89 complexed to the siderophore desferrioxamine B (DFB), a trihydroxamate, which represents the current state of the art chemistry and the agent currently in clinical use.  In the Zr-89-DFB imaging agents, Zr-89 dissociates from ...Wed, 02 Aug 2023 06:55:18 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Zirconium-89_PET_Imaging_Agent_for_CancerTAB-3947https://nih.technologypublisher.com/tech/EGFRvIII_Antibodies_for_the_Treatment_of_Human_CancerAbstract: Epidermal growth factor receptor variant III (EGFRvIII) is a variant of EGFR that is an excellent target for immunotherapy because of its expression in cancer cells and not in normal cells.  Inventors from the National Cancer Institute (NCI) have isolated seven mouse monoclonal antibodies that bind to the human EGFRvIII but not wildtype EGFR. These EGFRvIII antibodies can be used as either independent agents or targeting domains in recombinant immunotoxins (RITs), antibody-drug conjugates (ADCs), bispecific antibodies, and chimeric antigen receptors (CARs). Significantly, RITs using ...Wed, 02 Aug 2023 06:55:17 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/EGFRvIII_Antibodies_for_the_Treatment_of_Human_CancerTAB-3945https://nih.technologypublisher.com/tech?title=New_Cancer_Research_Model%3a_Spontaneously_Transformed_Mouse_Epithelial_Cancer_Cell_LinesAbstract: The National Cancer Institute Cancer Genetics Branch is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize mouse epithelial cancer cell lines. Investigators at the NIH have created a collection of 45 mouse epithelial cancer cell lines derived from six organs: bladder, cervix, colon, lung, kidney, and mammary glands.  These cells lines were obtained from spontaneously transformed primary cell cultures without genetic, viral or chemical manipulation so they can serve as mouse models for studying...Wed, 02 Aug 2023 06:55:14 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech?title=New_Cancer_Research_Model%3a_Spontaneously_Transformed_Mouse_Epithelial_Cancer_Cell_LinesTAB-3943https://nih.technologypublisher.com/tech/siRNA_Delivery_Using_Hexameric_Tetrahedral_RNA_Nanostructures_for_Gene_SilencingAbstract: RNA interference (RNAi) is a biological response to double-stranded RNA that regulates expression of protein-coding genes and is a natural mechanism for gene silencing. Delivery of short, interfering RNA (siRNA) leads to RNAi of the targeted genes.  Researchers at the National Cancer Institute (NCI), in collaboration with researchers at the University of California, Santa Barbara (UCSB), developed a tetrahedral-shaped RNA nanoparticle for the delivery of siRNA to activate RNAi. The tetrahedral RNA nanoparticle is comprised of four RNA nanorings as the “faces” of the tetrahedral scaff...Wed, 02 Aug 2023 06:55:13 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/siRNA_Delivery_Using_Hexameric_Tetrahedral_RNA_Nanostructures_for_Gene_SilencingTAB-3942https://nih.technologypublisher.com/tech/In_silico_design_of_RNA_nanoparticlesAbstract: RNA nanoparticles have the potential to serve as excellent drug or imaging delivery systems due to their designability and versatility. Furthermore, the RNA nanoparticles of the invention are also capable of self-assembly and potentially form nanotubes of various shapes which offer potentially broad uses in medical implants, gene therapy, nanocircuits, scaffolds and medical testing. This technology, which was co-invented by researchers at National Cancer Institute and the University of California at Santa Barbara (UCSB), describes the computational design of various RNA nanoparticles...Wed, 02 Aug 2023 06:55:11 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/In_silico_design_of_RNA_nanoparticlesTAB-3941https://nih.technologypublisher.com/tech/Analogues_of_Withanolide_E_Sensitize_Cancer_Cells_Toward_ApoptosisAbstract: The tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) protein has been a target of interest in cancer therapy because it plays a large role in inducing cell apoptosis in cancer cells but not in normal cells.  Although TRAIL has been reported to successfully target certain tumor cells which are resistant to traditional chemotherapy or radiation, TRAIL resistance has also been widely observed.  Similarly, Toll-like receptor (TLR) 3 ligands such as poly I:C have also been reported to promote apoptosis in certain cancer cells, though the apoptotic signaling in most ca...Wed, 02 Aug 2023 06:55:10 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Analogues_of_Withanolide_E_Sensitize_Cancer_Cells_Toward_ApoptosisTAB-3939https://nih.technologypublisher.com/tech/Gene_Therapy_Vector_for_the_Treatment_of_Glycogen_Storage_Disease_Type_Ia_(GSD-Ia)Abstract: GSD-Ia is an inherited disorder of metabolism associated with life-threatening hypoglycemia, hepatic malignancy, and renal failure caused by the deficiency of glucose-6-phosphatase-alpha (G6Pase-alpha or G6PC). Current therapy, which primarily consists of dietary modification, fails to prevent long-term complications in many patients, including growth failure, gout, pulmonary hypertension, renal dysfunction, osteoporosis, and hepatocellular adenomas (HCA). Gene therapy-based techniques, which directly address the underlying genetic deficiency driving the disorder, offer the prospect ...Wed, 02 Aug 2023 06:55:09 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Gene_Therapy_Vector_for_the_Treatment_of_Glycogen_Storage_Disease_Type_Ia_(GSD-Ia)TAB-3938https://nih.technologypublisher.com/tech/T_Cell_Receptor_Targeting_CD22_for_the_Treatment_of_Lymphomas_and_LeukemiasDescription of Technology: CD22 is a protein expressed by normal B cells and B-lymphoid malignancies. Its limited tissue expression pattern makes it a safe antigen for targeted therapies, such as T-cell Receptor (TCR)-T cell therapy. CD22-targeting therapies already on the market, mainly antibody-immunotoxin conjugates and chimeric antigen receptors (CAR)-T cells, have limitations such as resistance to treatment and/or side effects. Resistance mechanisms to the current CD22 therapies involve loss or modulation of target antigen on the cell surface. TCRs are expected to overcome these resistan...Wed, 02 Aug 2023 06:55:07 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/T_Cell_Receptor_Targeting_CD22_for_the_Treatment_of_Lymphomas_and_LeukemiasTAB-3936https://nih.technologypublisher.com/tech/Treatment_of_Prostate_Cancer_Using_Anti-androgen_Small_MoleculesAbstract: Castrate-resistant prostate cancer (CRPC) is characterized by androgen-independent cancer cells that have adapted to the depletion of hormones and continue to grow. Abnormal androgen receptor signaling is known to drive advanced castrate-resistant prostate cancer. The small molecule compounds of this invention are antiandrogens that target androgen receptor signaling in both androgen-independent and androgen-sensitive androgen receptor activity, and androgen receptors that are resistant to the current antiandrogens available.  Unlike the currently available antiandrogens, the new sma...Wed, 02 Aug 2023 06:55:04 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Treatment_of_Prostate_Cancer_Using_Anti-androgen_Small_MoleculesTAB-3935https://nih.technologypublisher.com/tech/Optical_Configuration_Methods_for_Spectral_Scatter_Flow_CytometryAbstract: Multi-parameter flow cytometry has been extensively used in multiple disciplines of biological discoveries, including immunology and cancer research. However, the disadvantage of traditional flow cytometry platforms using excitation lasers and fluorescence detectors is spectral overlap when using multiple dyes on the same biological sample. Metaethical compensation of spectral overlap could only be effective to a certain degree. Mass cytometry is advantageous compared to flow cytometry but is pricey and requires highly skilled operators.  The inventors from the National Cancer Instit...Wed, 02 Aug 2023 06:55:03 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Optical_Configuration_Methods_for_Spectral_Scatter_Flow_CytometryTAB-3933https://nih.technologypublisher.com/tech/T-cell_Receptor_Targeting_Human_Papillomavirus-16_E6_OncoproteinAbstract: Human papillomavirus (HPV) is a group of human viruses known to cause various malignancies. Of the group, HPV-16 is the most prevalent strain – an estimated 90% of adults have been exposed. HPV-16 is also the strain most commonly associated with malignancy, causing the vast majority of cervical, anal, vaginal, vulvar, and penile cancers. Currently, HPV-positive malignancies non-responsive to surgery or radiation are incurable and poorly palliated by existing systemic therapies. Thus, an alternative therapeutic approach for HPV-positive malignancies is needed.    Researchers at the Na...Wed, 02 Aug 2023 06:55:02 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/T-cell_Receptor_Targeting_Human_Papillomavirus-16_E6_OncoproteinTAB-3931https://nih.technologypublisher.com/tech/Optical_Microscope_Software_for_Breast_Cancer_DiagnosisAbstract: The successful treatment of cancer is correlated with the early detection of the cancerous cells. Conventional cancer diagnosis is largely based on qualitative morphological criteria, but more accurate quantitative tests could greatly increase early detection of malignant cells. It has been observed that the spatial arrangement of DNA in the nucleus is altered in cancer cells in comparison to normal cells. Therefore, it is possible to distinguish malignant cells by mapping the position of labeled marker genes in the nucleus. Researchers from NCI and Rudgers University developed  met...Wed, 02 Aug 2023 06:54:59 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Optical_Microscope_Software_for_Breast_Cancer_DiagnosisTAB-3930https://nih.technologypublisher.com/tech/Novel_Furoquinolinediones_as_Inhibitors_of_TDP2_and_Their_Potential_Use_to_Treat_CancerWed, 02 Aug 2023 06:54:58 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Novel_Furoquinolinediones_as_Inhibitors_of_TDP2_and_Their_Potential_Use_to_Treat_CancerTAB-3928https://nih.technologypublisher.com/tech/Optical_Trap_Methods_to_Determine_the_Viscoelastic_Properties_of_Biological_MaterialsAbstract: Optical traps (optical tweezers) have a focused laser beam able to trap a small bead at its focus, and are used to measure the microrheology of gels and other materials. They have recently been used to characterize properties of living cells, however issues of image spatial resolution and limited depth of interrogation have prevented application of an optical trap to measure microrheological (flow of matter) properties in complex (non-uniform) materials, such as multi-cellular systems or living organisms.  Scientists at the National Cancer Institute have developed optical trapping pr...Wed, 02 Aug 2023 06:54:56 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Optical_Trap_Methods_to_Determine_the_Viscoelastic_Properties_of_Biological_MaterialsTAB-3926https://nih.technologypublisher.com/tech/Angiogenesis-Based_Cancer_TherapeuticAbstract: Vascular Endothelial Growth Factor-A (VEGF-A) is an angiogenic agent that drives blood vessel formation in solid tumors and other diseases, such as macular degeneration and diabetic retinopathy. Several therapies that target the ability of VEGF to stimulate angiogenesis have been approved. These therapies regulate VEGF-A activity by binding VEGF-A, thereby blocking VEGF-A from binding to its receptor on target cells. This technology utilizes a different approach to regulating VEGF-A activity by providing a VEGF-A protein antagonist that is produced by engineering native VEGF-A protei...Wed, 02 Aug 2023 06:54:54 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Angiogenesis-Based_Cancer_TherapeuticTAB-3925https://nih.technologypublisher.com/tech/Co-Transcriptional_Assembly_of_Modified_RNA_NanoparticlesAbstract: The National Cancer Institute seeks parties interested in collaborative research to co-develop a method to generate RNA molecules suitable for nanoparticle and biomedical applications. The development of nanoparticles as a method of drug delivery is paving the way for precise targeted therapy making it a more attractive and effective method for treating cancer. However, the current methods of designing RNA nanoparticles are limited by three factors: 1) the cost and size limitations associated with chemical synthesis of RNA; 2) the complexity of RNA nanoparticle production; and 3) low...Wed, 02 Aug 2023 06:54:52 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Co-Transcriptional_Assembly_of_Modified_RNA_NanoparticlesTAB-3924https://nih.technologypublisher.com/tech/Chimeric_Adaptor_Proteins_(CAPs)_Containing_a_Linker_for_Activation_of_T_Cells_(LAT)_and_a_Kinase_Domain_for_Use_in_T_Cell-Based_ImmunotherapyAbstract: T cell immunotherapy is used in the treatment of various pathologies – including cancers and infections. Current therapies employ chimeric antigen receptors (CARs) consisting of the intracellular fragment of CD3-zeta as the signaling domain with varied combinations of co-stimulatory, transmembrane, spacer/hinge, and extracellular targeting domains. While effective in treating hematological malignancies, CAR T cells need to be activated through T cell receptor (TCR) activation. Such activation is subject to various regulatory and inhibitory mechanisms that can limit their full therape...Wed, 02 Aug 2023 06:54:51 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Chimeric_Adaptor_Proteins_(CAPs)_Containing_a_Linker_for_Activation_of_T_Cells_(LAT)_and_a_Kinase_Domain_for_Use_in_T_Cell-Based_ImmunotherapyTAB-3922https://nih.technologypublisher.com/tech?title=HLA-A*01%3a01_Restricted_Human_T_Cell_Receptor_Recognizing_the_NRAS_Q61K_Hotspot_MutationAbstract: Mutation of amino acid 61of the neuroblastoma rat sarcoma viral oncogene homologue (NRAS) is a known driver of oncogenesis in melanoma. Glutamine (Q) to lysine (K) mutation at this position of NRAS is prevalent in approximately 10% of all melanoma cases and associated with aggressive tumors and low patient survival. Therefore, Q61K mutated NRAS is an important candidate for targeted therapies, including cellular immunotherapy.  National Cancer Institute scientists developed a T-cell receptor (TCR) specific for NRAS Q61K for use in adoptive cell transfer (ACT) T-cell immunotherapy aga...Wed, 02 Aug 2023 06:54:50 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech?title=HLA-A*01%3a01_Restricted_Human_T_Cell_Receptor_Recognizing_the_NRAS_Q61K_Hotspot_MutationTAB-3919https://nih.technologypublisher.com/tech/Self-Assembling_Nanoparticles_Composed_of_Transmembrane_Peptides_and_Their_Application_for_Specific_Intra-Tumor_Delivery_of_Anti-Cancer_DrugsWed, 02 Aug 2023 06:54:47 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Self-Assembling_Nanoparticles_Composed_of_Transmembrane_Peptides_and_Their_Application_for_Specific_Intra-Tumor_Delivery_of_Anti-Cancer_DrugsTAB-3917https://nih.technologypublisher.com/tech/T-Cell_Therapy_Against_Patient-Specific_Cancer_MutationsAbstract: Human cancers contain genetic mutations that are unique to each patient. Some of the mutated peptides are immunogenic, can be recognized by T cells, and therefore, may serve as therapeutic targets. Scientists at the National Cancer Institute's Surgery Branch developed a method to identify T cells that specifically recognize immunogenic mutations expressed only by cancer cells. The scientists identified cancer-specific mutations from a patient with widely metastatic cholangiocarcinoma by sequencing tumor samples and comparing with normal cells. Using tandem minigene constructs encodin...Wed, 02 Aug 2023 06:54:44 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/T-Cell_Therapy_Against_Patient-Specific_Cancer_MutationsTAB-3910https://nih.technologypublisher.com/tech/Chimeric_Antigen_Receptors_to_CD276_for_Treating_CancerAbstract: Chimeric antigen receptors (CARs) are hybrid proteins consisting of an antibody binding fragment fused to protein signaling domains that cause T-cells which express the CAR to become cytotoxic.  Once activated, these cytotoxic T-cells can selectively eliminate the cells which they recognize via the antibody binding fragment of the CAR.  By engineering a T-cell to express a CAR that is specific for a certain cell surface protein, it is possible to selectively target those cells for destruction.  This is a promising new therapeutic approach known as adoptive cell therapy.   CD276 (a....Wed, 02 Aug 2023 06:54:37 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Chimeric_Antigen_Receptors_to_CD276_for_Treating_CancerTAB-3909https://nih.technologypublisher.com/tech/Bile_Acids_and_Other_Agents_that_Modulate_the_Gut_Microbiome_for_the_Treatment_of_Liver_CancerAbstract: Primary liver tumors and secondary hepatic malignancies are among the leading causes of cancer-related deaths. Liver metastases account for 95% of all hepatic cancers, and the liver is the most common site for organ metastasis in the body. The gut microbiome serves an important role in antitumor immunity regulating the efficacy of chemo- and immunotherapies. The liver is exposed to gut bacteria through blood from the intestine, with 70% of the whole liver’s blood supply coming from intestinal blood. Changes in the commensal microbiome may affect immune cell function in the liver. Com...Wed, 02 Aug 2023 06:54:36 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Bile_Acids_and_Other_Agents_that_Modulate_the_Gut_Microbiome_for_the_Treatment_of_Liver_CancerTAB-3908https://nih.technologypublisher.com/tech/Therapeutic_antibody-drug_conjugates_targeting_CD56-positive_cancersAbstract: The glycoprotein CD56, also known as a neural cell adhesion molecule (NCAM), plays an important role in normal physiological functions.  It is expressed in low levels in normal cells such as neurons, glia, skeletal muscle and natural killer cells. It is highly expressed on a variety of cancerous cells including those of neuroblastoma, small-cell lung cancer, and multiple myeloma.  In neuroblastoma, patients undergo a very aggressive standard of care regimen that results in a high mortality rate.  Many neuroblastomas have increased expression of CD56, which represents a possible thera...Wed, 02 Aug 2023 06:54:34 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Therapeutic_antibody-drug_conjugates_targeting_CD56-positive_cancersTAB-3907https://nih.technologypublisher.com/tech?title=Removal_of_Selected_Proteins_Using_Light_Energy%3a_PhotoimmunotherapyAbstract: Researchers at the NCI  Laboratory of Molecular Theranostics and the Molecular Imaging Program have developed a new method to modify, isolate and remove a single chemically-labeled molecule or a cluster of proteins associated with the chemically-labeled protein. The chemical label can be an antigen-antibody complex. This discovery is based on the mechanism of photo-immunotherapy (PIT). Unlike PIT, however, which is used for direct therapy, the above-identified technology can be used for controlled drug delivery (e.g., removing unbound drug moieties from circulation) and active detoxi...Wed, 02 Aug 2023 06:54:33 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech?title=Removal_of_Selected_Proteins_Using_Light_Energy%3a_PhotoimmunotherapyTAB-3905https://nih.technologypublisher.com/tech/Transgenic_Mouse_Model_of_Human_Basal_Triple_Negative_Breast_CancerAbstract: The NCI Laboratory of Cancer Biology and Genetics seeks parties interested in collaborative research to further develop this mouse model of triple-negative breast cancer (TNBC) to study cancer biology and for preclinical testing.  As a Research Tool, patent protection is not being pursued for this technology; more information to access this strain can be found here: https://www.jax.org/strain/030386. Basal triple-negative breast cancer (TNBC) is a common form of human breast cancer for which there are no specific, targeted therapies, unlike hormone-responsive or Her2+ breast cancers...Wed, 02 Aug 2023 06:54:32 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Transgenic_Mouse_Model_of_Human_Basal_Triple_Negative_Breast_CancerTAB-3903https://nih.technologypublisher.com/tech?title=A549_Cells%3a_Lung_Carcinoma_Cell_Line_for_AdenovirusAbstract: Scientists at the National Cancer Institute developed a cell line designated A549 that was derived from explanted cultures of human lung cancer tissue. The A549 cell line has been tested under the guidance of the United States Food and Drug Administration (FDA) so, under current Good Manufacturing Practices (GMP), these cells may be suitable for use in manufacturing constructs for use in clinical trials. The A549 cell line has also been found to be suitable for adenovirus production, most notably replicating adenovirus constructs that do not require complementation by the viral oncog...Wed, 02 Aug 2023 06:54:30 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech?title=A549_Cells%3a_Lung_Carcinoma_Cell_Line_for_AdenovirusTAB-3902https://nih.technologypublisher.com/tech/Method_and_Device_for_Selectively_Labeling_RNAAbstract: Current methods of labeling and synthesizing RNA do not allow for multiple labels or long RNA segments to be synthesized for large RNA on a milligram scale. Investigators at the NCI Structure Biophysics Lab and UT Health Science Center have developed a method to selectively label RNA at specific residues and/or segments using a hybrid solid-liquid phase enzymatic method.  Moreover, they have developed an automated robotic platform capable of performing this method.  The invention overcomes the limitations of current methods of synthesizing and labeling RNA by allowing synthesis of lo...Wed, 02 Aug 2023 06:54:29 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Method_and_Device_for_Selectively_Labeling_RNATAB-3901https://nih.technologypublisher.com/tech/Method_for_High-Throughput_Microdissection_and_Analysis_of_Biological_SamplesAbstract: The National Cancer Institute's Laboratory of Pathology is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize a method for target-activated microdissection. A variety of techniques have been used to micro-dissect specific cells or cell populations from a histological sample under direct microscopic visualization. Traditional  microdissection techniques involve painstaking manual dissection using needles or other micro-manipulation devices to isolate individual cells based on histologies. This ...Wed, 02 Aug 2023 06:54:28 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Method_for_High-Throughput_Microdissection_and_Analysis_of_Biological_SamplesTAB-3899https://nih.technologypublisher.com/tech?title=Humanized_Mouse_Model_to_Study_Mesothelin_(MSLN)_-targeted_Cancer_Therapeutics%3a_Bl6%2fTPO_MiceAbstract: Mesothelin (MSLN) is an antigen highly expressed in several human cancers including mesotheliomas, ovarian cancers and pancreatic cancers. As such, human MSLN (hMSLN) is a target for many anti-cancer drugs. Most therapeutics targeting hMSLN do not recognize the mouse isoform of MSLN (mMSLN) and therefore cannot be tested in mouse cancer models.  Investigators at the National Cancer Institute (NCI) have developed a mouse model wherein mice are genetically engineered to express hMSLN in the thyroid gland under the transcriptional control of a thyroid-specific (Tpo) gene promoter. Due t...Wed, 02 Aug 2023 06:54:26 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech?title=Humanized_Mouse_Model_to_Study_Mesothelin_(MSLN)_-targeted_Cancer_Therapeutics%3a_Bl6%2fTPO_MiceTAB-3897https://nih.technologypublisher.com/tech/National_Cancer_Institute_dosimetry_system_for_Computed_Tomography_(NCICT)_Computer_ProgramAbstract: About half of the per capita dose of radiation due to medical exposures is provided by computed tomography (CT) examinations. Approximately 80 million CTs are performed annually in the United States. CT scans most commonly look for internal bleeding or clots, abscesses due to infection, tumors and internal structures. Although CT provides great patient benefit, concerns exist about potential associated risks from radiation doses – especially in pediatric patients more sensitive to radiation. Better understanding of the magnitude of radiation dose delivered during CT examinations is c...Wed, 02 Aug 2023 06:54:24 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/National_Cancer_Institute_dosimetry_system_for_Computed_Tomography_(NCICT)_Computer_ProgramTAB-3896https://nih.technologypublisher.com/tech/A_Human_Monoclonal_Antibody_Against_Deacetylated_PNAG_for_Use_as_an_Antimicrobial_AgentWed, 02 Aug 2023 06:54:23 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/A_Human_Monoclonal_Antibody_Against_Deacetylated_PNAG_for_Use_as_an_Antimicrobial_AgentTAB-3895https://nih.technologypublisher.com/tech?title=Peptide_Mimetic_Ligands_of_Polo-like_Kinase_1_Polo_Box_Domain_(%e2%80%9cPlk1_PBD_Portfolio%e2%80%9d)Abstract: Polo-like kinase 1 (Plk1) is a critical protein involved in regulation of mitosis, and aberrant expression of this kinase is found in various cancer types.  Inhibition of Plk1 is currently being pursued in pre-clinical drug development for novel anti-cancer therapeutics.  Plk1 contains an allosteric domain, known as the polo-box domain (PBD), that is responsible for localizing the kinase domain to mitotic structures through protein-protein interactions.   The invention is directed to improved peptidomimetic inhibitors that disrupt Plk1-mediated protein interactions by targeting PBD. ...Wed, 02 Aug 2023 06:54:22 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech?title=Peptide_Mimetic_Ligands_of_Polo-like_Kinase_1_Polo_Box_Domain_(%e2%80%9cPlk1_PBD_Portfolio%e2%80%9d)TAB-3894https://nih.technologypublisher.com/tech/Immunocompetent_Mouse_Model_for_Tracking_Cancer_ProgressionAbstract: The National Cancer Institute seeks interested parties to co-develop transgenic mice having immunocompetent rat growth hormone-firefly Luciferase-enhanced green fluorescent protein. The technology is a transgenic mouse model tolerized to firefly Luciferase (ffLuc)- and enhanced green fluorescent protein (eGFP)-labeled tissue whilst maintaining normal immune function. Luc and eGFP are the most frequently used bioimaging markers to track cancer progression in pre-clinical mouse models. As these markers are immunogenic, their reporter activity becomes diminished over time and so their u...Wed, 02 Aug 2023 06:54:20 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Immunocompetent_Mouse_Model_for_Tracking_Cancer_ProgressionTAB-3893https://nih.technologypublisher.com/tech/T-cell_Phenotypes_Associated_with_Clinical_Response_to_Adoptive_ImmunotherapyAbstract: Adoptive T-cell therapy (ACT) utilizes tumor-reactive T cells to induce disease remission. While ACT has been used effectively to treat metastatic melanoma and certain epithelial cancers, most patients do not respond to treatment. Although the mechanisms underlying this variable response to therapy are not fully elucidated, the phenotype of the adoptively transferred cell is known to be a key determinant of treatment efficacy. Researchers at National Cancer Institute’s (NCI) Surgery Branch have now determined that the CD3+CD39-CD69- subpopulation of T cells are highly associated with...Wed, 02 Aug 2023 06:54:19 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/T-cell_Phenotypes_Associated_with_Clinical_Response_to_Adoptive_ImmunotherapyTAB-3892https://nih.technologypublisher.com/tech/Improved_CD22_Binders_for_Effective_Immunotherapy_Against_Relapsed_or_Refractory_Acute_Lymphoblastic_Leukemia_(ALL)Abstract: Targeting the CD22 receptor of B-cells with chimeric antigen receptor (CAR)-T cells has been a promising new therapy to treat B-cell malignancies in clinical trials, inducing remission in 70% of patients with relapsed acute lymphoblastic leukemia (ALL). However, diminished CD22 expression on B-cell surface can lead to relapse and decreased remission duration, which may be prevented through increasing CAR-T affinity towards CD22.  Researchers at the National Cancer Institute (NCI) developed an affinity-matured monoclonal antibody panel including an anti-CD22 antibody variant, L7, dis...Wed, 02 Aug 2023 06:54:17 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Improved_CD22_Binders_for_Effective_Immunotherapy_Against_Relapsed_or_Refractory_Acute_Lymphoblastic_Leukemia_(ALL)TAB-3890https://nih.technologypublisher.com/tech/Topical_Sodium_Nitrate_Ointment_for_Sickle_Cell_DiseaseAbstract: Chronic leg ulcers are a debilitating vasculopathic complication for some patients with sickle cell disease (SCD). Prevalence of leg ulcers varies based on age and geographic location; about 5-10% of all SCD patients may suffer leg ulcers. These leg ulcers are painful, result in infections, hospitalization, disability, and negatively impact the patient’s social and psychological wellbeing on an ongoing basis. Until recently, patients with SCD only had one drug treatment option: hydroxyurea, which was approved by the Food and Drug Administration (FDA) in 1998 in adults and in 2017, in...Wed, 02 Aug 2023 06:54:15 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Topical_Sodium_Nitrate_Ointment_for_Sickle_Cell_DiseaseTAB-3888https://nih.technologypublisher.com/tech/Clinical_Outcome_Predictors_for_Mantle_Cell_LymphomaAbstract: Mantle cell lymphoma (MCL) is a group of aggressive B-cell lymphomas displaying heterogeneous outcomes after treatment.  Some patients have the slowly progressing disease that does not require immediate treatment, while others have a disease that rapidly progresses despite highly aggressive treatment. A number of prognostic tools have been described to determine whether patients have slow or rapidly progressing diseases, including the mantle cell lymphoma International Prognostic Index (MIPI) and biomarkers, such as KI-67. Researchers have discovered a novel method of predicting a MC...Wed, 02 Aug 2023 06:54:13 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Clinical_Outcome_Predictors_for_Mantle_Cell_LymphomaTAB-3885https://nih.technologypublisher.com/tech?title=Bac-2-the-Future%3a_An_Improved_System_for_Production_of_Recombinant_BaculovirusAbstract: Baculoviruses have been used for decades to produce proteins in insect cell hosts. Current systems for generating recombinant baculovirus have several shortcomings which prevent their easy use in high-throughput applications.  Researchers within the Frederick National Laboratory for Cancer Research have developed an improved system called Bac-2-the-future, or B2F, to quickly and efficiently generate recombinant baculoviruses which produce recombinant proteins. In the new system, the baculovirus transfer vector, transposition helper plasmid, and E. coli strain carrying the bacmid DNA ...Wed, 02 Aug 2023 06:54:10 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech?title=Bac-2-the-Future%3a_An_Improved_System_for_Production_of_Recombinant_BaculovirusTAB-3884https://nih.technologypublisher.com/tech/Magnetic_Resonance_Specimen_Evaluation_Using_Multiple_Pulse_Field_Gradient_SequencesAbstract: Researchers at the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) developed an MRI-method that is based on the acquisition of multiple pulsed field gradient (m-PFG) rather than single-pulsed field gradient (s-PFG) MRI sequences. In particular, double PFG (dPFG) MRI sequences offer higher sensitivity and greater robustness, as they are more sensitive to the effects of “restriction;” i.e., to water trapped within the axon’s intracellular space, and thus to the diameter of the axons. Thus, it renders the MRI data more sensitive to “pore size” and...Wed, 02 Aug 2023 06:54:09 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Magnetic_Resonance_Specimen_Evaluation_Using_Multiple_Pulse_Field_Gradient_SequencesTAB-3882https://nih.technologypublisher.com/tech/Single_Domain_Antibodies_(Nanobodies)_Targeting_SARS-CoV-2_for_treating_COVID-19Abstract: The COVID-19 pandemic is a worldwide public health crisis with over 100 million confirmed cases and 2.4 million deaths as of February 2021. COVID-19 is caused by a novel coronavirus called SARS-CoV-2. SARS-COV-2 infects hosts via its spike (S) protein. The S protein contains the receptor binding domain (RBD) that binds to the angiotensin converting enzyme 2 (ACE2) receptor on human cells to facilitate viral entry and infection. There are few therapeutics available for COVID-19 patients that directly target SARS-CoV-2. Investigators at the National Cancer Institute (NCI) have isolated...Wed, 02 Aug 2023 06:54:07 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Single_Domain_Antibodies_(Nanobodies)_Targeting_SARS-CoV-2_for_treating_COVID-19TAB-3881https://nih.technologypublisher.com/tech/The_UBE2G2_Binding_Domain_in_the_Ubiquitin_Ligase_GP78_and_Methods_of_Use_ThereofAbstract: Cancer is the second leading cause of death worldwide. The primary cause of mortality from cancer is metastasis. While the underlying mechanisms of cancer metastasis are still being unraveled, the gp78 protein involved in ER-associated degradation (ERAD) appears to play a role in metastasis in sarcoma. Targeting gp78 may be a therapeutic option in cancer treatment. The prometastatic activity of ERAD requires the E3 ubiquitin ligase activity of gp78. Gp78 targets the transmembrane metastasis suppressor, KAI1, for degradation. Suppression of gp78 results in the accumulation of KAI1 and...Wed, 02 Aug 2023 06:54:06 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/The_UBE2G2_Binding_Domain_in_the_Ubiquitin_Ligase_GP78_and_Methods_of_Use_ThereofTAB-3880https://nih.technologypublisher.com/tech/New_Class_of_Immunotoxins_with_Extended_Half-Life_and_High_Anti-Tumor_ActivityAbstract: Recombinant immunotoxins (RITs) constitute a promising solution to hematologic cancers (e.g., Multiple Myeloma [MM]). RITs are chimeric proteins composed of a targeting domain fused to a bacterial toxin. Upon binding to a cancer cell displaying the target antigen, RITs are internalized, metabolized and the released toxin kills the cell. While highly active and effective, current RITs have short half-lives, requiring them to be used in high concentrations for treatment. At such high concentrations, RITs may show nonspecific activity and kill healthy cells. Scientists from the National...Wed, 02 Aug 2023 06:54:04 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/New_Class_of_Immunotoxins_with_Extended_Half-Life_and_High_Anti-Tumor_ActivityTAB-3877https://nih.technologypublisher.com/tech?title=An_Anti-Viral_Polypeptide%3a_GriffithsinWed, 02 Aug 2023 06:54:01 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech?title=An_Anti-Viral_Polypeptide%3a_GriffithsinTAB-3875https://nih.technologypublisher.com/tech/Use_of_Interleukin_(IL)-34_to_Treat_Retinal_Inflammation_and_NeurodegenerationAbstract: Interleukin (IL)-34 is a homodimer that is produced mainly by keratinocytes, neuronal cells and regulatory T cells (Tregs). It is believed to play important roles in chronic inflammation and the homeostasis of microglia. Currently, there is no effective treatment for many types of retinal degeneration. An improved treatment of autoimmune uveitis is also needed, as current uveitis treatment primarily uses steroidal anti-inflammation medication, which may produce significant unwanted side effects in long-term use. The inventors at the National Eye Institute (NEI) found that various ret...Wed, 02 Aug 2023 06:54:00 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Use_of_Interleukin_(IL)-34_to_Treat_Retinal_Inflammation_and_NeurodegenerationTAB-3874https://nih.technologypublisher.com/tech/Polarimetric_Accessory_for_ColposcopeAbstract: In medical diagnostic procedures for examining the cervix and the tissues of the vagina and vulva, long working-distance (-30 cm) lighted binocular microscopes (colposcope) that provide up to 25x optical magnification are used to create an illuminated magnified view. Speculum dilations can give rise to specular reflections from the tissue surface, causing physicians to overlook possible abnormalities – thus decreasing the quality of a colposcopy.  Researchers at the National Institute of Child Health and Human Development (NICHD) developed a polarimetric accessory that overcomes this...Wed, 02 Aug 2023 06:53:59 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Polarimetric_Accessory_for_ColposcopeTAB-3873https://nih.technologypublisher.com/tech?title=RNA%2fDNA_Nanoparticles_as_Cancer_TherapeuticsAbstract: The development of RNA-based nanostructures and their use in a variety of applications, including RNA interference (RNAi) and drug delivery, represents an emerging field of science, technology, and biomedicine.  RNA is a dynamic material because of its natural functionalities, its ability to fold into complex small structures, and its capacity to self-assemble.  Taking advantage of these characteristic, NCI Researchers have improved upon their existing invention of multi-functional RNA/DNA nanoparticles by adding a RNA toehold instead of a DNA toehold.  In in vitro studies, they hav...Wed, 02 Aug 2023 06:53:57 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech?title=RNA%2fDNA_Nanoparticles_as_Cancer_TherapeuticsTAB-3872https://nih.technologypublisher.com/tech?title=Tethered_Interleukin-15_(IL-15)%2fIL-21_to_Enhance_T_Cells_for_Cellular_TherapyAbstract: Interleukin-15 (IL-15) and IL-21 have been reported to support the function of anti-tumor T cells.  However, their use in the clinic has been constrained, in part, by dose-limiting toxicity and the need for repeated administration.  To overcome these limitations, researchers in the National Cancer Institute (NCI) Experimental Transplantation and Immunology Branch (ETIB) have developed synthetic IL-15 and IL-21 molecules for autocrine expression by the engineered therapeutic T cells. These molecules were designed with flexible linkers that connect to cell membrane anchors.  This, in t...Wed, 02 Aug 2023 06:53:56 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech?title=Tethered_Interleukin-15_(IL-15)%2fIL-21_to_Enhance_T_Cells_for_Cellular_TherapyTAB-3871https://nih.technologypublisher.com/tech/Radiographic_Marker_for_Portable_Chest_and_Abdominal_X-RaysWed, 02 Aug 2023 06:53:54 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Radiographic_Marker_for_Portable_Chest_and_Abdominal_X-RaysTAB-3870https://nih.technologypublisher.com/tech/La_Protein_as_a_Novel_Regulator_of_OsteoclastogenesisAbstract: Millions of patients in the United States are afflicted by a host of bone diseases caused by osteoclast (specialized calls arising from the macrophage/monocyte lineage) dysfunction. Diseases include Paget’s disease, osteoporosis, fibrous dysplasia and osteolytic bone metastasis. The current standard of care for these diseases uses broad-spectrum therapies that either coat the skeletal system or inhibit osteoclast development in an effort to modulate osteoclastogenesis. New therapies are needed that specifically target osteoclast fusion – allowing patients to forgo the off-target side...Wed, 02 Aug 2023 06:53:53 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/La_Protein_as_a_Novel_Regulator_of_OsteoclastogenesisTAB-3869https://nih.technologypublisher.com/tech/A_Rapid_Method_of_Isolating_Neoantigen-specific_T_Cell_Receptor_SequencesAbstract: Tumors can develop unique genetic mutations which are specific to an individual patient. Some of these mutations are immunogenic; giving rise to autologous T cells which are tumor-reactive. Once isolated and sequenced, these neoantigen-specific TCRs can form the basis of effective adoptive cell therapy cancer treatment regimens; however, current methods of isolation are inefficient. Moreover, the process is technically challenging due to TCR sequence diversity and the need to correctly pair the a and b chain of each receptor. Thus, there is an urgent need for more robust methods of i...Wed, 02 Aug 2023 06:53:52 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/A_Rapid_Method_of_Isolating_Neoantigen-specific_T_Cell_Receptor_SequencesTAB-3867https://nih.technologypublisher.com/tech/A_Novel_Carbohydrate_Antibody_to_GalNac1-3Gal_and_Its_Application_for_Cancer_Diagnostic_and_PrognosisAbstract: Cervical cancer is one of the most common cancers among women worldwide. Currently, physical descriptors such as tumor size and depth are the primary factors used for deciding the course of treatment. Despite significant efforts to identify prognostic biochemical markers or therapeutic targets to improve diagnosis and treatment, none have achieved routine clinical use. An example of one previously identified biomarker is the Tn antigen, a carbohydrate moiety composed of a GalNAc residue linked to serine or threonine. Previous studies examining Tn antigen levels present in cervical ca...Wed, 02 Aug 2023 06:53:49 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/A_Novel_Carbohydrate_Antibody_to_GalNac1-3Gal_and_Its_Application_for_Cancer_Diagnostic_and_PrognosisTAB-3865https://nih.technologypublisher.com/tech/Systems_and_Devices_for_Training_and_Imaging_an_Awake_Test_AnimalAbstract: Typical MRI imaging sessions can last over 45 minutes and depend on the subject remaining still during the procedure for accurate imaging. In particular, animals being imaged, such as rodents (rats) in an awakened state, are not readily compliant with the restricted movement required when being imaged. Current techniques for imaging awake animals focus on training them with full body restraints and head fixation using a bite bar and/or ear bars. Physically restraining the animal can induce stress, thereby resulting in unavoidable movement of the stressed animal and likely inaccurate ...Wed, 02 Aug 2023 06:53:48 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Systems_and_Devices_for_Training_and_Imaging_an_Awake_Test_AnimalTAB-3864https://nih.technologypublisher.com/tech?title=Hydrocarbon_Stapled_Peptides_that_Inhibit_the_Linear_Ubiquitin_Chain_Assembly_Complex_(LUBAC)_for_the_Therapy_of_the_Activated_B_Cell-like_(ABC)_Subtype_of_Diffuse_Large_B_Bell_Lymphoma_(A_Type_of_Non-Hodgkin%e2%80%99s_Lymphoma)Abstract: Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin’s lymphoma and consists of three subtypes: activated B-cell (ABC), germinal center B-cell (GBC), and primary mediastinal B-cell (PMB). Despite advances in the front-line therapy for DLBCL, approximately one-third of patients will relapse. Substantially worse outcomes have been reported for patients diagnosed with ABC DLBCL and treated with standard chemoimmunotherapy, suggesting the need for novel strategies that improve treatment outcomes. ABC DLBCL cell survival depends largely upon NF-κB signaling being c...Wed, 02 Aug 2023 06:53:46 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech?title=Hydrocarbon_Stapled_Peptides_that_Inhibit_the_Linear_Ubiquitin_Chain_Assembly_Complex_(LUBAC)_for_the_Therapy_of_the_Activated_B_Cell-like_(ABC)_Subtype_of_Diffuse_Large_B_Bell_Lymphoma_(A_Type_of_Non-Hodgkin%e2%80%99s_Lymphoma)TAB-3861https://nih.technologypublisher.com/tech/Multi-Foci_Sonications_For_Hyperthermia_Treatments_Using_Magnetic_Resource-Guided_High-Intensity_Focused_Ultrasound_(MR-HIFU)Wed, 02 Aug 2023 06:53:44 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Multi-Foci_Sonications_For_Hyperthermia_Treatments_Using_Magnetic_Resource-Guided_High-Intensity_Focused_Ultrasound_(MR-HIFU)TAB-3860https://nih.technologypublisher.com/tech?title=Atypical_Inhibitors_of_Monoamine_Transporters%3b_Method_of_Making%3b_and_Use_ThereofAbstract: Substance use disorder is a chronic medical condition, taking its toll on our public health care and judicial systems in an economically unsustainable way.  More than 20 million Americans suffer from substance use disorders. Certainly, the development of prevention and treatment options as alternatives to incarceration is the appropriate and ethical solution to this escalating global problem.  Although the recent opioid epidemic has redefined public perception of drug dependence, addiction is not a single illness for which one treatment modality will cure all.  Efforts to develop med...Wed, 02 Aug 2023 06:53:43 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech?title=Atypical_Inhibitors_of_Monoamine_Transporters%3b_Method_of_Making%3b_and_Use_ThereofTAB-3857https://nih.technologypublisher.com/tech/Use_of_Cucurbitacins_and_Withanolides_for_the_Treatment_of_CancerAbstract: Certain members of the cucurbitacin and Withanolide family have been identified that can sensitize some tumor cell lines to cell death (apoptosis) on subsequent exposure of the cells to pro-apoptotic receptor agonists (PARAS) of the TRAIL "death receptors". These PARAS include TRAIL itself, and agonist antibodies to two of its receptors death receptor-4 (DR4 or TRAIL-R1) and death receptor 5 (DR5, TRAIL-R2).  The protein TRAIL has a very interesting characteristic that it can preferentially cause death of cancer cells whereas normal non-transformed cells are unaffected.  Thus use of...Wed, 02 Aug 2023 06:53:40 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Use_of_Cucurbitacins_and_Withanolides_for_the_Treatment_of_CancerTAB-3855https://nih.technologypublisher.com/tech/Ex-vivo_Production_of_Regulatory_B-Cells_for_Use_in_Auto-immune_DiseasesAbstract: Regulatory B-cells (Breg) play an important role in reducing autoimmunity and reduced levels of these cells are implicated in etiology of several auto-inflammatory diseases. Despite their impact in many diseases, their physiological inducers are unknown.  Given that Bregs are a very rare B-cell, identifying factors that promote their development would allow in vivo modulation of Breg levels and ex-vivo production of large amounts of antigen-specific Bregs to use in immunotherapy for auto-inflammatory diseases.   Researchers at NEI's Molecular Immunology Section developed a method f...Wed, 02 Aug 2023 06:53:38 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Ex-vivo_Production_of_Regulatory_B-Cells_for_Use_in_Auto-immune_DiseasesTAB-874https://nih.technologypublisher.com/tech/Cloning_and_Characterization_of_an_Avian_Adeno-Associated_Virus_and_Uses_ThereofCurrently, adeno-associated virus (AAV) represents the gene therapy vehicle of choice because it has many advantages over current strategies for therapeutic gene insertion. AAV is less pathogenic than other virus types; stably integrates into dividing and non-dividing cells; integrates at a consistent site in the host genome; and shows good specificity towards various cell types for targeted gene delivery. To date, 11 AAV isolates have been isolated and characterized. New serotypes derived from non-human animal species have added to the specificity and repertoire of current AAV gene therapy t...Wed, 02 Aug 2023 06:28:04 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Cloning_and_Characterization_of_an_Avian_Adeno-Associated_Virus_and_Uses_ThereofTAB-3868https://nih.technologypublisher.com/tech/Therapeutic_Management_of_Menkes_Disease_and_Related_Copper_Transport_DisordersAbstract: The only currently available treatment for Menkes disease, subcutaneous copper histidinate injections, is successful only in patients with ATP7A gene mutations that do not completely corrupt ATP7A copper transport function (estimated 20-25% of affected patients) and when started at a very early age (first month of life). The combination of viral gene therapy with copper injections provides working copies of the ATP7A copper transporter into the brain, together with a source of the substrate (copper)  needed for proper brain growth and clinical neurodevelopment. Codon-optimized nuclei...Tue, 25 Jul 2023 08:45:51 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Therapeutic_Management_of_Menkes_Disease_and_Related_Copper_Transport_DisordersTAB-4451https://nih.technologypublisher.com/tech/Cancer-reactive_T_cells_from_Peripheral_BloodAbstract: Adoptive cell therapy (ACT) using genetically engineered T-cell receptors (TCRs) is a promising cancer treatment. These TCRs target genetic mutations unique to patients and play an important role in tumor regression. However, mutation-reactive T-cells and their TCRs can be difficult to identify and isolate from patients. Therefore, we need more efficient methods of isolating mutation-reactive T-cells for use with ACT.  Researchers at the National Cancer Institute (NCI) have developed a novel method of isolating mutation-reactive T-cells from a patient’s peripheral blood lymphocytes (...Mon, 24 Jul 2023 11:10:04 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Cancer-reactive_T_cells_from_Peripheral_BloodTAB-4184https://nih.technologypublisher.com/tech/Automated_Digital_Pathology_Device_for_High-Throughput_DemandAbstract: Computer and imaging technologies led to the development of digital pathology and the capture and storage of pathological specimens as digitally formatted images. The use of artificial intelligence (AI) in digital pathology, such as in three-dimensional (3D) reconstruction, requires analyses of high volumes of data. This resulted in increased demands for processing and acquisition of digital images of pathology samples. Increased usage cannot be met by the time-consuming, manual, and laborious methods currently used. Therefore, there is a need for automation of the techniques used in...Fri, 14 Jul 2023 12:29:37 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Automated_Digital_Pathology_Device_for_High-Throughput_DemandTAB-3946https://nih.technologypublisher.com/tech/Robotic_Exoskeleton_for_Treatment_of_Crouch_Gait_in_Children_with_Cerebral_Palsy_(CP)Abstract: Crouch gait is a common disorder in pediatric cerebral palsy (CP). Effective treatment of crouch during childhood is critical to maintain mobility into adulthood. Current interventions do not alleviate crouch gait long-term for most patients. This technology relates to a powered exoskeleton designed for gait assistance. The powered assistance may provide a physical therapy-type intervention to improve and maintain mobility.   Multiple factors contribute to crouch gait, including spasticity, contracture, muscle weakness and poor motor control. There are few effective interventions.  C...Fri, 14 Jul 2023 12:26:01 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Robotic_Exoskeleton_for_Treatment_of_Crouch_Gait_in_Children_with_Cerebral_Palsy_(CP)TAB-3912https://nih.technologypublisher.com/tech/Fibroblast_Growth_Factor_Receptor_4_(FGFR4)_Monoclonal_Antibodies_and_Methods_of_Their_UseAbstract: Several Fibroblast Growth Factor Receptor 4 (FGFR4) specific antibodies with binding affinity at the nanomolar range have been successfully developed at the Genetics Branch. These antibodies have been made into different formats of therapeutic including Antibody Drug Conjugate (ADC), Bispecific T cell engager (BiTE) ae well as Chimeric Antigen Receptor (CAR)-T cells. Proof of principle experiments have shown that when treated with FGFR4 positive tumor cells:   FGFR4 specific antibodies were able to deliver cytotoxic agents and killed those cells.   CD3 FGFR4 BiTE were able to recruit...Fri, 14 Jul 2023 12:22:29 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Fibroblast_Growth_Factor_Receptor_4_(FGFR4)_Monoclonal_Antibodies_and_Methods_of_Their_UseTAB-3911https://nih.technologypublisher.com/tech/Novel_Methods_for_Generating_Retinal_Pigment_Epithelium_Cells_from_Induced_Pluripotent_Stem_CellsAbstract: The retinal pigment epithelial cells (RPE) make up a polarized monolayer in the vertebrate eye that separates the neural retina from the choroid, and performs a crucial role in retinal physiology by forming a blood-retinal barrier and closely interacting with photoreceptors to maintain visual function.  Many ophthalmic diseases, such as age-related macular degeneration, are associated with a degeneration or deterioration of the RPE.  Researchers at NEI have developed high efficiency methods for producing retinal pigment epithelial cells (RPE) from induced pluripotent stem cells (iPSC...Fri, 14 Jul 2023 11:54:34 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Novel_Methods_for_Generating_Retinal_Pigment_Epithelium_Cells_from_Induced_Pluripotent_Stem_CellsTAB-4288https://nih.technologypublisher.com/tech/Transformation_of_Weak_or_Non-Immunogenic_Antigens_to_Produce_an_Immune_Response_and_Therapeutic_Polypeptides_for_the_Treatment_and_Prevention_of_CancerAbstract: A significant challenge in developing therapies for the treatment and prevention of cancer has been the discovery, selection, and exploitation of antigens. Researchers at the National Institute on Aging (NIA) have partially circumvented this issue in their development of novel strategies for rendering weakly or non-immunogenic, shared antigens immunogenic, or able to produce an immune response.  These strategies use proinflammatory chemokines to deliver antigens to immature dendritic cells (DCs) by targeting chemokine receptors differentially expressed on antigen presenting cells (AP...Thu, 22 Jun 2023 13:11:18 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Transformation_of_Weak_or_Non-Immunogenic_Antigens_to_Produce_an_Immune_Response_and_Therapeutic_Polypeptides_for_the_Treatment_and_Prevention_of_CancerTAB-1697https://nih.technologypublisher.com/tech/Micropatterning_of_Extracellular_Matrix_Proteins_Using_Microphoto-ablation_Of_Poly_vinyl_Alcohol_(PVA)_MonolayersAvailable for licensure and commercial development is a micro-photoablation (µPA) method used as a micro-patterning technique to attach ECM proteins or other biological molecules to specified locations. Advantages of this photolytic technique are that it: (a) is stampless, (b) allows for flexible pattern generation to the submicron level, (c) allows for live cell fluorescence imaging, retains cell viability, and (d) allows the use of multiple proteins. The technique has demonstrated experimentally that micropatterning with live cell fluorescence imaging can be used to precisely visualize study...Tue, 23 May 2023 10:49:56 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Micropatterning_of_Extracellular_Matrix_Proteins_Using_Microphoto-ablation_Of_Poly_vinyl_Alcohol_(PVA)_MonolayersTAB-3779https://nih.technologypublisher.com/tech/Monoclonal_Antibody_Against_Human_Alpha-5_Integrin_that_Does_Not_Disrupt_Adhesive_FunctionTue, 23 May 2023 10:22:19 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Monoclonal_Antibody_Against_Human_Alpha-5_Integrin_that_Does_Not_Disrupt_Adhesive_FunctionTAB-4205https://nih.technologypublisher.com/tech/Novel_Dopamine_Receptor_Ligands_As_Therapeutics_For_Central_Nervous_System_DisordersWed, 22 Mar 2023 02:37:55 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Novel_Dopamine_Receptor_Ligands_As_Therapeutics_For_Central_Nervous_System_DisordersTAB-3819https://nih.technologypublisher.com/tech?title=Novel_Inactivated_Zika_Vaccine_Candidate_Based_on_Purified_Wild-type_Zika_Virus_%e2%80%94_for_Zika_Vaccine_and_Diagnostic_Assay_DevelopmentZika virus (ZIKV) spreads to people primarily through bite by infected Aedes mosquitoes. ZIKV infection during pregnancy can cause stillbirths or affect the fetus by causing serious birth defects, such as microcephaly and other brain defects. Although uncommon, adults with ZIKV can also develop Guillain-Barre syndrome and other neurological disorders. According to the World Health Organization’s July 2019 report, a total of 87 countries and territories have had evidence of mosquito-borne transmission of ZIKV. While Zika virus poses a substantial public health threat, no FDA-approved vaccine o...Wed, 14 Dec 2022 18:24:35 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech?title=Novel_Inactivated_Zika_Vaccine_Candidate_Based_on_Purified_Wild-type_Zika_Virus_%e2%80%94_for_Zika_Vaccine_and_Diagnostic_Assay_DevelopmentTAB-3818https://nih.technologypublisher.com/tech/Multiplexing_Homocysteine_in_Primary_Newborn_Screening_Assays_Using_Maleimides_as_Select_Derivatization_AgentsHomocystinuria (HCU), a group of inherited disorders, causes symptoms ranging from failure to thrive and developmental delays in infants or young children to abnormal blood clots with onset in adults.1 Approximately 1 in 200,000 to 335,000 people have HCU globally.2 Various clinical settings use the dried blood spot (DBS) for sample collection methods such as newborn screening tests for HCU. Due to the complex chemistry of homocysteine (Hcy), which is elevated in people with HCU, and known interferences, labs cannot screen DBS for this biomarker in primary-tier newborn screening assays. Inste...Wed, 14 Dec 2022 18:24:34 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Multiplexing_Homocysteine_in_Primary_Newborn_Screening_Assays_Using_Maleimides_as_Select_Derivatization_AgentsTAB-3812https://nih.technologypublisher.com/tech/Minibody_for_Conditioning_prior_to_Hematopoietic_Stem_Cell_and_Progenitor_Cell_TransplantationPatient conditioning is a critical initial step in hematopoietic stem and progenitor cell (HSPC) transplantation procedures to enable marrow engraftment of infused cells. Conditioning regimens have traditionally been achieved by delivering cytotoxic doses of chemotherapeutic agents and radiation. However, these regimens are associated with significant morbidity and mortality, and cannot be used safely in elderly or subjects with comorbidities. Scientists at the National Heart, Lung, and Blood Institute (NHLBI), the University of Massachusetts Medical School (UMMS), and the University of Color...Tue, 06 Dec 2022 12:07:27 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Minibody_for_Conditioning_prior_to_Hematopoietic_Stem_Cell_and_Progenitor_Cell_TransplantationTAB-3809https://nih.technologypublisher.com/tech/Methods_for_Using_Modulators_of_Extracellular_Adenosine_or_an_Adenosine_Receptor_To_Enhance_Immune_Response_and_InflammationLocal inflammation processes are crucially important in the host defense against pathogens and for successful immunization because proinflammatory cytokines are necessary for initiation and propagation of an immune response. However, normal inflammatory responses are eventually terminated by physiological termination mechanisms, thereby limiting the strength and duration of immune responses, especially to weak antigens. The inventors have shown that adenosine A2a and A3a receptors play a critical role in down-regulation of inflammation in vivo. They act as the physiological termination mechani...Tue, 06 Dec 2022 12:07:26 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Methods_for_Using_Modulators_of_Extracellular_Adenosine_or_an_Adenosine_Receptor_To_Enhance_Immune_Response_and_InflammationTAB-3721https://nih.technologypublisher.com/tech/Longer-lived_Mouse_Models_for_Studying_Gaucher_DiseaseThe invention is a novel longer-lived mouse model for Gaucher disease. Gaucher disease is a genetic disorder that results from deficiencies in the enzyme glucocerebrosidase (GBA). The use of animal models to study how the disease progresses has been invaluable in research of this disorder. However, existing mouse models have been limited due to early mortality because the GBA enzyme plays an important role in lysosomal storage. Researchers at the National Institute of Mental Health (NIMH) generated the Gaucher mice were generated by inserting mutations that reduced GBA enzyme activity into no...Tue, 06 Dec 2022 12:07:08 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Longer-lived_Mouse_Models_for_Studying_Gaucher_DiseaseTAB-3687https://nih.technologypublisher.com/tech/A_Mood-Machine-Interface_as_an_Intervention_for_Emotional_Self-Regulation_in_Real-TimeThis technology relates to a closed-loop controller that is being developed as a phone app for emotional self-regulation in real-time. There is a significant association between emotion dysregulation and symptoms of depression, anxiety, eating pathology, and substance abuse, affecting millions worldwide. Consisting of a closed-loop controller that adjusts reward values in real-time according to individual mood response, the Mood Machine Interface technology compensates for adaptation to stimuli over time allowing it to generate substantial mood changes in the user. This provides a quantitative...Tue, 06 Dec 2022 12:07:03 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/A_Mood-Machine-Interface_as_an_Intervention_for_Emotional_Self-Regulation_in_Real-TimeTAB-3686https://nih.technologypublisher.com/tech/Radioligand_for_imaging_brain_PDE4_subtype_D_receptors_with_positron_emission_tomographyThe technology relates to the first radioligands that can be used to image and quantify the enzyme phosphodiesterase subtype D (PDE4D). The PDE4D proteins have a role in carrying out signal transduction pathways in several cell types and is thought to be the key target of various antidepressants. Current work with imaging the radioligands in monkey brains using positron emission tomography (PET) has been successful, and further work with humans is needed. An effective radioligand that can visualize PDE4D levels in human using PET can be useful in evaluation of health human subjects and in the ...Tue, 06 Dec 2022 12:07:02 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Radioligand_for_imaging_brain_PDE4_subtype_D_receptors_with_positron_emission_tomographyTAB-3685https://nih.technologypublisher.com/tech?title=Novel_NMDA_ligands_that_are_specific_and_selective_to_the_NR2B_subunits_based_on_the_derivatives_of_7-methoxy-3-(4-phenylbutyl)-2%2c3%2c4%2c5-tetrahydro-1H-benzo%5bd%5dazepin-1-olThis invention includes the design and synthesis of ligands that bind selectively and specifically to the NR2B subunit of the NMDA receptor. The NMDA receptor is thought to play a role in the pathophysiology of psychiatric disorders, including depression, stroke, drug addiction, and neuropathic pain. Existing ligands to the NMDA receptor are widely used to treat these conditions. Researchers at the National Institute of Mental Health (NIMH) have synthesized new ligands based on the 7-methoxy-3-(4-phenylbutyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepin-1-ol molecule. Binding affinities were checked,...Tue, 06 Dec 2022 12:07:01 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech?title=Novel_NMDA_ligands_that_are_specific_and_selective_to_the_NR2B_subunits_based_on_the_derivatives_of_7-methoxy-3-(4-phenylbutyl)-2%2c3%2c4%2c5-tetrahydro-1H-benzo%5bd%5dazepin-1-olTAB-3684https://nih.technologypublisher.com/tech?title=NIMH_DAO_Toolbox%3a_Data_acquisition_software_that_enables_real-time_sample_analysisThis technology relates to a software package called NIMH DAO Toolbox that uses multithreading and a unique buffer structure to shorten gaps in sample readouts. Data acquisition devices running in continuous sampling mode collect data samples at a given sampling rate. The samples are typically stored in a memory buffer and read out at a regular interval. If the sampling rate is short enough, there can be a gap between the time the first sample is acquired and the time that sample is available to the user. This gap is typically on the order of tens of milliseconds. However, the maximum delay to...Tue, 06 Dec 2022 12:07:00 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech?title=NIMH_DAO_Toolbox%3a_Data_acquisition_software_that_enables_real-time_sample_analysisTAB-3683https://nih.technologypublisher.com/tech?title=Stable%2c_High-Yield_Production_of_DT390-EGF_Fusion_Protein_for_Treatment_of_EGF-Receptor-Positive_CancersThis invention relates to the stable and high-yield production of a high-potency toxin protein called DT390-EGF. This toxin was developed for the treatment of EGF-receptor-positive cancers, including bladder cancer. Initial methods for synthesizing DT390-EGF relied on the use of E. coli. However, the production in E. coli was difficult to prepare and had limited stability. Repeated efforts to standardize the process in E. coli gave poor yields, purity, and high variation. To overcome the problems with production using E. coli, this invention employs the Pichia pastoris strain of yeast. To pro...Tue, 06 Dec 2022 12:06:58 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech?title=Stable%2c_High-Yield_Production_of_DT390-EGF_Fusion_Protein_for_Treatment_of_EGF-Receptor-Positive_CancersTAB-3682https://nih.technologypublisher.com/tech/Detecting_Levels_of_Chymotrypsin_and_Amylase_using_Rabbit_Polyclonal_Antibodies_Generated_from_Purified_Human_EnzymesThe invention relates to rabbit antisera raised against purified human chymotrypsin and amylase. Both chymotrypsin and amylase are produced by the pancreas and play important roles in digestion. Abnormal levels of chymotrypsin and amylase have been known to occur with multiple pancreas-related disorders, including pancreatitis. Measuring levels of these two enzymes using these polyclonal antibodies can help determine if a pancreas is functioning correctly.Tue, 06 Dec 2022 12:06:57 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Detecting_Levels_of_Chymotrypsin_and_Amylase_using_Rabbit_Polyclonal_Antibodies_Generated_from_Purified_Human_EnzymesTAB-3681https://nih.technologypublisher.com/tech/Stopping_Neurogenesis_in_Transgenic_Mice_and_Rat_Models_that_Express_the_HSV-thymidine_kinase_Gene_in_Neuronal_Precursor_CellsThis invention relates to novel mouse and rat models that permit the temporal death of neuronal precursor cells at any time point. Other existing methods of decreasing neurogenesis are relatively non-specific (e.g., injecting glucocorticoids) or require expensive equipment (e.g., focal x-irradiation) These mice and rats are being used to inhibit adult neurogenesis in order to study the normal function of adult neurogenesis and to model disease states thought to feature decreased neurogenesis, such as chronic stress, anxiety, and depression. The murine models have been engineered to express ...Tue, 06 Dec 2022 12:06:56 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Stopping_Neurogenesis_in_Transgenic_Mice_and_Rat_Models_that_Express_the_HSV-thymidine_kinase_Gene_in_Neuronal_Precursor_CellsTAB-3680https://nih.technologypublisher.com/tech/Diagnosis_and_Treatment_of_Pediatric_Acute_Neurologic_Syndrome_with_Antineuronal_AntibodiesThe invention is a panel of five tests of patient sera for immune responses that may attack the brain and lead to the characteristic symptoms of pediatric acute neurologic syndrome (PANS). PANS is a condition defined by a sudden onset of obsessive-compulsive symptoms, eating restrictions, and other cognitive and/or behavioral symptoms. Currently, the diagnosis of PANS is made when other possible symptoms are ruled out, a diagnosis of exclusion. The panel of tests in this invention provides a basis for the diagnosis and treatment of PANS in the setting of symptoms such as obsessions and compul...Tue, 06 Dec 2022 12:06:55 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Diagnosis_and_Treatment_of_Pediatric_Acute_Neurologic_Syndrome_with_Antineuronal_AntibodiesTAB-3679https://nih.technologypublisher.com/tech/Generation_of_mutant_mouse_alleles_that_functionally_disrupt_production_of_BDNF_from_its_ndividual_promotersThis technology relates to a mouse model that improves an existing method of disrupting the production of the BDNF protein in specific parts of the brain. A current avenue of research seeks to examine how gene expression may effect long-lasting changes in the nervous system. Previous work has resulted in a mouse line in which the production of BDNF was disrupted. However, these mice had an inadvertent genetic component left in: a neomycin cassette. This unintentional addition led to significant deleterious effects. Researchers at NCI and NIMH have updated these mouse models by removing the neo...Tue, 06 Dec 2022 12:06:54 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Generation_of_mutant_mouse_alleles_that_functionally_disrupt_production_of_BDNF_from_its_ndividual_promotersTAB-3678https://nih.technologypublisher.com/tech?title=Imaging_Inflammation_using_PET_Radioligands_that_Target_Translocator_Protein_18%3fkDa_with_High_Affinity_Regardless_of_GenotypeThis technology includes a group of radioligands that label inflammatory cells specifically, accurately, and across different genotypes and can be detected using Positron Emission Tomography (PET). The radioligands target the Translocator protein 18 kDa (TSPO) receptor which is present on the outer mitochondrial membrane and is involved in the production of steroids. Current TSPO radioligands either lack specificity or have highly variable inter-subject sensitivities due to TSPO genotypic differences. These new ligands permit a simplified interpretation and quantification of the binding signal...Tue, 06 Dec 2022 12:06:53 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech?title=Imaging_Inflammation_using_PET_Radioligands_that_Target_Translocator_Protein_18%3fkDa_with_High_Affinity_Regardless_of_GenotypeTAB-3677https://nih.technologypublisher.com/tech/A_Diagnostic_Kit_for_Assessing_Exposure_or_Infection_by_the_Koala_Family_of_RetrovirusesThis invention relates to a diagnostic kit for assessing exposure to or infection by a koala retrovirus. The kit consists of specific primers and probes for the detection of three distinct subtypes of infectious koala retrovirus and may be useful in various species, including humans, primates, and koalas. A family of infectious koala retroviruses are correlated with the development of malignant neoplasias, including lymphomas and leukemias. Infectious koala retroviruses have been shown to infect human cells in culture, though the health implications in humans have not yet been fully determine...Tue, 06 Dec 2022 12:06:52 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/A_Diagnostic_Kit_for_Assessing_Exposure_or_Infection_by_the_Koala_Family_of_RetrovirusesTAB-3676https://nih.technologypublisher.com/tech/Retroviral_Vector_Packaging_Cell_Lines_and_Purification_Methods_for_Gene_TherapyThis invention relates to a novel gammaretroviral vector packaging cell line and a method of producing gammaretroviral vectors suitable for gene therapy. The described vectors may contain the gibbon ape leukemia virus (GALV) envelope with a CD11D8 epitope tag enabling their purification on a monoclonal antibody conjugated column. These vectors have several advantages over existing systems, including a broader host range, higher infectivity, and lower potential for replication. Further, purification of retroviral vector particles via an epitope tag may remove cellular components and debris toxi...Tue, 06 Dec 2022 12:06:51 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Retroviral_Vector_Packaging_Cell_Lines_and_Purification_Methods_for_Gene_TherapyTAB-3675https://nih.technologypublisher.com/tech?title=Imaging_Inflammation_using_PET_Radioligands_that_Target_Translocator_Protein_18%3fkDa_with_High_Affinity_Regardless_of_GenotypeThis technology includes a group of radioligands that label inflammatory cells specifically, accurately, and across different genotypes and can be detected using Positron Emission Tomography (PET). The radioligands target the Translocator protein 18 kDa (TSPO) receptor which is present on the outer mitochondrial membrane and is involved in the production of steroids. Current TSPO radioligands either lack specificity or have highly variable inter-subject sensitivities due to TSPO genotypic differences. These new ligands permit a simplified interpretation and quantification of the binding signal...Tue, 06 Dec 2022 12:06:50 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech?title=Imaging_Inflammation_using_PET_Radioligands_that_Target_Translocator_Protein_18%3fkDa_with_High_Affinity_Regardless_of_GenotypeTAB-3671https://nih.technologypublisher.com/tech/Prematurely-Graying_Mouse_Line_Demonstrates_Regulation_of_Melanocyte_Stem_Cell_Development_by_SOX10_(Sry-Related_HMG-Box)_Transcription_Factor_for_Use_in_Regenerative_MedicineThis technology includes transgenic mice to be used in the study of melanocyte stem cells (MSCs) for utilization in regenerative medicine. Using the melanocyte system as a model, we investigated establishment of MSCs in the hair bulge - the stem cell compartment of the hair. During embryogenesis, all melanoblasts express SOX10, but this expression is downregulated during hair follicle morphogenesis and MSC differentiation. To further study the role of SOX10, we generated transgenic mice overexpressing SOX10 in melanoblasts. In these mice, named Tg(DctSox10), SOX10 expression was controlled by ...Tue, 06 Dec 2022 12:06:48 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Prematurely-Graying_Mouse_Line_Demonstrates_Regulation_of_Melanocyte_Stem_Cell_Development_by_SOX10_(Sry-Related_HMG-Box)_Transcription_Factor_for_Use_in_Regenerative_MedicineTAB-3670https://nih.technologypublisher.com/tech/Murine_Model_of_Niemann-Pick_Disease_Type_CThis technology includes a transgenic mouse model of Niemann-Pick Disease Type C (NPC), which is a rare neurodegenerative disorder, characterized by intracellular accumulation of cholesterol and gangliosides. The mouse strain, Tg(Npcl), expresses wild-type NPC1 gene under the control of the prion promoter. When combined with the NPC deficient mouse model, BALB/c npcnih/nih, also known as Npcl-/-, the transgene insertion allele rescues life expectancy of Npc1-/- mice. Npc1-/- mouse have reduced life expectancy and die around 8 weeks, making it a difficult model to be utilized. The Tg(Npcl) mous...Tue, 06 Dec 2022 12:06:47 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Murine_Model_of_Niemann-Pick_Disease_Type_CTAB-3666https://nih.technologypublisher.com/tech/Human_Fibroblast_Cell_Lines_with_PMM2_Congenital_Disorder_of_Glycosylation_for_Therapeutic_DevelopmentCongenital disorders of glycosylation (CDGs) are inherited disorders of abnormal protein glycosylation that affect multiple organ systems. More than 100 different CDGs have been described, affecting protein and lipid glycosylation. NHGRI investigators have been able to isolate fibroblasts from patients with PMM2 (phosphomannomutase)-CDG, also known at CDG type Ia, which is an inherited, broad-spectrum disorder with developmental and neurological abnormalities.Tue, 06 Dec 2022 12:06:45 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Human_Fibroblast_Cell_Lines_with_PMM2_Congenital_Disorder_of_Glycosylation_for_Therapeutic_DevelopmentTAB-3665https://nih.technologypublisher.com/tech/Human_Cell_Lines_with_Mannosyl_Oligosaccharide_Glucosidase_(MOGS)_Defect_for_the_Study_and_Prevention_of_InfectionThis technology includes human cell lines from patients who have genetic defects in MOGS, the gene encoding mannosyl-oligosaccharide glucosidase, causing the rare congenital disorder of glycosylation type IIb, also known as MOGS-CDG. This defects appears to impair the ability of viruses to infect a second round of cells, which can be used to study and prevent infections. This is likely related to impaired viral replication and cellular entry. This finding has implications for Ebola and Zika, as well as other viral infections.Tue, 06 Dec 2022 12:06:43 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Human_Cell_Lines_with_Mannosyl_Oligosaccharide_Glucosidase_(MOGS)_Defect_for_the_Study_and_Prevention_of_InfectionTAB-3655https://nih.technologypublisher.com/tech/Mouse_Model_of_Hutchinson-Gilford_Progeria_Syndrome_(HGPS)_and_Vascular_Abnormalities_(G608G)_mutated_form_of_human_LNMA)_for_Therapeutic_DevelopmentChildren with Hutchinson-Gilford progeria syndrome (HGPS) suffer from acceleration of certain aging symptoms, mainly cardiovascular disease that generally leads to death from myocardial infarction and/or stroke. The cause of HGPS has been discovered to be a de novo point mutation in lamin A (LNMA) gene. NHGRI Scientist have generated a transgenic mouse model of HGPS. This mouse carries a bacterial artificial chromosome (BAC) with a De novo mutation 1824 C to T (G608G) mutated form of human LNMA. The transgenic animals lack external phenotype seen in human progeria but have vascular abnormali...Tue, 06 Dec 2022 12:06:41 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Mouse_Model_of_Hutchinson-Gilford_Progeria_Syndrome_(HGPS)_and_Vascular_Abnormalities_(G608G)_mutated_form_of_human_LNMA)_for_Therapeutic_DevelopmentTAB-3646https://nih.technologypublisher.com/tech/Human_Cell_Lines_with_NGLY1_Mutations_for_the_Study_of_NGLY1_Deficiency_and_Therapeutic_DevelopmentCongenital disorders of glycosylation (CDGs) are a group of inborn errors characterized by abnormalities in the process of glycosylation of biomolecules. Although more than 100 different CDGs have been reported, only one has been thoroughly described, namely NGLY1 deficiency or NGLY1-CDG. NGLY1 encodes N-glycanase 1, an enzyme involved in the cytosolic degradation of misfolded glycoproteins and other glycoproteins bound for degradation. This technology includes fifteen fibroblast cell lines isolated from patients from 2.5 years to 21.3 years to be used to study the defects in NGLY1 gene and...Tue, 06 Dec 2022 12:06:38 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Human_Cell_Lines_with_NGLY1_Mutations_for_the_Study_of_NGLY1_Deficiency_and_Therapeutic_DevelopmentTAB-3645https://nih.technologypublisher.com/tech/Lymphoblastoid_Cell_Lines_with_a_Specific_Allele_of_ABCA7_Gene_for_the_Screening_of_Small_Molecules_for_Therapeutic_DevelopmentThis technology includes lymphoblastoid cell lines from individuals genotyped as carrying the minor (G) allele of ABCA7 SNP rs113809142 [ss491752998; SNV-chr19-1007244], to be used for small molecule screening and eventual therapeutic development. The ABCA7 gene is the ATP-binding cassette, sub-family A (ABC1), member 7. It encodes a protein that is a transporter and has been associated with such diseases as neonatal respiratory failure and Asperger's syndrome. It is also known to play a role in phagocytosis of apoptotic cells by macrophages and may mediate cholesterol efflux.Tue, 06 Dec 2022 12:06:37 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Lymphoblastoid_Cell_Lines_with_a_Specific_Allele_of_ABCA7_Gene_for_the_Screening_of_Small_Molecules_for_Therapeutic_DevelopmentTAB-3644https://nih.technologypublisher.com/tech/DNA_Methylation_Based_Non-invasive_Blood_Diagnostic_Assay_for_Precision_Cancer_Detection_and_ClassificationThis technology includes a panel of 46 genomic loci of DNA methylation (represented by CpG dinucleotides on different chromosomes) with application in blood-based cancer screening. The markers robustly distinguish tumor from normal samples using 8 loci and classify 13 different tumor types. Using 39 loci, inventors were able to discriminate between individual tumor types or peripheral blood. In 4052 tumor samples from 13 tumor types, the true positive rate of classification was 91.4%. The false positive rate was 1.2% from 11 normal tissue types (in 646 samples) and 0% using 2711 normal periphe...Tue, 06 Dec 2022 12:06:36 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/DNA_Methylation_Based_Non-invasive_Blood_Diagnostic_Assay_for_Precision_Cancer_Detection_and_ClassificationTAB-3643https://nih.technologypublisher.com/tech/Staphylococcus_Epidermidis_Isolates_from_Human_Skin_Samples_for_Use_as_Clinical_Molecular_MarkersThis technology includes a catalog of commensal and pathogenic staphylococci from human skin for utilization as clinical molecular markers of skin conditions and infections. The study of microbial diversity of human skin in both healthy and disease states is important to develop tools to track infections, outbreaks, and multi-drug resistant organisms, particularly in atopic dermatitis, eczema and other microbial-associated infections. Commensal skin S. epidermidis have an open pan-genome and show considerable diversity between isolates.Tue, 06 Dec 2022 12:06:35 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Staphylococcus_Epidermidis_Isolates_from_Human_Skin_Samples_for_Use_as_Clinical_Molecular_MarkersTAB-3638https://nih.technologypublisher.com/tech/Mouse_Model_Created_Using_Glucocerebrosidase-Deficient_Neuronal_Cell_Line_to_Study_Gaucher_Disease_Pathophysiology_and_Evaluate_New_TherapiesThis technology includes a high-yield, easy-to-culture mouse neuronal cell model with nearly complete glucocerebrosidase deficiency representative of Gaucher disease (GD) to study pathophysiology and evaluate new therapies. GD is an autosomal recessive lysosomal storage disorder caused by loss-of function mutations in the GBA1 gene, which codes for the lysosomal hydrolase glucocerebrosidase (GCase). Inventors have successfully immortalized cortical neurons from embryonic null allele GBA-/- mice and the control littermate (GBA+/+) by infecting differentiated primary cortical neurons in culture ...Tue, 06 Dec 2022 12:06:33 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Mouse_Model_Created_Using_Glucocerebrosidase-Deficient_Neuronal_Cell_Line_to_Study_Gaucher_Disease_Pathophysiology_and_Evaluate_New_TherapiesTAB-3637https://nih.technologypublisher.com/tech/Human_Fibroblast_Cell_Lines_Heterozygous_for_Glucocerebrosidase_(GBA1)_Mutation_N370S_for_the_Study_of_Neurodegenerative_Disorders_and_their_TreatmentsThis technology includes six cell lines for the study of Glucocerebrosidase (GBA1) mutations which could be used for the evaluation and eventual treatments for conditions such as Gaucher's disease and Parkinson's disease. GBA1 is a lysosomal enzyme, responsible for breakdown of a fatty material called glucocerebroside (or glucosyl ceramide). Deficiency or malfunction of GBA1 leads to the accumulation of insoluble glucocerebrosides (derived mostly from ingested red and white blood cell membranes) in tissues, which is a major symptom of Gaucher disease. Gaucher disease is a rare and heterogeneou...Tue, 06 Dec 2022 12:06:32 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Human_Fibroblast_Cell_Lines_Heterozygous_for_Glucocerebrosidase_(GBA1)_Mutation_N370S_for_the_Study_of_Neurodegenerative_Disorders_and_their_TreatmentsTAB-3636https://nih.technologypublisher.com/tech/Fibroblast_Cell_Lines_Homozygous_for_Glucocerebrosidase_(GBA1)_Mutation_N370S_for_the_Screening_of_Small_Molecules_for_Gaucher_Disease_TreatmentThis technology includes two human fibroblast cell lines be used to study the defects in GBA1 gene and protein and to screen small molecules for involvement in Gaucher disease. Glucocerebrosidase (GBA1 or GCase or beta-glucosidase) is a lysosomal enzyme, responsible for breakdown of a fatty material called glucocerebroside (or glucosyl ceramide). Deficiency or malfunction of GBA1 leads to the accumulation of insoluble glucocerebrosides in tissues, which is a major symptom of Gaucher disease. Gaucher disease is a rare and heterogeneous disorder, caused by inherited genetic mutations in GBA1. In...Tue, 06 Dec 2022 12:06:31 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Fibroblast_Cell_Lines_Homozygous_for_Glucocerebrosidase_(GBA1)_Mutation_N370S_for_the_Screening_of_Small_Molecules_for_Gaucher_Disease_TreatmentTAB-3635https://nih.technologypublisher.com/tech?title=Fibroblast_Cell_Lines_(with_L444P%2fRecNci1_Genotype)_for_the_Screening_of_Small_Molecules_for_Gaucher_Disease_TreatmentThis technology includes two human fibroblast cell lines to be used to study the defects in GBA1 gene and protein and to screen small molecules for involvement in Gaucher disease. Glucocerebrosidase (GBA1 or GCase or beta-glucosidase) is a lysosomal enzyme, responsible for breakdown of a fatty material called glucocerebroside (or glucosyl ceramide). Deficiency or malfunction of GBA1 leads to the accumulation of insoluble glucocerebrosides in tissues, which is a major symptom of Gaucher disease. Gaucher disease is a rare and heterogeneous disorder, caused by inherited genetic mutations in GBA1....Tue, 06 Dec 2022 12:06:30 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech?title=Fibroblast_Cell_Lines_(with_L444P%2fRecNci1_Genotype)_for_the_Screening_of_Small_Molecules_for_Gaucher_Disease_TreatmentTAB-3633https://nih.technologypublisher.com/tech/Human_Serous_Endometrial_Cancer_Cell_Lines_CRISPR-edited_to_knock-in_FBXW7_mutations_for_Use_in_Cancer_related_Molecular_and_Cellular_StudiesThis technology includes endometrial cancer cell lines for use in molecular and cellular studies to determine the effects of cancer-associated FBXW7 (F-box and WD repeat domain-containing 7) mutations, including but not limited to biochemical studies, proteomic studies, and drug sensitivity/resistance studies. Clustered Regularly Interspaced Palindromic Repeats (CRISPR) editing was used to knock-in individual FBXW7 mutations into the ARK1 serous EC cell line, which lacks detectable endogenous FBXW7 mutation(s). For each CRISPR-edited cell line, and parental ARK1 cells, STR (Short Tandem Repeat...Tue, 06 Dec 2022 12:06:29 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Human_Serous_Endometrial_Cancer_Cell_Lines_CRISPR-edited_to_knock-in_FBXW7_mutations_for_Use_in_Cancer_related_Molecular_and_Cellular_StudiesTAB-3630https://nih.technologypublisher.com/tech?title=Murine_Models_of_an_Autoinflammatory_Disease%2c_Familial_Mediterranean_Fever_(FMF)%2c_to_Study_the_Pathophysiology_of_Inherited_Disorders_of_Inflammation_and_Evaluate_New_TherapiesThis technology includes mouse models (heterozygous for the knock-in (KI) and homozygous for the knock-out (KO)) to be used as research reagents and to study molecular mechanisms and potential therapies for Familial Mediterranean fever (FMF). FMF is the prototype of a group of inherited disorders characterized by recurring, spontaneous episodes of fever and localized inflammation. The gene responsible for FMF is composed of 10 exons encoding a 781 amino acid protein known as pyrin. In addition to FMF, some recent findings show that an abnormal activation of the pyrin inflammasome is the inflam...Tue, 06 Dec 2022 12:06:28 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech?title=Murine_Models_of_an_Autoinflammatory_Disease%2c_Familial_Mediterranean_Fever_(FMF)%2c_to_Study_the_Pathophysiology_of_Inherited_Disorders_of_Inflammation_and_Evaluate_New_TherapiesTAB-3629https://nih.technologypublisher.com/tech/Human_Fibroblast_Cell_Lines_from_Patients_with_Gangliosidosis_Diseases_for_the_Screening_of_Disease_TherapeuticsThis technology includes cell lines from patients with gangliosidosis diseases for the screening of potential therapeutics. Gangliosidosis contains different types of lipid storage disorders caused by the accumulation of lipids known as gangliosides. GM1 gangliosidosis is an ultra-rare lysosomal storage disorder caused by mutations in galactosidase beta 1 (GLB1) that result in a deficiency of beta-galactosidase. GM2 gangliosidoses are a group of autosomal recessive lysosomal storage disorders caused by accumulation of GM2 ganglioside due to the absence or near absence of B-hexosamindase. GM2 g...Tue, 06 Dec 2022 12:06:27 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Human_Fibroblast_Cell_Lines_from_Patients_with_Gangliosidosis_Diseases_for_the_Screening_of_Disease_TherapeuticsTAB-3625https://nih.technologypublisher.com/tech/Synthetic_Genes_for_the_Treatment_of_Propionic_Acidemia_(PA)_Caused_by_Mutations_in_Propionyl-coA_Carboxylase_Alpha_(PCCA)Propionic acidemia (PA) is an autosomal recessive metabolic disorder caused by mutations in either PCCA or PCCB. The products of these genes form the alpha and beta subunits of the enzyme propionyl-Co A carboxylase (PCC), a critically important mitochondrial enzyme involved in the catabolism of branched chain amino acids. NHGRI scientist have developed a new set of synthetic PCCA genes that can be used to treat PA caused by PCCA mutation(s). In brief, the amino acid sequence of PCCA was reverse translated, using a variety of algorithms and expert input, to generate novel DNA sequences encodi...Tue, 06 Dec 2022 12:06:25 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Synthetic_Genes_for_the_Treatment_of_Propionic_Acidemia_(PA)_Caused_by_Mutations_in_Propionyl-coA_Carboxylase_Alpha_(PCCA)TAB-3624https://nih.technologypublisher.com/tech/Serum_Protein_Biomarkers_that_Predict_the_Response_to_Liver_Directed_Therapy_in_Methymalonic_Acidemia_(MMA)_and_Propionic_Acidemia_(PA)Isolated Methylmalonic Acidemia (MMA) comprises a relatively common and heterogeneous group of inborn errors of metabolism. The most common cause of isolated MMA is genetic deficiency of the enzyme methylmalonyl-coA mutase (MUT), which, unfortunately for the affected patients, is also the most clinically severe. NHGRI scientist have discovered biomarkers previously described cytokines that has never been associated with MMA or propionic acidemia (PA) such as FGF-21 (fibroblast like-growth factor - 21). The cytokines have been studied in patients with mitochondrial myopathies and other unrela...Tue, 06 Dec 2022 12:06:24 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Serum_Protein_Biomarkers_that_Predict_the_Response_to_Liver_Directed_Therapy_in_Methymalonic_Acidemia_(MMA)_and_Propionic_Acidemia_(PA)TAB-3623https://nih.technologypublisher.com/tech?title=Novel_mouse_models_of_methylmalonic_acidemia_(MMA)_%3a_C57Bl6%2fSv129_Mut-%2f-_(full_knock-out)_and_(C57Bl6%2fSv129)_FvBN_Mut_-%2f-_(full_knock-out)Methylmalonic acidemia (MMA) is an autosomal recessive disorder caused by the deficiency of the mitochondrial enzyme methylmalonyl-CoA mutase (MUT). It is characterized by metabolic instability, multiorgan pathology, and poor prognosis for long-term survival. To study MMA caused by MUT deficiency, a series of murine models have been constructed using gene targeting and analyzed. The model is a full knock out of the mouse Mut gene that produces neonatal lethality on the C57Bl6/Sv129 background. Another embodiment of this allele is used to create a related mouse model of Mut deficiency that ca...Tue, 06 Dec 2022 12:06:23 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech?title=Novel_mouse_models_of_methylmalonic_acidemia_(MMA)_%3a_C57Bl6%2fSv129_Mut-%2f-_(full_knock-out)_and_(C57Bl6%2fSv129)_FvBN_Mut_-%2f-_(full_knock-out)TAB-3622https://nih.technologypublisher.com/tech?title=Novel_mouse_model_of_mut-_methylmalonic_acidemia_(MMA)_Mut-%2f-_Tg_CBAMutG715V_%3a_Mut_partial-deficiencyMethylmalonic acidemia (MMA) is an autosomal recessive disorder, caused by the deficiency of the mitochondrial enzyme methylmalonyl-CoA mutase (MUT). It is characterized by metabolic instability, multiorgan pathology, and poor prognosis for long-term survival. A well-characterized human mutation, p.G717V, has been introduced into mice. This mutation has been characterized as a "pure" adenosylcobalamin Km mutation. NHGRI scientist have used site-directed mutagenesis to generate the homologous mouse mutation, p.G715V, and verified the kinetic properties of this mutant enzyme in vitro. They have...Tue, 06 Dec 2022 12:06:22 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech?title=Novel_mouse_model_of_mut-_methylmalonic_acidemia_(MMA)_Mut-%2f-_Tg_CBAMutG715V_%3a_Mut_partial-deficiencyTAB-3621https://nih.technologypublisher.com/tech?title=Novel_mouse_model_of_methylmalonic_acidemia_(MMA)_Mut-%2f-_Tg_INS-Mck-MutMethylmalonic acidemia (MMA) is an autosomal recessive disorder, caused by the deficiency of the mitochondrial enzyme methylmalonyl-CoA mutase (MUT). It is characterized by metabolic instability, multiorgan pathology, and poor prognosis for long-term survival. Deletion of Mut in mice results in neonathal lethality, thus, to overcome this limitation, we have generated novel transgenic mice that have the Mut knockout background but express the Mut gene under the control of a muscle-specific creatine kinase promoter (Mut-/- Tg INS-Mck-Mut). These animals are viable but display massive elevations...Tue, 06 Dec 2022 12:06:21 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech?title=Novel_mouse_model_of_methylmalonic_acidemia_(MMA)_Mut-%2f-_Tg_INS-Mck-MutTAB-3619https://nih.technologypublisher.com/tech/Novel_Adeno-associated_Viral_(AAV)_Vectors_to_Treat_Hereditary_Methylmalonic_Acidemia_(MMA)_Caused_by_Methylmalonyl-coA_Mutase_(MMUT)_DeficiencyDeficiency of the enzyme in methylmalonyl-CoA mutase (MMUT) results is a life-threatening disease, methylmalonic acidemia (MMA), that carries high rates of morbidity and mortality. NHGRI scientists have developed novel AAV vectors that combine the proprietary codon-optimized synMMUT alleles with either a liver-specific promoter from the human alpha-1 antitrypsin (hAA T) locus to produce a vector that directs MMUT protein expression in a liver-specific fashion or the human elongation factor 1a (EF1 alpha) promoter to produce a vector that expresses the MMUT protein at moderate levels in a glob...Tue, 06 Dec 2022 12:06:19 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Novel_Adeno-associated_Viral_(AAV)_Vectors_to_Treat_Hereditary_Methylmalonic_Acidemia_(MMA)_Caused_by_Methylmalonyl-coA_Mutase_(MMUT)_DeficiencyTAB-3618https://nih.technologypublisher.com/tech/Non-invasive_Isotopic_Biomarkers_that_Predict_the_Response_to_Liver_Directed_Therapy_in_Methymalonic_Acidemia_(MMA)_and_Propionic_Acidemia_(PA)Isolated Methylmalonic Acidemia (MMA) comprises a relatively common and heterogeneous group of inborn errors of metabolism. The most common cause of isolated MMA is genetic deficiency of the enzyme methylmalonyl-coA mutase (MUT), which, unfortunately for the affected patients, is also the most clinically severe. NHGRI scientist have invented a series of assays to assess hepatic MUT activity using a stable isotopic tracing assays to measure MUT function to assess corrective therapy on hepatic mitochondrial function. The assays involve preparation of the isotope, mixing the isotope, dosing the...Tue, 06 Dec 2022 12:06:18 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Non-invasive_Isotopic_Biomarkers_that_Predict_the_Response_to_Liver_Directed_Therapy_in_Methymalonic_Acidemia_(MMA)_and_Propionic_Acidemia_(PA)TAB-3617https://nih.technologypublisher.com/tech/Propionyl-CoA_Carboxylase_Beta_(PCCB)_Alleles_in_Propionic_Acidemia_(PA)_mouse_modelsPropionic acidemia (PA) is an autosomal recessive metabolic disorder caused by mutations in either Propionyl-CoA carboxylase alpha (PCCA) or Propionyl-CoA carboxylase beta (PCCB). The products of these genes form the alpha and beta subunits of the enzyme propionyl-Co A carboxylase (PCC), a critically important mitochondrial enzyme involved in the catabolism of branched chain amino acids. NHGRI scientist have developed new mouse models that recapitulate the human clinical phenotype of severe propionic acidemia caused by PCCB deficiency, namely neonatal lethality and increased propionyl-CoA der...Tue, 06 Dec 2022 12:06:17 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Propionyl-CoA_Carboxylase_Beta_(PCCB)_Alleles_in_Propionic_Acidemia_(PA)_mouse_modelsTAB-3616https://nih.technologypublisher.com/tech?title=Mmut_P.R106C%2fP.R106C_Knock-In_Methylmalonyl-CoA_Mutase_(Mmut)_Allele_mouse_models_for_the_Study_of_Methylmalonic_Acidemia_(MMA)Isolated Methylmalonic Acidemia (MMA) comprises a relatively common and heterogeneous group of inborn errors of metabolism. In order to create mouse models of MMA to resemble the pathogenic mutations seen in patients, the NHGRI scientist used genome editing to generate new mutants of the Mmut allele - p.R106C. This allele recapitulates a missense mutation seen in multiple patients with the disorder. Of note and emphasis is the fact that there are no transgene cassettes or other alternations to the Mmut locus in these new mouse models. These mice display elevations of MMA biomarkers, such as 2...Tue, 06 Dec 2022 12:06:16 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech?title=Mmut_P.R106C%2fP.R106C_Knock-In_Methylmalonyl-CoA_Mutase_(Mmut)_Allele_mouse_models_for_the_Study_of_Methylmalonic_Acidemia_(MMA)TAB-3615https://nih.technologypublisher.com/tech?title=Mmut_P.Pro207%24Lysl10del%2fP.Pro207%24Lysl10del_Knock-In_Methylmalonyl-CoA_Mutase_(Mmut)_Allele_Mouse_Models_for_the_Study_of_Methylmalonic_Acidemia_(MMA)Isolated Methylmalonic Acidemia (MMA) comprises a relatively common and heterogeneous group of inborn errors of metabolism. In order to create mouse models of MMA to resemble the pathogenic mutations seen in patients, the NHGRI scientist used genome editing to generate new mutants of the Mmut allele -p.Pro207 _Lys210del. In order to create mouse models of MMA to resemble the pathogenic mutations seen in patients, the NHGRI scientist used genome editing to generate new mutants of Mmut allele -p.Pro207 _Lys210del. This allele recapitulates a 12-nucleotide deletion in exon 3 of Mmut. Of note a...Tue, 06 Dec 2022 12:06:15 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech?title=Mmut_P.Pro207%24Lysl10del%2fP.Pro207%24Lysl10del_Knock-In_Methylmalonyl-CoA_Mutase_(Mmut)_Allele_Mouse_Models_for_the_Study_of_Methylmalonic_Acidemia_(MMA)TAB-3614https://nih.technologypublisher.com/tech?title=Mmut_p.G715v%2fp.G71_Knock-ln_Methylmalonyl-CoA_Mutase_(Mmut)_Allele_Mouse_Models_for_the_Study_of_Methylmalonic_Acidemia_(MMA)Isolated Methylmalonic Acidemia (MMA) comprises a relatively common and heterogeneous group of inborn errors of metabolism. In order to create mouse models of MMA to resemble the pathogenic mutations seen in patients, the NHGRI scientist used genome editing to generate new mutants of Mmut allele -p.G715V. This allele recapitulates a missense mutation seen in multiple patients with the disorder. Of note and emphasis is the fact that there are no transgene cassettes or other alternations to the Mmut locus in these new mouse models. These mice display elevations of MMA biomarkers, such as 2-meth...Tue, 06 Dec 2022 12:06:14 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech?title=Mmut_p.G715v%2fp.G71_Knock-ln_Methylmalonyl-CoA_Mutase_(Mmut)_Allele_Mouse_Models_for_the_Study_of_Methylmalonic_Acidemia_(MMA)TAB-3613https://nih.technologypublisher.com/tech/Improved_Propionyl-CoA_Carboxylase_Alpha_(PCCA)_Alleles_in_Mouse_Models_for_the_Study_of_Propionic_Acidemia_(PA)_and_its_Potential_TreatmentsPropionic acidemia (PA) is an autosomal recessive metabolic disorder caused by mutations in either PCCA or PCCB. The products of these genes form the alpha and beta subunits of the enzyme propionyl-Co A carboxylase (PCC), a critically important mitochondrial enzyme involved in the catabolism of branched chain amino acids. NHGRI scientist have developed new mouse models that more closely mimic the nature of mutations seen in patients, such as missense mutations, small insertion and deletions, splicing defects, and frameshift changes. Also, there are no rescue transgenes and the alleles are at ...Tue, 06 Dec 2022 12:06:13 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Improved_Propionyl-CoA_Carboxylase_Alpha_(PCCA)_Alleles_in_Mouse_Models_for_the_Study_of_Propionic_Acidemia_(PA)_and_its_Potential_TreatmentsTAB-3612https://nih.technologypublisher.com/tech?title=High_Concentration_Methylcobalamin_(Me-Cbl)_or_Combination_of_Methyl-_and_Hydroxocobalamin_(Me%2fOH-Cbl)_for_the_Treatment_of_Cobalamin_C_Deficiency_and_Related_DisordersCobalamin C deficiency (cblC), caused by mutations in MMACHC, is the most common inborn error of intracellular vitamin B12 metabolism. NHGRI scientist have generated a number of Mmachc knockout mouse models. The cblC mice present with early lethality, recapitulate the neurological phenotype seen in patients, and have enabled proof of concept testing with traditional hydroxocobalamin formulations and doses. The scientist have also developed a novel combination of hydroxo- and methylcobalamin, having superior performance to traditional hydroxocobalamin only treatment. The immediate use of the r...Tue, 06 Dec 2022 12:06:11 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech?title=High_Concentration_Methylcobalamin_(Me-Cbl)_or_Combination_of_Methyl-_and_Hydroxocobalamin_(Me%2fOH-Cbl)_for_the_Treatment_of_Cobalamin_C_Deficiency_and_Related_DisordersTAB-3611https://nih.technologypublisher.com/tech/Gene_Therapy_for_Cobalamin_C_Deficiency_(cblC)_with_Viable_Mouse_ModelsCobalamin C deficiency (cblC) is the most common inborn error of intracellular cobalamin metabolism and is caused by mutations in MMACHC, a gene responsible for processing and trafficking dependent enzymes: intracellular cobalamin, resulting in elevated methylmalonic acid and homocysteine and methionine deficiency. Disease manifestations include growth failure, anemia, cardial defects and progressive blindness. NHGRI scientist have generated the first viable mouse models of cblC using TALEN mediated genome editing and created two specific mutants of MMACHC that manifested the cblC-related bio...Tue, 06 Dec 2022 12:06:10 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Gene_Therapy_for_Cobalamin_C_Deficiency_(cblC)_with_Viable_Mouse_ModelsTAB-3610https://nih.technologypublisher.com/tech/Aberrant_Post-translational_Modifications_(PTMs)_in_Methyl-_and_Propionic_Acidemia_and_the_Construction_of_a_Novel_Sirtuin_(SIRT)_Gene_to_Metabolize_PTMsIsolated Methylmalonic Acidemia (MMA) and the related disorder Propionic Acidemia (PA) comprise a relatively common and heterogeneous group of inborn errors of metabolism. NHGRI scientist discovered that in isolated MMA, a novel inhibitory PTM, methylmalonyllysine, is generated and inactivates protein targets through the failure of SIRT-mediated deacylation, and identified a series of antibodies for PTM specificity. A novel acylation resistant SIRT5 was created that did not exhibit enzymatic inhibition after hyper-methylmalonylation and appears to be resistant to inhibition by nicotinamide, w...Tue, 06 Dec 2022 12:06:09 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Aberrant_Post-translational_Modifications_(PTMs)_in_Methyl-_and_Propionic_Acidemia_and_the_Construction_of_a_Novel_Sirtuin_(SIRT)_Gene_to_Metabolize_PTMsTAB-3608https://nih.technologypublisher.com/tech/Novel_Codon-Optimized_MUT_Gene_Therapeutic_for_Methylmalonic_Acidemia_(MMA)Methylmalonic Acidemia (MMA) is a metabolic disorder characterized by increased acidity in the blood and tissues due to toxic accumulation of protein and fat by-products resulting in seizures, strokes, and chronic kidney failure. A significant portion of MMA cases stem from a deficiency in a key mitochondrial enzyme, methylmalonyl-CoA mutase (MUT), required to break down amino acids and lipids. Currently, there are no treatments for MMA and the disease is managed primarily with dietary restriction of amino acid precursors and liver-kidney transplantation in severe cases. The present inventio...Tue, 06 Dec 2022 12:06:07 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Novel_Codon-Optimized_MUT_Gene_Therapeutic_for_Methylmalonic_Acidemia_(MMA)TAB-3607https://nih.technologypublisher.com/tech/Mouse_Model_of_Cobalamin_A_(cblA)_Class_Isolated_Methylmalonic_Acidemia_(MMA)_to_Study_New_TherapiesIsolated Methylmalonic Acidemia (MMA) comprises a relatively common and heterogeneous group of inborn errors of metabolism. Most affected individuals display severe multisystemic disease characterized by metabolic instability, chronic renal disease, and neurological complications. Patients with the cobalamin A (cblA) subtype of MMA can have variable presentations, spanning the full spectrum of MMA associated symptoms and pathology, yet always harbor an element of clinical and biochemical responsiveness to injectable vitamin B12. NHGRI scientist have developed a model that would allow the testi...Tue, 06 Dec 2022 12:06:06 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Mouse_Model_of_Cobalamin_A_(cblA)_Class_Isolated_Methylmalonic_Acidemia_(MMA)_to_Study_New_TherapiesTAB-3606https://nih.technologypublisher.com/tech/Creation_and_Use_of_12-LO_inhibitors_(4-((2-hydroxy-3-methoxybenzyl)amino)benzenesulfonamide_derivatives)_for_the_Treatment_of_Diabetes_and_Large_Platelet-Derived_ClotsThis technology includes the discovery and use of novel selective 12-LO (lipoxygenase) inhibitors, 4-((2-hydroxy-3-methoxybenzyl)amino)benzenesulfonamide derivatives, for attenuating large clots and for the treatment of Type 1/2 diabetes. A 12-LO inhibitor could be a potent intracellular approach to block platelets from forming large clots in response to vessel injury or activation of the coagulation pathway, either due to diabetes and/or cardiovascular disease. Blocking clot formation can significantly decrease the occurrence of myocardial infarction and death.Tue, 06 Dec 2022 12:06:05 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Creation_and_Use_of_12-LO_inhibitors_(4-((2-hydroxy-3-methoxybenzyl)amino)benzenesulfonamide_derivatives)_for_the_Treatment_of_Diabetes_and_Large_Platelet-Derived_ClotsTAB-3605https://nih.technologypublisher.com/tech/Discovery_of_Proteasome_Inhibitors_to_Target_PMP22_Gene_Expression_for_the_Treatment_of_Charcot-Marie-Tooth_Disease_Type_1AThis technology includes the use of proteasome inhibitors, such as Bortezomib, for the treatment of the most prevalent form of Charcot-Marie-Tooth disease type 1A (CMT1A). Duplication of the peripheral myelin protein 22 (PMP22) gene, normally involved in myelination of the peripheral nervous system, is the causative agent in most forms of CMT1A. A drug discovery program was initiated and found that proteasome inhibitors can be used to target PMP22.Tue, 06 Dec 2022 12:06:04 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Discovery_of_Proteasome_Inhibitors_to_Target_PMP22_Gene_Expression_for_the_Treatment_of_Charcot-Marie-Tooth_Disease_Type_1ATAB-3604https://nih.technologypublisher.com/tech/Inhibition_of_Thioredoxin_Reductase_1_(Trxr1)_by_Pyridine_Compounds_for_Cancer_TreatmentThis technology includes the use of pyridines for anticancer treatment. A common feature of cancer cells is a high level of reactive oxygen species with a concomitant increase of two antioxidative systems to combat the toxicity: the glutathione and thioredoxin systems. Inhibiting either, or both, of these systems is a promising avenue to target cancer cells. Thioredoxin Reductase 1 (Trxr1) is an important selenoprotein in the thioredoxin antioxidative system which has been implicated as a potential anti-cancer target. The inventors have found that pyridinyl sulphone compounds may achieve highl...Tue, 06 Dec 2022 12:06:03 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Inhibition_of_Thioredoxin_Reductase_1_(Trxr1)_by_Pyridine_Compounds_for_Cancer_TreatmentTAB-3603https://nih.technologypublisher.com/tech?title=Use_of_beclin_1_Inhibitors%2c_including_17-hydroxy_Wortmannin%2c_to_Treat_TRAIL-resistant_CancerThis technology includes the use of a beclin 1 inhibitor, 17-hydroxy Wortmannin, for the treatment of TRAIL-resistant colon cancer. TRAIL (TNF-related apoptosis-inducing ligand) binds to death receptors (DR4/DR5) and activates apoptosis in cancer cells. Multiple clinical trials have focused on promoting TRAIL-induced death but have had a lack of efficacy due to TRAIL resistance developing quickly in cancer cells. Recent work has found that this resistance may be mediated by a lack of activation of the apoptosis/autophagy regulator beclin 1. A compound screen was performed to find inhibitors of...Tue, 06 Dec 2022 12:06:01 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech?title=Use_of_beclin_1_Inhibitors%2c_including_17-hydroxy_Wortmannin%2c_to_Treat_TRAIL-resistant_CancerTAB-3602https://nih.technologypublisher.com/tech?title=Development_and_Use_of_O-linked_beta-N-acetylglucosamine_(O-GlcNAc)_Transferase_(OGT)_Inhibitors_for_Multiple_Conditions%2c_Including_CancerThis technology includes the development and use of small molecules that inhibit O-linked beta-N-acetylglucosamine (O-GlcNAc) transferase (OGT) for a variety of pathologies, including Alzheimer's disease, cancer, cancer, diabetes, and neurodegenerative disorders the treatment of cancer and as a potential antiviral. OGT is a ubiquitous enzyme that catalyzes the transfer of N-acetylglucosamine (GlcNAc) to the serine or threonine residues of nuclear and cytoplasmic proteins. The addition of GlcNAc to proteins is a similar post-translational modification as phosphorylation and has been described t...Tue, 06 Dec 2022 12:06:00 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech?title=Development_and_Use_of_O-linked_beta-N-acetylglucosamine_(O-GlcNAc)_Transferase_(OGT)_Inhibitors_for_Multiple_Conditions%2c_Including_CancerTAB-3601https://nih.technologypublisher.com/tech/Development_of_a_Therapy_for_the_Treatment_of_Zellweger_Spectrum_DisorderThis technology includes a method for selecting a therapeutic effective amount of one of two compounds (including naltriben and naltrin) for the treatment of Zellweger Spectrum Disorder (ZSD), or any disease associated with peroxisome dysfunction. The compounds were identified using a cell-image based high-content screening (HCS) assay to identify small molecules that enhance peroxisome assembly in immortalized skin fibroblasts obtained from a ZSD patient.Tue, 06 Dec 2022 12:05:59 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Development_of_a_Therapy_for_the_Treatment_of_Zellweger_Spectrum_DisorderTAB-3599https://nih.technologypublisher.com/tech/Repurposing_CDK_Inhibitors_for_the_Treatment_of_Zika_Virus_InfectionThis invention includes the discovery and use of a group of CDK inhibitors that were found during a drug repurposing screen designed to find compounds that inhibit Zika virus caused cell death. The identified CDK inhibitors have all previously been used in clinical trials for other diseases, potentially reducing the long time course needed for new drug discovery and development.Tue, 06 Dec 2022 12:05:58 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Repurposing_CDK_Inhibitors_for_the_Treatment_of_Zika_Virus_InfectionTAB-3598https://nih.technologypublisher.com/tech?title=Novel_ACRV1%2fALK2_Inhibitors_and_Methods_for_Inhibiting_BMP_Signaling_for_the_Treatment_of_Fibrodysplasia_Ossificans_Progressiva_(FOP)This technology includes the identification and use of novel ACRV1/ALK2 inhibitors for the treatment of fibrodysplasia ossificans progressiva (FOP), an autosomal-dominant rare disease that affects one person in every 1-2 million. FOP is characterized by malformation of the great (big) toes during embryonic development and by progressive heterotopic endochondral ossification (HEO) postnatally, which leads to the formation of a second skeleton of heterotopic bone. Individuals with the classical features of FOP have the identical heterozygous activating mutation (R206H) in the gene encoding ACRV1...Tue, 06 Dec 2022 12:05:57 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech?title=Novel_ACRV1%2fALK2_Inhibitors_and_Methods_for_Inhibiting_BMP_Signaling_for_the_Treatment_of_Fibrodysplasia_Ossificans_Progressiva_(FOP)TAB-3597https://nih.technologypublisher.com/tech/The_Use_of_Emetine_for_the_Treatment_of_SARS-CoV-2_InfectionThis technology includes the clinical use of the small compound emetine for the treatment of SARS-CoV-2. Previous work has shown that emetine has antiviral properties against some DNA and RNA viruses. It is thought that the mechanism may involve blocking protein synthesis. Work has shown that emetine has potential antiviral activity in multiple tissues that may make it suitable for the treatment of COVID-19.Tue, 06 Dec 2022 12:05:56 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/The_Use_of_Emetine_for_the_Treatment_of_SARS-CoV-2_InfectionTAB-3596https://nih.technologypublisher.com/tech?title=The_NCGC_BioPlanet%3a_A_Computational_Algorithm_to_Display_Networks_in_Three_DimensionsThis technology includes a novel computational algorithm and software implementation to map and display biological pathways and their relationship on the surface of a globe in a three-dimensional space. Currently, biological pathways and genes are represented as two-dimensional networks, which is not effective for displaying complicated relationships between pathways and genes.Tue, 06 Dec 2022 12:05:55 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech?title=The_NCGC_BioPlanet%3a_A_Computational_Algorithm_to_Display_Networks_in_Three_DimensionsTAB-3595https://nih.technologypublisher.com/tech/Repurposed_Use_of_the_Alkaloids_Emetine_and_Cephaeline_to_Treat_Zika_Virus_InfectionThis technology includes the use of two related compounds, Emetine and Cephaeline, as a potent inhibitor of the Zika virus (ZIKV). Emetine and it's analog Cephaeline were identified in a high-throughput assay aimed at identifying anti-ZIKV compounds. Both Emetine and Cephaeline are potent inhibitors of ZIKV infection in cell culture, and Emeline is a potent inhibitor of ZIKV infection in a live mouse model. These compounds were previously identified in an ipecac root crude extract which was used as a treatment for amoebic dysentery in addition to being used as an emetic agent, depending on dos...Tue, 06 Dec 2022 12:05:54 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Repurposed_Use_of_the_Alkaloids_Emetine_and_Cephaeline_to_Treat_Zika_Virus_InfectionTAB-3594https://nih.technologypublisher.com/tech?title=Creation_of_a_High-density_Screening_Format_and_the_Identification_of_Small_Molecule_Inhibitors_of_the_SIX%2fEYA_Interaction_for_the_Treatment_of_CancersThe technology includes the creation of a high-throughput assay and the identification and use of small molecules that inhibit the SIX/EYA interaction as a treatment for cancer. The Eya proteins are phosphatases that form a complex and are activated by the Six family of homeobox transcription factors. The interaction of Eya and Six mediates breast cancer cell transformation, migration, invasion and metastasis. An assay was designed to screen a large collection of compounds to identify inhibitors of the SIX/EYA interaction.Tue, 06 Dec 2022 12:05:53 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech?title=Creation_of_a_High-density_Screening_Format_and_the_Identification_of_Small_Molecule_Inhibitors_of_the_SIX%2fEYA_Interaction_for_the_Treatment_of_CancersTAB-3593https://nih.technologypublisher.com/tech?title=Identification_and_Use_of_12%2f15-Lipoxygenase_(LOX)_Inhibitors_for_Post-Strike_TreatmentThis technology includes the identification and use of 12/15-lipoxygenase (LOX) inhibitors, including ML351 and related analogs, for post-stroke treatment. The 12/15-LOX directly oxidizes lipid membranes leading to their direct attack. After a stroke, the activity of 12/15-LOX is upregulated and is thought to contribute to increased neuronal loss and blood-brain barrier leakage. A high-throughput screen was undertaken to find inhibitors, which were then subjected to medical chemistry optimization.Tue, 06 Dec 2022 12:05:52 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech?title=Identification_and_Use_of_12%2f15-Lipoxygenase_(LOX)_Inhibitors_for_Post-Strike_TreatmentTAB-3591https://nih.technologypublisher.com/tech?title=Identification_and_Use_of_a_Novel_Functionally_Selective_GHSR1a_Ghrelin_Receptor_Inhibitor%2c_including_NCGC00538279%2c_for_the_Treatment_of_Food_and_Chemical_AddictionThis technology includes a chemical series, including the NCGC00538279 compound, that selectively activates the GHSR1a G-protein pathway for calcium mobilization while only partially activating the beta-arrestin-2 translocation pathway. The resulting chemical series may be therapeutically valuable for addictive disorders. Activation of the GHSR1a G-protein pathway promotes production and secretion of multiple hormones, including insulin, growth hormone, and IGF1. Activation of the beta-arrestin-2 pathway stimulates dopamine production and may mediate addictive behaviors. Work with non-selectiv...Tue, 06 Dec 2022 12:05:51 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech?title=Identification_and_Use_of_a_Novel_Functionally_Selective_GHSR1a_Ghrelin_Receptor_Inhibitor%2c_including_NCGC00538279%2c_for_the_Treatment_of_Food_and_Chemical_AddictionTAB-3590https://nih.technologypublisher.com/tech/A_Group_of_Compounds_that_Activate_AMP-activated_protein_kinase_(AMPK)_that_may_Treat_Niemann-Pick_Disease_Type_C_(NPC)This technology relates to the identification and use of a group of compounds that activate the AMP-activated protein kinase (AMPK) and also effectively reduce lysosomal cholesterol accumulation in patients with Niemann-Pick disease Type C (NPC). Clinical trials are currently underway to determine the efficacy of beta-cyclodextrin in treating patients with NPC. A potential mechanism has been proposed indicating that beta-cyclodextrin activated AMP-activated protein kinase, leading to restoration of autophagy in cells from NPC patients. A computer modeling was used to identify the group of comp...Tue, 06 Dec 2022 12:05:48 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/A_Group_of_Compounds_that_Activate_AMP-activated_protein_kinase_(AMPK)_that_may_Treat_Niemann-Pick_Disease_Type_C_(NPC)TAB-3588https://nih.technologypublisher.com/tech?title=Treatment_of_Acute_Myeloid_Leukemia_(AML)_with_the_Multi-kinase_FLT3-IRAK1%2f4_Inhibitor%2c_NCGC1481%2c_to_Avoid_Adaptive_ResistanceThis technology includes the identification and use of a novel small molecule, NCGC1481, to inhibit both the FLT3 and IRAK1/4 kinase pathways for treating acute myeloid leukemia (AML). An activating mutation of the FMS-like receptor kinase 3 (FMT3) occurs in approximately 25% of AML cases. Consequently, FLT3 inhibitors (FLT3i) have a good initial clinical response, however patients relapse with FLT3i-resistance. This adaptive resistance following FLT3i treatment is partially conferred by activation of the IRAK1/4 kinase complex. Given the challenges of achieving multi-drug combination regimens...Tue, 06 Dec 2022 12:05:47 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech?title=Treatment_of_Acute_Myeloid_Leukemia_(AML)_with_the_Multi-kinase_FLT3-IRAK1%2f4_Inhibitor%2c_NCGC1481%2c_to_Avoid_Adaptive_ResistanceTAB-3587https://nih.technologypublisher.com/tech?title=Process_for_Practical%2c_Scalable%2c_Commercially-viable_Method_for_the_Synthesis_of_Enantio-enriched_Aminoalcohols%2c_Including_the_Novel_Antifungal_VT-1129_Used_to_Treat_Cryptococcal_MeningitisThis technology relates to the discovery and development of a practical, scalable, and commercially viable method for the synthesis of the novel antifungal VT-1129. Cryptococcal meningitis (CM) is a fungal infection that is particularly prevalent in immune-compromised patients and can be treated by VT-1129. CM has a current estimated patient population of 1-1.25 million, predominately in sub-Saharan Africa and the developing world. Several deficiencies and difficulties preclude large-scale preparation and manufacturing with previous processes, which include high cost and potential safety issue...Tue, 06 Dec 2022 12:05:46 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech?title=Process_for_Practical%2c_Scalable%2c_Commercially-viable_Method_for_the_Synthesis_of_Enantio-enriched_Aminoalcohols%2c_Including_the_Novel_Antifungal_VT-1129_Used_to_Treat_Cryptococcal_MeningitisTAB-3586https://nih.technologypublisher.com/tech?title=Discovery_of_imidazo%5b1%2c2-b%5dpyridazines_with_Anticancer_PropertiesThis technology includes a series of imidazo[1,2-b]pyridazines that display potent inhibition of FLT3, as well as potent binding and activity against FLT3 tyrosine kinase domain and gatekeeper mutations. This chemotype exhibits superior anti-leukemic activity against the common clinically-relevant FLT3-mutant acute myeloid leukemia (AML) in vitro and in vivo. Tyrosine kinase domain mutations are a common cause of acquired resistance to FLT3 inhibitors used to treat FLT3-mutant AML.Tue, 06 Dec 2022 12:05:45 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech?title=Discovery_of_imidazo%5b1%2c2-b%5dpyridazines_with_Anticancer_PropertiesTAB-3585https://nih.technologypublisher.com/tech/A_Novel_High-Throughput_Assay_for_Identifying_Zike_Virus_NS2B-NS3_Protease_InhibitorsThis invention includes a novel high-throughput assay to identify orthosteric inhibitors blocking the Zika virus NS2B-NS3 protease. Pathogenic flaviviruses, including Zika, require the NS2B-NS3 protease for viral replication. There is currently an unmet need for specific antiviral therapeutics against the Zika virus. Preliminary screening using the NCGC Pharmaceutical Collection library identified a group of drugs including temoporfin, erythrosin B, niclosamide, and nitazoxanide that can significantly inhibit the interactions between NS2B and NS3.Tue, 06 Dec 2022 12:05:44 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/A_Novel_High-Throughput_Assay_for_Identifying_Zike_Virus_NS2B-NS3_Protease_InhibitorsTAB-3584https://nih.technologypublisher.com/tech/Formulation_of_a_Modified_Stable_FGF-1_(TTHX1114)_to_Accelerate_Corneal_Endothelium_RegenerationThis technology includes the use of a novel formulation for an engineered version of Fibroblast Growth Factor 1 (FGF1), TTHX1114, that can be used to accelerate regeneration of the corneal endothelium after surgical lesions. FGFs are well-established regulators of migration and proliferation of corneal endothelial cells (CECs).Tue, 06 Dec 2022 12:05:43 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Formulation_of_a_Modified_Stable_FGF-1_(TTHX1114)_to_Accelerate_Corneal_Endothelium_RegenerationTAB-3583https://nih.technologypublisher.com/tech?title=Use_of_the_Ketamine_Metabolite_(R%2c6R)-hydroxynorketamine_in_DepressionThis technology includes the identification and use of a ketamine metabolite, (2R,6R)-2-amino-2-(2-chlorophenyl)-6-hydroxycyclohexanone (HNK), for the treatment of depression. Ketamine is an NMDA receptor antagonist that exerts a rapid and sustained antidepressant and anti-suicidal effect. However, even low doses of ketamine has addictive and psychomimetic effects. The downstream metabolite, (2R,6R)-HNK, does not inhibit the NMDA receptor but recapitulates the antidepressant and anti-suicidal effect of ketamine. Further clinical work could establish a ketamine metabolite, such as (2R,6R)-HNK, ...Tue, 06 Dec 2022 12:05:42 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech?title=Use_of_the_Ketamine_Metabolite_(R%2c6R)-hydroxynorketamine_in_DepressionTAB-3582https://nih.technologypublisher.com/tech/Treatment_of_primary_hyperoxalurias_with_small_molecule_lactate_dehydrogenase_inhibitors_such_as_WO2018005807A1This technology includes the use of novel lactate dehydrogenase (LDH) inhibitors, including WO2018005807A1, for the treatment of primary hyperoxalurias (PHs). PHs are rare autosomal recessive disorders caused by overproduction of oxalate, leading to recurrent calcium oxalate kidney stone disease, and in some cases end-stage renal disease. One potential strategy to treat PHs is to reduce the production of oxalate by diminishing the activity of LDH, the proposed key enzyme responsible for converting glyoxylate to oxalate. Biochemical and cell-based assays were used to identify and characterize n...Tue, 06 Dec 2022 12:05:41 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Treatment_of_primary_hyperoxalurias_with_small_molecule_lactate_dehydrogenase_inhibitors_such_as_WO2018005807A1TAB-3581https://nih.technologypublisher.com/tech/Patient-derived_induced_pluripotent_stem_cell_(iPSC)_lines_for_the_study_of_lysosomal_storage_diseases_(LSDs)This technology includes the generation and use of human induced pluripotent stem cell (iPSC) lines that can be used to study and screen potential therapeutics for lysosomal storage diseases (LSDs). LSDs are a group of 50 genetic disorders caused by mutations in the genes encoding lysosomal enzymes and proteins. Although various therapeutic approaches exist, most cases of LSDs are not effectively treated due to a lack of therapeutics (including stem cells and recombinant proteins). The iPSC lines in this technology were generated from patient fibroblasts that were differentiated into neural st...Tue, 06 Dec 2022 12:05:40 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Patient-derived_induced_pluripotent_stem_cell_(iPSC)_lines_for_the_study_of_lysosomal_storage_diseases_(LSDs)TAB-3580https://nih.technologypublisher.com/tech/Creation_and_Use_of_Kinetin_Derivatives_for_Treating_RNA_Missplicing_Diseases_Such_as_Familial_DysautonomiaThis technology includes the creation and use of compounds, including kinetin derivatives, that improve mRNA splicing in a cell for the treatment of disorders associated with misspliced mRNA, including familial dysautonomia (FD). FD, the best-known and most common member of a group of congenital sensory and autonomic neuropathies, affects neuronal development and is associated with progressive neuronal degeneration. This disease is caused by mutations in the splicing of intron 20 of the IKMKAP gene that results in a unique pattern of tissue-specific exon skipping.Tue, 06 Dec 2022 12:05:39 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Creation_and_Use_of_Kinetin_Derivatives_for_Treating_RNA_Missplicing_Diseases_Such_as_Familial_DysautonomiaTAB-3578https://nih.technologypublisher.com/tech/A_Cell_Line_that_Expresses_secNluc_and_GFP_to_Recapitulate_PMP22_Gene_Expression_for_Studying_Peripheral_NeuropathyThis technology includes a cell line that expresses two reporters (a secreted luciferase, secNLuc, and GFP) in a pattern that recapitulates the endogenous expression of the peripheral myelin protein 22 (Pmp22) gene. Pmp22 is mainly expressed in the Schwann cells of the peripheral nervous system. Many neurological disorders are associated with aberrations in Schwann cells, including the most common inherited peripheral neuropathy known as Charcot-Marie-Tooth (CMT) disease. This cell line will permit the study of the regulatory elements behind the gene.Tue, 06 Dec 2022 12:05:38 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/A_Cell_Line_that_Expresses_secNluc_and_GFP_to_Recapitulate_PMP22_Gene_Expression_for_Studying_Peripheral_NeuropathyTAB-3577https://nih.technologypublisher.com/tech/Sensor_for_Real-time_Detection_of_Plasma_Metabolites_Levels_for_the_Diagnosis_and_Care_of_Metabolic_DisordersThis technology includes the development of devices capable of real-time evaluation of metabolite levels for the treatment of numerous metabolic disorders, including hyperammonemia and aminoacidopathies. Currently, the monitoring of metabolite levels is done in a hospital setting with specialized mass spectrometry instrumentation. As a consequence, susceptible patients who are undergoing a crisis need to visit the hospital for testing to determine if there is a metabolite disturbance. The development of a device, including an electrode with immobilized enzymes, could transform the care of thes...Tue, 06 Dec 2022 12:05:37 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Sensor_for_Real-time_Detection_of_Plasma_Metabolites_Levels_for_the_Diagnosis_and_Care_of_Metabolic_DisordersTAB-3576https://nih.technologypublisher.com/tech?title=Small_Molecule_Inhibitors_of_the_p53%2fS100B_Interaction_for_Treating_CancerThis technology includes newly identified best-in-class inhibitors of the p53-S100B interaction that plays a role in malignant melanoma. S100B contributes to cancer cell proliferation (particularly malignant melanoma) by binding to p53 and inhibiting its tumor suppressor function. A high-throughput screen was used to find p53-S100B inhibitors, leading to the identification of a putative inhibitor, which was then subjected to medicinal chemistry optimization. Structure-based design was then used to develop compounds with significantly improved potency.Tue, 06 Dec 2022 12:05:36 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech?title=Small_Molecule_Inhibitors_of_the_p53%2fS100B_Interaction_for_Treating_CancerTAB-3575https://nih.technologypublisher.com/tech/A_Novel_Chemical_Series_for_Inhibiting_Bromodomain-containing_Protein_4_(BRD4)_for_Treating_CancerThis technology includes the design, synthesis, and use of a novel chemical series for multiple treatments, including for treating cancer. A series of substituted bicyclic heteroaryl small molecules were found to be a potent inhibitor of bromodomain-containing protein 4 (BRD4) for multiple uses, including cancer. A BRD4 inhibitor is in a class of drugs known as BET inhibitors that are used broadly as anti-inflammatories and as anti-cancer agents. The chemical series exhibited less hepatocyte toxicity compared to existing treatments. For example, the series also identified N-methyl 2-pyridone 1...Tue, 06 Dec 2022 12:05:35 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/A_Novel_Chemical_Series_for_Inhibiting_Bromodomain-containing_Protein_4_(BRD4)_for_Treating_CancerTAB-3558https://nih.technologypublisher.com/tech/Identification_and_Use_of_Heterocyclic_Alcohol_Compounds_for_the_Treatment_of_SULT1A1-expressing_Cancers1,000 caner cell lines identified a compound called YC-1 (also called Lificiguat) that is effective across cancer cell types that express the phase 2 detoxifying enzyme SULT1A1.]]>Tue, 06 Dec 2022 12:05:33 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Identification_and_Use_of_Heterocyclic_Alcohol_Compounds_for_the_Treatment_of_SULT1A1-expressing_CancersTAB-3497https://nih.technologypublisher.com/tech/Rapid_and_Robust_Differentiation_of_Human_iPSCs_into_Motor_NeuronsThis technology includes a system that allows for robust differentiation of human-induced pluripotent stem cells (iPSC) into motor neurons within a time frame of 7 to 10 days. To differentiate the iPSC, a stable transgene is inserted into the CLYBL safe harbor locus in the human genome using TALENs. The transgene allows for doxycycline-inducible expression of the transcription factors (NGN2, ISL1, and LHX3) that are needed for the cells to differentiate to motor neurons. The technology is described in detail in the protocol paper published by Fernandopulle et al, cited below. We knocked in a d...Tue, 06 Dec 2022 12:05:25 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Rapid_and_Robust_Differentiation_of_Human_iPSCs_into_Motor_NeuronsTAB-3496https://nih.technologypublisher.com/tech/Potentiating_Antibody_Therapy_by_Targeting_Complement_Deposited_on_Cancer_CellsMonoclonal antibodies (mAbs) have become a mainstay of therapy for many cancers. However, antibody therapy is not completely effective in some applications due to loss of the target surface antigen on cancer cells. Such mAb-induced “escape variants” are no longer sensitive to the therapeutic mAb therapy. It was observed that the escape variants carried covalently bound complement activation fragments, especially C3d. NIH inventors have generated several C3d-specific mouse and rabbit monoclonal antibodies to re-target cells that have escaped from mAb therapy. Proof of principle for this “one-t...Tue, 06 Dec 2022 12:05:24 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Potentiating_Antibody_Therapy_by_Targeting_Complement_Deposited_on_Cancer_CellsTAB-3482https://nih.technologypublisher.com/tech/Monoclonal_Antibodies_To_Prevent_or_Treat_SARS-CoV-2_InfectionThe ongoing COVID-19 pandemic, caused by severe respiratory syndrome coronavirus 2 (SARS-CoV-2), has created an immense public health, social, and economic burden. Variants of concern continue to emerge that have increased transmissibility, pathogenicity, or both and that reduce the effectiveness of current therapeutics and vaccines. Thus, there is a great need for broadly protective therapeutics. This technology relates to two monoclonal antibodies targeting the spike protein of SARS-CoV-2 that between the two have picomolar activity against wild-type SARS-CoV-2 and the Alpha, Beta, Delta, an...Tue, 06 Dec 2022 12:05:22 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Monoclonal_Antibodies_To_Prevent_or_Treat_SARS-CoV-2_InfectionTAB-3480https://nih.technologypublisher.com/tech/Development_of_a_Polyclonal_Antibody_for_Neuroligin_4_pThr707_and_a_Polyclonal_Antibody_for_Neuroligin_1_pTHR739This invention includes the generation and use of two polyclonal antibodies that specifically recognizes the phosphorylation site pThr707 of Neuroligin 4 and pThr739 of Neuroligin 1. A peptide of the site around the phosphorylation site was generated and injected into rabbits to create an immune response. Serum was collected from the rabbits that was then affinity purified. The specificity of the resulting polyclonal antibodies was then determined using biochemical techniques.Tue, 06 Dec 2022 12:05:21 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Development_of_a_Polyclonal_Antibody_for_Neuroligin_4_pThr707_and_a_Polyclonal_Antibody_for_Neuroligin_1_pTHR739TAB-3479https://nih.technologypublisher.com/tech/A_Device_to_Measure_Force_Continuously_During_Handgrip_Contraction_and_Relaxation_for_Myotonic_DystrophiesThis invention relates to two devices that reliably, sensitively, and accurately measures force during handgrip contraction and subsequent relaxation. A delayed relaxation after a sustained and forceful handgrip is a cardinal symptom of myotonic dystrophies (DM). This delayed relaxation, handgrip myotonia, may be a therapeutic response biomarker in clinical trials. The Hand Clasp Load Cell Device is an assembly of an upper piece to be held between the fingers and palm and a lower palmar piece embedded with force sensing transducers to measure grip strength and relaxation time. The accompanyin...Tue, 06 Dec 2022 12:05:20 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/A_Device_to_Measure_Force_Continuously_During_Handgrip_Contraction_and_Relaxation_for_Myotonic_DystrophiesTAB-3481https://nih.technologypublisher.com/tech?title=OASIS%3a_Automated_brain_lesion_detection_using_cross-sectional_multimodal_magnetic_resonance_imagingThis invention is a novel statistical method for automatically detecting lesions in cross-sectional brain magnetic resonance imaging (MRI) studies. OASIS uses multimodal MRI from one image acquisition session and produces voxel-level probability maps of the brain that quantifies the likelihood that each voxel is part of a lesion. Binary lesion segmentations are created from these probability maps using a validated population-level threshold. In this application, fluid attenuated inversion recovery (FLAIR), proton density (PD), T2-weighted, and Tl-weighted volumes were used. The OASIS lesion se...Tue, 06 Dec 2022 12:05:19 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech?title=OASIS%3a_Automated_brain_lesion_detection_using_cross-sectional_multimodal_magnetic_resonance_imagingTAB-3456https://nih.technologypublisher.com/tech/Tumor_Associated_Calcium_Signal_Transducer_2_(TACSTD2)-Overexpressing_Huh7.5_Cells_That_Are_More_Permissive_to_HCV_Cell_Entry_and_Replication_Compared_to_the_Model_Huh7.5_Cell_LineWorldwide, 130-150 million individuals are chronically infected with hepatitis C virus (HCV), a major cause of liver-associated morbidity and mortality worldwide. Despite recent advances in antiviral drugs that can cure some individuals, a rapid decline of the global disease burden is hampered by remarkably high treatment costs and a high number of undiagnosed infections. Moreover, a significant number of patients develop resistance and additional treatment modalities may be needed to dramatically reduce the worldwide incidence of HCV infection. The subject cell line may be a useful tool for s...Tue, 06 Dec 2022 12:05:16 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Tumor_Associated_Calcium_Signal_Transducer_2_(TACSTD2)-Overexpressing_Huh7.5_Cells_That_Are_More_Permissive_to_HCV_Cell_Entry_and_Replication_Compared_to_the_Model_Huh7.5_Cell_LineTAB-3459https://nih.technologypublisher.com/tech/Novel_VAR2CSA_Immunogens_and_Methods_of_Use_ThereofThe invention provides immunogen polypeptides comprising fragments of VAR2CSA protein expressed by P. falciparum as potential second-generation placental malaria vaccine candidates. VAR2CSA is the leading antigen target for a placental malaria vaccine, where associated antibody titers are correlated with protection. Aspects of the inventive immunogen polypeptides comprise all or portions of the chondroitin sulfate A (CSA) binding regions of VAR2CSA, as identified by a structural study of VAR2CSA conducted by the inventors, that possess great sequence conservation among P. falciparum strains wh...Tue, 06 Dec 2022 12:05:15 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Novel_VAR2CSA_Immunogens_and_Methods_of_Use_ThereofTAB-3455https://nih.technologypublisher.com/tech/Pre-Biotic_Formulation_of_Topical_Chemicals_for_Use_on_Human_SkinAtopic dermatitis (AD) is a common, recurrent, chronic inflammatory skin disease that is a cause of considerable economic and social burden. It is one of the most prevalent skin disorders, affecting ~25% of children in developed and developing countries and is expected to continue to escalate. This increased rate of incidence has changed the focus of research on AD toward epidemiology, prevention, and treatment. Scientists at NIAID have developed novel topical formulations that promote the growth of health-associated strains of commensal bacteria and inhibit disease-associated bacteria, thereb...Tue, 06 Dec 2022 12:05:14 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Pre-Biotic_Formulation_of_Topical_Chemicals_for_Use_on_Human_SkinTAB-3454https://nih.technologypublisher.com/tech/Mononegavirales_Vectors_Expressing_Chimeric_AntigensHuman respiratory syncytial virus (RSV) continues to be the leading viral cause of severe acute lower respiratory tract disease in infants and children worldwide, and also is an important cause of morbidity and mortality in the elderly. A licensed vaccine or antiviral drug suitable for routine use remains unavailable. This invention relates to the use of murine pneumonia virus (MPV—previously known as pneumonia virus of mice, PVM—of family Pneumovirida e) as a vaccine vector expressing the RSV fusion protein F, the most important protective antigen of RSV. MPV is not a human pathogen and is no...Tue, 06 Dec 2022 12:05:13 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Mononegavirales_Vectors_Expressing_Chimeric_AntigensTAB-3449https://nih.technologypublisher.com/tech?title=Recombinant_Chimeric_Bovine%2fHuman_Parainfluenza_Virus_3_Expressing_SARS-CoV-2_Spike_Protein_and_Its_UseVaccines for SARS-CoV-2 are increasingly available under emergency use authorizations; however, indications are currently limited to individuals twelve (12) years or older. They also involve intramuscular immunization, which does not directly stimulate local immunity in the respiratory tract, the primary site of SARS-CoV-2 infection, shedding and spread. While the major burden of COVID-19 disease is in adults, infection and disease also occur in infants and young children, contributing to viral transmission. Therefore, the development of safe and effective pediatric COVID-19 vaccines is import...Tue, 06 Dec 2022 12:05:12 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech?title=Recombinant_Chimeric_Bovine%2fHuman_Parainfluenza_Virus_3_Expressing_SARS-CoV-2_Spike_Protein_and_Its_UseTAB-3448https://nih.technologypublisher.com/tech/Human_Monoclonal_and_Bispecific_Antibodies_Targeting_SARS-CoV-2_CoronavirusSARS-CoV-2 is a virus of the Coronavirus family that has emerged as a major public health concern. The first cases of SARS-CoV-2 were reported in China and rapidly spread worldwide leading to a global pandemic. The highest morbidity and mortality have been reported in the elderly and immunocompromised. Antibody therapeutics have great importance for advanced cases of SARS-CoV-2 where a vaccine would not be effective and may be more effective than a vaccine in certain high-risk populations. Scientists at NIAID have developed recombinant monoclonal antibodies that are effective in vitro and in ...Tue, 06 Dec 2022 12:05:11 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Human_Monoclonal_and_Bispecific_Antibodies_Targeting_SARS-CoV-2_CoronavirusTAB-3437https://nih.technologypublisher.com/tech?title=Improved_Live-Attenuated_Vaccine_for_Respiratory_Syncytial_Virus_(RSV)_Bearing_Codon-Pair_Deoptimized_NS1%2c_NS2%2c_N%2c_P%2c_M_and_SH_Genes_and_Additional_Point_Mutations_in_the_P_GeneRSV is the most important viral agent of severe respiratory disease in infants and young children worldwide and also causes substantial morbidity and mortality in older adults. RSV is estimated to cause more than 33 million lower respiratory tract illnesses, three million hospitalizations, and nearly 200,000 childhood deaths worldwide annually, with many deaths occurring in developing countries. However, despite the prevalence of RSV and the dangers associated with infection, no RSV vaccine has been successfully developed to date. Accordingly, there is a public health need for RSV vaccines. Th...Tue, 06 Dec 2022 12:05:09 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech?title=Improved_Live-Attenuated_Vaccine_for_Respiratory_Syncytial_Virus_(RSV)_Bearing_Codon-Pair_Deoptimized_NS1%2c_NS2%2c_N%2c_P%2c_M_and_SH_Genes_and_Additional_Point_Mutations_in_the_P_GeneTAB-3431https://nih.technologypublisher.com/tech/Epstein-Barr_Virus_Antibody_That_Blocks_Fusion_And_Neutralizes_Virus_Infection_of_B_CellsEpstein-Barr virus (EBV) is the most common cause of infectious mononucleosis and is associated with nearly 200,000 cancers and 140,000 deaths each year. EBV-associated cancers include Hodgkin's lymphoma, non-Hodgkin's lymphoma, Burkitt B cell lymphoma, and EBV post-transplant lymphoproliferative disease. The latent reservoir for EBV in the body is the B lymphocyte. Thus, blocking B cell infection is important for reducing EBV-related disease. EBV can infect both B cells and epithelial cells; however, the method of entry differs between these two cell types. To initiate B cell infection, EBV g...Tue, 06 Dec 2022 12:05:07 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Epstein-Barr_Virus_Antibody_That_Blocks_Fusion_And_Neutralizes_Virus_Infection_of_B_CellsTAB-3436https://nih.technologypublisher.com/tech/Reducing_Bloodstream_Neutrophils_as_a_Treatment_for_Lung_Infection_and_InflammationDuring lung infection, bloodstream neutrophils (PMNs) responding to infection travel to the airspace lumen. Although successful arrival of microbicidal PMNs to the airspace is essential for host defense against inhaled pathogens, excessive accumulation of PMNs in the lung contributes to the pathogenesis of several prevalent lung disorders, including acute lung injury, bronchiectasis, and COPD. Unfortunately, there is no treatment for controlling PMN accumulation in the lung. NIEHS researchers identified epithelial membrane protein 2 (EMP2) as a lung epithelial protein that regulates PMN entry ...Tue, 06 Dec 2022 12:05:05 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Reducing_Bloodstream_Neutrophils_as_a_Treatment_for_Lung_Infection_and_InflammationTAB-3428https://nih.technologypublisher.com/tech/COMBINATION_THERAPIES_FOR_COVID-19_(SARS-COV-2)The coronavirus disease 2019 (COVID-19) is caused by a novel RNA enveloped coronavirus, SARS-CoV-2 when the virus enters human airway cells via an ACE2-mediated entry process. This entry pathway is facilitated by the cell surface heparan sulfate proteoglycan (HSPG), which enhances viral attachment to the cell surface. Researchers at NIDDK and NCATS have discovered a collection of FDA-approved drugs that can interfere with the entry of SARS-CoV-2. These drugs can be grouped into three classes based on the distinct steps in the viral entry pathway that they target. Specifically, Mitoxantrone,...Tue, 06 Dec 2022 12:05:04 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/COMBINATION_THERAPIES_FOR_COVID-19_(SARS-COV-2)TAB-3427https://nih.technologypublisher.com/tech/High-Throughput_COVID-19_Diagnostic_Test_that_Detects_Both_Viral_and_Host_Nucleic_AcidThe rapid worldwide spread and impact of COVID-19 caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has created a need for accurate, reliable, and readily accessible testing on a massive scale. NIEHS researchers developed a massively paralleled multiplexed screening method using next generation sequencing (NGS). This method uses sample-specific barcoded indexes that detect both SARS-COV-2 virus and the host’s transcriptional response to infection simultaneously. By matching existing laboratory protocols for PCR-based sample processing, this assay is easily incorporated i...Tue, 06 Dec 2022 12:05:03 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/High-Throughput_COVID-19_Diagnostic_Test_that_Detects_Both_Viral_and_Host_Nucleic_AcidTAB-3417https://nih.technologypublisher.com/tech/A_method_to_label_heparan_sulfate_proteoglycan_in_the_plasma_membrane_of_mammalian_cellsHeparan sulfate proteoglycan (HSPG) is a group of lipid-anchored proteoglycans, engaged in a variety of key biological functions on cell surface. HSPG-mediated endocytosis of neurotoxic protein aggregates has been linked to aging related neurodegenerative diseases. Labeling HSPG is a promising technique to trace cell profile in cell research, monitor its trafficking in live cells and in tissues. Researchers at the NIDDK have discovered a method in which a positively charged fluorescent protein binds specifically to HSPG on cell surface. This is a promising cost-effective technique that will he...Tue, 06 Dec 2022 12:05:01 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/A_method_to_label_heparan_sulfate_proteoglycan_in_the_plasma_membrane_of_mammalian_cellsTAB-3390https://nih.technologypublisher.com/tech/Therapeutic_and_Diagnostic_Targets_for_Severe_RSV_InfectionRespiratory Syncytial Virus (RSV) infects nearly all children by their second birthday. RSV usually causes mild respiratory illness, however, a subset of patients experience severe infection that require hospitalization. Successful host defense against viral pathogens requires rapid recognition of the virus and activation of both innate and adaptive immunity. Toll-Like Receptors (TLRs) are responsible for mounting an innate immune response and genetic variations within TLRs modulate severity of infection. Researchers at NIEHS have identified a single nucleotide polymorphism (SNP) in TLR8 that ...Tue, 06 Dec 2022 12:04:58 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Therapeutic_and_Diagnostic_Targets_for_Severe_RSV_InfectionTAB-3384https://nih.technologypublisher.com/tech/Real-Time_PCR_Assay_for_HIV-1_Subtype_Diagnosis_and_Global_Surveillance_of_Drug_ResistanceCDC researchers have developed a patented set of RT-PCR and sequencing primers based on HIV-1 group M sequences. Evaluation of the primers using samples collected around the world demonstrated broad detection capacity for multiple HIV-1 group subtypes and predominant circulating recombinant forms. Commercially available HIV-1 drug resistance (HIVDR) genotyping assays are expensive and have limited ability to detect non-B subtypes. This optimized assay is broadly sensitive in genotyping HIV-1 group M viral strains and more sensitive than other assays in detecting mixed viral populations. This t...Tue, 06 Dec 2022 12:04:56 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Real-Time_PCR_Assay_for_HIV-1_Subtype_Diagnosis_and_Global_Surveillance_of_Drug_ResistanceTAB-3381https://nih.technologypublisher.com/tech?title=Potent_Nucleotide_Inhibitors_of_Ecto-5%27-Nucleotidase_(CD73)These small molecules are novel nucleotide derivatives, containing either a purine or pyrimidine nucleobase, that competitively block the enzyme CD73, also known as ecto-5'-nucleotidase. This enzyme converts extracellular AMP (not a potent activator of adenosine receptors) to adenosine (the native activator of 4 subtypes of adenosine receptors. CD73 inhibitors are being used, in clinical trials and preclinical research, in conjunction with cancer immunotherapy. CD73 is upregulated around tumors to produce excessive adenosine, and blocking this enzyme greatly reduces immunosuppressive adenosine...Tue, 06 Dec 2022 12:04:54 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech?title=Potent_Nucleotide_Inhibitors_of_Ecto-5%27-Nucleotidase_(CD73)TAB-3303https://nih.technologypublisher.com/tech/A_Novel_Reagent_for_Labeling_PET_Tracers_at_Trifluoromethyl_GroupsThe molecular imaging technique of positron emission tomography (PET) is an increasingly important tool in biomedical research and in drug discovery and development. Many small molecule drugs and potential PET radiotracers carry trifluoromethyl (CF3) groups. Because CF3 groups are generally considered to be metabolically stable, there is a strong interest in developing drugs with these groups. This invention describes a novel method and apparatus for producing no-carrier added [11C]fluoroalkanes, which can be used as labeling agents for PET radiotracers at CF3 groups. Prior to this technology,...Tue, 06 Dec 2022 12:04:47 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/A_Novel_Reagent_for_Labeling_PET_Tracers_at_Trifluoromethyl_GroupsTAB-3290https://nih.technologypublisher.com/tech/Edema_Factor_Adenylate_Cyclase_Variants_Having_Potencies_That_Are_Highly_Dependent_On_the_N-end_RuleB. anthracis strains BH480; plasmids encoding anthrax edema factor (EF) variants pSJ136EFOS, pSJ 136EFA and pSJ 136EFR.Tue, 06 Dec 2022 12:04:45 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Edema_Factor_Adenylate_Cyclase_Variants_Having_Potencies_That_Are_Highly_Dependent_On_the_N-end_RuleTAB-3289https://nih.technologypublisher.com/tech?title=Polyclonal_and_Monoclonal_Antibodies_to_Human_Eosinophil_Major_Basic_Protein%2c_Eosinophil_Peroxidase%2c_Eosinophil_Cationic_Protein%2c_and_Eosinophil-Derived_NeurotoxinReagents particularly useful in configuring multiplex assays for simultaneous measurement and quantification of multiple eosinophil granule proteins and for immunohistochemistry. Ultimately these reagents may be used as diagnostics for many eosinophil-mediated disorders.Tue, 06 Dec 2022 12:04:44 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech?title=Polyclonal_and_Monoclonal_Antibodies_to_Human_Eosinophil_Major_Basic_Protein%2c_Eosinophil_Peroxidase%2c_Eosinophil_Cationic_Protein%2c_and_Eosinophil-Derived_NeurotoxinTAB-3288https://nih.technologypublisher.com/tech/WR_(Western_Reserve)_Strain_of_Vaccinia_Virus_with_K151E_Mutation_in_A34R_GeneMutation in gene A34R can regulate the release of progeny virions from the surface of parental cells.Tue, 06 Dec 2022 12:04:43 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/WR_(Western_Reserve)_Strain_of_Vaccinia_Virus_with_K151E_Mutation_in_A34R_GeneTAB-3283https://nih.technologypublisher.com/tech?title=Resurfaced_Stabilized_Core_3_(RSC3)_Protein%2c_Derived_Proteins%2c_and_DNA_Encoding_These_Proteins%3a_RSC3%2c_RSC3_delta371I%2c_RSC3_delta371I%2fP363N%2c_RSC3_G367RTue, 06 Dec 2022 12:04:39 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech?title=Resurfaced_Stabilized_Core_3_(RSC3)_Protein%2c_Derived_Proteins%2c_and_DNA_Encoding_These_Proteins%3a_RSC3%2c_RSC3_delta371I%2c_RSC3_delta371I%2fP363N%2c_RSC3_G367RTAB-3281https://nih.technologypublisher.com/tech?title=Expression%2c_Purification%2c_and_Validation_of_Anthrax_Toxin_ProteinsExpression, purification, and validation of anthrax toxin proteins.Tue, 06 Dec 2022 12:04:38 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech?title=Expression%2c_Purification%2c_and_Validation_of_Anthrax_Toxin_ProteinsTAB-3280https://nih.technologypublisher.com/tech/CCR9_Knockout_MiceCcr9-/- mice may be useful for studying the role of CCR9 in T lymphocyte development and migration. Mice will be distributed by The Jackson Laboratory; details about this mouse strain (Stock No. 027041) may be found at https://www.jax.org/strain/027041.Tue, 06 Dec 2022 12:04:37 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/CCR9_Knockout_MiceTAB-3279https://nih.technologypublisher.com/tech?title=Amino_Acid_Substitutions_Mutants_of_Anthrax_Protective_Antigen%2c_Lethal_Factor%2c_and_Edema_FactorAnthrax toxin proteins available for licensing. Bacillus anthracis hosts containing plasmids expressing the following proteins are available. (Host strains are generally BH480, or sometimes BH460. Modest amounts of purified proteins (10-50 mg) could also be provided): PA. Protective antigen, wild type PA-3M (PA D683A, L685E, Y688K) PA-3M Cys PA-U7 PA F427A PA K563C PA L687A PA-U7 K562C PA D512K PA GN PA-3M SoSi-H6 FP59-AGG EF-A K313R LFn-linker-Cys LF E687A LFnBLA LFnFLA Tue, 06 Dec 2022 12:04:36 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech?title=Amino_Acid_Substitutions_Mutants_of_Anthrax_Protective_Antigen%2c_Lethal_Factor%2c_and_Edema_FactorTAB-3278https://nih.technologypublisher.com/tech?title=RL-5_%e2%80%93_Rabbit_T_Cell_Line_Derived_From_a_Herpesvirus_Ateles-induced_Rabbit_Tumor_From_the_Inbred_Rabbit_Line_B%2fJTue, 06 Dec 2022 12:04:35 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech?title=RL-5_%e2%80%93_Rabbit_T_Cell_Line_Derived_From_a_Herpesvirus_Ateles-induced_Rabbit_Tumor_From_the_Inbred_Rabbit_Line_B%2fJTAB-3266https://nih.technologypublisher.com/tech/Potential_New_Drugs_for_Treating_or_Preventing_PruritusNIH scientists have identified new compositions that could potentially be used to treat or prevent pruritus (itchiness). The newly discovered compounds can block a newly identified itch pathway and might be effective for persistent itch caused by psoriasis, atopic dermatitis, renal failure, liver cirrhosis and chemotherapy. These compounds are different from commonly used antihistamines which induce drowsiness and sedation. These compounds have the potential to be used for human and animals.Tue, 06 Dec 2022 12:04:33 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Potential_New_Drugs_for_Treating_or_Preventing_PruritusTAB-3265https://nih.technologypublisher.com/tech/Novel_Magnetic_Resonance_Spectroscopy_(MRS)_Technique_to_Quantify_Brain_MetabolitesWith respect to quantification of metabolites in the brain, conventional methods of magnetic resonance spectroscopy (MRS) yield results that are highly variable and highly dependent on the sequence type being applied. This invention describes a novel MRS technique that involves preparing longitudinal steady states at different flip angles using trains of RF pulses interspersed with field gradients to quantify metabolites. The method allows quantification of metabolites and their relaxation rates under specified parameters, which may create new ways of analyzing and interpreting tissue properti...Tue, 06 Dec 2022 12:04:31 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Novel_Magnetic_Resonance_Spectroscopy_(MRS)_Technique_to_Quantify_Brain_MetabolitesTAB-3264https://nih.technologypublisher.com/tech/Inner_Curvature_Charge_Concentration_Device_for_Tissue_LacerationLeft ventricular outflow tract obstruction is a life-threatening complication of transcatheter mitral valve replacement caused by septal displacement of the anterior mitral leaflet (AML). The AML is a mobile structure that physically separates inflow and outflow zones of the left ventricle. Preserving the AML during surgical mitral valve replacement can cause left ventricular outflow tract obstruction, either when the prosthesis struts protrude into the left ventricular outflow tract or when along redundant anterior leaflet prolapses into the left ventrical outflow tract. The invention relates...Tue, 06 Dec 2022 12:04:30 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Inner_Curvature_Charge_Concentration_Device_for_Tissue_LacerationTAB-3274https://nih.technologypublisher.com/tech/Non-invasive_Method_for_Ebola_Virus_Infection_Detection_in_Great_Apes_and_Other_Wildlife_HostsEbola virus surveillance in wildlife vectors of infection transmission to humans.Tue, 06 Dec 2022 12:04:29 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Non-invasive_Method_for_Ebola_Virus_Infection_Detection_in_Great_Apes_and_Other_Wildlife_HostsTAB-3273https://nih.technologypublisher.com/tech/Recombinant_LL-SXP-1_and_Plasmid_Encoding_LL-SXP-1_for_the_Immunodiagnosis_of_Loa_LoaA Loa loa specific antigen that can be used as the basis of an immunoassay for the diagnosis of Loa loa infection.Tue, 06 Dec 2022 12:04:28 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Recombinant_LL-SXP-1_and_Plasmid_Encoding_LL-SXP-1_for_the_Immunodiagnosis_of_Loa_LoaTAB-3261https://nih.technologypublisher.com/tech/Prefusion_Coronavirus_Spike_Proteins_and_Their_UseCoronaviruses (CoVs) can cause severe respiratory disease with high fatality rates in humans. The 2002-2003 SARS-CoV epidemic resulted in 8098 cases and 744 deaths, and MERS-CoV, which emerged in 2012, has resulted in 2144 cases and over 750 deaths as of March 2018. Currently, there are no effective prophylactic or therapeutic measures, and because other CoVs are poised to emerge as new human pathogens, there is a need to define a general CoV vaccine solution. Past efforts to develop CoV vaccines have used whole-inactivated virus, live-attenuated virus, recombinant protein subunit, or genetic ...Tue, 06 Dec 2022 12:04:26 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Prefusion_Coronavirus_Spike_Proteins_and_Their_UseTAB-3260https://nih.technologypublisher.com/tech/Novel_Multivalent_Nanoparticle_VaccinesCurrent seasonal influenza vaccines are designed to elicit immunity to circulating strains of influenza each year. The targeted strains are selected based on predictions of which strains are likely to be predominant in the human population for a given year. This prediction must be made well ahead of the influenza season to allow time for vaccine production and can be inaccurate. Scientists at NIAID's Vaccine Research Center are developing an alternative approach for design and production of seasonal influenza vaccines. The design includes recombinant fusion proteins that self-assemble into nan...Tue, 06 Dec 2022 12:04:25 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Novel_Multivalent_Nanoparticle_VaccinesTAB-3259https://nih.technologypublisher.com/tech/Mononegavirales_Vectors_expressing_Chimeric_AntigensHuman respiratory syncytial virus (RSV) continues to be the leading viral cause of severe acute lower respiratory tract disease in infants and children worldwide. A licensed vaccine or antiviral drug suitable for routine use remains unavailable. This invention relates to the use of murine pneumonia virus (MPV), a virus to which humans normally are not exposed to and that is not cross-protected with RSV, as a vector to express the RSV fusion (F) glycoprotein as an RSV vaccine candidate. The RSV F ORF was codon optimized. The RSV F ORF was placed under the control of MPV transcription signals a...Tue, 06 Dec 2022 12:04:24 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Mononegavirales_Vectors_expressing_Chimeric_AntigensTAB-3263https://nih.technologypublisher.com/tech/Stabilized_Influenza_Hemagglutinin_Stem_Region_Trimers_and_Uses_ThereofAn effective universal influenza vaccine would eliminate the uncertain and costly process of seasonal influenza vaccine development each year. Researchers at the National Institute of Allergy and Infectious Diseases (NIAID) are developing immunogens which elicit neutralizing antibodies to the highly conserved stem region of the influenza viral protein hemagglutinin. By targeting this highly conserved region, which is nearly identical in various strains of influenza virus, these immunogens could train the immune system to defend against a wide variety of influenza strains including pandemic str...Tue, 06 Dec 2022 12:04:22 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Stabilized_Influenza_Hemagglutinin_Stem_Region_Trimers_and_Uses_ThereofTAB-3277https://nih.technologypublisher.com/tech/HIV-1_Clone_Bal.01Tue, 06 Dec 2022 12:04:21 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/HIV-1_Clone_Bal.01TAB-3254https://nih.technologypublisher.com/tech/Protein_Nanoparticles_for_Antigen_Display_in_VaccinesThe technology relates to a protein-based nanoparticle platform that allows presentation of immunogenic molecules such as influenza virus antigens. This protein platform is made up of hepatitis B capsid/core proteins. The core proteins contain immunogenic loop c/e1, where other antigens can be inserted and the chimeric protein retains the ability to form capsid-like particles. The technology describes the insertion of one or more copies of influenza epitopes derived from the globular head or the stem region of hemagglutinin protein into or around the c/e1 loop of the core protein. The nanopart...Tue, 06 Dec 2022 12:04:20 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Protein_Nanoparticles_for_Antigen_Display_in_VaccinesTAB-3253https://nih.technologypublisher.com/tech?title=Novel_Human_Rotavirus_Vaccine_CDC-6_Strain_for_Impacted_Subgroup%2c_the_Lewis_Negative_PopulationRotaviral infection is the most common gastrointestinal illness of children in the world, affecting both developed and developing economies. There is no specific drug treatment for rotavirus infection. Vaccination and good hygiene are key to prevention. Approximately 5-10% of the world's population are Lewis histoblood group antigen negative, that percentage is as high as 30% in some African countries. Despite vaccination, the Lewis negative population show a disproportionate prevalence and recurrence of rotavirus infection. However, initial studies have shown that infection with a rotavirus G...Tue, 06 Dec 2022 12:04:19 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech?title=Novel_Human_Rotavirus_Vaccine_CDC-6_Strain_for_Impacted_Subgroup%2c_the_Lewis_Negative_PopulationTAB-3251https://nih.technologypublisher.com/tech?title=Real-Time_RT-PCR_Detection_of_Rickettsia_species_--_PanR6%2fTotal_Nucleic_Acid_Assay_with_High_Sensitivity_and_SpecificityRickettsial infections are caused by bacteria from the Rickettsia genus which are often spread by biting ticks, fleas, mites or lice. Rickettsia can cause mild to severe illness and Rickettsia species can be found worldwide. Early stage, nonspecific symptoms of infections can make clinical diagnosis difficult. Rickettsial infection symptoms, if present, typically develop within 1 -2 weeks of exposure and include fever, headache, malaise, rash, nausea, and vomiting. Some rickettsial diseases such as Rocky Mountain spotted fever (RMSF), Mediterranean spotted fever, and typhus fever, can be life ...Tue, 06 Dec 2022 12:04:18 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech?title=Real-Time_RT-PCR_Detection_of_Rickettsia_species_--_PanR6%2fTotal_Nucleic_Acid_Assay_with_High_Sensitivity_and_SpecificityTAB-3250https://nih.technologypublisher.com/tech?title=Near_Real-time%2c_Low-cost%2c_Hand-held_Sensors_for_Measuring_Elemental_Concentration_of_Airborne_Particles_for_Indoor_or_Outdoor_Air_Quality_MonitoringAirborne particles can have great impact on air quality, weather, and human health. In particular, long-term inhalation of toxic particulate matter in workplaces could pose a significant health risk. NIOSH scientists have developed a new, low-cost approach based on application of atmospheric radio frequency glow discharge (rf-GD) optical emission spectroscopy for near real-time measurement of elemental concentration in aerosols. The method involves collection of aerosol particles on an electrode tip in a coaxial microelectrode system, followed by excitation of the particles using rf-GD. NIOSH ...Tue, 06 Dec 2022 12:04:17 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech?title=Near_Real-time%2c_Low-cost%2c_Hand-held_Sensors_for_Measuring_Elemental_Concentration_of_Airborne_Particles_for_Indoor_or_Outdoor_Air_Quality_MonitoringTAB-3248https://nih.technologypublisher.com/tech/Personalized_Cancer_Evaluation_(PERCEVAL)_Method_and_SoftwareCancer represents the leading cause of morbidity and mortality worldwide, with approximately 14 million new cases and 8.2 million cancer related deaths in 2012. This number is predicted to rise by approximately 70% over the next two decades according to the World Health Organization. Prognosis depends heavily on both early detection and frequent monitoring of the patient's response to treatment. Cancerous tumors shed nucleic acids into blood, which can be detected by ultra-deep sequencing of mitochondrial DNA (mtDNA). This method has the potential to provide early detection in asymptomatic ind...Tue, 06 Dec 2022 12:04:16 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Personalized_Cancer_Evaluation_(PERCEVAL)_Method_and_SoftwareTAB-3246https://nih.technologypublisher.com/tech/Monoclonal_Antibodies_for_Specific_Detection_of_Dengue_Virus_Sub-type_4_in_Human_SerumDengue Virus (DENV) non-structural protein 1 (NS1) is secreted in blood during the acute phase of viremic DENV infection. While there are commercially available ELISA assays for DENV NS1 detection, these tests have limited sensitivity (50-70%), do not determine the serotype of the infecting DENV, do not detect all four serotypes equally, or are less sensitive in subsequent DENV infections. There is a critical need for serotype specific diagnostics to inform public health and potentially clinical care interventions. CDC developed three hybridoma cell lines and three DENV-4 serotype-specific mo...Tue, 06 Dec 2022 12:04:13 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Monoclonal_Antibodies_for_Specific_Detection_of_Dengue_Virus_Sub-type_4_in_Human_SerumTAB-3245https://nih.technologypublisher.com/tech?title=Zika_Virus_NS1_Protein_Monoclonal_Antibodies_for_Research%2c_Development%2c_and_Novel_DiagnosticsZika virus is a flavivirus that is spread by the bite of infected Aedes mosquitoes. The current outbreak and swift dissemination/spread of Zika virus (ZIKV) and its linkage to birth defects and neurological syndromes has prompted the development of novel diagnostic tests. Because ZIKV is serologically similar to other flaviviruses such as dengue virus (DNV), cross-reactivity occurs in diagnostic tests and can result in misdiagnoses. This is especially evident in populations that live in dengue-endemic regions or have received heterologous flaviviral vaccines (i.e., yellow fever 17D). CDC resea...Tue, 06 Dec 2022 12:04:12 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech?title=Zika_Virus_NS1_Protein_Monoclonal_Antibodies_for_Research%2c_Development%2c_and_Novel_DiagnosticsTAB-3243https://nih.technologypublisher.com/tech/Heartland_Virus_Humanized_Monoclonal_Antibodies_for_Diagnostic_and_Therapeutic_DevelopmentHeartland virus (HRTV) is a novel tick-borne virus first discovered in 2009 that causes flu-like symptoms such as fever, headaches, fatigue, muscle aches, and diarrhea. Patients with HRTV often have low white blood cell counts, low platelet counts, and abnormal liver function tests which can become severe. Cases of Heartland virus disease have been identified in the Midwestern and southern United States. There are no vaccines to prevent or medications to treat Heartland virus infections. HRTV presents symptoms and generates a similar immune response to other tick-borne viruses, making diagnosi...Tue, 06 Dec 2022 12:04:10 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Heartland_Virus_Humanized_Monoclonal_Antibodies_for_Diagnostic_and_Therapeutic_DevelopmentTAB-3242https://nih.technologypublisher.com/tech/Regenerative_Therapy_for_Cartilage_DamageThe subject technology discloses a tissue engineering method for treating cartilage damage. Stem cells from bone marrow are attached to a novel scaffold, hyaluronic acid-coated fibrin microbeads, and transferred to a live host to form cartilage. The regenerated cartilage is stable and not hypertrophic, which has been problematic in the current regenerative methods.Tue, 06 Dec 2022 12:04:09 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Regenerative_Therapy_for_Cartilage_DamageTAB-3241https://nih.technologypublisher.com/tech?title=Enhanced_Tissue_Clearing_Solution%2c_Clearing-Enhanced_3D_(Ce3D)%2c_Compatible_with_Advanced_Fluorescence_Microscopy_ImagingNIH immunologists have created a solution, Clearing-enhanced 3D (Ce3D), that can be used to make entire organs extremely transparent (top right panel). This allows the tissue to be imaged using advanced fluorescence microscopy techniques (bottom panel). Unlike current tissue clearing solutions, the Ce3D tissue clearing solution is robustly compatible with a variety of staining methods, and preserves tissue morphology and reporter fluorescence. Ce3D enabled microscopy provides unprecedented insight into the spatial organization of cells within intact organs. Further, when Ce3D enabled microscop...Tue, 06 Dec 2022 12:04:08 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech?title=Enhanced_Tissue_Clearing_Solution%2c_Clearing-Enhanced_3D_(Ce3D)%2c_Compatible_with_Advanced_Fluorescence_Microscopy_ImagingTAB-3240https://nih.technologypublisher.com/tech/Portable_Laser-Operated_Counterfeit_Drug_Identifier_(CoDI)_for_TabletsCounterfeit drugs (also known as “fake or falsified medicines”) have become a major world-wide public health concern. Falsified medicines may contain toxic substances, the wrong active ingredients, suboptimal amounts of active ingredients, or no active ingredients at all. CDC researchers developed a portable (handheld), battery-operated, and relatively inexpensive device that non-trained personnel can use quickly to evaluate a particular branded tablet for authenticity. The low-cost and simple-to-use CoDI can aid the general public as well as hospitals, clinics, and pharmacies to assess drug q...Tue, 06 Dec 2022 12:04:07 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Portable_Laser-Operated_Counterfeit_Drug_Identifier_(CoDI)_for_TabletsTAB-3239https://nih.technologypublisher.com/tech/A_Novel_Thermal_Method_to_Inactivate_Rotavirus_for_Use_in_VaccinesRotavirus is a highly contagious, diarrhea-inducing pathogen that annually causes approximately 250,000 deaths worldwide and millions of hospitalizations, especially afflicting infants and young children. One strategy to combat this virus is through vaccination. Continuing safety and efficacy concerns with the currently existing live, oral vaccines against rotavirus have led researchers to search for alternative treatment approaches, such as vaccines containing inactivated rotavirus. This technology describes a method for inactivating rotavirus. Traditional inactivation strategies use chemical...Tue, 06 Dec 2022 12:04:06 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/A_Novel_Thermal_Method_to_Inactivate_Rotavirus_for_Use_in_VaccinesTAB-3234https://nih.technologypublisher.com/tech?title=West_Nile%2fZika_Virus_Chimeras_for_Inactivated_Zika_Vaccine_and_Diagnostic_Assay_DevelopmentZika virus (ZIKV) is a flavivirus primarily transmitted by infected Aedes mosquitoes. Infection with ZIKV during pregnancy can affect the fetus causing microcephaly, neurological complications, and other birth defects. Adults are also at risk of developing Guillain-Barre syndrome and other neurological disorders from ZIKV infection. In response to the 2015-2016 Zika outbreak, CDC researchers developed new Zika virus chimeras that can be used for inactivated Zika vaccine candidates and faster Zika antibody (Ab) neutralization assay testing. CDC scientists successfully engineered cDNA clones for...Tue, 06 Dec 2022 12:04:04 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech?title=West_Nile%2fZika_Virus_Chimeras_for_Inactivated_Zika_Vaccine_and_Diagnostic_Assay_DevelopmentTAB-3233https://nih.technologypublisher.com/tech/Rapid_Colorimetric_Detection_of_Zika_Virus_from_Serum_and_Urine_Specimens_by_RT-LAMP_(Reverse_Transcription_Loop-Mediated_Isothermal_Amplification).The Zika virus (ZIKV) can be passed from a pregnant woman to her fetus. Resulting infection by this virus can cause early miscarriage and a pattern of severe birth defects in fetuses and infants. Therefore, a rapid diagnostic assay that can be performed throughout pregnancy in a clinical setting is vital for prenatal care of women living in areas where this virus may be transmitted. CDC has developed a RT-LAMP assay for the rapid screening of ZIKV RNA from urine and serum. As few as 10 copies of ZIKV RNA per microliter can be detected using this assay, showing that it is highly sensitive. It w...Tue, 06 Dec 2022 12:04:03 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Rapid_Colorimetric_Detection_of_Zika_Virus_from_Serum_and_Urine_Specimens_by_RT-LAMP_(Reverse_Transcription_Loop-Mediated_Isothermal_Amplification).TAB-3231https://nih.technologypublisher.com/tech?title=Monoclonal_Antibody_Specific_for_DNA%2fRNA_Hybrid_MoleculesNIAID has a hybridoma available for non-exclusive licensing that produces a monoclonal antibody specific for DNA/RNA hybrids. This antibody, which has been extensively characterized by NIH researchers, is already a widely-used research tool. It is currently the only monoclonal antibody available that is specific for DNA/RNA hybrids, making it a unique reagent. It is used in immuno-fluorescence (IF) microscopy, where it can be used to detect sites of transcriptional activity and potentially sites of viral replication. It has also been used in DNA/RNA immunoprecipitation (DRIP) experiments by a ...Tue, 06 Dec 2022 12:04:02 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech?title=Monoclonal_Antibody_Specific_for_DNA%2fRNA_Hybrid_MoleculesTAB-3226https://nih.technologypublisher.com/tech?title=Chimeric_Dengue%2fZika_Viruses_for_Live-Attenuated_Zika_Vaccine_DevelopmentZika virus (ZIKV) can be passed from a pregnant woman to her fetus. Infection during pregnancy can cause microcephaly and other severe birth defects. Currently, there are no vaccines to prevent or medications to treat Zika infections. CDC engineered chimeric Zika viruses on the dengue virus (DENV) sub-type 2 (D2) PDK-53 vaccine backbone (D2 PDK-53) for potential development of a live-attenuated Zika vaccine. These chimeric viruses could also be used for other research purposes such as development of diagnostic tests. The cDNA genetic clones for the chimeric constructs have been successfully en...Tue, 06 Dec 2022 12:04:00 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech?title=Chimeric_Dengue%2fZika_Viruses_for_Live-Attenuated_Zika_Vaccine_DevelopmentTAB-3218https://nih.technologypublisher.com/tech/Real-Time_PCR_Assay_for_Detection_of_Carbapenem_Antibiotic_Resistance_Genes_of_the_IMP-typeAntibiotic resistance is one of the world's most pressing health concerns. ß-lactamases, such as carbapenemases, are enzymes produced by bacteria that provide resistance to multiple ß-lactam antibiotics (e.g., penicillins, cephamycins, and carbapenems) by breaking down the antibiotic molecules and deactivating their antibacterial properties. Carbapenems are broad-spectrum antibiotics often prescribed to treat serious infections in hospitalized patients, and infections with carbapenem-resistant Enterobacteriaceae (CRE) have become a challenge in healthcare settings. Clinical laboratories frequ...Tue, 06 Dec 2022 12:03:59 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Real-Time_PCR_Assay_for_Detection_of_Carbapenem_Antibiotic_Resistance_Genes_of_the_IMP-typeTAB-3205https://nih.technologypublisher.com/tech/Real-Time_RT-PCR_Assay_for_the_Rapid_Detection_of_Rabies_and_Other_LyssavirusesRabies occurs in more than 150 countries and territories, resulting in at least 55,000 human deaths per year worldwide according to World Health Organization estimates. Rabies is a vaccine-preventable viral disease caused by numerous lyssaviruses that are found in a variety of animal species throughout the world. Rabies virus infects the central nervous system, causing disease in the brain with almost 100% mortality once clinical symptoms manifest. Rapid and accurate laboratory diagnosis of rabies in humans and other animals is essential for timely administration of post-exposure prophylaxis. ...Tue, 06 Dec 2022 12:03:55 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Real-Time_RT-PCR_Assay_for_the_Rapid_Detection_of_Rabies_and_Other_LyssavirusesTAB-3202https://nih.technologypublisher.com/tech/Regulator_of_G_Protein_Signaling_(RGS13)_Knock-Out_MouseRGS13, an intracellular protein in mast cells, was shown to suppress IgE-mediated anaphylactic response in mice. The RGS13-/- mouse may be used to screen compounds that inhibit mast cell degranulation.Tue, 06 Dec 2022 12:03:52 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Regulator_of_G_Protein_Signaling_(RGS13)_Knock-Out_MouseTAB-3201https://nih.technologypublisher.com/tech/Conformation_Dependent_Anti-major_Outer_Membrane_Protein_(MOMP)_Monoclonal_Antibody_BD5A murine hybridoma expressing mAb BD3 was found to react with a conformationally dependent epitope on the chlamydial Major Outer Membrane Protein (MOMP), a primary target of neutralizing antibodies and vaccine development. The BD3 neutralized the in vitro infectivity of C. trachomatis serovars B, Ba, D, E, L2. It is useful for verifying the correct conformation of MOMP in vaccines against chlamydia trachomatis, Serovars B, BA, D, E, AND L2.Tue, 06 Dec 2022 12:03:49 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Conformation_Dependent_Anti-major_Outer_Membrane_Protein_(MOMP)_Monoclonal_Antibody_BD5TAB-3200https://nih.technologypublisher.com/tech?title=Hybridoma_Cell_Line_D8H21%2c_Monoclonal_Antibody_to_the_Specific_Peptide-MHC_Class_II_ComplexHybridoma Cell Line D8H21, as described in Proc Natl Acad Sci U S A. 1997 Dec 9;94(25):13856-61 and developed in the laboratory of Dr. Ronald Germain.Tue, 06 Dec 2022 12:03:47 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech?title=Hybridoma_Cell_Line_D8H21%2c_Monoclonal_Antibody_to_the_Specific_Peptide-MHC_Class_II_ComplexTAB-3199https://nih.technologypublisher.com/tech?title=Hybridoma_Cell_Line_B6GE1%2c_Monoclonal_Antibody_to_the_Specific_Peptide-MHC_Class_II_ComplexHybridoma Cell Line B6GE1 as described in Proc Natl Acad Sci U S A. 1997 Dec 9;94(25):13856-61 and developed in the laboratory of Dr. Ronald Germain.Tue, 06 Dec 2022 12:03:45 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech?title=Hybridoma_Cell_Line_B6GE1%2c_Monoclonal_Antibody_to_the_Specific_Peptide-MHC_Class_II_ComplexTAB-3198https://nih.technologypublisher.com/tech?title=Hybridoma_Cell_Line_25-D1.16_Producing_Monoclonal_Anti-H-2Kb%2fSIINFEKL_Complex_AntibodyAn H-2Kb/OVA hybridoma cell line producing a monoclonal antibody specific for the H-2Kb/SIINFEKL complex (clone 25-D1.16) as described in Immunity 1997 Jun;6(6):715-26 and developed in the laboratory of Dr. Ronald Germain at the National Institute of Allergy and Infectious Diseases.Tue, 06 Dec 2022 12:03:42 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech?title=Hybridoma_Cell_Line_25-D1.16_Producing_Monoclonal_Anti-H-2Kb%2fSIINFEKL_Complex_AntibodyTAB-3197https://nih.technologypublisher.com/tech/Hybridoma_Cell_Line_715_Producing_Monoclonal_Antibody_Specific_for_Murine_Leukemia_Virus_gp70Tue, 06 Dec 2022 12:03:41 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Hybridoma_Cell_Line_715_Producing_Monoclonal_Antibody_Specific_for_Murine_Leukemia_Virus_gp70TAB-3196https://nih.technologypublisher.com/tech/Hybridoma_Cell_Line_500_Producing_Monoclonal_Antibody_Specific_for_Murine_Leukemia_Virus_gp80Tue, 06 Dec 2022 12:03:40 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Hybridoma_Cell_Line_500_Producing_Monoclonal_Antibody_Specific_for_Murine_Leukemia_Virus_gp80TAB-3195https://nih.technologypublisher.com/tech/Hybridoma_Cell_Line_273_Producing_Monoclonal_Antibody_Specific_for_Murine_Leukemia_Virus_gp70Tue, 06 Dec 2022 12:03:39 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Hybridoma_Cell_Line_273_Producing_Monoclonal_Antibody_Specific_for_Murine_Leukemia_Virus_gp70TAB-3194https://nih.technologypublisher.com/tech?title=Hybridoma_Cell_Line_H9.2B8_Producing_Monoclonal_Anti-mouse_CD51_(Vitronectin_receptor%2c_alpha_chain)_AntibodyA hybridoma cell line producing a monoclonal hamster antibody specific to mouse CD51 (vitronectin receptor, alpha chain) (clone H9.2B8) as described in J Exp Med. 1989 Jun 1;169(6):2173-90 and developed by the laboratory of Dr. Ethan Shevach at the National Institute of Allergy and Infectious Diseases.Tue, 06 Dec 2022 12:03:38 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech?title=Hybridoma_Cell_Line_H9.2B8_Producing_Monoclonal_Anti-mouse_CD51_(Vitronectin_receptor%2c_alpha_chain)_AntibodyTAB-3192https://nih.technologypublisher.com/tech/Hybridoma_Cell_Line_H1.2F3_Producing_Monoclonal_Anti-mouse_CD69_(Early_activation_marker)_AntibodyA hybridoma cell line producing a monoclonal hamster antibody specific to mouse CD69 (early activation marker) (clone H1.2F3) as described in J Immunol. 1988 Jul 15;141(2):369-76 and developed by the laboratory of Dr. Ethan Shevach at the National Institute of Allergy and Infectious Diseases.Tue, 06 Dec 2022 12:03:37 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Hybridoma_Cell_Line_H1.2F3_Producing_Monoclonal_Anti-mouse_CD69_(Early_activation_marker)_AntibodyTAB-3191https://nih.technologypublisher.com/tech?title=Hybridoma_Cell_Line_D7_Producing_Monoclonal_Anti-mouse_Ly-6A%2fE_(Sca-1)_AntibodyA hybridoma cell line producing a monoclonal rat antibody specific to mouse Ly-6A/E (Sca-1) (clone D7) as described in J Immunol. 1986 Nov 15;137(10):3240-6 and developed by the laboratory of Dr. Ethan Shevach at the National Institute of Allergy and Infectious Diseases.Tue, 06 Dec 2022 12:03:35 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech?title=Hybridoma_Cell_Line_D7_Producing_Monoclonal_Anti-mouse_Ly-6A%2fE_(Sca-1)_AntibodyTAB-3190https://nih.technologypublisher.com/tech?title=Hybridoma_Cell_Line_3C7_Producing_Monoclonal_Anti-mouse_CD25_(IL-2_receptor%2c_alpha_chain)_AntibodyA hybridoma cell line producing a monoclonal rat antibody specific to mouse CD25 (IL-2 receptor, alpha chain) (clone 3C7) as described in J Immunol. 1984 Oct;133(4):1970-5 and developed by the laboratory of Dr. Ethan Shevach at the National Institute of Allergy and Infectious Diseases.Tue, 06 Dec 2022 12:03:34 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech?title=Hybridoma_Cell_Line_3C7_Producing_Monoclonal_Anti-mouse_CD25_(IL-2_receptor%2c_alpha_chain)_AntibodyTAB-3189https://nih.technologypublisher.com/tech/Hybridoma_Cell_Line_7D4_Producing_Monoclonal_Anti-mouse_CD25_(IL-2_receptor)_AntibodyA hybridoma cell line producing a monoclonal rat antibody specific to mouse CD25 (IL-2 receptor) (clone 7D4) as described in Proc Natl Acad Sci U S A. 1983 Sep;80(18):5694-8 and developed by the laboratory of Dr. Ethan Shevach at the National Institute of Allergy and Infectious Diseases.Tue, 06 Dec 2022 12:03:33 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Hybridoma_Cell_Line_7D4_Producing_Monoclonal_Anti-mouse_CD25_(IL-2_receptor)_AntibodyTAB-3188https://nih.technologypublisher.com/tech/Chlamydial_Vaccine_TechnologiesThe National Institute of Allergy and Infectious Diseases has invented three chlamydial vaccine technologies, which have shown promising preclinical efficacy. Chlamydia trachomatis infection is the most common sexually transmitted bacterial infection. If left untreated, chlamydia infection can lead to pelvic inflammatory disease and infertility. Chlamydia is also the leading cause of preventable blindness in the world. Despite increased surveillance, prevalence continues to increase, and the need to develop an effective chlamydial vaccine remains. Technologies: 1. A plasmid-deficient Chlamydi...Tue, 06 Dec 2022 12:03:32 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Chlamydial_Vaccine_TechnologiesTAB-3186https://nih.technologypublisher.com/tech/Plasmids_Encoding_and_Producing_Anthrax_Toxin_ProteinsPlasmid pSJ136-EF-A — A plasmid encoding mutant anthrax toxin proteins such as lethal factor (LF) or edema factor (EF). Anthrax toxin and anthrax toxin fusion proteins may be used as therapeutic agents for cancer. Plasmid PSJ115-LFOS — A plasmid expressing anthrax toxin proteins such as lethal factor (LF) or edema factor (EF) which has the original n-terminal amino acid sequence.Tue, 06 Dec 2022 12:03:31 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Plasmids_Encoding_and_Producing_Anthrax_Toxin_ProteinsTAB-3176https://nih.technologypublisher.com/tech?title=Human_CC_Chemokine_Receptor_CX3CR1_%2f_CMKBRL1_cDNAA plasmid encodes human CC chemokine receptor CX3CR1/CMKBRL1 as described in DNA Cell Biol. 1995 Aug;14(8):673-80, and developed in the laboratory of Philip M. Murphy at the National Institute of Allergy and Infectious Diseases.Tue, 06 Dec 2022 12:03:30 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech?title=Human_CC_Chemokine_Receptor_CX3CR1_%2f_CMKBRL1_cDNATAB-3175https://nih.technologypublisher.com/tech/Neutralizing_Antibodies_to_Influenza_HA_and_Their_Use_and_IdentificationThe effectiveness of current influenza vaccines varies by strain and season, in part because influenza viruses continuously evolve to evade human immune responses. While the majority of seasonal influenza infections cause relatively mild symptoms, each year influenza virus infections result in over 500,000 hospitalizations in the United States and Europe. Current standard of care for individuals hospitalized with uncomplicated influenza infection is administration of neuraminidase inhibitors. However, frequent use of such antiviral drugs increases the risk that the virus will develop drug re...Tue, 06 Dec 2022 12:03:29 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Neutralizing_Antibodies_to_Influenza_HA_and_Their_Use_and_IdentificationTAB-3169https://nih.technologypublisher.com/tech/Broadly_Neutralizing_Antibodies_Against_HIV-1_Directed_to_the_CD4_Binding_Site_of_HIV_Envelope_ProteinInhibiting the ability of HIV-1, the virus that causes AIDS, to infect cells is one approach to both prevention and treatment of HIV. Scientists at the NIAID Vaccine Research Center have isolated and characterized neutralizing antibodies (VRC01, 02, 03, and 07) that bind to the CD4 binding site of HIV-1 envelope glycoprotein gp120. These human monoclonal antibodies can potentially be used as a therapeutic to: (1) treat an HIV infection, (2) decrease and prevent HIV-transmission from mother to infant, and (3) be effectively combined with anti-retroviral drug therapy. Additionally, the antibodie...Tue, 06 Dec 2022 12:03:27 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Broadly_Neutralizing_Antibodies_Against_HIV-1_Directed_to_the_CD4_Binding_Site_of_HIV_Envelope_ProteinTAB-3177https://nih.technologypublisher.com/tech/CXCR1_-_Human_IL-8_Receptor_cDNAA plasmid encodes human interleukin-8 (IL-8) receptor CXCR1. IL-8 is a chemo-attractant cytokine that attracts and activates neutrophils in inflammatory regions.Tue, 06 Dec 2022 12:03:26 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/CXCR1_-_Human_IL-8_Receptor_cDNATAB-3183https://nih.technologypublisher.com/tech/Human_CCR3_cDNAA plasmid encodes human C-C motif chemokine receptor 3 (CCR3). It may contribute to the accumulation and activation of eosinophil and other inflammatory cells in the allergic airway.Tue, 06 Dec 2022 12:03:25 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Human_CCR3_cDNATAB-3182https://nih.technologypublisher.com/tech/Human_CCR2_cDNAA plasmid encodes human C-C chemokine receptor type 2 (CCR2). CCR2 play important roles in the recruitment of monocytes/macrophages and T cells.Tue, 06 Dec 2022 12:03:24 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Human_CCR2_cDNATAB-3166https://nih.technologypublisher.com/tech/Human_and_Veterinary_Cancer_Therapeutic_Agent_Utilizing_Anthrax_Toxin-Based_TechnologyDue to the disorganized nature of blood vessels that run through tumors, chemotherapeutic agents often fail to penetrate tumors and kill cancer cells at the tumor’s center. This can lead to ineffective chemotherapeutic treatments, because tumors can quickly grow back if the entire tumor is not destroyed. NIH researchers have developed a therapeutic agent that solves this problem facing current chemotherapy treatments. By elegantly exploiting cell surface proteases present at high levels in tumors, they have developed a tumor-targeted anthrax based toxin that inactivates the blood vessels wit...Tue, 06 Dec 2022 12:03:23 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Human_and_Veterinary_Cancer_Therapeutic_Agent_Utilizing_Anthrax_Toxin-Based_TechnologyTAB-3165https://nih.technologypublisher.com/tech/Zika_Virus_VLP_(Virus-like_Particle)_Antigens_for_Vaccine_Candidate_and_Diagnostic_DevelopmentZika virus (ZIKV) is a flavivirus primarily transmitted by infected Aedes mosquitoes. Infection with ZIKV during pregnancy can affect the fetus causing microcephaly, neurological complications, and other birth defects. Adults are also at a heightened risk of developing Guillain-Barre syndrome and other neurological disorders. In response to the 2015-2016 Zika outbreak, CDC scientists developed a recombinant vaccine candidate as well as reagents and methods to detect ZIKV infection. The recombinant vaccine candidate utilizes adenovirus vector expressed viral envelope proteins. This vector-based...Tue, 06 Dec 2022 12:03:22 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Zika_Virus_VLP_(Virus-like_Particle)_Antigens_for_Vaccine_Candidate_and_Diagnostic_DevelopmentTAB-3180https://nih.technologypublisher.com/tech?title=Human_FPRL1_%2f_FPR2_cDNAA plasmid encodes human formyl peptide receptor-like 1 (FPRL1/FPR2).Tue, 06 Dec 2022 12:03:21 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech?title=Human_FPRL1_%2f_FPR2_cDNATAB-3179https://nih.technologypublisher.com/tech?title=Human_fMLP_Receptor_%2f_FPR_cDNAA plasmid encodes human fMLP receptor. Formyl peptide receptor (FPR, fMLP receptor) is a G protein-coupled receptor and mediates anti-inflammatory reactions in human neutrophils and other tissues.Tue, 06 Dec 2022 12:03:20 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech?title=Human_fMLP_Receptor_%2f_FPR_cDNATAB-3164https://nih.technologypublisher.com/tech?title=Nucleic_Acid_Primers_and_Probes_for_Detecting_Ebola_Virus_(species_%3cem%3eZaire_ebolavirus%3c%2fem%3e)The 2014-2016 Ebola Virus Disease (EVD) outbreak in West Africa was the largest in history, causing more than 28,000 suspected, probable, and confirmed infections and more than 11,000 deaths across nine countries. CDC scientists designed nucleic acid primers and probes which can be used in a sensitive test for detecting all known strains of Ebola virus (species Zaire ebolavirus) including the 2014/2015 strain that emerged in West Africa and the more recent strain that caused an EVD outbreak in the Democratic Republic of Congo in 2017. The primer and probe set can be used on blood samples for b...Tue, 06 Dec 2022 12:03:19 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech?title=Nucleic_Acid_Primers_and_Probes_for_Detecting_Ebola_Virus_(species_%3cem%3eZaire_ebolavirus%3c%2fem%3e)TAB-3163https://nih.technologypublisher.com/tech/Chimeric_Antibodies_Against_Hepatitis_B_e-AntigenThe invention relates to recombinant chimeric rabbit/human monoclonal antibody fragments (Fabs) against hepatitis B Virus e-antigen (HBeAg), notably Fab me6. Viral hepatitis is the seventh leading cause of death worldwide. Hepatitis B core antigen (HBcAg) forms an icosahedral structure containing the viral genome. Both the HBcAg and the HBeAg of interest here are expressed by two different start codons of the viral C gene. Unlike the related HBcAg which activates type 1 T helper (Th1) cells leading to immune attack, the HBeAg activates Th2 cells which promote immune tolerance. The long-term pe...Tue, 06 Dec 2022 12:03:18 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Chimeric_Antibodies_Against_Hepatitis_B_e-AntigenTAB-3162https://nih.technologypublisher.com/tech/Improved_simian_HIV_(SHIV)_prevention_in_non-human_primate_models_with_chemoprophylaxis_combination_that_can_be_taken_in_one_or_two_oral_doses_before_or_after_exposureHIV and AIDS remain persistent problems for the United States and countries around the world. In 2015, nearly 40,000 people were diagnosed with HIV in the US alone. Pre-exposure prophylaxis (PrEP) can help prevent HIV infections in people who are not infected with HIV but are at high risk of becoming infected with HIV. PrEP involves taking daily medications and is the most effective when medications are taken consistently. However, many people find it challenging to adhere to a daily pill schedule and cannot fully benefit from PrEP. CDC researchers have developed a medication dosing regimen w...Tue, 06 Dec 2022 12:03:16 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Improved_simian_HIV_(SHIV)_prevention_in_non-human_primate_models_with_chemoprophylaxis_combination_that_can_be_taken_in_one_or_two_oral_doses_before_or_after_exposureTAB-3161https://nih.technologypublisher.com/tech?title=CDC_Trioplex_%e2%80%93_A_Real-Time_RT-PCR_Assay_for_the_Diagnosis_of_Zika%2c_and_Differentiation_from_Dengue_%2b_Chikungunya_Virus_InfectionsAs of March 2017, 64 countries and territories had travel notices for active Zika virus transmissions. CDC developed the Trioplex rRT-PCR test to detect evidence of Zika virus infection and aid in differentiating this infection from dengue and chikungunya virus infections, all of which are spread by the same types of Aedes species mosquitoes and cause similar illness. The Trioplex Real-time RT-PCR assay is for qualitative detection and differentiation of RNA from dengue, chikungunya and Zika viruses in serum, whole blood, urine, amniotic fluid and cerebral spinal fluid, and for the qualitative...Tue, 06 Dec 2022 12:03:15 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech?title=CDC_Trioplex_%e2%80%93_A_Real-Time_RT-PCR_Assay_for_the_Diagnosis_of_Zika%2c_and_Differentiation_from_Dengue_%2b_Chikungunya_Virus_InfectionsTAB-3158https://nih.technologypublisher.com/tech/Evans_Blue_Dye_Derivatives_for_Serum_Albumin_LabelingThe invention is an imaging agent and method of use for imaging blood pools and the lymphatic system. The imaging agent binds with high affinity to serum albumin, the most abundant serum protein, and can be tagged with several isotopes making it suitable for magnetic resonance imaging or positron emission tomographic imaging. To date, only very few blood-pool tracers have been introduced for positron emission tomography. The existing ones have short half-lives (20.4 min for 11C and 2.05 min for 15O) and thus can only be used in centers with an in-house cyclotron. Compared with these radiometal...Tue, 06 Dec 2022 12:03:14 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Evans_Blue_Dye_Derivatives_for_Serum_Albumin_LabelingTAB-3157https://nih.technologypublisher.com/tech/Hybrid_Computer_Tomography_Scanning_SystemThe invention relates to a combination hybrid computer tomography (CT) system that is particularly suited for elucidating stages in pulmonary diseases, notably cystic fibrosis and lung cancer. Improved visualization of lung parenchyma and the margins of lung cysts (non-invasive “virtual biopsy”) may provide sufficient detail to distinguish the types of cystic lesions such that the typical lung tissue pathologic biopsy would not be needed to make a diagnosis. The system includes placing one or more x-ray detector panels near the patient’s body initially outside the view of a CT scanner and then...Tue, 06 Dec 2022 12:03:13 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Hybrid_Computer_Tomography_Scanning_SystemTAB-3156https://nih.technologypublisher.com/tech/Pyrophosphate_Analog_HIV-1_Reverse_Transcriptase_InhibitorsThe invention relates to compounds that inhibit HIV-1 DNA synthesis mediated by reverse transcriptase (RT). HIV-1 DNA synthesis by RT utilizes deoxynucleoside 5’-triphosphate (dNTP) as substrate and like many other enzymes, the reaction is reversible. Pyrophosphate analogs like imidodiphosphate strongly promote reverse reaction dNTP products containing the imidodiphosphate group instead of the naturally occurring pyrophosphate group. This imidodiphosphate-containing dNTP was found to be a potent inhibitor of the forward RT reaction. Whereas pyrophosphorolysis is limited by a nonchemical step, ...Tue, 06 Dec 2022 12:03:12 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Pyrophosphate_Analog_HIV-1_Reverse_Transcriptase_InhibitorsTAB-3155https://nih.technologypublisher.com/tech/Development_of_a_Transferrable_Norwalk_Virus_Epitope_and_Detector_Monoclonal_AntibodyNoroviruses are now recognized as the major cause of non-bacterial gastroenteritis in all age groups, and efforts are underway to develop an effective vaccine. The lack of a robust cell culture system for human noroviruses has complicated vaccine development. Hence, norovirus virus like particles (VLPs) have played an important role in the understanding of virus structure, immune response, antigenic diversity, and vaccine design. The development of monoclonal antibodies (MAbs) against norovirus VLPs has allowed the identification and characterization of key antigenic sites of the virus capsid ...Tue, 06 Dec 2022 12:03:11 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Development_of_a_Transferrable_Norwalk_Virus_Epitope_and_Detector_Monoclonal_AntibodyTAB-3185https://nih.technologypublisher.com/tech?title=Regulators_of_G_Protein_Signalling_(RGS)_1%2c3%2c4%2c5_%2b_13_cDNAsPlasmids encode regulators of G protein signalling (RGS).Tue, 06 Dec 2022 12:03:09 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech?title=Regulators_of_G_Protein_Signalling_(RGS)_1%2c3%2c4%2c5_%2b_13_cDNAsTAB-3152https://nih.technologypublisher.com/tech/Real-Time_RT-PCR_Assay_for_Influenza_B_Lineage_CharacterizationInfluenza B causes significant morbidity and mortality yearly around the world. There are two genetically and antigenically distinct lineages of influenza B that are known to co-circulate within the same influenza season. Currently, the trivalent influenza vaccine only has one influenza B lineage component. CDC researchers developed technology that detects and distinguishes the two major co-circulating antigenic lineages of influenza B viruses (B/Yamagata/16/88 (YAM) and B/Victoria/2/87 (VIC)) and provides accurate and timely surveillance data that are less prone to contamination than current ...Tue, 06 Dec 2022 12:03:08 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Real-Time_RT-PCR_Assay_for_Influenza_B_Lineage_CharacterizationTAB-3151https://nih.technologypublisher.com/tech/Direct_Reading_Detection_Kits_for_Surface_Contamination_by_Anti-Neoplastic_(Anti-Cancer)_DrugsAnti-neoplastic drugs, also known as anti-cancer drugs or chemotherapy, are used in the treatment of many types of cancer. However, these drugs are harmful to healthy cells as well as the cancerous cells. Exposure of healthcare workers to anti-neoplastic drugs from contaminated surfaces and drug vials in hospitals and pharmacies is a continuing problem as the drugs can cause both acute and long-term effects. Although there are sensitive techniques to evaluate contamination, results from these tests take time and must be performed in a laboratory. CDC researchers developed a real-time detection...Tue, 06 Dec 2022 12:03:07 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Direct_Reading_Detection_Kits_for_Surface_Contamination_by_Anti-Neoplastic_(Anti-Cancer)_DrugsTAB-2975https://nih.technologypublisher.com/tech/Tristetraprolin_(TTP)_Plasmid_Vectors_for_Human_and_Mouse_TTPTristetraprolin (TTP) is involved in the physiological regulation of the secretion of at least two important cytokines, tumor necrosis factor alpha (TNF) and granulocyte-macrophage colony-stimulating factor (GM-CSF). TTP exerts its effects by directly binding to the mRNAs encoding these proteins and destabilizing them, resulting in less secretion. Conversely, TTP deficiency results in an excess of both cytokines, leading to a systemic inflammatory syndrome. This invention include three categories of reagents related to TTP:1) Plasmid DNAs and mammalian expression vectors for human and mouse TT...Tue, 06 Dec 2022 12:03:06 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Tristetraprolin_(TTP)_Plasmid_Vectors_for_Human_and_Mouse_TTPTAB-2974https://nih.technologypublisher.com/tech/A_Genetic_System_in_Yeast_for_Functional_Identification_of_Human_p53_MutationsMutations in the p53 gene are associated with 50% of all cancers and nearly 80% of the p53 mutations are missense changes. We have developed genetic assays based in yeast that can functionally categorize expressed p53 mutant proteins. The combined assays are referred to as the FIP53 system. Because human p53 cDNA can be conveniently cloned in yeast, the FIP53 system provides a rapid and sophisticated system for the functional analysis of p53 mutants. Four categories of mutations have already been identified. The FIP53 system provides the first in vivo battery for tests that can subdivide many ...Tue, 06 Dec 2022 12:03:05 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/A_Genetic_System_in_Yeast_for_Functional_Identification_of_Human_p53_MutationsTAB-2971https://nih.technologypublisher.com/tech/Immunological_Detection_of_Free_Radicals_In_Animals_and_In_VitroElectron Spin Resonance (ESR) is an universal, specific tool for the detection of free radicals in biological systems. Its application to the investigation of free radicals from whole animals, organs, and cells has been made possible by the spin-trapping technique. In a Spin-trapping experiment, a spin trap such as DMPO (5,5-dimetryl-1-pyrroline N-oxide) reacts specifically with one or more types of free radical to form radical-derived nitrone adducts that are much more stable than the original free radicals. In decades of investigation, very few artifacts have been discovered with the use of ...Tue, 06 Dec 2022 12:03:04 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Immunological_Detection_of_Free_Radicals_In_Animals_and_In_VitroTAB-2970https://nih.technologypublisher.com/tech/Genome_Wide_DNase_I_Hypersensitive_Sites_Detection_in_Formalin-Fixed_Paraffin-Embedded_Single_CellsA method of detecting DNase I hypersensitive sites ((DHS) in a single cell or very small number of cells, including cells recovered from formalin-fixed paraffin-embedded (FFPE) tissue slides of patient samples. DHS has revealed a large number of potential regulatory elements for transcriptional regulation in various cell types. The application of DNase-Seq techniques to patient samples can elucidate pathophysiological mechanisms of gene function in a variety of diseases as well as provide potentially important diagnostic and prognostic information. Unfortunately, the current DNase-Seq techn...Tue, 06 Dec 2022 12:03:03 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Genome_Wide_DNase_I_Hypersensitive_Sites_Detection_in_Formalin-Fixed_Paraffin-Embedded_Single_CellsTAB-2969https://nih.technologypublisher.com/tech?title=Prevention_or_Treatment_of_Viral_Infections_by_Inhibition_of_the_Histone_Methyltransferases_EZH1%2f2Herpes simplex viral infections, including herpes simplex virus type 1 (HSV-1) and type 2 (HSV-2), are exceptionally common worldwide. These viruses establish lifelong persistent infections with cycles of lytic reactivation to produce recurrent diseases including oral and genital lesions, herpetic keratitis/blindness, congenital-developmental syndromes, and viral encephalitis. Infection with HSV-2 increases the rate of human immunodeficiency virus (HIV) transmission in coinfected individuals. DNA replication inhibitors are typically used to treat herpesvirus infections. However, these comp...Tue, 06 Dec 2022 12:03:02 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech?title=Prevention_or_Treatment_of_Viral_Infections_by_Inhibition_of_the_Histone_Methyltransferases_EZH1%2f2TAB-2942https://nih.technologypublisher.com/tech/Boron_Amino_Acid_Mimetics_for_PET_Imaging_of_CancerAvailable for licensing and commercial development as imaging agents for positron emission tomography of cancer are boramino acid compounds. The inventors showed that mimetics created by substituting the carboxylate group (-COO-) of an amino acid with trifluoroborate (-BF3-) are metabolically stable and allow for the use of fluorene-18 (18F) as the radiolabel. Using boroamino acid for 18F-labeling allows for integrating the 18F radiolabel into the core molecular backbone rather than the side-chains thus increasing the agent's target specificity. There is a direct relationship between amino aci...Tue, 06 Dec 2022 12:03:01 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Boron_Amino_Acid_Mimetics_for_PET_Imaging_of_CancerTAB-2940https://nih.technologypublisher.com/tech/Swing-Away_Winch_Cathead_GuardShrimp boat operators use two trawl retrieval mechanisms mounted on the same winch frame. The main spools are used in the first operation; the shrimpers stand within inches of rotating cathead drums and guide incoming wire rope onto the main spools. Second, lazy lines are wrapped multiple times around each of the two spinning catheads (horizontal beams that raise and secure the anchor). Lastly, the guarding ends are pulled by the operators to cinch the rope to the rotating spool aiding trawl retrieval, but poses a hazard for operators to get entangled in the spinning cathead spools. Researcher...Tue, 06 Dec 2022 12:02:59 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Swing-Away_Winch_Cathead_GuardTAB-2939https://nih.technologypublisher.com/tech/Emergency_Maritime_Battery_ChargerBoats and other watercrafts have emergency lifesaving equipment like strobe lamps to help rescuers locate individuals overboard in the event of a disaster. The battery life of the equipment is limited, so the amount of time rescuers have to find the victims is also limited. An emergency battery charger that can power emergency equipment is needed to remove this limitation. Investigators at NIOSH have developed a battery that is powered by wave action in the water. Using a derivation of Faraday's Law, the principles of Lentz's Law were used to induce a current in a wire coil and manipulated to ...Tue, 06 Dec 2022 12:02:58 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Emergency_Maritime_Battery_ChargerTAB-2938https://nih.technologypublisher.com/tech/Monoclonal_Antibodies_to_the_HIV-1_Core_Protein_p24The core proteins of HIV-1 are secreted into the environment during replication in the human body. The detection of the core protein p24 (molecular mass of 24 kilodaltons) serves as an indicator of early HIV-1 infection, and assays detecting it have been available since the late 1980s. However, the development of a rapid assay for the detection of HIV-1 p24 has only recently become available. Monoclonal antibodies developed in our laboratory for research and development of a rapid HIV-1 p24 assay would provide large quantities of material at a much lower price than could be obtained in the com...Tue, 06 Dec 2022 12:02:57 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Monoclonal_Antibodies_to_the_HIV-1_Core_Protein_p24TAB-2937https://nih.technologypublisher.com/tech/Real-time_RT-PCR_assay_for_Detection_of_Live_Attenuated_Influenza_Vaccine_for_A_and_B_VirusesUpon intranasal vaccination, live attenuated influenza vaccine (LAIV) viruses may replicate within the nose for several days. Current clinical diagnostic tests cannot distinguish between LAIV viruses and multiple influenza viruses in recently inoculated patients that present with respiratory symptoms. This poses a problem for the diagnosis and treatment of patients with respiratory symptoms, as these symptoms may not be caused by influenza. CDC researchers have developed a real-time RT-PCR assay to detect the presence of LAIV viruses. This test is rapid, accurate, and provides diagnostic data ...Tue, 06 Dec 2022 12:02:56 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Real-time_RT-PCR_assay_for_Detection_of_Live_Attenuated_Influenza_Vaccine_for_A_and_B_VirusesTAB-2936https://nih.technologypublisher.com/tech/Rapid_Method_for_the_Detection_of_Antigen-Specific_Antibodies_in_Any_SpeciesCurrently available identification methods for antigen-specific antibodies require live pathogens, antisera (that are only available for a limited number of species), and species-specific secondary antibodies (also a limited resource). Thus, detection or surveillance of pathogens in wild avian species or zoo animals, for example, is complex and cumbersome. Researchers at the CDC have developed methods to rapidly detect antigen-specific antibodies in any species, including those for which secondary antibodies and/or antisera are unavailable. The unique methods involve direct labelling of biolog...Tue, 06 Dec 2022 12:02:54 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Rapid_Method_for_the_Detection_of_Antigen-Specific_Antibodies_in_Any_SpeciesTAB-2935https://nih.technologypublisher.com/tech/A_Novel_Therapeutic_Vector_for_Hemoglobin_DisordersInvestigators at the National Heart, Lung, and Blood Institute have designed a novel lentiviral vector as a potential gene therapy for sickle cell anemia and beta-thalassemia. The novel lentiviral vector encodes the beta-globin gene in a forward orientation and can produce 5-10 fold higher viral titer and 4-10 fold higher gene transfer efficiency to hematopoietic stem cells than reverse-oriented lentiviral vectors. In vivo studies conducted in rhesus macaques show beta-globin production after transplantation with this novel lentiviral vector. This technology could provide an alternative therap...Tue, 06 Dec 2022 12:02:53 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/A_Novel_Therapeutic_Vector_for_Hemoglobin_DisordersTAB-2932https://nih.technologypublisher.com/tech/Adaptor_for_Suspending_a_Cryovial_Over_a_Centrifuge_TubeThe invention pertains to a device and system for expediting the thawing of frozen specimens (e.g., cryopreserved cells) contained in cryo-vials. An adaptor support suspends cryo-vials over a centrifuge tube containing culture medium in an inverted position. The adaptor has an elongated tubular body. While relatively basic, the adaptor dramatically expedites the process of recovering viable cells from frozen specimens. It reduces the labor time for thawing from several minutes to a few seconds. There is virtually no labor involved and enables a single person to load hundreds of samples wi...Tue, 06 Dec 2022 12:02:52 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Adaptor_for_Suspending_a_Cryovial_Over_a_Centrifuge_TubeTAB-2917https://nih.technologypublisher.com/tech/CXCR4_Reduction_Leads_to_Enhancement_of_Engraftment_of_Hematopoietic_Stem_CellsMethods of enhancing engraftment of donor hematopoietic stem cells (HSCs) by reducing expression or activity of CXCR4 in HSCs is described. HSC are the only cells in the bone marrow that are both pluripotent and long lived. Bone marrow transplantation (BMT) using HSC is an increasingly common medical therapy for severe hematologic cancers and primary hematologic immunodeficiencies. However, for significant HSC engraftment to occur there must usually be pre-transplant conditioning with either irradiation or chemotherapy or both. The technology described herein shows that it is possible to r...Tue, 06 Dec 2022 12:02:49 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/CXCR4_Reduction_Leads_to_Enhancement_of_Engraftment_of_Hematopoietic_Stem_CellsTAB-2907https://nih.technologypublisher.com/tech/T_Cell-Based_Adoptive_Transfer_Immunotherapy_for_Polyomavirus-Associated_PathologiesAvailable for licensing are methods to generate T cells responsive to multiple polyomaviruses. The resulting T cell populations could be useful in treating immunosuppressed individuals with polyomavirus infections or polyomavirus-associated pathologies such as Merkel cell carcinoma (MCC), polyomavirus-associated nephropathy (PVAN), hemorrhagic cystitis, progressive multifocal leukoencephalopathy (PML), and trichodysplasia spinulosa (TS). The methods could also be used to restore polyomavirus-specific immunity in immunocompromised individuals.Tue, 06 Dec 2022 12:02:47 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/T_Cell-Based_Adoptive_Transfer_Immunotherapy_for_Polyomavirus-Associated_PathologiesTAB-2905https://nih.technologypublisher.com/tech?title=LRRK2_Inhibitors%3a_Novel_Treatment_for_Intestinal_Bowel_DisordersUse of Leucine Rich Repeat Kinase 2 (LRRK2) inhibitors for the treatment of Intestinal Bowel Disorders (IBD) is disclosed. IBD is a broad term that describes conditions with chronic or recurring immune response and inflammation of the gastrointestinal tract. Crohn's disease and ulcerative colitis, two common forms of idiopathic IBD, are chronic, relapsing inflammatory disorders of the gastrointestinal tract. LRRK2 is a kinase encoded by a gene that contains a non-coding polymorphism (SNP). LRRK2 has been associated with and is a risk factor for inflammatory bowel disease. NIH inventors hav...Tue, 06 Dec 2022 12:02:46 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech?title=LRRK2_Inhibitors%3a_Novel_Treatment_for_Intestinal_Bowel_DisordersTAB-2899https://nih.technologypublisher.com/tech/Highly_Sensitive_Tethered-Bead_Immune_Sandwich_AssayThis technology is a highly sensitive tethered-bead immune sandwich assay. Analyte molecules are captured between two antibodies, a capture antibody and a detection antibody. The capture antibody on a micron-size bead binds analyte from a sample fluid. The bead-captured analyte is then exposed to a “detection” antibody that binds to the bead-captured analyte, forming a “sandwich”. The sandwiched analyte-bead complex then connects to a flexible polymer (such as DNA) anchored on a solid surface to form tethered particles. Binding the analyte-bead complex to a flexible polymer forms tethered part...Tue, 06 Dec 2022 12:02:43 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Highly_Sensitive_Tethered-Bead_Immune_Sandwich_AssayTAB-2898https://nih.technologypublisher.com/tech/Octopod_(8-Pointed_Star)_Iron_Oxide_Nanoparticles_Enhance_MRI_T2_ContrastThe octopod-shaped iron oxide nanoparticles of this technology significantly enhance contrast in MRI imaging compared to spherical superparamagnetic iron oxide nanoparticle T2 contrast agents. These octopod iron oxide nanoparticles show a transverse relaxivity that is over five times greater than comparable spherical agents. Because the unique octopod shape creates a greater effective radius than spherical agents, but maintains similar magnetization properties, the relaxation rate is improved. The improved relaxation rate greatly enhances the contrast of images. These octopod agents appear to ...Tue, 06 Dec 2022 12:02:42 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Octopod_(8-Pointed_Star)_Iron_Oxide_Nanoparticles_Enhance_MRI_T2_ContrastTAB-2897https://nih.technologypublisher.com/tech/Cannabinoid_Receptor_Meditating_Compounds_for_Metabolic_DiseaseThere is evidence that the metabolic effects of endocannabinoids are mediated by CB1 receptors in peripheral tissues. While prior attempts at generating CB1 receptor blockers have had serious neuropsychiatric side effects, inventors at NIH have discovered compounds that block CB1 receptors with reduced brain penetrance. In addition, some of these compounds also have a direct inhibitory effect on inducible nitric oxide synthase (iNOS), whereas another group of the compounds directly activates AMP kinas. These dual-target compounds may be useful for treating metabolic disease and related cond...Tue, 06 Dec 2022 12:02:41 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Cannabinoid_Receptor_Meditating_Compounds_for_Metabolic_DiseaseTAB-2896https://nih.technologypublisher.com/tech?title=Ultra-sensitive_Diagnostic_Detects_fg%2fmL-pg%2fmL_Pathogen%2fDisease_Protein_by_Visual_Color_ChangeThis technology is an ultra-sensitive colorimetric assay, based on an enzyme-catalyzed gold nanoparticle growth process, for detection of disease-associated proteins (biomarkers) and disease diagnosis. Current detection methods, such as ELISA immunoassays, measure concentrations above 0.1 ng/mL in a sample. PCR, although more sensitive than ELISA, requires expensive and specialized equipment and reagents, skilled labor, and complex analysis techniques. This assay detects fg/mL to pg/mL concentrations, allowing detection and diagnosis in the earliest stage of disease or infection. A simple to r...Tue, 06 Dec 2022 12:02:40 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech?title=Ultra-sensitive_Diagnostic_Detects_fg%2fmL-pg%2fmL_Pathogen%2fDisease_Protein_by_Visual_Color_ChangeTAB-2895https://nih.technologypublisher.com/tech/A_Novel_Virus-Based_Expression_SystemThe present invention is related to a recombinant viral vector for vaccines. Currently available poxvirus vectors for humans and other animals exhibit suboptimal expression of recombinant gene(s) and high expression of vector proteins which causes weak immunogenicity and high anti-vector immune response. The present novel virus-based expression vectors are non-replicating in human and animals, have high expression of exogenous genes to achieve strong immunogenicity, demonstrate low expression of vector proteins to minimize anti-vector immune responses and minimize competition with expression o...Tue, 06 Dec 2022 12:02:39 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/A_Novel_Virus-Based_Expression_SystemTAB-2894https://nih.technologypublisher.com/tech/Microscopy_System_for_Distinguishing_Stimulated_Emissions_as_a_Means_of_Increasing_SignalThe invention pertains to a system and method for distinguishing stimulated emissions as a means of enhancing signal strength of fluorescent markers in fluorescence microscopy applications. The system is arranged such that an excitation beam (e.g., laser beam) illuminates a sample along some axis exciting the fluorescent markers used in the sample. A second light beam, a stimulation beam, illuminates the sample along another axis, possibly the same as that of the excitation beam. It has been found that if the excited fluorescent molecules are illuminated with light of a stimulation beam at a p...Tue, 06 Dec 2022 12:02:38 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Microscopy_System_for_Distinguishing_Stimulated_Emissions_as_a_Means_of_Increasing_SignalTAB-2891https://nih.technologypublisher.com/tech/Novel_Method_and_Kit_Using_Monoclonal_Antibodies_for_More_Sensitive_Detection_of_Dengue_VirusFollowing primary dengue virus (DENV) infection, non-structural protein 1 (NS1), a dengue-specific glycoprotein, is present in blood and is easily detected by various assays. However, for any infection thereafter (secondary infection), bioavailability of the glycoprotein greatly reduces sensitivity of DENV detection. Since secondary DENV infection is a risk factor for developing hemorrhagic fever, there is increasing need for more sensitive detection at this stage. CDC investigators have developed a versatile method and monoclonal antibodies for detection of primary and secondary DENV infectio...Tue, 06 Dec 2022 12:02:36 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Novel_Method_and_Kit_Using_Monoclonal_Antibodies_for_More_Sensitive_Detection_of_Dengue_VirusTAB-2890https://nih.technologypublisher.com/tech/Mobile_Instrumentation_for_the_Detection_and_Sampling_of_Aerosol_ParticlesTue, 06 Dec 2022 12:02:35 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Mobile_Instrumentation_for_the_Detection_and_Sampling_of_Aerosol_ParticlesTAB-2889https://nih.technologypublisher.com/tech?title=High-Titer%2c_Fast-Growth_Chimeric_Dengue%2fWest_Nile_Viruses_for_Vaccine_and_Diagnostics_DevelopmentMosquito-transmitted dengue virus is one of the leading causes of illness in the tropics and subtropics. There is currently no vaccine available and a number of DENV diagnostic and research applications depend on the production of large amounts of these viruses. However, due to the slow growing nature of DENVs these protocols are very time-consuming. Researchers at the CDC have engineered stable, rapidly growing dengue-like viruses by combining the fast replicative ability of the West Nile virus with the immunogenic premembrane and envelope surface proteins of DENV serotypes 1, 2, 3, and 4, re...Tue, 06 Dec 2022 12:02:33 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech?title=High-Titer%2c_Fast-Growth_Chimeric_Dengue%2fWest_Nile_Viruses_for_Vaccine_and_Diagnostics_DevelopmentTAB-2888https://nih.technologypublisher.com/tech/Autodock_Vina_Software_Process_for_Efficient_Large-Scale_Cognate_Ligand_ScreeningThe invention pertains to software processes, additions, and docking approaches to Autodock Vina that speeds the rate and efficiency of analyzing ligand interactions with a receptor by cognate ligands and rewards conformations in the scoring algorithm for residue interactions that are based on the biological data. The score is multiplied by a weighting factor to control the degree of ligand-residue interactions that are considered. This multiplier is then added to the docking score for confirmation. This new scoring mechanism is used to score each compound in each generation of the evolutionar...Tue, 06 Dec 2022 12:02:32 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Autodock_Vina_Software_Process_for_Efficient_Large-Scale_Cognate_Ligand_ScreeningTAB-2887https://nih.technologypublisher.com/tech/Heterocyclic_Compounds_for_the_Treatment_of_Hepatitis_C_VirusThe vast majority of people infected with Hepatitis C Virus (HCV) will have chronic infection. Over decades, this can lead to liver disease and liver cancer. In fact, HCV infection is the leading cause of liver transplants in the U.S. Several new drugs have recently come into the market that have changed the HCV treatment paradigm. However, the effectiveness of these new drugs can vary depending on the HCV genotype. Furthermore, all oral, interferon free therapeutic regimens for HCV infection will need combinations of drugs that target different aspects of the HCV life cycle. Thus, there...Tue, 06 Dec 2022 12:02:31 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Heterocyclic_Compounds_for_the_Treatment_of_Hepatitis_C_VirusTAB-2884https://nih.technologypublisher.com/tech/Novel_Codon-Optimized_Gene_Therapeutic_for_Methylmalonic_AcidemiaMethylmalonic Acidemia (MMA) is a metabolic disorder characterized by increased acidity in the blood and tissues due to toxic accumulation of protein and fat by-products resulting in seizures, strokes, and chronic kidney failure. A significant portion of MMA cases stem from a deficiency in a key mitochondrial enzyme, methylmalonyl-CoA mutase (MUT), required to break down amino acids and lipids. Currently, there are no treatments for MMA and the disease is managed primarily with dietary restriction of amino acid precursors and liver-kidney transplantation in severe cases. The present invention...Tue, 06 Dec 2022 12:02:30 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Novel_Codon-Optimized_Gene_Therapeutic_for_Methylmalonic_AcidemiaTAB-2882https://nih.technologypublisher.com/tech/Resolution_Enhancement_for_Line-Scanning_Excitation_MicroscopyThe invention describes a method for improving the spatial resolution of optical microscopes that use line-scanning excitation, such as line-scanning confocal microscopes, line-scanning STED microscopes, or line-scanning light-sheet microscopes. Common elements of the invention include: a) an apparatus for exciting and scanning a line-like excitation focus through the sample; b) an optical arrangement on the detection side of the microscope for manipulating the spacing and/or width of the resulting fluorescence emissions; c) integration and optional post-processing of the manipulated fluoresce...Tue, 06 Dec 2022 12:02:29 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Resolution_Enhancement_for_Line-Scanning_Excitation_MicroscopyTAB-2881https://nih.technologypublisher.com/tech/Resolution_Enhancement_for_Light_Sheet_Microscopy_SystemsThe invention pertains to a technique for enhancing the resolution of images in light sheet microscopy by adding additional enhanced depth-of-focus optical arrangements and high numerical aperture objective lenses. The technique employs an arrangement of three objective lenses and a processor for combining captured images. The image composition utilizes the greater resolving power of the third high numerical aperture objective lens by imaging the light sheet and enhanced depth-of-focus arrangement resulting in improved overall resolution of the light sheet system. The depth of field arrange...Tue, 06 Dec 2022 12:02:27 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Resolution_Enhancement_for_Light_Sheet_Microscopy_SystemsTAB-2875https://nih.technologypublisher.com/tech?title=A_Current_Amplifier_for_Local_Coil_Pre-amplification_of_NMR%2fMRI_SignalsThe magnetic resonance imaging (MRI) systems are used for a variety of imaging application. The present invention discloses an improving MRI device and method by amplifying signals received by resonant NMR coils of MRI systems. It utilizes positive feedback from low-noise Field-Effect Transistor to amplify the signal current that can be coupled out to receiving loops positioned externally without loss in sensitivity. Therefore, the NMR coil can be flexibly positioned near internal tissues and used to develop high-resolution images in highly invasive situations. The disclosed device can be ...Tue, 06 Dec 2022 12:02:26 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech?title=A_Current_Amplifier_for_Local_Coil_Pre-amplification_of_NMR%2fMRI_SignalsTAB-2863https://nih.technologypublisher.com/tech/A_Novel_X-ray_Grating_to_Enhance_Phase_Contrast_ImagingThe present invention relates to improving x-ray phase contrast imaging. The invention discloses a novel grating interferometer for phase contrast imaging with hard x-rays that overcomes limitations in the level of sensitivity by utilizing the advantages of far-field interferometers. The novel design and fabrication process can easily acquire absolute and differential phase images of lightly absorbing samples.Tue, 06 Dec 2022 12:02:23 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/A_Novel_X-ray_Grating_to_Enhance_Phase_Contrast_ImagingTAB-2862https://nih.technologypublisher.com/tech/A_Novel_Demodulation_System_in_X-ray_ImagingIn various x-ray imaging methods, including scattering correction and phase contrast imaging, intensity modulation in space is introduced into the projection images by the use of masks, gratings, or apertures. The present invention relates to a process to demodulate the modulation. The current demodulation processes are either to remove the modulation pattern through digital processing or to move the modulation pattern on the detector in a series of images that requires mechanical movements of a component and tends to lose some information of the imaged object. The demodulation of the prese...Tue, 06 Dec 2022 12:02:22 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/A_Novel_Demodulation_System_in_X-ray_ImagingTAB-2854https://nih.technologypublisher.com/tech/Inhibition_of_HIV_Infection_through_Chemoprophylaxis_Using_Emtricitabine_and_TenofovirThe invention is directed to prophylactic administration of emtricitabine (FTC) in combination with tenofovir or its prodrug, tenofovir disoproxil fumarate (TDF), to protect against transmission of human immunodeficiency virus (HIV) infection. Also disclosed are other nucleoside reverse transcriptase inhibitors (NRTIs) and nucleotide reverse transcriptase inhibitors (NtRTIs) that, when administered in combination, protect against HIV infection. CDC researchers demonstrated that daily pre-exposure prophylaxis (PrEP) with a combination of antiretroviral NRTI and NtTRI drugs, including FTC and TD...Tue, 06 Dec 2022 12:02:21 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Inhibition_of_HIV_Infection_through_Chemoprophylaxis_Using_Emtricitabine_and_TenofovirTAB-2847https://nih.technologypublisher.com/tech/Novel_Epstein-Barr_Virus_VaccinesEpstein-Barr Virus (EBV) is the causative agent of infectious mononucleosis and is associated with certain types of cancers, such as Hodgkin's lymphoma, Burkitt's lymphoma, gastric carcinoma, and nasopharyngeal carcinoma. There are currently no vaccines against EBV on the market and there is only supportive treatment available for EBV infection. The subject technologies are novel vaccine candidates against EBV that employ fusion proteins consisting of immunogenic portions of the EBV envelope glycoproteins (i.e. gp350, gH/gL, etc.) that are found on the surface of the virus fused with a self-a...Tue, 06 Dec 2022 12:02:19 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Novel_Epstein-Barr_Virus_VaccinesTAB-2840https://nih.technologypublisher.com/tech/Polypeptides_and_Methods_for_Enhancing_and_Balancing_Monovalent_or_Multivalent_Flavivirus_VaccinesCDC researchers have developed a potent immunogenic enhancer polypeptide useful for improving flavivirus vaccines. Flaviviruses such as dengue virus (1, 2, 3 and 4), Japanese encephalitis virus, Murray Valley encephalitis virus, St. Louis encephalitis virus, yellow fever virus and tick-borne encephalitis virus are a great burden on public health. This technology describes an identified CD4+ T cell epitope occurring within the E-glycoprotein of West Nile virus and methods of using this polypeptide to increase vaccine immunogenicity in monovalent vaccines. Many attempts to develop multivalent ...Tue, 06 Dec 2022 12:02:17 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Polypeptides_and_Methods_for_Enhancing_and_Balancing_Monovalent_or_Multivalent_Flavivirus_VaccinesTAB-2839https://nih.technologypublisher.com/tech/Novel_Enzyme-Based_Immunoassay_for_Simultaneous_Detection_of_Hepatitis_C_Virus_Antigen_and_Antibody_in_Human_Serum_or_PlasmaCDC scientists have developed a novel enzyme immunoassay for the simultaneous detection of hepatitis C virus (HCV) core antigen and circulating HCV antibodies. Serological testing procedures for HCV circulating antibodies are well established. There is, however, a window of time between HCV infection and seroconversion that generates an opportunity for false negative results. This period varies from two months in immunocompetent subjects to six to twelve months in immunodeficient patients. Combination testing, utilizing both serological testing and PCR-based techniques, can be used to overcom...Tue, 06 Dec 2022 12:02:16 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Novel_Enzyme-Based_Immunoassay_for_Simultaneous_Detection_of_Hepatitis_C_Virus_Antigen_and_Antibody_in_Human_Serum_or_PlasmaTAB-2836https://nih.technologypublisher.com/tech/Small_Molecule_Imaging_of_Fungi_by_Positron_Emission_Tomography_ScanningThis technology relates to the field of radioactive, isotopically-labeled calcofluor derivatives and uses of such compounds to detect a broad spectrum of filamentous fungi including pathogenic species such as Aspergillus and Mucorales, by diagnostic imaging methods such as positron emission tomography (PET) scanning. Aspergillosis and other filamentous fungal infections are increasingly common fungal lung infection with high mortality rates (over 50%) in immune compromised patients, such as those receiving chemotherapy, stem cell/organ transplantation, or HIV patients. One-year survival of the...Tue, 06 Dec 2022 12:02:15 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Small_Molecule_Imaging_of_Fungi_by_Positron_Emission_Tomography_ScanningTAB-2832https://nih.technologypublisher.com/tech/AMA1-RON2_Complex-Based_Vaccine_Against_MalariaThis technology relates to a malaria vaccine composed of a protein complex of Apical Membrane Antigen (AMA1) and rhoptry neck protein 2 (RON2) with an adjuvant. AMA1 is a crucial component of the Plasmodium invasion machinery and is a leading candidate for antimalarial vaccine development. AMA1-based vaccines have shown ability to block red cell invasion in in vitro assays, but protection has so far not translated to in vivo human infections. NIAID investigators have demonstrated that interaction between AMA1 and RON2 (or peptide thereof) is essential for malaria parasites to successfully ...Tue, 06 Dec 2022 12:02:13 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/AMA1-RON2_Complex-Based_Vaccine_Against_MalariaTAB-2830https://nih.technologypublisher.com/tech/Treatment_of_Chronic_Kidney_Disease_with_Synthetic_Amphipathic_PeptidesThe invention is directed to treatment of chronic kidney disease by administering a synthetic, amphipathic helical peptide known as 5A-37pA, and novel derivatives thereof. Scientists at NIDDK have demonstrated that invention peptides antagonize activity of a particular scavenger receptor known as CD36. Using an in vivo model, NIDDK scientists have shown that invention peptides slowed progression of chronic kidney disease and can potentially be utilized as a therapeutic treatment. Additionally, certain invention peptides bind selectively to CD36 with high specificity over other homologous scave...Tue, 06 Dec 2022 12:02:12 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Treatment_of_Chronic_Kidney_Disease_with_Synthetic_Amphipathic_PeptidesTAB-2828https://nih.technologypublisher.com/tech?title=On-site_in_vitro_Diagnostic%3a_Real-time_Loop-Mediated_Isothermal_Amplification_Detection_of_HIV-2_Groups_A_and_BThis CDC-developed technology entails a nucleic acid-based HIV-2 in vitro diagnostic assay that is well-suited for use in mobile testing units/vehicles or resource-limited settings, for example, many areas of West Africa. Because HIV-2 requires unique treatment regimens, accurate, early diagnosis is crucial for effective care and directing treatment. Recently, new HIV testing recommendations have been proposed for laboratory settings, which include the use of a HIV-1/HIV-2 discriminatory assay. The use of a discriminatory assay will aid clinicians in the detection of HIV-2 infection; howev...Tue, 06 Dec 2022 12:02:11 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech?title=On-site_in_vitro_Diagnostic%3a_Real-time_Loop-Mediated_Isothermal_Amplification_Detection_of_HIV-2_Groups_A_and_BTAB-2827https://nih.technologypublisher.com/tech?title=Occupational_Health%3a_Wearable_Kneel-Sit_Support_Device_for_Manual_Labor_and_Heavy_Industry_ApplicationsThis CDC-developed technology describes a novel ergonomic device that supports a portion of the worker's weight while kneeling, relieving the knee pressure and pain common to many manual labor occupations. Unfortunately, many of the devices that have been used in the past to relieve pressure on the knees are bulky, heavy, and of questionable durability. This device relieves pressure from the knees while kneeling, is easily portable, is attachable to the body, and can be moved automatically by the user without the user having to pick up the device and manually move it to a new position. The dev...Tue, 06 Dec 2022 12:02:09 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech?title=Occupational_Health%3a_Wearable_Kneel-Sit_Support_Device_for_Manual_Labor_and_Heavy_Industry_ApplicationsTAB-2826https://nih.technologypublisher.com/tech?title=Occupational_Safety%3a_Portable_Exposure_Assessment_System_for_Prevention_of_Musculoskeletal_InjuryCDC researchers have developed the Portable Exposure Assessment System (PEAS), a field-based, remotely deployed tool to monitor and provide early warning of working conditions that have a high likelihood of musculoskeletal injury. PEAS is a noninvasive, real-time, instrument-based system. Sensor technology simultaneously measures and collects data regarding the body loads and awkward postures imposed by package handling as well as driving-related, low-frequency vibrations. Wireless technology establishes communication links between the sensors and a data logger and between the data logger an...Tue, 06 Dec 2022 12:02:08 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech?title=Occupational_Safety%3a_Portable_Exposure_Assessment_System_for_Prevention_of_Musculoskeletal_InjuryTAB-2825https://nih.technologypublisher.com/tech?title=Hearing_Safety_Devices%3a_System_for_Monitoring_Exposure_to_Impulse_NoiseThis CDC-developed technology entails a system for monitoring and assessing the risk of auditory damage from exposure to impulse noise, such as noise created by construction machinery and firearms. Noise dosimeters have been used extensively over the past two decades to document personal exposure to noise and assure workplaces comply with permissible noise exposure levels. However, due to older methods of calculating "noise dose," current noise dosimeters often inaccurately determine the risk of an impulse event. Further, current state-of-the-art noise dosimeters have a sound pressure level...Tue, 06 Dec 2022 12:02:07 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech?title=Hearing_Safety_Devices%3a_System_for_Monitoring_Exposure_to_Impulse_NoiseTAB-2824https://nih.technologypublisher.com/tech/Improved_Acoustic_Plethysmograph_System_for_Noninvasive_Measurement_of_Pulmonary_FunctionCDC researchers have developed a novel acoustic whole body plethysmograph (AWBP) that allows measurement of tidal volume in lab animals, independent of gas compression in the lung. This system provides particular advantages over the traditional whole body plethysmograph (WBP) when measuring model animals with increased gas compression due to increased airway resistance or increased acceleration in the breathing pattern. Measurement of tidal volume in conscious, unrestrained mice has traditionally been performed using WBP. An animal is placed in a chamber where pressure changes due to respirat...Tue, 06 Dec 2022 12:02:06 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Improved_Acoustic_Plethysmograph_System_for_Noninvasive_Measurement_of_Pulmonary_FunctionTAB-2823https://nih.technologypublisher.com/tech/Focused_Electrostatic_Collection_of_Aerosol_Particles_for_Chemical_Analysis_by_Spectroscopic_TechniquesThis CDC-developed technology is an aerosol preconcentration unit (APU) designed for use with spectroscopic detection techniques, including emission, Raman, or infrared spectroscopies. Most existing pulsed microplasma techniques, such as laser-induced breakdown, for aerosols rely mainly on filter-based collection and suffer from poor accuracy, precision, and detection limits and require long sample collection times. The APU is designed to address these drawbacks by pre-concentrating the aerosol particles on a tip of a microelectrode (a few hundreds of micrometers in diameter) to allow near-rea...Tue, 06 Dec 2022 12:02:04 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Focused_Electrostatic_Collection_of_Aerosol_Particles_for_Chemical_Analysis_by_Spectroscopic_TechniquesTAB-2822https://nih.technologypublisher.com/tech?title=Multiplex_Assay_for_Rapid_Salmonella_Serotyping_from_Human%2c_Animal%2c_Food_and_Environmental_Sources2,500 known serotypes using current methods is difficult, expensive and laborious. Many clinical Salmonella isolates can require three to five days to determine serotype, delaying conclusive serotype identification and postponing alerts to public health monitoring progra...]]>Tue, 06 Dec 2022 12:02:03 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech?title=Multiplex_Assay_for_Rapid_Salmonella_Serotyping_from_Human%2c_Animal%2c_Food_and_Environmental_SourcesTAB-2821https://nih.technologypublisher.com/tech?title=MDCK-based_Reporter_System_for_Detection_of_Influenza_Viruses%2c_Antiviral_Drug_Screening%2c_and_Analysis_of_Neutralizing_AntibodiesCDC researchers have developed a Madin-Darby Canine Kidney (MDCK) reporter cell line that is exceptionally permissive for influenza virus replication and provides a highly specific, sensitive approach for the simultaneous detection and isolation of influenza viruses. Simplified antibody neutralization assays and high-throughput antiviral drug screening can also be easily and efficiently implemented using this reporter system. Laboratories generally rely on embryonated chicken eggs or mammalian cell cultures for isolation and propagation of influenza viruses. This approach is hampered by the r...Tue, 06 Dec 2022 12:02:02 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech?title=MDCK-based_Reporter_System_for_Detection_of_Influenza_Viruses%2c_Antiviral_Drug_Screening%2c_and_Analysis_of_Neutralizing_AntibodiesTAB-2820https://nih.technologypublisher.com/tech/Discrete_Cross-Reactive_Epitopes_for_Flavivirus_Serological_Diagnostics_and_VaccinesCDC researchers have identified and characterized discrete flavivirus cross-reactive epitopes useful for improving serodiagnosis and vaccination of flaviviruses, such as dengue virus, yellow fever virus, Japanese encephalitis virus, West Nile virus and the tick-borne encephalitis viruses. The flavivirus envelope glycoprotein is one of the primary antigens inducing protective immunity in a host. Human flavivirus infections stimulate virus species-specific as well as flavivirus-genus cross-reactive immune responses. These cross-reactive antibodies create a serious problem for serodiagnosis, es...Tue, 06 Dec 2022 12:02:01 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Discrete_Cross-Reactive_Epitopes_for_Flavivirus_Serological_Diagnostics_and_VaccinesTAB-2819https://nih.technologypublisher.com/tech/A_Device_for_Simultaneous_and_Rapid_Diagnosis_and_Detection_of_Recent_and_Long_Term_HIV-1_InfectionCDC scientists have developed a device for simultaneous rapid diagnosis of HIV infection and for identification of recent HIV-1 infection. The device utilizes immunochromatographic or flow-through principles to detect HIV antibodies within clinical samples. This device may be used for diagnosis of HIV infection, as well as to distinguish between recent infection (1 year). This latter application has added significance for surveillance, counseling, partner notification and other related prevention concerns, including the estimation of HIV incidence in cross-sectional populations. The device, if...Tue, 06 Dec 2022 12:02:00 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/A_Device_for_Simultaneous_and_Rapid_Diagnosis_and_Detection_of_Recent_and_Long_Term_HIV-1_InfectionTAB-2818https://nih.technologypublisher.com/tech?title=Simple%2c_Field-Usable_Fluorescence-Based_Isothermal_LAMP_Assay_for_the_On-Site_Diagnosis_of_MalariaCDC researchers have developed improved Loop-Mediated Isothermal Amplification (LAMP) assays for the nucleic acid-based diagnosis of malaria in field settings. The approach employs Plasmodium genus-specific LAMP primers and a portable tube scanner to run the LAMP reaction and measure fluorescence signal (e.g., SYBR green) as a measure of DNA amplification in real time. Using this platform, the researchers were able to detect several different species of the human malaria parasites. This LAMP approach has demonstrated the ability of this assay to detect P. falciparum in clinical samples with ap...Tue, 06 Dec 2022 12:01:59 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech?title=Simple%2c_Field-Usable_Fluorescence-Based_Isothermal_LAMP_Assay_for_the_On-Site_Diagnosis_of_MalariaTAB-2817https://nih.technologypublisher.com/tech?title=Local_Positioning_System_for_Position-Time-Condition_Correlation%2c_Data-logging_and_AnalysisThis CDC-developed technology describes an automated system for monitoring worker hazard exposures by recording data about where and when hazards occur in a workplace or other environment. This allows the hazards to be avoided and harmful exposures and risks reduced. This field-tested technology consists of an integrated, hand-held electronics instrument and software system that will precisely correlate multiple exposure levels with position coordinates of the user and features real-time data acquisition. Workers in many outdoor occupations move about frequently during a typical day of work. ...Tue, 06 Dec 2022 12:01:58 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech?title=Local_Positioning_System_for_Position-Time-Condition_Correlation%2c_Data-logging_and_AnalysisTAB-2816https://nih.technologypublisher.com/tech/Methods_for_Near_Real-time_Chemical_Analysis_of_Aerosols_using_Microwave-induced_Plasma_SpectroscopyThis CDC developed technology entails a novel method of near real-time elemental analysis of aerosols by corona assisted microwave induced plasma spectroscopy (CAMPS). Analysis of elemental composition of aerosol particles holds significant implications for environmental and workplace pollution monitoring. Various plasma based analytical techniques, including laser-induced breakdown spectroscopy (LIBS) and spark-induced breakdown spectroscopy (SIBS), have been successfully used for multi-elemental analyses in solids, liquids, and gases, including aerosols. However, the characterization of fine...Tue, 06 Dec 2022 12:01:57 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Methods_for_Near_Real-time_Chemical_Analysis_of_Aerosols_using_Microwave-induced_Plasma_SpectroscopyTAB-2813https://nih.technologypublisher.com/tech/Novel_Dopamine_D2_Receptor_Antagonists_and_Methods_of_Their_UseInvestigators at the NIH have identified a series of novel, small molecule antagonists of the dopamine D2 receptor. Among the dopamine receptor (DAR) subtypes, D2 DAR is arguably one of the most validated drug targets in neurology and psychiatry. For instance, all receptor-based anti-Parkinsonian drugs work via stimulating the D2 DAR, whereas all FDA approved antipsychotic agents are antagonists of this receptor. Unfortunately, most agents that act as antagonists of D2 DAR are problematic, either they are less efficacious than desired or cause multiple adverse effects. Thus, it is desirable to...Tue, 06 Dec 2022 12:01:55 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Novel_Dopamine_D2_Receptor_Antagonists_and_Methods_of_Their_UseTAB-2811https://nih.technologypublisher.com/tech/Real_Time_Medical_Image_Processing_Using_Cloud_ComputingThe invention pertains to a system for reconstructing images acquired from MR and CT scanners in a robust Gadgetron based cloud computing system. A hardware interface connects clinical imaging instruments (e.g., MR or CT scanners) with a cloud computing environment that includes image data reconstruction and processing software not limited by the computational constraints typical of static hardware with finite processor power. Raw imaging data acquired from an MR or CT instrument is evaluated and categorized based on a pre-prioritized dimensionality parameter (e.g., spatial dimension paramete...Tue, 06 Dec 2022 12:01:54 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Real_Time_Medical_Image_Processing_Using_Cloud_ComputingTAB-2809https://nih.technologypublisher.com/tech/Viral_Like_Particles_Based_Chikungunya_VaccinesChikungunya virus (CHIKV) is mosquito-borne alphavirus endemic in Africa, India, and Southeast Asia. In 2013 CHIKV infection has also emerged in the Caribbean and a pandemic of CHIKV has re-emerged in the Philippines following Typhoon Haiyan. Currently, there is no vaccine available for the prevention of CHIKV infection and no specific therapy exists to treat the illness. Researchers at the Vaccine Research Center (VRC) of the National Institute of Allergy and Infectious Diseases (NIAID) have developed a CHIKV Viral Like Particle (CHIKV VLP) vaccine based on plasmid expression vectors encodi...Tue, 06 Dec 2022 12:01:53 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Viral_Like_Particles_Based_Chikungunya_VaccinesTAB-2808https://nih.technologypublisher.com/tech/Use_of_Antihistamine_Compounds_for_the_Treatment_of_Hepatitis_C_VirusThe vast majority of people infected with Hepatitis C Virus (HCV) will have chronic infection. Over decades, this can lead to liver disease and liver cancer. In fact, HCV infection is the leading cause of liver transplants in the U.S. Several new drugs have recently come into the market that will likely change the HCV treatment paradigm. However, the effectiveness of these new drugs can vary depending on the HCV genotype. Thus, there is still the need for additional new therapeutics against HCV. The subject technology are small molecule compounds identified using a novel cell-based high t...Tue, 06 Dec 2022 12:01:51 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Use_of_Antihistamine_Compounds_for_the_Treatment_of_Hepatitis_C_VirusTAB-2804https://nih.technologypublisher.com/tech/Engineering_Neural_Stem_Cells_Using_Homologous_RecombinationMethods for modifying the genome of a Neural Stem Cell (NSC) are disclosed. Also, methods for differentiating NSCs into neurons and glia are described. NSCs are multipotent, self-renewing cells found in the central nervous system, capable of differentiating into neurons and glia. NSCs can be generated efficiently from pluripotent stem cells (PSCs) and have the capacity to differentiate into any neuronal or glial cell type of the central nervous system. Improvements in genome engineering of NSCs can potentially facilitate cellular replacement therapies for the treatment of neurodegenerative d...Tue, 06 Dec 2022 12:01:49 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Engineering_Neural_Stem_Cells_Using_Homologous_RecombinationTAB-2800https://nih.technologypublisher.com/tech/Compositions_and_Methods_for_Improved_Lyme_Disease_DiagnosisThis CDC-developed technology entails novel compositions and methods related to the diagnosis of Lyme disease. Lyme disease, caused by the Borrelia burgdorferi bacterium, is the most common tick-borne infectious disease in the US and Europe. Diagnosis of Lyme disease is particularly challenging as symptoms often appear long after exposure. At present, the only FDA-approved diagnostic for Lyme disease involves patient blood tests for particular antibodies; these include an ELISA to measure patient antibody levels and a Western blot assay to detect antibodies specific to B. burgdorferi. One ...Tue, 06 Dec 2022 12:01:47 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Compositions_and_Methods_for_Improved_Lyme_Disease_DiagnosisTAB-2799https://nih.technologypublisher.com/tech/Novel_Small_Molecule_Antimalarials_for_Elimination_of_Malaria_TransmissionThe transmission of malaria begins with injection of sporozoites into a human from the bite of a female anopheles mosquito, which initiates the malarial life cycle in humans. When a mosquito bites an infected human, the ingested male and female malaria gametocytes fuse to form a zygote that eventually becomes an oocyst. Each oocyst produces thousands of sporozoites which migrate to the mosquito salivary glands, ready to infect a new human host. Currently, the available therapeutics for malaria can effectively eliminate the asexual stages of malarial parasites that cause clinical symptoms in ...Tue, 06 Dec 2022 12:01:46 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Novel_Small_Molecule_Antimalarials_for_Elimination_of_Malaria_TransmissionTAB-2796https://nih.technologypublisher.com/tech/Human_iPSC-Derived_Mesodermal_Precursor_Cells_and_Differentiated_CellsCells, cell culture methods, and cell culture media compositions useful for producing and maintaining iPSC-derived cell lines that are of higher purity and maintain cell type integrity better than current iPSC-derived cell lines are disclosed. Human induced pluripotent stem cells (hiPSCs) can be generated by reprogramming somatic cells by the expression of four transcription factors. The hiPSCs exhibit similar properties to human embryonic stem cells, including the ability to self-renew and differentiate into all three embryonic germ layers: ectoderm, endoderm, or mesoderm. Human iPSCs can be...Tue, 06 Dec 2022 12:01:44 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Human_iPSC-Derived_Mesodermal_Precursor_Cells_and_Differentiated_CellsTAB-2794https://nih.technologypublisher.com/tech?title=Dengue_Vaccines%3a_Tools_for_Redirecting_the_Immune_Response_for_Safe%2c_Efficacious_Dengue_VaccinationThis CDC-developed invention relates to dengue vaccines that have been specifically developed for improved efficacy and directed immune response to avoid antibody-dependent enhancement (ADE) safety issues that, theoretically, may be associated with dengue vaccines and vaccinations. Dengue viral infection typically causes a debilitating but non-lethal illness in hosts. However, dengue hemorrhagic fever (DHF), the much more severe and life-threatening condition, is generally attributed to secondary dengue infections caused by a serotype different from the initial infection serotype by way of ...Tue, 06 Dec 2022 12:01:42 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech?title=Dengue_Vaccines%3a_Tools_for_Redirecting_the_Immune_Response_for_Safe%2c_Efficacious_Dengue_VaccinationTAB-2793https://nih.technologypublisher.com/tech?title=Silica_Exposure_Safety%3a_Mini-baghouse_Systems_and_Methods_for_Controlling_Particulate_Release_from_Large_Sand_Transfer_EquipmentCDC/NIOSH scientists have developed an effective point-source control for silica-containing dusts that can be generated from machinery on sites where hydraulic fracturing is occurring. The CDC/NIOSH mini-baghouse retrofit assembly is a bolt-on control designed to contain silica-containing respirable dusts generated during refill operations of sand movers during hydraulic fracturing. In the U.S., most new oil and gas wells are hydraulically fractured to enhance well production. Most hydraulic fracturing operations have 2-5 sand movers on-site that transfer thousands to millions of pounds of si...Tue, 06 Dec 2022 12:01:41 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech?title=Silica_Exposure_Safety%3a_Mini-baghouse_Systems_and_Methods_for_Controlling_Particulate_Release_from_Large_Sand_Transfer_EquipmentTAB-2792https://nih.technologypublisher.com/tech?title=Human_Influenza_Virus_Real-time_RT-PCR%3a_Detection_and_Discrimination_of_Influenza_A_(H3N2)_Variant_from_Seasonal_Influenza_A_(H3N2)_Viruses%2c_Including_H3v_and_Seasonal_H3_AssaysThis invention relates to methods of rapidly detecting influenza, including differentiating between type and subtype. CDC researchers have developed a rapid, accurate, real-time RT-PCR assay that has several advantages over culture and serological tests, which require 5 to 14 days for completion; this assay can also be easily implemented in kit form. To date, hundreds of human cases of infection with the H3N2 variant virus have been confirmed. The increased numbers of human infection of H3N2 variant virus has led to a need for a highly sensitive and specific assay for the diagnosis and conf...Tue, 06 Dec 2022 12:01:39 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech?title=Human_Influenza_Virus_Real-time_RT-PCR%3a_Detection_and_Discrimination_of_Influenza_A_(H3N2)_Variant_from_Seasonal_Influenza_A_(H3N2)_Viruses%2c_Including_H3v_and_Seasonal_H3_AssaysTAB-2791https://nih.technologypublisher.com/tech/Deconvolution_Software_for_Modern_Fluorescence_MicroscopyThis software invention pertains to Joint Richardson-Lucy (RL) deconvolution methods used to combine multiple images of an object into a single image for improving resolution in modern fluorescence microscopy. RL deconvolution merges images with very different point spread functions, such as in multi-view light-sheet microscopes, while preserving the best resolution information present in each image. RL deconvolution is also easily applied to merge high-resolution, high noise images with low-resolution, low noise images, relevant when complementing conventional microscopy with localization mic...Tue, 06 Dec 2022 12:01:38 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Deconvolution_Software_for_Modern_Fluorescence_MicroscopyTAB-2789https://nih.technologypublisher.com/tech/Computer_Controlled_Aerosol_Generator_with_Multi-Walled_Carbon_Nanotube_Inhalation_Testing_CapabilitiesThis invention pertains to a CDC developed sonic aerosol generator that provides a controllable, stable concentration of particulate aerosol over a long period of time for aerosol exposure studies. Specifically, in situ testing data indicate uniform aerosol stability can be maintainable for greater than 30 hours at concentrations of 15 mg/m3 or more. Additionally, the technology was specifically developed for, and validated in, animal studies assessing exposure to airborne multi-walled carbon nanotubes (MWCNT). It has been suggested that workers may be at risk for exposure to nanosized part...Tue, 06 Dec 2022 12:01:37 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Computer_Controlled_Aerosol_Generator_with_Multi-Walled_Carbon_Nanotube_Inhalation_Testing_CapabilitiesTAB-2788https://nih.technologypublisher.com/tech?title=Mining_Safety%3a_Personal_Dust_Monitor_Filters_for_Accurate%2c_Quantifiable_Spectrometric_Analysis_and_Assessment_of_Worker_Exposure_LevelsThis CDC-developed invention pertains to a novel dust monitor filter that is specially constructed of organic materials for spectrometric analysis, ultimately allowing for detection and accurate quantification of a particular chosen analyte (e.g., crystalline silica/quartz dust that may lead to silicosis). For miners, the risk of lung disease increases with the extent of dust exposure, and coal worker's pneumoconiosis (aka, black lung disease) and silicosis are still dangers routinely faced by those in the industry. Expectedly, both the concentration and the composition of airborne particulat...Tue, 06 Dec 2022 12:01:35 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech?title=Mining_Safety%3a_Personal_Dust_Monitor_Filters_for_Accurate%2c_Quantifiable_Spectrometric_Analysis_and_Assessment_of_Worker_Exposure_LevelsTAB-2786https://nih.technologypublisher.com/tech?title=Cable-line_Safety_System%3a__Electro%2fhydraulic_Emergency_Stop_Device_for_a_Winch%2c_Drum_or_CapstanThis CDC-developed invention entails a system of electrical and hydraulic circuits used to stop a rotating winch in an emergency. Amongst other locations, one stop switch can be positioned on a capstan winch horn. This location makes it available to a victim entangled in rope being retrieved on a gypsy drum. As designed, the stop circuit could be used with an electrically, hydraulically or pneumatically operated winch. A variant of this safety system has been successfully tested on a purse seining fishing vessel in Alaskan waters.Tue, 06 Dec 2022 12:01:33 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech?title=Cable-line_Safety_System%3a__Electro%2fhydraulic_Emergency_Stop_Device_for_a_Winch%2c_Drum_or_CapstanTAB-2785https://nih.technologypublisher.com/tech?title=Rabies_Vaccine_for_the_Oral_Immunization_of_Domesticated_Animals%2c_Wildlife_and_Feral_AnimalsThis invention, developed by the CDC and collaborators, entails a live, attenuated recombinant rabies virus vaccine that can elicit an effective anti-rabies immune response in animal recipients. Inoculation with a live, attenuated, rabies virus allows for the optimized production of immunity in the absence of pathogenicity. Oral administration of rabies vaccines is often a preferred route of vaccine delivery because it is most effective in wildlife. Unfortunately, availability of an oral vaccine for canines has been a significant hurdle to date. This vaccine technology could be used for imm...Tue, 06 Dec 2022 12:01:31 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech?title=Rabies_Vaccine_for_the_Oral_Immunization_of_Domesticated_Animals%2c_Wildlife_and_Feral_AnimalsTAB-2781https://nih.technologypublisher.com/tech?title=Air_Quality_Assurance%3a_A_Monitor_for_Continuous%2c_Simultaneous_Analysis_of_Atmospheric_or_Aerosolized_Particulate_MixturesThis technology pertains to monitors for measuring the mass concentration of ambient particulate matter in an atmosphere containing both larger/coarser (e.g., respirable dust) and smaller/finer (sub-micrometer particles such as diesel particulate matter - DPM) particulate mixtures. The monitoring device can be configured for operation with a controller unit adapted to ionization sensor and/or light-scattering modules. The controller translates the sensor output signal into a quantifiable value, determining mass concentration of particulate matter within the ionization chamber. For example, ...Tue, 06 Dec 2022 12:01:28 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech?title=Air_Quality_Assurance%3a_A_Monitor_for_Continuous%2c_Simultaneous_Analysis_of_Atmospheric_or_Aerosolized_Particulate_MixturesTAB-2779https://nih.technologypublisher.com/tech?title=Multivalent%2c_Multiple-Antigenic-Peptides_for_Serological_Detection_of_HIV-1_Groups_-M%2c_-N%2c_-O%2c_and_HIV-2This CDC-developed invention pertains to multivalent antigenic peptides (MAPs) that can be used in a variety of HIV/AIDS diagnostics. There are two types of HIV: HIV-1 and HIV-2. HIV-1 is subdivided into groups M, N, and O, while HIV-2 is subdivided into subtypes A and B. Within HIV -1 group M, several different subtypes and numerous forms of recombinant viruses exist. To detect all types, groups, and subtypes of HIV by serological methods, a mixture of antigens derived from different viral strains representing different HIV types and subtypes is needed. However, due to the competition and...Tue, 06 Dec 2022 12:01:27 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech?title=Multivalent%2c_Multiple-Antigenic-Peptides_for_Serological_Detection_of_HIV-1_Groups_-M%2c_-N%2c_-O%2c_and_HIV-2TAB-2777https://nih.technologypublisher.com/tech/Recombinant_Sulfated_HIV_Envelope_Protein_and_Methods_for_Making_ProteinThis technology comprises sulfated recombinant gp120 proteins and peptides. Also included are methods for producing sulfated recombinant gp120 proteins. The focus of this technology is on sulfation of two tyrosines in the V2 loop of the HIV major envelope glycoprotein, gp120, which increase the stability of gp120 and promote the synthesis of gp120 protein in its native "closed" conformation. Gp120 in its native form is highly sulfated; however, recombinant gp120 produced for vaccines or structural analyses typically display low levels of V2 tyrosine sulfation. Sulfation of the V2 loop result...Tue, 06 Dec 2022 12:01:26 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Recombinant_Sulfated_HIV_Envelope_Protein_and_Methods_for_Making_ProteinTAB-2776https://nih.technologypublisher.com/tech/Methods_for_Amelioration_and_Treatment_of_Pathogen-associated_Inflammatory_ResponseThis CDC invention provides methods for preventing or treating inflammatory response-linked, infection induced pathologies, which are mediated by endogenous substance P. Substance P is a naturally-occurring and major pro-inflammatory neuromediator or neuromodulator, and elevated levels of substance P have been implicated in numerous inflammation-associated diseases. More specifically, this technology entails administration of anti-substance P antibodies or anti-substance P antibody fragments to a subject in need, thereby inhibiting the activity of endogenous substance P. Small molecule anti-...Tue, 06 Dec 2022 12:01:24 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Methods_for_Amelioration_and_Treatment_of_Pathogen-associated_Inflammatory_ResponseTAB-2775https://nih.technologypublisher.com/tech/Multiple_Antigenic_Peptide_Assays_for_Detection_of_HIV_and_SIV_Type_RetrovirusesCDC scientists have developed multiple antigenic peptide immunoassays for the detection of human immunodeficiency virus (HIV) and/or simian immunodeficiency virus (SIV). HIV can be subdivided into two major types, HIV-1 and HIV-2, both of which are believed to have originated as result of zoonotic transmission. Humans are increasingly exposed to many different SIVs by wild primates. For example, human exposure to SIVs frequently occurs as a consequence of the bush meat hunting and butchering trade in Africa. Human exposure to SIVs may lead, or may have already led, to transmission of SIV...Tue, 06 Dec 2022 12:01:23 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Multiple_Antigenic_Peptide_Assays_for_Detection_of_HIV_and_SIV_Type_RetrovirusesTAB-2774https://nih.technologypublisher.com/tech/Auscultatory_Training_System_and_Telemedicine_Tool_with_Accurate_Reproduction_of_Physiological_SoundsThis CDC developed auscultatory training apparatus includes a database of prerecorded physiological sounds (e.g., lung, bowel, or heart sounds) stored on a computer for playback. Current teaching tools, which utilize previously recorded sounds, suffer from the disadvantage that playback environments cause considerable distortion and errors in sound reproduction. For example, to those trainees using such systems, the reproduced respiratory sounds do not “sound” as if they are being generated by a live patient. Moreover, the aforementioned playback distortions often make it difficult for the ...Tue, 06 Dec 2022 12:01:22 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Auscultatory_Training_System_and_Telemedicine_Tool_with_Accurate_Reproduction_of_Physiological_SoundsTAB-2773https://nih.technologypublisher.com/tech/Diagnostic_Antigens_for_the_Identification_of_Latent_Tuberculosis_InfectionCDC researchers have developed technology for sero-diagnosis of typically symptomless latent stage tuberculosis disease, posing a threat to individuals under immunosuppressive or anti-inflammatory therapies. Specifically, this diagnostic approach exploits M. tuberculosis secreted latency specific antigens, such as alpha-crystallin, in the blood or urine of patients. This type of test could easily be developed into an inexpensive dip-stick format with high specificity (no cross-reactivity with other mycobacteria), rapidity, and sensitivity (fewer bacteria needed for a positive identification). ...Tue, 06 Dec 2022 12:01:21 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Diagnostic_Antigens_for_the_Identification_of_Latent_Tuberculosis_InfectionTAB-2772https://nih.technologypublisher.com/tech/Novel_In_Vitro_Granuloma_Model_for_Studying_Tuberculosis_and_Drug_EfficacyCDC researchers have developed an in vitro model system designed to simulate early-stage Mycobacterium tuberculosis infection and induced granuloma formation. This modeling platform can be used for studying tuberculosis pathogenicity, identifying phenotypically-interesting clinical isolates, studying early-stage host cytokine/chemokine responses, and in vitro candidate-drug screening. The approach incorporates autologous human macrophages, human peripheral blood mononuclear cells, and mycobacteria to mimic in situ granuloma formation in a controllable in vitro environment. This technology w...Tue, 06 Dec 2022 12:01:20 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Novel_In_Vitro_Granuloma_Model_for_Studying_Tuberculosis_and_Drug_EfficacyTAB-2770https://nih.technologypublisher.com/tech/Peptide_Sequences_for_Chlamydophila_pneumoniae_Vaccine_and_Serological_DiagnosisCDC researchers have isolated select Chlamydophila pneumoniae peptide epitopes for development of vaccines and diagnostic assays. Currently, C. pneumoniae infection of humans has been linked to a wide variety of acute and chronic diseases, such as asthma, endocarditis, atherosclerotic vascular disease, chronic obstructive pulmonary disease, sarcoidosis, reactive arthritis and multiple sclerosis. There is presently no available peptide vaccine for the pathogen and reliable and accurate diagnostic methods are limited. This technology encompasses polypeptide sequences that are specifically reco...Tue, 06 Dec 2022 12:01:19 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Peptide_Sequences_for_Chlamydophila_pneumoniae_Vaccine_and_Serological_DiagnosisTAB-2768https://nih.technologypublisher.com/tech/Recombinant_Polypeptides_for_Clinical_Detection_of_Taenia_solium_and_Diagnosis_of_CysticercosisCDC scientists have developed synthetic/recombinant polypeptides that can be used for the creation of inexpensive, high-quality cysticercosis diagnostic assays. Taenia solium is a species of pathogenic tapeworm. Intestinal infection with this parasite is referred to as taeniasis and it is acquired by ingestion of T. solium cysticerci found in raw and undercooked pork, or food contaminated with human or porcine excrement. Many infections are asymptomatic, but infection may be characterized by insomnia, anorexia, abdominal pain and weight loss. Cysticercosis is the formation of cysticerci in...Tue, 06 Dec 2022 12:01:17 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Recombinant_Polypeptides_for_Clinical_Detection_of_Taenia_solium_and_Diagnosis_of_CysticercosisTAB-2767https://nih.technologypublisher.com/tech/Methods_for_the_Simultaneous_Detection_of_Multiple_AnalytesCDC researchers have developed a method of simultaneously detecting and distinguishing multiple antigens within a biological sample. Epidemiological and vaccine studies require species serotype identification. Current methods of serotyping are labor intensive and can easily give subjective, errant results. This technology utilizes serotype specific antibodies bound to fluorescent beads, allowing for simultaneous single tube capture and detection of multiple antigens in one rapid, high-throughput flow cytometry assay. Such technology has an extremely wide range of useful applications, inclu...Tue, 06 Dec 2022 12:01:16 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Methods_for_the_Simultaneous_Detection_of_Multiple_AnalytesTAB-2766https://nih.technologypublisher.com/tech/Improved_Culture_Medium_for_Stem_Cell_Maintenance_and_DifferentiationA novel low protein culture medium with defined chemical components that allows pluripotent stem cell maintenance and differentiation is disclosed. The present technology also provides for production of high quality cardiac cells from human embryonic and induced pluripotent stem cells in chemically defined medium conditions. Human pluripotent stem cells, including human embryonic stem cells and human induced pluripotent stem cells, can be propagated indefinitely while still retaining the capacity to differentiate into all somatic cell types, and are a potentially inexhaustible supply of huma...Tue, 06 Dec 2022 12:01:15 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Improved_Culture_Medium_for_Stem_Cell_Maintenance_and_DifferentiationTAB-2764https://nih.technologypublisher.com/tech/Enterovirus_Molecular_Diagnostic_Test_KitCDC researchers have developed a reverse transcription/semi-nested polymerase chain reaction (RT-snPCR) assay for diagnosis of enterovirus infections within clinical specimens. Clinical laboratories currently identify enteroviruses by virus isolation and subsequent virus neutralization tests, or serological assays. In addition to being time consuming, these approaches are labor, cost and material intensive. The enterovirus molecular diagnostic test is prepared in a kit form, consisting of three reagent preparations (three separate test steps), to which a technician adds enzymes and RNA extra...Tue, 06 Dec 2022 12:01:13 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Enterovirus_Molecular_Diagnostic_Test_KitTAB-2762https://nih.technologypublisher.com/tech?title=Inexpensive%2c_Personal_Dust_Detector_Tube%2fDosimeter_Operating_on_a_Gas_Detector_Tube_PlatformThis CDC developed dust detector tube is designed to provide inexpensive, short-term, time weighted average dust exposure data feedback directly to device users. This invention operates upon a conventional gas detector tube platform and can be used with any low volume pump that can electronically measure pump back pressure. The device consists of three sections: the first defines the size of the dust and removes moisture, the second uses a filter whose pressure differential corresponds with cumulative dust loading, and a final section employs a pressure transducer. Current methods require exp...Tue, 06 Dec 2022 12:01:10 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech?title=Inexpensive%2c_Personal_Dust_Detector_Tube%2fDosimeter_Operating_on_a_Gas_Detector_Tube_PlatformTAB-2761https://nih.technologypublisher.com/tech?title=Automated_Microscopic_Image_Acquisition%2c_Compositing_and_Display_Software_Developed_for_Applied_Microscopy%2fCytology_Training_and_AnalysisMicro-Screen is a CDC developed software program designed to capture images and archive and display a compiled image(s) from a portion of a microscope slide in real time. This program allows for the re-creation of larger images that are constructed from individual microscopic fields captured in up to five focal planes and two magnifications. This program may be especially useful for the creation of data archives for diagnostic and teaching purposes and for tracking histological changes during disease progression.Tue, 06 Dec 2022 12:01:09 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech?title=Automated_Microscopic_Image_Acquisition%2c_Compositing_and_Display_Software_Developed_for_Applied_Microscopy%2fCytology_Training_and_AnalysisTAB-2760https://nih.technologypublisher.com/tech/Ultrasonic_in_situ_Respirator_Seal-Leakage_Detection_with_Real-time_Feedback_CapabilitiesThis CDC invention entails methods and apparatuses for in situ testing seal integrity and improved operation of respiratory masks (respirators). A variety of external factors, such as individual face shape, user environment, mask age and material used to construct the respirator, can lead to device malfunction and failure to sufficiently protect a user. To address these limitations, this invention relies on ultrasonic wave detection to assess face seal quality and other potential leak paths, as needed. Airborne ultrasound travel through atmosphere and will travel through respirator leaks. ...Tue, 06 Dec 2022 12:01:08 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Ultrasonic_in_situ_Respirator_Seal-Leakage_Detection_with_Real-time_Feedback_CapabilitiesTAB-2759https://nih.technologypublisher.com/tech/Physiologic_Sampling_Pump_Capable_of_Rapidly_Adapting_to_User_Breathing_RateThis CDC developed physiologic sampling pump (PSP) overcomes shortcomings of previous devices by the use of calibrated valves in conjunction with a constant speed pump. This novel approach obviates typical PSP inertia that inherently limits system response, functionality and accuracy. All prior PSP designs have attempted to follow a user's breathing pattern by changing pump speed, thereby altering sampling rate. In that approach, pump inertia will limit system response and function due to the time required to adjust speed. Additionally, variable pump speeds often produce size selective samp...Tue, 06 Dec 2022 12:01:07 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Physiologic_Sampling_Pump_Capable_of_Rapidly_Adapting_to_User_Breathing_RateTAB-2757https://nih.technologypublisher.com/tech?title=Extension-Ladder_Safety%3a_Multimodal-feedback_Indicator_for_Improved_Ladder_Positioning_Safety_and_EfficiencyImproper positioning of an extension ladder frequently results in "ladder slide-outs," which are the most common cause of ladder-fall scenarios. This invention relates to an extension ladder positioning indicator which is easily installed in a ladder rung; provides multiple cues (visual, sound, and vibration) for rapidly identifying and positioning correct ladder inclination. CDC-NIOSH researchers found that this technology improved accuracy and efficiency of ladder positioning for both "experienced" and "novice" ladder users, as compared to the "no instruction" method and the standard anthro...Tue, 06 Dec 2022 12:01:06 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech?title=Extension-Ladder_Safety%3a_Multimodal-feedback_Indicator_for_Improved_Ladder_Positioning_Safety_and_EfficiencyTAB-2758https://nih.technologypublisher.com/tech/Cylindrical_Handle_Dynamometer_for_Improved_Grip-Strength_MeasurementCDC researchers have developed an improved dynamometer device and method for measuring maximum hand grip force or grip-strength. Human test subjects were used in conducting experiments to evaluate the handle and to assess the measurement method. In contrast to the currently used "Jamar handle" grip strength dynamometer devices, the cylindrical handle proved to be able to determine the overall grip strength for a subject, as well as show the grip force distribution around the circumference of the handle. The cylindrical dynamometer handle is accurate with less than 4% error, and it demonstra...Tue, 06 Dec 2022 12:01:04 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Cylindrical_Handle_Dynamometer_for_Improved_Grip-Strength_MeasurementTAB-2751https://nih.technologypublisher.com/tech/Novel_One-Well_Limiting-Antigen_Avidity_Enzyme_Immunoassay_to_Detect_Recent_HIV-1_Infection_Using_a_Multi-subtype_Recombinant_ProteinThis CDC developed Limiting-Antigen avidity Enzyme Immunoassay (LAg-avidity-EIA) provides an easy way to measure increasing binding strength (avidity) of HIV antibodies as part of maturation HIV antibodies after seroconversion, providing a method to distinguish early-stage from long-term HIV-1 infection. Surveillance of HIV-1 provides information on prevalence rates of the disease, but determination of new infection rates (HIV-1 incidence) is difficult to deduce. Longitudinal follow up is expensive and can be biased. Unlike assays which use antigens derived from only one subtype and use two we...Tue, 06 Dec 2022 12:01:02 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Novel_One-Well_Limiting-Antigen_Avidity_Enzyme_Immunoassay_to_Detect_Recent_HIV-1_Infection_Using_a_Multi-subtype_Recombinant_ProteinTAB-2752https://nih.technologypublisher.com/tech?title=Improved_Botulism%2c_Botulinum_Neurotoxin_Type-E_DiagnosticsCDC researchers have improved upon a prior, HHS patented mass spectrometry-based Endopep-MS assay that is able to rapidly detect and differentiate all seven botulinum neurotoxin (BoNT) types A to G. This current improvement comprises the addition of two optimized substrate peptides that increases the assay's sensitivity,relative to prior substrates, for botulinum neurotoxin type-E (BoNT/E) by greater than 100 fold. Currently, the primary method of detecting BoNT contamination entails mouse lethality bioassays. In addition to the sacrifice of numerous animals, these lethality assays are expen...Tue, 06 Dec 2022 12:01:01 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech?title=Improved_Botulism%2c_Botulinum_Neurotoxin_Type-E_DiagnosticsTAB-2750https://nih.technologypublisher.com/tech?title=Simple%2c_Rapid%2c_and_Sensitive_Real-Time_PCR_Assays_for_Detecting_Drug_Resistance_of_HIVThis novel assay features real-time PCR reagents and methods for detecting drug-resistance related mutations in HIV, for newly diagnosed patients and those individuals currently receiving antiretroviral therapies. As the use of antiretroviral compounds to treat HIV infection proliferates, viruses adapt and evolve mutations limiting the efficacy of these drugs and disrupting the success of treatment. To address this problem, CDC researchers have developed this RT-PCR assay, intended for diagnosis of different point mutations in patient samples at an achievable sensitivity of 1-2 log greater t...Tue, 06 Dec 2022 12:01:00 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech?title=Simple%2c_Rapid%2c_and_Sensitive_Real-Time_PCR_Assays_for_Detecting_Drug_Resistance_of_HIVTAB-2747https://nih.technologypublisher.com/tech?title=Recombinant_Nucleic-Acid_Based_Flavivirus_Nucleic_Acids_for_Development_of_Vaccines_and%2for_Sero-diagnosticsCDC scientists have developed recombinant flavivirus nucleic acids for the generation of broad protective immunity against flaviviruses, as well as the development of sensitive serologic diagnostic tools. Mosquito borne viral encephalitis is often caused by a flavivirus, such as Japanese encephalitis virus, dengue virus or West Nile virus. Infection by these pathogens is often lethal to both humans and animals. Specifically, these novel recombinant nucleic acids encode critical structural proteins of flaviviruses, such as yellow fever virus. The invention provides for a method of immunizing ...Tue, 06 Dec 2022 12:00:55 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech?title=Recombinant_Nucleic-Acid_Based_Flavivirus_Nucleic_Acids_for_Development_of_Vaccines_and%2for_Sero-diagnosticsTAB-2746https://nih.technologypublisher.com/tech/Vaccine_Attenuation_via_Deoptimization_of_Synonymous_CodonsResearch scientists at CDC have developed compositions and methods that can be used to develop attenuated vaccines having well-defined levels of replicative fitness and enhanced genetic stabilities. Infections by intracellular pathogens, such as viruses, bacteria, and parasites, are cleared in most cases after activation of specific T-cell immune responses that recognize foreign antigens and eliminate infected cells. Vaccines against those infectious organisms traditionally have been developed by administration of whole live attenuated or inactivated microorganisms. Although research has be...Tue, 06 Dec 2022 12:00:53 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Vaccine_Attenuation_via_Deoptimization_of_Synonymous_CodonsTAB-2745https://nih.technologypublisher.com/tech/Photoinduced_Electron_Transfer_Fluorescent_Primer_for_Nucleic_Acid_AmplificationCDC scientists have developed a rapid and cost-efficient method for generating fluorescently labeled primers for PCR and real-time PCR. At present, fluorescent primers are useful for detecting and identifying microbes and specific nucleic acid sequences, amplifying nucleic acids for pyro-sequencing, determining the levels of gene expression, and many other uses. However, problems exist with current techniques used to create fluorescent primers. For one, labeling is not one hundred percent efficient, leading to inaccurate results. Further, it is expensive and time consuming for researchers to ...Tue, 06 Dec 2022 12:00:52 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Photoinduced_Electron_Transfer_Fluorescent_Primer_for_Nucleic_Acid_AmplificationTAB-2744https://nih.technologypublisher.com/tech/Virus_Replicon_Particles_as_Rift_Valley_Fever_VaccinesRift Valley fever (RVF) virus primarily infects animals but also has the capacity to infect humans. The disease causes abortion and death among RVF-infected livestock, resulting in substantial economic loss to people living in many parts of Africa and Arabian Peninsula. Currently, there is no commercial vaccine for RVF. CDC scientists have developed a RVF virus replicon particle (VRP) vaccine candidate. Research findings revealed that immunization of mice with a single dose of the RVF-VRP was found to be safe and elicited immune response that offered 100% protection following exposure to l...Tue, 06 Dec 2022 12:00:50 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Virus_Replicon_Particles_as_Rift_Valley_Fever_VaccinesTAB-2743https://nih.technologypublisher.com/tech?title=Molecular_Detection_and_Viral-Load_Quantification_for_HIV-1_Groups_M%2c_N_and_O%2c_and_Simian_Immunodeficiency_Virus-cpz_(SIVcpz)This invention provides materials, methods, and assays for detecting HIV-1 groups M and O and optionally HIV-1 group N and simian immunodeficiency virus-cpz (SIV-cpz). Specific nucleic acid primers for hybridization, amplification, and detection of HIV-1 are also provided for. The nucleic acid amplification assays can detect small concentrations of HIV-1 and are also useful for quantitative examinations of viral load concentrations within biological samples.Tue, 06 Dec 2022 12:00:48 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech?title=Molecular_Detection_and_Viral-Load_Quantification_for_HIV-1_Groups_M%2c_N_and_O%2c_and_Simian_Immunodeficiency_Virus-cpz_(SIVcpz)TAB-2741https://nih.technologypublisher.com/tech/Fluorescent_Primer(s)_Creation_for_Nucleic_Acid_Detection_and_AmplificationCDC researchers have developed technology that consists of a simple and inexpensive technique for creating fluorescent labeled primers for nucleic acid amplification. Fluorescent chemical-labeled probes and primers are extensively used in clinical and research laboratories for rapid, real-time detection and identification of microbes and genetic sequences. During nucleic acid amplification, the "UniFluor" primer is incorporated into newly synthesized double stranded DNA. As a consequence, quenching of the dye's fluorescent signal occurs decreasing the fluorescence of the sample several fold...Tue, 06 Dec 2022 12:00:46 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Fluorescent_Primer(s)_Creation_for_Nucleic_Acid_Detection_and_AmplificationTAB-2740https://nih.technologypublisher.com/tech/Multi-Antigenic_Peptide(s)_Vaccine_and_Immunogen_for_Conferring_Streptococcus_pneumoniae_ImmunityDisease caused by Streptococcus pneumoniae (pneumococcus) is an important cause of morbidity and mortality in the United States and developing countries. Pneumococcal disease is prevalent among the very young, the elderly and immunocompromised individuals. This invention is an improved, immunogenic peptide construct consisting of a combination of antigenic epitopes of the PsaA (37-kDa) protein from S. pneumoniae. In addition, the peptides of the invention have the capability of serving as specific immunogens in a subject, effectively eliciting the production of antibodies and conferring pr...Tue, 06 Dec 2022 12:00:45 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Multi-Antigenic_Peptide(s)_Vaccine_and_Immunogen_for_Conferring_Streptococcus_pneumoniae_ImmunityTAB-2739https://nih.technologypublisher.com/tech?title=Device_to_Measure_Muscle_Contractile-Relaxant_and_Epithelial_Bioelectric_Responses_of_Perfused%2c_Intact_Tracheal_Airways_Tissue_In_VitroCDC and collaborative researchers have developed a device allowing for simultaneous measurement of smooth muscle contractile/relaxant activity and transepithelial potential difference (Vt) [or short circuit currents (Isc)] and resistance (Rt) within an intact airway in vitro. Investigation of the underlying mechanisms of lung diseases, such as asthma or cystic fibrosis, involves understanding the roles of airway smooth muscle and epithelium. Smooth muscle is involved in the control of the airway diameter; epithelium regulates the ionic composition of the liquid lining the airways through ele...Tue, 06 Dec 2022 12:00:44 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech?title=Device_to_Measure_Muscle_Contractile-Relaxant_and_Epithelial_Bioelectric_Responses_of_Perfused%2c_Intact_Tracheal_Airways_Tissue_In_VitroTAB-2737https://nih.technologypublisher.com/tech/A_Bias-free_Sampling_and_Collection_Trap_for_Resting_MosquitoesThis CDC developed collection device is a small (approximately 1 cubic foot) open-sided container that attracts mosquitoes seeking a daytime resting location. The container is dark-colored and constructed of molded wood-fiber or recycled, high-density plastic. Mosquitoes that enter the dark space of the container are aspirated through a battery-powered fan into a collection receptacle. The receptacle is especially attractive to Culex and Anopheles mosquitos' vectors of West Nile Virus and malaria parasites, respectively. For research aims, this device avoids the sampling biases associated w...Tue, 06 Dec 2022 12:00:42 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/A_Bias-free_Sampling_and_Collection_Trap_for_Resting_MosquitoesTAB-2735https://nih.technologypublisher.com/tech/Exposure_and_Activity_Detection_Assays_for_Anthrax_Lethal_Factor_and_Lethal_ToxinThis CDC developed invention identifies an assay for extremely fast and sensitive detection of Bacillus anthracis lethal toxin (LTx), the toxin responsible for the lethal effects of anthrax infection. This assay has already been successfully tested in animals and will allow for early detection of anthrax exposure and screening of lethal factors to monitor anthrax toxicity, for example for vaccine trial candidates. LTx is composed of two proteins, protective antigen (PA) and lethal factor (LF). In one scenario, the assay effectively detects LF by first using magnetic protein G beads to captur...Tue, 06 Dec 2022 12:00:40 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Exposure_and_Activity_Detection_Assays_for_Anthrax_Lethal_Factor_and_Lethal_ToxinTAB-2734https://nih.technologypublisher.com/tech/Select_M._tuberculosis_Peptides_as_Mucosal_Vaccines_Against_Pulmonary_TuberculosisThis CDC-developed technology relates to novel vaccines or boosters directed against pulmonary tuberculosis. There is currently only a single vaccine against tuberculosis, the (Bacillus Calmette-Guérin) BCG vaccine. Reports suggest widely variable effectiveness for the BCG vaccine and that BCG administration has very limited success against prevention of the primary pulmonary form of the disease. With a marginally useful vaccine and rising rates of multidrug-resistant and extensively drug-resistant (MDR and XDR) tuberculosis strains, it is clear there is a public health need that must be me...Tue, 06 Dec 2022 12:00:39 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Select_M._tuberculosis_Peptides_as_Mucosal_Vaccines_Against_Pulmonary_TuberculosisTAB-2733https://nih.technologypublisher.com/tech?title=Sensitive_Method_for_Detection_and_Quantification_of_Anthrax%2c_Bordetella_pertussis%2c_Clostridium_difficile%2c_Clostridium_botulinum_and_Other_Pathogen-Derived_Toxins_in_Human_and_Animal_PlasmaCDC research scientists have developed a method to identify and quantify the activity of pathogenic bacterial adenylate cyclase toxins by liquid chromatography tandem mass spectrometry (LC-MS/MS). Bacterial protein toxins are among the most potent natural poisons known, causing paralysis, immune system collapse, hemorrhaging and death in some cases. A useful tool for quantitative detection of specific toxin activity in clinical samples will provide insights into the kinetics of intoxication, stage of infection and present stage of pathogenesis. This rapid, high-throughput analysis method wil...Tue, 06 Dec 2022 12:00:38 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech?title=Sensitive_Method_for_Detection_and_Quantification_of_Anthrax%2c_Bordetella_pertussis%2c_Clostridium_difficile%2c_Clostridium_botulinum_and_Other_Pathogen-Derived_Toxins_in_Human_and_Animal_PlasmaTAB-2732https://nih.technologypublisher.com/tech?title=A_Simple_Colorimetric_Assay_for_Anti-malarial_Drugs_Quality_Assurance_and_Rapid%2c_On-site_Counterfeit_DetectionThis CDC assay aims to lessen the anti-malarial drug counterfeiting epidemic by testing for the artemisinin-type drugs (the active compound), through the use of a simple, inexpensive colorimetric test. Poor quality and counterfeit drugs pose an immediate threat to public health and undermine malaria control efforts, resulting in resistant-parasites and invalidates effective compounds, i.e. the artemisinins. In response to this threat, CDC researchers have developed a simple, inexpensive, field-adapted colorimetric test to determine artemesin-derivative authenticity in anti-malarial tablets. ...Tue, 06 Dec 2022 12:00:37 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech?title=A_Simple_Colorimetric_Assay_for_Anti-malarial_Drugs_Quality_Assurance_and_Rapid%2c_On-site_Counterfeit_DetectionTAB-2731https://nih.technologypublisher.com/tech/Use_of_Detector_Response_Curves_to_Optimize_Settings_for_Mass_SpectrometryThis CDC developed optimization technology allows one to characterize the behavior of the coefficient of variation (CV) for a range of mass spectrometer machine settings. Surface-enhanced laser desorption/ionization (SELDI) and matrix-assisted laser desorption/ionization (MALDI) are used for the early detection of numerous diseases, for example cervical cancer . A critical step in the analytical process is the optimization of experiment and machine settings to ensure the best possible reproducibility of results, as measured by the CV. The high cost of this procedure includes man hours spent...Tue, 06 Dec 2022 12:00:36 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Use_of_Detector_Response_Curves_to_Optimize_Settings_for_Mass_SpectrometryTAB-2728https://nih.technologypublisher.com/tech?title=Non-radioactive%2c_Miniature_Bipolar_Aerosol_Particle_Charger_for_Personal%2c_Portable_InstrumentationThis CDC developed invention is a novel device for a miniature, nonradioactive bipolar charger to electrically charge aerosol particles for use in personal and portable aerosol instrumentation. Such devices are an integral component of aerosol instruments employing electrical mobility-based techniques. Current, commercial state-of-the-art mobility instruments employ aerosol chargers using radioactivity to achieve bipolar particle charging and, therefore, are not suitable for field-portable instruments. Due to strict regulatory restrictions on use of radioactive materials, these radioactive c...Tue, 06 Dec 2022 12:00:34 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech?title=Non-radioactive%2c_Miniature_Bipolar_Aerosol_Particle_Charger_for_Personal%2c_Portable_InstrumentationTAB-2730https://nih.technologypublisher.com/tech?title=Antigen%2c_Encoding_Gene%2c_Related_Monoclonal_Antibody_and_Hybridoma_Clones_for_Streptococcus_pneumoniae_Serological_DiagnosticsThis CDC developed invention pertains to Streptococcus pneumoniae protein "pneumococcal fimbrial protein A (PfpA)," as well as the encoding pfpA gene. S. pneumoniae linked pneumococcal disease is prevalent among the very young, the elderly and also immunocompromised individuals. This invention covers the breadth of directly PfpA-related technology that might be employed for development of diagnostic tests for S. pneumoniae and/or vaccines directed against the pathogen. In addition to the the intellectual property protected amino acid sequence and encoding plasmid, monoclonal antibodies and ...Tue, 06 Dec 2022 12:00:33 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech?title=Antigen%2c_Encoding_Gene%2c_Related_Monoclonal_Antibody_and_Hybridoma_Clones_for_Streptococcus_pneumoniae_Serological_DiagnosticsTAB-2727https://nih.technologypublisher.com/tech/Rapid_Detection_of_Antiretroviral(s)_Drug-Resistant_HIV-1_within_Clinical_SamplesOne of the problems with the development of current therapies for HIV infection is that the virus rapidly develops resistance to drugs such as reverse transcriptase (RT) inhibitors. CDC researchers have developed an enzyme-based methodology for detecting phenotypic resistance to antiretroviral drugs whose mode of action decreases the efficiency of the HIV-1 RT enzyme. This invention will enhance clinical monitoring by providing data that tells physicians if and when the HIV-1 infecting a patient has become resistant to commonly used antiretroviral drugs, such as zidovudine/azidothymidine (AZT...Tue, 06 Dec 2022 12:00:32 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Rapid_Detection_of_Antiretroviral(s)_Drug-Resistant_HIV-1_within_Clinical_SamplesTAB-2726https://nih.technologypublisher.com/tech/Multiplexed_Immunoassay_for_Rapid_Serological_Diagnosis_of_a_Specific_Viral_Infection_in_Clinical_SamplesCDC researchers have developed a multiplexed diagnostic assay for sensitive detection and distinction between viral group members based on the presence/absence of infection-generated antibodies within a clinical serum sample. For example, this assay can be used for rapid discrimination of a clinical unknown as specifically a West Nile or St. Louis encephalitis viral infection. This is particularly beneficial as these two viruses are typically difficult to distinguish by standard serological assays. This new technique uses microsphere/microbead-based flow-analysis as a platform. Because of a ...Tue, 06 Dec 2022 12:00:31 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Multiplexed_Immunoassay_for_Rapid_Serological_Diagnosis_of_a_Specific_Viral_Infection_in_Clinical_SamplesTAB-2725https://nih.technologypublisher.com/tech?title=Novel_Primate_T-cell_Lymphotropic_Viruses_(HTLV%2c_STLV)_for_Development_of_Diagnostics%2c_Therapeutics%2c_Research_Tools%2c_and_VaccinesCDC researchers have isolated and characterized the novel primate T-lymphotropic viruses denoted human T-lymphotropic viruses 3 and 4 (HTLV-3 and HTLV4), that are believed to have resulted from cross-species transmission at some point in the past. It has been previously established that HTLV-1 causes adult T cell leukemia and other inflammatory diseases; HTLV-2 is considered less pathogenic than HTLV-1 and has been associated with a neurologic disease similar to HTLV-1-associated myelopathy. At present, the human pathologies of HTLV-3 and HTLV-4 are yet uncharacterized, but have been identi...Tue, 06 Dec 2022 12:00:30 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech?title=Novel_Primate_T-cell_Lymphotropic_Viruses_(HTLV%2c_STLV)_for_Development_of_Diagnostics%2c_Therapeutics%2c_Research_Tools%2c_and_VaccinesTAB-2724https://nih.technologypublisher.com/tech?title=Method_for_Finding_Usable_Portion_of_Sigmoid_Curve_(the_Taylor_Method)%2c_Improved_Assay_Readouts%2c_and_Enhanced_Quality_Control%2fAssuranceCDC researchers have developed algorithmic methods for determining sigmoid curve optimums and calculating component concentrations. Sigmoid curves are commonly generated in bioassays and used to calculate results. Various techniques have been used to define the curve, analyze the observations, and calculate a concentration. This technology is an algorithmic approach to identifying the usable portion of a sigmoid curve. This approach is more objective than other methods, reducing the variability introduced by individuals and/or by repetition and allows substantially higher throughput in a s...Tue, 06 Dec 2022 12:00:29 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech?title=Method_for_Finding_Usable_Portion_of_Sigmoid_Curve_(the_Taylor_Method)%2c_Improved_Assay_Readouts%2c_and_Enhanced_Quality_Control%2fAssuranceTAB-2723https://nih.technologypublisher.com/tech/Real-time_PCR_and_High_Resolution_Melt_Analysis_for_Genotyping_of_Chlamydophila_psittaciThis nucleic acid assay employs Light Upon Extension (LUX) chemistry and High Resolution Melt (HRM) analysis to detect and distinguish the different genotypes of Chlamydophila psittaci. C. psittaci is an atypical pathogen which may result in severe pneumonia upon infection of birds, mammals and humans (depending on inter-relationships between host and pathogen genotypes). Presently, C. psittaci clinical identification is achieved by a cumbersome and time-intensive mix of ompA gene sequencing, microarray analysis, RFLP and/or serological testing. Accurate and timely molecular C. psittaci diag...Tue, 06 Dec 2022 12:00:28 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Real-time_PCR_and_High_Resolution_Melt_Analysis_for_Genotyping_of_Chlamydophila_psittaciTAB-2722https://nih.technologypublisher.com/tech/Universal_Diagnostic_Assay_for_Detection_and_Identification_of_Poxviruses_in_Clinical_SamplesCDC researchers have developed an assay for detection and diagnosis of poxviruses within clinical samples or from lab culture-systems. The assay specifically targets chordopoxviruses (except avipoxviruses) for PCR-based identification; an improvement upon the current standard of cell culturing methodologies. Individual chordopoxvirus species can cause disease in humans (e.g., vaccinia, cowpox, monkeypox/Molluscum contagiosum) and animals (e.g., sheeppox, myxoma, swinepox, mule deer pox, tanapox/Orf virus, Bovine popular stomatitis virus). Some poxvirus species impart unique and obvious symptom...Tue, 06 Dec 2022 12:00:27 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Universal_Diagnostic_Assay_for_Detection_and_Identification_of_Poxviruses_in_Clinical_SamplesTAB-2721https://nih.technologypublisher.com/tech/Respiratory_Syncytial_Virus_Immunogens_for_Vaccine_and_Therapeutics_DevelopmentCDC researchers have developed specific Respiratory Syncytial Virus (RSV) immunogens for use in the development of RSV-directed vaccines and therapeutics. RSV is the most common cause of serious respiratory disease in infants and young children and an important cause of disease in the elderly. To date, efforts to make a mutually safe and effective vaccine have been largely unsuccessful. This invention addresses both problems. CDC and collaborative researchers have demonstrated that a vaccine based on amino acid sequences corresponding to group-specific regions of the RSV G-protein can effec...Tue, 06 Dec 2022 12:00:26 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Respiratory_Syncytial_Virus_Immunogens_for_Vaccine_and_Therapeutics_DevelopmentTAB-2720https://nih.technologypublisher.com/tech/Controlled_Expression_and_Assembly_of_Human_Group-C_Rotavirus-like_Particles_for_Creation_of_Rotavirus_Diagnostic_Assays_and_Improved_Vaccine_FormulationsCDC researchers have developed methods of producing unlimited quantities of Group-C (GpC) rotavirus antigens. GpC rotaviruses are a major, worldwide cause of acute gastroenteritis in children and adults that is distinct from Group-A rotavirus. However, GpC rotaviruses cannot be grown in culture, resulting in a lack of tools for detection and treatment of GpC rotavirus disease. Consequently, the true clinical burden of GpC rotavirus disease has not been clearly established. This technology allows for the expression of the three major capsid proteins (VP2, VP6 and VP7) of GpC rotavirus by recom...Tue, 06 Dec 2022 12:00:25 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Controlled_Expression_and_Assembly_of_Human_Group-C_Rotavirus-like_Particles_for_Creation_of_Rotavirus_Diagnostic_Assays_and_Improved_Vaccine_FormulationsTAB-2719https://nih.technologypublisher.com/tech/Real-time_RT-PCR_Assay_for_the_Detection_of_Rift_Valley_Fever_Virus_in_Humans_and_LivestockA quantitative RT-PCR-based assay has been developed to rapidly detect all known strains of Rift Valley fever virus (RVFV). RVFV infections occur in both humans and livestock animals resulting in significant mortality and economic loss. Upon outbreak, RVFV has been known to cause devastating loss among livestock (primarily sheep and cattle) with outbreaks characterized by sweeping "abortion storms" and elevation newborn animal mortality approaching 100% in affected areas. The CDC-developed assay is capable of detecting and quantifying RVFV infection in both human and veterinary samples.Tue, 06 Dec 2022 12:00:24 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Real-time_RT-PCR_Assay_for_the_Detection_of_Rift_Valley_Fever_Virus_in_Humans_and_LivestockTAB-2718https://nih.technologypublisher.com/tech?title=Entangling%2fEntrapping_Synthetic_Setae_for_Control_of_Insects_and_Other_PestsIn nature, some beetle larvae possess specialized barbed hastate setae that serve as an entanglement defense mechanism and incapacitate other insects. CDC researchers have developed synthetic setae for control and entrapment of insects and other pests. While smaller synthetic setae can trap mosquitoes and small insects, larger “macro” setae can be used for entrapment of bats, rodents, etc. Once used, the setae can be "reset" by a vigorous shaking of the fabric. This solution to pest control would be long-lasting and non-toxic, with the additional benefit of avoiding the evolutionary select...Tue, 06 Dec 2022 12:00:23 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech?title=Entangling%2fEntrapping_Synthetic_Setae_for_Control_of_Insects_and_Other_PestsTAB-2717https://nih.technologypublisher.com/tech/Recombinant_Stabilized_Prefusion_Protein_of_Respiratory_Syncytial_Virus_for_Use_as_a_Subunit_VaccineThe invention, a stabilized recombinant prefusion F protein (pre F), is a candidate subunit vaccine for Respiratory Syncytial Virus (RSV). Pre-F is stabilized in the prefusion conformation and displays epitopes not present in postfusion F protein. Several potent RSV neutralizing antibodies bind pre F, but not postfusion F. Therefore, immunization with pre F may elicit an immune response superior to the response generated by postfusion F. NIH researchers have engineered pre F to expose an antigenic site 0, which is targeted by extremely potent RSV neutralizing antibodies. Structure-based desi...Tue, 06 Dec 2022 12:00:21 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Recombinant_Stabilized_Prefusion_Protein_of_Respiratory_Syncytial_Virus_for_Use_as_a_Subunit_VaccineTAB-2716https://nih.technologypublisher.com/tech/Methods_of_Treating_or_Preventing_Pruritis_(Itch)This technology provides a novel method of treating or preventing pruritis (itch) using natriuretic polypeptide b (Nppb) blocking agents. Itch (also known as pruritis) is a sensation that may be perceived as an unpleasant skin irritation and may drive an urge to scratch. Conditions such as, for example, psoriasis, atopic dermatitis, renal failure, liver cirrhosis and some cancers may cause persistent itch. Itch is triggered by somatosensory neurons expressing the ion channel TRPV1 (transient receptor potential cation channel subfamily V member 1). The inventors of this technology show that the...Tue, 06 Dec 2022 12:00:20 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Methods_of_Treating_or_Preventing_Pruritis_(Itch)TAB-2712https://nih.technologypublisher.com/tech/Detection_and_Differentiation_of_Pathogenic_Fungi_in_Clinical_Samples_Using_a_Multi-Analyte_Profiling_SystemThis invention provides a rapid, sensitive and specific diagnostic tool for the detection of pathogenic fungi and subsequent species-specific discrimination. CDC scientists have developed nucleic acid probes to identify the six most medically important Candida species and endemic mycoses, and to differentiate them from other medically important fungi in a multi-analyte profiling system. Candida fungi are one of the leading causes of clinically-acquired bloodstream infections and, although improved antifungal compounds have been recently introduced, they have unique, species-specific treatmen...Tue, 06 Dec 2022 12:00:18 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Detection_and_Differentiation_of_Pathogenic_Fungi_in_Clinical_Samples_Using_a_Multi-Analyte_Profiling_SystemTAB-2711https://nih.technologypublisher.com/tech/Personal_Air_Sampler_for_Collecting_Airborne_Aerosol_Particulates_for_Molecular_Analysis_by_SizeThis invention consists of a sampling apparatus that utilizes one or more cyclone separators to collect airborne particles from the atmosphere. The apparatus not only separates out aerosols from the atmosphere, but also serves as a collection tube for aerosol particles. Through its unique design, this CDC-developed apparatus is able to use the centrifugal force of the air flow on aerosolized particles forcing them to separate by size. Since the sample is collected directly in a microcentrifuge tube, in situ analysis of the ambient particulates can be performed. Analysis may include, but is...Tue, 06 Dec 2022 12:00:17 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Personal_Air_Sampler_for_Collecting_Airborne_Aerosol_Particulates_for_Molecular_Analysis_by_SizeTAB-2710https://nih.technologypublisher.com/tech/Warning_System_for_Mobile_Machinery_Hazardous_ZonesThis invention relates to a warning system designed to protect individuals working near hazardous machinery. The system consists of a proximity-warning transmitter mounted to hazardous machinery and a receiver, worn by a worker, capable of detecting the transmitter signal. This worker-safety system can incorporate visual alerts and audible alerts. It also allows automatic shutdown of machinery upon receiver activation and may be particularly useful in the mining industry.Tue, 06 Dec 2022 12:00:16 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Warning_System_for_Mobile_Machinery_Hazardous_ZonesTAB-2709https://nih.technologypublisher.com/tech/Diisocyanate_Specific_Monoclonal_Antibodies_for_Occupational_and_Environmental_Monitoring_of_Polyurethane_Production__Exposure-related_Asthma_and_Allergy_and_Clinical_DiagnosisCDC researchers have developed monoclonal antibodies useful as diagnostics for diisocyanate (dNCO) exposure and for toxicity characterization of specific dNCOs. Currently, dNCOs are used in the production of all polyurethane products and are the most commonly reported cause of occupational-induced asthma and also linked to allergic contact dermatitis. Presumptive diagnosis of dNCO asthma is presently dependent on criteria such as work history, report of work-related asthma-like symptoms and nonspecific airway reactivity to methacholine challenge. This invention is a cost-effective, objectiv...Tue, 06 Dec 2022 12:00:15 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Diisocyanate_Specific_Monoclonal_Antibodies_for_Occupational_and_Environmental_Monitoring_of_Polyurethane_Production__Exposure-related_Asthma_and_Allergy_and_Clinical_DiagnosisTAB-2703https://nih.technologypublisher.com/tech/Nucleic_Acid-based_Compositions_and_Methods_for_the_Species-Specific_Detection_of_Pathogenic_Candida_FungiThis invention pertains to the development of oligonucleotides for the rapid nucleic acid-based identification of the Candida fungi species C. haemulonii, C. kefyr, C. lambica, C. lusitaniae, C. norvegensis, C. norvegica, C. rugosa, C. utilis, C. viswanathii, C. zeylanoides, C. dubliniensis, and C. pelliculosa within biological samples. This identification is accomplished by the targeting the internally transcribed spacer-2 (ITS2) region that are specific for each species. The assay is sensitive, specific and rapid. Implementation of the technology will facilitate earlier specific diagnoses,...Tue, 06 Dec 2022 12:00:13 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Nucleic_Acid-based_Compositions_and_Methods_for_the_Species-Specific_Detection_of_Pathogenic_Candida_FungiTAB-2702https://nih.technologypublisher.com/tech/Improved_Protein_Quantification_Process_and_Vaccine_Quality_Control_ProductionThis CDC invention is a method for identifying and quantifying a group of proteins in a complex mixture by a liquid chromatography-tandem mass spectrometry assay. The technology was developed for influenza although it can be used for a wide variety of protein quantification applications. As specifically developed, conserved peptides from the proteins of influenza (hemagglutinin, neuramidase, matrix 1 and 2, and nucleoprotein) have been synthesized and labeled to be used as internal standards for the quantification of those proteins in a complex (biological or manufactured) matrix. One or more...Tue, 06 Dec 2022 12:00:12 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Improved_Protein_Quantification_Process_and_Vaccine_Quality_Control_ProductionTAB-2701https://nih.technologypublisher.com/tech/Nucleic_Acid-based_Compositions_and_Methods_for_the_Detection_of_Pathogenic_Candida_or_Aspergillus_Fungi_SpeciesThis invention pertains to the development of oligonucleotides for the rapid nucleic acid-based identification of Candida or Aspergillus fungi species in biological samples. This identification is accomplished by the targeting the internally transcribed spacer-2 (ITS2) region that are unique to various Candida species. The assay is sensitive, specific and rapid. Implementation of the technology will facilitate earlier specific diagnoses, and lead to better antifungal therapy implementation for infected patients.Tue, 06 Dec 2022 12:00:11 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Nucleic_Acid-based_Compositions_and_Methods_for_the_Detection_of_Pathogenic_Candida_or_Aspergillus_Fungi_SpeciesTAB-2700https://nih.technologypublisher.com/tech/Nucleic_Acid_Assays_for_the_Detection_and_Discrimination_of_Aspergillus_Fungi_Species_within_Biological_SamplesThis invention relates to assays for the detection and species-specific identification of Aspergillus fungi. Accurate clinical diagnosis of Aspergillus species has become increasingly important as certain species, such as A. terreus and A. fumigatus, are resistant to specific commonly employed antifungal compounds. Most contemporary fungal diagnostic methods are time-consuming and inaccurate. This invention directly addresses those inadequacies by providing a method to rapidly and accurately differentiate all medically important species of Aspergillus based on differences in the DNA sequence...Tue, 06 Dec 2022 12:00:10 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Nucleic_Acid_Assays_for_the_Detection_and_Discrimination_of_Aspergillus_Fungi_Species_within_Biological_SamplesTAB-2698https://nih.technologypublisher.com/tech/Nucleic_Acid_Detection_of_the_Fungal_Pathogen_Histoplasma_capsulatum_from_Clinical_and_Environmental_SamplesThis invention relates to detecting Histoplasma capsulatum by PCR using oligonucleotide probes specific for the fungus. Histoplasmosis is a mycotic infection of varying severity, usually localized in the lungs. Caused by H. capsulatum, infections are usually symptomatic but can develop into chronic disease, especially in immunocompromised individuals. Test samples may originate from the environment (soil, for example), where H. capsulatum spores are found or from clinical samples obtained from patients. Furthermore, the invention also provides for methods that detect the presence of H. capsu...Tue, 06 Dec 2022 12:00:07 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Nucleic_Acid_Detection_of_the_Fungal_Pathogen_Histoplasma_capsulatum_from_Clinical_and_Environmental_SamplesTAB-2697https://nih.technologypublisher.com/tech/Species-specific_Nucleic_Acid_Detection_Assay_for_FungiThis invention pertains to nucleic acid-based assays for the detection of Aspergillus and other filamentous fungi. Assays cover the species-specific detection and diagnosis of infection by Aspergillus, Fusarium, Mucor, Penecillium, Rhizomucor, Absidia, Cunninghamella, Pseudallescheria or Sporthrix in a subject. This can reduce identification time from several days by conventional culture methods to a matter of hours. Furthermore, genus-specific probes are also provided for Aspergillus, Fusarium and Mucor, in addition to an "all-fungus" nucleic acid probe. This technology is readily adaptabl...Tue, 06 Dec 2022 12:00:06 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Species-specific_Nucleic_Acid_Detection_Assay_for_FungiTAB-2696https://nih.technologypublisher.com/tech/Novel_Rift_Valley_Fever_Virus_VaccinesThis invention relates to recombinant Rift Valley fever (RVF) viruses containing deletions in one or more virulence genes. The recombinant RVF viruses, generated using a plasmid-based reverse genetics system, can be used as vaccines to prevent RVF infection in livestock and humans. The recombinant RVF viruses grow to high titers, provide protective immunity following a single injection, and allow for the differentiation between vaccinated animals and animals infected with wild-type RVF virus. Additionally, this technology relates to a method of using reverse genetics to generate recombinant ...Tue, 06 Dec 2022 12:00:05 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Novel_Rift_Valley_Fever_Virus_VaccinesTAB-2695https://nih.technologypublisher.com/tech/Human_Rotavirus_Strains_and_Vaccines_for_Neonatal_Childhood_ProtectionThis invention relates to rotavirus vaccine compositions and methods of vaccination. Rotaviral infection is the most commonly occurring gastrointestinal illness of children world, affecting both developed and developing economies. Additionally, rotavirus infections can affect livestock (especially calves and piglets), and resulting mortality/morbidity cause major economic losses for farmers and nations each year. The vaccine strains include Rotavirus A CDC-9 (P[4]Gl) and CDC-66 (P[4]G2 serotype). These strains represent common rotavirus serotypes and may serve as improvements or alternativ...Tue, 06 Dec 2022 12:00:04 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Human_Rotavirus_Strains_and_Vaccines_for_Neonatal_Childhood_ProtectionTAB-2694https://nih.technologypublisher.com/tech/Novel_Epitopes_of_Bacillus_anthracis_Lethal_Factor_for_Development_of_Diagnostics_and_TherapeuticsCDC researchers have characterized epitopes of Bacillus anthracis Lethal Factor (LF), a critical component of the B. anthracis lethal toxin. These epitopes may allow for development of therapeutics for the treatment or prevention of B. anthracis infection. They may also allow screening for B. anthracis LF in a sample and development of a peptide anthrax vaccine.Tue, 06 Dec 2022 12:00:02 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Novel_Epitopes_of_Bacillus_anthracis_Lethal_Factor_for_Development_of_Diagnostics_and_TherapeuticsTAB-2683https://nih.technologypublisher.com/tech?title=Mouse_Model_for_Methylmalonic_Acidemia%2c_an_Inherited_Metabolic_DisorderMethylmalonic Acidemia (MMA) is a metabolic disorder affecting 1 in 25,000 to 48,000 individuals globally. MMA is characterized by increased acidity in the blood and tissues due to toxic accumulation of protein and fat by-products resulting in seizures, strokes, and chronic kidney failure. About 60% of MMA cases stem from mutations in the methylmalonyl CoA mutase (MUT) gene encoding a key enzyme required to break down amino acids and lipids. Previous efforts to develop mice with null mutations in MUT have been unsuccessful, as such mutations result in neonatal death. The inventors have develo...Tue, 06 Dec 2022 12:00:00 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech?title=Mouse_Model_for_Methylmalonic_Acidemia%2c_an_Inherited_Metabolic_DisorderTAB-2681https://nih.technologypublisher.com/tech/Use_of_Antisense_Oligodeoxynucleotides_for_Inhibiting_JC_VirusProgressive multifocal leukoencephalopathy (PML) is a rare, fatal demyelinating disease of the brain caused by the polyomavirus JC (JCV) under immunosuppressive conditions. It is pathologically characterized by progressive damage of white matter of the brain by destroying oligodendrocytes at multiple locations. Clinically, PML symptoms include weakness or paralysis, vision loss, impaired speech, and cognitive deterioration. The prognosis of PML is generally poor. No effective therapy for PML has been established. The current strategies to develop a PML therapy focus on blocking viral infection...Tue, 06 Dec 2022 11:59:57 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Use_of_Antisense_Oligodeoxynucleotides_for_Inhibiting_JC_VirusTAB-2673https://nih.technologypublisher.com/tech/Intranasal_Nebulizer_with_Disposable_Drug_Cartridge_for_Improved_Delivery_of_Vaccines_and_TherapeuticsIntranasal delivery is a simple, inexpensive and needle-free route for administration of vaccines and therapeutics. This intranasal delivery technology, developed with Creare LLC., includes low-cost, disposable drug cartridges (DDCs) that mate with a durable hand-held device. The rechargeable-battery-powered device transmits ultrasonic energy to the DDC to aerosolize the drug and is capable of performing for eight hours at 120 vaccinations per hour. Potential applications for this platform technology include intranasal vaccination (e.g. seasonal or pandemic influenza vaccines) and intranasal d...Tue, 06 Dec 2022 11:59:54 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Intranasal_Nebulizer_with_Disposable_Drug_Cartridge_for_Improved_Delivery_of_Vaccines_and_TherapeuticsTAB-2674https://nih.technologypublisher.com/tech/Device_for_Vascular_DilationThe invention is an enhanced vascular dilator that eliminates the vascular injury caused by the size mismatch between vascular introducer sheaths and vascular dilators, as the two are advanced into a blood vessel. The invention provides a “shoulder” to match the diameter of the introducer sheath so that there is a smooth transition, without size mismatch, between the dilator and the introducer sheath. The invention allows the dilator to be withdrawn in segments from the introducer sheath. This is especially valuable to reduce vascular injury when using large-bore introducer sheaths for interve...Tue, 06 Dec 2022 11:59:53 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Device_for_Vascular_DilationTAB-2672https://nih.technologypublisher.com/tech/Human_Influenza_Virus_Real-time_RT-PCR_Detection_and_Characterization_PanelThis invention relates to methods of rapidly detecting influenza, including differentiating between type and subtype. Unlike culture and serological tests requiring 5 to 14 days for completion, CDC researchers developed a rapid, accurate assay, which is easily adapted to kit form. This assay also requires less labor input than immunoassays. These methods can be used to quickly identify a broad variety of influenza types and subtypes, including viruses that may be involved in pandemics (such as H5N1, for example).Tue, 06 Dec 2022 11:59:52 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Human_Influenza_Virus_Real-time_RT-PCR_Detection_and_Characterization_PanelTAB-2671https://nih.technologypublisher.com/tech?title=Diagnostics%2c_Vaccines%2c_and_Delivery-Vehicles_Related_to_Novel_PhlebovirusThis CDC invention relates to primers and probes that specifically hybridize with Heartland virus (HRTLDV), a unique member of the genus Phlebovirus. It further relates to polyclonal antibodies specific for HRTLDV proteins. Serological detection assays using HRTLDV nucleic acid molecules, proteins, probes, primers, and antibodies are provided. Importantly, the HRTLDV genome can be engineered using reverse genetics to be attenuated, allowing development of a vaccine for other viruses within the Phlebovirus genus or Bunyaviridae family. Individual proteins or peptides of the HRTLDV can also ...Tue, 06 Dec 2022 11:59:51 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech?title=Diagnostics%2c_Vaccines%2c_and_Delivery-Vehicles_Related_to_Novel_PhlebovirusTAB-2670https://nih.technologypublisher.com/tech/Intranasal_Dry_Powder_Inhaler_for_Improved_Delivery_of_Vaccines_and_TherapeuticsThis Intranasal Dry Powder Inhaler (DPI), developed with Creare, Inc., allows low-cost delivery of powder vaccines. Nasal delivery has numerous advantages compared to traditional injected vaccines, including: 1) safe, needle-less administration by minimally-trained staff or patient; 2) better protection due to mucosal and cross-protection; and 3) decreased biohazard waste. Further, dry powder aerosol vaccine delivery is superior to liquid aerosol delivery in a number of ways, including: 1) no dose reconstitution required; 2) highly thermostable and may not need cold chain storage; 3) costs le...Tue, 06 Dec 2022 11:59:49 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Intranasal_Dry_Powder_Inhaler_for_Improved_Delivery_of_Vaccines_and_TherapeuticsTAB-2669https://nih.technologypublisher.com/tech/Recombinant_NIE_Antigen_from_Strongyloides_stercoralisStrongyloides stercoralis is an intestinal nematode endemic that affects an estimated 30 to 100 million people worldwide. Many of these individuals may be asymptomatic for decades. The present invention discloses a NIE recombinant antigen that can be used in improved assays and diagnostics for S. stercoralis infection. The NIE antigen is the only one that is non-cross-reactive with sera from humans with other related filaria infections. The NIE antigen can be utilized as a skin test antigen for immediate hypersensitivity as well as for use in ELISA or other assays.Tue, 06 Dec 2022 11:59:48 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Recombinant_NIE_Antigen_from_Strongyloides_stercoralisTAB-2665https://nih.technologypublisher.com/tech/Peptide_Vaccines_Against_Group_A_StreptococciThis invention relates to synthetic immunoreactive peptides, which are portions of the M proteins of the most prevalent Group A Streptococcus (GAS) serotypes in the United States. These peptides may be useful in development of a flexible, multivalent GAS vaccine. They can be recognized by M type-specific antibodies and are capable of eliciting functional opsonic antibodies. Additionally, the peptides or isolated antibodies raised in response to the peptides may be useful for GAS diagnostics.Tue, 06 Dec 2022 11:59:46 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Peptide_Vaccines_Against_Group_A_StreptococciTAB-2664https://nih.technologypublisher.com/tech/T24_Antigen_for_Diagnosing_or_Treating_Taenia_solium_CysticercosisIn order to develop a simple detection assay for field use, CDC researchers cloned and sequenced the Taenia solium T24 diagnostic protein. The T24 sequences can be used to detect and diagnose T. solium infection or can be formulated into a pharmaceutical composition. T. solium is a species of tapeworm. Intestinal infection with T. solium is referred to as taeniasis. Many taeniasis infections are asymptomatic but may be characterized by insomnia, anorexia, abdominal pain and weight loss. Cysticercosis infection, which can be fatal, may develop if T. solium larvae migrate out of the intestine an...Tue, 06 Dec 2022 11:59:45 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/T24_Antigen_for_Diagnosing_or_Treating_Taenia_solium_CysticercosisTAB-2663https://nih.technologypublisher.com/tech?title=HIV-1_Multi-Clade%2c_Multivalent_Recombinant_Vaccine_ConstructCDC scientists developed immunogenic multi-clade, multivalent (HIV1MCMV) recombinant constructs for use as HIV-1 vaccines. These polypeptides include immunogenic CTL, T- and/or B-cell determinants that are capable of eliciting broad and effective immune responses against diverse subtypes of HIV-1. It is believed that these HIV-1 constructs provide universal vaccines, capable of effective use in any part of the world affected by the HIV-1 epidemic. The construct contains specific cellular targeting epitopes that allow optimized antigen processing and recognition, and the design of the construct...Tue, 06 Dec 2022 11:59:44 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech?title=HIV-1_Multi-Clade%2c_Multivalent_Recombinant_Vaccine_ConstructTAB-2659https://nih.technologypublisher.com/tech/Real-time_RT-PCR_Assay_For_Detection_and_Quantification_of_Hepatitis_D_Virus_InfectionCDC scientists have developed a one-step TaqMan quantitative/real-time reverse transcription-polymerase chain reaction (qRT-PCR) assay for detecting hepatitis D virus (HDV) RNA. Additionally, a quantifiable synthetic RNA control to determine viral load has been created. HDV is an operatively defective virus that requires hepatitis B virus (HBV) surface antigen (HBsAg) for its assembly. Compared to individuals infected with HBV alone, individuals infected with both HDV and HBV viruses present with more severe hepatitis, progress to liver disease more quickly, and have a higher mortality rate....Tue, 06 Dec 2022 11:59:42 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Real-time_RT-PCR_Assay_For_Detection_and_Quantification_of_Hepatitis_D_Virus_InfectionTAB-2657https://nih.technologypublisher.com/tech/Development_of_Immune_System_Tolerance_for_the_Treatment_of_Autoimmune_DiseaseThe present invention provides a therapeutic method for the treatment of autoimmune or autoinflammatory diseases by first breaking down the dysregulated immune system and then reprogramming the immune system to restore tolerance to the patient's self-antigens by induction of antigen specific regulatory T cells. The inventors have shown that only with the combination of apoptosis, phagocytes, and antigen can antigen-specific regulatory T cells (Treg) cells be optimally generated to develop long-term immune tolerance. This strategy for developing immune tolerance can be applied to the treatment ...Tue, 06 Dec 2022 11:59:41 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Development_of_Immune_System_Tolerance_for_the_Treatment_of_Autoimmune_DiseaseTAB-2658https://nih.technologypublisher.com/tech/Real-Time_PCR_Assay_for_Specific_Detection_of_Haemophilus_influenzae_Serotypes_A_and_BHaemophilus influenzae is responsible for life-threatening respiratory infections including meningitis. This assay allows for the qualitative detection of the bacterial meningitis pathogen H. influenzae serotype A (Hia) and serotype B (Hib) in fluid samples, without detecting any of the other serotypes of H. influenzae. This invention is capable of detecting even the very small numbers of Hia or Hib within clinical specimens.Tue, 06 Dec 2022 11:59:39 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Real-Time_PCR_Assay_for_Specific_Detection_of_Haemophilus_influenzae_Serotypes_A_and_BTAB-2655https://nih.technologypublisher.com/tech/Small_Interfering_RNA_Inhibition_of_Cannabanoid-1_Receptor_(CB1R)_for_Treating_Type_2_DiabetesThe invention pertains to the use of glucan encapsulated non-immunostimulatory small interfering RNAs (siRNAs) to treat type-2 diabetes. Endocannabinoids (EC) are lipid signaling molecules that act on the same cannabinoid receptors that recognize and mediate the effects of endo- and phytocannabanoids. EC receptor CB1R activation is implicated in the development of obesity and its metabolic consequences, including insulin resistance and type 2 diabetes. Beta-cell loss has been demonstrated in a Zucker diabetic fatty (ZDF) rat model of type-2 diabetes through CB1R-mediated activation of a macrop...Tue, 06 Dec 2022 11:59:38 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Small_Interfering_RNA_Inhibition_of_Cannabanoid-1_Receptor_(CB1R)_for_Treating_Type_2_DiabetesTAB-2650https://nih.technologypublisher.com/tech/Method_of_Enhancing_OpsonophagocytosisThis invention aims to bolster the human body's own mechanisms to fight infection by enhancing an innate immune response, opsonophagocytosis. The specific 24 amino acid sequence (P4) acts as a polymorphonuclear cell activator. P4 can be administered in vivo along with a disease's specific antibody to enhance systemic bacterial clearance, thus leading to prolonged survival. This technology enhances the body's response to infections such as S. pneumoniae and S. aureus.Tue, 06 Dec 2022 11:59:36 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Method_of_Enhancing_OpsonophagocytosisTAB-2649https://nih.technologypublisher.com/tech/Novel_Live-Attenuated_Rabies_VaccineThe critical feature of this technology is the Evelyn-Rokitnicki-Abelseth (ERA) rabies whole genome DNA sequence. With the availability of the entire rabies genome, a recombinant vaccine can be developed using reverse genetics. Using this technology, CDC researchers have developed a recombinant, live-attenuated vaccine shown to confer protection against lethal doses of live, street-rabies virus in multiple survival studies. This vaccine offers better protection than traditional inactivated vaccinations, as demonstrated in co-infection studies. Further, a single intramuscular vaccination with...Tue, 06 Dec 2022 11:59:35 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Novel_Live-Attenuated_Rabies_VaccineTAB-2648https://nih.technologypublisher.com/tech/Real-time_PCR_Multiplex_Assay_for_Detection_of_Bacterial_Respiratory_Pathogens_in_Clinical_SpecimensCDC researchers have developed a single-tube, real-time PCR assay for the simultaneous detection of three bacterial respiratory pathogens (Mycoplasma pneumoniae, Chlamydiophila pneumoniae and Legionella spp.). The assay has an internal control testing for presence of human DNA. This four-plex real-time PCR assay could potentially become a routine screening test for patients with respiratory illness. Ninety four clinical specimens (in a 96-well format) can be tested at once. This assay is non-invasive, rapid and cost-effective. It has the potential for point-of-care applications in population-b...Tue, 06 Dec 2022 11:59:33 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Real-time_PCR_Multiplex_Assay_for_Detection_of_Bacterial_Respiratory_Pathogens_in_Clinical_SpecimensTAB-2647https://nih.technologypublisher.com/tech/Novel_Recombinant_Rabies_Vaccine_Also_Capable_of_ImmunocontraceptionThis invention relates to a recombinant, attenuated rabies vaccine that is also capable of inhibiting reproductive fertility. An Evelyn-Rokitnicki-Abelseth (ERA) rabies vaccine backbone, combined with a reproductive-specific protein, such as gonadotropin-releasing hormone (GnRH) or the sperm-binding zona-pellucida-glycoprotein-3 (ZP3) receptor, allows reduction in both rabies transmission and uncontrolled reproduction in stray animals. The ERA rabies vaccine backbone has previously shown strong efficacy in animal studies. This vaccine may be delivered via injection or orally, including in an ...Tue, 06 Dec 2022 11:59:32 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Novel_Recombinant_Rabies_Vaccine_Also_Capable_of_ImmunocontraceptionTAB-2646https://nih.technologypublisher.com/tech/Diagnostic_Assays_Utilizing_Real-Time_Taqman_or_Seminested_RT-PCR_for_Parechovirus_Detection_and_DiscriminationThe CDC developed a real-time reverse transcription polymerase chain reaction (RT-PCR) Taqman assay and an RT-semi nested PCR (RT-snPCR) assay for the detection of parechoviruses. Similar to enteroviruses, parechoviruses are responsible for gastrointestinal, respiratory and central nervous system infections. All tests target conserved regions in the 5'-nontranslated region (5-'NTR) of the parechovirus genome and share forward and reverse primers. The Taqman probe and RTsnPCR nested primer target the same conserved site but vary in length. Both assays detect all known human parechoviruses (P...Tue, 06 Dec 2022 11:59:31 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Diagnostic_Assays_Utilizing_Real-Time_Taqman_or_Seminested_RT-PCR_for_Parechovirus_Detection_and_DiscriminationTAB-2645https://nih.technologypublisher.com/tech/Multiplex_Real-time_PCR_Assay_for_Detection_of_Numerous_Bacterial_PathogensIn order to address a global need for rapid, cost-effective, sensitive, and specific assays for many pathogens, CDC scientists have developed a broad-use, multiplexed RT-PCR assay. This comprehensive assay covers numerous pathogens that are common causes of infection in neonates and also important to food-safety. Specifically, this assay (and respective probes, primers, and kits) is capable of detecting one or more of Acinetobacter baumannii, Pseudomonas aeruginosa, Klebsiella pneumoniae, Toxoplasma gondii, Moraxella catarrhalis, Escherichia coli, Shigella, Staphylococcus aureus, Pneumocystis...Tue, 06 Dec 2022 11:59:30 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Multiplex_Real-time_PCR_Assay_for_Detection_of_Numerous_Bacterial_PathogensTAB-2644https://nih.technologypublisher.com/tech/Methods_of_Detecting_and_Identifying_Both_Known_and_Novel_Influenza_VirusesThis invention describes materials and methods of detecting novel influenza virus in a sample. As highlighted by the recent H1N1 pandemic strain, influenza viruses are constantly evolving and novel reassortments can quickly spread around the world. The reagents and methods of this particular technology are capable of detecting any type of influenza virus (such as influenza A virus, influenza B virus, and influenza C virus) in a sample, including novel or previously unknown influenza viruses. Such methods and compositions are useful for diagnosing influenza virus infection in humans and anima...Tue, 06 Dec 2022 11:59:29 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Methods_of_Detecting_and_Identifying_Both_Known_and_Novel_Influenza_VirusesTAB-2642https://nih.technologypublisher.com/tech/Recombinant_Pan-Lyssavirus_for_Use_in_Rabies_and_Broad-Lyssavirus_VaccinationCDC researchers have developed recombinant lyssaviruses that can be used for the development of an improved, broad-spectrum vaccine against several rabies genotypes. Lyssaviruses are single-stranded RNA viruses that cause rabies and rabies-like diseases in mammals. Currently, there are commercially available vaccines that are considered to be effective against infections from a single viral phylogroup; however, these vaccines confer little or no protection against viruses outside of the phylogroup. The present recombinants have glycoprotein-encoding genes from at least two different lyssavi...Tue, 06 Dec 2022 11:59:27 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Recombinant_Pan-Lyssavirus_for_Use_in_Rabies_and_Broad-Lyssavirus_VaccinationTAB-2641https://nih.technologypublisher.com/tech/Real-time_PCR_Assay_for_Detection_of_Pneumococcal_DNA_and_Diagnosis_of_Pneumococcal_DiseaseCDC scientists have developed a real-time PCR assay for diagnosing pneumococcal disease using amplification of the bacterial gene encoding pneumococcal surface adhesin A (PsaA). Pneumococcal isolation and identification is often complicated by 1) antimicrobial suppression of growth in culture and 2) contamination by normal flora alpha-streptococci. Further, pneumococcal detection by culture and serological methods can be time-consuming, relatively expensive, laborious and, ultimately, indeterminate. Sensitive and specific assays that can be completed quickly in the clinical laboratory are e...Tue, 06 Dec 2022 11:59:25 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Real-time_PCR_Assay_for_Detection_of_Pneumococcal_DNA_and_Diagnosis_of_Pneumococcal_DiseaseTAB-2640https://nih.technologypublisher.com/tech?title=Real-time_PCR_Assays_for_Selective_Detection_and_Differentiation_of_B._pertussis%2c_B._parapertussis_and_B._homesiiCDC researchers developed a real-time PCR assay targeting insertion sequence (IS481) and pertussis toxin subunit 1 (ptxS1) of Bordetella pertussis. This real-time nucleic acid assay offers rapid, sensitive, and quantitative results. The employed primers have been validated through extensive diagnostic testing of 41 Bordetella and 64 non-Bordetella clinical isolates. This technology can be used to diagnose and distinguish B. pertussis, B. parapertussis and B. homesii, the three most common Bordetella human upper respiratory pathogens. A standalone assay or multi-faceted kit may be used.Tue, 06 Dec 2022 11:59:24 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech?title=Real-time_PCR_Assays_for_Selective_Detection_and_Differentiation_of_B._pertussis%2c_B._parapertussis_and_B._homesiiTAB-2639https://nih.technologypublisher.com/tech/Antigen-capture_Electrochemiluminescent_Assay_for_Determining_Rabies_Vaccine_PotencyCDC researchers developed a more efficient method of assessing rabies vaccine potency using an antigen-capture electrochemiluminescent (ECL) assay. This assay utilizes SULFO-NHS-Ester labeled murine monoclonal antibodies to quantify glycoprotein concentration, which is an indicator of vaccine potency. Currently, the potency of rabies vaccines is determined by the effective-dose (ED50) mouse study evaluation method, which is more than 50 years old. The labor-intensive ED50 evaluation method has high operating costs, extensive biosafety requirements, and requires the sacrifice of a large numbe...Tue, 06 Dec 2022 11:59:23 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Antigen-capture_Electrochemiluminescent_Assay_for_Determining_Rabies_Vaccine_PotencyTAB-2637https://nih.technologypublisher.com/tech/sodC-Based_Real-Time_PCR_Assay_for_Detection_of_Neisseria_meningitidis_InfectionCDC researchers have developed a real-time PCR assay for the detection of Neisseria meningitidis sodC within clinical specimens. The ability to detect all strains of N. meningitidis, regardless of individual serogroup, is the central innovation of this technology. Further, the assay is sensitive enough to detect even the very limited sample sizes of N. meningitidis that would typically be found in clinical specimens. This technology avoids potentially catastrophic false-negative results associated with current N. meningitidis carriage study testing methods. At least 16% of carried N. mening...Tue, 06 Dec 2022 11:59:20 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/sodC-Based_Real-Time_PCR_Assay_for_Detection_of_Neisseria_meningitidis_InfectionTAB-2636https://nih.technologypublisher.com/tech/Monoclonal_Antibodies_that_Neutralize_NorovirusVaccines and therapies to prevent and treat Norovirus infections do not exist, despite the worldwide prevalence of Norovirus infections. Outbreaks of human gastroenteritis attributable to Norovirus commonly occur in group setting, such as hospitals, nursing homes, schools, dormitories, cruise ships and military barracks. This technology relates to chimpanzee-human chimeric monoclonal antibodies, which specifically bind to Norovirus and have therapeutic potential. The antibodies that were tested in a primate model of infection have shown protection against Norovirus. These Norovirus antibodies...Tue, 06 Dec 2022 11:59:19 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Monoclonal_Antibodies_that_Neutralize_NorovirusTAB-2635https://nih.technologypublisher.com/tech/Dipicolylamine-based_Nanoparticles_for_Delivery_of_LigandsMany potential nucleic acid therapeutics have not transitioned from the research laboratory to clinical application in large part because delivery technologies for these therapies are not effective. Most nucleic acid delivery technologies are lipid-based or positively charged and require chemical or physical conjugation with the nucleic acid. These delivery systems are often therapeutically unacceptable due to toxicity or immune system reactivity. The present technology is a nanoparticle complex, containing a polymer substrate, such as a hyaluronic acid, and Zn2+-dipicolylamine (Zn-DPA), that ...Tue, 06 Dec 2022 11:59:17 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Dipicolylamine-based_Nanoparticles_for_Delivery_of_LigandsTAB-2633https://nih.technologypublisher.com/tech/Signatures_of_Genetic_Control_in_Digestive_and_Liver_DisordersOur technology describes unique genetic signatures in patients with digestive diseases and liver disorders. Using comprehensive analysis of 735 microRNAs and 19,000 mRNAs, we have identified a unique set of microRNAs and/or mRNAs which predict disease phenotypes in patients with digestive and liver disorders. The identification of such point-of- care genetic signatures is significant for both personalized biomarkers and novel targeted biotherapeutics. These microRNAs and mRNAs function either together or separately thus modulating protein expressions in one or more signaling pathways. A partic...Tue, 06 Dec 2022 11:59:16 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Signatures_of_Genetic_Control_in_Digestive_and_Liver_DisordersTAB-2631https://nih.technologypublisher.com/tech/Aortic_Access_from_Vena_Cava_for_Large_Caliber_Transcatheter_Cardiovascular_InterventionsThe invention pertains to a device and method for transcatheter correction of cardiovascular abnormalities, such as the delivery of prosthetic valves to the heart. Featured is a device implant for closing a caval-aortic iatrogenic fistula created by the introduction of a transcatheter device from the inferior vena cava into the abdominal aorta. The occlusion device includes an expandable transvascular implant with an elastomeric surface capable of extending between a vein and artery which conforms to the boundaries of an arteriovenous fistula tract between the artery and vein. A guidewire ch...Tue, 06 Dec 2022 11:59:14 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Aortic_Access_from_Vena_Cava_for_Large_Caliber_Transcatheter_Cardiovascular_InterventionsTAB-2624https://nih.technologypublisher.com/tech/Reduced_Virulence_Crimean-Congo_Hemorrhagic_Fever_Virus_for_Vaccine_DevelopmentThis invention relates to a genetically modified hemorrhagic fever virus that can be used as an effective live vaccine agent. Hemorrhagic fever evades the human immune response using the viral ovarian tumor domain (vOTU) protease, which inhibits critical host-immunity functions. The present genetically modified virus has a vOTU protease with decreased ability to remove ubiquitin (Ub) and ISG15 tags from proteins in cells it infects. Thus, the virulence is reduced, creating an immunogenic and non-pathogenic virus for use as a live vaccine against Crimean-Congo hemorrhagic fever (CCHF) virus. Un...Tue, 06 Dec 2022 11:59:13 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Reduced_Virulence_Crimean-Congo_Hemorrhagic_Fever_Virus_for_Vaccine_DevelopmentTAB-2623https://nih.technologypublisher.com/tech/Generation_of_Artificial_Mutation_Controls_for_Diagnostic_TestingThis technology relates to a method of generating artificial compositions that can be used as positive controls in a genetic testing assay, such as a diagnostic assay for a particular genetic disease. Such controls can be used to confirm the presence or absence of a particular genetic mutation. The lack of easily accessible, validated mutant controls has proven to be a major obstacle to the advancement of clinical molecular genetic testing, validation, quality control (QC), quality assurance (QA), and required proficiency testing. This method provides a consistent and renewable source of posit...Tue, 06 Dec 2022 11:59:12 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Generation_of_Artificial_Mutation_Controls_for_Diagnostic_TestingTAB-2622https://nih.technologypublisher.com/tech/Composition_and_Methods_for_Rapid_Detection_of_HIV_by_Loop-mediated_Isothermal_AmplificationThis invention relates to methods and compositions for rapid detection of HIV nucleic acids in a biological sample. Specifically, it involves the use of the loop-mediated isothermal amplification (LAMP) for rapid detection of HIV-1 and/or HIV-2. The use of rapid HIV tests is highly attractive for screening of patient samples, especially in developing countries where resources are limited, because they are quick, easy to perform, and do not require any special equipment. Rapid tests for the identification of HIV antibody, however, will remain negative during the 4 to 5 week window post-infecti...Tue, 06 Dec 2022 11:59:11 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Composition_and_Methods_for_Rapid_Detection_of_HIV_by_Loop-mediated_Isothermal_AmplificationTAB-2621https://nih.technologypublisher.com/tech/Linear_Epitopes_of_Anthrax_Toxin_Protective_Antigen_for_Development_of_a_Peptide_VaccineBacillus anthracis is a gram-positive, spore-forming bacteria that causes anthrax infection in humans. CDC inventors have identified epitope sequences of B. anthracis protective antigen (PA) that may be useful for development of peptide-based anthrax vaccines. This invention also relates to methods for determining whether post-vaccination protection is achieved. Specifically, this invention relates to a screening method for determining protection against B. anthracis infection that involves testing a biological sample for the presence of antibodies to one or more predefined regions of B. anthr...Tue, 06 Dec 2022 11:59:10 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Linear_Epitopes_of_Anthrax_Toxin_Protective_Antigen_for_Development_of_a_Peptide_VaccineTAB-2617https://nih.technologypublisher.com/tech/Human_and_Veterinary_Cancer_Therapeutic_Agent_Utilizing_Anthrax_Toxin-Based_TechnologyDue to the disorganized nature of blood vessels that run through tumors, chemotherapeutic agents often fail to penetrate tumors and kill cancer cells at the tumor’s center. This can lead to ineffective chemotherapeutic treatments, because tumors can quickly grow back if the entire tumor is not destroyed. NIH researchers have developed a therapeutic agent that solves this problem facing current chemotherapy treatments. By elegantly exploiting cell surface proteases present at high levels in tumors, they have developed a tumor-targeted anthrax based toxin that inactivates the blood vessels wi...Tue, 06 Dec 2022 11:59:08 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Human_and_Veterinary_Cancer_Therapeutic_Agent_Utilizing_Anthrax_Toxin-Based_TechnologyTAB-2616https://nih.technologypublisher.com/tech/Monoclonal_Antibodies_That_Recognize_the_Human_Type_I_Interferon_Receptor_and_Block_Interferon_SignalingType I interferons play a critical role in both innate and adaptive immunity through the stimulation of the IFNAR1 which initiates interferon signaling in response to viral and bacterial infections. However, abnormal interferon signaling is associated with human diseases, such as lupus. The present invention discloses six hybridomas that produce mouse monoclonal antibodies specific for the extracellular domain of human IFNAR1. Two of the monoclonal antibodies are able to bind IFNAR1 and reduce interferon signaling. As such, they can be utilized as a research tool for studying the expression o...Tue, 06 Dec 2022 11:59:06 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Monoclonal_Antibodies_That_Recognize_the_Human_Type_I_Interferon_Receptor_and_Block_Interferon_SignalingTAB-2615https://nih.technologypublisher.com/tech/Nucleic_Acid_Amplification_Technique_for_Rapid_Diagnostic_AnalysisCDC researchers developed a simple target-specific isothermal nucleic acid amplification technique, termed Genome Exponential Amplification Reaction (GEAR). The method employs a set of four primers (two inner and two outer). The outer primer pair targets three specific nucleic acid sequences at a constant 60°C, while the inner pair of primers accelerates and improves the sensitivity of the assay. The GEAR technique is an improvement over loop-mediated isothermal amplification (LAMP) in three ways. First, the GEAR method uses two Tab primers which target three genomic regions (corresponding LAM...Tue, 06 Dec 2022 11:59:05 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Nucleic_Acid_Amplification_Technique_for_Rapid_Diagnostic_AnalysisTAB-2614https://nih.technologypublisher.com/tech/Monoclonal_Antibodies_for_Detection_of_Stachybotrys_chartarum_(a_Fungus)CDC NIOSH researchers have developed a simple and rapid detection technique for Stachybotrys chartarum (a type of mold that commonly grows on wet building materials) by producing monoclonal antibodies which reacts with proteins in Stachybotrys chartarum. These antibodies can be used in immunologic detection assays to detect and possibly quantify Stachybotrys chartarum in environmental samples, and to our knowledge, they do not cross react with other fungi. The presence of mold in indoor environments has been associated with adverse health effects such as infections (in immunocompromised people...Tue, 06 Dec 2022 11:59:04 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Monoclonal_Antibodies_for_Detection_of_Stachybotrys_chartarum_(a_Fungus)TAB-2613https://nih.technologypublisher.com/tech/Real-Time_PCR_for_Detecting_Legionella_Species_and_Discriminating_Legionella_pneumophilaLegionella pneumophila is the causative species in most cases of Legionnaires' disease (LD). CDC scientists have developed a real-time PCR assay capable of detecting all Legionella species and discriminating L. pneumophila from other Legionella species. LD is typically difficult to diagnose from a clinical standpoint as it confers no unique clinical features or symptoms. This assay provides a rapid and accurate alternative to laborious PCR assays, prone to aberrant results. It provides a sensitive alternative for diagnosis of Legionnaires' disease and detection of L. pneumophila.Tue, 06 Dec 2022 11:59:03 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Real-Time_PCR_for_Detecting_Legionella_Species_and_Discriminating_Legionella_pneumophilaTAB-2612https://nih.technologypublisher.com/tech/Real-time_TaqMan_RT-PCR_Assays_for_Selective_Detection_of_Human_RhinovirusThis invention relates to selective detection of human rhinovirus (HRV) in biological media. Specifically, this invention discloses a real-time TaqMan RT-PCR assay targeting the 5'-noncoding region of the HRV genome. This is a one-step, real-time nucleic acid assay that offers rapid, sensitive, and quantitative results. The assay is validated against all 100 recognized HRV prototype strains. HRV is the most frequent cause of the common cold. From a clinical standpoint, diagnosis of HRV infection is quite difficult as the related symptoms can be caused by other agents as well. Additionally, ...Tue, 06 Dec 2022 11:59:02 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Real-time_TaqMan_RT-PCR_Assays_for_Selective_Detection_of_Human_RhinovirusTAB-2611https://nih.technologypublisher.com/tech/Rapid_Detection_of_Multi-Drug-Resistant_Mycobacterium_tuberculosis_Using_Real-Time_PCR_and_High-Resolution_Melt_AnalysisCDC scientists have developed a rapid, sensitive, and specific real-time PCR assay that is capable of detecting the presence of Mycobacterium tuberculosis and determining its resistance profile to antibiotics, such as rifampicin and isoniazid. Currently, there are few assays available that are capable of both detecting M. tuberculosis and determining the bacteria's drug resistance. This assay incorporates multiple fluorescent chemistries, providing a simple and cost-effective method of determining the bacteria's drug resistance. Additionally, this assay may be used to quickly discriminate My...Tue, 06 Dec 2022 11:59:01 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Rapid_Detection_of_Multi-Drug-Resistant_Mycobacterium_tuberculosis_Using_Real-Time_PCR_and_High-Resolution_Melt_AnalysisTAB-2610https://nih.technologypublisher.com/tech/Diffusion_Through_Skull_as_Route_of_Delivery_for_Treatment_of_Brain_Injury_and_DiseaseTraumatic Brain injury (TBI) often results from head impact and is a major cause of death and disability. Brain injuries vary in severity and can be associated with hemorrhaging, swelling, inflammation, and death of brain tissue. Inventors at NINDS developed a novel approach to treating brain injuries that involves transcranial application of small molecules. They discovered, using two photon laser scanning microscopy, that compounds as large as 40,000 molecular weight (MW) can pass directly through the intact skull into the underlying cerebral spinal fluid (CSF) that circulates through the ...Tue, 06 Dec 2022 11:58:59 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Diffusion_Through_Skull_as_Route_of_Delivery_for_Treatment_of_Brain_Injury_and_DiseaseTAB-2608https://nih.technologypublisher.com/tech/Cotranslational_Protein_Expression_System_for_High-throughput_ScreeningReporter gene-based assays are used extensively in high-throughput screening (HTS) to identify chemical modulators of cellular pathways for drug discovery and development. However, such screening frequently results in a large number of false “hits” due to interactions of screened compounds with reporter proteins, producing confounding results. Thus, validation of results using these assays often involves significant time and expense. The inventors have developed an assay system that significantly improves detection of target-relevant active compounds by discriminating between signals arising...Tue, 06 Dec 2022 11:58:58 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Cotranslational_Protein_Expression_System_for_High-throughput_ScreeningTAB-2607https://nih.technologypublisher.com/tech/MRI_Scanner_Bore_CoveringThis invention pertains to a bore covering for creating controlled environments and specifically for maintaining temperature within the bore of an MRI scanner. The bore covering includes a covering sheet with fastening means (e.g., weak-tack adhesive, pressure-sensitive adhesive or low-tack adhesive) around its inner surfaces that permits reversible attachment to the scanner. The adhesive ends can be peeled away to expose an edge of the bore opening or the entire sheet may be constructed with peel away gaps so that warm air can be pumped into the bore. On the inner surface the bore covering m...Tue, 06 Dec 2022 11:58:57 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/MRI_Scanner_Bore_CoveringTAB-2605https://nih.technologypublisher.com/tech/Rabbit_Antibody_to_Mouse_Sphingosine_kinase_2_(SphK2)Two isoforms of sphingosine kinase, sphingosine kinase 1 (SphK1) and sphingosine kinase 2 (SphK2), convert sphingosine to sphingosine 1-phosphate (S1P) in mammalian cells. While the importance of SphK1 has been known for some time, information about SphK2 is still being revealed. Therefore, researchers at NIH have developed an antibody against mouse SphK2, which can be used to further understand the role of this enzyme.Tue, 06 Dec 2022 11:58:56 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Rabbit_Antibody_to_Mouse_Sphingosine_kinase_2_(SphK2)TAB-2604https://nih.technologypublisher.com/tech/Rabbit_Antibody_to_Mouse_Sphingosine-1-phosphate_(S1P)_lyaseThe cleavage of sphingoid base phosphates by sphingosine-1-phosphate (S1P) lyase to produce phosphoethanolamine and a fatty aldehyde is the final degradative step in the sphingolipid metabolic pathway. Researchers at NIH injected rabbits with the C-terminal peptide of the mouse S1P lyase — 551-TTDPVTQGNQMNGSPKPR-568 — to develop an antibody that can be used in western blotting to study this pathway.Tue, 06 Dec 2022 11:58:55 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Rabbit_Antibody_to_Mouse_Sphingosine-1-phosphate_(S1P)_lyaseTAB-2603https://nih.technologypublisher.com/tech/Multiplex_Assay_for_Detection_of_Dengue_VirusDengue virus (DENV) is the cause of dengue illness (dengue fever, dengue hemorrhagic fever, and dengue shock syndrome). CDC researchers have developed a RT-PCR multiplex assay that, prior to sero-conversion, selectively detects dengue virus in biological or other fluid media, such as whole blood, plasma, or serum. The primers and probes from this assay are sufficiently specific to amplify and detect all four DENV serotypes. This FDA-approved technology may provide an improved method for rapid and accurate serotyping of dengue virus in clinical and research settings.Tue, 06 Dec 2022 11:58:54 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Multiplex_Assay_for_Detection_of_Dengue_VirusTAB-2602https://nih.technologypublisher.com/tech?title=CDC_Mosquito_Trap_for_Control_and_Surveillance_of_Mosquitoes_Including_Carriers_of_Zika_%2b_Other_VirusesMosquitoes are responsible for spreading many viruses that can make people sick, including dengue, Zika, chikungunya, yellow fever, and more. The Centers for Disease Control and Prevention's (CDC's) new autocidal gravid ovitrap (AGO) mosquito trap is an inexpensive, simple-to-assemble, and easy-to-maintain trap that targets female mosquitoes looking for a place to lay eggs. The current trap model stands 18 inches (45cm) tall and is made of a 5-gallon (18L) bucket. The AGO trap's unique design lures mosquitoes by using water and an all-natural, organic hay attractant. Once inside, female mosqui...Tue, 06 Dec 2022 11:58:52 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech?title=CDC_Mosquito_Trap_for_Control_and_Surveillance_of_Mosquitoes_Including_Carriers_of_Zika_%2b_Other_VirusesTAB-2601https://nih.technologypublisher.com/tech/Use_of_Vitronectin_as_a_Biomarker_for_the_Detection_of_Dengue_Hemorrhagic_FeverDengue hemorrhagic fever (DHF) is a severe, potentially deadly infection spread by mosquitos. CDC scientists have identified vitronectin as an important biomarker of DHF. They have shown vitronectin is significantly reduced in DHF and severe dengue infections when compared to dengue non-hemorrhagic fever patients. Presently, DHF is established by assessing antibody concentrations and other rule-of-thumb criteria, but often these assays can be difficult to interpret and lead to false conclusions. Establishing vitronectin levels provides a specific, novel biomarker for DHF, leading to increased...Tue, 06 Dec 2022 11:58:51 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Use_of_Vitronectin_as_a_Biomarker_for_the_Detection_of_Dengue_Hemorrhagic_FeverTAB-2600https://nih.technologypublisher.com/tech/Real-Time_RT-PCR_Assay_for_Detection_of_NorovirusesA specific and sensitive TaqMan-based real-time (rt) RT-PCR assay has been developed by CDC scientists for detection of noroviruses in clinical and environmental specimens. This assay can be implemented to rapidly detect and distinguish norovirus strains from genogroups I and II, which are responsible for the majority of human infections. Additionally, the assay is multiplexed with an internal extraction control virus (coliphage MS2) to validate the results of the assay. Since the virus cannot be grown in cell culture and enzyme immunoassays lack the necessary sensitivity, this technology is ...Tue, 06 Dec 2022 11:58:49 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Real-Time_RT-PCR_Assay_for_Detection_of_NorovirusesTAB-2599https://nih.technologypublisher.com/tech/Simultaneous_Detection_of_Non-pneumophila_Legionella_Strains_Using_Real-time_PCRLegionnaires' disease is caused by a type of bacteria called Legionella. CDC scientists have developed a real-time multiplex PCR assay for diagnosis and identification of Legionella strains. The assay consists of five sets of primers (targeting L. bozemanii, L. dumoffii, L. feeleii, L. longbeachae, or L. micdadei) and corresponding probes. Each probe is labeled with a different fluorophore which allows the detection of a particular strain in a single tube reaction. Using this assay format, the presence of any one of the five pathogenic non-pneumophila strains of Legionella can be detected rap...Tue, 06 Dec 2022 11:58:47 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Simultaneous_Detection_of_Non-pneumophila_Legionella_Strains_Using_Real-time_PCRTAB-2598https://nih.technologypublisher.com/tech/Device_for_Non-Surgical_Tricuspid_Valve_AnnuloplastyThis is a non-surgical tricuspid annuloplasty to treat functional tricuspid valve regurgitation, meaning regurgitation with intact valve leaflets. The device is delivered using novel catheter techniques into the pericardial space and positioned along the atrioventricular groove. A compression member is positioned along the tricuspid annular free wall and tension applied through a variably-applied tension element. In the best embodiment, the compression member has an M shaped portion with at least two inflection points between the segments of difference curvatures.Tue, 06 Dec 2022 11:58:44 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Device_for_Non-Surgical_Tricuspid_Valve_AnnuloplastyTAB-2955https://nih.technologypublisher.com/tech/WNT1-Induced_Secreted_Protein-1_Knockout_Mouse_ModelTue, 06 Dec 2022 11:58:43 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/WNT1-Induced_Secreted_Protein-1_Knockout_Mouse_ModelTAB-3105https://nih.technologypublisher.com/tech/Zika_Virus_VaccinesZika virus (ZIKV) is a flavivirus transmitted by mosquitos that is strongly linked to neurological complications including Guillain-Barré syndrome, meningoencephalitis, and microcephaly. The association between active ZIKV infection during pregnancy and microcephaly and intrauterine growth retardation in the fetus has been confirmed in murine models of ZIKV infection. Scientists at NIAID have developed nucleic acid-based vaccine candidates to prevent ZIKV infection in humans. The current lead candidate vaccine is a plasmid DNA vaccine demonstrated to accord protection in preclinical model...Tue, 06 Dec 2022 11:58:41 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Zika_Virus_VaccinesTAB-2589https://nih.technologypublisher.com/tech/Encircling_Suture_Delivery_SystemThe invention provides a novel delivery system for delivering an encircling suture which includes two separate hollow limbs held together at an articulation by the suture to be delivered. The suture can extend through the hollow limbs, which slide along the suture. The distal ends of the limbs can be compressed into a desired delivery shape that allows the limbs to be advanced through the lumen of a delivery catheter (e.g., a transcutaneous, transvascular or intraluminal catheter) into any body cavity. As the distal portions of the limbs move out of the delivery catheter, the limbs cooperativ...Tue, 06 Dec 2022 11:58:38 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Encircling_Suture_Delivery_SystemTAB-3100https://nih.technologypublisher.com/tech/A_Human_Progenitor_Mast_Cell_Line_for_Allergic_and_Fibrotic_Research_and_Therapeutic_ScreeningHermansky-Pudlak Syndrome type-1 (HPS-1) is a rare genetic disorder that affects around 1 in 500,000 people worldwide and 1 in 1,800 Puerto Ricans. Patients with HPS-1 display oculocutaneous albinism, bleeding due to platelet abnormality, and pulmonary fibrosis. Those that develop pulmonary fibrosis often succumb and live no more than a decade after early onset of breathing problems. Scientists at the National Institute of Allergy and Infectious Diseases (NIAID) have developed the HPS-1 proMastocyte (HPM) cell line, containing an HPS-1 mutation. This cell line resembles a progenitor mast ce...Tue, 06 Dec 2022 11:58:34 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/A_Human_Progenitor_Mast_Cell_Line_for_Allergic_and_Fibrotic_Research_and_Therapeutic_ScreeningTAB-2586https://nih.technologypublisher.com/tech/Transgenic_Mice_Overexpressing_Islet_Beta_Cell_M3_Muscarinic_Acetylcholine_ReceptorsResearchers at NIH have generated transgenic mice in which the M3 muscarinic receptor is overexpressed in pancreatic beta cells. This was done by placing the receptor gene under the control of the 650 bp rat insulin promoter II (RIP II). The resulting mice show a pronounced increase in glucose tolerance and enhanced plasma insulin levels. Strikingly, these mutant mice were resistant to diet-induced glucose intolerance and hyperglycemia.Tue, 06 Dec 2022 11:58:31 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Transgenic_Mice_Overexpressing_Islet_Beta_Cell_M3_Muscarinic_Acetylcholine_ReceptorsTAB-2583https://nih.technologypublisher.com/tech/Safer_Attenuated_Virus_Vaccines_with_Missing_or_Diminished_Latency_of_InfectionThis technology describes recombinant viruses that have weakened ability to establish and/or maintain latency and their use as live vaccines. The viruses have one or more genetic mutations that allow for continued replication but that inhibit latency. The vaccine materials and methods for their construction are exemplified with the virus that causes chickenpox and whose latent infection results in shingles, a condition that affects up to an estimated 1 million people per year in the United States alone. Additionally, there are veterinary applications of this technology. Specific examples o...Tue, 06 Dec 2022 11:58:30 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Safer_Attenuated_Virus_Vaccines_with_Missing_or_Diminished_Latency_of_InfectionTAB-2585https://nih.technologypublisher.com/tech/Transgenic_Mice_with_Constitutively_Active_M3_Muscarinic_Receptor_in_Islet_Beta_CellsQ490L point mutation was introduced into the rat M3 muscarinic receptor cDNA to confer persistent, constitutive (ligand-independent) activity. Expression of the M3 receptor mutant was placed under the control of a 650 bp fragment of the rat insulin promoter II (RIP II) to limit expression to the islet beta cell.Tue, 06 Dec 2022 11:58:29 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Transgenic_Mice_with_Constitutively_Active_M3_Muscarinic_Receptor_in_Islet_Beta_CellsTAB-2584https://nih.technologypublisher.com/tech/Islet_Beta_Cell_Only_M3_Muscarinic_Acetylcholine_Receptor_Knockout_MouseResearchers at NIH have developed islet beta cell M3 muscarinic acetylcholine receptor knockout mouse. The mice were generated by crossing floxed mouse M3 muscarinic acetylcholine receptor mice with mice in which Cre recombinase was controlled by the beta-cell specific rat insulin promoter (RIP-Cre mice).Tue, 06 Dec 2022 11:58:28 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Islet_Beta_Cell_Only_M3_Muscarinic_Acetylcholine_Receptor_Knockout_MouseTAB-2579https://nih.technologypublisher.com/tech?title=Rat_Model_for_Alzheimer%27s_DiseaseThe present invention is directed to a transgenic rat model of Alzheimer's Disease (AD) termed TgF344-19+/-. The invention rat overexpresses two human genes (APPswe and PS1deltaE9 genes), each of which are believed to be independent dominant causes of early-onset AD. The hemizygote exhibits major features of AD pathology (i.e., dense and diffuse amyloid plaques, neurofibrillary tangles, cerebral amyloid angiopathy, hyperphosphorylated tau, paired-helical filaments, Hirano bodies, granulovacuolar degeneration, cognitive impairment, and cortical neuronal loss). The rat included in this technol...Tue, 06 Dec 2022 11:58:26 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech?title=Rat_Model_for_Alzheimer%27s_DiseaseTAB-2577https://nih.technologypublisher.com/tech/Intra-bone_Drug_Delivery_Device_and_MethodThe invention pertains to devices for directly infusing cellular therapeutics into patient bone. The device monitors intra-bone pressure using pressure sensors disposed at its proximal end and adjusts infusion pressures during infusion such that intra-bone pressure does not exceed levels of systemic blood pressure. Such devices, apparatus and methods are particularly suitable for use in performing bone marrow transplants, particularly transplants that utilize cord blood as a stem cell source.Tue, 06 Dec 2022 11:58:25 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Intra-bone_Drug_Delivery_Device_and_MethodTAB-2576https://nih.technologypublisher.com/tech/Engineered_Anthrax_Toxin_Variants_that_Target_CancerThis technology describes the use of novel mutated anthrax protective antigen (PA) protein variants to target tumor cells and tumor vasculature. NIH scientists have engineered two PA variants that selectively complement one another and combine to form active octamers that target tumor cells. This controlled oligomeric activation of the PA proteins makes the likelihood of toxicity to non-tumor cells very low since non-tumor tissue does not express certain cell-surface proteases required to activate the PA variants. Using proteases that are highly expressed in tumor cells, e.g., matrix metal...Tue, 06 Dec 2022 11:58:24 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Engineered_Anthrax_Toxin_Variants_that_Target_CancerTAB-2574https://nih.technologypublisher.com/tech?title=Super-Resolution_Fluorescence_Enhanced_Imaging_using_Bleaching%2fBlinking_Assisted_Localization_Microscopy_(BALM)The invention relates to systems and methods for localization microscopy for superresolution imaging of fluorescent molecules. The method utilizes intrinsic bleaching/blinking properties of fluorophores in which superresolution is achieved by capturing successive images and subtracting from each either the subsequent image. The location of a single fluorescent molecule can be identified when the molecules either photobleach, blink off, or blink between successive images using a higher magnification lens to achieve a smaller pixel size.Tue, 06 Dec 2022 11:58:23 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech?title=Super-Resolution_Fluorescence_Enhanced_Imaging_using_Bleaching%2fBlinking_Assisted_Localization_Microscopy_(BALM)TAB-2564https://nih.technologypublisher.com/tech/Pyruvate_Kinase_M2_Activators_for_the_Treatment_of_CancerThis technology describes a series of small-molecule activators of the pyruvate kinase M2 isoform (PK-M2). Pyruvate kinase (PK) is a critical metabolic enzyme that catalyzes the last step of the glycolytic pathway. It exists in several isoforms with different patterns of tissue expression. One isoform, PK-M2, is expressed in cells with a high rate of nucleic acid synthesis, including most tumors, which makes this enzyme an attractive target for cancer therapy. PK-M2 can occur in either a tetrameric form or a dimeric form in proliferating cells; a high tetramer to dimer ratio leads to energ...Tue, 06 Dec 2022 11:58:20 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Pyruvate_Kinase_M2_Activators_for_the_Treatment_of_CancerTAB-3143https://nih.technologypublisher.com/tech/Human_and_Veterinary_Cancer_Therapeutic_Agent_Utilizing_Anthrax_Toxin-Based_TechnologyDue to the disorganized nature of blood vessels that run through tumors, chemotherapeutic agents often fail to penetrate tumors and kill cancer cells at the tumor’s center. This can lead to ineffective chemotherapeutic treatments, because tumors can quickly grow back if the entire tumor is not destroyed. NIH researchers have developed a therapeutic agent that solves this problem facing current chemotherapy treatments. By elegantly exploiting cell surface proteases present at high levels in tumors, they have developed a tumor-targeted anthrax based toxin that inactivates the blood vessels wi...Tue, 06 Dec 2022 11:58:18 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Human_and_Veterinary_Cancer_Therapeutic_Agent_Utilizing_Anthrax_Toxin-Based_TechnologyTAB-2560https://nih.technologypublisher.com/tech/Parvovirus_B19_VaccineParvovirus B19 (B19V) infection causes fifth disease, a disease characterized by rashes to the face and other parts of the body that primarily affects children. However, adults can also develop fifth disease and it can lead to more severe conditions. Patients that are immunocompromised, such as those who are HIV infected, organ transplant recipients, and cancer patients, can be particularly susceptible to more severe outcomes from B19V infection. Infection can also cause anemia and in pregnant women, it can lead to hydrops fetalis. The subject technologies are expression vectors for the pro...Tue, 06 Dec 2022 11:58:16 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Parvovirus_B19_VaccineTAB-2559https://nih.technologypublisher.com/tech/Stapled_Peptides_for_Treatment_of_Cardiovascular_Diseases_and_InflammationThe invention is directed to small molecule mimetics of apolipoproteins that have an inter-helical hydrocarbon bond, which stabilizes helix formation. Apolipoproteins facilitate the transport of lipids and cholesterol in the body. Mimetics of apolipoproteins have been used to treat cholesterol-related disorders. However, these mimetics are susceptible to degradation in biological fluids and as a result, their ability to bind cholesterol becomes diminished over time. Scientists at NHLBI have devised methods to stabilize and improve the performance of apolipoprotein mimetic peptides, using a mod...Tue, 06 Dec 2022 11:58:15 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Stapled_Peptides_for_Treatment_of_Cardiovascular_Diseases_and_InflammationTAB-2558https://nih.technologypublisher.com/tech/Induced_Pluripotent_Stem_Cells_Generated_Using_Lentivirus-based_ReprogrammingFive human induced pluripotent stem cells (iPSC) lines are generated using lentivirus-based reprogramming technology. These lines are pluripotent, meaning they have the potential to differentiate into all cells in the body, and theoretically can proliferate/self-renew indefinitely. The iPSC lines are: NC1 (derived from female's fibroblasts), NC2 (derived from female's fibroblasts ), NC3 (derived from male's HUVECS), NC4 (derived from male's fibroblasts) and NC5 (derived from female's fibroblasts). Further details of these cells are available upon request. NC1 uses a retrovirus delivery sys...Tue, 06 Dec 2022 11:58:14 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Induced_Pluripotent_Stem_Cells_Generated_Using_Lentivirus-based_ReprogrammingTAB-2554https://nih.technologypublisher.com/tech/Novel_Tocopherol_and_Tocopheryl_Quinone_Derivatives_as_Therapeutics_for_Lysosomal_Storage_DisordersNovel tocopherol derivatives and tocopheryl quinone derivatives useful in the decrease of lysosomal substrate accumulation, the restoration of normal lysosomal size, and the treatment of lysosomal storage disorders (LSDs) are provided. The inventors have discovered that tocopherol and tocopheryl quinone derivatives with side chain modifications (such as terminal tri-halogenated methyl groups) exhibit improved pharmacokinetics, modulation of mitochondrial potential and restoration of some LSDs phenotypes. These molecules by themselves or in combination with Cyclodextrins (CDs) increase intra...Tue, 06 Dec 2022 11:58:11 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Novel_Tocopherol_and_Tocopheryl_Quinone_Derivatives_as_Therapeutics_for_Lysosomal_Storage_DisordersTAB-2967https://nih.technologypublisher.com/tech/mNFHcre_Transgenic_MiceKnockout mouse is a valuable model to study biological functions of target genes. When Cre expressing mice are bred with mice containing a loxP-flanked gene, the gene between the loxP sites will be deleted in the offsprings. Scientists at the NIH have generated mNF-H-cre transgenic mouse lines that express Cre recombinase under the control of the promoter of the neurofilament-H gene, which is expressed in the late stage of neuronal maturation. The transgenic mice express cre in neurons (but not astrocytes) with highest expression in the cortex and hippocampus. The mNF-H-cre transgenic mouse li...Tue, 06 Dec 2022 11:58:10 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/mNFHcre_Transgenic_MiceTAB-3114https://nih.technologypublisher.com/tech?title=N6%2c_A_Novel%2c_Broad%2c_Highly_Potent_HIV-specific_AntibodyThis is a new antibody coming out of NIAID’s intramural program. N6 has evolved a unique mode of binding that depends less on a variable area of the HIV envelope known as the V5 region and focuses more on conserved regions, which change relatively little among HIV strains. This allows N6 to tolerate changes in the HIV envelope, including the attachment of sugars in the V5 region, a major mechanism by which HIV develops resistance to other VRC01-class antibodies. N6 was shown in pre-clinical studies to neutralize 98 percent of HIV isolates tested. The studies also demonstrate that N6 neutral...Tue, 06 Dec 2022 11:58:08 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech?title=N6%2c_A_Novel%2c_Broad%2c_Highly_Potent_HIV-specific_AntibodyTAB-2545https://nih.technologypublisher.com/tech/Highly_Potent_and_Selective_Deubiquitinating_Enzyme_InhibitorAvailable for licensing are inhibitors that target the USP1/ UAF1 deubiquitinating enzyme (DUB) complex. The FDA approval and commercial success of Velcade®, a small molecule proteasome inhibitor, has established the ubiquitin-proteasome system (UPS) as a valid target for anticancer treatment. However, proteasome inhibitors in general suffer from a narrow therapeutic index and acquired resistance. A promising alternative to proteasome inhibition has been to target the enzymes upstream of proteasome-mediated protein degradation, i.e. the ubiquitin conjugation and deconjugation, to generate m...Tue, 06 Dec 2022 11:58:07 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Highly_Potent_and_Selective_Deubiquitinating_Enzyme_InhibitorTAB-2543https://nih.technologypublisher.com/tech/mTOR_Inhibition_for_the_Prevention_of_Epithelial_Stem_Cell_Loss_and_MucositisThe integrity of the epidermis and mucosal epithelia is highly dependent on self-renewing stem cells and, therefore, is vulnerable to physical and chemical damage from common cancer treatments, such as radiation or chemotherapy. Consequently, many cancer patients undergoing these treatments develop mucositis, a debilitating condition involving painful and deep mucosal ulcerations. Since current prevention and treatment options for mucositis are limited, providing only minor relief and no protection to stem cells, novel therapies are needed. The NIH inventors have recently discovered that the ...Tue, 06 Dec 2022 11:58:06 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/mTOR_Inhibition_for_the_Prevention_of_Epithelial_Stem_Cell_Loss_and_MucositisTAB-2536https://nih.technologypublisher.com/tech/Novel_Vaccine_for_Prevention_and_Treatment_of_Chlamydia_InfectionThe invention provides novel vectors, attenuated pathogens, compositions, methods and kits for preventing and/or treating chlamydia infections. Chlamydia trachomatis is an obligate intracellular human pathogen with a unique biphasic developmental growth cycle. It's the etiological agent of trachoma, the world's leading cause of preventable blindness and the most common cause of bacterial sexually transmitted disease. C. trachomatis isolates maintain a highly conserved plasmid and naturally occurring plasmidless clinical isolates are rare, implicating its importance in chlamydial pathogenesis. ...Tue, 06 Dec 2022 11:58:03 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Novel_Vaccine_for_Prevention_and_Treatment_of_Chlamydia_InfectionTAB-2535https://nih.technologypublisher.com/tech/Modified_Peptide_Nucleic_Acids_(PNAs)_for_Detection_of_DNA_or_RNA_and_Identification_of_a_Disease_or_PathogenThe NIH announces a novel method for fast, simple, and accurate detection of nucleic acids outside the modern laboratory. Nucleic acid testing is highly specific and often provides definitive identification of a disease or pathogen. Methods to detect nucleic acid sequences and identify a disease or pathogen are dominated by PCR, but applying PCR-based techniques in remote settings is challenging. Researchers at the NIH have developed a universal, colorimetric, nucleic acid-responsive diagnostic system that uses two short peptide nucleic acid (PNA) probes and does not rely on PCR. The design...Tue, 06 Dec 2022 11:58:02 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Modified_Peptide_Nucleic_Acids_(PNAs)_for_Detection_of_DNA_or_RNA_and_Identification_of_a_Disease_or_PathogenTAB-2532https://nih.technologypublisher.com/tech/Background-Free_Fluorescent_Nanodiamond_ImagingAvailable for licensing and commercial development are intellectual property rights covering a method of imaging a biological specimen (e.g., human tissue) using fluorescent nanodiamonds implanted into the subject of interest, applying a magnetic field to said subject and producing a resultant image by a net juxtaposition of a second acquired image. This process suppresses the background and permits selective imaging of the nanodiamonds in the presence of background fluorescence that exceeds the signal from the nanodiamonds. Another aspect of the invention provides an imaging method in whic...Tue, 06 Dec 2022 11:58:00 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Background-Free_Fluorescent_Nanodiamond_ImagingTAB-2531https://nih.technologypublisher.com/tech/Software_to_Improve_the_Quality_of_Microscopy_ImagesAvailable for licensing and commercial use is software based on an iterative deconvolution procedure that recovers images that have been blurred by a known point spread function. The software provides superior results when multiple independent observations of the same specimen are obtained. An example of such observations might be the multiple views of a specimen collected by a selective illumination plane microscope (SPIM). By using the blurring function and observations (raw images) corresponding to each view in sequential order through the iteration loop, the resulting output contains highe...Tue, 06 Dec 2022 11:57:59 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Software_to_Improve_the_Quality_of_Microscopy_ImagesTAB-2517https://nih.technologypublisher.com/tech/Derivatives_of_Docosahexaenoylethanolamide_(DEA)_for_NeurogenesisThe invention pertains to derivatives of docosahexaenoylethanolamide (synaptamide or DEA) and their use in inducing neurogenesis, neurite growth, and/or synaptogenesis. As such, these DEA derivatives can be used as therapeutics for neurodegenerative diseases such as traumatic brain injury, spinal cord injury, peripheral nerve injury, stroke, multiple sclerosis, autism, Alzheimer's disease, Huntington's disease, Parkinson's disease, amyotrophic lateral sclerosis. The DEA derivatives of the invention have increased potency and hydrolysis resistance as compared to native DEA. Docosahexaenoic acid...Tue, 06 Dec 2022 11:57:56 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Derivatives_of_Docosahexaenoylethanolamide_(DEA)_for_NeurogenesisTAB-2515https://nih.technologypublisher.com/tech/SIRT2_Inhibitors_as_Novel_Therapeutics_for_Myocardial_Infarction_and_Ischemic_Stroke_and_to_Prevent_NecrosisSirtuin 2 (SIRT2) inhibitors to reduce necrosis and, thereby, as novel therapeutics to treat ischemic stroke and myocardial infarction. Accumulating evidence indicates that programmed necrosis plays a critical role in cell death during ischemia-reperfusion. NIH investigators have shown that the NAD-dependent deacetylase SIRT2 binds constitutively to receptor-interacting protein 3 (RIP3) and that deletion or knockdown of SIRT2 prevents formation of the RIP1-RIP3 complex in mice. These investigators also found that genetic or pharmacological inhibition of SIRT2 blocks cellular necrosis induce...Tue, 06 Dec 2022 11:57:54 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/SIRT2_Inhibitors_as_Novel_Therapeutics_for_Myocardial_Infarction_and_Ischemic_Stroke_and_to_Prevent_NecrosisTAB-2507https://nih.technologypublisher.com/tech?title=Methods_and_Composition_for_Identification_of_Variants_of_JC_Virus_DNA%3b_An_Etiologic_Agent_for_Progressive_Multifocal_Leukoencephalopathy_(PML)JC Virus causes a fatal disease in the brain called progressive multifocal leukoencephalopathy (PML) that occurs in many patients with immunocompromised conditions. The finding of JCV DNA in the patients with neurological symptoms of PML is a diagnostic criterion and is needed to confirm the diagnosis of PML to rule out other neurological conditions. Certain JC virus variants are known to have a greater association with PML. For example, "Prototype" JC virus is far more pathogenic than "Archetype" JC virus. This invention claims novel assays for identifying Archetype and/or Prototype JC vi...Tue, 06 Dec 2022 11:57:52 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech?title=Methods_and_Composition_for_Identification_of_Variants_of_JC_Virus_DNA%3b_An_Etiologic_Agent_for_Progressive_Multifocal_Leukoencephalopathy_(PML)TAB-2506https://nih.technologypublisher.com/tech/Transmission-Blocking_Malaria_VaccineThere is no vaccine for malaria, and there is growing resistance to existing anti-malarial drugs. Sexual stage-specific antigens are of interest as vaccine candidates because disruption of these antigens would reduce the fertility and, thus, the infectivity of the parasite. This invention claims methods and compositions for delivering a Plasmodium P47 vaccine or antibody to P47 to prevent Plasmodium falciparum or Plasmodium vivax malaria. P47 and other antigens have been mentioned as potential transmission-blocking vaccines due to their surface location on gametes. The gene for P47 antigen...Tue, 06 Dec 2022 11:57:51 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Transmission-Blocking_Malaria_VaccineTAB-2504https://nih.technologypublisher.com/tech?title=Diagnostic_Test_and_Therapeutic_Target_for_Sjogren%27s_SyndromeSjögren's syndrome is an autoimmune disease that attacks salivary glands resulting in chronic dry mouth and dry eyes. Currently, there is no single diagnostic test to confirm the presence of Sjögren's. Physicians presently reach diagnosis after conducting a series of blood and functional tests for tear and salivary production. Diagnosis is further complicated as Sjögren's symptoms frequently mimic those of other autoimmune diseases (e.g., lupus, rheumatoid arthritis, etc.) and is often overlooked as dryness associated with medications being taken by the patient. Researchers at NIDCR have id...Tue, 06 Dec 2022 11:57:50 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech?title=Diagnostic_Test_and_Therapeutic_Target_for_Sjogren%27s_SyndromeTAB-2502https://nih.technologypublisher.com/tech/Axon_Regeneration_After_Brain_or_Spinal_Cord_InjuryThe invention is directed to modification of a particular sugar by the enzyme arylsulfatase B (ARSB), which results in axon regeneration. Following traumatic brain or spinal cord injury, glial scars prevent regeneration of axons. Chondroitin sulfate proteoglycans (CSPGs) are major components of glial scars. CSPGs are made of a protein core containing glycosaminoglycan (GAG) sugar side chains, which, when sulfated, are responsible for the inhibitory activity of glial scars. Specifically, NIH researchers have shown that the 4-sulfate unit on a certain sugar on GAG is responsible for inhibiti...Tue, 06 Dec 2022 11:57:49 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Axon_Regeneration_After_Brain_or_Spinal_Cord_InjuryTAB-2501https://nih.technologypublisher.com/tech/Glucocorticoid-induced_TNFR_Family-Related_Receptor_Ligand_(GITRL)_Antibodies_for_Diagnosis_and_Treatment_of_Immune_System_DisordersThis technology provides novel antibodies and methods for diagnostics and treatment of disorders arising from dysregulation of the immune system using antibodies directed against glucocorticoid-induced tumor necrosis factor receptor family-related receptor ligand (GITRL). Also available are hybridomas producing anti-mouse GITRL monoclonal antibodies (clone 5F1). Glucocorticoid-induced TNFR family-related receptor (GITR, also known as TNFRSF18) is expressed on the surface of responder T cells (CD4+CD25- or CD8+CD25- T cells). Upon activation of the immune response, GITR is up-regulated and bi...Tue, 06 Dec 2022 11:57:48 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Glucocorticoid-induced_TNFR_Family-Related_Receptor_Ligand_(GITRL)_Antibodies_for_Diagnosis_and_Treatment_of_Immune_System_DisordersTAB-2500https://nih.technologypublisher.com/tech/Small_Molecule_MRS5474_with_Anticonvulsant_Activity_for_Treatment_of_EpilepsyAdenosine modulates many physiological processes by activating specific adenosine receptors. These adenosine receptors play a critical role in the regulation of cellular signaling and are broadly distributed throughout the body. Thus, the ability to modulate adenosine receptor-mediated signaling is an attractive therapeutic strategy for a broad range of diseases. This technology relates to a group of compounds that display high affinity and specificity for the A1 adenosine receptor subtype. One of the compounds, MRS5474, displays anticonvulsant activity in the 6 Hz animal model of clonic seizu...Tue, 06 Dec 2022 11:57:47 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Small_Molecule_MRS5474_with_Anticonvulsant_Activity_for_Treatment_of_EpilepsyTAB-2499https://nih.technologypublisher.com/tech/Adeno-Associated_Virus_Gene_Therapy_for_Diabetes_and_ObesityThis invention is directed to adeno-associated virus (AAV) vector delivery of exendin-4 (Ex-4) to salivary glands as treatment for diabetes and obesity. Ex-4 is a potent and long-acting agonist of the receptor for glucagon-like peptide 1 (GLP-1). Scientists at NIDCR have shown that AAV-mediated delivery of Ex-4 resulted in improved glucose homeostasis and weight profile in two rat models of obesity and type 2 diabetes. Further, AAV-mediated delivery of Ex-4 to rat salivary glands resulted in localized and sustained expression of Ex-4 that was biologically active and well tolerated. AAV-mediat...Tue, 06 Dec 2022 11:57:46 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Adeno-Associated_Virus_Gene_Therapy_for_Diabetes_and_ObesityTAB-2498https://nih.technologypublisher.com/tech/Novel_Small_Molecule_Agonists_of_the_Relaxin_Receptor_as_Potential_Therapy_for_Heart_Failure_and_FibrosisThe present invention is directed to novel small molecule agonists of the mammalian relaxin family receptor 1 (RXFP1), including human RXFP1. Activation of RXFP1 induces: 1) vasodilation due to up-regulation of the endothelin system; 2) extracellular matrix remodeling; 3) moderation of inflammation by reducing levels of inflammatory cytokines; and 4) angiogenesis. Small molecule agonists of RXFP1 may be useful in treating acute heart failure (AHF), scleroderma, fibrosis, other conditions associated with the biology of relaxin, and in improving reproductive health and wound healing. These co...Tue, 06 Dec 2022 11:57:45 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Novel_Small_Molecule_Agonists_of_the_Relaxin_Receptor_as_Potential_Therapy_for_Heart_Failure_and_FibrosisTAB-2494https://nih.technologypublisher.com/tech/Cyclodextrins_as_Therapeutics_for_Lysosomal_Storage_DisordersCyclodextrins (CD), alone or in combination with other agents (e.g., vitamin E), as therapeutics for the treatment of lysosomal storage disorders (LSDs) caused by the accumulation of non-cholesterol lipids. CDs are sugar molecules in a ring form. The alpha-CD (6 sugars), beta-CD (7 sugars) and gamma-CD (8 sugars) are commonly used cyclodextrins. The hydroxypropyl-beta cyclodextrin (HPbCD) has been approved for pharmaceutical use. Recent reports show that beta-cyclodextrin including HPbCD and beta-methyl-cyclodextrin reduced cholesterol accumulation and neuronal cell loss in the mouse model of ...Tue, 06 Dec 2022 11:57:43 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Cyclodextrins_as_Therapeutics_for_Lysosomal_Storage_DisordersTAB-2493https://nih.technologypublisher.com/tech?title=Glucocerebrosidase_Non-inhibitory_Chaperones_for_the_Treatment_of_Gaucher_Disease%2c_Parkinson%27s_Disease%2c_and_Other_ProteinopathiesGaucher disease is a rare lysosomal storage disease that is characterized by a loss of function of the glucocerebrosidase (GCase) enzyme, which results in a decreased ability to degrade its lipid substrate, glucocerebroside. The intracellular build up of this lipid causes a broad range of clinical manifestations, ranging from enlarged spleen/liver and anemia to neurodegeneration. In Gaucher disease, the loss of GCase function has been attributed to low levels of the protein in the lysosomal compartment, resulting from improper GCase folding and transport. Also, mutations in the GCase gene ha...Tue, 06 Dec 2022 11:57:42 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech?title=Glucocerebrosidase_Non-inhibitory_Chaperones_for_the_Treatment_of_Gaucher_Disease%2c_Parkinson%27s_Disease%2c_and_Other_ProteinopathiesTAB-2488https://nih.technologypublisher.com/tech/Antimalarial_Inhibitors_that_Target_the_Plasmodial_Surface_Anion_Channel_(PSAC)_Protein_and_Development_of_the_PSAC_Protein_as_Vaccine_TargetsThere are two related technologies, the first being small molecule inhibitors of the malarial plasmodial surface anion channel (PSAC) and the second being the PSAC protein itself as a vaccine candidate. The PSAC protein is produced by the malaria parasite within host erythrocytes and is crucial for mediating nutrient uptake. In vitro data show that the PSAC inhibitors are able to inhibit growth of malaria parasites, have high specificity, and low toxicity. Portions of the PSAC protein are found on the outer surface of infected host erythrocytes and the protein was recently shown to be encod...Tue, 06 Dec 2022 11:57:40 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Antimalarial_Inhibitors_that_Target_the_Plasmodial_Surface_Anion_Channel_(PSAC)_Protein_and_Development_of_the_PSAC_Protein_as_Vaccine_TargetsTAB-2486https://nih.technologypublisher.com/tech?title=Magnetic_Resonance_Arterial_Wall_Imaging_Methods_that_Compensate_for_Patient_Aperiodic_Intrinsic_Cardiac%2c_Chest_Wall%2c_and_Blood_Flow-Induced_MotionsThe technology includes MRI methods, systems, and software for reliably imaging vasculature and vascular wall thickness while compensating for aperiodic intrinsic motion of a patient during respiration. To overcome the loss of the orthogonality due to uncompensated residual motions and after a lapse of time equal to the trigger delay commenced at the cardiac cycle, the system acquires multiple consecutive time-resolved images of the arterial wall. The cine images are processed offline and a wall thickness measurement is produced. The method improves arterial wall imaging by increasing the su...Tue, 06 Dec 2022 11:57:39 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech?title=Magnetic_Resonance_Arterial_Wall_Imaging_Methods_that_Compensate_for_Patient_Aperiodic_Intrinsic_Cardiac%2c_Chest_Wall%2c_and_Blood_Flow-Induced_MotionsTAB-2485https://nih.technologypublisher.com/tech/Zuma_Mutant_Mice_as_a_Tool_for_Investigating_Mammalian_Developmental_DefectsIn vertebrates, mutations in different ribosomal protein subunits result in a variety of phenotypes, suggesting unique and perhaps extra-ribosomal functions for these proteins. Diamond-Blackfan Anemia (DBA) is a ribosomal protein disease, in which the bone marrow fails to produce red blood cells. NHGRI investigators recently generated a mouse line with a mutation in small ribosomal protein7 (Rps7), known to be involved in DBA. This line named Zuma (made with the use of the mutagen N-ethyl-N-nitrosourea (ENU)) carries a point mutation in exon 7 of Rps7, which is predicted to cause a substitutio...Tue, 06 Dec 2022 11:57:38 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Zuma_Mutant_Mice_as_a_Tool_for_Investigating_Mammalian_Developmental_DefectsTAB-2481https://nih.technologypublisher.com/tech/A_Method_to_Expand_a_Population_of_Regulatory_T_Cells_Optimal_for_the_Treatment_of_Autoimmune_DiseasesThe transfusion of regulatory T cells (Tregs) has been used in the clinic to successfully prevent graft vs. host disease and is currently being evaluated in the treatment of other autoimmune diseases, such as organ graft rejection, type 1 diabetes and multiple sclerosis. Prior to transfusion, adoptive regulatory T cell transfer requires the expansion of regulatory T cells in culture; this results in a mixed population of regulatory T cells that limits the effectiveness of the transferred cells. Scientists at the NIH have developed a method that promotes the expansion of regulatory T cells that...Tue, 06 Dec 2022 11:57:37 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/A_Method_to_Expand_a_Population_of_Regulatory_T_Cells_Optimal_for_the_Treatment_of_Autoimmune_DiseasesTAB-2467https://nih.technologypublisher.com/tech?title=Polyclonal_Antibodies_for_the_Specialized_Signaling_G_protein%2c_Gbeta5Researchers at NIDDK have developed polyclonal antibodies against the G protein, Gbeta5. Gbeta5 is a unique and highly specialized G protein that exhibits much less homology than other Gbeta isoforms (~50%) and is preferentially expressed in brain and neuroendocrine tissue. It is expressed prominently in the neuronal cell membrane, as well as in the cytosol and nucleus. Although this distribution pattern suggests that Gbeta5 may shuttle information between classical G protein-signaling elements at the plasma membrane and the cell interior, its function in the brain is largely unknown. The ...Tue, 06 Dec 2022 11:57:24 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech?title=Polyclonal_Antibodies_for_the_Specialized_Signaling_G_protein%2c_Gbeta5TAB-2464https://nih.technologypublisher.com/tech/Salen-Manganese_Compounds_for_Therapy_of_Viral_InfectionsSalen-manganese compounds are synthetic, stable, low toxicity, low cost agents that may provide protection from immune reaction-related oxidative cell damage associated with many illnesses. In particular, oxidative cell damage has been associated with many viral infections including influenza. This invention demonstrates that treating mice with salen-manganese compounds, after lethal pandemic influenza virus infection, significantly enhances survival. Salen-manganese treatment also reduces lung pathology and also improved cellular recovery and repair. Because oxidative damage is observed in ma...Tue, 06 Dec 2022 11:57:22 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Salen-Manganese_Compounds_for_Therapy_of_Viral_InfectionsTAB-2463https://nih.technologypublisher.com/tech/Self-Assembled_Ferritin_Nanoparticles_Expressing_Hemagglutinin_as_an_Influenza_VaccineNIH inventors at the Vaccine Research Center have developed a novel influenza virus hemagglutinin (HA)-ferritin nanoparticle influenza vaccine that is easily manufactured, potent, and elicits broadly neutralizing influenza antibodies against multiple strains of influenza. This novel influenza nanoparticle vaccine elicited two types of broadly neutralizing, cross-protective antibodies, one directed to the highly conserved HA stem and a second proximal to the conserved receptor binding site (RBS) of the viral HA, providing a new platform for universal and seasonal influenza. In addition, HA-ferr...Tue, 06 Dec 2022 11:57:20 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Self-Assembled_Ferritin_Nanoparticles_Expressing_Hemagglutinin_as_an_Influenza_VaccineTAB-2459https://nih.technologypublisher.com/tech/Antagonists_of_Hyaluronan_Signaling_for_Treatment_of_Airway_DiseasesAirway diseases, such as Asthma and Chronic Obstructive Pulmonary Disease (COPD), constitute a major health burden worldwide. It is estimated, for example, that nearly 15.0% of the adult population in the US are affected with such diseases, and the economic cost burden is over $23 billion annually. Unfortunately, the current options for treatment of such diseases are quite limited, consisting only of bronchodilators and inhaled steroids. The need for a novel and more effective class of therapeutics agents is imperative. The subject invention provides for a potentially more specific and effecti...Tue, 06 Dec 2022 11:57:19 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Antagonists_of_Hyaluronan_Signaling_for_Treatment_of_Airway_DiseasesTAB-2455https://nih.technologypublisher.com/tech/A3_Adenosine_Receptor_Agonists_to_Treat_Chemotherapy-induced_Peripheral_NeuropathyThis invention claims species-independent agonists of A3AR, specifically (N)-methanocarba adenine nucleosides and related pharmaceutical compositions. The A3 adenosine receptor (A3AR) subtype has been linked with helping protect the heart from ischemia, controlling inflammation, and regulating cell proliferation. Agonists of the human A3AR subtype have been developed that are also selective for the mouse A3AR while retaining selectivity for the human receptor. This solves a problem for clinical development because animal model testing is important for pre-clinical validation of drug function...Tue, 06 Dec 2022 11:57:17 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/A3_Adenosine_Receptor_Agonists_to_Treat_Chemotherapy-induced_Peripheral_NeuropathyTAB-2453https://nih.technologypublisher.com/tech/Fast_Acting_Molecular_Probes_for_Real-Time_In_Vivo_Study_of_Disease_and_TherapeuticsThis technology is for fast acting molecular probes made from a fluorescent quencher molecule, a fluorophore, an enzyme cleavable oligopeptide (for example targeted by protease) and FDA-approved polyethylene glycol (PEG) as well as associated methods to identify cell activity with these probes. Proteases regulate many cell processes such as inflammation as well as pathological processes in cancer and cardiovascular disease. High protease activity is associated with metastatic cancers. Proteases are also active in apoptosis, and tissue remodeling in cardiovascular disease. Although highly u...Tue, 06 Dec 2022 11:57:16 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Fast_Acting_Molecular_Probes_for_Real-Time_In_Vivo_Study_of_Disease_and_TherapeuticsTAB-2452https://nih.technologypublisher.com/tech/Mouse_Model_of_STAT5_for_the_Drug_Screen_and_the_Research_of_Cancer_and_AutoimmunityThe invention is a STAT5 mutant mouse that can be used in research related to cancer, autoimmunity and infectious diseases as well as drug screening. The mouse model itself has multiple immunological defects resulting in formation of STAT5 dimers but not tetramers. It reports that only a minority of IL-2-modulated genes is regulated by STAT5 tetramers. Therefore, selectively targeting tetramer formation might be a relatively specific therapeutic tool wherein one could modulate only part of the actions of a cytokine or growth factor, which allows a new therapeutic approach to modulating immune...Tue, 06 Dec 2022 11:57:15 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Mouse_Model_of_STAT5_for_the_Drug_Screen_and_the_Research_of_Cancer_and_AutoimmunityTAB-2450https://nih.technologypublisher.com/tech/Endothelial_Cell_Line_to_Study_Prevention_of_AtherosclerosisAtherosclerosis underlies most cases of cardiovascular disease (CVD), which is now the major cause of morbidity and mortality in developed countries. An inflammatory reaction is an essential component in the appearance and development of an atherosclerotic lesion. The inflammatory process is associated with the expression of adhesion molecules such as vascular cell adhesion molecule (VCAM) at the surface of endothelial cells. Antiatherogenic lipoprotein, high density lipoprotein (HDL), is known to down regulate the expression of VCAM. Increasing levels of HDL is a promising way to reduce t...Tue, 06 Dec 2022 11:57:14 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Endothelial_Cell_Line_to_Study_Prevention_of_AtherosclerosisTAB-2448https://nih.technologypublisher.com/tech/Treatment_of_Viral_Infection_by_Blocking_Interleukin-21Blocking interleukin (IL-21) may be an effective method to treat or prevent various viral infections. In the course of an immune response to a virus, IL-21, produced primarily by CD4+ T cells, can inhibit or stimulate (regulate), immune cell function (B cells, T cells, natural killer cells, dendritic cells). IL-21 regulation may be either protective or pathological; autoimmune disease pathology has been associated with IL-21 promoted inflammation (in: type 1 diabetes, lupus, and multiple sclerosis). This technology describes methods of blocking IL-21 that may reduce damaging inflammatory re...Tue, 06 Dec 2022 11:57:12 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Treatment_of_Viral_Infection_by_Blocking_Interleukin-21TAB-2442https://nih.technologypublisher.com/tech?title=Rabbit_Polyclonal_Antibody_to_Detect_a_Pro-peptide_Fragment_of_NSAID-activated_Gene_(NAG-1)%2fGDF15%2c_a_Protein_Associated_with_CancerChronic inflammation is clearly associated with an increase in the risk of cancer. Non-steroidal anti-inflammatory drugs (NSAIDs) are well documented as agents that inhibit tumor growth and with long-term use can prevent tumor development. NSAID-activated gene (NAG-1), a unique member of the TGF-beta superfamily, is highly induced by NSAIDs and numerous drugs and chemicals with anti-tumorigenic activities. The protein product of NAG-1 is first formed into an immature peptide dimer that must be cut at a specific site before it can be secreted as a mature protein. Currently available antibodies ...Tue, 06 Dec 2022 11:57:11 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech?title=Rabbit_Polyclonal_Antibody_to_Detect_a_Pro-peptide_Fragment_of_NSAID-activated_Gene_(NAG-1)%2fGDF15%2c_a_Protein_Associated_with_CancerTAB-2440https://nih.technologypublisher.com/tech/M3_Muscarinic_Receptor_Knockout_Mice_(Chrm3_tm1Jwe)_for_the_Study_of_Obesity_and_Other_Metabolic_DisordersThe five Muscarinic Acetylcholine (ACh) receptors are G-protein coupled receptors (M1R-M5R). M3 muscarinic ACh receptors are present in the central nervous system and the periphery. M3R knockout mice are viable and fertile, and have no major morphological abnormalities. They have a lean phenotype due to a combination of reduced caloric intake and increased energy expenditure. Because of their lean phenotype, M3R knockout mice have improved glucose tolerance and increased insulin sensitivity. Pharmacological blockade of central M3Rs may be a novel strategy for the treatment of obesity and ...Tue, 06 Dec 2022 11:57:10 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/M3_Muscarinic_Receptor_Knockout_Mice_(Chrm3_tm1Jwe)_for_the_Study_of_Obesity_and_Other_Metabolic_DisordersTAB-2439https://nih.technologypublisher.com/tech?title=GLI-Similar_3(GLIS3)_Knock_Out_(KO)_Mice_as_Models_to_Screen_Therapeutics_for_Diabetes%2c_Polycystic_Kidney_Disease%2c_and_HypothyroidismGLI-similar (Glis) 1-3 proteins constitute a subfamily of the Krüppel-like zinc finger transcription factors that are closely related to the Gli family. Mutations in human GLIS3 have been implicated in a syndrome characterized by neonatal diabetes and congenital hypothyroidism (NDH) and in some patients accompanied by polycystic kidney disease, glaucoma, and liver fibrosis. To further identify and study the physiological functions of GLIS3, NIEHS investigators generated mice in which GLIS3 is ubiquitously knocked out (GLIS3-KO) or conditionally knocked out in a cell type-specific manner. GL...Tue, 06 Dec 2022 11:57:09 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech?title=GLI-Similar_3(GLIS3)_Knock_Out_(KO)_Mice_as_Models_to_Screen_Therapeutics_for_Diabetes%2c_Polycystic_Kidney_Disease%2c_and_HypothyroidismTAB-2437https://nih.technologypublisher.com/tech/Antagonist_of_A3_Adenosine_Receptor_Fluorescent_Probes_for_the_Study_of_Diseases_that_Involve_A3_SignalingThis molecular probe may serve as a companion tool to identify and stratify patient populations based on the prevalence of the target A3 adenosine receptors. Small molecule drugs, A3AR-selective agonists, are currently in advanced clinical trials for the treatment of hepatocellular carcinoma, autoimmune inflammatory diseases, such as rheumatoid arthritis, psoriasis, and dry eye disease, and other conditions.Tue, 06 Dec 2022 11:57:07 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Antagonist_of_A3_Adenosine_Receptor_Fluorescent_Probes_for_the_Study_of_Diseases_that_Involve_A3_SignalingTAB-2436https://nih.technologypublisher.com/tech/Java_Applet_for_Modeling_Human_Metabolism_and_Energy_Expenditure_for_Adaptive_Dieting_and_Exercise_RegimensKnown methods for predicting weight loss fail to account for slowing of metabolism as weight is lost and therefore overestimate the degree of weight loss. While this limitation of the 3500 Calorie per pound rule has been known for some time, it was not clear how to dynamically account for the metabolic slowing. The invention provides a Java applet for modeling of human metabolism to improve the weight change predictions. The model has been validated using previously published human data and the model equations have been published. A web-based implementation of the published dynamic model has b...Tue, 06 Dec 2022 11:57:06 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Java_Applet_for_Modeling_Human_Metabolism_and_Energy_Expenditure_for_Adaptive_Dieting_and_Exercise_RegimensTAB-3083https://nih.technologypublisher.com/tech/Immortalized_Organ_of_Corti_Cell_Line_OC-k3Available for nonexclusive licensing as a research material is a conditionally immortalized Organ of Corti cell line called OC-k3. Sensory cells from the auditory organ, the Organ of Corti, are terminally differentiated and cannot be cultured. Moreover, few of them can be isolated per cochlea and survive only few hours after isolation making impossible to use on them many biochemical and molecular biology techniques. OC-k3, expresses many markers of sensory cells and it has already been used as an in vitro model for a variety of studies.Tue, 06 Dec 2022 11:57:05 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Immortalized_Organ_of_Corti_Cell_Line_OC-k3TAB-2434https://nih.technologypublisher.com/tech/Human_DNA_Polymerase_Gamma_for_Testing_the_Effect_of_Drugs_on_Mitochondrial_FunctionOne of the primary means for treating HIV infection is the use of antiviral nucleotide or nucleoside analogs. These analogs work by inhibiting the activity of reverse transcriptase, the enzyme responsible for preparing the HIV genome for integration into the DNA of the host cell. Although these analogs do not have an effect on the polymerases responsible for replicating the human genome, the polymerase responsible for replicating the mitochondrial genome is sensitive to these analogs. When patients are exposed to nucleotide or nucleoside analogs through long-term treatment regimens, the replic...Tue, 06 Dec 2022 11:57:04 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Human_DNA_Polymerase_Gamma_for_Testing_the_Effect_of_Drugs_on_Mitochondrial_FunctionTAB-2433https://nih.technologypublisher.com/tech/Multilayer_X-Ray_Transmission_Grating_Array_for_Phase-Contrast_Imaging_and_TomographyClassical X-ray Computed Tomography (CT) and radiography are based on X-ray absorption and cannot show soft tissue structures as well as Magnetic Resonance Imaging (MRI). Detecting the phase delay/advance of X-rays that travel through the body could enhance soft tissue contrast 10 - 100 times. Submicron-period X-ray transmission gratings for medical x-ray energies can substantially enhance the phase detection sensitivity, but fabrication is a great challenge. This invention includes a method to fabricate multilayer transmission gratings of large areas. The design uses multilayer deposition...Tue, 06 Dec 2022 11:57:03 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Multilayer_X-Ray_Transmission_Grating_Array_for_Phase-Contrast_Imaging_and_TomographyTAB-2432https://nih.technologypublisher.com/tech/Transgenic_Hspa2-Cre_Mice_for_Studying_Spermatogenesis_and_Male_InfertilityHSPA2 is a member of the HSP70 family of heat-shock proteins that serve as molecular chaperones. Hspa2-cre expression mimics the spermatogenic cell-specific expression of endogenous HSPA2 within the testis, being first observed in leptotene/zygotene spermatocytes. Expression of the transgene is also detected at restricted sites in the brain, as occurs for endogenous HSPA2. Researchers at NIEHS developed the first transgenic mouse line that expresses Cre-recombinase under the control of the promoter of the heat shock protein A2 (Hspa2) gene. Expression of the Hspa2-Cre transgene during meio...Tue, 06 Dec 2022 11:57:01 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Transgenic_Hspa2-Cre_Mice_for_Studying_Spermatogenesis_and_Male_InfertilityTAB-2428https://nih.technologypublisher.com/tech/Broadly_Neutralizing_Human_Anti-HIV_Monoclonal_Antibody_10E8_and_Related_Antibodies_Capable_of_Neutralizing_Most_HIV-1_StrainsThe uses for human anti-HIV monoclonal antibody 10E8 and its variants include passive immunization, therapeutic vaccination, and the development of vaccine immunogens. 10E8 is one of the most potent HIV-neutralizing antibodies isolated and it neutralizes up to 98% of diverse HIV-1 strains. 10E8 is specific to the membrane-proximal external region (MPER) of the HIV envelope protein gp41 and 10E8 is orthogonal to other anti-HIV antibodies. In combination with other antibodies 10E8 may provide an antibody response that neutralizes nearly all strains of HIV-1. Additionally, 10E8 effectively induce...Tue, 06 Dec 2022 11:57:00 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Broadly_Neutralizing_Human_Anti-HIV_Monoclonal_Antibody_10E8_and_Related_Antibodies_Capable_of_Neutralizing_Most_HIV-1_StrainsTAB-2431https://nih.technologypublisher.com/tech/Hspa2_Knockout_Mice_for_Study_of_Spermatogenesis_and_Male_InfertilityHSPA2 is a member of the HSP70 family of heat-shock proteins that serve as molecular chaperones. Researchers discovered that HSPA2 protein is expressed in spermatogenesis during the meiotic phase. Spermatogenic cells lacking the HSPA2 protein arrest in mid-meiosis and undergo apoptosis. HSPA2 is present in the synaptonemal complex of wild-type mice and the chromosomes fail to separate in HSPA2-deficient mice (previously known as Hsp70-2-/- mice), suggesting that HSPA2 is required for the chromosomal events of meiosis such as synapsis, crossing over, or recombination. Researchers at NIEHS de...Tue, 06 Dec 2022 11:56:59 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Hspa2_Knockout_Mice_for_Study_of_Spermatogenesis_and_Male_InfertilityTAB-2427https://nih.technologypublisher.com/tech/Construct_for_Tetracycline_Inducible_Podocyte_Specific_Gene_Expression_in_MiceThe National Institutes of Health announces the generation of a construct by ligating 2.5kb human podocin promoter sequence to gene encoding reverse tetracycline-controlled transcriptional activator which enables tetracycline-inducible podocyte specific gene of interest expression with another construct consisting of tetracycline responsive element, minimal CMV promoter and gene of interest. Podocytes are post-mitotic epithelial cells that are positioned on the exterior aspect of the glomerular capillary wall and contribute to the selective molecular permeability of glomeruli. Podocyte damage...Tue, 06 Dec 2022 11:56:58 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Construct_for_Tetracycline_Inducible_Podocyte_Specific_Gene_Expression_in_MiceTAB-2421https://nih.technologypublisher.com/tech/MUP-tTA_Mouse_Model_for_Liver_Function_StudiesTetracycline-responsive transcriptional activator driven by the liver-specific mouse major urinary protein promoter (MUP-tTA). The E. Coli tetracycline operon regulatory system was used to generate a liver-specific transcription activation system that was inhibited by tetracycline. The transcription activator was a fused protein consisting of a tetracycline repressor gene (tetR) that was only active in the presence of tetracycline and a herpes simplex virus protein (VP-16) transcription activating domain (Tet-Off). Transcription was induced only in the absence of tetracycline (Tet-Off). A ...Tue, 06 Dec 2022 11:56:56 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/MUP-tTA_Mouse_Model_for_Liver_Function_StudiesTAB-2420https://nih.technologypublisher.com/tech/Alb-tTA_(Tg(Alb1-tTA)3123Lng)_Mouse_Model_for_Liver_Function_StudiesTetracycline-responsive transcriptional activator driven by the liver-specific mouse albumin promoter (Alb-tTA). The E. Coli tetracycline operon regulatory system was used to generate a liver-specific transcription activation system that was inhibited by tetracycline. The transcription activator was a fused protein consisting of a tetracycline repressor gene (tetR) that was only active in the presence of tetracycline and a herpes simplex virus protein (VP-16) transcription activating domain. Transcription was induced only in the absence of tetracycline (Tet-Off). A liver-specific promoter ...Tue, 06 Dec 2022 11:56:55 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Alb-tTA_(Tg(Alb1-tTA)3123Lng)_Mouse_Model_for_Liver_Function_StudiesTAB-2419https://nih.technologypublisher.com/tech/Fgfr2_Knockout_(Fgfr2tm1Cxd)_Mouse_Model_for_Developmental_Biology_StudiesFGFR2 knockout is an embryonic lethal mutation and blocks limb bud initiation. Fibroblast Growth Factor Receptor 2 (FGFR2) is a high affinity receptor for several members of the FGF family. The FGFR2 gene was inactivated by deleting the entire immunoglobulin-like domain of the receptor which is critical for FGF binding and FGFR2 activity. Embryos that lack this domain die at E10-11.5 owing to a failure in chorioallantoic fusion or placental formation. The deletion also blocks limb bud initiation, establishing FGFR2 as the major receptor that mediates FGF signals during limb induction.Tue, 06 Dec 2022 11:56:55 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Fgfr2_Knockout_(Fgfr2tm1Cxd)_Mouse_Model_for_Developmental_Biology_StudiesTAB-2418https://nih.technologypublisher.com/tech/Fgfr3_Knockout_Mouse_Model_for_Developmental_Biology_StudiesFGFR3 knockout. Complete knockout of the FGFR3 gene, the gene in which missense mutants cause short statue achondroplasia, fails to restrain cartilage growth at the bone growth plate, allowing bones to elongate excessively but fail to ossify. Endochondral ossification is a major mode of bone formation. Cartilage proliferates, undergoes hypertrophy, begins to calcify, undergoes a program of cell death, and is replaced by osteoblasts. Fibroblast Growth Factor Receptor 3 (FGFR3) is expressed in cartilage rudiments of a wide variety of bones, and dominant missense mutations in the human FGFR3 g...Tue, 06 Dec 2022 11:56:53 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Fgfr3_Knockout_Mouse_Model_for_Developmental_Biology_StudiesTAB-2417https://nih.technologypublisher.com/tech/Sirt1_LoxP_(Sirt1tm1Cxd)_Mouse_Model_for_Metabolism_and_Hepatology_StudiesGeneration of floxed Sirtuin 1 Exon5-Exon6 for the construction of conditional knockout mice. Sirtuin 1 (Sirt1), a homolog of yeast Sir 2, is an NAD-dependent histone and protein deacetylase. It has a wide range of biological functions, ranging from DNA damage repair to effects on glucose metabolism. Sirt1 null mice die before birth due to chromosomal aberrations and impaired DNA damage repair. Sirt1 is thought to affect energy metabolism, but the mechanism remains poorly understood. In order to study tissue-specific metabolic effects of Sirt1, floxed Sirt1 was constructed so that exons 5 ...Tue, 06 Dec 2022 11:56:53 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Sirt1_LoxP_(Sirt1tm1Cxd)_Mouse_Model_for_Metabolism_and_Hepatology_StudiesTAB-2416https://nih.technologypublisher.com/tech/Sirt6_LoxP_(Sirt6tm1.1Cxd)_Mouse_Model_for_Liver_StudiesGeneration of floxed Sirtuin 6 for the construction of conditional knockout mice. The Sirtuins (Sirt1-7), a family of seven proteins related to yeast Sir2, are histone deacetylases that regulate many critical biological processes including genomic stability, adaptation to calorie restriction and aging. Mice with a targeted disruption of Sirt6 had very low levels of blood glucose (and paradoxically, low insulin levels) and died shortly after weaning. Hypoglycemia, attributed to increased sensitivity to insulin, was the major cause for lethality. Because of the post-weaning mortality of Sirt6 ...Tue, 06 Dec 2022 11:56:52 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Sirt6_LoxP_(Sirt6tm1.1Cxd)_Mouse_Model_for_Liver_StudiesTAB-2415https://nih.technologypublisher.com/tech/Sirt1_Knockout_(Sirt1tm1.1Cxd)_Mouse_Model_for_Oncology_and_Metabolism_StudiesSirt1 knockout: Sirt1, a protein deacetylase, is a tumor suppressor that promotes genome stability and regulates proteins involved in energy metabolism. Yeast Sir2, a nicotinamide adenine dinucleotide (NAD)-dependent protein deacetylase, has been implicated in chromatin silencing, longevity and genome stability. Mammals contain a family of related deacetylases, the sirtuins, of which 7 have been identified. Sirt1 is the closest mammalian orthologue of yeast Sir 2. The Sirt1 gene in mice was disrupted by homologous recombination in embryonic stem cells. The majority of Sirt1 (-/-) embryos d...Tue, 06 Dec 2022 11:56:51 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Sirt1_Knockout_(Sirt1tm1.1Cxd)_Mouse_Model_for_Oncology_and_Metabolism_StudiesTAB-2414https://nih.technologypublisher.com/tech/Sirt3_Knockout_(Sirt3tm1.1Cxd)_Mouse_Model_for_Cardiology_and_Metabolism_StudiesSirt3 knockout: Sirt3 is a mitochondrial-localized tumor suppressor that maintains mitochondrial integrity and metabolism during stress. Sirt3 is a mitochondrial protein that is a member of the Sirtuin family of NAD-dependent protein deacetylases. Sirt3(-/-) mice are phenotypically normal, but exhibit many proteins whose acetylation is increased. They generate more reactive oxygen species and are more susceptible to mammary tumors than normal mice. Sirt3 is inactivated in a large percentage of human breast and ovarian cancers, suggesting that Sirt3 may be a mitochondria-localized tumor sup...Tue, 06 Dec 2022 11:56:50 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Sirt3_Knockout_(Sirt3tm1.1Cxd)_Mouse_Model_for_Cardiology_and_Metabolism_StudiesTAB-2413https://nih.technologypublisher.com/tech/UTX_LoxP_Mouse_Model_for_Oncology_ResearchUTX-flox. Conditional knockout mice for the histone demethylase UTX (Kdm6a) conditional knockout will help understand its role as a tumor suppressor. Di- and tri-methylations on histone H3 lysine 27 (H3K27me2 and H3K27me3) are epigenetic marks for gene repression. UTX (ubiquitously transcribed X chromosome protein), also known as Kdm6a (lysine (K)-specific demethylase 6a) is a histone demethylase that specifically removes H3K27me2 and H3K27me3. UTX knockout mice are embryonic lethal, so we have generated UTX conditional knockout mice (UTX-flox) in which exon 24 is flanked with loxP sites. U...Tue, 06 Dec 2022 11:56:49 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/UTX_LoxP_Mouse_Model_for_Oncology_ResearchTAB-2412https://nih.technologypublisher.com/tech/Gs_Alpha_LoxP_(Gnastm1Lsw)_Mouse_Model_for_Metabolism_StudiesGeneration of a floxed Gnsa gene for the G-protein Gs alpha (Gsalpha) for the construction of conditional knockout mice. The heterotrimeric G protein Gsalpha couples many receptors to adenylyl cyclase and is essential for hormone-stimulated cAMP generation. Previous mouse models with germ-line mutations in Gnas, the gene that encodes Gsalpha had limited usefulness in trying to decipher the role of Gsalpha pathways in specific tissues since only heterozygotes were viable and could be analyzed. Analysis was further complicated by the fact that Gsalpha is imprinted expressed in many metabolicall...Tue, 06 Dec 2022 11:56:48 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Gs_Alpha_LoxP_(Gnastm1Lsw)_Mouse_Model_for_Metabolism_StudiesTAB-2411https://nih.technologypublisher.com/tech/Stat5a_Knockout_(Stat5atm1Mam)_Mouse_Model_for_Mammopoietic_and_Lactogenic_Signaling_StudiesStat 5a Knockout: Stat5a deficiency results in the loss of prolactin-dependent mammary gland development and lactogenesis. Prolactin induces mammary gland development and lactogenesis. Binding of Prolactin to its receptor leads to the phosphorylation and activation of STAT (signal transducers and activators of transcription) proteins. Two Stat proteins, Stat 5a and Stat5b, are expressed in mammary tissues during pregnancy. Stat5a null mice developed normally, and were indistinguishable from hemizygous and wild-type littermates in size, weight and fertility. Mammary lobulo-alveolar outgrow...Tue, 06 Dec 2022 11:56:47 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Stat5a_Knockout_(Stat5atm1Mam)_Mouse_Model_for_Mammopoietic_and_Lactogenic_Signaling_StudiesTAB-2410https://nih.technologypublisher.com/tech/Bcl-x_LoxP_(Bcl2l1_tm1.1Mam)_Mouse_Model_for_Developmental_Biology_StudiesFloxed Bcl-x: Conditional knockout of pro-survival Bcl-x in primordial germ cells was used to study the balance between pro-apoptotic Bax during embryogenesis. Bcl-x is a pro-survival protein that opposes the pro-apoptotic action of Bax which interacts with mitochondria to activate the caspase 9 pathway. Mice in which the Bcl-x gene is inactivated die at E12.5. To be able to study lineage-specific activities of Bcl-x at different stages of development, the Cre-LoxP recombination system was used. Homologous recombination was used to flank the promoter, exon1, and major coding exon2 of the B...Tue, 06 Dec 2022 11:56:46 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Bcl-x_LoxP_(Bcl2l1_tm1.1Mam)_Mouse_Model_for_Developmental_Biology_StudiesTAB-2409https://nih.technologypublisher.com/tech?title=Stat5a_LoxP%2fStat5b_LoxP_(Stat5a%2fStat5btm2Mam)_Mouse_Model_for_Mammopoietic_and_Lactogenic_Signaling_StudiesConditional knockout of Stat5a and Stat5b: Combined deletion of conserved Stat5a and Stat5b in mammary epithelium at different times during pregnancy reveal multiple distinct functions. The signal transducer and activator of transcription (STAT) family of transcription factors conveys signals from membrane receptors to the nucleus, where they activate diverse genetic programs. Stat5a and Stat5b are highly conserved proteins that are activated by many cytokines, erythropoietin, prolactin and growth hormone. Despite their similarities, they have many unique functions. Stat5a deficiency resul...Tue, 06 Dec 2022 11:56:45 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech?title=Stat5a_LoxP%2fStat5b_LoxP_(Stat5a%2fStat5btm2Mam)_Mouse_Model_for_Mammopoietic_and_Lactogenic_Signaling_StudiesTAB-2408https://nih.technologypublisher.com/tech?title=Tg(MMTV-Cre)%23Mam_Mouse_Model_for_Developmental_Biology%2c_Hepatology%2c_and_Oncology_StudiesCre-recombinase under the control of mouse mammary tumor virus long terminal repeat (MMTV) was expressed in the salivary gland and mammary epithelial cells of adult mice, and induced recombination in all tissues. The Cre recombinase from bacteriophage P1 excises intervening DNA sequences located between two unidirectional lox sites positioned on the same linear DNA segment, leaving one lox site behind. Through insertion of lox sites via homologous recombination into the gene of interest and targeting Cre recombinase expression to a specific cell type using a tissue-specific promoter, it is p...Tue, 06 Dec 2022 11:56:44 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech?title=Tg(MMTV-Cre)%23Mam_Mouse_Model_for_Developmental_Biology%2c_Hepatology%2c_and_Oncology_StudiesTAB-2407https://nih.technologypublisher.com/tech/Tg(Wap-cre)11738Mam_Mouse_Model_for_Developmental_Biology_StudiesCre-recombinase under the control of the whey acidic acid protein was only detected in alveolar epithelial cells of mammary tissue during lactation, and transcription occurred at all stages of mammary development. The Cre recombinase from bacteriophage P1 excises intervening DNA sequences located between two unidirectional lox sites positioned on the same linear DNA segment, leaving one lox site behind. Through insertion of lox sites via homologous recombination into the gene of interest and targeting Cre recombinase expression to a specific cell type using a tissue-specific promoter, it is ...Tue, 06 Dec 2022 11:56:43 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Tg(Wap-cre)11738Mam_Mouse_Model_for_Developmental_Biology_StudiesTAB-2406https://nih.technologypublisher.com/tech/Stat1LoxP_(Stat1_tm1Mam_)_Mouse_Model_for_Oncology_and_Immunology_StudiesSelective inactivation of Stat1 in mammary cells indicates that its effect as a tumor suppressor in breast is direct. STAT1 is considered a tumor suppressor, but it is not known if this effect occurs directly in mammary cells or secondarily by disrupting interferon signaling through the JAK/STAT1 pathway to induce immune responses. ERBB2/neu-induced breast cancer appeared sooner in mice lacking STAT1 only in mammary cells than in wild-type mice, indicating that STAT1 tumor suppression was intrinsic to mammary cells and not secondary to an induced immune response.Tue, 06 Dec 2022 11:56:42 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Stat1LoxP_(Stat1_tm1Mam_)_Mouse_Model_for_Oncology_and_Immunology_StudiesTAB-2405https://nih.technologypublisher.com/tech/M5_Muscarinic_Receptor_Knockout_(Chrm5tm1Jwe)_Mouse_Model_for_Neurological_StudiesM5 muscarinic receptor knockout: Deficiency of M5Rs reduces drug-seeking behavior. The five Muscarinic Acetylcholine (ACh) receptors are G-protein coupled receptors (M1R-M5R). M1R, M3R and M5R selectively couple to Gq/G11; M2R and M4R selectively couple to Gi/Go. M5R knockout mice are viable and fertile, and have no major morphological abnormalities. M5 muscarinic ACh receptors are located in the central nervous system and may contribute to the cognitive-enhancing effects of ACh. M5R knockout mice show deficits in two hippocampus-dependent cognitive tasks, and exhibit reduced cerebral blood ...Tue, 06 Dec 2022 11:56:41 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/M5_Muscarinic_Receptor_Knockout_(Chrm5tm1Jwe)_Mouse_Model_for_Neurological_StudiesTAB-2404https://nih.technologypublisher.com/tech?title=mEpoR_Knockout%2fTg(hEpoR)_Mouse_Model_for_Anemia_and_Renal_Function_StudiesmEpoR-/- hEpoR+: The mouse Erythropoietin Receptor knockout that contains a human Erythropoietin Receptor transgene can be used to define the potency of recombinant erythropoietin preparations used to treat anemia associated with chronic kidney disease. Erythropoietin, acting by binding to Erythropoietin receptors (EpoR) on erythroid progenitor cells, is required for erythropoiesis. Absence of erythropoietin or the EpoR in mice interrupts erythropoiesis in the fetal liver and result in death at embryonic day 13.5. An 80-kb human EpoR transgene bred onto a mouse EpoR null background (provide...Tue, 06 Dec 2022 11:56:40 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech?title=mEpoR_Knockout%2fTg(hEpoR)_Mouse_Model_for_Anemia_and_Renal_Function_StudiesTAB-2403https://nih.technologypublisher.com/tech/Fgfr4_Knockout_Mouse_Model_for_Respiratory_System_StudiesFGFR4 knockout: Lung alveoli fail to develop normally in double mutant with FGFR4 and FGFR3 knockouts. The fibroblast growth factor receptor 4 (fgfr-4) gene was inactivated by targeted disruption and homozygous recombination to study its possible role in lung development. FGFR-4 is expressed in postnatal lung, and FGFR-4 null mice have no obvious abnormalities. However, mice that are doubly homozygous for targeted disruptions of FGFR3 and FGFR4 display novel phenotypes, including pronounced dwarfism and lung abnormalities. The lungs of the double knockout mice are normal at birth, but they f...Tue, 06 Dec 2022 11:56:39 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Fgfr4_Knockout_Mouse_Model_for_Respiratory_System_StudiesTAB-2402https://nih.technologypublisher.com/tech/Smad4_Knockout_(Smad4tm1Cxd)_Mouse_Model_for_Developmental_Biology_StudiesSmad4 knockout: Smad4 is essential for epiblast proliferation, egg cylinder formation and mesoderm induction in early embryogenesis. The TGF-beta-related superfamily plays an important role in multiple biological systems including embryogenesis. TGF-beta ligands activate specific receptors, which interact with specific Smad proteins, which in turn form a complex with a common partner, Smad4, that conveys the signal to downstream targets. Exon 8 of the Smad4 gene was disrupted using homologous recombination in embryonic stem cells. Exon 8 encodes the C-terminal domain of Smad4 that is essen...Tue, 06 Dec 2022 11:56:38 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Smad4_Knockout_(Smad4tm1Cxd)_Mouse_Model_for_Developmental_Biology_StudiesTAB-2401https://nih.technologypublisher.com/tech?title=Monoclonal_Antibodies_Targeting_Human_DNA_Polymerase_beta%2c_a_DNA_Repair_EnzymeAvailable for licensing are monoclonal antibodies targeting human DNA polymerase beta (Pol B). Pol B is a constitutively expressed "housekeeping" enzyme that plays a role in base excision repair (BER), a cellular defense mechanism that repairs DNA base damage and loss. Aberrant Pol B expression is associated with genomic instability indicating that Pol B is required for DNA maintenance, replication and recombination. These antibodies can be utilized to elucidate BER's mechanism of action and Pol B's structure and function. Moreover, the antibodies can be used to detect Pol B in samples with...Tue, 06 Dec 2022 11:56:37 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech?title=Monoclonal_Antibodies_Targeting_Human_DNA_Polymerase_beta%2c_a_DNA_Repair_EnzymeTAB-2400https://nih.technologypublisher.com/tech/Cytochromes_P450_CYP2J_and_CYP2C_Polyclonal_Antibodies_and_Recombinant_ProteinsThe National Institutes of Health announces polyclonal antibodies against mouse cytochrome P450s CYP2J and CYP2C. Cytochrome P450s catalyze the metabolism of a wide range of exogenous compounds, including drugs, industrial chemicals, environmental pollutants, and carcinogens. The 2C family of cytochrome P450 metabolizes an extensive number of drugs which include tolbutamide, S-Warfarin, mephenytoin, diazepam and taxol. Many of the P450 enzymes are also active in the NADPH-dependent oxidation of arachidonic acid to various eicosanoids found in several species. The 2J family is expressed at ...Tue, 06 Dec 2022 11:56:36 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Cytochromes_P450_CYP2J_and_CYP2C_Polyclonal_Antibodies_and_Recombinant_ProteinsTAB-2395https://nih.technologypublisher.com/tech/Potential_Use_of_anti-IgE_in_the_Treatment_of_Lupus_NephritisSystemic lupus erythematosus (SLE) is a multi-organ inflammatory disease characterized by a significant morbidity and mortality related to both disease evolution as well as therapeutic side effects. At least half of SLE patients develop lupus nephritis. The inventors have used a Lyn -/- mouse model that develops an autoimmune disease exhibiting some features of human SLE. Using this model the inventors identified basophils and self-reactive IgEs as important components in the development of autoantibody-mediated kidney disease. The inventors found that depletion of basophils or the absence of ...Tue, 06 Dec 2022 11:56:34 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Potential_Use_of_anti-IgE_in_the_Treatment_of_Lupus_NephritisTAB-3072https://nih.technologypublisher.com/tech/Enhanced_Functionalization_of_Carbon_Nanoparticles_for_Biomedical_ApplicationsThe invention pertains to methods of increasing the density of carboxylic acids on the surface of a carbon nanoparticle that can be functionalized with biologically relevant molecules, such as antibodies or peptides, for biomedical applications. Advantageously, the method could increase functionalization of a nanoparticle by at least about 1x107 functional groups/g of nanoparticle. The method includes contacting an oxygen-containing functional group on a surface of a carbon nanoparticle with a reducing agent to provide a hydroxyl group; reacting the hydroxyl group with a diazoacetate ester in ...Tue, 06 Dec 2022 11:56:33 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Enhanced_Functionalization_of_Carbon_Nanoparticles_for_Biomedical_ApplicationsTAB-2386https://nih.technologypublisher.com/tech/Personalized_Body_Weight_Management_System_Using_Monitoring_Devices_and_Mathematical_Models_of_MetabolismAttempts to manage body weight are often unsuccessful or only temporary. This is, in part, due to antiquated dieting methods that attempt to address calorie consumption while ignoring metabolic and physical changes. Personalized and more comprehensive methods to track and manage body weight may be more effective. To that end, scientists at the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) developed and launched the Body Weight Planner (http://www.niddk.nih.gov/health-information/weight-management/body-weight-planner) that uses validated mathematical models of human ...Tue, 06 Dec 2022 11:56:31 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Personalized_Body_Weight_Management_System_Using_Monitoring_Devices_and_Mathematical_Models_of_MetabolismTAB-2383https://nih.technologypublisher.com/tech/Small-Molecule_Inhibitors_of_Human_Galactokinase_for_the_Treatment_of_Galactosemia_and_CancersLactose, found in dairy products and other foods, is comprised of two simple sugars, glucose and galactose. In galactosemia, where galactose is not properly metabolized, build-up of toxic compounds, such as galactose-1-phosphate, can lead to liver disease, renal failure, cataracts, brain damage, and even death if this disorder is left untreated. Currently, the only treatment for galactosemia is elimination of lactose and galactose from the diet, but in some cases this is not sufficient to avoid long-term complications from the disorder. This technology describes selective small-molecule inhi...Tue, 06 Dec 2022 11:56:29 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Small-Molecule_Inhibitors_of_Human_Galactokinase_for_the_Treatment_of_Galactosemia_and_CancersTAB-2373https://nih.technologypublisher.com/tech/Non-toxic_Compounds_that_Inhibit_the_Formation_and_Spreading_of_TumorsAvailable for licensing are novel pyrrolopyrimidine compounds that disrupt the assembly of the perinucleolar compartment (PNC), a sub-nuclear structure highly prevalent in metastatic tumors. These notable compounds act without overt cytotoxicity. The presence of the PNC positively correlates with metastatic capacity, making it a potential marker for cancer development and prognosis. These compounds could also serve as useful tools to elucidate the biology driving the formation and maintenance of the PNC, and unravel its association with metastasis.Tue, 06 Dec 2022 11:56:25 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Non-toxic_Compounds_that_Inhibit_the_Formation_and_Spreading_of_TumorsTAB-2372https://nih.technologypublisher.com/tech/Model_Cell_Lines_With_and_Without_AKT1_Mutations_Derived_from_Proteus_Syndrome_PatientsThe Proteus syndrome is a congenital disorder characterized by patchy overgrowth and hyperplasia (cell proliferation) of multiple tissues and organs, along with susceptibility to developing tumors. It is a rare disorder, with incidence of less than one case per million, caused by a somatic mutation. It is also a mosaic disorder, that is one in which cells of the same person have different genetic content from one another. The NHGRI inventors have generated cell lines from patients with Proteus syndrome and discovered that a somatic activating mutation in the serine-threonine kinase AKT1 is a...Tue, 06 Dec 2022 11:56:24 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Model_Cell_Lines_With_and_Without_AKT1_Mutations_Derived_from_Proteus_Syndrome_PatientsTAB-3106https://nih.technologypublisher.com/tech/Single-Chain_Antibodies_Directed_to_Norovirus_GI.1_and_GII.4_and_Their_UseVaccines and therapies to prevent and treat Norovirus infections are not available, despite the worldwide prevalence of Norovirus infections. Outbreaks of human gastroenteritis attributable to Norovirus commonly occur in group settings, such as hospitals, nursing homes, schools, dormitories, cruise ships and military barracks. This application claims isolated VHH monoclonal antibodies that specifically bind to a Norovirus polypeptide. Llama-derived single chain antibody fragments (also called VHH) are small, recombinant monoclonal antibodies of 15 kDa (“nanobodies”) with several advantages ...Tue, 06 Dec 2022 11:56:23 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Single-Chain_Antibodies_Directed_to_Norovirus_GI.1_and_GII.4_and_Their_UseTAB-3071https://nih.technologypublisher.com/tech/Capsid-Free_AAV_Vectors_for_Gene_Delivery_and_Their_Use_for_Gene_TherapyThe invention concerns novel capsid-free AAV vectors that can be used for gene delivery and gene therapy applications. The invention provides for a linear nucleic acid molecule comprising in this order: a first adeno-associated virus (AAV) inverted terminal repeat (ITR), a nucleotide sequence of interest, and a second AAV ITR, wherein said nucleic acid molecule is devoid of AAV capsid protein coding sequences. The said nucleic acid molecule can be applied to a host at repetition without eliciting an immune response. Methods of producing and purifying this nucleic acid molecule, as well as its ...Tue, 06 Dec 2022 11:56:21 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Capsid-Free_AAV_Vectors_for_Gene_Delivery_and_Their_Use_for_Gene_TherapyTAB-2357https://nih.technologypublisher.com/tech/Transgenic_Human_Interleukin-21_Mouse_ModelAvailable for licensing is a mouse model that constitutively expresses human interleukin-21 (IL-21). Traditionally, human IL-21 transgenic mouse models are difficult to produce as those with high IL-21 levels exhibit growth retardation and die before sexual maturity. The investigators generated transgenic mice that express human IL-21, which can stimulate murine cells in vitro thereby providing an accurate model to elucidate IL-21's role in immunity, immune disorders, and cancer. IL-21 is a type I cytokine whose receptor is expressed on T, B, and natural killer cells. IL-21 has pleiotropic ...Tue, 06 Dec 2022 11:56:19 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Transgenic_Human_Interleukin-21_Mouse_ModelTAB-2353https://nih.technologypublisher.com/tech/Modulating_Autophagy_as_a_Treatment_for_Lysosomal_Storage_DiseasesResearchers at NIAMS have developed a technology for treatment of lysosomal storage diseases by inhibition of autophagy. Pompe disease is an example of a genetic lysosomal storage disease caused by a reduction or absence of acid alpha-glucosidase (GAA). Patients with Pompe disease have a lysosomal buildup of glycogen in cardiac and skeletal muscle cells and severe cardiomyopathy and skeletal muscle myopathy. Treatment of Pompe disease by GAA enzyme replacement therapy is quite ineffective for the skeletal muscle myopathy. Skeletal muscle resistance to therapy is associated with increased ce...Tue, 06 Dec 2022 11:56:18 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Modulating_Autophagy_as_a_Treatment_for_Lysosomal_Storage_DiseasesTAB-2349https://nih.technologypublisher.com/tech/New_Cholera_Vaccine_and_Method_for_Conjugating_Bacterial_Polysaccharides_to_ProteinsA new conjugate vaccine for cholera has been developed. The invention includes a new method to conjugate the O-specific polysaccharide-core part of the bacterial lipopolysaccharide and protein subcomponents. Conventional technology has entailed chemical treatment of both components to introduce linkers, which made them amenable for covalent linking. The new method simplifies production by utilizing squaric acid chemistry for conjugating the free amine-containing species (e.g. polysaccharides) directly to amine-containing species (e.g. proteins) without prior modification of either component...Tue, 06 Dec 2022 11:56:16 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/New_Cholera_Vaccine_and_Method_for_Conjugating_Bacterial_Polysaccharides_to_ProteinsTAB-2341https://nih.technologypublisher.com/tech/Fibroblast_Growth_Factor_Receptor_1_(Fgfr1)_Conditional_Knock_Out_MouseScientists at NIDDK have developed a fibroblast growth factor receptor 1 (Fgfr1) conditional knock out mouse. Fgfr1 is a member of the Fgfr family of transmembrane protein receptors with intrinsic tyrosine kinase activity. Fgfr1 is important in multiple biological processes, including mesoderm induction and patterning, cell growth and migration, organ formation and bone growth. Fgfr1 is highly expressed in central nervous system tissues and plays a critical role in proliferation, migration, and survival of neurons and glial cells. Additionally, overexpression of Fgfr1 has been associated w...Tue, 06 Dec 2022 11:56:14 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Fibroblast_Growth_Factor_Receptor_1_(Fgfr1)_Conditional_Knock_Out_MouseTAB-2342https://nih.technologypublisher.com/tech/Biomarkers_for_Cancer-Related_Fatigue_and_Their_Use_in_the_Management_of_Such_Fatigue_(CRF)The invention relates to the diagnosis and management of cancer-related fatigue (CRF). More specifically the invention relates to identification and measurement of a single Biomarker or a group of biomarkers (e.g. genes) that are associated with cancer related fatigue. The identification and measurement of such biomarkers can be utilized in the diagnosis and management of fatigue and may facilitate the development of therapy for such fatigue. In particular, the invention provides for a method of diagnosing a subject with CRF by detecting expression of at least one gene associated with CRF i...Tue, 06 Dec 2022 11:56:13 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Biomarkers_for_Cancer-Related_Fatigue_and_Their_Use_in_the_Management_of_Such_Fatigue_(CRF)TAB-2330https://nih.technologypublisher.com/tech/Protease_Deficient_Bacillus_anthracis_with_Improved_Recombinant_Protein_Yield_CapabilitiesSpecies of Bacillus, such as Bacillus anthracis, Bacillus cereus, and Bacillus subtilis, are attractive microorganisms for recombinant protein production in view of their fast growth rate, high yield, and ability to secrete produced products directly into the medium. Bacillus anthracis is also attractive in view of its ability to produce anthrax toxin and ability to fold proteins correctly. This application claims a B. anthracis strain in which more than one secreted protease is inactivated by genetic modification. Such a protease-deficient B. anthracis has an improved ability to produce rec...Tue, 06 Dec 2022 11:56:09 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Protease_Deficient_Bacillus_anthracis_with_Improved_Recombinant_Protein_Yield_CapabilitiesTAB-2328https://nih.technologypublisher.com/tech?title=Human_Phospho-Serine134_Glucocorticoid_Receptor_Polyclonal_Antibody%3a_Useful_for_the_Characterization_of_Glucocorticoid_Signaling_Processes%2c_e.g.%2c_in_Cancer_and_InflammationThe glucocorticoid receptor (GR) functions as a hormone-dependent transcription factor that is involved in the maintenance of basal and stress-related homeostasis. Serine 134 is a newly discovered phosphorylation target on the human glucocorticoid receptor that becomes phosphorylated during stress-activating conditions such as ultraviolet irradiation, nutrient starvation, and oxidative stress. The inventors have developed a rabbit polyclonal antibody that specifically recognizes the Ser 134 phosphorylated form of the human glucocorticoid receptor. This antibody may be particularly useful fo...Tue, 06 Dec 2022 11:56:08 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech?title=Human_Phospho-Serine134_Glucocorticoid_Receptor_Polyclonal_Antibody%3a_Useful_for_the_Characterization_of_Glucocorticoid_Signaling_Processes%2c_e.g.%2c_in_Cancer_and_InflammationTAB-2325https://nih.technologypublisher.com/tech/mGluR5_Tumor_Mouse_ModelGlutamate receptor mGluR5 has been reported to function in the brain. There were no prior reports of it being involved in melanoma. The NIH investigators have discovered that when over expressed in transgenic animals, mGluR5 induces melanoma. The establishment of an mGluR5 tumor mouse model will provide a unique opportunity to help elucidate the mechanisms underlying tumor formation, and allow the study of aggressive melanoma in animals and a screen of potential therapeutics. Such an mGluR5 tumor mouse model is established at the National Institutes of Health and is available for licensing.Tue, 06 Dec 2022 11:56:07 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/mGluR5_Tumor_Mouse_ModelTAB-2323https://nih.technologypublisher.com/tech/Platform_Technology_Using_Ubiquitin_to_Improve_the_Delivery_and_Efficacy_of_Cytosolic_Targeted_ToxinsTargeted toxins (TT) are hybrid protein drugs consisting of ligands that bind to the surface of cancer cells and deliver polypeptide toxins that kill malignant cells by inactivating cytosolic protein synthesis and inducing cell death. A major challenge in the construction of targeted toxins is reducing the nonspecific binding of the toxin moiety to normal tissues and increasing the cytotoxicity of the treatment. To address these issues, the NIH inventors have identified that the protein ubiquitin, a small protein in eukaryotic cells that plays a role in protein recycling, can separate the targ...Tue, 06 Dec 2022 11:56:06 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Platform_Technology_Using_Ubiquitin_to_Improve_the_Delivery_and_Efficacy_of_Cytosolic_Targeted_ToxinsTAB-3041https://nih.technologypublisher.com/tech/Bag6_Polyclonal_Antibodies_That_Recognize_Human_Bag6_ProteinBag6 (BCL2 associated athanogene 6) is a multifunctional chaperone involved in tail anchored protein biogenesis, endoplasmic reticulum-associated protein degradation, and degradation of mislocalized membrane proteins. It is the central component of a stable three chaperone complex that also contains two cofactors-Ubl4A and Trc35. This complex acts in conjunction with the co-chaperone SGTA to channel proteins bearing an exposed hydrophobic segment in the cytosol to avoid protein aggregation. The complex also associates with several ubiquitin ligases including gp78 and RNF126, which link it t...Tue, 06 Dec 2022 11:56:04 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Bag6_Polyclonal_Antibodies_That_Recognize_Human_Bag6_ProteinTAB-2319https://nih.technologypublisher.com/tech/Humanized_Monoclonal_Antibodies_Efficient_for_Neutralization_of_Tick-Borne_Encephalitis_Virus_(TBEV)TBEV causes serious illnesses from meningitis to meningo-encephalitis, totaling 3,000 cases of hospitalization in Europe and between 5,000-10,000 cases in Russia reported every year. The Far Eastern hemorrhagic TBEV strains are associated with a mortality rate (between 1-2%), higher than other strains isolated in the Siberia or Western Europe. There is a high proportion (up to 46%) of TBEV patients with temporary or permanent neurological sequelae. The number of TBEV infections has increased steadily and TBEV cases have been reported in new areas, probably reflecting an increased spread of vec...Tue, 06 Dec 2022 11:56:03 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Humanized_Monoclonal_Antibodies_Efficient_for_Neutralization_of_Tick-Borne_Encephalitis_Virus_(TBEV)TAB-3031https://nih.technologypublisher.com/tech/Field-Adapted_Spot_Test_for_Evaluating_Materials_Treated_with_Permethrin_Insect_RepellentMilitary uniforms and mosquito nets are treated with permethrin, a repellent and insecticide used for personal protection against biting flies, mosquitoes, and other disease-carrying insects. Vector-borne diseases such as malaria, leishmaniasis (a parasitic infection spread by sandflies), Zika virus, West Nile virus, Lyme disease, and more can be diminished if treated nets or clothing containing the proper amount of permethrin are utilized. Washing and wear depletes the insecticide on the material, eventually rendering it ineffective. Currently, there are no commercially available colorimetric...Tue, 06 Dec 2022 11:56:02 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Field-Adapted_Spot_Test_for_Evaluating_Materials_Treated_with_Permethrin_Insect_RepellentTAB-3033https://nih.technologypublisher.com/tech/Remotely_Monitored_Mouse_Feeding_Experimentation_DeviceHow much does a mouse eat per day? If a researcher is conducting dietary studies, the answer is very important. For instance, obesity studies require accurate measures of feeding. Existing automated methods for taking feeding measurements are expensive and use specialized caging that is not compatible with typical vivarium colony racks. As a result, many researchers simply weigh food each day or two to determine how much food the mice ate. This is time-consuming, can be error prone, and provides a low temporal resolution view of feeding. To address this need, a compact, 3D printed, elect...Tue, 06 Dec 2022 11:56:00 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Remotely_Monitored_Mouse_Feeding_Experimentation_DeviceTAB-2313https://nih.technologypublisher.com/tech/A_Novel_Optomechanical_Module_that_Enables_a_Conventional_inverted_Microscope_to_Provide_Selective_Plane_Illumination_Microscopy_(iSPIM)The invention describes an optomechanical module that, when engaged with a conventional inverted microscope, provides selective plane illumination microscopy (iSPIM). The module is coupled to the translational base of the microscope whereby a SPIM excitation objective is engaged to one portion of the mount body, and a SPIM detection objective (having a longitudinal axis perpendicular to that of the excitation objective) is engaged to another portion of the mount body. Such a system offers the advantages of SPIM (optically sectioned, high-speed volumetric interrogation of living samples, enabl...Tue, 06 Dec 2022 11:55:59 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/A_Novel_Optomechanical_Module_that_Enables_a_Conventional_inverted_Microscope_to_Provide_Selective_Plane_Illumination_Microscopy_(iSPIM)TAB-2321https://nih.technologypublisher.com/tech/Diagnostic_Assays_and_Methods_of_Use_for_Detection_of_Filarial_InfectionThe effort targeting the mosquito borne neglected tropical disease lymphatic filariasis for elimination through mass drug administration by 2020 will require accurate, cost effective methods for detecting early infections. The World Health Organization-recommended immunochromatographic test detects adult Wuchereria bancrofti (Wb) antigen in blood, but shows variable efficacy due to the complex life cycle of the parasites and cross reactivity with other organisms. This variability may hinder effective lymphatic filariasis elimination efforts. This new technology improves available detection met...Tue, 06 Dec 2022 11:55:58 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Diagnostic_Assays_and_Methods_of_Use_for_Detection_of_Filarial_InfectionTAB-2310https://nih.technologypublisher.com/tech?title=Transgenic_Mice_Expressing_Human_Arginase_II_Gene_in_Endothelium%3a_Useful_for_Studying_Atherosclerosis_and_Other_VasculopathiesCardiovascular disorders associated with endothelial dysfunction, like atherosclerosis, have decreased endothelial nitric oxide (NO) bioavailability. L-arginine, the primary substrate for endothelial nitric oxide synthase (eNOS), is important in the regulation of NO production. Arginase competes with eNOS for L-arginine and has been implicated in the endothelial dysfunction. NIH investigators have generated transgenic mice with human ArgII (hArgII) gene under control of endothelial-specific Tie2 promoter. In these mice, hArgII was expressed at very high levels in all tissues except liver. ...Tue, 06 Dec 2022 11:55:56 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech?title=Transgenic_Mice_Expressing_Human_Arginase_II_Gene_in_Endothelium%3a_Useful_for_Studying_Atherosclerosis_and_Other_VasculopathiesTAB-2307https://nih.technologypublisher.com/tech/Methods_of_Treating_Giardiasis_Using_FDA-Approved_CompoundsThis technology includes a group of at least twenty-nine, diverse, commercially available compounds that are newly identified for activity against Giardia lamblia parasites. At least six of the candidate compounds, Bortezomib, Decitabine, Hydroxocobalamin, Amlexanox, Idarubicin, and Auranofin have preexisting FDA approval for human use for other (non-Giardia) conditions. Another three compounds, Fumagillin, Nitarsone and Carbadox have preexisting approval for veterinary use for non-Giardia conditions. Additional active compounds identified include: Acivicin, Riboflavin butyrate, BTO-1, GW9...Tue, 06 Dec 2022 11:55:53 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Methods_of_Treating_Giardiasis_Using_FDA-Approved_CompoundsTAB-2306https://nih.technologypublisher.com/tech/Monoclonal_Antibodies_Against_PoliovirusEarly work by Hammond at al. showed gamma globulin to be effective for the prevention of poliomyelitis. Therefore, passive immunotherapy could be another way to treat chronic excretors. Even though prior attempts to use intravenous immunoglobulin (IVIG) and breast milk were unsuccessful, there is reason to think that higher doses of antipoliovirus antibodies could result in complete clearance of poliovirus from chronically infected individuals. Six poliovirus-neutralizing MAbs were recovered from a combinatorial Fab phage display library constructed from bone marrow-derived lymphocytes of imm...Tue, 06 Dec 2022 11:55:52 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Monoclonal_Antibodies_Against_PoliovirusTAB-2295https://nih.technologypublisher.com/tech/An_In-Vitro_Cell_System_Useful_For_Identification_of_RORgamma_AntagonistsThe retinoid-related orphan receptors alpha, beta and gamma (RORalpha, beta and gamma , also referred to as NR1F1, 2 and 3, respectively) comprise a distinct subfamily of nuclear receptors. Study of ROR-deficient mice has implicated RORs in the regulation of a number of biological processes and revealed potential roles for these proteins in several pathologies. NIH investigators have developed an in-vitro system using CHO cells stably expressing a TET-On expression vector regulating RORgamma and a RORE-Luciferase reporter. This system allows inducible expression of RORgamma upon addition of ...Tue, 06 Dec 2022 11:55:49 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/An_In-Vitro_Cell_System_Useful_For_Identification_of_RORgamma_AntagonistsTAB-2294https://nih.technologypublisher.com/tech/Conditionally_Immortalized_Human_Podocyte_Cell_LinesPodocytes, cells of the visceral epithelium in the kidneys, are a key component of the glomerular filtration barrier. Podocyte damage and loss contribute to the initiation of glomerular diseases. NIH investigators recently established long-term urinary cell cultures from two patients with focal segmental glomerulosclerosis and two healthy volunteers, via transformation with the thermosensitive SV40 large T antigen (U19tsA58) together with human telomerase (hTERT). Characterization of randomly selected clonal cell lines from each human subject showed mRNA expression for the podocyte markers ...Tue, 06 Dec 2022 11:55:48 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Conditionally_Immortalized_Human_Podocyte_Cell_LinesTAB-3042https://nih.technologypublisher.com/tech/Transgenic_Mice_Expressing_CNO-sensitive_Gq-_or_Gs-coupled_Designer_Receptors_Selectively_in_Pancreatic_Beta_CellsImpaired functioning of pancreatic beta cells is a key hallmark of type 2 diabetes. Beta cell function is modulated by the actions of different classes of heterotrimeric G proteins. The functional consequences of activating specific beta cell G protein signaling pathways in vivo are not well understood at present, primarily due to the fact that beta cell G protein-coupled receptors (GPCRs) are also expressed by many other tissues. To circumvent these difficulties, we developed a strategy that allows for the conditional and selective activation of specific beta cell G proteins in intact animals...Tue, 06 Dec 2022 11:55:46 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Transgenic_Mice_Expressing_CNO-sensitive_Gq-_or_Gs-coupled_Designer_Receptors_Selectively_in_Pancreatic_Beta_CellsTAB-3040https://nih.technologypublisher.com/tech?title=Triazole_Derivatives_of_4%2c7-disubstituted_2_naphthoic_acid_(PPTN)_as_P2Y14_Receptor_AntagonistsThe Molecular Recognition Section of NIDDK announces the availability of a novel triazole-based probes, structures which act as antagonists at human P2Y14 receptors. Although the physiologic functions of this receptor remain undefined, recently it has been strongly implicated in immune and inflammatory responses. Prior work with a 4,7-disubstituted 2 naphthoic acid derivative (PPTN) established the ability to inhibit chemotaxis of human neutrophils in the lung and kidney. In this series, the triazole moiety is used as a bioisosteric replacement for the naphthoic acid core of PPTN. This sub...Tue, 06 Dec 2022 11:55:45 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech?title=Triazole_Derivatives_of_4%2c7-disubstituted_2_naphthoic_acid_(PPTN)_as_P2Y14_Receptor_AntagonistsTAB-2287https://nih.technologypublisher.com/tech/Multivalent_Vaccines_for_Rabies_Virus_and_FilovirusesNo vaccine candidates against Ebola virus (EBOV) or Marburg virus (MARV) are nearing licensure and the need to develop a safe and efficacious vaccine against filoviruses continues. Whereas several preclinical vaccine candidates against EBOV or MARV exist, their further development is a major challenge based on safety concerns, pre-existing vector immunity, and issues such as manufacturing, dosage, and marketability. The inventors have developed a new platform based on live or chemically inactivated (killed) rabies virus (RABV) virions containing EBOV glycoprotein (GP) in their envelope. In p...Tue, 06 Dec 2022 11:55:44 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Multivalent_Vaccines_for_Rabies_Virus_and_FilovirusesTAB-2281https://nih.technologypublisher.com/tech/Wirelessly_Powered_MRI_Signal_Amplification_System_and_MethodThe invention is in the field of MRI, and more specifically relates to device and method that may provide great improvements in the area of interventional MRI. The technology describes an MRI detection coil that has been integrated with a parametric amplifier to provide local signal detection fully integrated with amplification. This amplification is done in a way that is inherently wireless, thus enabling efficient signal transmission. The integrated MRI detector/amplifier can be used in a number of applications. First, it can replace conventional MRI amplification typically done with transis...Tue, 06 Dec 2022 11:55:42 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Wirelessly_Powered_MRI_Signal_Amplification_System_and_MethodTAB-2989https://nih.technologypublisher.com/tech/Mice_with_a_Floxed_Allele_of_the_alpha_Subunit_of_the_Heterotrimeric_G_Protein_Go_or_Gi2Heterotrimeric G proteins couple signals between GPCRs (G protein coupled receptors) and effectors such as adenylyl cyclase, phospholipase C and ion channels. Among the G proteins are Go and Gi2. Go is highly expressed in the brain and some endocrine tissues while Gi2 is widely expressed throughout the body. The ß?-subunits of Go interact with ion channels, and the a subunit has been shown to inhibit adenylyl cyclase. However a physiological role of the Gi2a has not been determined in a tissue specific manner. In this invention, mice with a floxed allele of the Go-a subunit and mice with a f...Tue, 06 Dec 2022 11:55:40 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Mice_with_a_Floxed_Allele_of_the_alpha_Subunit_of_the_Heterotrimeric_G_Protein_Go_or_Gi2TAB-2276https://nih.technologypublisher.com/tech/Mouse_Model_and_Derived_Cells_That_Hypersecrete_Leukemia_Inhibitory_Factor_(LIF)Embryonic stem cells (ESCs) are pluripotent cells that can be cultured indefinitely, and maintain their capability to differentiate into all cell lineages. To maintain these cells as well as various types of related induced stem cells and progenitor cells in culture, Mouse Embryonic Fibroblasts (MEFs) are routinely used as feeder cells, largely to serve as a source of Leukemia Inhibitory Factor (LIF). ESCs can also be cultured without feeders if the medium is supplemented with recombinant LIF and other factors. However, these methods of culturing ESCs suffer from certain drawbacks, such as lim...Tue, 06 Dec 2022 11:55:39 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Mouse_Model_and_Derived_Cells_That_Hypersecrete_Leukemia_Inhibitory_Factor_(LIF)TAB-2266https://nih.technologypublisher.com/tech?title=Polyclonal_Antibodies_for_the_Gbeta5-associated_Regulator_of_G_Protein_Signaling_Protein%2c_RGS7Researchers at NIDDK have developed polyclonal antibodies against the Regulator of G Protein Signalling (RGS) protein, RGS7. RGS7 binds tightly to Gbeta5, a unique and highly specialized G protein that exhibits much less homology than other Gbeta isoforms (~50%). RGS7 is preferentially expressed in brain and neuroendocrine tissue. Like Gbeta5, RGS7 is expressed prominently in the cell membrane, as well as in the cytosol. Although this distribution pattern suggests that complexes containing Gbeta5 and RGS7 may shuttle information between classical G protein-signaling elements at the plasma ...Tue, 06 Dec 2022 11:55:37 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech?title=Polyclonal_Antibodies_for_the_Gbeta5-associated_Regulator_of_G_Protein_Signaling_Protein%2c_RGS7TAB-2264https://nih.technologypublisher.com/tech?title=Mouse_Model_for_Cerebral_Cavernous_Malformation%2c_an_Inherited_Brain_DisorderCerebral Cavernous Malformation (CCM) is a brain disease affecting up to 0.5% of the worldwide population. CCM is characterized by grossly dilated vessels prone to leaking and hemorrhage which result in severe headaches, seizures, and strokes. Inherited forms of the disease are due to mutations in one of three loci, CCM1, CCM2, and CCM3. Prior efforts to develop mice with targeted null mutations in Ccm1, Ccm2, or Ccm3 have been unsuccessful, as such mutations result in embryonic death. The inventors have developed the first mouse model available for the study of CCM, in which mouse Ccm2 can...Tue, 06 Dec 2022 11:55:35 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech?title=Mouse_Model_for_Cerebral_Cavernous_Malformation%2c_an_Inherited_Brain_DisorderTAB-2263https://nih.technologypublisher.com/tech?title=Novel_Small_Molecule_Inhibitors_for_the_Treatment_of_Huntington%e2%80%99s_DiseaseThis technology is a collection of small molecules screened for their ability to prevent or reduce the cytotoxic effects of the protein, Huntingtin. Huntington's disease is a neurodegenerative disorder due to a dominantly acting expansion of a CAG trinucleotide repeat in exon 1 of the Huntington (HTT) gene resulting in production of the altered (mutant) protein Huntingtin, which has a long chain of polyglutamine (poly Q) attached to the exon 1 encoded protein sequence. Clinical and statistical analyses have shown that an increased number of poly Q repetition correlates with the probability of...Tue, 06 Dec 2022 11:55:34 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech?title=Novel_Small_Molecule_Inhibitors_for_the_Treatment_of_Huntington%e2%80%99s_DiseaseTAB-2259https://nih.technologypublisher.com/tech/Methods_and_Devices_for_Transcatheter_Cerclage_AnnuloplastyThe invention relates to techniques and devices for cardiovascular valve repair, particularly annuloplasty techniques and devices in which tensioning elements are positioned to treat regurgitation of the mitral valve or tricuspid valve. More specifically, the technology pertains to a new device for myocardial septal traversal ("cerclage reentry") that also serves to capture (ensnare) and externalize the traversing guidewire. The focus of the invention is to avoid a phenomenon in cardiac surgery known as "trabecular entrapment." The device features an expandable and collapsible mesh deployed in...Tue, 06 Dec 2022 11:55:33 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Methods_and_Devices_for_Transcatheter_Cerclage_AnnuloplastyTAB-2257https://nih.technologypublisher.com/tech/Mouse_IL-12p40_Expressing_Cell_LineThe subject invention is a recombinant human 293T cell line that expresses mouse IL-12p40 protein to high levels. IL-12p40 is a subunit of both Interleukin-12 (IL-12) and IL-23; however, it can also be expressed as a monomer (IL-12p40) and as a homodimer (IL-12p80). IL-12p40 is produced mainly by antigen presenting cells such as macrophages, neutrophils, microglia, and dendritic cells in response to pathogens or inflammatory agents. It is an immunostimulatory messenger molecule that can disseminate in the body and signal the presence of a pathogen. The role of IL-12p40 is still being eluci...Tue, 06 Dec 2022 11:55:31 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Mouse_IL-12p40_Expressing_Cell_LineTAB-2252https://nih.technologypublisher.com/tech/Glucocerebrosidase_Activators_as_a_Treatment_for_Gaucher_DiseaseThis technology is a collection of small molecule activators of a genetically defective version of the enzyme called glucocerebrosidase (GCase), which causes Gaucher disease. Gaucher disease is a rare disease affecting 1 in 40,000 babies born. Ashkenazi Jews of eastern European descent (about 1 in 800 live births) are at particular risk of carrying this genetic defect. It is caused by inherited genetic mutations in the gene that encodes GCase, which result in reduced activity of the enzyme. This enzyme is normally made and then transported to an organelle called a lysosome, which is dedicat...Tue, 06 Dec 2022 11:55:30 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Glucocerebrosidase_Activators_as_a_Treatment_for_Gaucher_DiseaseTAB-2251https://nih.technologypublisher.com/tech/Improved_Standard_for_Immune_System_Recovery_AssayMonitoring an immune system that has been depleted by infection (e.g., HIV), chemotherapy, or progenitor cell transplantation is vital to assessing individual’s recovery status. This technology provides a new plasmid standard to be used as part of the existing TREC assay. This new plasmid has a shorter insert than the commercially available one, which means it now matches the PCR product generated in the qPCR reaction in the TREC assay. Additionally, the new plasmid is easier to grow up than the existing standard.Tue, 06 Dec 2022 11:55:28 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Improved_Standard_for_Immune_System_Recovery_AssayTAB-2990https://nih.technologypublisher.com/tech/TRPC_Knockout_(KO)_Mice_and_Mice_with_a_Floxed_Allele_of_TRPC_Ion_Channel_GenesTRPCs (Canonical Transient Receptor Potential Channels) are a group of non-selective cation channels that allow sodium and calcium into cells. There are seven different genes in mice that code TRPCs. The in vivo roles played by TRPCs as a whole are poorly understood and very little is known about the in vivo roles played by individual TRPCs nor the role of these channels in specific tissues or cells. In this invention, mice with a floxed allele of TRPC3, TRPC5, or TRPC7 were generated. Knockout mice of TRPC3, TRPC5, or TRPC7 can be used to study the function of the respective genes. The knoc...Tue, 06 Dec 2022 11:55:27 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/TRPC_Knockout_(KO)_Mice_and_Mice_with_a_Floxed_Allele_of_TRPC_Ion_Channel_GenesTAB-2247https://nih.technologypublisher.com/tech/NAG-1_Transgenic_Mouse_ModelThe nonsteroidal anti-inflammatory drug-activated gene-1 (NAG-1) encodes a protein that has anti-inflammatory, proapoptotic, and antitumor properties. It plays a pivotal role in antitumorigenesis induced by chemopreventive compounds. Transgenic mice expressing human NAG-1 have been developed by the NIH investigator and collaborator. The NAG-1 transgenic mice are shown to develop few tumors in response to carcinogenic stimuli than wild type mice. They are also leaner with less fat than their wild type counterparts. As such, these mice can be used to investigate the development of cancers, and...Tue, 06 Dec 2022 11:55:26 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/NAG-1_Transgenic_Mouse_ModelTAB-2243https://nih.technologypublisher.com/tech/Modulation_of_Leucine-rich_Repeats_and_Calponin_Homology_Domain-containing_Protein_4_(Lrch4)_Activity_for_Therapeutic_ApplicationsNIH Inventors have recently discovered a novel Leucine-rich repeat and calponin homology domain-containing protein 4 (Lrch4) in a proteomic screen of the plasma membrane of lipopolysaccharide (LPS)-exposed macrophages. Expression data by RT-PCR revealed that all Lrch family members (1-4) are expressed in macrophages, but only Lrch4 was recruited into lipid rafts (signaling microdomains of the plasma membrane) by LPS. Lrch4 is the most highly expressed Lrch family member in mouse tissues. It is a predicted single-spanning transmembrane protein that is encoded by the Lrch4 gene in humans. Th...Tue, 06 Dec 2022 11:55:24 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Modulation_of_Leucine-rich_Repeats_and_Calponin_Homology_Domain-containing_Protein_4_(Lrch4)_Activity_for_Therapeutic_ApplicationsTAB-2239https://nih.technologypublisher.com/tech/Therapeutic_Approach_to_Neurodegenerative_Disorders_Using_a_TFP5-PeptideThis invention discloses methods for treating neurodegenerative diseases by administering cyclin dependent kinase 5 (Cdk5) inhibitory peptides derived from P35, the activator of Cdk5. Abnormally hyperactive Cdk5 has been shown to be associated with a variety of neurodegenerative disorders. Disclosed in this invention are isolated peptide fragments, pharmaceutical compositions and methods for use of such for treating subjects with a neurodegenerative disease, such as Alzheimer’s disease (AD), Amyotrophic Lateral Sclerosis (ALS) and Parkinson’s disease (PD). An inhibitory fragment, TFP5, disclos...Tue, 06 Dec 2022 11:55:21 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Therapeutic_Approach_to_Neurodegenerative_Disorders_Using_a_TFP5-PeptideTAB-2238https://nih.technologypublisher.com/tech/Identification_of_EGFR_as_A_Receptor_for_AAV6_TransductionAAV vectors offer unique advantages in gene therapy applications. Studies have shown that these replication deficient parvovirus vectors can deliver DNA to specific tissues and confer long-term transgene expression in a variety of systems. Although many studies have looked at the tissue-specific expression elicited by each of the AAV serotypes, a true understanding of how AAV transduces these tissues is still unclear. Of the large AAV family, only a few receptors or co-receptors have been identified. The ability to better target transduction to specific tissues on the basis of the receptor...Tue, 06 Dec 2022 11:55:20 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Identification_of_EGFR_as_A_Receptor_for_AAV6_TransductionTAB-3013https://nih.technologypublisher.com/tech/Alloreactive_T_Cell_Depletion_Method_For_Preventing_Graft-Versus-Host_DiseaseThe invention relates to the use of adenosine to deplete alloreactive T cells from donor grafts to prevent graft-versus-host disease (GVHD). The method includes culturing donor cells that include T cells with recipient antigen presenting cells (APCs) to form a mixture of cells. The recipient’s APCs activate donor T cells. The activated T cells are treated with high doses of adenosine or an adenosine-like molecule to decrease or inhibit viability of the activated donor T-cells. The adenosine or adenosine-like molecule is filtered away from the mixture resulting in cells that can be transplant...Tue, 06 Dec 2022 11:55:19 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Alloreactive_T_Cell_Depletion_Method_For_Preventing_Graft-Versus-Host_DiseaseTAB-2234https://nih.technologypublisher.com/tech/Active_Adaptive_Detuning_Systems_to_Improve_Safety_of_Interventional_DevicesThe invention offered for licensing and commercial development is in the field of Interventional Magnetic Resonance Imaging (“iMRI”). More specifically the invention discloses interventional devices in which the heat generated at the device during the imaging process can be controlled to not exceed acceptable levels. Active MRI compatible intravascular devices contain RF antenna to so that they are visible under MRI. However, these metallic structures may heat up significantly during interventional MRI procedures due to eddy current formation over the conductive transmission lines. The electri...Tue, 06 Dec 2022 11:55:18 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Active_Adaptive_Detuning_Systems_to_Improve_Safety_of_Interventional_DevicesTAB-2233https://nih.technologypublisher.com/tech/Single_Channel_MRI_GuidewireThe invention offered for licensing and commercial development is in the field of Interventional Magnetic Resonance Imaging (“iMRI”). More specifically the invention discloses a guidewire for magnetic resonance imaging with a single channel design to reduce complexity and to provide conspicuous tip visibility under MRI. In the design of the present device, the guidewire body includes an antenna formed from a rod and a helical coil coupled together. The helical coil can have multiple windings without a gap between the windings. The rod passes through the windings of the helical coil and is c...Tue, 06 Dec 2022 11:55:17 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Single_Channel_MRI_GuidewireTAB-2224https://nih.technologypublisher.com/tech/Selective_12-Human_Lipoxygenase_Inhibitors_for_the_Treatment_of_Diabetes_and_ClottingThis invention discloses small molecule inhibitors of human 12-lipoxygenase (12-hLO). 12-lipoxygenase expression, activation, and lipid metabolites have been implicated in type 1 and type 2 diabetes, cardiovascular disease, hypertension, Alzheimer’s, and Parkinson’s disease. The development of 12-hLO inhibitors may be a potent intracellular approach to decreasing the ability of platelets to form large clots in response to vessel injury or activation of the coagulation pathway. Thus, 12-hLO inhibition has the potential to attenuate platelet-mediated clot formation caused by diabetes and/or car...Tue, 06 Dec 2022 11:55:13 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Selective_12-Human_Lipoxygenase_Inhibitors_for_the_Treatment_of_Diabetes_and_ClottingTAB-2215https://nih.technologypublisher.com/tech/A_Computer_Program_to_Predict_Optimal_Sites_on_Protein_Sequences_for_Production_of_Peptide-Directed_Antibodies_(NHLBI_AbDesigner)Tue, 06 Dec 2022 11:55:09 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/A_Computer_Program_to_Predict_Optimal_Sites_on_Protein_Sequences_for_Production_of_Peptide-Directed_Antibodies_(NHLBI_AbDesigner)TAB-3004https://nih.technologypublisher.com/tech/Gene_Therapy_for_Niemann-Pick_Disease_Type_CInvestigators at the National Human Genome Research Institute (NHGRI) of the National Institutes of Health (NIH) are seeking collaborators to further develop gene therapy to treat Niemann-Pick Disease Type C (NPC). NPC is a rare, autosomal recessive, neurodegenerative disease. Approximately 95% of patients with NPC have mutations in NPC1, a gene implicated in intracellular cholesterol trafficking. Mutations of NPC1 cause intracellular accumulation of unesterified cholesterol in late endosomal/lysosomal structures and marked accumulation of glycosphingolipids, especially in neuronal tissue. ...Tue, 06 Dec 2022 11:55:06 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Gene_Therapy_for_Niemann-Pick_Disease_Type_CTAB-2202https://nih.technologypublisher.com/tech/Pyruvate_Kinase_M2_Activators_for_the_Treatment_of_CancerNIH investigators have discovered a series of small compounds with the potential to treat a variety of cancers as well as hemolytic anemia. Contrary to most cancer medications, these molecules can be non-toxic to normal cells because they target a protein specific to the metabolic pathways in tumors, thus representing a significant clinical advantage over less-specific chemotherapeutics. The invention described here is a series of small molecules that activate pyruvate kinase (PK) isoform M2. PK-M2 is a critical metabolic enzyme that is affected in all forms of cancer. Inactivation of PK-M2...Tue, 06 Dec 2022 11:55:05 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Pyruvate_Kinase_M2_Activators_for_the_Treatment_of_CancerTAB-2201https://nih.technologypublisher.com/tech/Compounds_That_Treat_Malaria_and_Prevent_Malaria_TransmissionMalaria is the single leading cause of death, especially among children, in the developing world. Malaria is caused by infection with parasites of the genus Plasmodium, transmitted by mosquitos. In addition to transmission, vital steps in the parasite lifecycle occur in the mosquito host. The invention offered for licensing relates to therapeutic compounds and related pharmaceutical compositions that can be used in the prevention and treatment of malaria infection. More specifically, the invention is drawn to compounds that may kill sexual and mosquito stage malaria parasites to block transmis...Tue, 06 Dec 2022 11:55:04 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Compounds_That_Treat_Malaria_and_Prevent_Malaria_TransmissionTAB-2196https://nih.technologypublisher.com/tech/Novel_Therapeutic_Compounds_for_Treatment_of_Cancer_and_Immune_DisordersThe global market for cancer therapeutics is over $40 billion and is anticipated to continue to rise in the future. There remains a significant unmet need for therapeutics for cancers that affect blood, bone marrow, and lymph nodes and the immune system, such as leukemia, multiple myeloma, and lymphoma. The proteasome inhibitor bortezomib, which may prevent degradation of pro-apoptotic factors permitting activation of programmed cell death in neoplastic cells dependent upon suppression of pro-apoptotic pathways, has been a successful mode of treatment for such cancers. However, some patient’s ...Tue, 06 Dec 2022 11:55:02 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Novel_Therapeutic_Compounds_for_Treatment_of_Cancer_and_Immune_DisordersTAB-2190https://nih.technologypublisher.com/tech/Myosin-Based_Protein-Protein_Interaction_AssayInvestigators at the National Institute on Deafness and Other Communication Disorders (NIDCD) have developed an assay for the detection of protein-protein interactions in living cells. This assay uses readily-available reagents and straightforward techniques that avoid the difficulty of purifying proteins or generating antibodies required for other binding studies. Proof-of-concept for this assay has been demonstrated, and a manuscript is in preparation for publication. This technology utilizes a molecular motor, myosin X, which migrates along actin filaments within cells. A protein fused to...Tue, 06 Dec 2022 11:55:00 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Myosin-Based_Protein-Protein_Interaction_AssayTAB-2174https://nih.technologypublisher.com/tech/Prevention_and_Treatment_of_Herpes_Virus_Infection_by_Inhibition_of_the_JMJD2_Family_of_Histone_DemethylasesInvestigators at the NIH have discovered a potential means for preventing or treating a herpes virus infection by inhibiting the activity of the host cell’s histone demethylases. When herpesviruses enter a cell, they are inactivated by cellular defense mechanisms that wrap the viral genome in repressive chromatin structures. In order for viral replication to progress, the host’s own histone demethylases are recruited to the viral genome to reverse this repression. In a preceding invention, the laboratory disclosed that viral replication and reactivation can be significantly reduced through inh...Tue, 06 Dec 2022 11:54:56 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Prevention_and_Treatment_of_Herpes_Virus_Infection_by_Inhibition_of_the_JMJD2_Family_of_Histone_DemethylasesTAB-2173https://nih.technologypublisher.com/tech/Mouse_Anti-Mouse_CXCL9_(Mig)_Monoclonal_AntibodiesThis technology describes monoclonal antibodies against mouse chemokine (C-X-C motif) ligand 9 (CXCL9), also known as Monokine induced by gamma interferon (Mig). CXCL9 is a secreted protein that functions to attract white cells and increased expression of CXCL9 has been linked to several diseases. The inventors at the NIH generated over 100 anti-mouse CXCL9 antibodies from a CLXL9/Mig knockout mouse and further characterized several antibodies to show neutralization of CXCL9. As such, these antibodies could be used to measure concentrations of mouse CLXL9 in laboratory samples and block the a...Tue, 06 Dec 2022 11:54:53 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Mouse_Anti-Mouse_CXCL9_(Mig)_Monoclonal_AntibodiesTAB-2171https://nih.technologypublisher.com/tech/Full-Length_Infectious_cDNA_Clones_of_Tick_Borne_FlavivirusThe tick-borne encephalitis virus complex of flavivirus family includes tick-borne encephalitis (TBEV), Kyasanur forest disease, Langat, Louping ill, Negishi, Omsk hemorrhagic fever and Povassan viruses. These viruses are endemic throughout most of the Northern Hemisphere and except for Langat, cause human disease of varying severity that can have mortality as high as 20 to 30%. Tick-borne encephalitis remains a pressing public health problem in Eastern Europe and Russia, where 9,000 to 12,000 patients are diagnosed annually and there is a need for a vaccine which can prevent this disease. ...Tue, 06 Dec 2022 11:54:52 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Full-Length_Infectious_cDNA_Clones_of_Tick_Borne_FlavivirusTAB-2162https://nih.technologypublisher.com/tech?title=Phantasmidine%2c_a_Nicotinic_Receptor_Agonist_for_the_Treatment_of_Addiction_and_Neurological_DisordersThe inventors have isolated and characterized an alkaloid, phantasmidine, from the skin of the Ecuadoran poison frog E. anthonyi. Phantasmidine is selective for beta4-containing receptor subtypes, unlike many nicotinic receptor agonists currently in development, which target beta2-containing receptor subtypes. This selectivity makes phantasmidine a unique pharmacological probe, as well as a promising lead compound for the development of selective therapeutics targeting beta4-containing receptor subtypes, which appear to play any important role in nicotine addiction and other substance depend...Tue, 06 Dec 2022 11:54:49 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech?title=Phantasmidine%2c_a_Nicotinic_Receptor_Agonist_for_the_Treatment_of_Addiction_and_Neurological_DisordersTAB-2157https://nih.technologypublisher.com/tech/Superresolution_Microscopy_via_Azicon_Beam_Polarization_DevicesThe technology offered for licensing pertains to novel polarizers that produce tangentially and radially polarized beams. The polarizers and polarizing beam splitter of the technology include one or more pairs of axicons (also known as conical lenses) that are configured to separate an input beam into a radially polarized component and a tangentially (or azimuthally) polarized component. A second axicon pair can be positioned to recombine the tangentially polarized component so as to provide a more uniform beam intensity. The radial polarized component can be reflected or otherwise directed so...Tue, 06 Dec 2022 11:54:47 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Superresolution_Microscopy_via_Azicon_Beam_Polarization_DevicesTAB-2150https://nih.technologypublisher.com/tech/System_and_Method_for_Producing_Nondiffracting_Light_Sheets_that_Improves_the_Performance_of_Selective_Plane_Illumination_Microscopy_(SPIM)The technology offered for licensing relates to a system and method of producing nondiffracting beams of light that spatially overlap, but do not interfere with each other when intersecting the detection plane of an optical arrangement. The system includes an illumination source (i.e. ultrafast laser) for transmitting a beam of light through the optical arrangement that includes a diffraction grating for diffracting the light beam to produce beams of light having different wavelengths, which are then passed through an annular aperture that transforms the beams of light into nondiffracting beam...Tue, 06 Dec 2022 11:54:46 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/System_and_Method_for_Producing_Nondiffracting_Light_Sheets_that_Improves_the_Performance_of_Selective_Plane_Illumination_Microscopy_(SPIM)TAB-2149https://nih.technologypublisher.com/tech?title=Method_of_Producing_Immortalized_Primary_Human_Keratinocytes_for_HPV_Investigation%2c_Testing_of_Therapeutics%2c_and_Skin_Graft_GenerationOne of the major limitations of using cultured keratinocytes for research studies is that primary keratinocytes senesce after a few passages. Keratinocytes from specific anatomical sites are also difficult to culture. Scientists at the NIH have demonstrated that primary keratinocytes, from several anatomical sites, when treated with a small-molecule inhibitor of the ROCK protein maintain a proliferative state and become immortal without genetic modification to the cells. Keratinocytes are also the host cells for human papillomaviruses (HPVs) and other viruses and this technology enables the st...Tue, 06 Dec 2022 11:54:44 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech?title=Method_of_Producing_Immortalized_Primary_Human_Keratinocytes_for_HPV_Investigation%2c_Testing_of_Therapeutics%2c_and_Skin_Graft_GenerationTAB-2143https://nih.technologypublisher.com/tech/N-Methanocarba_Adenosine_Derivatives_and_Their_Dendrimer_Conjugates_as_A3_Receptor_AgonistsThis technology relates to specific (N)-methanocarba adenine nucleosides that have been developed and dendrimers that connect these compounds to create molecules with multiple targets. Dendrimers are essentially repeated molecular branches presenting the core receptor-binding molecules. The compounds synthesized function as agonists and antagonists of a receptor of the G-protein coupled receptor (GPCR) superfamily. In particular, the receptors of interest for this invention include A3 adenosine receptors and agonists and antagonists of P2Y receptors, such as P2Y1 and P2Y14. Dendrimer conjuga...Tue, 06 Dec 2022 11:54:42 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/N-Methanocarba_Adenosine_Derivatives_and_Their_Dendrimer_Conjugates_as_A3_Receptor_AgonistsTAB-2142https://nih.technologypublisher.com/tech/A_Novel_Scaffold_for_Multivalent_Display_of_LigandsMultivalent interactions are important in cell attachment, wound healing and immune responses. Such interactions are associated with cancer metastasis, blood clotting and the generation of antibodies from a vaccination. Mimicking multivalent interactions on a synthetic scaffold is challenging especially when large numbers of ligands (such as 5 or more) need to be displayed. There are numerous synthetic scaffolds that have been developed, but there are significant limitations that remain. Scientists at the NIH have designed a novel multivalent scaffold that can display anywhere from 1 to 200 l...Tue, 06 Dec 2022 11:54:41 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/A_Novel_Scaffold_for_Multivalent_Display_of_LigandsTAB-2133https://nih.technologypublisher.com/tech/Novel_Antigen_for_Use_as_Vaccine_Against_Nematode_InfectionThis invention describes a new vaccine against Strongyoides stercoralis, which establishes a parasitic infection that affects an estimated 100-200 million people worldwide. The potential for fatal disease associated with S. stercoralis infection and the difficulty in treating hyperinfection underscores the need for prophylactic vaccines against the disease. This vaccine uses S. stercoralis immunoreactive antigen (SsIR); a novel antigen capable of providing 70-90 % protection for mice immunized with the antigen. In addition, sera from immunized mice have also been used to effectively protect na...Tue, 06 Dec 2022 11:54:38 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Novel_Antigen_for_Use_as_Vaccine_Against_Nematode_InfectionTAB-2119https://nih.technologypublisher.com/tech/Sound_Attenuation_Canopy_for_Reducing_Noise_Transmitted_Through_Suspended_CeilingsAvailable for licensing and commercial implementation in commercial facilities design and construction are intellectual property rights covering a sound attenuation canopy for reducing noise transmitted through suspended ceiling systems commonly used in most office buildings. The canopy is designed to absorb sound energy and effectively reduce the direct path of sound travelling within open plenum suspended ceilings like those used in most office building environments. The canopy can also act as an umbrella to shield loose debris and dust which may be located in the plenum and potentially fal...Tue, 06 Dec 2022 11:54:35 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Sound_Attenuation_Canopy_for_Reducing_Noise_Transmitted_Through_Suspended_CeilingsTAB-2114https://nih.technologypublisher.com/tech/Software_System_for_Processing_and_Analysis_of_Multi-dimensional_NMR_DataAvailable for licensing is a software system useful in applications involving nuclear magnetic resonance (NMR). The software system, called NMRPipe, is written in the C programming language, and makes use of the TCL/TK scripting environment. The system includes over 500 modules for processing and analyzing experimental data of one to four dimensions collected on NMR spectrometers. The system exploits the UNIX computer operating system facilities of pipelines and scripts to link modules in a highly flexible, user-definable manner. NMR is a widely used analytical method, applied to both solutio...Tue, 06 Dec 2022 11:54:33 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Software_System_for_Processing_and_Analysis_of_Multi-dimensional_NMR_DataTAB-2113https://nih.technologypublisher.com/tech?title=Simple%2c_Quantitative_Sensitive_High-throughput_Antibody_Detection_for_Lyme_DiseaseThis technology is for compositions and methods for diagnosis of Lyme disease. Currently, Lyme disease is diagnosed by clinical exam and a history of exposure to endemic regions. Although, laboratory tests may aid diagnosis, the best tests currently available are slow and labor intensive and require understanding of the test, and infection stage. A two-step antibody based test process is currently the recommended laboratory test. The first step is either an enzyme immunoassay (EIA), or an indirect immunofluorescence assay (IFA). If the first step is positive, a “Western blot” test is then ...Tue, 06 Dec 2022 11:54:31 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech?title=Simple%2c_Quantitative_Sensitive_High-throughput_Antibody_Detection_for_Lyme_DiseaseTAB-2110https://nih.technologypublisher.com/tech/Parvovirus_B19_Codon_Optimized_Structural_Proteins_for_Vaccine_and_Diagnostic_ApplicationsParvovirus B19 (B19V) is the only known pathogenic human parvovirus. Infection by this viral pathogen can cause transient aplastic crisis in individuals with high red cell turnover, pure red cell aplasia in immunosuppressed patients, and hydrops fetalis during pregnancy. In children, B19V most commonly causes erythema infectiosum, or fifth's disease. Infection can also cause arthropathy and arthralgia. The virus is very erythrotropic, targeting human erythroid (red blood) progenitors found in the blood, bone marrow, and fetal liver. Currently, there are no approved vaccines or antiviral d...Tue, 06 Dec 2022 11:54:30 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Parvovirus_B19_Codon_Optimized_Structural_Proteins_for_Vaccine_and_Diagnostic_ApplicationsTAB-2109https://nih.technologypublisher.com/tech/Erythroid_Progenitor_Cell_Line_for_Hematological_Disease_ApplicationsPlasmodium vivax (malaria) is a significant health concern in many parts of Asia, Latin America, North Africa, and the Middle East. There is a lack of continuous culture systems for this pathogen. The subject technology is an erythroid progenitor continuous cell line (termed CD36E) identified by erythroid markers CD36, CD33, CD44, CD71, CD235, and globoside. These CD36E cells are heterozygous for Fya and Fyb (Duffy antigen). Due to recent evidence that Plasmodium vivax (P. vivax) can infect erythroid progenitor cells (reference: YX Ru et al. and T Panichakul et al.), these cells can be pot...Tue, 06 Dec 2022 11:54:28 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Erythroid_Progenitor_Cell_Line_for_Hematological_Disease_ApplicationsTAB-2100https://nih.technologypublisher.com/tech/A_Method_of_Reducing_Cholesterol_Biosynthesis_with_Specific_MicroRNAsThis technology is directed to the discovery of specific microRNAs that target and downregulate enzymes within the cholesterol biosynthetic pathway and is currently being tested in vivo. Briefly, microRNAs regulate the translation of messenger RNAs (mRNAs) into protein. The inventors have discovered a set of specific microRNAs that downregulate the expression of multiple enzymes in the cholesterol biosynthetic pathway. Importantly, this technology may provide the benefits of cholesterol lowering therapies to patients that are not suited for statin-based treatments. Statins block the cholest...Tue, 06 Dec 2022 11:54:25 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/A_Method_of_Reducing_Cholesterol_Biosynthesis_with_Specific_MicroRNAsTAB-2099https://nih.technologypublisher.com/tech?title=New_Mouse_Strain_with_Conditional_Deletion_of_SMAD7%3a_Analysis_of_Disease_Processes_Involving_Immunological%2c_Fibrotic_or_Cardiovascular_IndicationsSMAD7 conditional knockout mice are available for licensing. SMAD7 can be knocked out by breeding with CRE-recombinase transgenic mice with a variety of promoters to yield tissue or cell type-specific deletions of SMAD7. SMAD7 has been shown to play a role in bone morphogenesis, cardiovascular tissue generation, immune regulation and fibrosis. Therefore, these mice provide a unique model to examine the role of the SMAD7 gene in disease processes that involve immunological, fibrotic, or cardiovascular components. Specifically, these mice may represent a novel model of Scleroderma, a disease...Tue, 06 Dec 2022 11:54:24 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech?title=New_Mouse_Strain_with_Conditional_Deletion_of_SMAD7%3a_Analysis_of_Disease_Processes_Involving_Immunological%2c_Fibrotic_or_Cardiovascular_IndicationsTAB-2097https://nih.technologypublisher.com/tech/Composite_Probes_and_Use_Thereof_in_Super_Resolution_MicroscopyThe technology is in the field of fluorescence microscopy. More specifically, the invention describes and claims the composite probes for super resolution optical techniques using super resolution via transiently activated quenchers (STAQ). The composite probes include a donor moiety and an acceptor moiety joined by a linker. The acceptor moiety, when excited by incident radiation, is excited to a state which, for example, absorbs in the donor emission region, such that the acceptor moiety in its excited state quenches at least a portion of the donor moiety emission. Other transiently activate...Tue, 06 Dec 2022 11:54:22 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Composite_Probes_and_Use_Thereof_in_Super_Resolution_MicroscopyTAB-2096https://nih.technologypublisher.com/tech/Reversible_SNAP-Tag_and_CLIP-Tag_Ligands_for_Live_Cell_ImagingRecently-developed protein tags enable the specific covalent attachment of synthetic ligands, incorporating fluorophores or other substituted groups, to fusion proteins containing these tags. For example, SNAP and CLIP tags bind O6-benzylguanine-containing and O2-benzylcytosine containing ligands respectively, which can be derivatized with a wide variety of labels, including fluorescent dyes, affinity probes, and cross-linkers. This system provides a powerful tool to study a variety of highly dynamic processes within cells, including protein trafficking, turnover, and complex formation. How...Tue, 06 Dec 2022 11:54:21 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Reversible_SNAP-Tag_and_CLIP-Tag_Ligands_for_Live_Cell_ImagingTAB-2093https://nih.technologypublisher.com/tech/Use_of_Modified_Peptide_Nucleic_Acids_for_Visualizing_DNAThe compounds described in this technology may be useful in the development of nucleic acid detection kits for various pathogens. Technologies for genomic detection most commonly use DNA probes to hybridize to target sequences, and require the use of Polymerase Chain Reaction (PCR) to amplify target sequences. Replacing the DNA probe with peptide nucleic acid (PNA) can greatly eliminate the need for PCR because the binding strength of PNAs to complementary DNA is stronger than DNA binding to complementary DNA. In addition, PNAs are nuclease and protease resistant, and form very stable and hi...Tue, 06 Dec 2022 11:54:20 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Use_of_Modified_Peptide_Nucleic_Acids_for_Visualizing_DNATAB-2080https://nih.technologypublisher.com/tech/Defensin-Based_Therapeutics_for_the_Treatment_of_Pulmonary_DiseaseInvestigators at the National Heart, Lung and Blood Institute have developed modified defensins that are resistant to degradation, have improved characteristics compared to unmodified defensins, and are promising candidates for pulmonary disease therapeutics. Defensins are small cationic peptides that defend the lung against pathogenic microorganisms and play an important role in innate immunity. However, during lung inflammation, defensin concentrations can reach levels that are cytotoxic for airway epithelial cells. Therefore, the development of methods to produce modified defensins that e...Tue, 06 Dec 2022 11:54:17 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Defensin-Based_Therapeutics_for_the_Treatment_of_Pulmonary_DiseaseTAB-2079https://nih.technologypublisher.com/tech/Caspase_Inhibitors_Useful_for_the_Study_of_Autoimmune_or_Inflammatory_DiseasesNovel and potent caspase 1 inhibitors are available for licensing. In particular, this technology discloses potent and selective caspase 1 inhibitors that target the active site of the enzyme. Caspase 1 is known to play a pro-inflammatory role in numerous autoimmune and inflammatory diseases and therefore represents an excellent target for treatment of a broad range of diseases, including but not limited to Huntington's, amyotrophic lateral sclerosis, ischemia, rheumatoid arthritis, osteoarthritis, inflammatory bowel disease, and sepsis. Not surprisingly this enormous potential has resulted...Tue, 06 Dec 2022 11:54:15 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Caspase_Inhibitors_Useful_for_the_Study_of_Autoimmune_or_Inflammatory_DiseasesTAB-2072https://nih.technologypublisher.com/tech/Diagnostic_Biomarker_of_Metastasis_for_Improved_Clinical_Management_of_Head_and_Neck_CancerSquamous Cell Carcinoma of the Head and Neck (HNSCC) is associated with poor prognosis due to the advanced stage of disease (metastasis) typically found at the time of diagnosis. Investigators at the NIH have developed a sensitive method using a protein biomarker for detecting even just a few HNSCC tumor cells in lymph nodes with occult disease. Combination of this staging technique with intraoperative sentinel lymph node mapping would improve the management of HNSCC by identifying patients for which radical lymph node dissection is most appropriate, sparing those for which it is not, and info...Tue, 06 Dec 2022 11:54:12 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Diagnostic_Biomarker_of_Metastasis_for_Improved_Clinical_Management_of_Head_and_Neck_CancerTAB-2068https://nih.technologypublisher.com/tech/Methods_to_Increase_Stability_of_Recombinant_Vaccinia-Vectored_Vaccines_and_Increase_Expression_of_a_Foreign_Gene_Inserted_in_Such_VaccinesThe technology offered for licensing is in the field of vaccinia-based recombinant vaccines. In particular the invention relates to methods of stabilizing the recombinant virus, thus resulting in efficient production of the vaccine and efficient expression of the inserted gene. Stabilization of the recombinant virus is achieved by the insertion of the exogenous gene into an intergenic region (IGR) of the viral genome (i.e. Modified Vaccinia Ankara, MVA), where the IGR is flanked by open reading frames of conserved poxvirus genes. Furthermore, the invention relates to plasmids vectors useful t...Tue, 06 Dec 2022 11:54:11 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Methods_to_Increase_Stability_of_Recombinant_Vaccinia-Vectored_Vaccines_and_Increase_Expression_of_a_Foreign_Gene_Inserted_in_Such_VaccinesTAB-2059https://nih.technologypublisher.com/tech/T-Cell-Specific_Gfi-1_Knockout_MouseThis is a mouse model available to study T-cell differentiation. Growth factor independent 1 (GFi-1) is a transcriptional repressor that is transiently induced during T-cell activation. This knockout mouse line is a GFi-1[flox/flox] introduced into a mouse Cre controlled by a CD4 promoter, which allows selective removal of GFi-1 exclusively in T-cells. It has thus-far been used to demonstrate that GFi-1 plays a critical role in enhancing Th2 cell expansion and repressing induction of Th17 and CD103+ iTreg cells.Tue, 06 Dec 2022 11:54:07 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/T-Cell-Specific_Gfi-1_Knockout_MouseTAB-2053https://nih.technologypublisher.com/tech?title=Non-Contact_Total_Emission_Detection_Methods_for_Multiphoton_Microscopy%3a_Improved_Image_Fidelity_and_Biological_Sample_AnalysisThe technology offered for licensing and for further development is in the field of multiphoton microscopy (MPM). More specifically, the invention pertains to optical designs that can enhance and extend the capabilities of MPM in spectral imaging of biological samples. The unique design of the light collection and the detection optics maximizes the collection of emitted light, thus increasing the signal and hence the signal-to-noise ratio (SNR). Improvement in image fidelity will result in improved analysis of biological samples and thus will favorably impact medical research and possibly clin...Tue, 06 Dec 2022 11:54:05 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech?title=Non-Contact_Total_Emission_Detection_Methods_for_Multiphoton_Microscopy%3a_Improved_Image_Fidelity_and_Biological_Sample_AnalysisTAB-2049https://nih.technologypublisher.com/tech/Device_for_Selective_Partitioning_of_Frozen_Cellular_ProductsCryopreservation using liquid nitrogen frozen polyvinyl bags allows for storing cellular materials for extended periods while maintaining their activity and viability. Such bags are commonly used in the clinic to store blood products including blood cells, plasma, hematopoietic stem cells, umbilical cord blood for future uses including transplantation. These materials, typically obtained in limited quantities, may be of great therapeutic value, as is the case of stem cells or cord blood derived cells which can be used to potentially treat a number of diseases. Currently, even if only a small p...Tue, 06 Dec 2022 11:54:03 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Device_for_Selective_Partitioning_of_Frozen_Cellular_ProductsTAB-2047https://nih.technologypublisher.com/tech/Vaccines_Against_Malarial_DiseasesThe invention offered for licensing is in the field of use of vaccines for malaria. The invention provides gene sequences encoding an erythrocyte binding protein of a malaria pathogen for the expression of the erythrocyte binding protein. The codon composition of the synthetic gene sequences approximates the mammalian codon composition. The synthetic gene sequences are useful for incorporation into DNA vaccine vectors, for the incorporation into various expression vectors for production of malaria proteins, or both. The synthetic genes may be modified to avoid post-translational modification o...Tue, 06 Dec 2022 11:54:02 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Vaccines_Against_Malarial_DiseasesTAB-2046https://nih.technologypublisher.com/tech?title=Device_and_Method_for_Direct_Measurement_of_Isotopes_of_Expired_Gases%3a_Application_in_Research_of_Metabolism_and_Metabolic_Disorders%2c_and_in_Medical_Screening_and_DiagnosticsThe technology offered for licensing and for further development concerns a novel device for intervallic collection of expired gas from subjects and subsequent measurement of the isotopic content of such expired gases. The device is specifically designed for medical research and clinical applications, and in particular in the area of metabolic disorders. The device may facilitate the development and testing of new therapies for such disorders and may be used for medical screening and diagnostics of metabolic diseases. The unique design of the device includes a constant volume respiratory chamb...Tue, 06 Dec 2022 11:54:01 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech?title=Device_and_Method_for_Direct_Measurement_of_Isotopes_of_Expired_Gases%3a_Application_in_Research_of_Metabolism_and_Metabolic_Disorders%2c_and_in_Medical_Screening_and_DiagnosticsTAB-2972https://nih.technologypublisher.com/tech/Three-Dimensional_Curved_Catheter_for_Right_Atrial_Appendage_TraversalAvailable for licensing and commercial development is a three-dimensionally configured curved catheter for safe traversal of the right atrial appendage (RAA). The device is configured to optimize one-way access of the pericardial space through the right atrium and into the RAA reducing the risk of coronary lacerations. Specifically the curved catheter is best described in three segments: a proximal segment, a transitional segment and a distal segment; the transition segment having a clockwise spiral shaped curvature. When inserted into a patient, the proximal segment is positioned within the ...Tue, 06 Dec 2022 11:54:00 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Three-Dimensional_Curved_Catheter_for_Right_Atrial_Appendage_TraversalTAB-2041https://nih.technologypublisher.com/tech/RORgamma_(RORC)_Deficient_Mice_Which_Are_Useful_for_the_Study_of_Lymph_Node_Organogenesis_and_Immune_ResponsesThe retinoid-related orphan receptor gamma (RORgamma) is a member of the nuclear receptor superfamily. NIH investigators used homologous recombination in embryonic stem cells to generate mice in which the RORgamma gene was disrupted. RORgamma deficient mice lack peripheral and mesenteric lymph nodes and Peyer's patches indicating that ROR expression is indispensable for lymph node organogenesis. In addition, RORgamma is required for the generation of Th17 cells which play a critical role in autoimmune disease. The RORgamma deficient mice are useful to identify the physiological functions of...Tue, 06 Dec 2022 11:53:58 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/RORgamma_(RORC)_Deficient_Mice_Which_Are_Useful_for_the_Study_of_Lymph_Node_Organogenesis_and_Immune_ResponsesTAB-2024https://nih.technologypublisher.com/tech/A_Target_for_the_Development_of_Diagnostics_and_Therapeutics_for_Abnormal_HematopoiesisThe zinc finger protein ZFP36L2 has been shown by the inventors to play an essential role in hematopoiesis, a process that is dysregulated in hematological cancers, anemia, and other conditions. Thus, ZFP36L2 has promise for use in a diagnostic test to detect abnormal hematopoiesis, or as a target for the development of therapeutics to treat abnormal hematopoiesis. Hematopoiesis is the formation of blood cellular components, through the differentiation of hematopoietic stem cells into lineages with a variety of roles, such as carrying oxygen, immune function, and blood clotting. Abnormally h...Tue, 06 Dec 2022 11:53:54 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/A_Target_for_the_Development_of_Diagnostics_and_Therapeutics_for_Abnormal_HematopoiesisTAB-2023https://nih.technologypublisher.com/tech?title=Biological%2fResearch_Material_for_HIV_Vaccine_ResearchOffered for licensing is a recombinant attenuated vaccinia virus, MVA, that expresses SIV 239gagpol. The materials can be used for research purposes and in particular in the area of HIV/AIDS vaccines. Plasmid insertion vector pJH-4, containing the foreign gene SIV 239 GagPol controlled by vaccinia early/late promoter, inserts into del III of attenuated vaccinia MVA virus to make recombinant MVA virus. The resulting recombinant virus made from pJH4, MVA/SIV239gagpol, expresses the SIV 239gagpol gene and thus can be used to conduct vaccine studies in animal models such as Rhesus macaques. The l...Tue, 06 Dec 2022 11:53:53 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech?title=Biological%2fResearch_Material_for_HIV_Vaccine_ResearchTAB-2022https://nih.technologypublisher.com/tech?title=Biological%2fResearch_Material_for_H1N1_Influenza_Virus_Vaccine_ResearchOffered for licensing is a recombinant attenuated vaccinia virus, MVA, that expresses the haemagglutinin (HA) and nucleoprotein (NP) of influenza virus A/PR/8/34 (H1N1). The virus has been shown to stimulate protective immunity to influenza virus in mice. The materials can be used for research purposes and in particular in the area of influenza virus vaccines. The related publications listed below demonstrate the usefulness of this biological material in influenza virus vaccine research.Tue, 06 Dec 2022 11:53:52 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech?title=Biological%2fResearch_Material_for_H1N1_Influenza_Virus_Vaccine_ResearchTAB-2006https://nih.technologypublisher.com/tech?title=Monoclonal_Antibodies_That_React_With_the_Capsule_of_%3ci%3eBacillus_anthracis%3c%2fi%3eBacillus anthracis is the causative agent of anthrax and is surrounded by a polypeptide capsule of poly-gamma-D-glutamic acid (gammaDPGA). gammaDPGA is poorly immunogenic and has antiphagocytic properties. The bacterial capsule is essential for virulence. Antibodies to the capsule have been shown to enhance phagocytosis and killing of encapsulated bacilli. These antibodies in combination with antibodies that neutralize the toxins of B. anthracis could provide enhanced protection by their dual antibacterial and antitoxic activities. Such antibodies would be especially useful for antibiotic...Tue, 06 Dec 2022 11:53:47 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech?title=Monoclonal_Antibodies_That_React_With_the_Capsule_of_%3ci%3eBacillus_anthracis%3c%2fi%3eTAB-2005https://nih.technologypublisher.com/tech?title=Antigenic_Chimeric_Tick-Borne_Encephalitis_Virus%2fDengue_Virus_Type_4_Recombinant_VirusesThe tick-borne encephalitis virus (TBEV) complex is a group of viruses that can cause severe neutrotropic disease and up to thirty percent (30%) mortality. While these viruses can be found in many parts of the world, the largest impact of the disease occurs in Europe and Russia, where approximately fourteen thousand (14,000) hospitalized TBEV cases occur annually. TBEV is in the family Flaviviridae, genus flavivirus and is composed of a positive-sense single stranded RNA genome that contains 5' and 3' non-coding regions and a single open reading frame encoding ten (10) proteins. At present,...Tue, 06 Dec 2022 11:53:46 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech?title=Antigenic_Chimeric_Tick-Borne_Encephalitis_Virus%2fDengue_Virus_Type_4_Recombinant_VirusesTAB-2003https://nih.technologypublisher.com/tech/Antigen_Mixtures_for_Serological_Detection_of_HHV-8_InfectionThis invention describes a highly specific and sensitive serological test for human herpesvirus 8 (HHV-8) infection that uses the Luciferase Immunoprecipitation System (LIPS). A mixture of four virus-specific antigens, including K8.1, v-cyclin, ORF65 and LANA, was shown to provide more robust detection of HHV-8 infection than traditional methods due its ability to detect very low viral loads. In addition, one of the antigens, v-cyclin, was identified as a new serological marker for HHV-8 infection, and its similarity to a known human oncogene, cyclin-D, raises the possibility of its use as a...Tue, 06 Dec 2022 11:53:45 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Antigen_Mixtures_for_Serological_Detection_of_HHV-8_InfectionTAB-3015https://nih.technologypublisher.com/tech/Murine_Cell_Models_for_Metastatic_Squamous_Cell_CarcinomaTwo cell lines isolated from Pam 212 cells (SCC): Pam LY (lymph node metastasis) and Pam LU (lung metastasis) from metastated in vivo growth in mouse. These stably established cell lines exhibited higher potential to metastasize to lymph nodes and lungs, respectively, in mouse models than their parental Pam 212 cells.Tue, 06 Dec 2022 11:53:44 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Murine_Cell_Models_for_Metastatic_Squamous_Cell_CarcinomaTAB-2000https://nih.technologypublisher.com/tech/Recombinant_Vaccines_Based_on_Poxvirus_VectorsThe technology offered for licensing is foundational in the area of recombinant DNA vaccines. In the last several years, facilitated through a licensing program of the NIH, the technology has been broadly applied in the development and commercialization of several novel human and veterinary vaccines in the areas of infectious disease as well as cancer therapeutics. The NIH wishes to expand its licensing program of the subject technology in a variety of applications that will benefit public health. Briefly, the technology describes and claims methods of constructing recombinant vaccines utilizi...Tue, 06 Dec 2022 11:53:42 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Recombinant_Vaccines_Based_on_Poxvirus_VectorsTAB-1999https://nih.technologypublisher.com/tech/Multilayered_RF_Coil_System_for_Improving_Transmit_B1_Field_Homogeneity_in_High-Field_MRIAvailable for licensing and commercial development is a multilayered radio-frequency (RF) coil system for improving the transmit B1 field homogeneity for magnetic resonance imaging (MRI) at high field strengths. The current invention aims at manipulating the inhomogeneous profile of the transmit B1 field, which causes MR images to become less uniform as the magnetic field strength is increased, by utilizing an inner array of RF elements (e.g. surface coils) within and coupled to an outer transmit unit (e.g. a birdcage coil or other volume coil). Improvement in B1 field homogeneity is achieved...Tue, 06 Dec 2022 11:53:39 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Multilayered_RF_Coil_System_for_Improving_Transmit_B1_Field_Homogeneity_in_High-Field_MRITAB-1996https://nih.technologypublisher.com/tech/Methods_for_Treating_or_Ameliorating_Fibrosis_by_Inhibiting_the_Interaction_between_IL-21_Receptor_(IL-21R)_and_IL-21This invention includes methods for treating or ameliorating fibrosis by inhibiting the interaction between IL-21 Receptor (IL-21R) and IL-21 using either anti-IL-21R monoclonal antibodies (or binding fragments of anti-IL-21R mAbs), anti-IL-21 monoclonal antibodies (or binding fragments of anti-IL-21 mAbs) or soluble IL-21R (or binding fragments of IL-21R). It is believed that the TH2 immune response, induced by IL-21, plays a major role in the in the pathogenesis of tissue fibrosis. Antagonism of IL-21R by anti-IL-21R monoclonal antibodies or the sequestration of IL-21 by soluble IL-21R or ...Tue, 06 Dec 2022 11:53:38 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Methods_for_Treating_or_Ameliorating_Fibrosis_by_Inhibiting_the_Interaction_between_IL-21_Receptor_(IL-21R)_and_IL-21TAB-1995https://nih.technologypublisher.com/tech/Therapeutic_Peptide_Treatment_for_Dyslipidemic_and_Vascular_DisordersThis invention is directed to use of certain peptide analogs comprising multiple amphipathic helical domains that are able to promote cellular lipid efflux and stimulate lipoprotein lipase activity. As a result, administration of invention peptides lead to reduced incidences of hypertriglyceridemia without inducing toxicity. Existing peptides that stimulate efflux of lipids from cells exhibit unacceptably high toxicity. Invention peptides are superior to existing peptides and can also be used to treat or prevent a vast range of vascular diseases, and their dyslipidemic precursors. Exemplary va...Tue, 06 Dec 2022 11:53:36 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Therapeutic_Peptide_Treatment_for_Dyslipidemic_and_Vascular_DisordersTAB-1991https://nih.technologypublisher.com/tech/Truncated_Methanocarba_Adenosine_Derivatives_as_A3_Adenosine_Receptor_AntagonistsNovel A3 adenosine antagonists available for licensing. A3 receptors are particularly highly expressed in inflammatory cells, making it a potentially desirable target for inflammatory diseases. This technology relates to highly specific antagonists and partial agonists of A3 adenosine receptors, which are negatively coupled to adenylate cyclase and have been broadly implicated in inflammation, cardiovascular disease, endocrine conditions and cancer. Further, A3 adenosine receptors have been implicated in asthma and glaucoma.Tue, 06 Dec 2022 11:53:33 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Truncated_Methanocarba_Adenosine_Derivatives_as_A3_Adenosine_Receptor_AntagonistsTAB-1978https://nih.technologypublisher.com/tech/A_Locking_Device_for_Permanently_Securing_Surgical_Suture_LoopsThis technology relates to a device that can be used to non-invasively secure surgical suture loops when combined with a percutaneous delivery system. It has been shown to be effective in correcting mitral valve regurgitation (MVR) in an animal model. During the procedure, a guidewire is percutaneously conveyed to the atrium of the heart and is used to secure the "cerclage" suture encircling the mitral valve annulus, which is delivered using a delivery catheter. The locking device is advanced over the suture by the delivery catheter and it permanently secures the suture and maintains the tensi...Tue, 06 Dec 2022 11:53:30 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/A_Locking_Device_for_Permanently_Securing_Surgical_Suture_LoopsTAB-1977https://nih.technologypublisher.com/tech/qPCR_Assay_for_Detection_of_JC_VirusJC Virus causes a fatal disease in the brain called progressive multifocal leukoencephalopathy (PML) that occurs in many patients with immunocompromised conditions. For example, more than five percent (5%) of AIDS patients develop PML. Additionally, these conditions include, but are not limited to, cancers such as leukemias and lymphomas, organ transplants such as kidney, heart and autoimmune conditions with treatment that modulates the immune system such as Multiple Sclerosis (MS), rheumatoid arthritis, psoriasis, and systemic lupus erythematosus. The finding of JCV DNA in the patients wit...Tue, 06 Dec 2022 11:53:29 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/qPCR_Assay_for_Detection_of_JC_VirusTAB-1973https://nih.technologypublisher.com/tech/A_Novel_System_for_Producing_Infectious_Hepatitis_C_Virus_(HCV)_Virions_and_Development_of_a_Novel_Reporter_System_for_Studying_HCV_EntryHCV has infected an estimated 3% of the world population in whom viral infection persists for more than two third of the cases, often resulting in life-threatening complications. The standard of care (pegylated interferon alpha-2 plus ribavirin) is efficient in only 50% of treated patients, costly and has numerous side effects. In addition, viral resistance to newly developed drugs -- targeting viral protease or RNA polymerase -- has been described, but no vaccine is yet available. The difficulty in developing HCV vaccines is largely due to the broad sequence-diversity displayed by HCV, the fr...Tue, 06 Dec 2022 11:53:27 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/A_Novel_System_for_Producing_Infectious_Hepatitis_C_Virus_(HCV)_Virions_and_Development_of_a_Novel_Reporter_System_for_Studying_HCV_EntryTAB-1968https://nih.technologypublisher.com/tech/Enhanced_Immune_Response_Against_Influenza_Virus_by_Priming_with_a_DNA-based_VaccineAvailable for licensing and commercial development are compositions and methods for enhancing an immune response to influenza viruses by priming with DNA-based vaccines encoding influenza proteins. The priming compositions contain DNA constructs with inserted nucleic acids encoding influenza virus hemagglutinin (HA) or an epitope-bearing domain thereof, while the boosting compositions are inactivated influenza vaccines. The DNA constructs are based on proprietary expression systems that increase protein expression relative to commonly used alternatives. A potential influenza pandemic caused...Tue, 06 Dec 2022 11:53:25 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Enhanced_Immune_Response_Against_Influenza_Virus_by_Priming_with_a_DNA-based_VaccineTAB-1965https://nih.technologypublisher.com/tech/Self-Expanding_Stent_for_Valve_ReplacementAortic stenosis and aortic regurgitation are the most common types of aortic valvular diseases. Such diseased aortic valves in the body are traditionally replaced with valve prosthesis by an open surgical implantation. Available for licensing and commercial development is intellectual property covering stents for use with valve prostheses. As illustrated below, one possible embodiment of the invention includes a self-expandable stent with an elastic tubular latticework having radial and longitudinal direction. The stent geometry and mechanical parameters provide more anatomically-correct plac...Tue, 06 Dec 2022 11:53:23 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Self-Expanding_Stent_for_Valve_ReplacementTAB-1963https://nih.technologypublisher.com/tech/Interactive_Venn_Diagram_Software_Designed_for_Microarray_AnalysisMultiple conditions from any source, but designed for experiments involving microarrays, will produce (significant gene lists for arrays) lists from each condition, thus multiple lists. This Java® based software provides investigators with a method of displaying multiple conditions in a single graphic along with producing a text output of genes that are the product of these conditional intersections along with each conditions unique list. A standard Venn diagram is limited to only display three (3) comparisons; this software can display any number of comparisons and will automatically create...Tue, 06 Dec 2022 11:53:22 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Interactive_Venn_Diagram_Software_Designed_for_Microarray_AnalysisTAB-1935https://nih.technologypublisher.com/tech/Genetic_Mutations_Associated_with_StutteringNIH investigators, for the first time, identified specific mutations associated with stuttering. These mutations are located within the genes encoding three enzymes, Glc-NAc phosphotransferase catalytic subunit [GNPTAB], Glc-NAc phosphotransferase recognition subunit [GNPTG], and N-acetylglucosamine-1-phosphodiester alpha-N-acetylglucosaminidase [NAGPA]. Together these constitute the pathway that targets lysosomal enzymes to their proper location. This pathway is associated with lysosomal storage disorders, and thereby this discovery provides potential novel therapeutic targets for ameliorat...Tue, 06 Dec 2022 11:53:15 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Genetic_Mutations_Associated_with_StutteringTAB-1934https://nih.technologypublisher.com/tech/Polyclonal_Antibodies_to_the_Kidney_Protein_Urea_Transporter_1_(UTA1)Antibodies to UTA1, useful for immunoblotting and immunocytochemistry, are available to resell for research purposes. Urea Transporter 1 (UTA1) is activated by vasopressin and is responsible for urea transport across the apical membrane into the intracellular space within the renal inner medullary collecting duct. The inventor has developed rabbit polyclonal antibodies directed against a peptide sequence in human UTA1. Antibody also recognizes UTA3, another product of the same gene.Tue, 06 Dec 2022 11:53:15 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Polyclonal_Antibodies_to_the_Kidney_Protein_Urea_Transporter_1_(UTA1)TAB-1933https://nih.technologypublisher.com/tech?title=Polyclonal_Antibodies_to_NKCC2%2c_a_Kidney-Specific_Member_of_the_Cation_Chloride_Co-transporter_Family%2c_SLC12A1Antibodies to NKCC2, useful for immunoblotting and immunocytochemistry, are available to resell for research purposes. NKCC2 is found on the apical surface of the thick ascending limb of the loop of Henle, where it facilitates transport of sodium, potassium, and chloride ions from the lumen of the renal thick ascending limb into the cell. Transport of sodium dilutes the luminal fluid, decreasing its osmolality creating an osmotic driving force for water reabsorption in the connecting tubule and cortical collecting duct under the influence of the hormone vasopressin. NKCC2 is blocked by loop...Tue, 06 Dec 2022 11:53:14 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech?title=Polyclonal_Antibodies_to_NKCC2%2c_a_Kidney-Specific_Member_of_the_Cation_Chloride_Co-transporter_Family%2c_SLC12A1TAB-1932https://nih.technologypublisher.com/tech/Polyclonal_Antibodies_to_Thiazide-Sensitive_Sodium-Chloride_Cotransporter_(NCC)Antibodies to thiazide-sensitive sodium-chloride cotransporter (NCC), useful for immunoblotting and immunocytochemistry, are available to resell for research purposes. NCC is found on the apical membrane of the distal convoluted tubule, where it is the principal mediator of Na+ and CI- reabsorption in this segment of the nephron. NCC is the target of thiazide diuretics used in the treatment of hypertension. The inventors have developed rabbit polyclonal antibodies directed against a peptide sequence in the C-terminal region of NCC.Tue, 06 Dec 2022 11:53:13 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Polyclonal_Antibodies_to_Thiazide-Sensitive_Sodium-Chloride_Cotransporter_(NCC)TAB-1931https://nih.technologypublisher.com/tech/Polyclonal_Antibodies_to_the_Kidney_Protein_Sodium-Hydrogen_Exchanger_3_(NHE3)Antibodies to NHE3, useful for immunoblotting and immunocytochemistry, are available to resell for research purposes. NHE3 is a membrane Na+/H+ exchanger involved in maintenance of fluid volume homeostasis in the kidney. It is expressed on the apical membrane of the renal proximal tubule and plays a major role in NaCl and HCO3 absorption. The inventor has developed rabbit polyclonal antibodies directed against a peptide sequence common to human, rat and mouse NHE3.Tue, 06 Dec 2022 11:53:12 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Polyclonal_Antibodies_to_the_Kidney_Protein_Sodium-Hydrogen_Exchanger_3_(NHE3)TAB-1930https://nih.technologypublisher.com/tech/Small_Molecule_Activators_of_Human_Pyruvate_Kinase_for_Treatment_of_Cancer_and_Enzyme-Deficient_Hemolytic_AnemiaNIH investigators have discovered a series of small compounds with the potential to treat a variety of cancers as well as hemolytic anemia. Contrary to most cancer medications, these molecules can be non-toxic to normal cells because they target a protein specific to the metabolic pathways in tumors, thus representing a significant clinical advantage over less-specific chemotherapeutics. The invention described here is a series of small molecules that activate pyruvate kinase (PK) isoform M2. PK-M2 is a critical metabolic enzyme that is affected in all forms of cancer. Inactivation of PK-M...Tue, 06 Dec 2022 11:53:11 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Small_Molecule_Activators_of_Human_Pyruvate_Kinase_for_Treatment_of_Cancer_and_Enzyme-Deficient_Hemolytic_AnemiaTAB-1913https://nih.technologypublisher.com/tech/Mouse_Monoclonal_Antibodies_to_Human_Tristetraprolin_(TTP)TTP has been implicated in autoimmune and inflammatory diseases through its role as a regulator of the transcripts encoding several pro-inflammatory cytokines, including tumor necrosis factor alpha. However, it has been difficult to study endogenous TTP in man and other animals because it is expressed at very low levels in most cells and tissues, and because of the lack of mouse monoclonal antibodies directed at the human protein. Scientists at the NIH have developed three mouse monoclonal antibodies (TTP-16, TTP-214 and TTP-409) that react to different regions of the human TTP to allow for ...Tue, 06 Dec 2022 11:53:07 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Mouse_Monoclonal_Antibodies_to_Human_Tristetraprolin_(TTP)TAB-1910https://nih.technologypublisher.com/tech/Cell_Based_ImmunotherapyThe invention hereby offered for licensing is in the field of Immunotherapy and more specifically in therapy of autoimmune diseases such as Type I diabetes, multiple sclerosis, rheumatoid arthritis and systemic lupus erythematosis and immune mediated allergies such as asthma as well as in transplantation-related disorders, such as graft acceptance and graft-versus-host-disease (GVHD). While the role of FOXP3+ regulatory T cells (Tregs) in the maintenance of self-tolerance and immune homeostasis has been established and thus their use in adoptive immunotherapy has been contemplated, there is s...Tue, 06 Dec 2022 11:53:05 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Cell_Based_ImmunotherapyTAB-1909https://nih.technologypublisher.com/tech/Radiotracers_for_Imaging_P-glycoprotein_Transporter_FunctionThis invention offers technology to help treat certain brain diseases, such as Alzheimer's disease and Parkinson's, and may lead to more effective and personalized treatments. P-glycoprotein transporter (P-gp) acts as a pump at the blood-brain barrier to exclude a wide range of xenobiotics (e.g., toxins, drugs, etc.) from the brain and is also expressed in a tumor in response to exposure to established/prospective chemotherapeutics (a phenomenon known as multidrug resistance; MDR). The instant invention relates to compounds that are avid substrates for P-gp, and their preparation and use as ...Tue, 06 Dec 2022 11:53:04 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Radiotracers_for_Imaging_P-glycoprotein_Transporter_FunctionTAB-2985https://nih.technologypublisher.com/tech?title=SIRT1_KO_Human_Cell_Lines_Generated_by_CRISPR%2fCas9-mediated_DNA_EditingSIRT1, a NAD+-dependent protein deacetylase, is the most conserved member of the sirtuins family. Through deacetylation of a number of protein substrates that are important transcription factors or co-factors, SIRT1 regulates many vital biological processes such as metabolism, cellular stress response, stem cell pluripotency, and development. The present invention describes SIRT1 KO human cell lines in three different cell types generated by using the CRISPR/Cas9-hSIRT1 DNA editing constructs designed and provided by Horizon Discovery, a UK based biotechnology company. The cells lines can be...Tue, 06 Dec 2022 11:53:02 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech?title=SIRT1_KO_Human_Cell_Lines_Generated_by_CRISPR%2fCas9-mediated_DNA_EditingTAB-1893https://nih.technologypublisher.com/tech/MDCK_Cells_with_Enhanced_Characteristics_for_Vaccine_and_Virus_ProductionThis technology relates to compositions and methods for improving the growth characteristics of cells engineered to produce live viruses such as the Influenza virus. Featured is a method that uses the gene candidate, siat7e, or its expressed or inhibited products in Madin Darby Canine Kidney (MDCK) cells. The gene expression modulates anchorage-dependence of the cell line thereby allowing scale-up on bioreactor platforms without the use of microcarrier beads and reducing production costs. More specifically, this technology claims use of the methods embodied in the patent application for produc...Tue, 06 Dec 2022 11:52:59 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/MDCK_Cells_with_Enhanced_Characteristics_for_Vaccine_and_Virus_ProductionTAB-1887https://nih.technologypublisher.com/tech/Humanized_Monoclonal_Antibodies_that_Specifically_Bind_Japanese_Encephalitis_Virus_(JEV)_and_Their_UseJapanese encephalitis virus (JEV) is the prototype virus of the Japanese encephalitis (JE) group belonging to the Flavivirus genus of the Flaviviridae family. Other members of the group include Kunjin virus, St. Louis encephalitis virus, and West Nile encephalitis virus (WNV). JEV is widely distributed in South Asia, Southeast Asia, and the Asian Pacific Rim. In recent years, JE epidemics have spread to previously unaffected areas, such as northern Australia, Pakistan, India and Indonesia. The JE outbreak in India during July to November of 2005 was the longest and most severe in recent years,...Tue, 06 Dec 2022 11:52:57 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Humanized_Monoclonal_Antibodies_that_Specifically_Bind_Japanese_Encephalitis_Virus_(JEV)_and_Their_UseTAB-1884https://nih.technologypublisher.com/tech?title=Mouse_Monoclonal_Antibodies_to_MAD1%2c_a_Human_Spindle_Assembly_Checkpoint_Protein_for_Maintaining_Chromosomal_SegregationScientists at the National Institutes of Health have developed mouse monoclonal antibodies against the human spindle assembly checkpoint protein, MAD1. The spindle assembly checkpoint in mitotic cell division regulates the fidelity of chromosome segregation during cell division. MAD1 is an important component of this checkpoint control, which if compromised, can lead to the initiation of cancer cell growth. These monoclonal antibodies are the first available antibodies against MAD1 and can be used in laboratory research and diagnostics.Tue, 06 Dec 2022 11:52:55 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech?title=Mouse_Monoclonal_Antibodies_to_MAD1%2c_a_Human_Spindle_Assembly_Checkpoint_Protein_for_Maintaining_Chromosomal_SegregationTAB-1876https://nih.technologypublisher.com/tech/Use_of_Mono-Amine_Oxidase_Inhibitors_to_Prevent_Herpes_Virus_Infections_and_Reactivation_from_LatencyAvailable for licensing are methods of using Monoamine Oxidase Inhibitors (MAOIs) to prevent alpha-herpesvirus lytic infections, such as those caused by Herpes simplex virus (HSV-1 or HSV-2) and Varicella zoster virus (VZV), and to possibly prevent the periodic reactivation of these viruses from latency. MAOIs have been historically used to treat depression, hypertension, and related diseases. The invention describes how MAOIs can also inhibit LSD1, a histone/protein demethylase that is required for initiation of alpha-herpesvirus lytic infection. After an initial lytic infection, alpha-her...Tue, 06 Dec 2022 11:52:53 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Use_of_Mono-Amine_Oxidase_Inhibitors_to_Prevent_Herpes_Virus_Infections_and_Reactivation_from_LatencyTAB-1870https://nih.technologypublisher.com/tech?title=AFMAnalyze%3a_Software_Automation_and_Analysis_of_Atomic_Force_Microscopy_(AFM)_DataAFMAnalyze is a software package that is designed to significantly enhance the analysis and application of Atomic Force Microscopy (AFM) data. This software automates AFM data collection and analysis, and is equipped with a Graphical User Interface (GUI)-intensive computational tool that is capable of replacing the manual or algorithmic methods for reconstructing, analyzing and interpreting large AFM data sets. AFMAnalyze provides a more robust, objective, and automated method for collecting and interpreting AFM results. A user, for example, can compute the Young’s modulus of a sample at the p...Tue, 06 Dec 2022 11:52:50 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech?title=AFMAnalyze%3a_Software_Automation_and_Analysis_of_Atomic_Force_Microscopy_(AFM)_DataTAB-1864https://nih.technologypublisher.com/tech/Mice_with_a_Conditional_LoxP-Flanked_Glucosylceramide_Synthase_Allele_Controlling_Glycosphingolipid_SynthesisGlycosphingolipids are organizational building blocks of plasma membranes that participate in key cellular functions, such as signaling and cell-to-cell interactions. Glucosylceramide synthase - encoded by the Ugcg gene - controls the first committed step in the major pathway of glycosphingolipid synthesis. Global disruption of the Ugcg gene in mice is lethal during gastrulation. The inventors have established a Ugcg allele flanked by loxP sites (floxed). When cre recombinase was expressed in the nervous system under control of the nestin promoter, the floxed gene underwent recombination, resu...Tue, 06 Dec 2022 11:52:48 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Mice_with_a_Conditional_LoxP-Flanked_Glucosylceramide_Synthase_Allele_Controlling_Glycosphingolipid_SynthesisTAB-1858https://nih.technologypublisher.com/tech?title=Mouse_Monoclonal_Antibody_to_the_Nitrone_Spin_Trap_5%2c5-dimethyl-1-pyrroline_N-oxide_(DMPO)Oxidative stress resulting in the formation of biological radicals has been implicated in a number of human diseases, such as cancer as well as aging. There is, however, a paucity of reliable methods for in vivo or ex vivo detection of radical formation. Until now the only general technique that allowed for the detection of these highly reactive species was electron spin resonance (ESR) using spin traps. One of the most popular of these spin traps is 5,5-dimethyl-1-pyrroline N-oxide (DMPO). In the ESR method, radicals are trapped by DMPO, and the DMPO spin adduct signal is measured quantit...Tue, 06 Dec 2022 11:52:46 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech?title=Mouse_Monoclonal_Antibody_to_the_Nitrone_Spin_Trap_5%2c5-dimethyl-1-pyrroline_N-oxide_(DMPO)TAB-1839https://nih.technologypublisher.com/tech?title=Scalable_Purification_of_AAV2%2c_AAV4_or_AAV5_Using_Ion-Exchange_ChromatographyAdeno-associated viruses (AAVs) constitute, as a group, the vehicle of choice for gene therapy because of several attractive features. Among others, AAVs are less pathogenic than other viruses, and they can be used for the long-term expression of therapeutic genes. This invention describes a simple ion-exchange (HPLC) methodology to purify different AAV serotypes. The protocol, which can be readily scaled up, details the efficient concentration of fully infective AAV particles, and is applicable to a number of promising serotypes for which efficient purification methodologies are currently la...Tue, 06 Dec 2022 11:52:40 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech?title=Scalable_Purification_of_AAV2%2c_AAV4_or_AAV5_Using_Ion-Exchange_ChromatographyTAB-1836https://nih.technologypublisher.com/tech/Prostatic_Adenocarcinoma_Cells_Expressing_or_Lacking_the_Tumor_Suppressor_Gene_PTENPTEN is a tumor suppressor gene that is frequently deleted or mutated in a variety of human cancers, including prostate, breast, endometrial, lung, and ovarian cancers. In prostate cancer cells, PTEN deletion is the most common event observed. The loss of PTEN is thought to play and important role in tumor cell proliferation and metastasis due to a lack of control of the signaling pathways that mediate cellular processes such as apoptosis and migration. Previously PTEN had been shown to down regulate cyclin D1 expression as well as regulate p53 protein levels and transcriptional activity, a...Tue, 06 Dec 2022 11:52:39 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Prostatic_Adenocarcinoma_Cells_Expressing_or_Lacking_the_Tumor_Suppressor_Gene_PTENTAB-1827https://nih.technologypublisher.com/tech/A_Novel_Treatment_for_Malarial_InfectionsThe inventions described herein are antimalarial small molecule inhibitors of the plasmodial surface anion channel (PSAC), an essential nutrient acquisition ion channel expressed on human erythrocytes infected with malaria parasites. These inhibitors were discovered by high-throughput screening of chemical libraries and analysis of their ability to kill malaria parasites in culture. Two separate classes of inhibitors were found to work synergistically in combination against PSAC and killed malaria cultures at markedly lower concentrations than separately. These inhibitors have high affinity...Tue, 06 Dec 2022 11:52:36 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/A_Novel_Treatment_for_Malarial_InfectionsTAB-1825https://nih.technologypublisher.com/tech/Respiratory_Syncytial_Virus_(RSV)_Vaccines_Based_on_Promoter-Proximate_AttenuationAvailable for licensing and commercial development is a patent estate and related biological materials for producing therapeutic or prophylactic vaccines against Respiratory Syncytial Virus (RSV). The claimed vaccine strategy relates to the engineering and creation of live-attenuated RSV vaccine candidates by shifting the position of one or more viral genes relative to the viral promoter (aka promoter-proximal attenuation). The gene shifts can be constructed by insertion, deletion or rearrangement of genes or genome segments within the recombinant genome or antigenome. Viral replication can i...Tue, 06 Dec 2022 11:52:34 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Respiratory_Syncytial_Virus_(RSV)_Vaccines_Based_on_Promoter-Proximate_AttenuationTAB-1824https://nih.technologypublisher.com/tech/Active_Guidewire_Visualization_Device_and_System_for_MRI_Guided_InterventionsAvailable for licensing and commercial development is a guidewire device and system for MRI guidance of vascular interventions. The guidewire design, and its coupled system, enables interventionalists to visualize the location of the tip and distal shaft of an MRI compatible guidewire relative to the vascular system and surrounding anatomy. Visualization of both the shaft and tip enables interventionalists to advance the guidewire through tortuous vessels reducing the risk of puncturing vessel walls and also steering it through labyrinthine vasculature. The guidewire provided by the present...Tue, 06 Dec 2022 11:52:33 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Active_Guidewire_Visualization_Device_and_System_for_MRI_Guided_InterventionsTAB-1823https://nih.technologypublisher.com/tech/Microfabricated_Particles_Useful_as_MRI_Contrast_AgentsMRI contrast agents are versatile yet lack the sensitivity and multiplexing capabilities of optical agents. Available for licensing is an invention pertaining to microfabricated structures that can be used as MRI contrast agents with enhanced functionality or as micro-RFID (radio-frequency identification) tags. The microstructures can be engineered to appear as different effective colors when resolved using MRI as opposed to strictly grey-scale contrast of existing MRI agents. In this way they can be thought as radio-frequency analogs to quantum dots. A set of agents could be produced that...Tue, 06 Dec 2022 11:52:31 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Microfabricated_Particles_Useful_as_MRI_Contrast_AgentsTAB-1831https://nih.technologypublisher.com/tech?title=Transgenic_Mice_with_Conditionally-Enhanced_Bone_Morphogen_Protein_(BMP)_Signaling%3a__A_Model_for_Human_Bone_DiseasesThis technology relates to novel animal models of several human bone diseases that have been linked to enhanced BMP signaling. More specifically, this mouse model expresses a mutant receptor for BMP, known as Alk2 that is always actively signaling. This receptor is under the control of the Cre-loxP system, which allows control of expression of the mutant Alk2 in both a developmental and tissue-specific manner. As a result, the enhanced signaling conditions exhibited in multiple human bone-related diseases can be studied with the same animals.Tue, 06 Dec 2022 11:52:29 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech?title=Transgenic_Mice_with_Conditionally-Enhanced_Bone_Morphogen_Protein_(BMP)_Signaling%3a__A_Model_for_Human_Bone_DiseasesTAB-1796https://nih.technologypublisher.com/tech?title=Species-Independent_A3_Adenosine_Receptor_Agonists_Which_May_Be_Useful_for_Treating_Ischemia%2c_Controlling_Inflammation%2c_and_Regulating_Cell_ProliferationThis invention claims species-independent agonists of A3AR, specifically (N)-methanocarba adenine nucleosides and pharmaceutical compositions comprising such nucleosides. The A3 adenosine receptor (A3AR) subtype has been linked with helping protect the heart from ischemia, controlling inflammation, and regulating cell proliferation. Agonists of the human A3AR subtype have been developed that are also selective for the mouse A3AR while retaining selectivity for the human receptor. This solves a problem for clinical development because animal model testing is important for pre-clinical valida...Tue, 06 Dec 2022 11:52:18 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech?title=Species-Independent_A3_Adenosine_Receptor_Agonists_Which_May_Be_Useful_for_Treating_Ischemia%2c_Controlling_Inflammation%2c_and_Regulating_Cell_ProliferationTAB-1781https://nih.technologypublisher.com/tech/Rapid_and_Sensitive_Detection_of_Nucleic_Acid_Sequence_VariationsThe ability to easily detect small mutations in nucleic acids, such as single base substitutions, can provide a powerful tool for use in cancer detection, perinatal screens for inherited diseases, and analysis of genetic polymorphisms such as genetic mapping or for identification purposes. Current approaches make use of the mismatch that occurs between complimentary strands of DNA when there is a genetic mutation, the electrophoretic mobility differences caused by small sequence changes, and chemicals or enzymes that can cleave heteroduplex sites. Some of these methods, however, prove to be to...Tue, 06 Dec 2022 11:52:12 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Rapid_and_Sensitive_Detection_of_Nucleic_Acid_Sequence_VariationsTAB-3116https://nih.technologypublisher.com/tech/A_Full-Length_Infectious_cDNA_Clone_of_Zika_Virus_from_the_2015_Epidemic_in_Brazil_as_a_Genetic_Platform_for_Studies_of_Virus-Host_Interactions_and_Vaccine_DevelopmentAn arthropod-borne virus, Zika virus (ZIKV), has recently emerged as a major human pathogen. Associated with complications during perinatal development and Guillain-Barré syndrome in adults, ZIKV raises new challenges for understanding the molecular determinants of flavivirus pathogenesis. This underscores the necessity for the development of a reverse genetic system based on an epidemic ZIKV strain. This technology relates to the generation and characterization in cell cultures of an infectious cDNA clone of ZIKV isolated from the 2015 epidemic in Brazil. The cDNA-derived ZIKV replicated ...Tue, 06 Dec 2022 11:52:08 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/A_Full-Length_Infectious_cDNA_Clone_of_Zika_Virus_from_the_2015_Epidemic_in_Brazil_as_a_Genetic_Platform_for_Studies_of_Virus-Host_Interactions_and_Vaccine_DevelopmentTAB-2957https://nih.technologypublisher.com/tech?title=Chicken_Polyclonal_Antiserum_to_the_Nitrone_Spin_Trap_5%2c5-dimethyl-1-pyrroline_N-oxide_(DMPO)Biological radicals resulted from oxidative stress has been implicated in human diseases, such as cancer and aging. There is, however, a paucity of reliable methods for in vivo or ex vivo detection of either radical formation, the end-products of radical formation or susceptibility for radical formation. The chicken polyclonal anti-DMPO can be used to detect the stable nitrone end-product of protein and DNA radicals in ELISA assays, blot analyses and confocal microscopy. This chicken polyclonal anti-DMPO antiserum will supplement both the mouse monoclonal anti-DMPO and the rabbit polyclonal...Tue, 06 Dec 2022 11:52:04 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech?title=Chicken_Polyclonal_Antiserum_to_the_Nitrone_Spin_Trap_5%2c5-dimethyl-1-pyrroline_N-oxide_(DMPO)TAB-1758https://nih.technologypublisher.com/tech/Muramyl_Dipeptide_as_a_Therapeutic_Agent_for_InflammationThe nucleotide-binding oligomerization domain 2 (NOD2) protein plays a key role in innate immunity as a sensor of muramyl dipeptide (MDP), a breakdown product of bacterial peptidoglycan. Bacterial peptidoglycan promotes the innate immune response through the activation of Toll-like receptor 2 (TLR2), which ultimately provokes inflammation. Activation of NOD2 by MDP negatively regulates the activity of TLR2, and thus reduces inflammation. The inventors have demonstrated that administration of MDP prevents the development of experimental colitis in mice. They have also determined that MDP re...Tue, 06 Dec 2022 11:52:03 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Muramyl_Dipeptide_as_a_Therapeutic_Agent_for_InflammationTAB-1736https://nih.technologypublisher.com/tech/Generation_of_Wild-Type_Dengue_Viruses_for_Use_in_Rhesus_Monkey_Infection_StudiesDengue virus is a positive-sense RNA virus belonging to the Flavivirus genus of the family Flaviviridae. Dengue virus is widely distributed throughout the tropical and semitropical regions of the world and is transmitted to humans by mosquito vectors. Dengue virus is a leading cause of hospitalization and death in children in at least eight tropical Asian countries. There are four serotypes of dengue virus (DEN-1, DEN-2, DEN-3, and DEN-4) that annually cause an estimated 50-100 million cases of dengue fever and 500,000 cases of the more severe form of dengue virus infection known as dengue ...Tue, 06 Dec 2022 11:51:58 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Generation_of_Wild-Type_Dengue_Viruses_for_Use_in_Rhesus_Monkey_Infection_StudiesTAB-1734https://nih.technologypublisher.com/tech/Nitrite_and_Nitrite-Methemoglobin_Therapy_to_Detoxify_Stroma-Free_Hemoglobin_Based_Blood_SubstitutesCell-free hemoglobin based oxygen carriers (HBOCs) are blood substitutes and resuscitative agents that can be used to replace whole blood donations, alleviate blood shortages and reduce the risks of infections such as HIV and hepatitis. Stroma-free HBOCs offer the advantages of increased stability, consistency of supply, and reduced immunogenicity over the use of the alternative cell based sources. However, the side effects associated with their use, including vascular toxicity, pulmonary and systemic hypertension, myocardial infarction, inflammation, and platelet aggregation severely limit ...Tue, 06 Dec 2022 11:51:57 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Nitrite_and_Nitrite-Methemoglobin_Therapy_to_Detoxify_Stroma-Free_Hemoglobin_Based_Blood_SubstitutesTAB-2993https://nih.technologypublisher.com/tech/Metallic_Nanoparticles_for_Photothermal_TherapyThe invention relates to the preparation and application of 20-150nm metallic nanoparticulate vesicles for photothermal anti-cancer therapy. The vesicles comprise metallic nanoparticles covalently bound to a hydrophilic and hydrophobic polymer. The preparation method generally entails dispersing a polymer-bound metallic nanoparticle in an organic solvent, adding an aqueous solution with a dispersing aid, sonicating the mixture, and finally removing the organic solvent until the vesicle forms. The final vesicle is stable wherein the metallic nanoparticle is covalently bound to the hydrophobi...Tue, 06 Dec 2022 11:51:56 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Metallic_Nanoparticles_for_Photothermal_TherapyTAB-3014https://nih.technologypublisher.com/tech/Albumin_Binding_Immunomodulatory_CompositionsThe invention relates to molecules wherein Evan’s Blue dye is chemically conjugated to CpG Oligonucleotides that elicit anti-tumoral or infection fighting immunity. Evans Blue, a symmetric azo dye, has high binding affinity to albumin. Albumin binding ability of Evans blue is utilized with CpGs and tumor-specific antigens, in order to leverage endogenous albumin that increases the safety and the potency of molecular vaccines. As such, the molecular entities provided here enable efficient delivery and prolonged retention in lymph nodes and reduce systemic toxicity of Evans Blue and enhanced the...Tue, 06 Dec 2022 11:51:54 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Albumin_Binding_Immunomodulatory_CompositionsTAB-1720https://nih.technologypublisher.com/tech/HIV_Monoclonal_AntibodiesThis technology describes several hybridomas that produce monoclonal antibodies (mAbs) useful in HIV research applications. The mAbs are specific for either gp41 or gp120. In particular, the hybridomas producing mAbs designated D19, D56, M12, T8 and T24 (all anti-gp120), and T32 and T33 (gp41 specific) were found to be of particular utility. Additional hybridomas expressing mAbs disclosed in the publications may also be available.Tue, 06 Dec 2022 11:51:52 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/HIV_Monoclonal_AntibodiesTAB-1717https://nih.technologypublisher.com/tech/PSM_Peptides_as_Vaccine_Targets_Against_Methicillin-Resistant_Staphylococcus_aureusAvailable for licensing and commercial development are compositions and methods for the treatment and inhibition of Methicillin-resistant Staphylococcus aureus (MRSA), a dangerous human pathogen. The invention concerns immunogenic peptides that can be used to induce protective immunity against MRSA, including phenol-soluble modulin (PSM) peptides. In addition to the MRSA infections that occur in immunocompromised patients in hospitals, new MRSA strains have recently emerged that can cause severe infections (such as necrotizing fasciitis) or death in otherwise healthy adults. These strains are...Tue, 06 Dec 2022 11:51:50 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/PSM_Peptides_as_Vaccine_Targets_Against_Methicillin-Resistant_Staphylococcus_aureusTAB-1716https://nih.technologypublisher.com/tech?title=Eeyarestatins%3a_Novel_Deubiquitination_Inhibitors_for_the_Treatment_of_Drug-Resistant_CancersThe ubiquitin-proteasome system has recently been recognized to play a central role in tumor biology. Bortezomib, an inhibitor of the chymotrypsin-like activity of the proteasome, has clinical activity in a variety of hematologic malignancies and is FDA approved for use in Multiple Myeloma and Mantle Cell Lymphoma. The present invention for the first time describes that Eeyarestatins, a new class of small molecules, are potential anti-cancer agents. The compounds inhibit the deubiquitination of proteins by targeting the deubiquitination enzymes in the protein degradation pathway. More spec...Tue, 06 Dec 2022 11:51:49 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech?title=Eeyarestatins%3a_Novel_Deubiquitination_Inhibitors_for_the_Treatment_of_Drug-Resistant_CancersTAB-1711https://nih.technologypublisher.com/tech/A_Fold-Back_Diabody_Format_for_Diphtheria_Toxin-Based_Immunotoxins_That_Can_Increase_Binding_and_PotencyNIH inventors, in collaboration with Scott and White Memorial Hospital inventors, have developed new immunotoxins comprising a mutant diphtheria toxin linked to an anti-prostate specific membrane antigen (PSMA) fold-back diabody. The fold-back diabody construct has a shortened linker region between the heavy and light chains of the antibody variable domain. This construct allows interactions between the longer-linked variable domains while preventing interactions between the shorter-linked variable domains. This results in increased efficiency of epitope recognition and delivery to the appr...Tue, 06 Dec 2022 11:51:47 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/A_Fold-Back_Diabody_Format_for_Diphtheria_Toxin-Based_Immunotoxins_That_Can_Increase_Binding_and_PotencyTAB-1708https://nih.technologypublisher.com/tech/The_Use_of_alpha-4_beta-7_integrin_Inhibitors_to_Inhibit_HIV_Transmission_and_InfectionThis invention involves the use of inhibitors of alpha-4 beta-7 (a4b7) integrin to inhibit HIV transmission/infection, as a prophylactic to inhibit onset of the acute stage of HIV infection or to treat HIV infection. The a4b7 integrin inhibitors were previously developed for use in other diseases, such as multiple sclerosis or inflammatory bowel disease. a4b7 integrin is a multifaceted target for HIV infection and recent studies indicate that it is important for establishing HIV infection through multiple paths. Studies indicate that: 1) CD4 T-cells present in vaginal and anal mucosa have hig...Tue, 06 Dec 2022 11:51:46 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/The_Use_of_alpha-4_beta-7_integrin_Inhibitors_to_Inhibit_HIV_Transmission_and_InfectionTAB-1707https://nih.technologypublisher.com/tech/Recombinant_Modified_Bacillus_anthracis_Protective_Antigen_for_Use_in_VaccinesThis invention relates to improved methods of preparing Bacillus anthracis protective antigen (PA) for use in vaccines. PA is a secreted, non-toxic protein with a molecular weight of 83 KDa. PA is a major component of the currently licensed human vaccine (Anthrax Vaccine Adsorbed, AVA). Although the licensed human vaccine has been shown to be effective against cutaneous anthrax infection in animals and humans and against inhalation anthrax in rhesus monkeys, the licensed vaccine has several limitations: (1) AVA elicits a relatively high degree of local and systemic adverse reactions, probably ...Tue, 06 Dec 2022 11:51:45 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Recombinant_Modified_Bacillus_anthracis_Protective_Antigen_for_Use_in_VaccinesTAB-1698https://nih.technologypublisher.com/tech/Chimeric_SHIV_Gag_Proteins_Optimize_T-Cell_Response_Against_HIV_GagHIV Gag has been included in nearly all HIV vaccines entering clinical trials because of its importance in SIV models and its correlation with protection in HIV-infected long-term non-progressors. However, HIV Gag has proven less immunogenic than Env in phase I clinical trial studies. Through sequence comparison, two regions in HIV Gag have been identified as contributing to the decreased immunogenicity observed for HIV Gag. Replacement of these regions with corresponding SIV sequences significantly increased the resulting T-cell response to HIV Gag in mice. Utilization of these chimera in an ...Tue, 06 Dec 2022 11:51:42 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Chimeric_SHIV_Gag_Proteins_Optimize_T-Cell_Response_Against_HIV_GagTAB-1694https://nih.technologypublisher.com/tech/Aquaporin_2_Polyclonal_AntibodiesAquaporins, also known as water channels, form pores in cell membranes and selectively transport water in and out of the cell. Aquaporins are involved in regulation of water balance and blood pressure, and thirteen different isoforms have been found in mammals. Aquaporin 2 (AQP2) is located in the collecting duct of the kidney, and is regulated by the peptide hormone vasopressin. AQP2 expression is increased in conditions where there is water retention, such as pregnancy and congestive heart failure, and mutations of AQP2 are associated with nephrogenic diabetes insipidus. Also, lithium tr...Tue, 06 Dec 2022 11:51:38 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Aquaporin_2_Polyclonal_AntibodiesTAB-1685https://nih.technologypublisher.com/tech?title=Hybridoma_C4H3%2c_Monoclonal_Antibody_to_a_Specific_Peptide-MHC_Class_II_ComplexT lymphocytes play an important role in the immune system by recognizing foreign protein motifs on cells. T lymphocytes are stimulated to recognize these motifs through their interactions with peptide-MHC complexes (pMHC). Thus, studying pMHC is an important aspect of understanding how the immune system works, particularly with regard to the development of vaccines. Unfortunately, the detection of pMHC is largely dependent on indirect assays, due to the difficulty of producing antibodies for specific pMHC. This invention regards the development of hybridomas (C4H3) for the production of ant...Tue, 06 Dec 2022 11:51:34 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech?title=Hybridoma_C4H3%2c_Monoclonal_Antibody_to_a_Specific_Peptide-MHC_Class_II_ComplexTAB-1678https://nih.technologypublisher.com/tech/Cell-Nanofiber_Composite_and_Cell-Nanofiber_Composite_Amalgam_Based_Engineered_Intervertebral_DiscDiseased or damaged musculoskeletal tissues are often replaced by an artificial material, cadaver tissue or donated, allogenic tissue. Tissue engineering offers an attractive alternative whereby a live, natural tissue is generated from a construct made up of a patient’s own cells or an acceptable/compatible cell source in combination with a biodegradable scaffold for replacement of defective tissue. Degeneration of the intervertebral disc (IVD) is a common and significant source of morbidity in our society. Approximately 8 of 10 adults at some point in their life will experience an episode o...Tue, 06 Dec 2022 11:51:32 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Cell-Nanofiber_Composite_and_Cell-Nanofiber_Composite_Amalgam_Based_Engineered_Intervertebral_DiscTAB-3127https://nih.technologypublisher.com/tech/Efficient_mRNA-Based_Genetic_Engineering_of_Human_NK_Cells_with_High-Affinity_CD16_and_CCR7A highly efficient method to genetically modify natural killer (NK) cells to induce expression of high affinity CD16 (HA-CD16) through mRNA electroporation, to potentiate NK cell-mediated antibody-dependent cellular cytotoxicity (ADCC). ADCC is mediated by CD16+ NK cells following adoptive NK cell transfer, but most humans express CD16 which has a relatively low affinity for IgG1 antibodies. However, a single nucleotide polymorphism (SNP rs396991) in the CD16 gene, resulting in an amino acid substitution at position 158 (F158V), is associated with substantially higher affinity and superior NK ...Tue, 06 Dec 2022 11:51:29 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Efficient_mRNA-Based_Genetic_Engineering_of_Human_NK_Cells_with_High-Affinity_CD16_and_CCR7TAB-1669https://nih.technologypublisher.com/tech?title=Novel_Roles_of_a_DNA_Repair_Protein%2c_DNA-PKcs%2c_in_Obesity%2c_Neurological_Function%2c_and_AgingThe catalytic subunit of the DNA-dependent protein kinase complex (DNA-PKcs) has been shown to be important in DNA repair and VDJ recombination in lymphocytes. The inventors have discovered that DNA-PKcs also plays novel, important roles in energy regulation and neurological function. The inventors observed that mature DNA-PKcs-deficient mice (also known as SCID mice) have a lower proportion of fat, resist obesity, and have significantly greater physical endurance than wild-type control mice, particularly with increasing age. The inventors also observed that DNA-PKcs-deficient mice have bet...Tue, 06 Dec 2022 11:51:26 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech?title=Novel_Roles_of_a_DNA_Repair_Protein%2c_DNA-PKcs%2c_in_Obesity%2c_Neurological_Function%2c_and_AgingTAB-1646https://nih.technologypublisher.com/tech/Hepatitis_C_Virus_Cell_Culture_SystemHepatitis C virus (HCV) infection causes chronic liver disease and is a major global health problem with an estimated 170 million people affected worldwide and 3-4 million new cases every year. Therapeutic advances will be greatly aided by the ability of researchers to successfully replicate and characterize the virus in vitro. The study of HCV replication has, however, been hindered by the lack of an efficient virus culture system. One approach, using cell culture adaptive mutations in the viral RNA has been found to significantly enhance HCV virus production, but it has been difficult to ...Tue, 06 Dec 2022 11:51:24 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Hepatitis_C_Virus_Cell_Culture_SystemTAB-1611https://nih.technologypublisher.com/tech/Collagen-Induced_Platelet_Aggregation_Inhibitor_from_Mosquito_Salivary_GlandsExposed collagen in injured blood vessels provides a substrate for platelets to adhere and aggregate initiating the first step in thrombosis, the formation of blood clots inside a blood vessel. Despite the essential role of platelets in vascular injury, excessive platelet aggregation may also result in thrombotic diseases such as stroke and heart attack. Available for licensing is a collagen binding protein, named aegyptin, which selectively inhibits collagen-platelet aggregation, but not platelet aggregation induced by other agonists. Collagen initiates recruitment of circulating platelets ...Tue, 06 Dec 2022 11:51:20 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Collagen-Induced_Platelet_Aggregation_Inhibitor_from_Mosquito_Salivary_GlandsTAB-1610https://nih.technologypublisher.com/tech/Chlamydia_VaccineChlamydia trachomatis is an obligate intracellular bacterial pathogen that colonizes and infects oculogenital mucosal surfaces. The organism exists as multiple serovariants that infect millions of people worldwide. Ocular infections cause trachoma, a chronic follicular conjunctivitis that results in scarring and blindness. The World Health Organization estimates that 300–500 million people are afflicted by trachoma, making it the most prevalent form of infectious preventable blindness. Urogenital infections are the leading cause of bacterial sexually transmitted disease in both industriali...Tue, 06 Dec 2022 11:51:18 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Chlamydia_VaccineTAB-1608https://nih.technologypublisher.com/tech/Monoclonal_Antibodies_Against_Dengue_and_Other_Viruses_With_Deletion_in_Fc_RegionThe four dengue virus (DENV) serotypes (DENV-1 to DENV-4) are the most important arthropod-borne flaviviruses in terms of morbidity and geographic distribution. Up to 100 million DENV infections occur every year, mostly in tropical and subtropical areas where vector mosquitoes are abundant. Infection with any of the DENV serotypes may be asymptomatic or may lead to classic dengue fever or more severe dengue hemorrhagic fever (DHF) and dengue shock syndrome (DSS), which are increasingly common in the dengue endemic areas. Immunity to the same virus serotype (homotypic immunity) is life-long,...Tue, 06 Dec 2022 11:51:17 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Monoclonal_Antibodies_Against_Dengue_and_Other_Viruses_With_Deletion_in_Fc_RegionTAB-1605https://nih.technologypublisher.com/tech/Probe_Set_Global_OptimizationAvailable for licensing and commercial development are methods to optimize sequence-based assays such as microarrays, multiplexed PCR or multiplexed antibody methods. This computational method uses numerical optimization to identify an optimal probe set to be used in an assay for the measurement of a specified set of targets. The method incorporates the sequence information of the target (protein, DNA, RNA or other polymer), the assay characteristics, limits on probe set size and assay probe length in its optimization. The method selectively optimizes the total information provided by the a...Tue, 06 Dec 2022 11:51:14 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Probe_Set_Global_OptimizationTAB-1604https://nih.technologypublisher.com/tech/Recombinant_Baculoviruses_Containing_Inserts_of_the_Major_Structural_Genes_(vp1)_of_the_Human_Polyomaviruses_JCV_and_BKVThe development of sensitive and specific tests for JC virus and BK virus activity may provide tools essential in the steps required to find a treatment for these fatal infections. This invention describes a Recombinant Vpl protein (rVp1) that can be used 1) as an antigen source for ELISA assays 2) for studies of viral proteins in cells and 3) for the self assembly of icosahedral particles encapsidating DNA [gene expression of choice in range of up to 5.1kb size gene]. rVp1 can be utilized in ELISA assays to detect both JCV and BKV antibodies. The JCV and BKV rVp1 proteins may serve as anti...Tue, 06 Dec 2022 11:51:12 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Recombinant_Baculoviruses_Containing_Inserts_of_the_Major_Structural_Genes_(vp1)_of_the_Human_Polyomaviruses_JCV_and_BKVTAB-1602https://nih.technologypublisher.com/tech/Neutralizing_Monoclonal_Antibodies_to_Respiratory_Syncytial_VirusRespiratory syncytial virus (RSV) is the most common cause of bronchiolitis and pneumonia among infants and children under 1 year of age. Illness begins most frequently with fever, runny nose, cough, and sometimes wheezing. During their first RSV infection, between 25% and 40% of infants and young children have signs or symptoms of bronchiolitis or pneumonia, and 0.5% to 2% require hospitalization. Most children recover from illness in 8 to 15 days. The majority of children hospitalized for RSV infection are under 6 months of age. RSV also causes repeated infections throughout life, usual...Tue, 06 Dec 2022 11:51:10 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Neutralizing_Monoclonal_Antibodies_to_Respiratory_Syncytial_VirusTAB-1601https://nih.technologypublisher.com/tech/Monoclonal_Antibodies_Against_OrthopoxvirusesConcerns that variola (smallpox) virus might be used as a biological weapon have led to the recommendation of widespread vaccination with vaccinia virus. While vaccination is generally safe and effective for prevention of smallpox, it is well documented that various adverse reactions in individuals have been caused by vaccination with existing licensed vaccines. Vaccinia immune globulin (VIG) prepared from vaccinated humans has historically been used to treat adverse reactions arising from vaccinia immunization. However, VIG lots may have different potencies and carry the potential to trans...Tue, 06 Dec 2022 11:51:09 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Monoclonal_Antibodies_Against_OrthopoxvirusesTAB-2984https://nih.technologypublisher.com/tech/Mouse_Model_for_Study_of_Diabetic_Nephropathy_and_Role_of_Soluble_Epoxide_HydrolaseDiabetic nephropathy (DN) is the leading cause of renal failure and is characterized by proteinuria that progresses to renal inflammation and decline in the glornerular filtration barrier (GFB). Podocytes are specialized epithelia cells in the glomerular capsule that have a role in filtration of blood and maintaining the integrity of the GFB; dysfunction of these cells plays a significant role in the pathogenesis of DN. Soluble epoxide hydrolase (sEH) is a cytosolic enzyme whose inhibition has beneficial effects in inflammatory diseases. In the present invention, mice with a podocyte-specifi...Tue, 06 Dec 2022 11:51:07 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Mouse_Model_for_Study_of_Diabetic_Nephropathy_and_Role_of_Soluble_Epoxide_HydrolaseTAB-1591https://nih.technologypublisher.com/tech/Targeting_Poly-Gamma-Glutamic_Acid_to_Treat_Staphylococcus_Epidermidis_and_Related_InfectionsOver the past decade, Staphylococcus epidermidis has become the most prevalent pathogen involved in nosocomial infections. Usually an innocuous commensal microorganism on human skin, this member of the coagulase-negative group of staphylococci can cause severe infection after penetration of the epidermal protective barriers of the human body. In the U.S. alone, S. epidermidis infections on in-dwelling medical devices, which represent the main type of infection with S. epidermidis, cost the public health system approximately $1 billion per year. Importantly, S. epidermidis is frequently resista...Tue, 06 Dec 2022 11:51:05 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Targeting_Poly-Gamma-Glutamic_Acid_to_Treat_Staphylococcus_Epidermidis_and_Related_InfectionsTAB-1589https://nih.technologypublisher.com/tech?title=A_Shuttle_Plasmid%2c_Recombinant_MVA%2fHIV1_Clinical_Vaccine_Constructs_and_a_Mechanism_for_Enhanced_Stability_of_Foreign_Gene_Inserts_by_Codon_Alternation_and_for_Insertion_of_the_Foreign_Gene_Between_Two_Vaccinia_Virus_Essential_GenesSince the onset of the AIDS epidemic more than two decades ago, enormous efforts have been directed to making a vaccine that will protect against human immunodeficiency virus-1 (HIV); an effective vaccine is thought to require the induction of cellular and humoral responses. Vaccine candidates have included a variety of HIV immunogens delivered as DNA, attenuated poxviruses, adenoviruses, vesicular stomatitis virus, proteins, and various combinations thereof. The inventors' efforts to design an HIV vaccine have focused on modified vaccinia virus Ankara (MVA) as a vector. The patent applicati...Tue, 06 Dec 2022 11:51:03 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech?title=A_Shuttle_Plasmid%2c_Recombinant_MVA%2fHIV1_Clinical_Vaccine_Constructs_and_a_Mechanism_for_Enhanced_Stability_of_Foreign_Gene_Inserts_by_Codon_Alternation_and_for_Insertion_of_the_Foreign_Gene_Between_Two_Vaccinia_Virus_Essential_GenesTAB-1588https://nih.technologypublisher.com/tech/Device_and_Method_for_Protecting_Against_Coronary_Artery_Compression_During_Transcatheter_Mitral_Valve_AnnuloplastyCatheter-based mitral valve regurgitation treatments that use a coronary sinus trajectory or coronary sinus implant can have unwanted effects because the coronary sinus and its branches have been found to cross the outer diameter of major coronary arteries in a majority of humans. As a result, pressure applied by any prosthetic device in the coronary sinus (such as tension on the annuloplasty device) can compress the underlying coronary artery and induce myocardial ischemia or infarction. Available for licensing and commercial development are devices and methods that avoid constricting coron...Tue, 06 Dec 2022 11:51:02 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Device_and_Method_for_Protecting_Against_Coronary_Artery_Compression_During_Transcatheter_Mitral_Valve_AnnuloplastyTAB-1585https://nih.technologypublisher.com/tech/Development_of_Dengue_Virus_Type_3_Vaccine_CandidatesThe disease burden associated with dengue virus infection has increased over the past several decades in the tropical and semi-tropical regions of the world, where over 2 billion people live at risk of dengue infection. Annually, there are an estimated fifty (50) to one hundred (100) million cases of dengue fever, making development of an effective vaccine a priority. In addition, there is a need for a "travelers vaccine" to protect those visiting dengue virus endemic areas, similar in scope to other currently available "travelers vaccines", such as hepatitis A vaccine. The previously identi...Tue, 06 Dec 2022 11:51:00 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Development_of_Dengue_Virus_Type_3_Vaccine_CandidatesTAB-1580https://nih.technologypublisher.com/tech?title=Monoclonal_Antibodies_that_Neutralize_%3ci%3eB._anthracis%3c%2fi%3e_Protective_Antigen_(PA)%2c_Lethal_Factor_(LF)_and_Edema_Factor_(EF)Anthrax, whether resulting from natural or bioterrorist-associated exposure, is a constant threat to human health. The lethality of anthrax is primarily the result of the effects of anthrax toxin, which has 3 components: a receptor-binding protein known as "protective antigen" (PA) and 2 catalytic proteins known as "lethal factor" (LF) and "edema factor" (EF). Although production of an efficient anthrax vaccine is an ultimate goal, the benefits of vaccination can be expected only if a large proportion of the population at risk is immunized. The low incidence of anthrax suggests that large-s...Tue, 06 Dec 2022 11:50:58 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech?title=Monoclonal_Antibodies_that_Neutralize_%3ci%3eB._anthracis%3c%2fi%3e_Protective_Antigen_(PA)%2c_Lethal_Factor_(LF)_and_Edema_Factor_(EF)TAB-1574https://nih.technologypublisher.com/tech/Mice_Genetically_Deficient_in_the_Chemoattractant_Receptor_FPR_(formyl_peptide_receptor)The present research tool is a knockout mouse model (FPR-/-) that lacks the high affinity N-formylpeptide receptor (FPR), created by targeted gene disruption. N-formylpeptides derive from bacterial and mitochondrial proteins, and bind to specific receptors on mammalian phagocytes. Since binding induces chemotaxis and activation of phagocytes in vitro, it has been postulated that N-formylpeptide receptor signaling in vivo may be important in antibacterial host defense, although direct proof has been lacking. The inventors have found that FPR-/- mice have no obvious developmental defects and d...Tue, 06 Dec 2022 11:50:55 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Mice_Genetically_Deficient_in_the_Chemoattractant_Receptor_FPR_(formyl_peptide_receptor)TAB-1571https://nih.technologypublisher.com/tech/Methods_of_Inducing_Immune_Tolerance_Using_ImmunotoxinsThe invention concerns immunotoxins and methods of using the immunotoxins for the treatment of rejection response in a patient, including graft-versus-host disease and transplantation of organs, tissues and cells into a host. In a specific embodiment of the invention, the transplant involves pancreatic islet cells. The immunotoxins are targeted via an antibody that is specific to T cells. This allows the specific ablation of resting T cells, resulting in an accentuation of immune tolerizing responses and an increased tolerance to transplants and grafts. The toxin portion of the immunotoxin...Tue, 06 Dec 2022 11:50:54 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Methods_of_Inducing_Immune_Tolerance_Using_ImmunotoxinsTAB-1572https://nih.technologypublisher.com/tech/Methods_for_Expression_and_Purification_of_ImmunotoxinsThe invention concerns immunotoxins and methods of making the immunotoxins. Targeting of the immunotoxins occurs via an antibody that is specific to T cells. This allows the specific ablation of malignant T cells and resting T cells. The transient ablation of resting T cells can "reset" the immune system by accentuating tolerizing responses. As a result, the immunotoxin can be used to treat autoimmune disease, malignant T cell-related cancers, and graft-versus-host disease. The toxin portion of the immunotoxin is engineered to maintain bioactivity when produced in yeast, specifically Pich...Tue, 06 Dec 2022 11:50:52 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Methods_for_Expression_and_Purification_of_ImmunotoxinsTAB-1566https://nih.technologypublisher.com/tech/Total_Emission_Detection_System_for_Multi-Photon_MicroscopyAvailable for licensing and commercial development is a novel two-photon microscope system, which would allow improved fluorescent light collection, the use of less excitation power and deeper penetration of tissue and isolated cells. Multi-photon fluorescence microscopy (MPFM) is an imaging technique that can investigate biological processes to sub-cellular resolution at depths of hundreds of microns below the surface of biological tissues. MPFM provides higher resolution imaging of tissues than confocal imaging, but is currently limited by the use of inefficient light collection systems, w...Tue, 06 Dec 2022 11:50:49 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Total_Emission_Detection_System_for_Multi-Photon_MicroscopyTAB-1563https://nih.technologypublisher.com/tech/Immunotoxin_with_in-vivo_T_cell_Suppressant_ActivityThe invention concerns immunotoxins and methods of using the immunotoxins for the treatment of autoimmune diseases and T cell malignancies. The immunotoxins are targeted via an antibody that is specific to T cells. This allows the specific ablation of malignant T cells and resting T cells. The transient ablation of resting T cells can "reset" the immune system by accentuating tolerizing responses. The toxin portion of the immunotoxin is genetically engineered to maintain bioactivity when recombinantly produced in Pichia pastoris. Data are available in transgenic animals expressing human C...Tue, 06 Dec 2022 11:50:46 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Immunotoxin_with_in-vivo_T_cell_Suppressant_ActivityTAB-1556https://nih.technologypublisher.com/tech/Diagnostic_and_Therapeutic_Use_of_Brother_of_the_Regulator_of_Imprinted_Sites_(BORIS)_Alternative_Splice_FormsThis technology identifies twenty five (25) new alternatively spliced transcripts of the BORIS gene. The transcripts lead to the expression of seventeen different protein isoforms with variable N- and C-termini encoded by BORIS gene locus. Differential expression levels of BORIS isoforms were observed in different cancers. While some BORIS alternative splice variants were expressed at different levels in all types of cancers, other expressed forms are specific to particular cancer(s).Tue, 06 Dec 2022 11:50:42 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Diagnostic_and_Therapeutic_Use_of_Brother_of_the_Regulator_of_Imprinted_Sites_(BORIS)_Alternative_Splice_FormsTAB-1549https://nih.technologypublisher.com/tech/Retrovirus_Packaging_Cell_Lines_Based_on_Gibbon_Ape_Leukemia_VirusGene therapy and gene transfer have recently been recognized as effective therapeutic tools to combat diseases. Accordingly, market demands for vectors and carriers to facilitate such interventions have surged in recent years. Retroviral vectors provide an efficient and safe means of gene transfer to eukaryotic cells. The present invention relates to genetic engineering involving retrovirus packaging cells that produce retroviral vectors. Specifically, the invention involves the expression plasmids encoding the envelop glycoproteins of a family of primate type C retrovirus, namely, the Gibbon ...Tue, 06 Dec 2022 11:50:40 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Retrovirus_Packaging_Cell_Lines_Based_on_Gibbon_Ape_Leukemia_VirusTAB-2959https://nih.technologypublisher.com/tech?title=Estrogen-related_Receptor_(ERR)_and_Proliferator-activated_Receptor_Gamma_Coactivator_(PGC)%2fERR_Reporter_Stable_Cell_LinesThe estrogen-related receptor alpha (ERRalpha) and proliferator-activated-receptor-gamma coactivator-1alpha (PGC-1alpha) play major roles in transcriptional control of cellular energy metabolism. In particular ERRs are required for the response to various environmental challenges that require high energy levels by the organism. As central regulators of energy homeostasis, ERRs may also implicate in the etiology of metabolic disorders, such as type 2 diabetes and metabolic syndrome. This invention, using a lentivirus delivery system, generated HEK293T cells lines stably expressing a Lucifera...Tue, 06 Dec 2022 11:50:36 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech?title=Estrogen-related_Receptor_(ERR)_and_Proliferator-activated_Receptor_Gamma_Coactivator_(PGC)%2fERR_Reporter_Stable_Cell_LinesTAB-1531https://nih.technologypublisher.com/tech?title=Antibodies_Against_TL1A%2c_a_TNF-Family_Cytokine%2c_for_the_Treatment_and_Diagnosis_of_Autoimmune_Inflammatory_DiseasesAutoimmune inflammatory diseases occur in greater than five percent of the United States population; this disease group includes asthma, multiple sclerosis, rheumatoid arthritis, and lupus. Treatments generally include immunosuppressants or anti-inflammatory drugs, which can have serious side effects; recently, more specific immunomodulatory therapies such as TNF-alpha antagonists have been developed. In experiments with mice, NIAMS inventors have shown that the interaction between the TNF family ligand TL1A with its receptor, DR3, is critical for development of disease in asthma, inflammato...Tue, 06 Dec 2022 11:50:34 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech?title=Antibodies_Against_TL1A%2c_a_TNF-Family_Cytokine%2c_for_the_Treatment_and_Diagnosis_of_Autoimmune_Inflammatory_DiseasesTAB-1519https://nih.technologypublisher.com/tech/Codon_Optimized_Genes_for_Subunit_VaccinesAvailable for licensing from the NIH are gene constructs that express immunogenic proteins based on viral genes that have been optimized for expression in mammalian cells. Using vaccine vectors expressing respiratory syncytial virus (RSV) proteins from the optimized genes, this technology was shown to result in a potent RSV-specific cellular immune responses with favorable phenotypic patterns. This technology was shown to generate a superior immune (both humoral and cellular) response when utilized as part of a heterologous vector prime-boost regimen. Such optimized genes could be an import...Tue, 06 Dec 2022 11:50:31 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Codon_Optimized_Genes_for_Subunit_VaccinesTAB-1517https://nih.technologypublisher.com/tech/High_Level_Expression_and_Purification_of_Untagged_and_Histidine-tagged_Human_Immunodeficiency_Virus_Type-1_Reverse_TranscriptaseHuman immunodeficiency virus type-1 reverse transcriptase (HIV-1 RT) gene encodes 560 amino acids. In the virus, however, HIV-1 RT occurs as a dimer of two related polypeptides, p66 and p51 subunits at a molar ratio of 1:1. The p51 subunit is derived from a C-terminal proteolytic cleavage of the p66 subunit. This invention describes a simplified protocol to purify large quantities of histidine-tagged and untagged heterodimeric forms of human immunodeficiency virus type-1 reverse transcriptase (HIV-1 RT) from Escherichia coli. The coding sequences of p66 and p51 subunits of RT were placed in ex...Tue, 06 Dec 2022 11:50:30 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/High_Level_Expression_and_Purification_of_Untagged_and_Histidine-tagged_Human_Immunodeficiency_Virus_Type-1_Reverse_TranscriptaseTAB-1514https://nih.technologypublisher.com/tech/Serotonin-Deficient_Knock-out_MouseSerotonin is an important modulator of many developmental, behavioral, and physiological processes, and it has been implicated in depression, anxiety, schizophrenia, obsessive compulsive disorders, and substance abuse. Serotonin’s pharmacology is extremely complex and it is mediated by seven of serotonin receptor subtypes and it is present in several tissues. Although it has been a subject of a number of studies, its role has been difficult to ascertain. To investigate the role of serotonin in these disorders, the murine gene was disrupted by homologous recombination. Results indicate that ser...Tue, 06 Dec 2022 11:50:29 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Serotonin-Deficient_Knock-out_MouseTAB-1515https://nih.technologypublisher.com/tech/Fluorescent_Intracellular_Calcium_IndicatorsCalcium is a key element in the regulation of many cellular processes, including muscle contraction, hormone excretion from gland cells, neurotransmitter release from nerve synapses, and the regulation of cellular metabolism. Elevated calcium levels are found in a number of diseases. The present invention relates to chromophoric or fluorescent dye calcium indicators that are superior for measurement of high concentrations of calcium ions due to their high dissociation constants. As a result of the high calcium ion dissociation constants, the perturbation resulting from introducing the indica...Tue, 06 Dec 2022 11:50:28 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Fluorescent_Intracellular_Calcium_IndicatorsTAB-3084https://nih.technologypublisher.com/tech/Non-invasive_Pan-Cancer_Detection_MethodOne of four deaths in the United States is due to cancer despite an emphasis on prevention, early detection, and treatment that has lowered cancer death rates by 20% in the past two decades. Further improvements in survival rates are likely to come from improving the limits of detection sensitivity at earlier stages of cancer. New approaches that rely heavily on genomic information, however, may change future testing strategies. This invention is a method for detecting the presence of cancer in an individual by detecting the methylation state of a region in the promoter of the ZNF154 gene. A ...Tue, 06 Dec 2022 11:50:26 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Non-invasive_Pan-Cancer_Detection_MethodTAB-3113https://nih.technologypublisher.com/tech/Simple_and_Rapid_Assay_to_Detect_Acute_Subtype_B_and_Group_M_HIV-1_InfectionsWithin recent years, point-of-care (POC) testing has allowed for many individuals to be screened for and provided with HIV test results. It is critical to be able to accurately detect acute HIV infections as this is a stage where the risk of transmission is great. Additionally, early HIV detection could lead to less high-risk behavior, thereby reducing transmission. Currently, there are no rapid, cost-effective diagnostic tests sensitive enough to detect acute HIV-1 infections for the POC setting. Researchers at the CDC have developed an HIV-1 detection assay using reverse-transcription loop-m...Tue, 06 Dec 2022 11:50:24 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Simple_and_Rapid_Assay_to_Detect_Acute_Subtype_B_and_Group_M_HIV-1_InfectionsTAB-1506https://nih.technologypublisher.com/tech/Novel_System_for_HIV-1_Vaccine_DevelopmentThe available technologies describe specific immunogenic peptides, peptide modifications and methods for identifying additional immunogens against HIV-1 surface proteins, gp120 and gp41. Additionally, detailed methods for use of the described immunogenic peptides in the development of vaccines and diagnostics for HIV-1 are disclosed. The current technologies further include a comprehensive system for immunogen design, comprising in silico design coupled to feedback from X-ray crystallography, antigenic analysis, and immunization. The described methodology demonstrates how to transplant a giv...Tue, 06 Dec 2022 11:50:23 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Novel_System_for_HIV-1_Vaccine_DevelopmentTAB-1503https://nih.technologypublisher.com/tech?title=Model_for_Study_of_Glomerular_Disorders%3a_Conditionally-Immortalized_Mouse_Podocyte_Cell_Line_with_Tet-on-Regulated_Gene_ExpressionPodocytes, cells of the visceral epithelium in the kidneys, are a key component of the glomerular filtration barrier. As such, they play a vital role in glomerular disorders, which are a major cause of chronic kidney disease. Examples of these disorders include focal segmental glomerulosclerosis, membranous glomerulonephritis, minimal change disease, and diabetic nephropathy. The inventors have developed a conditionally-immortalized mouse podocyte cell line with tightly controlled conditional gene expression. The cell line has been conditionally immortalized through the introduction of the ...Tue, 06 Dec 2022 11:50:22 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech?title=Model_for_Study_of_Glomerular_Disorders%3a_Conditionally-Immortalized_Mouse_Podocyte_Cell_Line_with_Tet-on-Regulated_Gene_ExpressionTAB-1501https://nih.technologypublisher.com/tech/A_Varicella-Zoster_Virus_Mutant_that_is_Markedly_Impaired_for_Latent_Infection_Available_for_the_Development_of_Shingles_Vaccines_and_DiagnosticsReactivation of latent Varicella-Zoster virus (VZV) infection is the cause of shingles, which is prominent in adults over the age of 60 and individuals who have compromised immune systems, due to HIV infection, cancer treatment and/or transplant. Shingles is a worldwide health concern that affects approximately 600,000 Americans each year. The incidence of shingles is also high in Europe, South America, and India; the latter having an estimated two million individuals affected, yearly. Recent research studies show that VZV vaccines have a significant effect on decreasing the incidence of sh...Tue, 06 Dec 2022 11:50:21 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/A_Varicella-Zoster_Virus_Mutant_that_is_Markedly_Impaired_for_Latent_Infection_Available_for_the_Development_of_Shingles_Vaccines_and_DiagnosticsTAB-1492https://nih.technologypublisher.com/tech/Enriched_Natural_Killer_Cells_for_Adoptive_Infusion_Cancer_TherapyImmuno-therapy has taken a lead among the new cancer therapeutic approaches. It is one of the most promising new therapeutic approaches that exploit the innate immune mechanism of an individual to fight against a certain disease. Natural killer (NK) cells are a form of cytotoxic lymphocytes which constitute a major portion of the innate immune system. NK cells have tumor cytotoxic properties independent of tumor specific antigens and have been shown in murine models to control and prevent tumor growth and dissemination. Inactivation of NK cells potentially allows cancer cells to evade host N...Tue, 06 Dec 2022 11:50:18 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Enriched_Natural_Killer_Cells_for_Adoptive_Infusion_Cancer_TherapyTAB-1493https://nih.technologypublisher.com/tech/Epithelial_Cell_Line_Expressing_a_Cystic_Fibrosis_PhenotypeCystic fibrosis (CF) is a common genetic disease that affects the entire body, producing thick, sticky mucus that clogs the lungs, pancreas, and other organs. It is the most common fatal genetic disease in the United States, and is caused by a mutation in the cystic fibrosis transmembrane conductance regulator (CFTR). Researchers at NIEHS have developed a cell line, CF/T43, which was produced by infection of airway epithelial cells isolated from CF patients with an SV40T retrovirus. CF/T43 cells maintain the abnormal ion transport characteristics of CF while having proliferation capability be...Tue, 06 Dec 2022 11:50:17 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Epithelial_Cell_Line_Expressing_a_Cystic_Fibrosis_PhenotypeTAB-1473https://nih.technologypublisher.com/tech?title=ARH3%2c_a_Therapeutic_Target_for_Cancer%2c_Ischemia%2c_and_InflammationADP-ribosylation is important in many cellular processes, including DNA replication and repair, maintenance of genomic stability, telomere dynamics, cell differentiation and proliferation, and necrosis and apoptosis. Poly-ADP-ribose is important in a number of critical physiological processes such as DNA repair, cellular differentiation, and carcinogenesis. Until recently, only one human enzyme, PARG, had been identified that degrades the ADP-ribose polymer. Another ADP-ribose, O-acetyl-ADP ribose, is formed via the deacetylation of proteins, such as acetyl-histone, by proteins in the Sir2 ...Tue, 06 Dec 2022 11:50:12 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech?title=ARH3%2c_a_Therapeutic_Target_for_Cancer%2c_Ischemia%2c_and_InflammationTAB-1462https://nih.technologypublisher.com/tech/A_Novel_Magnetic_Resonance_Radio-Frequency_Coil_Array_that_Eliminates_Inductive_CouplingParallel magnetic resonance imaging (MRI) techniques employ RF coil arrays for faster data acquisition, and have been shown to reduce the overall length of MRI procedures, improve signal-to–noise ratio (SNR) and image quality, thus making MRI more attractive and less costly. Elimination of inductive coupling is an essential step in designing RF coil arrays for parallel MRI. If mutual inductance remains among coils in the RF coil array, the MR signal obtained from one coil may disturb the flux in another coil, making it difficult to match the impedance of each individual element to the input ...Tue, 06 Dec 2022 11:50:08 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/A_Novel_Magnetic_Resonance_Radio-Frequency_Coil_Array_that_Eliminates_Inductive_CouplingTAB-1455https://nih.technologypublisher.com/tech?title=Swine_Hepatitis_E_Virus_Available_For_Use_in_Diagnosis%2c_Prevention_and_Treatment_of_Hepatitis_EHepatitis E virus (HEV) is the cause of Hepatitis E, a liver disease that occurs primarily in developing countries due to fecal contaminated drinking water. Outbreaks of HEV infection have caused epidemics in Africa, Central and Southeast Asia and Mexico and cases of the disease have also been reported sporadically in more developed countries. Hepatitis E is most often overcome by a host’s natural defenses; however the disease is more severe in pregnant women, who exhibit a 20% mortality rate due to HEV infection. Presently, no vaccines or therapeutic agents, which prevent or treat HEV infe...Tue, 06 Dec 2022 11:50:06 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech?title=Swine_Hepatitis_E_Virus_Available_For_Use_in_Diagnosis%2c_Prevention_and_Treatment_of_Hepatitis_ETAB-3120https://nih.technologypublisher.com/tech/Compositions_and_Methods_for_Detecting_Loa_loaLoa loa is a filarial nematode estimated to infect 3-13 million people in Central and Western Africa. In parts of Africa, mass administration of ivermectin is common for onchocerciasis and lymphatic filariasis control. However, some individuals infected with Loa loa microfilariae in high densities are known to experience post-ivermectin severe adverse events, such as encephalopathy, coma, or even death. Therefore, diagnostic tools that can accurately identify and differentiate Loa loa microfilariae from other filarial infections are needed. Microscopic evaluation of blood samples is the only...Tue, 06 Dec 2022 11:50:02 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Compositions_and_Methods_for_Detecting_Loa_loaTAB-1421https://nih.technologypublisher.com/tech/Neutralizing_Monoclonal_Antibodies_to_Botulinum_Neurotoxin_Type_ATwo chimpanzee mAbs specifically reacted with light chain of the botulinum neurotoxin A and neutralize the toxin in the mouse model. They can be used for emergency prophylaxis and treatment of either naturally acquired or terrorist associated botulism. Since the sequence of chimpanzee immune globulin is virtually identical to that of humans, the MAbs are not expected to have problems in repeated administration as equine antibodies. They can also be used for rapid diagnosis of botulinum neurotoxin A.Tue, 06 Dec 2022 11:50:00 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Neutralizing_Monoclonal_Antibodies_to_Botulinum_Neurotoxin_Type_ATAB-1393https://nih.technologypublisher.com/tech/Model_Th1_Clone_Producing_IFN-gamma_and_IL-2Available for licensing is the A.E7 T cell clone, a model Th1 clone described in Matis et al., J Immunol. 1983 Apr;130(4):1527-1535 [PubMed abs] and J Immunol. 1983 Sep;131(3):1049-1055 [PubMed abs]. This clone has been further utilized as a model for studying T cell clonal anergy.Tue, 06 Dec 2022 11:49:55 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Model_Th1_Clone_Producing_IFN-gamma_and_IL-2TAB-1389https://nih.technologypublisher.com/tech/A_Newly_Discovered_Bacterium_in_the_Family_AcetobacteraceaeAvailable for licensing and commercial development is a newly discovered bacterium in the Acetobacteraceae family. This bacterium was isolated, characterized and grown from lymph nodes of a patient with chronic granulomatous disease (CGD), a rare genetic disorder that impairs the immune system. This Gram-negative bacterium is an aerobic, facultative methylotroph that produces yellow pigmented colonies. The closest nucleic acid sequence match was to Gluconacetobacter sacchari (95.7% similarity) of the acetic acid bacteria. The newly described bacterium belongs to a new genus and species i...Tue, 06 Dec 2022 11:49:53 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/A_Newly_Discovered_Bacterium_in_the_Family_AcetobacteraceaeTAB-1364https://nih.technologypublisher.com/tech/Treatment_and_Prevention_of_Inflammatory_Bowel_Disease_(IBD)_using_Mutant_and_Chimeric_IL-13_MoleculesUlcerative colitis (UC) is a chronic inflammatory disease of the colorectum and affects approximately 400,000 people in the United States. The cause of UC is not known, although an abnormal immunological response to bacterial antigens in the gut microflora is thought to be involved. Present treatments for UC include anti-inflammatory therapy using aminosalicylates or corticosteroids, as well as immunomodulators and diet. However, 25-40% of ulcerative colitis patients must eventually have their colons removed due to massive bleeding, severe illness, rupture of the colon, risk of cancer or du...Tue, 06 Dec 2022 11:49:51 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Treatment_and_Prevention_of_Inflammatory_Bowel_Disease_(IBD)_using_Mutant_and_Chimeric_IL-13_MoleculesTAB-1360https://nih.technologypublisher.com/tech/Agonist_Epitopes_for_Renal_Cell_CarcinomaApproximately 30,000 patients are diagnosed with renal cell carcinoma (RCC) each year in the United States, and an estimated 12,000 patients die of this disease. Most patients are diagnosed with advanced local disease or metastatic disease. Metastatic RCC carries a poor prognosis with median survivals in the range of 10-12 months. Drugs that inhibit VEGF receptor tyrosine kinases such as Sorafenib and Sunitinib have recently been approved by the FDA to treat metastatic RCC. Although a significant percentage of patients will achieve a partial response or disease stabilization with these agen...Tue, 06 Dec 2022 11:49:49 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Agonist_Epitopes_for_Renal_Cell_CarcinomaTAB-1357https://nih.technologypublisher.com/tech/Image_Guided_Systems_and_Methods_for_Organ_Viability_AssessmentThe number of patients for organ transplants continues to grow, without an increase in the number of organs available for transplant. This has increased interest in transplanting organs from non-traditional sources, such as donations after cardiac death. However, there are currently no methods to objectively measure the effects of resuscitation and ischemia damage on organ viability. The present invention relates to systems and methods for evaluating the status and characterization of organs, determining their suitability for transplants, as well as restoring the viability of organs intende...Tue, 06 Dec 2022 11:49:46 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Image_Guided_Systems_and_Methods_for_Organ_Viability_AssessmentTAB-1356https://nih.technologypublisher.com/tech/Method_for_Improved_Phase_Contrast_MRI_ResolutionThis invention is a method to significantly improve the temporal or spatial resolution in a phase contrast MRI (PC-MRI) study. In general, conventional PC-MRI involves encoding the motion information of spins in the phase of the image. The velocity of the spin motion can be extracted by calculating the phase difference between two consecutive images acquired with two different bipolar encoding gradients. Two scans are required in order to reconstruct flow velocity data, resulting in an increase in image acquisition and reconstruction time by a factor of two compared to that of a standard an...Tue, 06 Dec 2022 11:49:45 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Method_for_Improved_Phase_Contrast_MRI_ResolutionTAB-1347https://nih.technologypublisher.com/tech/Novel_Methods_for_Using_Biomarkers_to_Monitor_Glucose_Levels_and_Screen_for_Diabetes_RiskA primary goal of diabetes therapy is to improve control of blood glucose levels (known as glycemic control) in patients. Prospective studies of both Type 1 and Type 2 diabetes indicate that careful glycemic control significantly reduces the risk of microvascular, neurological, and cardiovascular complications of diabetes. The current method of monitoring glycemic control involves measuring levels of the intracellular hemoglobin (HbA1C). However, levels of HbA1C reflect glycemic control over a timeframe of several months and are susceptible to a variety of perturbing factors such as hematologi...Tue, 06 Dec 2022 11:49:43 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Novel_Methods_for_Using_Biomarkers_to_Monitor_Glucose_Levels_and_Screen_for_Diabetes_RiskTAB-2958https://nih.technologypublisher.com/tech?title=Rabbit_Polyclonal_Antiserum_to_the_Nitrone_Spin_Trap_5%2c5-dimethyl-1-pyrroline_N-oxide_(DMPO)Biological radicals resulted from oxidative stress has been implicated in human diseases, such as cancer and aging. There is, however, a paucity of reliable methods for in vivo or ex vivo detection of either radical formation, the end-products of radical formation or susceptibility for radical formation. The Rabbit polyclonal anti-DMPO can be used to detect the stable nitrone end-product of protein and DNA radicals in ELISA assays, blot analyses and confocal microscopy. This rabbit polyclonal anti-DMPO antiserum will replace a previously licensed one which is no longer available (E-186-2003...Tue, 06 Dec 2022 11:49:41 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech?title=Rabbit_Polyclonal_Antiserum_to_the_Nitrone_Spin_Trap_5%2c5-dimethyl-1-pyrroline_N-oxide_(DMPO)TAB-1344https://nih.technologypublisher.com/tech/Identification_of_Candidate_Ligands_which_Modulate_Antigen_Presenting_CellsAvailable for licensing and commercial development are novel biotechnological tools, prophylactics, therapeutics, and methods for modulating the activation state of an antigen presenting cell (APC) and thereby modulating the activation of a killer T cell. The activation of a killer T cell can occur in a two cell complex and two sequential steps: a) in the first step, an APC stimulates a T helper T cell, which in turn stimulates or "superactivates" the APC to differentiate to a state where it can independently stimulate a killer T cell; b) in the second step, the APC encounters the killer T ce...Tue, 06 Dec 2022 11:49:40 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Identification_of_Candidate_Ligands_which_Modulate_Antigen_Presenting_CellsTAB-1338https://nih.technologypublisher.com/tech/Method_of_Inducing_Memory_B_Cell_Development_and_Terminal_DifferentiationCytokines exert their respective biochemical and physiological effects by binding to specific receptor molecules, which then stimulate signal transduction pathways. Interleukin-21 (IL-21) is a type I cytokine whose receptor is expressed on T, B, and NK cells. This invention specifically relates to the use of IL-21 to induce differentiation of immature B cells into memory B cells and plasma cells. This invention includes claims of methods for inducing differentiation of a B cell progenitor into memory B cells and/or plasma cells. It also includes claims for enhancing an immune response, tr...Tue, 06 Dec 2022 11:49:36 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Method_of_Inducing_Memory_B_Cell_Development_and_Terminal_DifferentiationTAB-1329https://nih.technologypublisher.com/tech/Monoclonal_Antibody_for_Lyme_Disease_Diagnostic_and_ResearchThe hybridoma producing a monoclonal antibody against the major flagellin protein (FlaB) is available for licensing. This antibody can be used in diagnostic and research applications related to Lyme disease or other Borrelia-caused conditions. More information about this antibody can be found in Barbour et al., Infection and Immunity, May 1986, volume 52(5), pages 549-554.Tue, 06 Dec 2022 11:49:33 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Monoclonal_Antibody_for_Lyme_Disease_Diagnostic_and_ResearchTAB-1324https://nih.technologypublisher.com/tech?title=A_Novel_MRI_Adiabatic_T%3csub%3e2%3c%2fsub%3e_Preparation_Sequence_with_Reduced_B1_SensitivityThis invention relates to a novel magnetic resonance angiography (MRA) method that accomplishes uniform contrast enhancement between coronary arteries and the surrounding tissue across the entire imaging volume. The disclosed technique utilizes an adiabatic refocusing transverse relaxation time (T2)-preparation pulse sequence, in which the magnetization is tipped into the transverse plane with a hard radio-frequency (RF) pulse and refocused using a pair of adiabatic fast-passage RF pulses. The isochromats are subsequently returned to the longitudinal axis using a hard RF pulse. Simulations ...Tue, 06 Dec 2022 11:49:31 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech?title=A_Novel_MRI_Adiabatic_T%3csub%3e2%3c%2fsub%3e_Preparation_Sequence_with_Reduced_B1_SensitivityTAB-1321https://nih.technologypublisher.com/tech/Live_Tissue_Imaging_GelThe National Heart Lung and Blood Institute (NHLBI), Laboratory of Cardiac Energetics, has created a gel with 0.3%-0.5% carbomer 940 which is easily used as an imaging immersion medium for confocal and two photon fluorescence emission microscopy and second harmonic generation imaging. This thick, but transparent, gel can be layered on tissue for microscopic analysis and retain the connection between the objective and tissue at a large working distance without supplementary retention. The thickness of the gel allows for optimal positioning on tissue for imaging in the living animal, which eli...Tue, 06 Dec 2022 11:49:30 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Live_Tissue_Imaging_GelTAB-1316https://nih.technologypublisher.com/tech/Transformation-Associated_Recombination_(TAR)_CloningTransformation-Associated Recombination (TAR) cloning in yeast is a unique method for selective isolation of large chromosomal fragments or entire genes from complex genomes without the time-consuming step of library construction.1 The technique involves homologous recombination during yeast spheroplast transformation between genomic DNA and a TAR vector that has short (approximately 60bp) 5’ and 3’ gene targeting sequences (hooks). Further, because up to 15% sequence divergence does not prevent recombination in yeast, TAR cloning is highly efficient for isolation of gene homologs and synthe...Tue, 06 Dec 2022 11:49:27 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Transformation-Associated_Recombination_(TAR)_CloningTAB-1308https://nih.technologypublisher.com/tech/Methods_for_Rapid_and_Specific_Fluorescent_Staining_of_Biological_Tissue_for_Laser_Capture_MicrodissectionAvailable for licensing and commercial development are methods for rapid and specific fluorescent staining of biological tissue samples that substantially preserve biological molecules such as mRNA. Also within the scope of the invention are methods for microdissecting tissue to obtain pure populations of cells or tissue structures based upon identifying and excising cells or tissue structures that are labeled with fluorescent specific binding agents. A laser capture microdissection (LCM) apparatus useful for identifying and isolating cells and tissue structures following rapid immunofluores...Tue, 06 Dec 2022 11:49:25 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Methods_for_Rapid_and_Specific_Fluorescent_Staining_of_Biological_Tissue_for_Laser_Capture_MicrodissectionTAB-1302https://nih.technologypublisher.com/tech/Human_Sweet_and_Umami_Taste_Receptor_VariantsThe complexity of taste discrimination (salty, sour, sweet, umami and bitter) varies between human individuals and populations. Sweet and umami (the taste of glutamate) tastes play a major role in the perception of calorically-rich and essential nutrients and there are well-documented differences in individual perception of sweet and umami flavorings, many of which appear to be genetic in origin. Studies of individuals within and between populations that vary in any of the taste receptors should be of direct interest to the multi-billion dollar food and flavoring industry as the characteriza...Tue, 06 Dec 2022 11:49:22 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Human_Sweet_and_Umami_Taste_Receptor_VariantsTAB-1294https://nih.technologypublisher.com/tech/Rapid_Anti-Depressant_Response_Produced_by_Low_Dose_Treatment_with_Anti-Muscarinic_DrugsAvailable for licensing are new methods of rapidly treating depression. The drugs currently used to treat depression work by increasing the activity at serotonin, norepinephrine and perhaps dopamine receptors in the CNS. However these drugs are effective in only 60-70% of patients, require 3-4 weeks of treatment before clinical improvement and have many side effects. These inventors have shown that in human patients, the administration of anti-muscarinic agents produces a rapid, prolonged alleviation of depressive symptoms. Beginning the day following administration of the anti-muscarinic agen...Tue, 06 Dec 2022 11:49:19 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Rapid_Anti-Depressant_Response_Produced_by_Low_Dose_Treatment_with_Anti-Muscarinic_DrugsTAB-1290https://nih.technologypublisher.com/tech/Active_MRI_Compatible_and_Visible_iMRI_CatheterMRI is a promising imaging modality that provides superior soft tissue contrast and multi planar real-time imaging without harmful ionizing radiation for therapeutic procedures. Interventional magnetic resonance imaging (iMRI) has gained important popularity in many fields such as interventional cardiology and radiology, owing to the development of minimally invasive techniques and visible catheters under MRI for conducting MRI-guided procedures and therapies. This invention relates to a novel MRI compatible and active visible catheter for conducting interventional and intraoperative proced...Tue, 06 Dec 2022 11:49:16 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Active_MRI_Compatible_and_Visible_iMRI_CatheterTAB-1288https://nih.technologypublisher.com/tech?title=A_Nurr1-Knockout_Mouse_Model_for_Parkinson%27s_Disease_and_Stem_Cell_DifferentiationThe researchers have generated Nurr1-knockout mice via genomic locus inactivation using homologous recombination. Transcription factor Nurr1 is an obligatory factor for neurotransmitter dopamine biosynthesis in ventral midbrain. From a neurological and clinical perspective, it suggests an entirely new mechanism for dopamine depletion in a region where dopamine is known to be involved in Parkinson's disease. Activation of Nurr1 may be therapeutically useful for Parkinson's disease patients; therefore, the mice would be useful in Parkinson's disease research. Additionally, Nurr1 has been shown ...Tue, 06 Dec 2022 11:49:15 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech?title=A_Nurr1-Knockout_Mouse_Model_for_Parkinson%27s_Disease_and_Stem_Cell_DifferentiationTAB-1283https://nih.technologypublisher.com/tech/A_Mouse_with_a_Targeted_Mutation_in_the_Uncoupling_Protein-3_(upc3)_GeneThe NIH announces the development of a transgenic mouse with a targeted mutation in the ucp3 gene. The ucp3 gene is implicated I the function of regulating energy metabolism. This regulatory function is thought to be accomplished by changing metabolic efficiency (causing energy expended as heat rather than used for ADP/ATP conversion) and/or by participating in fat metabolism. The mutation should inactivate the ucp3 function and the mouse provided a testing vehicle for the above hypotheses. If in fact ucp3 is involved in energy efficiency and/or fat metabolism, then variation in its sequen...Tue, 06 Dec 2022 11:49:13 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/A_Mouse_with_a_Targeted_Mutation_in_the_Uncoupling_Protein-3_(upc3)_GeneTAB-1281https://nih.technologypublisher.com/tech?title=A_Mouse_Model_of_Multiple_Endocrine_Neoplasia%2c_Type_IThe current invention embodies a mouse model which is heterozygous for a null allele at the Men1 locus of murine chromosome 19. Men1 has similar exon-intron organization and amino acid identity compared with its human analog MEN1, which has been implicated in the pathogenesis of multiple endocrine neoplasia, type I (MENI). This mouse model has been shown to develop features remarkably similar to those of MEN1, which include tumors of the endocrine pancreas, pituitary, and parathyroids. The model embodied in this invention appears to represent a valuable research tool for use in elucidating ...Tue, 06 Dec 2022 11:49:10 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech?title=A_Mouse_Model_of_Multiple_Endocrine_Neoplasia%2c_Type_ITAB-1270https://nih.technologypublisher.com/tech/The_Use_of_an_Inducible_Plasmid_Vector_Encoding_for_Active_TGF-beta_for_the_Treatment_of_Autoimmune_DiseasesThis application describes a composition and method for treating inflammatory bowel disease or other autoimmune diseases. The composition utilizes a vector which contains a first promoter which controls the expression of a regulatory transcription factor and a second inducible promoter which controls the expression of the gene of interest. The preferred gene of interest encodes an isoform of TGF-beta such as TGF-beta1 or TGF-beta3. The isoform of TGF-beta does not have to be hTGF-beta and can be a latent or active isoform of TGF-beta. The preferred inducible promoter is TRE-CMV which can be...Tue, 06 Dec 2022 11:49:07 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/The_Use_of_an_Inducible_Plasmid_Vector_Encoding_for_Active_TGF-beta_for_the_Treatment_of_Autoimmune_DiseasesTAB-1268https://nih.technologypublisher.com/tech/Monoclonal_Antibodies_That_Bind_or_Neutralize_Hepatitis_B_VirusHepatitis B virus (HBV) chronically infects over 300 million people worldwide. Many of them will die of chronic hepatitis or hepatocellular carcinoma. The present technology relates to the isolation and characterization of a novel neutralizing chimpanzee monoclonal antibody to HBV. The antibody was identified through a combinatorial antibody library constructed from bone marrow cells of a chimpanzee experimentally infected with HBV. The selected monoclonal antibody has been shown to react equally well with wild-type HBV and the most common neutralization escape mutant variants. Therefore, ...Tue, 06 Dec 2022 11:49:05 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Monoclonal_Antibodies_That_Bind_or_Neutralize_Hepatitis_B_VirusTAB-1260https://nih.technologypublisher.com/tech/Methods_and_Compositions_for_the_Inhibition_of_SARS-CoV_Replication_Propagation_and_TransmissionAvailable for licensing and commercial development is a method of inhibiting SARS-CoV replication, propagation and transmission using 2-cyano-3,12-dioxooleana-1,9-dien-28-oic (CDDO). Severe acute respiratory syndrome (SARS) is an infectious atypical pneumonia that has recently been recognized in patients in 32 countries and regions. The atypical pneumonia with unknown etiology was initially observed in Guangdong Province, China. This observation was followed by reports from Hong Kong, Vietnam, Singapore, Canada and Beijing of severe febrile respiratory illness that spread to household membe...Tue, 06 Dec 2022 11:49:02 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Methods_and_Compositions_for_the_Inhibition_of_SARS-CoV_Replication_Propagation_and_TransmissionTAB-1246https://nih.technologypublisher.com/tech/Treatment_for_Ichthyosiform_Skin_DiseasesA synthetic composition that contains the transglutaminase 1 (TGase I) enzyme and a lipid vesicle, which can be used to provide ameliorative therapy for inherited autosomal recessive ichthyoses (ARI). Icthyoses are rare inherited skin disorders that result in extensive scaling of the skin. Because this abnormality can affect heat and fluid transfer through the skin, individuals with this disease may have an increased risk for dehydration and skin infections. Each year, more than 16,000 babies are born with some form of ichthyosis. Ichthyosis affects people of all ages, races and gender. Curren...Tue, 06 Dec 2022 11:48:58 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Treatment_for_Ichthyosiform_Skin_DiseasesTAB-1241https://nih.technologypublisher.com/tech/Conjugate_Vaccine_for_Neisseria_MeningitidisThe invention discloses a vaccine which comprises lipooligosaccharide (LOS) isolated from N. meningitidis and conjugated to a carrier protein. The invention also discloses a method of making the acellular vaccine. The method consists of two main steps. In the first step the lipooligosaccharide (LOS), chosen so it does not contain the lacto-N-neotetraose human antigen (LNnT), is detoxified by a novel procedure which uses hydrazine to remove the O-linked fatty acids. In the second step, the detoxified LOS (dLOS) is covalently conjugated to a carrier protein such as Tetanus Toxoid (TT). The dLOS ...Tue, 06 Dec 2022 11:48:56 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Conjugate_Vaccine_for_Neisseria_MeningitidisTAB-1233https://nih.technologypublisher.com/tech/AAV5_Vector_and_Uses_ThereofThe invention described and claimed in this patent application provides for novel vectors and viral particles which comprise adeno-associated virus serotype 5 (AAV5). AAV5 is a single-stranded DNA virus of either plus or minus polarity which, like other AAV serotypes (e.g., AAV4, AAV2) requires a helper virus for replication. AAV type 2 has the interesting and potentially useful ability to integrate into human chromosome 19 q 13.3-q ter. This activity is dependent on the non-structural, Rep, proteins of AAV2. The Rep proteins of AAV types 2 and 5 are dissimilar and are not able to substitut...Tue, 06 Dec 2022 11:48:53 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/AAV5_Vector_and_Uses_ThereofTAB-1232https://nih.technologypublisher.com/tech?title=Methods_and_Materials_for_Identifying_Polymorphic_Variants%2c_Diagnosing_Susceptibilities%2c_and_Treating_DiseaseThis invention relates to materials and methods associated with polymorphic variants in two enzymes involved in folate-dependent and one-carbon metabolic pathways important in pregnancy-related complications and neural tube birth defects: MTHFD1 (5,10-methylenetrahydrofolate dehydrogenase, 5,10-methenyltetrahydrofolate cyclohydrolase, 10-formyltetrahydrofolate synthase) and methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 1-like (MTHFD1L). These enzymes are extremely important in the promotion of DNA synthesis, a process that is critical for normal placental and fetal development. R...Tue, 06 Dec 2022 11:48:52 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech?title=Methods_and_Materials_for_Identifying_Polymorphic_Variants%2c_Diagnosing_Susceptibilities%2c_and_Treating_DiseaseTAB-1222https://nih.technologypublisher.com/tech/Assay_for_the_Detection_of_a_Variety_of_Tumors_in_Biological_SpecimensThe inventors have developed methods and reagents for the detection of bone sialoprotein (BSP) in biological samples. The technology relates to the disruption of a serum complex that masks the majority of BSP from established detection systems. Furthermore, there is evidence that there may be a more acidic form of BSP secreted not by normal bone, but only by tumors. Detection of BSP in serum may be a good marker of various bone diseases and a variety of cancers including breast, prostate, lung, and thyroid.Tue, 06 Dec 2022 11:48:49 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Assay_for_the_Detection_of_a_Variety_of_Tumors_in_Biological_SpecimensTAB-1220https://nih.technologypublisher.com/tech/Artificial_Salivary_GlandThe present application describes an artificial fluid secreting prosthetic device for non-invasive insertion and methods of using this device. Specifically, compositions and methods based on the discovery of an artificial fluid secreting prosthesis are disclosed in this application. Currently, there is no conventional effective treatment for salivary gland hypofunction. And although the transplantation of mammalian salivary glands has also been tried, this option has not proven desirable due to lack of sufficient donor supplies. To date, the inventors have performed experiments that have d...Tue, 06 Dec 2022 11:48:48 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Artificial_Salivary_GlandTAB-3130https://nih.technologypublisher.com/tech/Human-derived_Monoclonal_Antibody_for_Treatment_of_Ebola_Virus_InfectionEbola virus infection can lead to severe hemorrhagic fever, known as Ebola virus disease (EVD), which is often fatal. The Zaire species of Ebola virus (EBOV) was responsible for the largest Ebola outbreak in history, which occurred in 2014. Scientists at the NIAID Vaccine Research Center have developed a human monoclonal neutralizing antibody, mAb114 for treatment and prevention of EBOV infection. Because there are very few treatments available to treat or prevent EBOV infection, there is a great need to develop effective pre- and post- exposure therapeutics before another outbreak occurs. Pre...Tue, 06 Dec 2022 11:48:47 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Human-derived_Monoclonal_Antibody_for_Treatment_of_Ebola_Virus_InfectionTAB-1217https://nih.technologypublisher.com/tech?title=Attenuated_Human_Parainfluenza_Virus_(PIV)_for_Use_as_Live%2c_Attenuated_Vaccines_and_as_Vector_VaccinesThe identified technologies describe self-replicating infectious recombinant paramyxoviruses with one or more attenuating mutations, such as a separate variant polynucleotide encoding a P protein and a separate monocistronic polynucleotide encoding a V protein, or at least one temperature sensitive mutation and one non-temperature sensitive mutation. Compositions and methods for recovering, making and using the infectious, recombinant paramyxoviruses as described are also included (e.g. recombinant human parainfluenza virus type 2 (HPIV2)). In addition, these inventions provide novel tools a...Tue, 06 Dec 2022 11:48:46 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech?title=Attenuated_Human_Parainfluenza_Virus_(PIV)_for_Use_as_Live%2c_Attenuated_Vaccines_and_as_Vector_VaccinesTAB-1204https://nih.technologypublisher.com/tech/Amelioration_of_Inflammatory_Arthritis_Targeting_the_Pre-ligand_Assembly_Domain_(PLAD)_of_Tumor_Necrosis_Factor_ReceptorsThe invention relates to compositions of matter and methods for treating arthritis by modulating Tumor Necrosis Factor Alpha (TNF-alpha) signaling. TNF-alpha plays a key role in the pathogenesis of numerous diseases including rheumatoid and septic arthritis, and other autoimmune and inflammatory diseases. TNF-alpha mediates its effects through receptors that contain a Pre-ligand Assembly Domain (PLAD). The inventors have discovered compounds that interfere with PLAD can block the effects of TNF-alpha in vitro. Treatment of mice with these compounds in vivo ameliorated disease in several mo...Tue, 06 Dec 2022 11:48:43 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Amelioration_of_Inflammatory_Arthritis_Targeting_the_Pre-ligand_Assembly_Domain_(PLAD)_of_Tumor_Necrosis_Factor_ReceptorsTAB-1193https://nih.technologypublisher.com/tech/Method_for_Inducing_T-Cell_ProliferationThis technology relates to the use of thymic stromal lymphopoietin (TSLP) to induce CD4+ T cell proliferation. This proliferation could be of particular relevance for patients in whom this cell population has been significantly reduced by HIV/AIDS or other conditions resulting in immunodeficiency. The proliferation of isolated CD4+ T cells can be induced through direct contact with TSLP or a nucleic acid encoding TSLP. The patent application also describes methods of inducing or enhancing an immune response through administration of CD4+ T cells that have been isolated and induced to proli...Tue, 06 Dec 2022 11:48:39 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Method_for_Inducing_T-Cell_ProliferationTAB-1185https://nih.technologypublisher.com/tech/Transmission-Blocking_Vaccine_Against_Malaria_(1)A transmission blocking vaccine developed against malaria contains a recombinant virus, which encodes a unique portion of the sexual stage surface antigen of Plasmodium falciparum (referred to as Pfs25), or the Pfs25 protein purified from infected host cells. Mice inoculated with the recombinant virus developed antibodies capable of blocking transmission of the virus. None of the monoclonal antibodies known to block transmission recognize the reduced Pfs25 antigen. This vaccine, which induces high, long-lasting titers at low cost, can be useful for controlling malaria.Tue, 06 Dec 2022 11:48:37 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Transmission-Blocking_Vaccine_Against_Malaria_(1)TAB-1181https://nih.technologypublisher.com/tech/Anti-Plasmodium_Compositions_and_Methods_of_UseThis invention describes methods and compositions of peptides that inhibit the binding of Plasmodium falciparum (P. falciparum) to erythrocytes. Malarial parasites enter the red blood cell through several erythrocyte receptors, each being specific for a given species of Plasmodia. For P. falciparum, the erythrocyte binding antigen (EBA-175) is the ligand of the plasmodia merozoites that interacts with the receptor glycophorin A on the surface of red blood cells. Inhibiting this ligand/receptor interaction is one method of preventing further malarial attacks and is an active area of vaccine ...Tue, 06 Dec 2022 11:48:36 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Anti-Plasmodium_Compositions_and_Methods_of_UseTAB-1176https://nih.technologypublisher.com/tech/TTP_as_a_Regulator_of_GM-CSF_mRNA_Deadenylation_and_StabilityThe disclosed invention provides materials and methods to treat granulocytopenia (low white cell count in the blood) which is characterized by a reduced number of granulocytes (relative) or an absence of granulocytes (absolute). This condition is commonly associated with cancer chemotherapy, but is seen less frequently in a number of conditions including the use of propylthiouracil, radiotherapy for marrow ablation for bone marrow transplantation, aplastic anemia, systemic lupus erythematosus, AIDS and a variety of other situations. The invention proposes a method to increase GM-CSF levels i...Tue, 06 Dec 2022 11:48:34 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/TTP_as_a_Regulator_of_GM-CSF_mRNA_Deadenylation_and_StabilityTAB-1175https://nih.technologypublisher.com/tech/AAV5_Vector_for_Transducing_Brain_Cells_and_Lung_CellsThe invention described and claimed in this patent application is related to the delivery of heterologous nucleic acids or genes to particular target cells. In particular, the application relates to methods of delivering a heterologous nucleic acid or gene of interest to particular target cells using an Adeno-Associated Virus of serotype 5 (AAV5). The particular target cells identified include the alveolar cells of the lung and cerebellar and ependymal cells of the brain. The methods described herein may be useful in carrying out gene therapy related to diseases of the brain or central nerv...Tue, 06 Dec 2022 11:48:33 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/AAV5_Vector_for_Transducing_Brain_Cells_and_Lung_CellsTAB-1174https://nih.technologypublisher.com/tech/AAV4_Vector_and_Uses_ThereofThe invention described and claimed in this patent application relates to the delivery of heterologous nucleic acids or genes to particular target cells. In particular, the application relates to methods of delivering a heterologous nucleic acid or gene of interest to particular target cells using Adeno-Associated Virus of serotype 4 (AAV4). The particular target cells identified are the ependymal cells of the brain. The methods described herein may be useful in carrying out gene therapy for diseases of the brain or central nervous system.Tue, 06 Dec 2022 11:48:32 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/AAV4_Vector_and_Uses_ThereofTAB-1170https://nih.technologypublisher.com/tech/Spatially_Selective_Fixed-Optics_Multicolor_Fluorescence_Detection_System_For_Microfluidic_DeviceAvailable for licensing and commercial development is a new scheme for sensitive spatially resolved and spectrally resolved laser-induced fluorescence detection from multiple microfluidic channels. The prototype instrument has been developed and is versatile in that it contains only fixed optical parts and has simultaneous five-color detection from eight microchannels in a plastic microchip for DNA analysis. The detection scheme could be applied to fluorescence detection for any microchip-based analysis in a transparent substrate. The economies of parallel detection and the importance of sp...Tue, 06 Dec 2022 11:48:30 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Spatially_Selective_Fixed-Optics_Multicolor_Fluorescence_Detection_System_For_Microfluidic_DeviceTAB-1160https://nih.technologypublisher.com/tech?title=Monoclonal_Antibody_to_the_Protein_NCOA6_(also_called_ASC-2%2c_AIB-3)The invention relates to monoclonal antibodies that bind to the transcription factor NCOA6 (ASC-2, AIB-3, TRB, TRAP250, NRC). The antibodies have proven successful reagents for Western blotting and for purifying complexes containing NCOA6. The Western blot experiments revealed that NCOA6 is over-expressed in several breast cancer cell lines, and the purification experiments identified a protein complex containing NCOA6 (the ASCOM complex). The monoclonal antibodies may be useful reagents for studying the role of NCOA6 in transcription and for studying the ASCOM complex.Tue, 06 Dec 2022 11:48:27 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech?title=Monoclonal_Antibody_to_the_Protein_NCOA6_(also_called_ASC-2%2c_AIB-3)TAB-1157https://nih.technologypublisher.com/tech?title=Isolation%2c_Cloning_and_Characterization_of_New_Adeno-Associated_Virus_(AAV)_SerotypesAdeno-associated viruses (AAV) are used in gene delivery, but with limited success due to toxicity. The novel AAVs described in this technology may be more effective and useful in gene therapy applications. This invention relates to new adeno-associated viruses (AAV), vectors and particles derived therefrom and also provides methods for delivering specific nucleic acids to cells using the AAV vectors and particles. The inventors cloned and sequenced the genomes of AAVs found in twelve (12) simian adenovirus isolates and determined that the AAVs were novel. Ten (10) of these isolates had hi...Tue, 06 Dec 2022 11:48:25 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech?title=Isolation%2c_Cloning_and_Characterization_of_New_Adeno-Associated_Virus_(AAV)_SerotypesTAB-1142https://nih.technologypublisher.com/tech?title=Recombinant_MVA_Viruses_Expressing_Clade_A%2fG_and_Clade_B_Modified_HIV_Env%2c_Gag_and_Pol_Genes_Useful_for_HIV_Vaccine_DevelopmentThe current technology relates to the construction, characterization and immunogenicity of modified vaccinia Ankara (MVA) recombinant viruses. The MVA double recombinant viruses express modified/truncated HIV-1 Env and mutated HIV Gag Pol under the control of vaccinia virus early/late promoters. This technology describes the MVA double recombinant viruses made by homologous recombination of single MVA recombinants, one expressing Env and one expressing Gag Pol. These single MVA recombinants are made using a transiently expressed GFP marker that is deleted in the final viruses. Two recombin...Tue, 06 Dec 2022 11:48:21 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech?title=Recombinant_MVA_Viruses_Expressing_Clade_A%2fG_and_Clade_B_Modified_HIV_Env%2c_Gag_and_Pol_Genes_Useful_for_HIV_Vaccine_DevelopmentTAB-1121https://nih.technologypublisher.com/tech?title=Farnesyltransferase_Inhibitors_for_Treatment_of_Laminopathies%2c_Cellular_Aging_and_AtherosclerosisHutchinson-Gilford Progeria Syndrome (HGPS) is a very rare progressive childhood disorder characterized by premature aging (progeria). Recently, the gene responsible for HGPS was identified (Eriksson M, et al. Nature 2003), and HGPS joined a group of syndromes — the laminopathies — all of which are caused by various mutations in the lamin A/C gene (LMNA). Lamin A is one of the family of proteins that is modified post-translationally by the addition of a farnesyl group. In progeria, the abnormal protein (progerin) can still be farnesylated, however, a subsequent cleavage is blocked. The pres...Tue, 06 Dec 2022 11:48:16 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech?title=Farnesyltransferase_Inhibitors_for_Treatment_of_Laminopathies%2c_Cellular_Aging_and_AtherosclerosisTAB-1120https://nih.technologypublisher.com/tech/Tristetraprolin_(TTP)_Knockout_MiceNational Institutes of Health researchers have developed knockout mice that do not express Tristetraprolin (TTP). TTP is an AU-rich element (ARE) binding protein and the prototype of a family of CCCH zinc finger proteins. AREs were identified as conserved sequences found in the 3’ untranslated region (3’ UTR) of a variety of transiently expressed genes including early response genes, proto-oncogenes, and other growth regulatory genes. AREs function as instability sequences that target ARE-containing transcripts for rapid mRNA decay. TTP functions by binding directly to the ARE sequence con...Tue, 06 Dec 2022 11:48:15 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Tristetraprolin_(TTP)_Knockout_MiceTAB-1115https://nih.technologypublisher.com/tech/Method_of_Diagnosing_Multidrug_Resistant_TuberculosisThe invention can be used to develop tests that are much more rapid than conventional tests for determining drug resistance. It relates to the discovery that a putative gene of Mycobacterium tuberculosis (MTb) with no previously identified function is responsible for the ability of the bacteria to activate a class of second line thioamide drugs used for MTb infections. The gene, termed "etaA", codes for the synthesis of a monooxygenase, the enzyme responsible for the oxidative activation of the drugs. Mutation in the etaA gene leads to the expression of mutated, inactivated enzyme, thus result...Tue, 06 Dec 2022 11:48:12 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Method_of_Diagnosing_Multidrug_Resistant_TuberculosisTAB-1112https://nih.technologypublisher.com/tech/Spatial_and_Temporal_Control_of_Gene_Expression_Using_a_Heat_Shock_Protein_Promoter_in_Combination_with_Local_HeatIn many instances, it is desirable to express exogenous genes only in certain tissues, and/or at will at certain times, and/or only to a certain degree. However, current gene transfer and exogenous gene expression protocols do not provide adequate means of simultaneously controlling which cells in a heterogeneous population are transformed and when, where, and to what degree the transferred genes are expressed. The invention provides methods for using local heat to control gene expression. The heat shock protein (hsp) gene promoter is recombined with a selected therapeutic gene and expresse...Tue, 06 Dec 2022 11:48:11 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Spatial_and_Temporal_Control_of_Gene_Expression_Using_a_Heat_Shock_Protein_Promoter_in_Combination_with_Local_HeatTAB-1101https://nih.technologypublisher.com/tech?title=The_Use_of_Rabbits_with_Defined_Immunoglobulin_Light_Chain_Genes_(C%3csub%3ekappa%3c%2fsub%3e_b_allotypes)_to_Optimize_Production_of_Chimeric_and_Humanized_Monoclonal_Antibodies_for_Therapeutic%2c_Imaging_and_Diagnostic_ApplicationsBiological materials are important research tools that can be used for diagnostic as well as therapeutic purposes. Antibodies have become viable drugs in the market today and there is a general market need for systems that may facilitate production of efficient and effective antibodies. In recent years, monoclonal antibodies have gained significant importance in their use, both as diagnostics and therapeutics, to intervene and combat diseases such as cancer, cardiovascular diseases, and infections. The present invention relates to the discovery of rabbits, genetically defined as b9, as the ...Tue, 06 Dec 2022 11:48:08 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech?title=The_Use_of_Rabbits_with_Defined_Immunoglobulin_Light_Chain_Genes_(C%3csub%3ekappa%3c%2fsub%3e_b_allotypes)_to_Optimize_Production_of_Chimeric_and_Humanized_Monoclonal_Antibodies_for_Therapeutic%2c_Imaging_and_Diagnostic_ApplicationsTAB-1100https://nih.technologypublisher.com/tech/Methods_for_Diagnosis_of_AtherosclerosisThe identification of more sensitive and specific markers of atherosclerosis that are non-invasive and cost-effective may have profound impacts on public health. One such strategy involves the detection of marker genes or their products in blood or serum. Such markers may help identify high-risk patients with subclinical atherosclerosis who may benefit from intensive primary prevention or they may help determine the activity of established disease for monitoring response to treatment, resulting in more targeted secondary prevention. The present invention relates to methods for detecting ath...Tue, 06 Dec 2022 11:48:07 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Methods_for_Diagnosis_of_AtherosclerosisTAB-1077https://nih.technologypublisher.com/tech/Wild-Type_and_DNA_Polymerase_beta_Null_Mouse_Embryotic_Fibroblast_Cell_Lines_Harboring_a_lambda-LIZ_TransgeneOf great utility in toxicology and DNA repair research are knockout mice with cell lines enabling one to evaluate generations of gene mutations as a direct function of base excision repair. Of particular importance are lambda-LIZ transgenes. Likewise, wild-type and beta-pol null cell lines are equally important. While there exist cell lines carrying the lambda-LIZ transgene, only wild-type cells are currently available. And while wild-type and beta-pol null cell lines exist, none carry the lambda-LIZ transgene. The present cell line incorporates both of these beneficial properties. These...Tue, 06 Dec 2022 11:48:01 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Wild-Type_and_DNA_Polymerase_beta_Null_Mouse_Embryotic_Fibroblast_Cell_Lines_Harboring_a_lambda-LIZ_TransgeneTAB-2998https://nih.technologypublisher.com/tech/Fluorescent_Nanodiamonds_as_Fiducial_Markers_for_MicroscopyThe invention relates to fluorescent nanodiamonds (FNDs) and their uses as fiducial markers for microscopy. FNDs are bright fluorescent probes that do not blink or bleach and have broad fluorescence excitation and emission peaks. The fluorescence intensity can be readily controlled by the size of the FND, the number of fluorescent centers produced in the nanodiamonds, or in situ through the application of a weak magnetic field. The particular advantage of the FND compositions of this invention are that they are particularly useful for extended imaging of a single sample over time periods th...Tue, 06 Dec 2022 11:47:58 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Fluorescent_Nanodiamonds_as_Fiducial_Markers_for_MicroscopyTAB-1061https://nih.technologypublisher.com/tech/Generation_of_Smad3-null_Mice_and_Smad4-conditional_MiceSMADs are a novel set of mammalian proteins that act downstream of TGF-beta family ligands. These proteins can be categorized into three distinct functional sets, receptor-activated SMADs (SMADs 1,2,3,5, and 8), the common mediator SMAD (SMAD 4), and inhibitory SMADs (SMADs 6 and 7). SMAD proteins are thought to play a role in vertebrate development and tumorigenesis. One of the research tools our NIH inventors have prepared is the Smad3-null mice model, created by disrupting exon 8 on the Smad3 gene. Symptomatic mice exhibit leukocytosis, with massive inflammation and pyogenous abscess fo...Tue, 06 Dec 2022 11:47:57 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Generation_of_Smad3-null_Mice_and_Smad4-conditional_MiceTAB-1052https://nih.technologypublisher.com/tech/Chromatin_Insulator_Protecting_Expressed_Genes_of_Interest_for_Human_Gene_Therapy_or_Other_Mammalian_Transgenic_SystemsThe technology provides the isolation of a functional DNA sequence comprising a chromatin insulating element from a vertebrate system and provides the first employment of the pure insulator element as a functional insulator in mammalian cells. The technology further relates to a method for insulating the expression of a gene from the activity of cis-acting regulatory sequences in eukaryotic chromatin. This technology could be of major importance in providing a mechanism and a tool to restrict the action of cis-acting regulatory elements on genes whose activities or encoded products are neede...Tue, 06 Dec 2022 11:47:54 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Chromatin_Insulator_Protecting_Expressed_Genes_of_Interest_for_Human_Gene_Therapy_or_Other_Mammalian_Transgenic_SystemsTAB-1051https://nih.technologypublisher.com/tech?title=Tyrosyl-DNA_Phosphodiesterases_(TDP)_and_Related_Polypeptides%2c_Nucleic_Acids%2c_Vectors%2c_TDP-Producing_Host_Cell%2c_Antibodies_and_Methods_of_UseTopisomerases are cellular enzymes that are vital for replication of the genome. However, if topisomerase and DNA form covalent complexes that prevent the resealing of DNA, this may lead to cell death. Essentially, this invention consists of a new isolated and cloned enzyme, tyrosyl-DNA phospodiesterase (TDP1) that is capable of hydrolyzing the covalent complexes between topisomerase and DNA, allowing the DNA to reseal. The mechanism that defines topiosomerases is their capacity to break DNA and, after an interval in which topological changes may occur, to reseal the break without the interv...Tue, 06 Dec 2022 11:47:53 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech?title=Tyrosyl-DNA_Phosphodiesterases_(TDP)_and_Related_Polypeptides%2c_Nucleic_Acids%2c_Vectors%2c_TDP-Producing_Host_Cell%2c_Antibodies_and_Methods_of_UseTAB-1045https://nih.technologypublisher.com/tech/Modified_Bacterial_Strain_for_Otitis_Media_VaccineThis invention relates to a strain of Moraxella catarrhalis containing a gene mutation that prevents endotoxic lipooligosaccharide (LOS) synthesis and potential use of the mutant for developing novel vaccines against the pathogen, for which there is currently no licensed vaccine. M. catarrhalis is one of the causative agents of otitis media (middle ear infection), sinusitis, and lung infections. The mutant is defective in the lpxA gene, whose enzyme product is relevant in lipid A biosynthesis (lipid A is part of the LOS). The nontoxic mutant was found to elicit high levels of antibodies wit...Tue, 06 Dec 2022 11:47:51 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Modified_Bacterial_Strain_for_Otitis_Media_VaccineTAB-1042https://nih.technologypublisher.com/tech/Antibody_to_Estrogen_Related_Receptor_alphaEstrogen related receptor alpha (ERRalpha) is a family member of the steroid/thyroid nuclear receptor superfamily. Estrogen related receptors are thought to regulate similar target genes in the absence of known ligands. For example, the inventors previously cloned the human estrogen receptor-related orphan receptor alpha1 cDNA and demonstrated that it enhances estrogen responsiveness of the lactoferrin gene promoter in transfected human endometrial carcinoma cells. The inventors have produced a peptide and fusion protein rabbit polyclonal antibody against ERRalpha1-C terminal (anti-ERRalpha-...Tue, 06 Dec 2022 11:47:49 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Antibody_to_Estrogen_Related_Receptor_alphaTAB-1041https://nih.technologypublisher.com/tech/Mouse_Lactoferrin_AntibodyLactoferrin, an iron-binding glycoprotein, kills bacteria and modulates inflammatory and immune responses. It is expressed in mucosa membrane and is present in saliva, tears, vaginal secretion and neutrophils. It modulates immune and inflammatory response by down-regulating several cytokines. Therefore, lactoferrin is an important protein in first line of defense and protecting health. Changes in lactoferrin expression could also be used as a marker of gene activation, especially estrogen-induced gene activity in the uterus. The inventors have uniquely purified a novel 70 kDa estrogen-stim...Tue, 06 Dec 2022 11:47:48 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Mouse_Lactoferrin_AntibodyTAB-1038https://nih.technologypublisher.com/tech/Compositions_and_Methods_for_the_Treatment_of_Immune-Related_DiseaseThe ability of the immune system to discriminate between self and non-self is controlled by central and peripheral tolerance mechanisms. One of the most important ways the immune system controls the outcome of such a response is through naturally occurring CD4+CD25+ regulatory T cells. The present invention relates to compositions and methods for treating immune related disease, a method for determining the presence of or predisposition to an immune related disease, and a pharmaceutical composition for treating an immune related disease in a mammal.Tue, 06 Dec 2022 11:47:46 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Compositions_and_Methods_for_the_Treatment_of_Immune-Related_DiseaseTAB-1034https://nih.technologypublisher.com/tech/Anti-Proliferative_Activity_of_an_Unexpected_mTOR_Kinase_InhibitorThe second leading cause of death in the United States is cancer and more than one million Americans are diagnosed with cancer each year, with this number likely to increase as the population ages. There remains a need for effective therapeutics with improved safety profiles, and promising results have been obtained from targeting the phosphatidylinositol-3-kinase (PI3K) signalling cascade (including PI3K, AKT/PKB and mammalian target of rapamycin (mTOR/S6K) kinases) which is integral to the regulation of cell growth, protein synthesis and apoptosis in response to nutrients and mitogens, and ...Tue, 06 Dec 2022 11:47:45 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Anti-Proliferative_Activity_of_an_Unexpected_mTOR_Kinase_InhibitorTAB-3108https://nih.technologypublisher.com/tech?title=Synergistic_Internal_Ribosomal_Entry_Site_(IRES)%e2%80%94MicroRNA-Based_Approach_for_Attenuation_of_Flaviviruses_and_Live_Vaccine_DevelopmentMany members of the Flaviviridae family are emerging and reemerging human pathogens that have caused outbreaks of devastating and often fatal diseases and represent a serious public health problem on a global scale. There is no single attenuation strategy that exists which is sufficient to prepare a safe, efficacious and immunogenic live attenuated virus vaccine that will work universally for Flaviviridae. This patent application claims live attenuated flavivirus vaccines, live attenuated multivalent flavivirus vaccines, and methods of preventing flavivirus infections as well as methods of m...Tue, 06 Dec 2022 11:47:43 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech?title=Synergistic_Internal_Ribosomal_Entry_Site_(IRES)%e2%80%94MicroRNA-Based_Approach_for_Attenuation_of_Flaviviruses_and_Live_Vaccine_DevelopmentTAB-1023https://nih.technologypublisher.com/tech/Monoclonal_Antibodies_to_HIV-1_VprAvailable for licensing are monoclonal antibodies against HIV-1 viral protein R (Vpr) and the respective hybridoma cell lines expressing the same. The antibodies provide a means for detecting HIV-1 Vpr. Currently, the mechanism of HIV pathogenesis believed to involve viral replication inside immune cells and other cells. At present, there are no clinical assays for detecting HIV-1 Vpr. Vpr circulates at detectable levels in the blood and is likely derived from degraded virions or released from infected cells. Vpr facilitates viral replication and disrupt normal cell function. Thus measure...Tue, 06 Dec 2022 11:47:34 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Monoclonal_Antibodies_to_HIV-1_VprTAB-1011https://nih.technologypublisher.com/tech/ApoA-1_Mimetic_Peptides_Promoting_Lipid_Efflux_from_Cells_for_Treatment_of_Vascular_DisordersThis invention involves ApoA-1 mimetic peptides with multiple amphipathic alpha-helical domains that promote lipid efflux from cells and are useful in the treatment and prevention of dyslipidemic, inflammatory and vascular disorders. IND-enabling studies for one of the peptides, named Fx-5A, are completed in preparation for an IND filing at the FDA, to be followed by a Phase I clinical trial planned for 2017. Disorders amenable to treatment with the peptides include hyperlipidemia, hyperlipoproteinemia, hypercholesterolemia, HDL deficiency, hypertriglyceridemia, apoA-I deficiency, acute coro...Tue, 06 Dec 2022 11:47:29 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/ApoA-1_Mimetic_Peptides_Promoting_Lipid_Efflux_from_Cells_for_Treatment_of_Vascular_DisordersTAB-1010https://nih.technologypublisher.com/tech?title=Novel_Methods_for_Reducing_Inflammation_and_Treating_Diseases_such_as_Parkinson%27s_and_Alzheimer%27s_DiseaseMicroglia activation leads to inflammation mediated dopaminergic degeneration in the brain of patients with Parkinson and Alzheimer's Disease. Thus Identification of drugs that reduce microglia activation could prevent or reverse neuronal degeneration in these diseases and other degenerative CNS disorders. This invention describes small-peptide and non-peptide molecules that inhibit microglia activation and prevent neuronal degeneration with a bi-modal dose response curve. The non-peptide compounds have also been shown to prevent dopamine neuronal degeneration in animal models. This inventio...Tue, 06 Dec 2022 11:47:28 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech?title=Novel_Methods_for_Reducing_Inflammation_and_Treating_Diseases_such_as_Parkinson%27s_and_Alzheimer%27s_DiseaseTAB-1003https://nih.technologypublisher.com/tech/Accelerated_Vaccination_Strategies_to_Provide_Protection_Against_Viral_InfectionsThe technology described in this patent application relates to recombinant viruses for use as vaccines. These viruses contain a single or plurality of sequences encoding antigens from pathogenic viruses heterologous to the recombinant virus. The antigenic sequences from pathogens such as influenza, RSV, measles, HPV, Epstein-Barr, Lassa, Polio, West Nile, Dengue, HIV-1 and 2, HTLV, herpes simplex virus, hepatitis viruses A, B, C, D, and E, Marburg, Ebola, and SARS are inserted into non-essential regions of either replication-competent or replication-defective adenovirus, adeno-associated vir...Tue, 06 Dec 2022 11:47:25 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Accelerated_Vaccination_Strategies_to_Provide_Protection_Against_Viral_InfectionsTAB-1001https://nih.technologypublisher.com/tech/Infectious_Clone_of_Human_Parvovirus_B19_and_Methods_of_UseThis technology described in this patent application relates the first reported infectious human parvovirus B19 clone, methods of cloning the parvovirus B19 genome as well as other viral genomes that have secondary DNA structures that are unstable in bacterial cells. The infectious clone and methods of producing the same would be useful in producing infectious virus, which can in turn be used, among other things, to identify and develop therapeutic agents for treatment and/or prevention of human parvovirus B19 infections. The infectious parvovirus B19 clone is also available for licensing. ...Tue, 06 Dec 2022 11:47:24 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Infectious_Clone_of_Human_Parvovirus_B19_and_Methods_of_UseTAB-996https://nih.technologypublisher.com/tech/Multimeric_Protein_Toxins_to_Target_Cells_Having_Multiple_Identifying_CharacteristicsThis technology relates to multimeric bacterial protein toxins which can be used to specifically target cells. Specifically, this is a modified recombinant anthrax toxin protective antigen (PrAg) that has been modified in several ways. First, the PrAg can be activated both by a metalloproteinase (MMP) and by urokinase plasminogen activator (uPA). Second, the native PrAg lethal factor (LF) binding site has been modified so that only a modified PrAg comprising two different monomers can bind anthrax LF. When administered with an effector component, the recombinant anthrax toxins are toxic only t...Tue, 06 Dec 2022 11:47:22 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Multimeric_Protein_Toxins_to_Target_Cells_Having_Multiple_Identifying_CharacteristicsTAB-978https://nih.technologypublisher.com/tech/Anti-Vaccinia_Monoclonal_AntibodyThe current technology describes a monoclonal antibody that reacts with a vaccinia virus protein abundantly expressed under an early viral promoter after infection of cells. The antibody is useful for quantitating vaccinia virus infected cells and for studying the function of the protein to which it binds, which is known to be a double stranded RNA binding protein involved in resistance of the virus to interferons. This antibody is available for licensing through a biological materials license agreement.Tue, 06 Dec 2022 11:47:16 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Anti-Vaccinia_Monoclonal_AntibodyTAB-946https://nih.technologypublisher.com/tech/Haplotypes_of_Human_Bitter_Taste_Receptor_GenesBitter taste has evolved in mammals as a crucial, important warning signal against ingestion of poisonous or toxic compounds. However, many beneficial compounds are also bitter, and taste masking of bitter tasting pharmaceutical compounds is a billion dollar industry. The diversity of compounds that elicit bitter-taste sensations is very large and more than two dozen members of the T2R bitter taste receptor family have been identified. Individuals are now known to be genetically predisposed to respond or not to respond to the bitter taste of a number of substances. For example, large indiv...Tue, 06 Dec 2022 11:47:08 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Haplotypes_of_Human_Bitter_Taste_Receptor_GenesTAB-925https://nih.technologypublisher.com/tech/Contrast_Agent_Enhancement_of_Chemical_Exchange_Dependent_Saturation_Transfer_(CEDST)_MRIAvailable for licensing is an MRI image improving system wherein at least one contrast agent is administered to a subject in amounts effective to perform chemical exchange dependent saturation transfer (CEDST) MRI analysis. Examples of contrast agents suitable for administration as exogenous contrast agents include at least one functional group bearing a proton capable of chemical exchange. Examples of these functional groups include, without limitation, amides, amines, and carboxyl, hydroxyl, and sulfhydryl groups. The contrast agent can be administered as a solid, as a dispersion or solu...Tue, 06 Dec 2022 11:47:03 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Contrast_Agent_Enhancement_of_Chemical_Exchange_Dependent_Saturation_Transfer_(CEDST)_MRITAB-923https://nih.technologypublisher.com/tech/Novel_Method_of_Fat_Suppression_in_Steady_State_Free_Precession_(SSFP)_Based_Magnetic_Resonance_Imaging_(MRI)Available for licensing is a technique for improving magnetic resonance imaging (MRI) that employs steady state free precession (SSFP). One such technique, fast imaging with steady-state free precession (FISP), is a well established and is a fast MR imaging method commonly used to evaluate cardiovascular anatomy and function. FISP provides high signal to noise ratio (SNR) images with excellent contrast between blood and the myocardium. However, these images are often contaminated with high signal from fatty tissue resulting in image artifacts. Conventional methods of fat signal suppression...Tue, 06 Dec 2022 11:47:02 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Novel_Method_of_Fat_Suppression_in_Steady_State_Free_Precession_(SSFP)_Based_Magnetic_Resonance_Imaging_(MRI)TAB-917https://nih.technologypublisher.com/tech/Cannula_for_Pressure_Mediated_Drug_DeliveryAvailable for licensing are methods and devices for selectively delivering therapeutic substances to specific histological or microanatomical areas of organs (e.g., introduction of the therapeutic substance into a hollow organ space such as the hepatobiliary duct or the gallbladder lumen) at a controlled pressure, volume and/or rate which allows the substance to reach a predetermined cellular layer. The volume or flow rate of the substance can be controlled so that the intralumenal pressure reaches a predetermined threshold beyond which subsequent subepithehal delivery of the substance occurs...Tue, 06 Dec 2022 11:47:00 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Cannula_for_Pressure_Mediated_Drug_DeliveryTAB-911https://nih.technologypublisher.com/tech?title=MVA_Expressing_Modified_HIV_envelope%2c_gag%2c_and_pol_GenesThis invention claims Modified Vaccinia Ankara (MVA), a replication-deficient strain of vaccinia virus, expressing Human Immunodeficiency Virus (HIV) env, gag, and pol genes, where the genes are isolated from Ugandan Clade D isolates, Kenyan Clade A isolates, and Tanzanian Clade C isolates. In a rhesus macaque SHIV model, DNA priming followed by a recombinant MVA (rMVA) booster controlled a highly pathogenic immunodeficiency challenge. Both the DNA and the rMVA components of the vaccine expressed multiple immunodeficiency virus proteins. Two DNA inoculations at zero (0) and eight (8) weeks ...Tue, 06 Dec 2022 11:46:57 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech?title=MVA_Expressing_Modified_HIV_envelope%2c_gag%2c_and_pol_GenesTAB-910https://nih.technologypublisher.com/tech?title=Construction_of_Recombinant_Baculoviruses_Carrying_the_Gene_Encoding_the_Major_Capsid_Protein%2c_VP1%2c_From_Calicivirus_Strains_(Including_Norovirus_Strains_Toronto%2c_Hawaii%2c_Desert_Shield%2c_Snow_Mountain%2c_and_MD145-12)The noroviruses (known as "Norwalk-like viruses") are associated with an estimated 23,000,000 cases of acute gastroenteritis in the United States each year. Norovirus illness often occurs in outbreaks, affecting large numbers of individuals, illustrated recently by well-publicized reports of gastroenteritis outbreaks on several recreational cruise ships and in settings such as hospitals and schools. Norovirus disease is clearly important in terms of medical costs and missed workdays, and accumulating data support its emerging recognition as important agents of diarrhea-related morbidity. Bec...Tue, 06 Dec 2022 11:46:56 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech?title=Construction_of_Recombinant_Baculoviruses_Carrying_the_Gene_Encoding_the_Major_Capsid_Protein%2c_VP1%2c_From_Calicivirus_Strains_(Including_Norovirus_Strains_Toronto%2c_Hawaii%2c_Desert_Shield%2c_Snow_Mountain%2c_and_MD145-12)TAB-909https://nih.technologypublisher.com/tech/Construction_of_an_Infectious_Full-Length_cDNA_Clone_of_the_Porcine_Enteric_Calicivirus_RNA_GenomeTue, 06 Dec 2022 11:46:54 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Construction_of_an_Infectious_Full-Length_cDNA_Clone_of_the_Porcine_Enteric_Calicivirus_RNA_GenomeTAB-908https://nih.technologypublisher.com/tech/Enzymatically-Active_RNA-Dependent_RNA_Polymerase_From_a_Human_Norovirus_(Calicivirus)Tue, 06 Dec 2022 11:46:52 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Enzymatically-Active_RNA-Dependent_RNA_Polymerase_From_a_Human_Norovirus_(Calicivirus)TAB-903https://nih.technologypublisher.com/tech/Full-Length_cDNA_Clone_Representing_the_Consensus_Sequence_of_the_RNA_Genome_of_a_Human_Norovirus_(strain_MD145-12)_That_Encodes_Biologically_Active_ProteinsThe invention provides for a full-length cloned cDNA copy of the RNA genome of a predominant norovirus strain (Genogroup II.4) designated MD145-12 that was associated with human gastrointestinal illness. The noroviruses, which were formerly known as "Norwalk-like" viruses are estimated to cause 23 million cases of acute gastroenteritis in the USA each year. The virus has been designated into category B of the CDC biodefense-related priority pathogens because it can be used as an agent of bioterrorism. The subject cDNA clone of the virus encodes proteins of the MD145-12 strain that, when expres...Tue, 06 Dec 2022 11:46:50 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Full-Length_cDNA_Clone_Representing_the_Consensus_Sequence_of_the_RNA_Genome_of_a_Human_Norovirus_(strain_MD145-12)_That_Encodes_Biologically_Active_ProteinsTAB-893https://nih.technologypublisher.com/tech?title=Modulators_of_Nuclear_Hormone_Receptor_Activity%3a_Novel_Compounds%2c_Diverse_Applications_for_Infectious_Diseases%2c_Including_Anthrax_B._anthracisNuclear hormones such as glucocorticoids dampen inflammatory responses, and thus provide protection to mammals against inflammatory disease and septic shock. The Anthrax lethal factor represses nuclear hormone receptor activity, and thus may contribute to the infectious agent causing even more damage to the host. This observation can be exploited to find new means of studying and interfering with the normal function of nuclear hormone receptors. Scientists at NIH have shown that under the appropriate conditions, these molecules can be used to modulate the activity of various nuclear hormone...Tue, 06 Dec 2022 11:46:47 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech?title=Modulators_of_Nuclear_Hormone_Receptor_Activity%3a_Novel_Compounds%2c_Diverse_Applications_for_Infectious_Diseases%2c_Including_Anthrax_B._anthracisTAB-885https://nih.technologypublisher.com/tech/Multipotent_Postnatal_Stem_Cells_From_Human_Periodontal_Ligament_and_Uses_ThereofIt is estimated that over 40 percent of the adult population in the United States has periodontal disease in one form or another. Periodontal Disease is a chronic infection of the periodontal ligament (PDL) and the adjacent bone and cementum. The effects of Periodontal Disease range from simple gum inflammation to, in extreme cases, tooth loss. The NIH announces a new technology wherein stem cells from the PDL have been isolated from adult human PDL. These cells are capable of forming cementum and PDL in immunocompromised mice. In cell culture, PDL stem cells differentiate into collagen fi...Tue, 06 Dec 2022 11:46:43 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Multipotent_Postnatal_Stem_Cells_From_Human_Periodontal_Ligament_and_Uses_ThereofTAB-878https://nih.technologypublisher.com/tech/Method_and_Apparatus_for_Bioweapon_DecontaminationIt is in the interest of the public health and national security that the Public Health Service find a licensee for the commercial development and rapid dissemination of the apparatus and method of this invention. The apparatus enables the decontamination of articles contaminated with bioweapons, more particularly sporolated bioweapons of which anthrax (Bacillus anthracis) is of notable concern. The system includes enclosing the article to be decontaminated in a humidified environment thus enhancing the susceptibility of spores to decontamination gases such as chlorine dioxide. Vacuum sealin...Tue, 06 Dec 2022 11:46:41 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Method_and_Apparatus_for_Bioweapon_DecontaminationTAB-875https://nih.technologypublisher.com/tech/Activation_of_Recombinant_Diphtheria_Toxin_Fusion_Proteins_by_Specific_Proteases_Highly_Expressed_on_the_Surface_of_Tumor_CellsThis invention relates to diphtheria toxin fusion proteins comprising a diphtheria toxin (DT) cell-killing component and a cell-binding component such as granulocyte macrophage colony-stimulating factor (GM-CSF), interleukin 2 (IL-2), or epidermal growth factor (EGF). Receptors for the latter three materials are present on many types of cancer cells; therefore, these fusion proteins bind preferentially to these cancer cells. A key feature is that these toxins are altered so as to require activation by a cell-surface protease that is overexpressed on many types of cancers. Examples of such p...Tue, 06 Dec 2022 11:46:40 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Activation_of_Recombinant_Diphtheria_Toxin_Fusion_Proteins_by_Specific_Proteases_Highly_Expressed_on_the_Surface_of_Tumor_CellsTAB-860https://nih.technologypublisher.com/tech/Brother_of_the_Regulator_of_Imprinted_Sites_(BORIS)The subject application discloses an isolated or purified nucleic acid molecule consisting essentially of a nucleotide sequence encoding a human or a non-human BORIS, or a fragment of either of the foregoing; an isolated or purified nucleic acid molecule consisting essentially of a nucleotide sequence that is complementary to a nucleotide sequence encoding a human or a non-human BORIS, or a fragment of either of the following; a vector comprising such an isolated or purified polypeptide molecule consisting essentially of an amino acid sequence encoding a human or a non-human BORIS, or a fragme...Tue, 06 Dec 2022 11:46:35 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Brother_of_the_Regulator_of_Imprinted_Sites_(BORIS)TAB-846https://nih.technologypublisher.com/tech/Codon-optimization_of_HIV-1_Viral_Infectivity_Factor_(VIF)_GeneExpression of the HIV-1 Vif protein in the absence of other viral factors such a Tat and Rev is extremely inefficient due to the presence of inhibitory sequences on its mRNA. This invention uses codon optimization to remove such inhibitory sequences without altering the amino acid sequence of the protein. The modified vif gene in the resulting pcDNA -hVIF vector is expressed under the control of the CMV promoter. In this, the protein functions as wild type and is more amendable to high-level expression in mammalian cells. Currently this vector is used in on-going studies of HIV infection an...Tue, 06 Dec 2022 11:46:32 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Codon-optimization_of_HIV-1_Viral_Infectivity_Factor_(VIF)_GeneTAB-843https://nih.technologypublisher.com/tech/IL-21_Critically_Regulates_Immunoglobulin_ProductionThe invention includes a mouse in which the IL-21 receptor gene is disrupted by homologous recombination, the disruption being sufficient to prevent expression of the IL-21 receptor and thus to inhibit the action of IL-21. The invention also includes a mouse in which both the IL-21 receptor gene and the IL-4 gene are simultaneously disrupted in fashions being sufficient to inhibit the action of IL-21 and the production of IL-4. In a homozygous state, these mutations produce a mouse that has diminished B cell function. This invention also relates to the use of agents that inhibit the interac...Tue, 06 Dec 2022 11:46:31 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/IL-21_Critically_Regulates_Immunoglobulin_ProductionTAB-832https://nih.technologypublisher.com/tech/Pain_Control_by_the_Selective_Local_Ablation_of_Nociceptive_NeuronsThe vanilloid receptor (VR) is a cation channel predominantly expressed on the peripheral processes and perikarya of nociceptive primary afferent neurons. Previous studies have shown that activation of the peripheral receptors by agonists such as capsaicin from hot peppers, or the much more potent resiniferatoxin, produces acute pain sensation which may be followed by desensitization. These inventors discovered that administration of VR agonists in the vicinity of neuronal cell bodies expressing the VR receptor can actually destroy those cells. To control pain and inflammatory disorders, th...Tue, 06 Dec 2022 11:46:28 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Pain_Control_by_the_Selective_Local_Ablation_of_Nociceptive_NeuronsTAB-828https://nih.technologypublisher.com/tech/A_Microfluidic_Flow-Through_Immunoassay_for_a_Simultaneous_Detection_of_Multiple_Proteins_in_a_Sub-Microliter_Biological_SampleThis invention presents a high throughput, multi-analyte microfluidic chip device. This device can be used for the detection and characterization of proteins, immuno-affinity assays as well as analyte detection in biological samples or other media. The sub-microliter volumes for use make this device applicable where biological samples are rare and difficult to obtain. The device consists of a series of channels that are connected via communication ports for sample flow. The channels can be individually loaded with detection reagents via portals at their ends. As such, the assay channels can ...Tue, 06 Dec 2022 11:46:26 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/A_Microfluidic_Flow-Through_Immunoassay_for_a_Simultaneous_Detection_of_Multiple_Proteins_in_a_Sub-Microliter_Biological_SampleTAB-823https://nih.technologypublisher.com/tech/Phenylthiocarbamide_(PTC)_Taste_ReceptorBitter taste has evolved in mammals as a central warning signal against ingestion of poisonous or toxic compounds. However, many beneficial compounds are also bitter and taste masking of bitter tasting pharmaceutical compounds is a billion dollar industry. The diversity of compounds that elicit bitter-taste sensations is vast and more than two dozen members of the TAS2R bitter taste receptor gene family have been identified. How individuals are genetically predisposed to respond or not to respond to the bitter taste of substances like nicotine and certain foods like broccoli may have broad ...Tue, 06 Dec 2022 11:46:24 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Phenylthiocarbamide_(PTC)_Taste_ReceptorTAB-817https://nih.technologypublisher.com/tech/A_Tet-Regulated_Mouse_Model_for_CataractCataract is the most common cause of blindness worldwide, with an estimated 25 million blind and 119 million visually impaired individuals worldwide. Over 20 million adults in the US alone are currently diagnosed with cataracts making this disease a major health concern. The incidence of cataract increases with age and a number of etiologic factors have been proposed in the pathogenesis of age-related cataract in humans including genetic factors, environmental factors and metabolic and biochemical changes in the crystalline lens. Ultraviolet radiation exposure and oxidative injury to the le...Tue, 06 Dec 2022 11:46:22 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/A_Tet-Regulated_Mouse_Model_for_CataractTAB-816https://nih.technologypublisher.com/tech/A_Mouse_Model_for_Type_2_DiabetesDiabetes affects over 120 million people worldwide (16 million in the US) and is a major health problem with associated health costs estimated at almost $100 billion dollars. Type 2 diabetes affects as many as 10% of the population of the Western World (with 15 million patients in the US alone) and arises from a heterogeneous etiology, with secondary effects from environmental influences. Risk factors for type 2 diabetes include obesity, high blood pressure, high triglycerides and age. Type 2 diabetes is an active area for drug development and there continues to be a need for novel animal m...Tue, 06 Dec 2022 11:46:21 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/A_Mouse_Model_for_Type_2_DiabetesTAB-814https://nih.technologypublisher.com/tech/A_Mouse_Model_for_Systemic_Inflammation_in_Glucocerebrosidase-Deficient_Mice_with_Minimal_Glucosylceramide_StorageGaucher disease, the most common lysosomal storage disease, is an inherited metabolic disorder in which harmful quantities of the lipid glucocerebroside accumulate in the spleen, liver, lungs, bone marrow and in rare cases in the brain, due to a deficiency of the enzyme glucocerebrosidase (Gba) that catalyses the first step in the biodegradation of glucocerebrosides. Type 1 Gaucher disease is the most common and is distinguished from the other forms of the disease, types 2 and 3, by the lack of neurologic involvement. The clinical features of Type 1 are heterogeneous, vary broadly in clinical...Tue, 06 Dec 2022 11:46:20 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/A_Mouse_Model_for_Systemic_Inflammation_in_Glucocerebrosidase-Deficient_Mice_with_Minimal_Glucosylceramide_StorageTAB-810https://nih.technologypublisher.com/tech/Particles_for_Imaging_CellsAvailable for licensing are NIH patent pending contrast particles for use in MRI and flow cytometry to track cells migration in real time. Present cell-tracking studies rely on labeling cells with ultra-small dextran-coated iron particles that are endocytosed. The contrast agent of the present invention uses larger iron oxide particles, approximately 1 µm, situated in a tri-layer structure. The inner structure is a magnetic molecular complex of FITC (a fluorescent marker) encased in a layer of superparamagnetic microparticles, which is then covered with a shell of inert polystyrene and di-vi...Tue, 06 Dec 2022 11:46:19 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Particles_for_Imaging_CellsTAB-807https://nih.technologypublisher.com/tech/HIV-Dependent_Expression_VectorThis invention provides a DNA construct that can be useful for both diagnostics and AIDS therapeutics. The construct can be incorporated into a retrovirus or into a cell line. This construct mediates the expression of a selected gene in the presence of HIV replication, but is silent in the absence of HIV. The cell line with the incorporated construct can be used as an indicator line for the presence of replication-competent HIV. The virus containing the construct can be used to co-infect a population of HIV-infected cells. If the construct-encoded gene is a reporter, it would specifically iden...Tue, 06 Dec 2022 11:46:17 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/HIV-Dependent_Expression_VectorTAB-788https://nih.technologypublisher.com/tech/Mouse_Lacking_the_Chemokine_Receptor_CX3CR1This mouse has been generated by targeted gene disruption. The mouse provides a model to investigate the function of the chemokine receptor CX3CR1, which is a proinflammatory receptor for the leukocyte chemoattractant CX3CL1 (aka fractalkine). As an example, the mouse is in use in the study of atherosclerosis. Further, the mouse may serve as a model study the role of the immune system during infection with pathogens as well as other immunologically mediated diseases and responses to tumors.Tue, 06 Dec 2022 11:46:12 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Mouse_Lacking_the_Chemokine_Receptor_CX3CR1TAB-787https://nih.technologypublisher.com/tech/Vaccines_Comprising_Sand_Fly_Salivary_Proteins_for_Control_of_Leishmania_InfectionThis invention relates to the use of several peptides from the salivary glands of various sand fly species for the control of leishmania infection. Many of these peptides were shown to be effective in eliciting potent immune responses in animal models and are excellent candidates for the development of vaccines against the disease. A vaccine comprising one of the peptides was used to protect mice challenged with parasites and salivary gland homogenates. A DNA vaccine containing the cDNA for this same peptide also provided protection that lasted at least 3 months after immunization and produ...Tue, 06 Dec 2022 11:46:11 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Vaccines_Comprising_Sand_Fly_Salivary_Proteins_for_Control_of_Leishmania_InfectionTAB-789https://nih.technologypublisher.com/tech/Factors_That_Bind_Intestinal_ToxinsThis invention discloses and covers polyphenolic compounds that will bind bacterial toxins, methods for the treatment of such infections, specifically Stx-1 toxins from STEC strains of E. coli. Bacterial infections not only cause disease by their presence but also upon the release of toxins. The common enteric bacteria, E. coli O157:H7 releases such toxins (Stx-1) upon treatment with antibiotics. These toxins, when released into the lumen of the intestinal tract, will cause cellular damage thus increasing the severity of the infection. Thus not only does the patient become sick by the i...Tue, 06 Dec 2022 11:46:10 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Factors_That_Bind_Intestinal_ToxinsTAB-778https://nih.technologypublisher.com/tech/Peptides_for_Treatment_of_Tumor_Necrosis_Factor_alpha_Mediated_Inflammatory_DiseaseTumor Necrosis Factor alpha (TNF-alpha) is a multifunctional cytokine that mediates inflammation, immune regulation, and cellular proliferation. This cytokine is converted to its active form by TNF-alpha converting enzyme (TACE). Pathological increases in TNF-alpha activity have been associated with a wide variety of inflammatory diseases, including inflammatory bowel disease, rheumatoid arthritis, and cancer. Inhibiting the conversion of TNF-alpha to its active form by inhibiting TACE represents a potential treatment for these diseases. The current technology provides peptides, derived from ...Tue, 06 Dec 2022 11:46:08 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Peptides_for_Treatment_of_Tumor_Necrosis_Factor_alpha_Mediated_Inflammatory_DiseaseTAB-777https://nih.technologypublisher.com/tech/Isolation_of_Hybridomas_Producing_Monoclonal_Antibodies_(MAbs)_Inhibitory_to_Human_CYP2J2The National Institutes of Health announces three specific monoclonal antibodies that strongly inhibit and/or immunoblot the human cytochrome P450 2J2 (CYP2J2). Cytochrome P450s catalyze the NADPH-dependent oxidation of arachidonic acid to various eicosanoids found in several species. The eicosanoids are biosynthesized in numerous tissues including pancreas, intestine, kidney, heart and lung where they are involved in many different biological activities. MAb 6-5-20-8 selectively inhibits CYP2J2-mediated arachidonic acid metabolism by more than 80% and also immunoblots the enzyme. MAb 6-2-...Tue, 06 Dec 2022 11:46:06 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Isolation_of_Hybridomas_Producing_Monoclonal_Antibodies_(MAbs)_Inhibitory_to_Human_CYP2J2TAB-776https://nih.technologypublisher.com/tech/Peptide_Mimotope_Candidates_for_Otitis_Media_VaccineThis technology describes peptide mimotopes of lipooligosaccharides (LOS) from nontypeable Haemophilus influenzae (NTHi) and Moraxella catarrhalis that are suitable for developing novel vaccines against the respective pathogens, for which there are currently no licensed vaccines. The mimotopes not only immunologically mimic LOSs from NTHi and M. catarrhalis but will also bind to antibodies specific for the respective LOS. NTHi and M. catarrhalis are common pathogens that cause otitis media in children and lower respiratory tract infections in adults. The effectiveness of a vaccine could be i...Tue, 06 Dec 2022 11:46:05 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Peptide_Mimotope_Candidates_for_Otitis_Media_VaccineTAB-771https://nih.technologypublisher.com/tech/Recombinant_Plasmids_for_Soluble_ImmunoreceptorsImmunoreceptors initiate signals leading to the activation of immune system against invasion pathogens. A number of soluble receptors, representing the extracellular ligand binding domains of the immunoreceptors, have been expressed using a recombinant bacteria expression and reconstitution system. This set of 21 plasmids, which can be used as immunological research reagents or to develop diagnostic tools, comprise the following: Plasmid Description CD16-28b Soluble CD16 CD94 (S34) - 30a Soluble CD94 truncated at S34 ...Tue, 06 Dec 2022 11:46:04 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Recombinant_Plasmids_for_Soluble_ImmunoreceptorsTAB-770https://nih.technologypublisher.com/tech/Variable_Curve_CatheterThe invention provides a deflectable tip guiding device, such as a catheter, that enables the operator to vary the radius of curvature of the tip of the catheter. This is a novel variation on the classic "fixed fulcrum" tip deflectors used in minimally invasive procedures in open surgical treatments. The described device permits a more comprehensive ability to navigate complex geometric pathways in patient's body and enables better access to target structures (e.g., to all endomyocardial walls from a transaortic approach). The guiding device can be made compatible with imaging methods like ...Tue, 06 Dec 2022 11:46:01 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Variable_Curve_CatheterTAB-764https://nih.technologypublisher.com/tech/Diagnostics_and_Therapeutics_for_HydrocephalusCongenital hydrocephalus is a significant public health problem, affecting approximately one in 500 live births in the United States. Congenital hydrocephalus has an adverse effect on developing brain and may persist as neurological defects in children and adults. Some of these defects may manifest as mental retardation, cerebral palsy, epilepsy and visual disabilities. Improved diagnostics are needed for assessing the risks of developing this debilitating disease. The inventors have shown that RFX4_v3, a splice variant of the Regulatory Factor X4 (RFX4) transcription factor, is associated...Tue, 06 Dec 2022 11:45:59 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Diagnostics_and_Therapeutics_for_HydrocephalusTAB-757https://nih.technologypublisher.com/tech/Oral_Treatment_of_HemophiliaThis invention portrays a simple method for treatment of antigen-deficiency diseases by orally administering to a subject a therapeutically effective amount of the deficient antigen, wherein the antigen is not present in a liposome. This method increases hemostasis in a subject having hemophilia A or B, by orally administering to the hemophiliac a therapeutically effective amount of the appropriate clotting factor, sufficient to induce oral tolerance and supply exogenous clotting factor to the subject.Tue, 06 Dec 2022 11:45:57 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Oral_Treatment_of_HemophiliaTAB-755https://nih.technologypublisher.com/tech/Detection_of_Mutational_Frequency_in_Human_Bone_MarrowTo date there have been no adequate methods to determine the frequency of mutations in humans. This invention discloses a method of measuring the mutational frequency of a mitochondrial DNA sequence by sequencing mitochondrial DNA from clonally expanded single cells such as CD34+ human stem cells. Sequencing for mitochondrial DNA polymorphisms and mutations may also be useful as a general method to detect minimal residual disease in leukemia. The mitochondrial genome is particularly susceptible to mutations and these may be used to measure genomic mutagenesis by virtue of comparison. The ap...Tue, 06 Dec 2022 11:45:56 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Detection_of_Mutational_Frequency_in_Human_Bone_MarrowTAB-743https://nih.technologypublisher.com/tech?title=Mouse_Monoclonal_Antibodies_Against_Human_IKKgamma%2fNEMO_ProteinNF-kB has been found to be important in immune responses, cell proliferation, apoptosis, and in organ development. Several years ago it was discovered that an IKKgamma/NEMO protein was essential as an adaptor molecule to mediate TNF-alpha, IL-1, and oncoprotein induced activation of NF-kB. Mutation in IKKgamma/NEMO also results in two human genetic diseases, Familial incontinentia pigmenti and hypohidrotic/anhidrotic ectodermal dysplasia. The NIH announces mouse monoclonal antibodies to IKKgamma/NEMO that are far superior to other immunological reagents. It is anticipated that the antibodi...Tue, 06 Dec 2022 11:45:53 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech?title=Mouse_Monoclonal_Antibodies_Against_Human_IKKgamma%2fNEMO_ProteinTAB-737https://nih.technologypublisher.com/tech/Methanocarba_Cycloalkyl_Nucleoside_AnaloguesPurines such as adenosine and ATP have been shown to play a wide array of roles in biological systems such as inter alia, modulator of vasodilation and hypotension, muscle relaxant, central depressant, inhibitor of platelet aggregation, regulator of energy supply/demand, responder to oxygen availability, neurotransmitter and neuromodulator. All P1 and P2 receptor nucleoside ligands suffer from chemical instability that is caused by the labile glycosidic linkage in the sugar moiety of the nucleoside. However, it has been found that relatively few ribose modifications are tolerated by the pres...Tue, 06 Dec 2022 11:45:51 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Methanocarba_Cycloalkyl_Nucleoside_AnaloguesTAB-736https://nih.technologypublisher.com/tech/Postnatal_Stem_Cells_and_Uses_ThereofMany individuals with ongoing and severe dental problems are faced with the prospect of permanent tooth loss. Examples of such dental problems include: dentinal degradation due to chronic dental disease (caries or periodontal); mouth injury; or through surgical removal, such as with tumors associated with the jaw. For many, a technology that offers a possible alternative to artificial dentures by designing and transplanting a set of living teeth fashioned from an individual's own pulp cells would greatly improve their quality of life. The NIH announces a new technology wherein human postnatal ...Tue, 06 Dec 2022 11:45:49 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Postnatal_Stem_Cells_and_Uses_ThereofTAB-721https://nih.technologypublisher.com/tech/Compositions_and_Methods_for_Inhibiting_Vascular_Channels_and_Methods_of_Inhibiting_ProliferationAngiogenesis, the recruitment of new blood vessels, is recognized as an important factor in tumor proliferation in many types of cancer. It is generally accepted that therapeutic approaches that inhibit angiogenesis effectively limit, or even prevent, the formation of solid tumors. It has also been shown that anti-angiogenic therapeutics allow conventional radiation therapy and chemotherapy to be more effective. This invention pertains to certain compounds that inhibit angiogenesis in a previously unrecognized way. These compounds also inhibit the proliferation of cells within intraepitheli...Tue, 06 Dec 2022 11:45:45 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Compositions_and_Methods_for_Inhibiting_Vascular_Channels_and_Methods_of_Inhibiting_ProliferationTAB-713https://nih.technologypublisher.com/tech/Method_for_the_Diagnosis_and_Treatment_of_Vascular_DiseaseCardiovascular disease is a major health risk throughout the industrialized world. Atherosclerosis, the most prevalent of cardiovascular diseases, is the principal cause of heart attack, stroke, and gangrene of the extremities. It is also the principal cause of death in the United States. This invention portrays a method for diagnosing decreased vascular function, detecting increased cardiovascular risk and diagnosing atherosclerosis. An embodiment includes assaying the number of endothelial progenitor cells and treating a subject with decreased vascular function by administering a therapeu...Tue, 06 Dec 2022 11:45:43 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Method_for_the_Diagnosis_and_Treatment_of_Vascular_DiseaseTAB-698https://nih.technologypublisher.com/tech/Novel_Acylthiol_Compositions_and_Methods_of_Making_and_Using_Them_Against_HIVThis invention provides a novel family of acylthiols and uses thereof. More specifically, this invention provides effective inhibitors of HIV that selectively target its highly conserved nucleocapsid protein (NCp7) by interacting with metal chelating structures of a zinc finger-containing protein. Because of the mutationally intolerant nature of NCp7, drug resistance is much less likely to occur with compounds attacking this target. In addition, these drugs should inactivate all types and strains of HIV and could also inactivate other retroviruses, since most retroviruses share one or two h...Tue, 06 Dec 2022 11:45:39 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Novel_Acylthiol_Compositions_and_Methods_of_Making_and_Using_Them_Against_HIVTAB-695https://nih.technologypublisher.com/tech?title=4G10%2c_a_Monoclonal_Antibody_Against_the_Chemokine_Receptor_CXCR4%2c_Raised_Against_a_Synthetic_Peptide_of_38_Residues_in_Length_Derived_from_the_N-terminal_Sequence_of_CXCR4This invention identifies a monoclonal antibody (4G10) against the chemokine receptor CXCR4 and is a mouse IgG1 antibody. CXCR4 has been identified as a co-receptor mediating entry of HIV-1 into T cells. Subsequently, CXCR4 has been implicated in normal physiological functions, including activation of B cells and B cell progenitors and guiding their migration into the bone marrow (via its ligand SDF-1). CXCR4 also functions in T cell progenitor migration and neural progenitor stem cell activation. Since 4G10 is a monoclonal antibody raised against a synthetic peptide derived from the N- te...Tue, 06 Dec 2022 11:45:37 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech?title=4G10%2c_a_Monoclonal_Antibody_Against_the_Chemokine_Receptor_CXCR4%2c_Raised_Against_a_Synthetic_Peptide_of_38_Residues_in_Length_Derived_from_the_N-terminal_Sequence_of_CXCR4TAB-2961https://nih.technologypublisher.com/tech?title=Mouse_Strain_CAR-KO_C3H%2fHeNCrl%2c_Deletion_of_Nuclear_Xenobiotic_Receptor_CARCAR (nuclear constitutive active receptor) is a member of the nuclear receptor superfamily, and is a key regulator of xenobiotic and endobiotic metabolism. It is primarily responsible for sensing foreign toxic substances and in response up regulating the expression of proteins involved in the detoxification and clearance of these substances from the body. CAR is constitutively active in the absence of a ligand but is regulated by both agonists and inverse agonists. The ligand binding results in the translocation of this protein to the nucleus, where it activates or represses target gene transc...Tue, 06 Dec 2022 11:45:36 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech?title=Mouse_Strain_CAR-KO_C3H%2fHeNCrl%2c_Deletion_of_Nuclear_Xenobiotic_Receptor_CARTAB-686https://nih.technologypublisher.com/tech/Fibroblast_Growth_Factor_3_(FGFR3)_Receptor_Knockin_MiceMissense mutations in Fibroblast Growth Factor Receptor 3 (FGFR3) result in several human skeletal dysplasias, including the most common form of dwarfism, achondroplasia. The NIH announces the generation of FGFR3 knockin mice, which have a Gly369Cys mutation, inserted into the mouse genome. Phenotypic analysis of the mice reveals that the FGF/FGFR3 signals affect both chondrogenesis and osteogenesis by regulating Stat proteins and cell-cycle inhibitors, and the activities of chondrocytes, osteoclasts, and osteoblasts during endochondral ossification. These mice provide a new animal model to...Tue, 06 Dec 2022 11:45:34 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Fibroblast_Growth_Factor_3_(FGFR3)_Receptor_Knockin_MiceTAB-684https://nih.technologypublisher.com/tech/A_Mouse_Model_for_Human_OsteoarthritisOsteoarthritis (OA) is the most common form of arthritis and affects more than 20 million Americans, costing billions of dollars in health care annually. Osteoarthritis is caused by the breakdown of joint cartilage, leading to a loss of the cartilage "cushion" between the bones of the joints. Risk factors associated with OA include age, obesity, traumatic injury and overuse due to sports or occupational stresses. There is no cure for OA and current treatments are directed at the symptomatic relief of pain, and at improving and maintaining joint function. There remains, however, a critical ...Tue, 06 Dec 2022 11:45:33 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/A_Mouse_Model_for_Human_OsteoarthritisTAB-672https://nih.technologypublisher.com/tech/VAC-BAC_Shuttle_Vector_System_for_Generating_Recombinant_PoxvirusesThis invention relates to a VAC-BAC shuttle vector system for the creation of recombinant poxviruses from DNA cloned in a bacterial artificial chromosome. A VAC-BAC is a bacterial artificial chromosome (BAC) containing a vaccinia virus genome (VAC) that can replicate in bacteria and produce infectious virus in mammalian cells.Tue, 06 Dec 2022 11:45:30 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/VAC-BAC_Shuttle_Vector_System_for_Generating_Recombinant_PoxvirusesTAB-671https://nih.technologypublisher.com/tech?title=Dengue_Tetravalent_Vaccine_Containing_a_Common_30_Nucleotide_Deletion_in_the_3%27-UTR_of_Dengue_Types_1%2c_2%2c_3%2c_and_4The invention relates to a dengue virus tetravalent vaccine containing a common 30-nucleotide deletion (delta30) in the 3'-untranslated region (UTR) of the genome of dengue virus serotypes 1, 2, 3, and 4. The previously identified delta30 attenuating mutation, created in dengue virus type 4 (DEN4) by the removal of 30 nucleotides from the 3'-UTR, is also capable of attenuating a wild-type strain of dengue virus type 1 (DEN1). Removal of 30 nucleotides from the DEN1 3'-UTR in a highly conserved region homologous to the DEN4 region encompassing the delta30 mutation yielded a recombinant virus ...Tue, 06 Dec 2022 11:45:29 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech?title=Dengue_Tetravalent_Vaccine_Containing_a_Common_30_Nucleotide_Deletion_in_the_3%27-UTR_of_Dengue_Types_1%2c_2%2c_3%2c_and_4TAB-667https://nih.technologypublisher.com/tech/Increased_Protein_Expression_Vector_for_Vaccine_ApplicationsAn expression vector with a unique promoter that results in higher level of protein expression than vectors currently in use is available for licensing from the NIH. The elevated levels of expression are achieved through use of a specific promoter, known as CMV/R, in which the Human T-Lymphotrophic Virus (HTLV-1) Long Terminal Repeat (LTR) R-U5 region is substituted for a portion of the intron downstream of the CMV immediate early region 1 enhancer (Barouch et al., 2005). Sequences of 95% or better homology to CMV/R can be used as well. CMV/R vectors are currently being used in a number of ...Tue, 06 Dec 2022 11:45:26 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Increased_Protein_Expression_Vector_for_Vaccine_ApplicationsTAB-664https://nih.technologypublisher.com/tech/Tryptophan_as_a_Functional_Replacement_for_ADP-ribose-arginine_in_Recombinant_ProteinsBacterial toxins such as cholera toxin and diphtheria toxin catalyze the ADP-ribosylation of important cellular target proteins in their human hosts, thereby, as in the case of cholera toxin, irreversibly activating adenylyl cyclase. In this reaction, the toxin transfers the ADP-ribose moiety of Nicotinamide Adenine Dinucleotide (NAD) to an acceptor amino acid in a protein or peptide. ADP-ribosylation leads to a peptide/protein with altered biochemical or pharmacological properties. Mammalians proteins catalyze reactions similar to the bacterial toxins. The ADP-ribosylated proteins represe...Tue, 06 Dec 2022 11:45:25 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Tryptophan_as_a_Functional_Replacement_for_ADP-ribose-arginine_in_Recombinant_ProteinsTAB-662https://nih.technologypublisher.com/tech/Rapid_Motion_Perception_MRI_Navigator_MethodAvailable for licensing and commercial development is a non-breathhold flow sensitive navigator technique for reducing respiratory motion artifacts in magnetic resonance (MR) images. The method, called Rapid Motion Perception (RaMP), tracks bulk translational motion of the heart in real-time. The position of the blood volume is a direct representation of the heart position. RaMP tracks fast-moving blood volume during systole as a marker for the heart position, while suppressing stationary or slow moving spins. This approach allows cardiac navigation in two orthogonal directions simultaneou...Tue, 06 Dec 2022 11:45:24 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Rapid_Motion_Perception_MRI_Navigator_MethodTAB-660https://nih.technologypublisher.com/tech/Modified_Defensins_and_Their_UseThe ubiquitous use of antibiotics has resulted in the selection of bacteria that are relatively resistant to these drugs. Furthermore, few drugs are effective against viral and fungal microorganisms. There is therefore a continuing need to identify novel agents that reduce or inhibit the growth of such microorganisms, or to identify ways of modifying existing agents in order to give them superior antimicrobial activities, or to identify agents that may recruit inflammatory cells. Defensins are broad-spectrum antimicrobial molecules that act against infectious agents and play important roles...Tue, 06 Dec 2022 11:45:23 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Modified_Defensins_and_Their_UseTAB-641https://nih.technologypublisher.com/tech/Stem_Cell_Factor-responsive_FcepsilonRI_Bearing_Human_Mast_Cell_Line_LAD2A human mast cell line LAD2 that more closely resembles normal in vivo and in vitro human mast cells by expressing functional FcepsilonRI receptors and responding to stem cell factor (SCF) with proliferation, as described in Leuk Res. 2003 Aug;27(8):677-82 and developed by the laboratory of Dr. Dean Metcalfe at the National Institute of Allergy and Infectious Diseases.  This cell line also releases mediators by cross-linking FcgammaRI (CD64) receptors and express FcgammaRII (CD32).Tue, 06 Dec 2022 11:45:16 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Stem_Cell_Factor-responsive_FcepsilonRI_Bearing_Human_Mast_Cell_Line_LAD2TAB-640https://nih.technologypublisher.com/tech/Methods_of_Inducing_Deacetylase_Inhibitors_to_Promote_Cell_Differentiation_and_RegenerationThe present invention discloses a method of enhancing progenitor cell differentiation, including enhancing myogenesis, neurogenesis and hematopoiesis, by contacting a progenitor cell with an effective amount of a deacetylase inhibitor (DI). The progenitor cell can be part of cell culture, such as a cell culture used for in vitro or in vivo analysis of progenitor cell differentiation, or can be part of an organism, such as a human or other mammal. Contacting the progenitor cell with a DI can lead to enhancement of expression of terminal cell-type specific genes in the progenitor cell, such as...Tue, 06 Dec 2022 11:45:15 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Methods_of_Inducing_Deacetylase_Inhibitors_to_Promote_Cell_Differentiation_and_RegenerationTAB-3021https://nih.technologypublisher.com/tech/Long_Acting_Therapeutic_Conjugates_with_Evans_BlueThis invention is a platform technology that pertains to the advantages of conjugating therapeutics to Evans Blue thus providing long lasting pharmacokinetic profiles by complexing with albumin. Notably, albumin bound therapeutic- or prodrug-Evans Blue conjugates provide a complex with a total molecular size above 60 kDa thus eliminating the risk for renal clearance. Interestingly, since albumin also crosses the blood-brain barrier and since all circulating Evans Blue is bound to albumin, Evans Blue bound therapeutics or prodrugs can also cross the blood-brain barrier. By way for example but n...Tue, 06 Dec 2022 11:45:08 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Long_Acting_Therapeutic_Conjugates_with_Evans_BlueTAB-602https://nih.technologypublisher.com/tech/Live_Attenuated_Vaccine_to_Prevent_Disease_Caused_by_West_Nile_VirusWest Nile virus (WNV) has recently emerged in the U.S. and is considered a significant emerging disease that has embedded itself over a considerable region of the U.S. WNV infections have been recorded in humans as well as in different animals. From 1999-2014, WNV killed 1,765 people in the U.S. and caused severe disease in more than 41,762 others. This project is part of NIAID's comprehensive emerging infectious disease program. The methods and compositions of this invention provide a means for prevention of WNV infection by immunization with attenuated, immunogenic viral vaccines against ...Tue, 06 Dec 2022 11:45:01 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Live_Attenuated_Vaccine_to_Prevent_Disease_Caused_by_West_Nile_VirusTAB-3125https://nih.technologypublisher.com/tech/Live_Attenuated_Zika_Virus_VaccineThis application claims live attenuated Zika viruses and vaccines, attenuated chimeric Zika viruses and vaccines, and multivalent immunogenic compositions comprising Zika vaccines and vaccines for other flaviviruses. The chimeric Zika viruses claimed include a first nucleotide sequence encoding at least one structural protein from a Zika virus (ZIKV), a second nucleotide sequence encoding at least one nonstructural protein from a first flavivirus, and a third nucleotide sequence of a 3' untranslated region from a second flavivirus. The multivalent immunogenic compositions claimed comprise an...Tue, 06 Dec 2022 11:44:58 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Live_Attenuated_Zika_Virus_VaccineTAB-587https://nih.technologypublisher.com/tech/Method_and_Apparatus_to_Improve_an_MRI_ImageThe invention is a method for improving image quality in MR imaging methods using the SENSE (SENSitivity Encoding) method, which is known to have degraded image quality due to numerical ill-conditioning (so called g-factor loss). The invention improves the numerical conditioning by means of an adaptive regularization (matrix conditioning), thereby improving image quality for a given scan time. This is accomplished by adaptively adjusting the regularization parameter for each pixel position to achieve a target ghost artifact suppression. In this manner, a higher degree of matrix conditioning is...Tue, 06 Dec 2022 11:44:57 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Method_and_Apparatus_to_Improve_an_MRI_ImageTAB-586https://nih.technologypublisher.com/tech/Endotracheal_Tube_Using_Unique_Leak_Hole_to_Lower_Dead_SpaceThrough injury or diseases, human or animal lungs may become too weak to sustain a sufficient flow of oxygen to the body and to remove adequate amounts of expired carbon dioxide. The present invention is a tracheal tube ventilation apparatus which efficiently rids patients of expired gases and promotes healthier breathing. This is accomplished by creating one or more leak holes in the wall of the endotracheal tube above the larynx, such as in the back of the mouth (i.e., oropharynx), so that expired gases can leak out of the endotracheal tube. The described apparatus is a two stage tube whe...Tue, 06 Dec 2022 11:44:55 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Endotracheal_Tube_Using_Unique_Leak_Hole_to_Lower_Dead_SpaceTAB-579https://nih.technologypublisher.com/tech/Production_of_Adeno-Associated_Viruses_in_Insect_CellsAdeno-associated virus (AAV) is being developed for gene therapy applications. This virus type presents several advantages over alternate vectors for therapeutic gene delivery. AAV is not considered pathogenic and transduces stably dividing and non-dividing cells. AAV also shows good serotype specificity to various cell types for targeted gene delivery. The present invention describes a highly scalable adeno-associated virus (AAV) vector production method in insect cells. The system for producing recombinant AAV (rAAV) uses the AAV Rep protein and an AAV ITR. This production method produc...Tue, 06 Dec 2022 11:44:53 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Production_of_Adeno-Associated_Viruses_in_Insect_CellsTAB-2960https://nih.technologypublisher.com/tech/Leucine_Rich_Repeats_and_Calponin_Homology_Containing_Protein_4_(Lrch4)-deficient_MouseLeucine rich repeats and calponin homology containing protein 4 (Lrch4) is a gene that encodes a protein predicted to have a C-terminal transmembrane domain, a calponin homology domain, and 5-8 leucine rich repeats (LRRs). We silenced Lrch4 in RAW 264.7 macrophages as well as CD14-MD2-TLR4-HEK293 cells and found that Lrch4 knockdown attenuates responsiveness of cells to LPS and other pathogen-associated molecules. These findings suggest that Lrch4 is a regulator of the innate immune response. In order to facilitate more physiologic in vivo investigations of the function and disease-relevant ro...Tue, 06 Dec 2022 11:44:52 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Leucine_Rich_Repeats_and_Calponin_Homology_Containing_Protein_4_(Lrch4)-deficient_MouseTAB-572https://nih.technologypublisher.com/tech/Development_of_Reagents_to_Examine_the_Expression_and_Function_of_CYP2J_Subfamily_P450sCytochrome P450s catalyze the metabolism of a wide range of exogenous compounds, including drugs, industrial chemicals, environmental pollutants, and carcinogens. The 2C family of cytochrome P450 metabolizes an extensive number of drugs which include tolbutamide, S-Warfarin, mephenytoin, diazepam and taxol. The inventors cloned the cDNAs for several different CYP2J subfamily members including human CYP2J2, rat CYP2J3, mouse CYP2J5, mouse CYP2J6, and mouse CYP2J9. The recombinant proteins were expressed in insect cells. Additionally, the inventors also developed specific peptide-based antibodie...Tue, 06 Dec 2022 11:44:50 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Development_of_Reagents_to_Examine_the_Expression_and_Function_of_CYP2J_Subfamily_P450sTAB-566https://nih.technologypublisher.com/tech?title=Anti-Arthropod_Vector_Vaccines%2c_Methods_of_Selecting%2c_and_Uses_ThereofLeishmania parasites are transmitted to their vertebrate hosts by infected phlebotomine sand fly bites. Sand fly saliva is known to enhance Leishmania infection, while immunity to the saliva protects against infection. This invention claims nine major salivary proteins from the sand fly vector of Leishmania major, Phlebotomus papatasi, nucleic acids encoding the proteins, vaccines comprising the proteins and/or nucleic acids, and methods of producing an immune response to prevent Leshmaniasis. The inventors have shown that one of these salivary proteins was able to protect vaccinated mice c...Tue, 06 Dec 2022 11:44:48 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech?title=Anti-Arthropod_Vector_Vaccines%2c_Methods_of_Selecting%2c_and_Uses_ThereofTAB-562https://nih.technologypublisher.com/tech/Vaccination_Strategies_to_Provide_Protection_Against_the_Ebola_VirusThis invention describes a method for vaccination against Ebola virus. Outbreaks of hemorrhagic fever caused by the Ebola virus, particularly the Zaire subtype, are associated with high mortality rates. The virus is very contagious, and during an outbreak, presents a threat to anybody who comes into contact with an infected person. Because the virus progresses so rapidly and the mortality rate is so high, there is little opportunity to develop natural immunity, making vaccination a promising intervention. This invention relates to a vaccine strategy employing DNA and adenoviral vectors exp...Tue, 06 Dec 2022 11:44:46 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Vaccination_Strategies_to_Provide_Protection_Against_the_Ebola_VirusTAB-560https://nih.technologypublisher.com/tech/Four_Chimpanzee_Monoclonal_Antibodies_that_Neutralize_Hepatitis_A_VirusThis invention claims antibodies and/or fragments thereof specific for hepatitis A virus (HAV) and the use of the antibodies in the diagnosis, prevention, and treatment of hepatitis A. Hepatitis A is the most common type of hepatitis reported in the United States, which reports an estimated 134,000 cases annually, and infects at least 1.4 million people worldwide each year. HAV is a positive sense RNA virus that is transmitted via the fecal-oral route, mainly through contaminated water supplies and food sources. HAV is thought to replicate in the oropharynx and epithelial lining of the inte...Tue, 06 Dec 2022 11:44:45 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Four_Chimpanzee_Monoclonal_Antibodies_that_Neutralize_Hepatitis_A_VirusTAB-553https://nih.technologypublisher.com/tech?title=TMC1%2c_a_Deafness-Related_GeneHearing loss is a common communication disorder affecting nearly 1 in 1,000 children in the United States alone, and nearly 50% of adults by the age of eighty. Hearing loss can be caused by environmental and disease-related factors; however, hearing loss due to genetic factors accounts for approximately 50% of cases. The NIH announces the isolation of two novel genes involved in hearing; TMC1, short for transmembrane channel-like gene 1. The inventors have discovered that dominant and recessive mutations in TMC1 underlie two forms of hereditary deafness, known as DFNA36 and DFNB7/11. TMC1 e...Tue, 06 Dec 2022 11:44:43 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech?title=TMC1%2c_a_Deafness-Related_GeneTAB-538https://nih.technologypublisher.com/tech/Major_Neutralization_Site_of_Hepatitis_E_Virus_and_Use_of_this_Neutralization_Site_in_Methods_of_VaccinationHepatitis E is endemic in many countries throughout the developing world, in particular on the continents of Africa and Asia. The disease generally affects young adults and has a very high mortality rate, up to 20%, in pregnant women. This invention relates to the identification of a neutralization site of hepatitis E virus (HEV) and neutralizing antibodies that react with it. The neutralization site is located on a polypeptide from the ORF2 gene (capsid gene) of HEV. This neutralization site was identified using a panel of chimpanzee monoclonal antibodies that are virtually identical to h...Tue, 06 Dec 2022 11:44:39 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Major_Neutralization_Site_of_Hepatitis_E_Virus_and_Use_of_this_Neutralization_Site_in_Methods_of_VaccinationTAB-535https://nih.technologypublisher.com/tech/Development_of_Mutations_Useful_for_Attenuating_Dengue_Viruses_and_Chimeric_Dengue_VirusesAlthough flaviviruses cause a great deal of human suffering and economic loss, there is a shortage of effective vaccines. This invention relates to dengue virus mutations that may contribute to the development of improved dengue vaccines. Site directed and random mutagenesis techniques were used to introduce mutations into the dengue virus genome and to assemble a collection of useful mutations for incorporation in recombinant live attenuated dengue virus vaccines. The resulting mutant viruses were screened for several valuable phenotypes, including temperature sensitivity in Vero cells or ...Tue, 06 Dec 2022 11:44:37 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Development_of_Mutations_Useful_for_Attenuating_Dengue_Viruses_and_Chimeric_Dengue_VirusesTAB-529https://nih.technologypublisher.com/tech/Imaging_of_Extracellular_Proteases_in_Cells_Using_Mutant_Anthrax_Toxin_Protective_AntigensThe claimed invention provides highly specific and sensitive methods for in vivo, in vitro, or ex vivo imaging of specific extracellular protease activity using an anthrax binary toxin system. The system targets cells that express extracellular proteases of interest. Such a system would be highly useful since various studies have demonstrated a positive correlation between the activity of extracellular proteases and various diseases and undesirable physiological conditions. For example, breakdown of the extracellular matrix by extracellular proteases is a prerequisite for the invasive growt...Tue, 06 Dec 2022 11:44:35 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Imaging_of_Extracellular_Proteases_in_Cells_Using_Mutant_Anthrax_Toxin_Protective_AntigensTAB-519https://nih.technologypublisher.com/tech/Recombinant_Proteins_of_the_Swine_Hepatitis_E_Virus_and_Their_Uses_as_a_Vaccine_and_Diagnostic_Reagents_for_Medical_and_Veterinary_ApplicationsThis invention is based on the discovery of the swine hepatitis E virus (swine HEV), the first animal strain of HEV identified and characterized, and its ability to infect across species. The inventors have found that the swine HEV is widespread in the general pig population in the United States and other countries and that swine HEV can infect non-human primates. The inventors have amplified and sequenced the complete genome of swine HEV. The capsid gene (ORF2) of swine HEV has been cloned and expressed in a baculovirus expression system. The possibility that swine HEV may infect humans ra...Tue, 06 Dec 2022 11:44:32 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Recombinant_Proteins_of_the_Swine_Hepatitis_E_Virus_and_Their_Uses_as_a_Vaccine_and_Diagnostic_Reagents_for_Medical_and_Veterinary_ApplicationsTAB-518https://nih.technologypublisher.com/tech/Mapping_Internal_and_Bulk_Motion_of_an_Object_with_Phase_Labeling_in_Magnetic_Resonance_ImagingCurrent MRI methods for tracking the motion of an object over a relatively long period of time requires the use of precisely defined grid points that may be inexact because of limited image resolution or the size of the element being tracked. Phase contrast velocity mapping generally provides high spatial resolution and simple data processing. However, it is generally unsuitable for motion tracking and prone to error. This invention is a cutting edge Magnetic Resonance Imaging (MRI) technique that provides a method for mapping the internal and bulk motion of a specimen by labeling the phase...Tue, 06 Dec 2022 11:44:31 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Mapping_Internal_and_Bulk_Motion_of_an_Object_with_Phase_Labeling_in_Magnetic_Resonance_ImagingTAB-497https://nih.technologypublisher.com/tech/Generalized_MRI_Artifact_Reduction_Using_Array_Processing_MethodThe invention is a phased array combining method for reducing artifacts in Magnetic Resonance (MR) imaging. The method uses a constrained optimization that optimizes signal-to-noise subject to the constraint of nulling ghost artifacts at known locations. The method is effective in reducing or canceling artifacts that arise in a wide variety of MR applications, including ghost artifacts from echo planar imaging and Gradient Recalled Echo with Echo Train (FGRE-ET) imaging used in cardiac or other rapid imaging applications. The strategy of using phase encode acquisition orders with distortion...Tue, 06 Dec 2022 11:44:26 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Generalized_MRI_Artifact_Reduction_Using_Array_Processing_MethodTAB-490https://nih.technologypublisher.com/tech/Infectious_cDNA_Clone_of_GB_Virus_B_and_Uses_ThereofThe current invention provides nucleic acid sequences comprising the genomes of infectious GB virus B, the most closely related member of the Flaviviridae to hepatitis C virus (HCV). It also covers chimeric GBVB-HCV sequences and polypeptides for use in the development of vaccines and diagnostic assays for HCV and the development of screening assays for the identification of antiviral agents for HCV. Additional information can be found in Bukh et al. (1999), Virology 262, 470-478.Tue, 06 Dec 2022 11:44:24 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Infectious_cDNA_Clone_of_GB_Virus_B_and_Uses_ThereofTAB-489https://nih.technologypublisher.com/tech?title=HCV%2fBVDV_Chimeric_Genomes_and_Uses_ThereofThe current invention provides nucleic acid sequences comprising chimeric viral genome of hepatitis C Virus (HCV) and bovine viral diarrhea viruses (BVDV). The chimeric viruses are produced by replacing the structural region or a structural gene of an infectious BVDV clone with the corresponding region or gene of an infectious HCV. It covers the use of these sequences and polypeptides encoded by all or part of the sequences in the development of vaccines and diagnostic assays for HCV and the development of screening assays for the identification of antiviral agents for HCV.Tue, 06 Dec 2022 11:44:23 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech?title=HCV%2fBVDV_Chimeric_Genomes_and_Uses_ThereofTAB-484https://nih.technologypublisher.com/tech/Real_Time_Interactive_Volumetric_Magnetic_Resonance_ImagingThe invention makes possible "live" volume renderings from a Magnetic Resonance Imaging (MRI) scanner. Previously, volume renderings from MRI data could only be generated off-line, some time after the image data was collected. In one embodiment of the invention, the time between data collection and volume rendering update (the latency) is approximately one third of a second at a frame rate of approximately 10 updates per second. User interaction with the rendering, such as rotation and cut planes, is allowed during imaging. This gives a caregiver real-time three-dimensional feedback while ...Tue, 06 Dec 2022 11:44:20 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Real_Time_Interactive_Volumetric_Magnetic_Resonance_ImagingTAB-478https://nih.technologypublisher.com/tech/Vitamin_D_Receptor_Antagonists_for_Treating_Breast_CancerVitamin D receptor (VDR) is a nuclear receptor that is activated by calcitriol, the active form of vitamin D. It is best known for regulating dietary calcium uptake necessary for bone growth, but it also affects cell proliferation and differentiation. Therefore, it was thought that treatment with calcitriol or its derivatives could be useful to treat the uncontrolled proliferation typical of cancer cells. However, this approach has been unsuccessful to date because it leads to toxic levels of calcium in the blood. This invention relates to derivatives of calcitriol that can block cell growt...Tue, 06 Dec 2022 11:44:18 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Vitamin_D_Receptor_Antagonists_for_Treating_Breast_CancerTAB-470https://nih.technologypublisher.com/tech/Attenuated_Host-Range_Restricted_Dengue_Viruses_Derived_by_Site-Directed_Mutagenesis_of_the_Conserved_3-Stem_and_Loop_Structure_in_Genomic_RNA_for_Use_as_VaccinesAlthough flaviviruses cause a great deal of human suffering and economic loss, there is a shortage of effective vaccines. The present invention is directed toward vector stage replication-defective flaviviruses that are replication-defective in mosquito vectors that transmit them to humans. The replication-defective flaviviruses of the present invention demonstrate a limited ability to replicate in the vector organisms that transmit flaviviruses from one host to another. More specifically, the present invention is directed toward the construction and propagation of flaviviruses that possess...Tue, 06 Dec 2022 11:44:15 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Attenuated_Host-Range_Restricted_Dengue_Viruses_Derived_by_Site-Directed_Mutagenesis_of_the_Conserved_3-Stem_and_Loop_Structure_in_Genomic_RNA_for_Use_as_VaccinesTAB-3022https://nih.technologypublisher.com/tech/Multi-Photon_Microscopy_System_Configured_for_Multiview_Non-Linear_Optical_ImagingThis invention is a microscopy device and system for multi-photon microscopy utilizing multi-view nonlinear optical imaging. Nonlinear optical imaging remains the premier technique for deep-tissue imaging in which typically a multi photon arrangement may be used to illuminate and excite a sample. However, the penetration depth, signal-to-noise ratio, and resolution of this technique is ultimately limited by scattering. The present system addresses these issues by sequential excitation of a sample through three or more objective lenses oriented at different axes intersecting the sample. Each ob...Tue, 06 Dec 2022 11:44:12 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Multi-Photon_Microscopy_System_Configured_for_Multiview_Non-Linear_Optical_ImagingTAB-460https://nih.technologypublisher.com/tech/Antibodies_that_Selectively_Detect_the_Human_Nestin_ProteinNestin is an intermediate filament protein first described in early embryonic neuroepithelial stem cells. Although not found in most cells of the mature CNS, nestin is the predominant marker used to detect the small population of undifferentiated cells. The presence of nestin identifies stem, progenitor and some tumor cells in the CNS, and also labels areas of reactive gliosis in the CNS. Available methods to detect nestin use antibodies generated against rat nestin protein. Since rat and human nestin have only about fifty percent sequence homology, these antibodies may not be optimal for ...Tue, 06 Dec 2022 11:44:11 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Antibodies_that_Selectively_Detect_the_Human_Nestin_ProteinTAB-439https://nih.technologypublisher.com/tech/Neuronal_Decoding_Algorithm_for_Prosthetic_LimbsThe invention is a new algorithm for decoding neuronal responses based on the discovery that neuronal spike trains can be described using order statistics. The device has applications in the direct control of prosthetic limbs by neuronal signals originating from electrodes placed in the brain. The method allows for decoding neuronal responses by monitoring sequences of potentials from neurons while specific motor tasks are carried out. The sequences are then characterized using the innovative technique of applying order statistics to the spike train, such that subsequent action potentials repr...Tue, 06 Dec 2022 11:44:04 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Neuronal_Decoding_Algorithm_for_Prosthetic_LimbsTAB-427https://nih.technologypublisher.com/tech/Adaptive_Sensitivity_Encoding_Incorporating_Temporal_Filtering_(TSENSE)The invention is an accelerated magnetic resonance imaging method developed to reduce the total imaging time for gated, segmented cine imaging or to increase the frame rate when imaging dynamic activity, such as heart motion or brain activity. The invention combines temporal filtering (e.g., the UNFOLD method) with a known spatial sensitivity encoding technique (SENSE or SMASH) to achieve a new technique that is the subject of the invention (TSENSE) having a higher degree of alias artifact rejection than could be obtained using either temporal or spatial filtering individually. The new techn...Tue, 06 Dec 2022 11:44:01 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Adaptive_Sensitivity_Encoding_Incorporating_Temporal_Filtering_(TSENSE)TAB-419https://nih.technologypublisher.com/tech/Hybrid_Adeno-Retroviral_Vector_for_the_Transformation_of_Cells_(E-312-2000)The invention described and claimed in these patent applications provides for novel hybrid vectors which may be used for cell transformation either in vivo, in vitro, or ex vivo. The hybrid vectors, which are capable of integrating into the chromosome of the host cell and are capable of transducing dividing and non-dividing cells, have an adenoviral serotype 5 backbone and two retroviral (Moloney murine leukemia virus) elements upstream and downstream of the transgene. These elements include part of the envelope sequence, the long terminal repeat (LTR) and the packaging signal sequence (upst...Tue, 06 Dec 2022 11:43:58 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Hybrid_Adeno-Retroviral_Vector_for_the_Transformation_of_Cells_(E-312-2000)TAB-399https://nih.technologypublisher.com/tech/Clones_Encoding_Mammalian_ADP-Ribosylarginine_HydrolasesADP-ribosylation of arginine residues in proteins may be involved in cell adhesion and is crucial for the action of cholera toxin and E. coli heat-labile enterotoxin, agents involved in the pathogenesis of cholera and traveller's diarrhoea, respectively. ADP-ribosylation is reversed by ADP-ribosylarginine hydrolases, which cleave the ADP-ribose-arginine bond. ADP-ribosylarginine hydrolases from a variety of mammalian species and tissues were isolated, and the coding regions for the hydrolases were cloned and expressed. The availability of this new hydrolase cDNA and expression system provides ...Tue, 06 Dec 2022 11:43:53 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Clones_Encoding_Mammalian_ADP-Ribosylarginine_HydrolasesTAB-393https://nih.technologypublisher.com/tech/Method_Of_Identifying_Inhibitors_Of_The_Jak-STAT_Signal_Transduction_PathwayThe invention provides identification methods for agents which inhibit the Jak-STAT signaling transduction pathway. Drugs identified by these methods are candidates for the treatment of proliferative disorders dependent on the Jak-STAT pathway, including those caused by HTLV-1. In addition, such agents may be potent immunosuppressive drugs with potential applications not only for organ transplantation but also for treatment of autoimmune diseases.Tue, 06 Dec 2022 11:43:51 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Method_Of_Identifying_Inhibitors_Of_The_Jak-STAT_Signal_Transduction_PathwayTAB-367https://nih.technologypublisher.com/tech/AAV4_Vector_And_Uses_ThereofThese patent applications describe the cloning and characterization of the full-length genome of adeno-associated virus type 4 (AAV4). AAV4, like other members of the AAV family, may be useful as a vector for gene therapy. When compared to AAV2, AAV4 may be better suited as a vector due to its larger size -- which permits efficient encapsidation of a larger recombinant genome -- and its greater buoyant density -- which allows for easier separation of AAV4 from contaminating helper virus. Other characteristics of AAV4 which distinguish it from AAV2 and AAV3 are its expanded promoter region, its...Tue, 06 Dec 2022 11:43:40 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/AAV4_Vector_And_Uses_ThereofTAB-366https://nih.technologypublisher.com/tech/Ultrasound-Hall_Effect_Imaging_System_And_MethodThe invention provides for a novel ultrasound-based imaging modality that is based on the interaction of a static magnetic field and conductive moieties in the imaged sample under electrical excitation. The invention also provides a novel ultrasound-based imaging modality that provides a contrast mechanism which reflects the conductivity distribution of the medium being imaged. The disclosed methods and system have the following advantages over other ultrasonic imaging systems: (a) the method is not limited to contrast based solely on acoustic properties; (b) it dispenses with acoustic beam...Tue, 06 Dec 2022 11:43:38 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Ultrasound-Hall_Effect_Imaging_System_And_MethodTAB-3085https://nih.technologypublisher.com/tech/Immortalized_Stria_Vascularis_Cell_Line_SV-k1Available for nonexclusive licensing for research uses is the cell line, SV-k1, derived from the Organ of Corti. The line was developed from the stria vascularis, an organ localized on the lateral wall of the cochlea, adjacent to the Organ of Corti, containing cell populations specialized in the production of an endolymph very rich in K+ characteristic of the mammalian inner ear. SV-k1 cells express a set of biomarkers completely different of those expressed by OC-k3 cells, and are not sensitive to ototoxic drugs.Tue, 06 Dec 2022 11:43:29 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Immortalized_Stria_Vascularis_Cell_Line_SV-k1TAB-347https://nih.technologypublisher.com/tech/Cloned_Genomes_Of_Infectious_Hepatitis_C_Virus_And_Uses_ThereofThe current invention provides nucleic acid sequences comprising the genomes of infectious hepatitis C viruses (HCV) of genotype 1a and 1b. It covers the use of these sequences, and polypeptides encoded by all or part of the sequences, in the development of vaccines and diagnostic assays for HCV and the development of screening assays for the identification of antiviral agents for HCV. Additional information can be found in: Yanagi et al., "Transcripts from a single full-length cDNA clone of hepatitis C virus are infectious when directly transfected into the liver of a chimpanzee," Proc. Nat...Tue, 06 Dec 2022 11:43:27 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Cloned_Genomes_Of_Infectious_Hepatitis_C_Virus_And_Uses_ThereofTAB-346https://nih.technologypublisher.com/tech/Signal_Transduction_Inhibitors_Of_Allergic_ReactionsAllergic reactions affect nearly 40 million persons in the United States. Allergic reactions are due to a sequential interaction beginning with the extracellular aggregation of the high affinity receptor for IgE (FcepsilonRI) followed by intracellular tyrosine phosphorylation which initiates a further cascade of events eventually leading to histamine and cytokine release. The reaction is initiated by Lyn kinase which is pre-associated with the FcepsilonRI. It was shown that the introduction of a unique portion of the N-terminal region of Lyn A kinase into cells inhibits the receptor tyrosine p...Tue, 06 Dec 2022 11:43:26 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Signal_Transduction_Inhibitors_Of_Allergic_ReactionsTAB-345https://nih.technologypublisher.com/tech/Genetic_Polymorphisms_Of_Interleukin-1_Alpha_And_Beta_Associated_With_Early_Onset_PeriodontitisPeriodontal disease occurs in 10-20% of adults, and constitutes a major cause of tooth loss. About 0.5% of U.S. adolescents between the ages of 14 to 17 years old (about 70,000) have localized early onset periodontitis and 0.1% (17,000) have the more destructive form known as generalized early onset periodontitis. Both types of early onset periodontitis often lead to tooth loss before the age of 20. Extrapolation of these figures up to age 35 leads to estimates of early onset periodontitis having a major impact on the dental health of 400,000 individuals in the U.S. population. Discovery of ge...Tue, 06 Dec 2022 11:43:25 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Genetic_Polymorphisms_Of_Interleukin-1_Alpha_And_Beta_Associated_With_Early_Onset_PeriodontitisTAB-337https://nih.technologypublisher.com/tech?title=CC_Chemokine_Receptor_5_DNA%2c_New_Animal_Models_and_Therapeutic_Agents_for_HIV_InfectionChemokine receptors are expressed by many cells, including lymphoid cells, and function to mediate cell trafficking and localization. CC chemokine receptor 5 (CCR5) is a seven-transmembrane, G protein-coupled receptor (GPCR) which regulates trafficking and effector functions of memory/effector T-lymphocytes, macrophages, and immature dendritic cells. Chemokine binding to CCR5 leads to cellular activation through pertussis toxin-sensitive heterotrimeric G proteins as well as G protein-independent signalling pathways. Like many other GPCRs, CCR5 is regulated by agonist-dependent processes whic...Tue, 06 Dec 2022 11:43:22 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech?title=CC_Chemokine_Receptor_5_DNA%2c_New_Animal_Models_and_Therapeutic_Agents_for_HIV_InfectionTAB-334https://nih.technologypublisher.com/tech/Calorimeter_And_Method_For_Simultaneous_Measurement_Of_Thermal_Conductivity_And_Specific_Heat_Of_FluidsThe present invention is a novel calorimeter and calorimetry apparatus and method for the ultrasensitive simultaneous measurement of heat capacity and thermal conductivity of fluids. The unique simultaneous measurement of the two parameters avoids sources of error seen in other methods. The calorimeter shows excellent accuracy of 1 part in 10,000 and run-to-run variability of 1 part in 100,000, as well as excellent long-term reproducibility. The invention is well suited for the study of biomaterials, such as lipids and proteins and other colloidal systems, which are not easily analyzed using c...Tue, 06 Dec 2022 11:43:20 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Calorimeter_And_Method_For_Simultaneous_Measurement_Of_Thermal_Conductivity_And_Specific_Heat_Of_FluidsTAB-322https://nih.technologypublisher.com/tech/Method_And_System_For_Doppler_Ultrasound_Measurement_Of_Blood_FlowThis invention discloses a system and method for providing Doppler flow velocity data that is corrected for misalignment between the flow direction within a vessel and the beam orientation of the ultrasound probe. A conventional ultrasonic Doppler color mapping system was adapted to include an apparatus to measure and record the free space position and orientation of the ultrasonic probe. A set of 2D image planes, which need not be parallel, is acquired. A structural representation derived from the acquired data is used to determine the flow direction for the imaged vessel. This apparatus and ...Tue, 06 Dec 2022 11:43:16 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Method_And_System_For_Doppler_Ultrasound_Measurement_Of_Blood_FlowTAB-3003https://nih.technologypublisher.com/tech/Software_for_Fully_Automating_Myocardial_Perfusion_QuantificationSoftware is has been developed and available for licensing that fully automates image processing for the quantification of myocardial blood flow (MBF) pixel maps from firstpass contrast-enhanced cardiac magnetic resonance (CMR) perfusion images. The system removes the need for laborious manual quantitative CMR perfusion pixel map processing and can process prospective and retrospective studies acquired from various imaging protocols. In full automation, arterial input function (AIF) images are processed for motion correction and myocardial perfusion images are corrected for intensity bias. The...Tue, 06 Dec 2022 11:43:13 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Software_for_Fully_Automating_Myocardial_Perfusion_QuantificationTAB-2976https://nih.technologypublisher.com/tech/A_Novel_Rapid_Point-of_Care_Diagnostic_Method_for_Infectious_and_Autoimmune_DiseasesRapid point-of-care, antibody-based testing is not available for the diagnosis of autoimmune and most infectious diseases. For detecting autoantibodies associated with most autoimmune conditions, fluid-phase immunoprecipitation assays are required. However, these assays usually involve radioactivity and are not feasible for point-of-care applications. The subject invention describes methods of using neodymium magnet for diagnosis of infectious and autoimmune diseases including lupus, Sjögren's syndrome, type I diabetes, HIV and Lyme disease. The assay takes 3.5 minutes, is highly efficient...Tue, 06 Dec 2022 11:43:07 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/A_Novel_Rapid_Point-of_Care_Diagnostic_Method_for_Infectious_and_Autoimmune_DiseasesTAB-298https://nih.technologypublisher.com/tech/Separation_Of_Polar_Compounds_By_Affinity_Countercurrent_ChromatographyA new and highly advantageous method of purifying polar organic compounds using affinity countercurrent chromatography, has been created. This invention permits separation of very hydrophilic organic compounds using countercurrent chromatography in which a ligand for the desired analytes is used to enhance the partitioning of polar species into the organic layer of an aqueous-organic solvent mixture. Examples of polar organic compounds which may be recovered using the present invention include: compounds having two or more functional groups on each molecule which are hydroxyl, amino, acid or l...Tue, 06 Dec 2022 11:43:05 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Separation_Of_Polar_Compounds_By_Affinity_Countercurrent_ChromatographyTAB-295https://nih.technologypublisher.com/tech/Method_For_Proton_Magnetic_Resonance_Spectroscopic_Imaging_With_Multiple_Spin-EchoesThis application describes a new method for proton magnetic resonance spectroscopic imaging. This new method does not have the limiting disadvantages of the previous techniques. The method combines multi-slice and multi-spin-echo techniques for high signal-to-noise ratio per unit time and high efficiency spectroscopic information. This invention can also produce compound weighted spectroscopic images by selecting the period between refocussing pulses according to the coupling constant of a group contained in the compound. Application of a pulse sequence to conventional MRI imaging apparatus al...Tue, 06 Dec 2022 11:43:03 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Method_For_Proton_Magnetic_Resonance_Spectroscopic_Imaging_With_Multiple_Spin-EchoesTAB-288https://nih.technologypublisher.com/tech/Mutants_Having_a_Deficit_of_Functional_Steroid_Hormone_ReceptorsThis invention concerns "knockout" animals, including mice, which have a deficit of functional steroid hormone receptors, DNA constructs containing the mutations, and methods for producing the animals. The mutation is introduced into the animal or its ancestors at an embryonic stage. These knockout animals provide a model system for studying the biological role of hormones, including steroid hormones and sex steroids, in growth, development, morphological differentiation, and sexual and reproductive behavior and cycles, etc. More specifically, the animals may serve as models for testing sex ho...Tue, 06 Dec 2022 11:43:01 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Mutants_Having_a_Deficit_of_Functional_Steroid_Hormone_ReceptorsTAB-269https://nih.technologypublisher.com/tech/Lipopolysaccharide_Carriers_For_Use_In_VaccinesThis invention is a new carrier for conjugate vaccines. The carrier is lipopolysaccharide (LPS) isolated from Brucella abortus (BA). The claims of the patent cover all conjugates comprising BA-LPS and an antigen from an infectious agent or tumor. BA-LPS, like other LPSs from gram-negative bacteria, raises antibody responses in a T-independent fashion, which allows antibodies to be raised in the absence of T cell help. BA-LPS is much less toxic than LPS from other bacteria, and is much less potent than other bacterial LPS in inducing inflammatory cytokines. Thus, BA-LPS is much less likely to c...Tue, 06 Dec 2022 11:42:57 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Lipopolysaccharide_Carriers_For_Use_In_VaccinesTAB-2962https://nih.technologypublisher.com/tech/Novel_Genetic_Tristetraprolin_(TTP)_Knock-in_MouseTristetraprolin (TTP) is the prototype member of a small family of RNA binding proteins that bind to specific types of AU-rich elements in the 3'UTRs of target mRNAs and promote their rapid turnover. One of the targets destabilized by TTP is Tumor necrosis factor alpha (TNF). TNF has long been a target of anti-inflammatory drug development, in which recombinant protein molecules based on TNF antibodies or TNF receptors have been used to bind directly to TNF and inactivate it. These therapies are very expensive because of their recombinant origin, require frequent injections because they are pr...Tue, 06 Dec 2022 11:42:54 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Novel_Genetic_Tristetraprolin_(TTP)_Knock-in_MouseTAB-243https://nih.technologypublisher.com/tech/Automated_Core_Biopsy_InstrumentThe invention is an automated core biopsy instrument that may be operated with one hand. The instrument has a single activation element that causes a stylet to advance into the tissue of interest as a cutting cannula disposed around the stylet is fired to shear off the tissue into specimen notches disposed in the stylet. The invention is constructed so that the stylet and cutting cannula may be separately driven and biased. The cocking mechanism of the automated core biopsy instrument is used to cock both the stylet assembly and cutting cannula assemblies against separate biasing springs. ...Tue, 06 Dec 2022 11:42:50 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Automated_Core_Biopsy_InstrumentTAB-209https://nih.technologypublisher.com/tech/Continuous_Positive_Airway_SystemThis invention is a novel method and apparatus for greatly improving and sustaining spontaneous breathing in patients with severe respiratory failure. Continuous positive airway pressure (CPAP) is widely used in the treatment of patients with mild respiratory failure. The constant back pressure in CPAP provides the force to expand some diseased parts of the lungs and, thus, improve oxygenation and carbon dioxide removal; however, presently available CPAP systems have limitations when used in patients with more severe respiratory failure who need endotracheal tubes, which have substantial airwa...Tue, 06 Dec 2022 11:42:42 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Continuous_Positive_Airway_SystemTAB-2966https://nih.technologypublisher.com/tech?title=Rabbit_Antisera_to_Various_Matrix%2c_Matricellular%2c_and_Other_Secreted_ProteinsThe extracellular matrix (ECM) is composed of a group of proteins that regulate many cellular functions, such as cell shape, adhesion, migration, proliferation, and differentiation. Deregulation of ECM protein production or function contributes to many pathological conditions, including asthma, chronic obstructive pulmonary disease, arthrosclerosis, and cancer. Scientists at the NIH have developed antisera against various ECM components such as proteoglycan, sialoprotein, collagen, etc.. These antisera can be used as research tools to study the biology of extracellular matrix molecules. The re...Tue, 06 Dec 2022 11:42:40 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech?title=Rabbit_Antisera_to_Various_Matrix%2c_Matricellular%2c_and_Other_Secreted_ProteinsTAB-196https://nih.technologypublisher.com/tech/Adult_Human_Dental_Pulp_Stem_Cells_in_vitro_and_in_vivoMany individuals with ongoing and severe dental problems are faced with the prospect of permanent tooth loss. Examples include dentinal degradation due to caries or periodontal disease; (accidental) injury to the mouth; and surgical removal of teeth due to tumors associated with the jaw. Clearly, a technology that offers a possible alternative to artificial dentures by designing and transplanting a set of living teeth fashioned from the patient's own pulp cells would greatly improve the individual's quality of life. The NIH announces a new technology wherein dental pulp stem cells from an indi...Tue, 06 Dec 2022 11:42:36 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Adult_Human_Dental_Pulp_Stem_Cells_in_vitro_and_in_vivoTAB-188https://nih.technologypublisher.com/tech/Therapeutic_Methods_Based_on_In_Vivo_Modulation_of_the_Production_of_Interferon_gammaThe technology offered for licensing is in the field of Therapeutics. More specifically, the technology relates to biological ligands and their use as modulators of the production of Interferon gamma as a means to treat a broad spectrum of diseases. The invention describes and claims antibodies and other ligands that can stimulate Natural Killer (NK) immune cells to produce Interferon gamma which contributes to the combat against foreign pathogens. Conversely, the invention also describes and claims methods that can inhibit such Interferon gamma production for treatment of diseases where exces...Tue, 06 Dec 2022 11:42:33 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Therapeutic_Methods_Based_on_In_Vivo_Modulation_of_the_Production_of_Interferon_gammaTAB-181https://nih.technologypublisher.com/tech?title=NAG-1%3a_A_Non-Steroidal_Anti-Inflammatory_Drug_Related_Gene_Which_Has_Anti-Tumorigenic_PropertiesNon-steroidal anti-inflammatory drugs (NSAIDs) are widely used in the treatment of inflammatory disease, and their anti-inflammatory effects are believed to result from their ability to inhibit the formation of prostaglandins by prostaglandin H synthase (COX). Two forms of prostaglandin H have been identified, COX-1 and COX-2. The former seems to be constitutively expressed in a variety of tissues while the high expression of the latter has been reported in colorectal tumors. NSAIDs have been shown to be effective in reducing human colorectal cancers and possibly breast and lung cancers. W...Tue, 06 Dec 2022 11:42:30 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech?title=NAG-1%3a_A_Non-Steroidal_Anti-Inflammatory_Drug_Related_Gene_Which_Has_Anti-Tumorigenic_PropertiesTAB-2954https://nih.technologypublisher.com/tech/A_Novel_Adeno-Associated_Virus_for_Gene_TherapyScientists at the NIH disclosed a novel adeno-associated virus (AAV) termed "44-9." AAV44-9 based vectors have high gene transfer activity in a number of cell types, including salivary gland cells, liver cells, and different types of neurons (e.g., cells of the cortex, olfactory bulb, and brain stem, and Purkinje cells of the cerebellum). These vectors can increase the transduction efficiency and decrease the potential of being neutralized by preexisting antibodies compared to the wild type AAV. Preliminary results from animal studies suggest that AAV44-9 vectors can efficiently deliver gene...Tue, 06 Dec 2022 11:42:29 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/A_Novel_Adeno-Associated_Virus_for_Gene_TherapyTAB-173https://nih.technologypublisher.com/tech/Ixodes_scapularis_Tissue_Factor_Pathway_InhibitorIxodes scapularis is a blood-sucking tick and the principal vector of Lyme disease, a spirochetal illness caused by Borrelia burgdorferi and now the most common vector-borne infection in the United States; more than 50,000 cases have been reported during the last ten years. The salivary gland of I. scapularis has a number of pharmacologically active molecules that help the tick to successfully feed on blood, such as inhibitors of complement system, in addition to coagulation and platelet aggregation inhibitors. This invention describes Ixolaris, a protein that inhibits the initiation of bloo...Tue, 06 Dec 2022 11:42:27 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Ixodes_scapularis_Tissue_Factor_Pathway_InhibitorTAB-132https://nih.technologypublisher.com/tech/MRI_Coil_Having_Inductively_Coupled_And_Individually_Tuned_Elements_Arranged_As_Free-Pivoting_ComponentsThis application describes an MRI probe/transmitter coil that is composed of concentric cylinders with resonant elements. The probe/transmitter can be tuned using a plurality of freely rotating resonant elements radially mounted between the two cylinders. This invention reduces the effects of subject characteristic variations on the coil resonant frequency in an MRI system. Further, this apparatus increases the sensitivity and efficiency in the magnetic resonance system by raising the Q factor of the probe coil/transmitter. Prototype apparatus effectively reduces the significant coil-subject c...Tue, 06 Dec 2022 11:42:17 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/MRI_Coil_Having_Inductively_Coupled_And_Individually_Tuned_Elements_Arranged_As_Free-Pivoting_ComponentsTAB-129https://nih.technologypublisher.com/tech/Methods_for_Diagnoses_and_Treatment_of_XSCIDThe invention provides a method of diagnosing X-linked severe combined immunodeficiency (XSCID) in males or determining whether females are carriers. This method is based upon the presence of either a mutated or truncated IL-2Rgamma gene. The invention also discloses a method of treating XSCID as well as a method for monitoring the therapy. Lastly, the invention provides a promoter which regulates the expression of IL-2Rgamma, a vector comprising a DNA molecule operably linked to the promoter, a cell host that has been transformed with the vector, and a transgenic mouse comprising the promoter...Tue, 06 Dec 2022 11:42:16 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Methods_for_Diagnoses_and_Treatment_of_XSCIDTAB-127https://nih.technologypublisher.com/tech/Parvovirus_B19_Receptor_And_Parvovirus_B19_DetectionThe claimed invention provides a method of detecting the presence of a parvovirus in a sample. Parvoviruses infect animals and man. In man, the only known pathogenic member of this family is parvovirus B19. The inventors have identified the parvovirus B19 receptor which provides for a method to diagnose, prevent, and treat parvovirus infection utilizing the binding affinity for the receptor.Tue, 06 Dec 2022 11:42:15 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Parvovirus_B19_Receptor_And_Parvovirus_B19_DetectionTAB-124https://nih.technologypublisher.com/tech/Versatile_Reagent_For_Detecting_Murine_Leukemia_VirusesMonoclonal antibodies directed at the proteins of murine leukemia viruses (MuLVs) have some value as immunological reagents, but differ greatly in their applicability. The kit described in this invention uses a monoclonal antibody designated 83A25, which identifies almost all ecotropic, xenotropic, polytropic, and amphotropic MuLVs. It can be used in a wide variety of procedures, including focal immunofluorescence assays on live or fixed monolayers, immunoblotting, immunoprecipitation, immunohistochemical, and flow cytometric procedures. This kit overcomes some of the problems associated with ...Tue, 06 Dec 2022 11:42:13 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Versatile_Reagent_For_Detecting_Murine_Leukemia_VirusesTAB-119https://nih.technologypublisher.com/tech/Human_T_Cell_Line_Chronically_Infected_With_HIVA stable line of human T cells (ACH-2) was developed in which cells infected chronically with the AIDS virus (HIV) remained nonproductive prior to exposure to phorbol esters or human cytokines. This situation mimics the latent state of HIV and the development of AIDS in humans and indicates that the full-blown disease may be triggered by cellular-derived substances (e.g., cytokines). This is the first description of such a cell line.Tue, 06 Dec 2022 11:42:11 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Human_T_Cell_Line_Chronically_Infected_With_HIVTAB-2953https://nih.technologypublisher.com/tech/Modified_AAV5_Vectors_for_Enhanced_Transduction_and_Reduced_Antibody_NeutralizationScientists at the NIH disclosed a mutated adeno-associated virus (AAV) serotype 5 by modifying sialic acid binding regions which mediate viral entry into host cells. Preliminary results from animal studies suggest that this modification can increase transduction by 3-4 folds in salivary glands and muscles, and can significantly decrease the potential of being neutralized by preexisting antibodies compared to the wild type AAV. Thus, the modified AAV5 vectors seem to be optimal for gene therapy. This invention overcomes two major issues in AAV-based gene therapy: the ability to efficiently t...Tue, 06 Dec 2022 11:42:08 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Modified_AAV5_Vectors_for_Enhanced_Transduction_and_Reduced_Antibody_NeutralizationTAB-103https://nih.technologypublisher.com/tech/Two-_and_Three-Dimensional_Autoradiographic_Imaging_Utilizing_Charge_Coupled_DevicesA novel two- and three-dimensional autoradiographic device offers to improve the imaging of body tissues. Numerous methods and apparati have been proposed to produce a three-dimensional map or image of a distribution of radioactively-tagged tissues or chemical substances; however, many of these devices merely detect the radiation, not image it. This new device uses a charged coupling device (CCD) in combination with a microtome to produce numerous two-dimensional images of the radioactively-tagged tissue. These two-dimensional images are then reconstructed into realtime imaging of metabolic or...Tue, 06 Dec 2022 11:42:06 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Two-_and_Three-Dimensional_Autoradiographic_Imaging_Utilizing_Charge_Coupled_DevicesTAB-97https://nih.technologypublisher.com/tech/Probe_To_Identify_Enteroinvasive_E._coli_And_Shigella_SpeciesStandard means for detecting pathogenic organisms in food or clinical specimens rely on animals or large DNA fragments, such as the 17 kb EcoRI fragment of Boileau. These methods are expensive, time-consuming, difficult to use, and have not been able to distinguish between nonvirulent enteroinvasive E. coli and Shigella. This invention describes DNA probes for enteroinvasive E. coli and Shigella species, including the sequence of the 2.5 kb fragment (SmaII and Falkow's) on which the probe is based. The probe is more reliable, more sensitive, and less expensive than methods now in use.Tue, 06 Dec 2022 11:42:04 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Probe_To_Identify_Enteroinvasive_E._coli_And_Shigella_SpeciesTAB-96https://nih.technologypublisher.com/tech/Laminin_A_PeptidesThis invention relates to peptides and derivatives thereof having laminin-like activity, as well as a pharmaceutical composition of the peptide. The peptides claimed include Serine-Isoleucine-Lysine-Valine-Alanine-Valine (SIKVAV). Methods for promoting increased adhesion and migration of epithelial cells is also disclosed. The peptides have wide usage in research, nerve regeneration and cancer treatment. For example, this invention may be useful as an adhesion and regeneration agent for nerve guides and as an adhesion agent for vascular prosthesis.Tue, 06 Dec 2022 11:42:03 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Laminin_A_PeptidesTAB-77https://nih.technologypublisher.com/tech/Electroacoustic_Imaging_Methods_and_ApparatusRecently, an electroacoustic imaging apparatus and two electroacoustic imaging methods have been developed. The two methods are "forward" and "reverse" electroacoustic imaging which requires the application of a probing signal, and the detection and measurement of an induced signal to produce images. The electroacoustic apparatus offers the advantage of generating 2D and 3D images non-invasively. It can simultaneously image several contrast mechanisms, including the Hall effect, the thermoacoustic effect, and the electroacoustic effect. Although this device uses a Piezoelectric transduc...Tue, 06 Dec 2022 11:41:57 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Electroacoustic_Imaging_Methods_and_ApparatusTAB-3282https://nih.technologypublisher.com/tech/Antigens_for_Use_in_Loa_Loa_Microfilariae_Quantitative_ImmunoassaysLoa loa microfilarial-specific peptide sequences that could be used as a research material as well as for development of immunoassays for detection of Loa loa microfilaremia.Tue, 06 Dec 2022 11:41:49 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Antigens_for_Use_in_Loa_Loa_Microfilariae_Quantitative_ImmunoassaysTAB-3276https://nih.technologypublisher.com/tech/pLAS-1_PlasmidShuttle vector for construction of recombinant MVA viruses.Tue, 06 Dec 2022 11:41:47 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/pLAS-1_PlasmidTAB-3275https://nih.technologypublisher.com/tech/Pneumonia_Virus_of_Mice_Expression_Vector_PSynK-PVMJ3666Pneumonia virus of mice expression vector PSynK-PVMJ3666.Tue, 06 Dec 2022 11:41:46 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Pneumonia_Virus_of_Mice_Expression_Vector_PSynK-PVMJ3666TAB-34https://nih.technologypublisher.com/tech/Local_Magnetization_Spoiling_Using_a_Gradient_Insert_for_Reducing_the_Field_of_View_in_Magnetic_Resonance_ImagingThe present invention provides a method and device for eliminating alias artifacts encountered in MRI when the field of view is made smaller than the subject being imaged. Significant advantages accrue from reducing the field of view to a smaller region of interest. These include reduced imaging time, increased spatial and temporal resolution, and less susceptibility to motion artifacts. The device operates by dephasing the magnetic resonance signal in regions away from the region of interest by means of a gradient insert.Tue, 06 Dec 2022 11:41:45 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Local_Magnetization_Spoiling_Using_a_Gradient_Insert_for_Reducing_the_Field_of_View_in_Magnetic_Resonance_ImagingTAB-3193https://nih.technologypublisher.com/tech/Hybridoma_Cell_Line_G7_Producing_Monoclonal_Anti-mouse_CD90_(Thy-1)_AntibodyA hybridoma cell line producing a monoclonal rat antibody specific to mouse CD90 (Thy-1) (clone G7) as described in J Exp Med. 1984 Mar 1;159(3):716-30 and developed by the laboratory of Dr. Ethan Shevach at the National Institute of Allergy and Infectious Diseases.Tue, 06 Dec 2022 11:41:44 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Hybridoma_Cell_Line_G7_Producing_Monoclonal_Anti-mouse_CD90_(Thy-1)_AntibodyTAB-3184https://nih.technologypublisher.com/tech/Mouse_CCR1_cDNAA plasmid encodes mouse C-C motif chemokine receptor 1 (CCR1). CCR1 plays an important role in host protection from inflammatory response, and susceptibility to virus and parasite.Tue, 06 Dec 2022 11:41:41 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Mouse_CCR1_cDNATAB-3181https://nih.technologypublisher.com/tech?title=Plasmid_pNL4-3%2c_HIV_Clone_For_Easy_Mutational_ChangesPlasmid DNA (clone pNL4-3) that produces infectious HIV-1 virus particles in a wide variety of cells as described in the J Virol. 1986 Aug;59(2):284-91 and developed in the laboratory of Dr. Malcolm Martin at the National Institute of Allergy and Infectious Diseases.Tue, 06 Dec 2022 11:41:39 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech?title=Plasmid_pNL4-3%2c_HIV_Clone_For_Easy_Mutational_ChangesTAB-3178https://nih.technologypublisher.com/tech?title=Human_Monocyte_Chemoattractant_Protein-1_(MCP-1%2fCCL2)_cDNAA plasmid encodes human monocyte chemoattractant protein-1 (MCP-1/CCL2). MCP-1/CCL2 is a chemokine that regulate migration and infiltration of monocytes/macrophages.Tue, 06 Dec 2022 11:41:36 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech?title=Human_Monocyte_Chemoattractant_Protein-1_(MCP-1%2fCCL2)_cDNATAB-352https://nih.technologypublisher.com/tech/Murine_Monoclonal_Antibodies_Effective_To_Treat_Respiratory_Syncytial_VirusAvailable for licensing through a Biological Materials License Agreement are the murine MAbs described in Beeler et al, "Neutralization epitopes of the F glycoprotein of respiratory syncytial virus: effect of mutation upon fusion function," J Virol. 1989 Jul;63(7):2941-2950 (PubMed abs). The MAbs that are available for licensing are the following: 1129, 1153, 1142, 1200, 1214, 1237, 1112, 1269, and 1243. One of these MAbs, 1129, is the basis for a humanized murine MAb (see U.S. Patent 5,824,307 to humanized 1129 owned by MedImmune, Inc.), recently approved for marketing in the United States....Wed, 09 Nov 2022 03:45:10 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Murine_Monoclonal_Antibodies_Effective_To_Treat_Respiratory_Syncytial_VirusTAB-488https://nih.technologypublisher.com/tech/Cloned_Genome_of_Infectious_Hepatitis_C_Virus_of_Genotype_2a_and_Uses_ThereofThe current invention provides a nucleic acid sequence comprising the genome of infectious hepatitis C viruses (HCV) of genotype 2a. The encoded polyprotein differs from those of the infectious clones of genotypes 1a and 1b (U.S. Patent 6,153,421) by approximately thirty (30) percent. It covers the use of this sequence and polypeptides encoded by all or part of the sequence, in the development of vaccines and diagnostic assays for HCV and the development of screening assays for the identification of antiviral agents for HCV. Additional information can be found in Yanagi et al. (1999), Virol...Wed, 09 Nov 2022 03:41:51 GMTnihott@nih.govhttps://nih.technologypublisher.com/tech/Cloned_Genome_of_Infectious_Hepatitis_C_Virus_of_Genotype_2a_and_Uses_Thereof